S2223|Safety|O
S2223|outcomes|O
S2223|were|O
S2223|assessed|O
S2223|throughout|O
S2223|the|O
S2223|36-week|O
S2223|treatment|O
S2223|and|O
S2223|48-week|O
S2223|follow-up|O
S2223|periods|O
S2223|.|O
S2268|Based|O
S2268|on|O
S2268|non-compartmental|O
S2268|analysis|O
S2268|,|O
S2268|the|O
S2268|mean|O
S2268|t1/2|O
S2268|values|O
S2268|of|O
S2268|quilizumab|O
S2268|across|O
S2268|the|O
S2268|dose|O
S2268|groups|O
S2268|ranged|O
S2268|from|O
S2268|16.4|O
S2268|to|O
S2268|18.7|O
S2268|days|O
S2268|,|O
S2268|which|O
S2268|suggests|O
S2268|that|O
S2268|steady-state|O
S2268|was|O
S2268|attained|O
S2268|by|O
S2268|the|O
S2268|time|O
S2268|the|O
S2268|final|O
S2268|doses|O
S2268|were|O
S2268|administered|O
S2268|for|O
S2268|both|O
S2268|monthly|O
S2268|and|O
S2268|quarterly|O
S2268|regimens|O
S2268|.|O
S2278|4|O
S2278|)|O
S2278|.|O
S2215|Asthma|O
S2215|exacerbations|O
S2215|were|O
S2215|defined|O
S2215|as|O
S2215|new|O
S2215|or|O
S2215|increased|O
S2215|asthma|O
S2215|symptoms|O
S2215|(|O
S2215|wheezing|O
S2215|,|O
S2215|cough|O
S2215|,|O
S2215|chest|O
S2215|tightness|O
S2215|,|O
S2215|shortness|O
S2215|of|O
S2215|breath|O
S2215|,|O
S2215|or|O
S2215|nighttime|O
S2215|awakening|O
S2215|due|O
S2215|to|O
S2215|symptoms|O
S2215|)|O
S2215|that|O
S2215|led|O
S2215|to|O
S2215|treatment|O
S2215|with|O
S2215|systemic|O
S2215|corticosteroids|O
S2215|for|O
S2215|at|O
S2215|least|O
S2215|3|O
S2215|days|O
S2215|or|O
S2215|to|O
S2215|hospitalization|O
S2215|.|O
S2236|Peripheral|O
S2236|blood|O
S2236|eosinophil|O
S2236|counts|O
S2236|were|O
S2236|obtained|O
S2236|from|O
S2236|standard|O
S2236|complete|O
S2236|blood|O
S2236|counts|O
S2236|.|O
S2256|There|O
S2256|were|O
S2256|no|O
S2256|major|O
S2256|imbalances|O
S2256|between|O
S2256|treatment|O
S2256|groups|O
S2256|,|O
S2256|but|O
S2256|the|O
S2256|300|O
S2256|mg|O
S2256|monthly|O
S2256|quilizumab|O
S2256|group|O
S2256|had|O
S2256|a|O
S2256|lower|O
S2256|mean|O
S2256|age|O
S2256|(|O
S2256|45|O
S2256|versus|O
S2256|47–48|O
S2256|years|O
S2256|)|O
S2256|and|O
S2256|a|O
S2256|lower|O
S2256|median|O
S2256|IgE|O
S2256|level|O
S2256|(|O
S2256|190|O
S2256|versus|O
S2256|234–254|O
S2256|IU/mL|O
S2256|)|O
S2256|compared|O
S2256|to|O
S2256|the|O
S2256|other|O
S2256|treatment|O
S2256|arms|O
S2256|(|O
S2256|Table|O
S2256|1|O
S2256|)|O
S2256|.|O
S2259|Safety|O
S2259|Quilizumab|O
S2259|was|O
S2259|well|O
S2259|tolerated|O
S2259|,|O
S2259|and|O
S2259|the|O
S2259|number|O
S2259|of|O
S2259|patients|O
S2259|experiencing|O
S2259|at|O
S2259|least|O
S2259|one|O
S2259|adverse|O
S2259|event|O
S2259|(|O
S2259|AE|O
S2259|)|O
S2259|was|O
S2259|comparable|O
S2259|between|O
S2259|all|O
S2259|treatment|O
S2259|groups|O
S2259|(|O
S2259|Table|O
S2259|2|O
S2259|)|O
S2259|.|O
S2232|Allergen-specific|O
S2232|and|O
S2232|total|O
S2232|IgE|O
S2232|were|O
S2232|measured|O
S2232|in|O
S2232|serum|O
S2232|by|O
S2232|ImmunoCAP®|O
S2232|Specific|O
S2232|IgE|O
S2232|blood|O
S2232|tests|O
S2232|(|O
S2232|ViraCor-IBT|O
S2232|Laboratories|O
S2232|,|O
S2232|Lee|O
S2232|’|O
S2232|s|O
S2232|Summit|O
S2232|,|O
S2232|MO|O
S2232|)|O
S2232|.|O
S2227|Baseline|O
S2227|values|O
S2227|were|O
S2227|derived|O
S2227|from|O
S2227|a|O
S2227|minimum|O
S2227|of|O
S2227|10|O
S2227|days|O
S2227|of|O
S2227|patient|O
S2227|diary|O
S2227|entries|O
S2227|during|O
S2227|the|O
S2227|14|O
S2227|days|O
S2227|prior|O
S2227|to|O
S2227|the|O
S2227|first|O
S2227|treatment|O
S2227|.|O
S2260|Through|O
S2260|Week|O
S2260|36|O
S2260|,|O
S2260|the|O
S2260|most|O
S2260|frequent|O
S2260|AEs|O
S2260|across|O
S2260|all|O
S2260|quilizumab|O
S2260|dose|O
S2260|groups|O
S2260|were|O
S2260|worsening|O
S2260|of|O
S2260|asthma|O
S2260|(|O
S2260|27|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|nasopharyngitis|O
S2260|(|O
S2260|15|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|upper|O
S2260|respiratory|O
S2260|tract|O
S2260|infection|O
S2260|(|O
S2260|7|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|bronchitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|sinusitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|and|O
S2260|injection|O
S2260|site|O
S2260|pain|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|.|O
S2280|5|O
S2280|)|O
S2280|.|O
S2246|The|O
S2246|relative|O
S2246|change|O
S2246|in|O
S2246|pre-bronchodilator|O
S2246|FEV1|O
S2246|from|O
S2246|baseline|O
S2246|was|O
S2246|calculated|O
S2246|as|O
S2246|the|O
S2246|absolute|O
S2246|change|O
S2246|in|O
S2246|FEV1|O
S2246|(|O
S2246|volume|O
S2246|in|O
S2246|liters|O
S2246|)|O
S2246|from|O
S2246|baseline|O
S2246|divided|O
S2246|by|O
S2246|the|O
S2246|FEV1|O
S2246|at|O
S2246|baseline|O
S2246|.|O
S2273|Peripheral|O
S2273|blood|O
S2273|eosinophils|O
S2273|and|O
S2273|FeNO|O
S2273|levels|O
S2273|were|O
S2273|not|O
S2273|modified|O
S2273|following|O
S2273|quilizumab|O
S2273|treatment|O
S2273|(|O
S2273|see|O
S2273|Additional|O
S2273|file|O
S2273|1|O
S2273|:|O
S2273|Figure|O
S2273|S3|O
S2273|)|O
S2273|.|O
S2243|The|O
S2243|rates|O
S2243|of|O
S2243|asthma|O
S2243|exacerbations|O
S2243|were|O
S2243|compared|O
S2243|between|O
S2243|study|O
S2243|groups|O
S2243|using|O
S2243|a|O
S2243|Poisson|O
S2243|regression|O
S2243|with|O
S2243|overdispersion|O
S2243|model|O
S2243|,|O
S2243|including|O
S2243|terms|O
S2243|for|O
S2243|periostin|O
S2243|status|O
S2243|(|O
S2243|<|O
S2243|50|O
S2243|,|O
S2243|≥50|O
S2243|ng/mL|O
S2243|)|O
S2243|,|O
S2243|number|O
S2243|of|O
S2243|prior|O
S2243|exacerbations|O
S2243|(|O
S2243|1|O
S2243|,|O
S2243|>|O
S2243|1|O
S2243|)|O
S2243|,|O
S2243|and|O
S2243|IgE|O
S2243|level|O
S2243|(|O
S2243|<|O
S2243|200|O
S2243|,|O
S2243|≥200|O
S2243|IU/mL|O
S2243|)|O
S2243|.|O
S2216|Exclusion|O
S2216|criteria|O
S2216|Patients|O
S2216|were|O
S2216|excluded|O
S2216|from|O
S2216|the|O
S2216|study|O
S2216|if|O
S2216|they|O
S2216|had|O
S2216|an|O
S2216|asthma|O
S2216|exacerbation|O
S2216|requiring|O
S2216|systemic|O
S2216|steroids|O
S2216|in|O
S2216|the|O
S2216|30|O
S2216|days|O
S2216|prior|O
S2216|to|O
S2216|screening|O
S2216|,|O
S2216|or|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|a|O
S2216|>|O
S2216|20|O
S2216|%|O
S2216|relative|O
S2216|change|O
S2216|in|O
S2216|FEV1|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|any|O
S2216|pre-existing|O
S2216|active|O
S2216|lung|O
S2216|disease|O
S2216|other|O
S2216|than|O
S2216|asthma|O
S2216|,|O
S2216|any|O
S2216|infections|O
S2216|,|O
S2216|elevated|O
S2216|IgE|O
S2216|levels|O
S2216|for|O
S2216|reasons|O
S2216|other|O
S2216|than|O
S2216|allergy|O
S2216|,|O
S2216|or|O
S2216|were|O
S2216|former|O
S2216|or|O
S2216|current|O
S2216|smokers|O
S2216|.|O
S2270|2|O
S2270|)|O
S2270|.|O
S2231|Biomarkers|O
S2231|Samples|O
S2231|for|O
S2231|biomarker|O
S2231|assessments|O
S2231|were|O
S2231|collected|O
S2231|throughout|O
S2231|the|O
S2231|study|O
S2231|.|O
S2254|Results|O
S2254|Patient|O
S2254|demographics|O
S2254|and|O
S2254|study|O
S2254|flow|O
S2254|1212|O
S2254|patients|O
S2254|were|O
S2254|screened|O
S2254|for|O
S2254|eligibility|O
S2254|and|O
S2254|578|B-Sample_Size_Actual_at_Enrollment
S2254|adult|O
S2254|asthma|O
S2254|patients|O
S2254|(|O
S2254|18–75|O
S2254|years|O
S2254|old|O
S2254|)|O
S2254|were|O
S2254|enrolled|O
S2254|(|O
S2254|Fig|O
S2254|.|O
S2226|For|O
S2226|the|O
S2226|analyses|O
S2226|of|O
S2226|symptom|O
S2226|scores|O
S2226|,|O
S2226|rescue|O
S2226|medication|O
S2226|use|O
S2226|,|O
S2226|and|O
S2226|nighttime|O
S2226|awakenings|O
S2226|,|O
S2226|daily|O
S2226|scores|O
S2226|were|O
S2226|averaged|O
S2226|over|O
S2226|the|O
S2226|previous|O
S2226|7|O
S2226|days|O
S2226|prior|O
S2226|to|O
S2226|the|O
S2226|time|O
S2226|point|O
S2226|of|O
S2226|interest|O
S2226|.|O
S2255|1|O
S2255|)|O
S2255|from|O
S2255|April|O
S2255|2012|O
S2255|to|O
S2255|September|O
S2255|2013|O
S2255|;|O
S2255|the|O
S2255|study|O
S2255|was|O
S2255|completed|O
S2255|in|O
S2255|November|O
S2255|2014|O
S2255|.|O
S2218|Secondary|O
S2218|efficacy|O
S2218|outcomes|O
S2218|included|O
S2218|assessments|O
S2218|of|O
S2218|lung|O
S2218|function|O
S2218|using|O
S2218|the|O
S2218|relative|O
S2218|change|O
S2218|in|O
S2218|pre-bronchodilator|O
S2218|FEV1|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Weeks|O
S2218|12|O
S2218|and|O
S2218|36|O
S2218|and|O
S2218|the|O
S2218|change|O
S2218|in|O
S2218|asthma|O
S2218|symptoms|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Week|O
S2218|36|O
S2218|,|O
S2218|using|O
S2218|total|O
S2218|and|O
S2218|daytime|O
S2218|symptom|O
S2218|severity|O
S2218|scores|O
S2218|derived|O
S2218|from|O
S2218|a|O
S2218|daily|O
S2218|patient|O
S2218|diary|O
S2218|.|O
S2258|The|O
S2258|sponsor|O
S2258|terminated|O
S2258|the|O
S2258|trial|O
S2258|early|O
S2258|because|O
S2258|of|O
S2258|the|O
S2258|lack|O
S2258|of|O
S2258|efficacy|O
S2258|for|O
S2258|the|O
S2258|primary|O
S2258|end-point|O
S2258|(|O
S2258|asthma|O
S2258|exacerbations|O
S2258|)|O
S2258|at|O
S2258|Week|O
S2258|36|O
S2258|,|O
S2258|with|O
S2258|the|O
S2258|median|O
S2258|time|O
S2258|in|O
S2258|the|O
S2258|study|O
S2258|at|O
S2258|72|O
S2258|weeks|O
S2258|.|O
S2275|In|O
S2275|the|O
S2275|ITT|O
S2275|population|O
S2275|,|O
S2275|the|O
S2275|reduction|O
S2275|in|O
S2275|the|O
S2275|asthma|O
S2275|exacerbation|O
S2275|rate|O
S2275|relative|O
S2275|to|O
S2275|placebo|O
S2275|was|O
S2275|19.6|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−21|O
S2275|to|O
S2275|47|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.38|O
S2275|)|O
S2275|,|O
S2275|−11.2|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−63|O
S2275|to|O
S2275|24|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.65|O
S2275|)|O
S2275|,|O
S2275|and|O
S2275|−5.7|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−55|O
S2275|to|O
S2275|28|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.81|O
S2275|)|O
S2275|in|O
S2275|the|O
S2275|300|O
S2275|mg|O
S2275|M|O
S2275|,|O
S2275|450|O
S2275|mg|O
S2275|Q|O
S2275|,|O
S2275|and|O
S2275|150|O
S2275|mg|O
S2275|Q|O
S2275|quilizumab|O
S2275|treatment|O
S2275|arms|O
S2275|,|O
S2275|respectively|O
S2275|(|O
S2275|Fig|O
S2275|.|O
S2285|Patient-reported|O
S2285|outcomes|O
S2285|During|O
S2285|the|O
S2285|36-week|O
S2285|treatment|O
S2285|period|O
S2285|,|O
S2285|no|O
S2285|meaningful|O
S2285|differences|O
S2285|were|O
S2285|observed|O
S2285|between|O
S2285|the|O
S2285|quilizumab|O
S2285|dose|O
S2285|groups|O
S2285|compared|O
S2285|with|O
S2285|the|O
S2285|placebo|O
S2285|group|O
S2285|for|O
S2285|the|O
S2285|total|O
S2285|mTASS|O
S2285|,|O
S2285|daytime|O
S2285|mTASS|O
S2285|,|O
S2285|ACQ-5|O
S2285|,|O
S2285|AQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|,|O
S2285|or|O
S2285|RQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|scores|O
S2285|(|O
S2285|Table|O
S2285|3|O
S2285|)|O
S2285|.|O
S2229|The|O
S2229|pharmacokinetic|O
S2229|outcomes|O
S2229|included|O
S2229|:|O
S2229|serum|O
S2229|concentrations|O
S2229|prior|O
S2229|to|O
S2229|dosing|O
S2229|at|O
S2229|Weeks|O
S2229|0|O
S2229|,|O
S2229|4|O
S2229|,|O
S2229|12|O
S2229|,|O
S2229|24|O
S2229|,|O
S2229|and|O
S2229|32|O
S2229|;|O
S2229|serum|O
S2229|concentrations|O
S2229|at|O
S2229|Week|O
S2229|5|O
S2229|and|O
S2229|Week|O
S2229|25|O
S2229|;|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentrations|O
S2229|(|O
S2229|Cmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|time|O
S2229|of|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentration|O
S2229|(|O
S2229|Tmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|and|O
S2229|terminal|O
S2229|elimination|O
S2229|half-life|O
S2229|(|O
S2229|t1/2|O
S2229|)|O
S2229|.|O
S2284|Analysis|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|biomarker|O
S2284|subgroups|O
S2284|demonstrated|O
S2284|no|O
S2284|consistent|O
S2284|or|O
S2284|meaningful|O
S2284|improvements|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|quilizumab-treated|O
S2284|arms|O
S2284|over|O
S2284|placebo|O
S2284|(|O
S2284|see|O
S2284|Additional|O
S2284|file|O
S2284|2|O
S2284|:|O
S2284|Table|O
S2284|S1|O
S2284|and|O
S2284|Additional|O
S2284|file|O
S2284|3|O
S2284|:|O
S2284|Table|O
S2284|S2|O
S2284|)|O
S2284|.|O
S2228|Pharmacokinetics|O
S2228|and|O
S2228|immunogenicity|O
S2228|Serum|O
S2228|levels|O
S2228|of|O
S2228|quilizumab|O
S2228|for|O
S2228|pharmacokinetic|O
S2228|assessments|O
S2228|were|O
S2228|measured|O
S2228|using|O
S2228|a|O
S2228|validated|O
S2228|enzyme-linked|O
S2228|immunosorbent|O
S2228|assay|O
S2228|(|O
S2228|ELISA|O
S2228|;|O
S2228|Genentech|O
S2228|,|O
S2228|Inc.|O
S2228|,|O
S2228|South|O
S2228|San|O
S2228|Francisco|O
S2228|,|O
S2228|CA|O
S2228|)|O
S2228|.|O
S2262|ATA|O
S2262|incidence|O
S2262|for|O
S2262|all|O
S2262|dosing|O
S2262|groups|O
S2262|was|O
S2262|1.6|O
S2262|%|O
S2262|(|O
S2262|7|O
S2262|of|O
S2262|427|O
S2262|quilizumab-dosed|O
S2262|patients|O
S2262|)|O
S2262|.|O
S2283|5|O
S2283|;|O
S2283|see|O
S2283|Additional|O
S2283|file|O
S2283|2|O
S2283|:|O
S2283|Table|O
S2283|S1|O
S2283|and|O
S2283|Additional|O
S2283|file|O
S2283|3|O
S2283|:|O
S2283|Table|O
S2283|S2|O
S2283|)|O
S2283|.|O
S2257|89|B-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|384/433|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|quilizumab|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|and|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|91|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|132/145|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|completed|O
S2257|the|O
S2257|study|O
S2257|treatment|O
S2257|.|O
S2214|Participants|O
S2214|Inclusion|O
S2214|criteria|O
S2214|Adult|O
S2214|asthma|O
S2214|patients|O
S2214|,|O
S2214|aged|O
S2214|18–75|O
S2214|years|O
S2214|,|O
S2214|were|O
S2214|required|O
S2214|to|O
S2214|have|O
S2214|:|O
S2214|bronchodilator|O
S2214|reversibility|O
S2214|of|O
S2214|either|O
S2214|≥12|O
S2214|%|O
S2214|β-agonist|O
S2214|reversibility|O
S2214|using|O
S2214|4|O
S2214|puffs|O
S2214|of|O
S2214|a|O
S2214|short-acting|O
S2214|β|O
S2214|−|O
S2214|agonist|O
S2214|(|O
S2214|SABA|O
S2214|)|O
S2214|or|O
S2214|a|O
S2214|PC20|O
S2214|FEV1|O
S2214|methacholine|O
S2214|(|O
S2214|provocative|O
S2214|concentration|O
S2214|of|O
S2214|methacholine|O
S2214|producing|O
S2214|a|O
S2214|20|O
S2214|%|O
S2214|fall|O
S2214|in|O
S2214|FEV1|O
S2214|(|O
S2214|forced|O
S2214|expiratory|O
S2214|volume|O
S2214|in|O
S2214|1|O
S2214|s|O
S2214|)|O
S2214|)|O
S2214|of|O
S2214|8|O
S2214|mg/mL|O
S2214|or|O
S2214|less|O
S2214|,|O
S2214|within|O
S2214|the|O
S2214|last|O
S2214|2|O
S2214|years|O
S2214|;|O
S2214|a|O
S2214|pre-bronchodilator|O
S2214|FEV1|O
S2214|at|O
S2214|screening|O
S2214|of|O
S2214|40–80|O
S2214|%|O
S2214|predicted|O
S2214|;|O
S2214|daily|O
S2214|use|O
S2214|of|O
S2214|ICS|O
S2214|(|O
S2214|≥400|O
S2214|μg/day|O
S2214|total|O
S2214|daily|O
S2214|dose|O
S2214|of|O
S2214|fluticasone|O
S2214|propionate|O
S2214|or|O
S2214|equivalent|O
S2214|)|O
S2214|and|O
S2214|a|O
S2214|second|O
S2214|controller|O
S2214|for|O
S2214|a|O
S2214|minimum|O
S2214|of|O
S2214|3|O
S2214|consecutive|O
S2214|months|O
S2214|;|O
S2214|inadequately-controlled|O
S2214|asthma|O
S2214|as|O
S2214|documented|O
S2214|by|O
S2214|a|O
S2214|5-item|O
S2214|Asthma|O
S2214|Control|O
S2214|Questionnaire|O
S2214|(|O
S2214|ACQ-5|O
S2214|)|O
S2214|score|O
S2214|≥1.50|O
S2214|at|O
S2214|screening|O
S2214|and|O
S2214|randomization|O
S2214|,|O
S2214|despite|O
S2214|compliance|O
S2214|with|O
S2214|asthma|O
S2214|controller|O
S2214|therapy|O
S2214|;|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|positive|O
S2214|aeroallergen-specific|O
S2214|IgE|O
S2214|(|O
S2214|≥0.35|O
S2214|kU|O
S2214|(|O
S2214|A|O
S2214|)|O
S2214|/L|O
S2214|)|O
S2214|,|O
S2214|or|O
S2214|a|O
S2214|total|O
S2214|serum|O
S2214|IgE|O
S2214|≥75|O
S2214|IU/mL|O
S2214|;|O
S2214|and|O
S2214|a|O
S2214|history|O
S2214|of|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|protocol-defined|O
S2214|asthma|O
S2214|exacerbation|O
S2214|in|O
S2214|the|O
S2214|18|O
S2214|months|O
S2214|prior|O
S2214|to|O
S2214|screening|O
S2214|.|O
S2220|Exploratory|O
S2220|outcome|O
S2220|measures|O
S2220|included|O
S2220|the|O
S2220|change|O
S2220|in|O
S2220|asthma|O
S2220|control|O
S2220|from|O
S2220|baseline|O
S2220|to|O
S2220|Week|O
S2220|36|O
S2220|,|O
S2220|as|O
S2220|measured|O
S2220|by|O
S2220|the|O
S2220|ACQ-5|O
S2220|.|O
S2224|Assessments|O
S2224|The|O
S2224|patient|O
S2224|daily|O
S2224|diary|O
S2224|included|O
S2224|two|O
S2224|sections|O
S2224|in|O
S2224|addition|O
S2224|to|O
S2224|peak|O
S2224|flow|O
S2224|measurements|O
S2224|:|O
S2224|1|O
S2224|)|O
S2224|a|O
S2224|morning|O
S2224|section|O
S2224|capturing|O
S2224|awakenings|O
S2224|and|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|at|O
S2224|night|O
S2224|,|O
S2224|and|O
S2224|symptoms|O
S2224|on|O
S2224|awakening|O
S2224|;|O
S2224|and|O
S2224|2|O
S2224|)|O
S2224|an|O
S2224|evening|O
S2224|section|O
S2224|capturing|O
S2224|daytime|O
S2224|symptom|O
S2224|severity|O
S2224|,|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|,|O
S2224|preventive|O
S2224|inhaler|O
S2224|use|O
S2224|,|O
S2224|activity|O
S2224|impairment|O
S2224|during|O
S2224|the|O
S2224|day|O
S2224|,|O
S2224|and|O
S2224|nasal|O
S2224|symptoms|O
S2224|.|O
S2245|Corresponding|O
S2245|two-sided|O
S2245|p-values|O
S2245|and|O
S2245|90|O
S2245|%|O
S2245|confidence|O
S2245|intervals|O
S2245|(|O
S2245|CI|O
S2245|)|O
S2245|were|O
S2245|reported|O
S2245|.|O
S2209|Patients|B-Blinding_Object_Patients
S2209|and|O
S2209|study|B-Blinding_Object_Care_Providers
S2209|site|I-Blinding_Object_Care_Providers
S2209|personnel|I-Blinding_Object_Care_Providers
S2209|were|O
S2209|blinded|O
S2209|to|O
S2209|treatment|O
S2209|assignments|O
S2209|until|O
S2209|all|O
S2209|follow-up|O
S2209|data|O
S2209|through|O
S2209|Week|O
S2209|84|O
S2209|were|O
S2209|collected|O
S2209|and|O
S2209|verified|O
S2209|.|O
S2233|Specific|O
S2233|IgE|O
S2233|was|O
S2233|measured|O
S2233|for|O
S2233|the|O
S2233|following|O
S2233|allergens|O
S2233|:|O
S2233|cat|O
S2233|,|O
S2233|house|O
S2233|dust|O
S2233|mite|O
S2233|(|O
S2233|HDM|O
S2233|)|O
S2233|Dermatophagoides|O
S2233|farinae|O
S2233|,|O
S2233|HDM|O
S2233|Dermatophagoides|O
S2233|pteronyssinus|O
S2233|,|O
S2233|ragweed|O
S2233|,|O
S2233|aspergillus|O
S2233|,|O
S2233|timothy|O
S2233|grass|O
S2233|,|O
S2233|bermuda|O
S2233|grass|O
S2233|,|O
S2233|oak|O
S2233|,|O
S2233|birch|O
S2233|,|O
S2233|plantain|O
S2233|,|O
S2233|and|O
S2233|orchard|O
S2233|grass|O
S2233|.|O
S2235|Only|O
S2235|observed|O
S2235|values|O
S2235|of|O
S2235|IgE|O
S2235|levels|O
S2235|were|O
S2235|analyzed|O
S2235|,|O
S2235|with|O
S2235|no|O
S2235|imputation|O
S2235|performed|O
S2235|for|O
S2235|missing|O
S2235|IgE|O
S2235|data|O
S2235|.|O
S2249|Missing|O
S2249|values|O
S2249|were|O
S2249|imputed|O
S2249|using|O
S2249|the|O
S2249|last-observation-carried-forward|O
S2249|(|O
S2249|LOCF|O
S2249|)|O
S2249|approach|O
S2249|,|O
S2249|as|O
S2249|prespecified|O
S2249|in|O
S2249|the|O
S2249|statistical|O
S2249|analysis|O
S2249|plan|O
S2249|.|O
S2276|3|O
S2276|)|O
S2276|.|O
S2217|Outcome|O
S2217|measures|O
S2217|The|O
S2217|primary|O
S2217|efficacy|O
S2217|outcome|O
S2217|was|O
S2217|the|O
S2217|annualized|O
S2217|rate|O
S2217|of|O
S2217|protocol-defined|O
S2217|asthma|O
S2217|exacerbations|O
S2217|from|O
S2217|baseline|O
S2217|to|O
S2217|Week|O
S2217|36|O
S2217|.|O
S2266|At|O
S2266|treatment|O
S2266|Weeks|O
S2266|4|O
S2266|,|O
S2266|12|O
S2266|,|O
S2266|and|O
S2266|24|O
S2266|,|O
S2266|the|O
S2266|mean|O
S2266|trough|O
S2266|serum|O
S2266|concentrations|O
S2266|of|O
S2266|quilizumab|O
S2266|were|O
S2266|:|O
S2266|(|O
S2266|150|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|5.7|O
S2266|±|O
S2266|2.3|O
S2266|μg/mL|O
S2266|,|O
S2266|2.6|O
S2266|±|O
S2266|2.0|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|1.3|O
S2266|±|O
S2266|4.6|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|(|O
S2266|450|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|17.1|O
S2266|±|O
S2266|7.0|O
S2266|μg/mL|O
S2266|,|O
S2266|7.2|O
S2266|±|O
S2266|3.8|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|2.3|O
S2266|±|O
S2266|2.2|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|and|O
S2266|(|O
S2266|300|O
S2266|mg|O
S2266|M|O
S2266|)|O
S2266|11.6|O
S2266|±|O
S2266|4.5|O
S2266|μg/mL|O
S2266|,|O
S2266|16.7|O
S2266|±|O
S2266|6.7|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|16.8|O
S2266|±|O
S2266|7.7|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|.|O
S2282|Relative|O
S2282|changes|O
S2282|from|O
S2282|baseline|O
S2282|in|O
S2282|FEV1|O
S2282|compared|O
S2282|to|O
S2282|placebo|O
S2282|were|O
S2282|3.8|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−1.2|O
S2282|to|O
S2282|8.9|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.21|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|5.6|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|0.6|O
S2282|to|O
S2282|10.6|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.07|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|150|O
S2282|mg|O
S2282|Q|O
S2282|treatment|O
S2282|arm|O
S2282|;|O
S2282|2.2|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−2.8|O
S2282|to|O
S2282|7.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.48|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−5.0|O
S2282|to|O
S2282|5.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.98|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|450|O
S2282|mg|O
S2282|Q|O
S2282|arm|O
S2282|;|O
S2282|and|O
S2282|1.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−3.9|O
S2282|to|O
S2282|6.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.72|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−4.9|O
S2282|to|O
S2282|5.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.96|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|300|O
S2282|mg|O
S2282|M|O
S2282|arm|O
S2282|(|O
S2282|Fig|O
S2282|.|O
S2240|Demographic|O
S2240|and|O
S2240|baseline|O
S2240|characteristics|O
S2240|were|O
S2240|summarized|O
S2240|using|O
S2240|descriptive|O
S2240|statistics|O
S2240|.|O
S2221|To|O
S2221|assess|O
S2221|the|O
S2221|change|O
S2221|in|O
S2221|allergy-related|O
S2221|quality-of-life|O
S2221|measures|O
S2221|from|O
S2221|baseline|O
S2221|to|O
S2221|Week|O
S2221|36|O
S2221|,|O
S2221|the|O
S2221|Standardized|O
S2221|Asthma|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|AQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|and|O
S2221|the|O
S2221|Standardized|O
S2221|Rhinoconjunctivitis|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|RQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|were|O
S2221|administered|O
S2221|at|O
S2221|patient|O
S2221|visits|O
S2221|throughout|O
S2221|the|O
S2221|treatment|O
S2221|and|O
S2221|follow-up|O
S2221|periods|O
S2221|.|O
S2206|Trial|O
S2206|design|O
S2206|The|O
S2206|COSTA|O
S2206|trial|O
S2206|of|O
S2206|quilizumab|O
S2206|was|O
S2206|a|O
S2206|Phase|B-Design_Phase_2
S2206|II|I-Design_Phase_2
S2206|,|O
S2206|randomized|O
S2206|,|O
S2206|double-blind|B-Blinding_Double_Blind
S2206|,|O
S2206|placebo-controlled|O
S2206|study|O
S2206|(|O
S2206|including|O
S2206|recruiting|B-Settings_Multicenter
S2206|sites|I-Settings_Multicenter
S2206|from|I-Settings_Multicenter
S2206|14|I-Settings_Multicenter
S2206|countries|I-Settings_Multicenter
S2206|:|O
S2206|Argentina|B-Settings_Location
S2206|,|I-Settings_Location
S2206|Belgium|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Bulgaria|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Canada|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Germany|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Hungary|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Mexico|I-Settings_Location
S2206|,|I-Settings_Location
S2206|New|I-Settings_Location
S2206|Zealand|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Peru|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Poland|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Romania|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Russia|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Ukraine|I-Settings_Location
S2206|,|I-Settings_Location
S2206|and|I-Settings_Location
S2206|the|I-Settings_Location
S2206|United|I-Settings_Location
S2206|States|I-Settings_Location
S2206|)|O
S2206|that|O
S2206|enrolled|O
S2206|578|B-Sample_Size_Actual_at_Enrollment
S2206|adults|O
S2206|with|O
S2206|uncontrolled|O
S2206|allergic|O
S2206|asthma|O
S2206|.|O
S2208|Randomization|O
S2208|was|O
S2208|stratified|B-Randomization_Type_Stratified
S2208|based|O
S2208|on|O
S2208|serum|B-Randomization_Stratified_Criteria
S2208|periostin|I-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|<|I-Randomization_Stratified_Criteria
S2208|50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|≥50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|exacerbation|B-Randomization_Stratified_Criteria
S2208|history|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|number|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|exacerbations|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|requiring|I-Randomization_Stratified_Criteria
S2208|use|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|systemic|I-Randomization_Stratified_Criteria
S2208|corticosteroids|I-Randomization_Stratified_Criteria
S2208|in|I-Randomization_Stratified_Criteria
S2208|the|I-Randomization_Stratified_Criteria
S2208|prior|I-Randomization_Stratified_Criteria
S2208|18|I-Randomization_Stratified_Criteria
S2208|months|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|IgE|B-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|≤75|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|75–200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|and|O
S2208|country|B-Randomization_Stratified_Criteria
S2208|.|O
S2277|Subgroup|O
S2277|analysis|O
S2277|by|O
S2277|baseline|O
S2277|serum|O
S2277|periostin|O
S2277|(|O
S2277|≥50|O
S2277|ng/ml|O
S2277|,|O
S2277|<|O
S2277|50|O
S2277|ng/ml|O
S2277|)|O
S2277|,|O
S2277|blood|O
S2277|eosinophils|O
S2277|(|O
S2277|≥300|O
S2277|cells/μl|O
S2277|,|O
S2277|<|O
S2277|300|O
S2277|cells/μl|O
S2277|)|O
S2277|,|O
S2277|FeNO|O
S2277|(|O
S2277|≥20|O
S2277|ppb|O
S2277|,|O
S2277|<|O
S2277|20|O
S2277|ppb|O
S2277|)|O
S2277|and|O
S2277|serum|O
S2277|total|O
S2277|IgE|O
S2277|(|O
S2277|≥200|O
S2277|IU/mL|O
S2277|,|O
S2277|<|O
S2277|200|O
S2277|IU/mL|O
S2277|)|O
S2277|demonstrated|O
S2277|no|O
S2277|consistent|O
S2277|effect|O
S2277|of|O
S2277|quilizumab|O
S2277|on|O
S2277|the|O
S2277|exacerbation|O
S2277|rate|O
S2277|across|O
S2277|all|O
S2277|doses|O
S2277|when|O
S2277|compared|O
S2277|to|O
S2277|the|O
S2277|ITT|O
S2277|population|O
S2277|(|O
S2277|Fig|O
S2277|.|O
S2234|The|O
S2234|maximum|O
S2234|specific|O
S2234|IgE|O
S2234|was|O
S2234|defined|O
S2234|as|O
S2234|the|O
S2234|specific|O
S2234|IgE|O
S2234|with|O
S2234|the|O
S2234|highest|O
S2234|titer|O
S2234|of|O
S2234|specific|O
S2234|IgEs|O
S2234|pre-dose|O
S2234|in|O
S2234|each|O
S2234|patient|O
S2234|.|O
S2210|Quilizumab|O
S2210|(|O
S2210|Genentech|O
S2210|,|O
S2210|Inc.|O
S2210|,|O
S2210|South|O
S2210|San|O
S2210|Francisco|O
S2210|,|O
S2210|CA|O
S2210|)|O
S2210|was|O
S2210|delivered|O
S2210|subcutaneously|O
S2210|at|O
S2210|nine|O
S2210|monthly|O
S2210|intervals|O
S2210|at|O
S2210|300|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|300|O
S2210|mg|O
S2210|M|O
S2210|)|O
S2210|,|O
S2210|or|O
S2210|at|O
S2210|three|O
S2210|quarterly|O
S2210|intervals|O
S2210|and|O
S2210|at|O
S2210|Week|O
S2210|4|O
S2210|at|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|Q|O
S2210|)|O
S2210|.|O
S2274|Asthma|O
S2274|exacerbation|O
S2274|rates|O
S2274|Quilizumab|O
S2274|treatment|O
S2274|did|O
S2274|not|O
S2274|produce|O
S2274|a|O
S2274|clinically|O
S2274|meaningful|O
S2274|reduction|O
S2274|of|O
S2274|the|O
S2274|rate|O
S2274|of|O
S2274|asthma|O
S2274|exacerbations|O
S2274|over|O
S2274|the|O
S2274|36-week|O
S2274|treatment|O
S2274|period|O
S2274|.|O
S2239|Statistical|O
S2239|methods|O
S2239|All|O
S2239|patients|O
S2239|received|O
S2239|at|O
S2239|least|O
S2239|one|O
S2239|dose|O
S2239|of|O
S2239|study|O
S2239|drug|O
S2239|(|O
S2239|intention-to-treat|O
S2239|,|O
S2239|ITT|O
S2239|population|O
S2239|)|O
S2239|and|O
S2239|were|O
S2239|included|O
S2239|in|O
S2239|all|O
S2239|safety|O
S2239|and|O
S2239|efficacy|O
S2239|analyses|O
S2239|.|O
S2267|For|O
S2267|the|O
S2267|150|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|450|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|and|O
S2267|300|O
S2267|mg|O
S2267|M|O
S2267|doses|O
S2267|,|O
S2267|the|O
S2267|mean|O
S2267|Cmax|O
S2267|,|O
S2267|obs|O
S2267|values|O
S2267|were|O
S2267|18|O
S2267|±|O
S2267|7.8|O
S2267|μg/mL|O
S2267|,|O
S2267|51.6|O
S2267|±|O
S2267|19.5|O
S2267|μg/mL|O
S2267|,|O
S2267|and|O
S2267|34|O
S2267|±|O
S2267|12.6|O
S2267|μg/mL|O
S2267|,|O
S2267|which|O
S2267|occurred|O
S2267|at|O
S2267|Tmax|O
S2267|,|O
S2267|obs|O
S2267|of|O
S2267|36.4|O
S2267|±|O
S2267|4.3|O
S2267|days|O
S2267|,|O
S2267|36.2|O
S2267|±|O
S2267|3.0|O
S2267|days|O
S2267|,|O
S2267|and|O
S2267|36.2|O
S2267|±|O
S2267|3.5|O
S2267|days|O
S2267|,|O
S2267|respectively|O
S2267|,|O
S2267|approximately|O
S2267|7|O
S2267|days|O
S2267|following|O
S2267|the|O
S2267|second|O
S2267|doses|O
S2267|.|O
S2222|We|O
S2222|also|O
S2222|evaluated|O
S2222|the|O
S2222|ability|O
S2222|of|O
S2222|biomarkers|O
S2222|(|O
S2222|serum|O
S2222|periostin|O
S2222|,|O
S2222|blood|O
S2222|eosinophils|O
S2222|,|O
S2222|exhaled|O
S2222|NO|O
S2222|,|O
S2222|and|O
S2222|serum|O
S2222|IgE|O
S2222|)|O
S2222|to|O
S2222|predict|O
S2222|benefit|O
S2222|from|O
S2222|quilizumab|O
S2222|.|O
S2281|The|O
S2281|highest|O
S2281|relative|O
S2281|improvement|O
S2281|compared|O
S2281|to|O
S2281|placebo|O
S2281|occurred|O
S2281|in|O
S2281|the|O
S2281|lowest|O
S2281|dose|O
S2281|arm|O
S2281|(|O
S2281|150|O
S2281|mg|O
S2281|Q|O
S2281|)|O
S2281|,|O
S2281|but|O
S2281|no|O
S2281|meaningful|O
S2281|improvements|O
S2281|were|O
S2281|observed|O
S2281|in|O
S2281|the|O
S2281|higher|O
S2281|dose|O
S2281|arms|O
S2281|(|O
S2281|450|O
S2281|mg|O
S2281|Q|O
S2281|and|O
S2281|300|O
S2281|mg|O
S2281|M|O
S2281|)|O
S2281|.|O
S2247|For|O
S2247|secondary|O
S2247|and|O
S2247|exploratory|O
S2247|end|O
S2247|points|O
S2247|,|O
S2247|the|O
S2247|means|O
S2247|and|O
S2247|standard|O
S2247|deviations|O
S2247|of|O
S2247|all|O
S2247|values|O
S2247|for|O
S2247|relative|O
S2247|change|O
S2247|were|O
S2247|calculated|O
S2247|according|O
S2247|to|O
S2247|study|O
S2247|group|O
S2247|at|O
S2247|Weeks|O
S2247|12|O
S2247|and|O
S2247|36|O
S2247|.|O
S2264|Pharmacokinetics|O
S2264|Quilizumab|O
S2264|displayed|O
S2264|linear|O
S2264|pharmacokinetics|O
S2264|with|O
S2264|a|O
S2264|dose-proportional|O
S2264|increase|O
S2264|in|O
S2264|exposure|O
S2264|as|O
S2264|shown|O
S2264|by|O
S2264|increases|O
S2264|in|O
S2264|Cmax|O
S2264|values|O
S2264|between|O
S2264|the|O
S2264|150|O
S2264|and|O
S2264|450|O
S2264|mg|O
S2264|Q|O
S2264|doses|O
S2264|at|O
S2264|Weeks|O
S2264|5|O
S2264|and|O
S2264|25|O
S2264|.|O
S2237|Serum|O
S2237|periostin|O
S2237|was|O
S2237|measured|O
S2237|by|O
S2237|immunoassay|O
S2237|using|O
S2237|the|O
S2237|Roche|O
S2237|Elecsys|O
S2237|platform|O
S2237|(|O
S2237|Roche|O
S2237|Diagnostics|O
S2237|Ltd.|O
S2237|,|O
S2237|Rotkreuz|O
S2237|,|O
S2237|Switzerland|O
S2237|)|O
S2237|.|O
S2248|The|O
S2248|mean|O
S2248|relative|O
S2248|changes|O
S2248|from|O
S2248|baseline|O
S2248|were|O
S2248|compared|O
S2248|between|O
S2248|the|O
S2248|study|O
S2248|groups|O
S2248|using|O
S2248|the|O
S2248|differences|O
S2248|between|O
S2248|the|O
S2248|means|O
S2248|for|O
S2248|each|O
S2248|group|O
S2248|,|O
S2248|with|O
S2248|the|O
S2248|associated|O
S2248|two-sided|O
S2248|90|O
S2248|%|O
S2248|CIs|O
S2248|.|O
S2269|Pharmacodynamic|O
S2269|biomarkers|O
S2269|Quilizumab|O
S2269|gradually|O
S2269|reduced|O
S2269|mean|O
S2269|serum|O
S2269|total|O
S2269|and|O
S2269|allergen-specific|O
S2269|IgE|O
S2269|,|O
S2269|reaching|O
S2269|a|O
S2269|30–40|O
S2269|%|O
S2269|reduction|O
S2269|at|O
S2269|Week|O
S2269|36|O
S2269|in|O
S2269|all|O
S2269|three|O
S2269|quilizumab|O
S2269|cohorts|O
S2269|(|O
S2269|p|O
S2269|<|O
S2269|0.01|O
S2269|compared|O
S2269|to|O
S2269|placebo|O
S2269|;|O
S2269|Fig|O
S2269|.|O
S2279|Lung|O
S2279|function|O
S2279|No|O
S2279|significant|O
S2279|evidence|O
S2279|of|O
S2279|improved|O
S2279|FEV1|O
S2279|at|O
S2279|Weeks|O
S2279|12|O
S2279|and|O
S2279|36|O
S2279|was|O
S2279|observed|O
S2279|in|O
S2279|quilizumab-treated|O
S2279|patients|O
S2279|compared|O
S2279|to|O
S2279|placebo|O
S2279|(|O
S2279|Fig|O
S2279|.|O
S2252|This|O
S2252|sample|O
S2252|size|O
S2252|provided|O
S2252|approximately|O
S2252|84|B-Sample_Size_Calculation_Power_Value
S2252|%|I-Sample_Size_Calculation_Power_Value
S2252|power|O
S2252|to|O
S2252|detect|O
S2252|a|O
S2252|50|O
S2252|%|O
S2252|reduction|O
S2252|in|O
S2252|average|O
S2252|exacerbation|O
S2252|rates|O
S2252|due|O
S2252|to|O
S2252|quilizumab|O
S2252|,|O
S2252|assuming|O
S2252|0.63|O
S2252|exacerbations|O
S2252|per|O
S2252|patient|O
S2252|in|O
S2252|the|O
S2252|placebo|O
S2252|group|O
S2252|over|O
S2252|a|O
S2252|36-week|O
S2252|treatment|O
S2252|period|O
S2252|,|O
S2252|and|O
S2252|a|O
S2252|significance|O
S2252|level|O
S2252|of|O
S2252|α|O
S2252|=|O
S2252|0.10|B-Sample_Size_Calculation_Alpha_Value
S2252|.|O
S2241|The|O
S2241|primary|O
S2241|endpoint|O
S2241|,|O
S2241|the|O
S2241|annualized|O
S2241|exacerbation|O
S2241|rate|O
S2241|,|O
S2241|was|O
S2241|calculated|O
S2241|by|O
S2241|the|O
S2241|total|O
S2241|number|O
S2241|of|O
S2241|protocol-defined|O
S2241|exacerbations|O
S2241|observed|O
S2241|in|O
S2241|the|O
S2241|group|O
S2241|over|O
S2241|the|O
S2241|treatment|O
S2241|period|O
S2241|divided|O
S2241|by|O
S2241|total|O
S2241|patient-weeks|O
S2241|at|O
S2241|risk|O
S2241|(|O
S2241|number|O
S2241|of|O
S2241|weeks|O
S2241|from|O
S2241|first|O
S2241|study|O
S2241|drug|O
S2241|administration|O
S2241|to|O
S2241|the|O
S2241|earliest|O
S2241|of|O
S2241|Week|O
S2241|36|O
S2241|or|O
S2241|study|O
S2241|discontinuation|O
S2241|)|O
S2241|for|O
S2241|the|O
S2241|group|O
S2241|and|O
S2241|multiplied|O
S2241|by|O
S2241|52|O
S2241|.|O
S2212|Ethics|O
S2212|,|O
S2212|consent|O
S2212|,|O
S2212|and|O
S2212|permissions|O
S2212|Quorum|O
S2212|Review|O
S2212|based|O
S2212|in|O
S2212|Seattle|O
S2212|,|O
S2212|WA|O
S2212|was|O
S2212|the|O
S2212|primary|O
S2212|central|O
S2212|IRB|O
S2212|used|O
S2212|by|O
S2212|sites|O
S2212|in|O
S2212|North|O
S2212|America|O
S2212|,|O
S2212|however|O
S2212|multiple|O
S2212|other|O
S2212|site-specific|O
S2212|institutional|O
S2212|review|O
S2212|boards|O
S2212|at|O
S2212|other|O
S2212|global|O
S2212|sites|O
S2212|approved|O
S2212|the|O
S2212|protocol|O
S2212|and|O
S2212|patients|O
S2212|gave|O
S2212|written|O
S2212|,|O
S2212|informed|O
S2212|consent|O
S2212|.|O
S2213|The|O
S2213|trial|O
S2213|was|O
S2213|conducted|O
S2213|in|O
S2213|full|O
S2213|conformance|O
S2213|with|O
S2213|the|O
S2213|International|O
S2213|Conference|O
S2213|on|O
S2213|Harmonisation|O
S2213|E6|O
S2213|guidelines|O
S2213|and|O
S2213|the|O
S2213|Declaration|O
S2213|of|O
S2213|Helsinki|O
S2213|,|O
S2213|or|O
S2213|laws|O
S2213|and|O
S2213|regulations|O
S2213|of|O
S2213|the|O
S2213|country|O
S2213|where|O
S2213|the|O
S2213|research|O
S2213|was|O
S2213|conducted|O
S2213|,|O
S2213|whichever|O
S2213|afforded|O
S2213|greater|O
S2213|protection|O
S2213|to|O
S2213|the|O
S2213|individual|O
S2213|.|O
S2219|The|O
S2219|diary|O
S2219|was|O
S2219|also|O
S2219|used|O
S2219|to|O
S2219|determine|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|who|O
S2219|had|O
S2219|no|O
S2219|nighttime|O
S2219|awakenings|O
S2219|due|O
S2219|to|O
S2219|asthma|O
S2219|symptoms|O
S2219|and|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|with|O
S2219|fewer|O
S2219|than|O
S2219|2|O
S2219|days|O
S2219|of|O
S2219|SABA|O
S2219|use|O
S2219|per|O
S2219|week|O
S2219|by|O
S2219|Week|O
S2219|36|O
S2219|.|O
S2244|For|O
S2244|biomarker|O
S2244|subgroup|O
S2244|analyses|O
S2244|,|O
S2244|unadjusted|O
S2244|asthma|O
S2244|exacerbation|O
S2244|rates|O
S2244|were|O
S2244|calculated|O
S2244|.|O
S2211|The|O
S2211|treatment|O
S2211|period|O
S2211|ended|O
S2211|36|O
S2211|weeks|O
S2211|after|O
S2211|randomization|O
S2211|and|O
S2211|was|O
S2211|followed|O
S2211|by|O
S2211|a|O
S2211|48-week|O
S2211|period|O
S2211|to|O
S2211|assess|O
S2211|the|O
S2211|sustained|O
S2211|efficacy|O
S2211|and|O
S2211|safety|O
S2211|of|O
S2211|quilizumab|O
S2211|(|O
S2211|see|O
S2211|Additional|O
S2211|file|O
S2211|1|O
S2211|:|O
S2211|Figure|O
S2211|S1|O
S2211|)|O
S2211|.|O
S2238|Fractional|O
S2238|exhaled|O
S2238|nitric|O
S2238|oxide|O
S2238|(|O
S2238|FeNO|O
S2238|)|O
S2238|was|O
S2238|measured|O
S2238|using|O
S2238|a|O
S2238|hand-held|O
S2238|portable|O
S2238|device|O
S2238|,|O
S2238|NIOX|O
S2238|MINO®|O
S2238|(|O
S2238|Niox|O
S2238|;|O
S2238|Morrisville|O
S2238|,|O
S2238|NC|O
S2238|)|O
S2238|,|O
S2238|according|O
S2238|to|O
S2238|American|O
S2238|Thoracic|O
S2238|Society/European|O
S2238|Respiratory|O
S2238|Society|O
S2238|2009|O
S2238|guidelines|O
S2238|.|O
S2271|The|O
S2271|largest|O
S2271|decreases|O
S2271|in|O
S2271|total|O
S2271|and|O
S2271|allergen-specific|O
S2271|IgE|O
S2271|were|O
S2271|observed|O
S2271|at|O
S2271|Week|O
S2271|42|O
S2271|in|O
S2271|the|O
S2271|300|O
S2271|mg|O
S2271|M|O
S2271|treatment|O
S2271|cohort|O
S2271|.|O
S2225|The|O
S2225|modified|O
S2225|total|O
S2225|asthma|O
S2225|symptom|O
S2225|score|O
S2225|(|O
S2225|mTASS|O
S2225|)|O
S2225|was|O
S2225|generated|O
S2225|from|O
S2225|a|O
S2225|subset|O
S2225|of|O
S2225|diary|O
S2225|questions|O
S2225|adapted|O
S2225|from|O
S2225|a|O
S2225|previous|O
S2225|questionnaire|O
S2225|,|O
S2225|scoring|O
S2225|nighttime|O
S2225|awakenings|O
S2225|(|O
S2225|0–3|O
S2225|)|O
S2225|,|O
S2225|symptoms|O
S2225|on|O
S2225|awakening|O
S2225|(|O
S2225|0–1|O
S2225|)|O
S2225|,|O
S2225|and|O
S2225|daytime|O
S2225|symptom|O
S2225|severity|O
S2225|(|O
S2225|0–4|O
S2225|)|O
S2225|,|O
S2225|for|O
S2225|a|O
S2225|total|O
S2225|score|O
S2225|range|O
S2225|of|O
S2225|0–8|O
S2225|.|O
S2261|The|O
S2261|treatment-emergent|O
S2261|ATA|O
S2261|rate|O
S2261|was|O
S2261|1.4|O
S2261|%|O
S2261|in|O
S2261|both|O
S2261|the|O
S2261|150|O
S2261|mg|O
S2261|Q|O
S2261|and|O
S2261|300|O
S2261|mg|O
S2261|M|O
S2261|groups|O
S2261|,|O
S2261|and|O
S2261|2.1|O
S2261|%|O
S2261|in|O
S2261|the|O
S2261|450|O
S2261|mg|O
S2261|Q|O
S2261|group|O
S2261|.|O
S2253|This|O
S2253|sample|O
S2253|size|O
S2253|also|O
S2253|provided|O
S2253|approximately|O
S2253|70|B-Sample_Size_Calculation_Power_Value
S2253|%|I-Sample_Size_Calculation_Power_Value
S2253|power|O
S2253|to|O
S2253|detect|O
S2253|a|O
S2253|50|O
S2253|%|O
S2253|reduction|O
S2253|in|O
S2253|average|O
S2253|exacerbation|O
S2253|rates|O
S2253|in|O
S2253|the|O
S2253|subgroup|O
S2253|of|O
S2253|periostin-high|O
S2253|patients|O
S2253|,|O
S2253|assuming|O
S2253|0.69|O
S2253|exacerbations|O
S2253|per|O
S2253|patient|O
S2253|in|O
S2253|the|O
S2253|placebo|O
S2253|group|O
S2253|over|O
S2253|the|O
S2253|36-week|O
S2253|period|O
S2253|,|O
S2253|a|O
S2253|significance|O
S2253|level|O
S2253|of|O
S2253|0.15|B-Sample_Size_Calculation_Alpha_Value
S2253|,|O
S2253|and|O
S2253|50|O
S2253|%|O
S2253|of|O
S2253|patients|O
S2253|in|O
S2253|each|O
S2253|treatment|O
S2253|arm|O
S2253|to|O
S2253|be|O
S2253|periostin|O
S2253|high|O
S2253|.|O
S2265|(|O
S2265|see|O
S2265|Additional|O
S2265|file|O
S2265|1|O
S2265|:|O
S2265|Figure|O
S2265|S2|O
S2265|)|O
S2265|.|O
S2207|Patients|O
S2207|were|O
S2207|randomly|O
S2207|assigned|O
S2207|(|O
S2207|1:1:1:1|B-Randomization_Ratio
S2207|)|O
S2207|to|O
S2207|one|B-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|three|I-Design_Parallel_Group
S2207|dosing|I-Design_Parallel_Group
S2207|regimens|I-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|quilizumab|I-Design_Parallel_Group
S2207|or|I-Design_Parallel_Group
S2207|placebo|I-Design_Parallel_Group
S2207|using|O
S2207|an|B-Randomization_Sequence_Generation_Method
S2207|interactive|I-Randomization_Sequence_Generation_Method
S2207|web|I-Randomization_Sequence_Generation_Method
S2207|response|I-Randomization_Sequence_Generation_Method
S2207|system|I-Randomization_Sequence_Generation_Method
S2207|.|O
S2286|Treatment|O
S2286|with|O
S2286|quilizumab|O
S2286|failed|O
S2286|to|O
S2286|increase|O
S2286|either|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|used|O
S2286|a|O
S2286|SABA|O
S2286|for|O
S2286|fewer|O
S2286|than|O
S2286|2|O
S2286|days|O
S2286|in|O
S2286|the|O
S2286|prior|O
S2286|week|O
S2286|or|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|did|O
S2286|not|O
S2286|awaken|O
S2286|at|O
S2286|night|O
S2286|due|O
S2286|to|O
S2286|asthma|O
S2286|symptoms|O
S2286|for|O
S2286|all|O
S2286|dosing|O
S2286|levels|O
S2286|relative|O
S2286|to|O
S2286|the|O
S2286|placebo|O
S2286|group|O
S2286|at|O
S2286|Week|O
S2286|36|O
S2286|(|O
S2286|Table|O
S2286|3|O
S2286|)|O
S2286|.|O
S2251|Sample|O
S2251|size|O
S2251|determination|O
S2251|We|O
S2251|planned|O
S2251|to|O
S2251|randomize|O
S2251|560|B-Sample_Size_Required
S2251|patients|O
S2251|to|O
S2251|one|O
S2251|of|O
S2251|three|O
S2251|dose|I-Design_Parallel_Group
S2251|regimens|I-Design_Parallel_Group
S2251|of|I-Design_Parallel_Group
S2251|quilizumab|I-Design_Parallel_Group
S2251|or|I-Design_Parallel_Group
S2251|placebo|I-Design_Parallel_Group
S2251|in|O
S2251|a|O
S2251|1:1:1:1|B-Randomization_Ratio
S2251|ratio|O
S2251|(|O
S2251|140|O
S2251|patients|O
S2251|per|O
S2251|group|O
S2251|)|O
S2251|.|O
S2242|For|O
S2242|patients|O
S2242|who|O
S2242|discontinued|O
S2242|the|O
S2242|study|O
S2242|prematurely|O
S2242|,|O
S2242|there|O
S2242|was|O
S2242|no|O
S2242|imputation|O
S2242|of|O
S2242|additional|O
S2242|exacerbations|O
S2242|.|O
S2263|There|O
S2263|was|O
S2263|no|O
S2263|apparent|O
S2263|impact|O
S2263|of|O
S2263|positive|O
S2263|ATA|O
S2263|results|O
S2263|on|O
S2263|either|O
S2263|pharmacokinetic|O
S2263|profiles|O
S2263|or|O
S2263|safety|O
S2263|.|O
S2250|An|O
S2250|analysis|O
S2250|of|O
S2250|covariance|O
S2250|(|O
S2250|ANCOVA|O
S2250|)|O
S2250|model|O
S2250|with|O
S2250|factors|O
S2250|for|O
S2250|baseline|O
S2250|level|O
S2250|,|O
S2250|periostin|O
S2250|status|O
S2250|(|O
S2250|<|O
S2250|50|O
S2250|ng/mL|O
S2250|,|O
S2250|≥50|O
S2250|ng/mL|O
S2250|)|O
S2250|,|O
S2250|number|O
S2250|of|O
S2250|prior|O
S2250|exacerbations|O
S2250|(|O
S2250|1|O
S2250|,|O
S2250|>|O
S2250|1|O
S2250|)|O
S2250|,|O
S2250|and|O
S2250|IgE|O
S2250|level|O
S2250|(|O
S2250|<|O
S2250|200|O
S2250|IU/mL|O
S2250|,|O
S2250|≥200|O
S2250|IU/mL|O
S2250|)|O
S2250|was|O
S2250|fit|O
S2250|to|O
S2250|assess|O
S2250|the|O
S2250|treatment|O
S2250|effect|O
S2250|.|O
S2272|Serum|O
S2272|total|O
S2272|and|O
S2272|allergen-specific|O
S2272|IgE|O
S2272|in|O
S2272|quilizumab-treated|O
S2272|patients|O
S2272|gradually|O
S2272|increased|O
S2272|throughout|O
S2272|the|O
S2272|safety|O
S2272|follow-up|O
S2272|period|O
S2272|,|O
S2272|but|O
S2272|did|O
S2272|not|O
S2272|return|O
S2272|to|O
S2272|pre-dose|O
S2272|levels|O
S2272|by|O
S2272|the|O
S2272|end|O
S2272|of|O
S2272|the|O
S2272|study|O
S2272|period|O
S2272|(|O
S2272|Week|O
S2272|84|O
S2272|)|O
S2272|.|O
S2230|Serum|O
S2230|anti-therapeutic|O
S2230|antibodies|O
S2230|(|O
S2230|ATAs|O
S2230|)|O
S2230|were|O
S2230|assessed|O
S2230|in|O
S2230|samples|O
S2230|at|O
S2230|Weeks|O
S2230|0|O
S2230|,|O
S2230|4|O
S2230|,|O
S2230|12|O
S2230|,|O
S2230|24|O
S2230|,|O
S2230|36|O
S2230|,|O
S2230|48|O
S2230|,|O
S2230|60|O
S2230|,|O
S2230|and|O
S2230|84|O
S2230|using|O
S2230|a|O
S2230|validated|O
S2230|bridging|O
S2230|ELISA|O
S2230|(|O
S2230|Genentech|O
S2230|,|O
S2230|Inc.|O
S2230|,|O
S2230|South|O
S2230|San|O
S2230|Francisco|O
S2230|,|O
S2230|CA|O
S2230|)|O
S2230|.|O
S2223|Safety|O
S2223|outcomes|O
S2223|were|O
S2223|assessed|O
S2223|throughout|O
S2223|the|O
S2223|36-week|O
S2223|treatment|O
S2223|and|O
S2223|48-week|O
S2223|follow-up|O
S2223|periods|O
S2223|.|O
S2268|Based|O
S2268|on|O
S2268|non-compartmental|O
S2268|analysis|O
S2268|,|O
S2268|the|O
S2268|mean|O
S2268|t1/2|O
S2268|values|O
S2268|of|O
S2268|quilizumab|O
S2268|across|O
S2268|the|O
S2268|dose|O
S2268|groups|O
S2268|ranged|O
S2268|from|O
S2268|16.4|O
S2268|to|O
S2268|18.7|O
S2268|days|O
S2268|,|O
S2268|which|O
S2268|suggests|O
S2268|that|O
S2268|steady-state|O
S2268|was|O
S2268|attained|O
S2268|by|O
S2268|the|O
S2268|time|O
S2268|the|O
S2268|final|O
S2268|doses|O
S2268|were|O
S2268|administered|O
S2268|for|O
S2268|both|O
S2268|monthly|O
S2268|and|O
S2268|quarterly|O
S2268|regimens|O
S2268|.|O
S2278|4|O
S2278|)|O
S2278|.|O
S2215|Asthma|O
S2215|exacerbations|O
S2215|were|O
S2215|defined|O
S2215|as|O
S2215|new|O
S2215|or|O
S2215|increased|O
S2215|asthma|O
S2215|symptoms|O
S2215|(|O
S2215|wheezing|O
S2215|,|O
S2215|cough|O
S2215|,|O
S2215|chest|O
S2215|tightness|O
S2215|,|O
S2215|shortness|O
S2215|of|O
S2215|breath|O
S2215|,|O
S2215|or|O
S2215|nighttime|O
S2215|awakening|O
S2215|due|O
S2215|to|O
S2215|symptoms|O
S2215|)|O
S2215|that|O
S2215|led|O
S2215|to|O
S2215|treatment|O
S2215|with|O
S2215|systemic|O
S2215|corticosteroids|O
S2215|for|O
S2215|at|O
S2215|least|O
S2215|3|O
S2215|days|O
S2215|or|O
S2215|to|O
S2215|hospitalization|O
S2215|.|O
S2236|Peripheral|O
S2236|blood|O
S2236|eosinophil|O
S2236|counts|O
S2236|were|O
S2236|obtained|O
S2236|from|O
S2236|standard|O
S2236|complete|O
S2236|blood|O
S2236|counts|O
S2236|.|O
S2256|There|O
S2256|were|O
S2256|no|O
S2256|major|O
S2256|imbalances|O
S2256|between|O
S2256|treatment|O
S2256|groups|O
S2256|,|O
S2256|but|O
S2256|the|O
S2256|300|O
S2256|mg|O
S2256|monthly|O
S2256|quilizumab|O
S2256|group|O
S2256|had|O
S2256|a|O
S2256|lower|O
S2256|mean|O
S2256|age|O
S2256|(|O
S2256|45|O
S2256|versus|O
S2256|47–48|O
S2256|years|O
S2256|)|O
S2256|and|O
S2256|a|O
S2256|lower|O
S2256|median|O
S2256|IgE|O
S2256|level|O
S2256|(|O
S2256|190|O
S2256|versus|O
S2256|234–254|O
S2256|IU/mL|O
S2256|)|O
S2256|compared|O
S2256|to|O
S2256|the|O
S2256|other|O
S2256|treatment|O
S2256|arms|O
S2256|(|O
S2256|Table|O
S2256|1|O
S2256|)|O
S2256|.|O
S2259|Safety|O
S2259|Quilizumab|O
S2259|was|O
S2259|well|O
S2259|tolerated|O
S2259|,|O
S2259|and|O
S2259|the|O
S2259|number|O
S2259|of|O
S2259|patients|O
S2259|experiencing|O
S2259|at|O
S2259|least|O
S2259|one|O
S2259|adverse|O
S2259|event|O
S2259|(|O
S2259|AE|O
S2259|)|O
S2259|was|O
S2259|comparable|O
S2259|between|O
S2259|all|O
S2259|treatment|O
S2259|groups|O
S2259|(|O
S2259|Table|O
S2259|2|O
S2259|)|O
S2259|.|O
S2232|Allergen-specific|O
S2232|and|O
S2232|total|O
S2232|IgE|O
S2232|were|O
S2232|measured|O
S2232|in|O
S2232|serum|O
S2232|by|O
S2232|ImmunoCAP®|O
S2232|Specific|O
S2232|IgE|O
S2232|blood|O
S2232|tests|O
S2232|(|O
S2232|ViraCor-IBT|O
S2232|Laboratories|O
S2232|,|O
S2232|Lee|O
S2232|’|O
S2232|s|O
S2232|Summit|O
S2232|,|O
S2232|MO|O
S2232|)|O
S2232|.|O
S2227|Baseline|O
S2227|values|O
S2227|were|O
S2227|derived|O
S2227|from|O
S2227|a|O
S2227|minimum|O
S2227|of|O
S2227|10|O
S2227|days|O
S2227|of|O
S2227|patient|O
S2227|diary|O
S2227|entries|O
S2227|during|O
S2227|the|O
S2227|14|O
S2227|days|O
S2227|prior|O
S2227|to|O
S2227|the|O
S2227|first|O
S2227|treatment|O
S2227|.|O
S2260|Through|O
S2260|Week|O
S2260|36|O
S2260|,|O
S2260|the|O
S2260|most|O
S2260|frequent|O
S2260|AEs|O
S2260|across|O
S2260|all|O
S2260|quilizumab|O
S2260|dose|O
S2260|groups|O
S2260|were|O
S2260|worsening|O
S2260|of|O
S2260|asthma|O
S2260|(|O
S2260|27|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|nasopharyngitis|O
S2260|(|O
S2260|15|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|upper|O
S2260|respiratory|O
S2260|tract|O
S2260|infection|O
S2260|(|O
S2260|7|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|bronchitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|sinusitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|and|O
S2260|injection|O
S2260|site|O
S2260|pain|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|.|O
S2280|5|O
S2280|)|O
S2280|.|O
S2246|The|O
S2246|relative|O
S2246|change|O
S2246|in|O
S2246|pre-bronchodilator|O
S2246|FEV1|O
S2246|from|O
S2246|baseline|O
S2246|was|O
S2246|calculated|O
S2246|as|O
S2246|the|O
S2246|absolute|O
S2246|change|O
S2246|in|O
S2246|FEV1|O
S2246|(|O
S2246|volume|O
S2246|in|O
S2246|liters|O
S2246|)|O
S2246|from|O
S2246|baseline|O
S2246|divided|O
S2246|by|O
S2246|the|O
S2246|FEV1|O
S2246|at|O
S2246|baseline|O
S2246|.|O
S2273|Peripheral|O
S2273|blood|O
S2273|eosinophils|O
S2273|and|O
S2273|FeNO|O
S2273|levels|O
S2273|were|O
S2273|not|O
S2273|modified|O
S2273|following|O
S2273|quilizumab|O
S2273|treatment|O
S2273|(|O
S2273|see|O
S2273|Additional|O
S2273|file|O
S2273|1|O
S2273|:|O
S2273|Figure|O
S2273|S3|O
S2273|)|O
S2273|.|O
S2243|The|O
S2243|rates|O
S2243|of|O
S2243|asthma|O
S2243|exacerbations|O
S2243|were|O
S2243|compared|O
S2243|between|O
S2243|study|O
S2243|groups|O
S2243|using|O
S2243|a|O
S2243|Poisson|O
S2243|regression|O
S2243|with|O
S2243|overdispersion|O
S2243|model|O
S2243|,|O
S2243|including|O
S2243|terms|O
S2243|for|O
S2243|periostin|O
S2243|status|O
S2243|(|O
S2243|<|O
S2243|50|O
S2243|,|O
S2243|≥50|O
S2243|ng/mL|O
S2243|)|O
S2243|,|O
S2243|number|O
S2243|of|O
S2243|prior|O
S2243|exacerbations|O
S2243|(|O
S2243|1|O
S2243|,|O
S2243|>|O
S2243|1|O
S2243|)|O
S2243|,|O
S2243|and|O
S2243|IgE|O
S2243|level|O
S2243|(|O
S2243|<|O
S2243|200|O
S2243|,|O
S2243|≥200|O
S2243|IU/mL|O
S2243|)|O
S2243|.|O
S2216|Exclusion|O
S2216|criteria|O
S2216|Patients|O
S2216|were|O
S2216|excluded|O
S2216|from|O
S2216|the|O
S2216|study|O
S2216|if|O
S2216|they|O
S2216|had|O
S2216|an|O
S2216|asthma|O
S2216|exacerbation|O
S2216|requiring|O
S2216|systemic|O
S2216|steroids|O
S2216|in|O
S2216|the|O
S2216|30|O
S2216|days|O
S2216|prior|O
S2216|to|O
S2216|screening|O
S2216|,|O
S2216|or|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|a|O
S2216|>|O
S2216|20|O
S2216|%|O
S2216|relative|O
S2216|change|O
S2216|in|O
S2216|FEV1|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|any|O
S2216|pre-existing|O
S2216|active|O
S2216|lung|O
S2216|disease|O
S2216|other|O
S2216|than|O
S2216|asthma|O
S2216|,|O
S2216|any|O
S2216|infections|O
S2216|,|O
S2216|elevated|O
S2216|IgE|O
S2216|levels|O
S2216|for|O
S2216|reasons|O
S2216|other|O
S2216|than|O
S2216|allergy|O
S2216|,|O
S2216|or|O
S2216|were|O
S2216|former|O
S2216|or|O
S2216|current|O
S2216|smokers|O
S2216|.|O
S2270|2|O
S2270|)|O
S2270|.|O
S2231|Biomarkers|O
S2231|Samples|O
S2231|for|O
S2231|biomarker|O
S2231|assessments|O
S2231|were|O
S2231|collected|O
S2231|throughout|O
S2231|the|O
S2231|study|O
S2231|.|O
S2254|Results|O
S2254|Patient|O
S2254|demographics|O
S2254|and|O
S2254|study|O
S2254|flow|O
S2254|1212|O
S2254|patients|O
S2254|were|O
S2254|screened|O
S2254|for|O
S2254|eligibility|O
S2254|and|O
S2254|578|B-Sample_Size_Actual_at_Enrollment
S2254|adult|O
S2254|asthma|O
S2254|patients|O
S2254|(|O
S2254|18–75|O
S2254|years|O
S2254|old|O
S2254|)|O
S2254|were|O
S2254|enrolled|O
S2254|(|O
S2254|Fig|O
S2254|.|O
S2226|For|O
S2226|the|O
S2226|analyses|O
S2226|of|O
S2226|symptom|O
S2226|scores|O
S2226|,|O
S2226|rescue|O
S2226|medication|O
S2226|use|O
S2226|,|O
S2226|and|O
S2226|nighttime|O
S2226|awakenings|O
S2226|,|O
S2226|daily|O
S2226|scores|O
S2226|were|O
S2226|averaged|O
S2226|over|O
S2226|the|O
S2226|previous|O
S2226|7|O
S2226|days|O
S2226|prior|O
S2226|to|O
S2226|the|O
S2226|time|O
S2226|point|O
S2226|of|O
S2226|interest|O
S2226|.|O
S2255|1|O
S2255|)|O
S2255|from|O
S2255|April|O
S2255|2012|O
S2255|to|O
S2255|September|O
S2255|2013|O
S2255|;|O
S2255|the|O
S2255|study|O
S2255|was|O
S2255|completed|O
S2255|in|O
S2255|November|O
S2255|2014|O
S2255|.|O
S2218|Secondary|O
S2218|efficacy|O
S2218|outcomes|O
S2218|included|O
S2218|assessments|O
S2218|of|O
S2218|lung|O
S2218|function|O
S2218|using|O
S2218|the|O
S2218|relative|O
S2218|change|O
S2218|in|O
S2218|pre-bronchodilator|O
S2218|FEV1|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Weeks|O
S2218|12|O
S2218|and|O
S2218|36|O
S2218|and|O
S2218|the|O
S2218|change|O
S2218|in|O
S2218|asthma|O
S2218|symptoms|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Week|O
S2218|36|O
S2218|,|O
S2218|using|O
S2218|total|O
S2218|and|O
S2218|daytime|O
S2218|symptom|O
S2218|severity|O
S2218|scores|O
S2218|derived|O
S2218|from|O
S2218|a|O
S2218|daily|O
S2218|patient|O
S2218|diary|O
S2218|.|O
S2258|The|O
S2258|sponsor|O
S2258|terminated|O
S2258|the|O
S2258|trial|O
S2258|early|O
S2258|because|O
S2258|of|O
S2258|the|O
S2258|lack|O
S2258|of|O
S2258|efficacy|O
S2258|for|O
S2258|the|O
S2258|primary|O
S2258|end-point|O
S2258|(|O
S2258|asthma|O
S2258|exacerbations|O
S2258|)|O
S2258|at|O
S2258|Week|O
S2258|36|O
S2258|,|O
S2258|with|O
S2258|the|O
S2258|median|O
S2258|time|O
S2258|in|O
S2258|the|O
S2258|study|O
S2258|at|O
S2258|72|O
S2258|weeks|O
S2258|.|O
S2275|In|O
S2275|the|O
S2275|ITT|O
S2275|population|O
S2275|,|O
S2275|the|O
S2275|reduction|O
S2275|in|O
S2275|the|O
S2275|asthma|O
S2275|exacerbation|O
S2275|rate|O
S2275|relative|O
S2275|to|O
S2275|placebo|O
S2275|was|O
S2275|19.6|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−21|O
S2275|to|O
S2275|47|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.38|O
S2275|)|O
S2275|,|O
S2275|−11.2|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−63|O
S2275|to|O
S2275|24|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.65|O
S2275|)|O
S2275|,|O
S2275|and|O
S2275|−5.7|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−55|O
S2275|to|O
S2275|28|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.81|O
S2275|)|O
S2275|in|O
S2275|the|O
S2275|300|O
S2275|mg|O
S2275|M|O
S2275|,|O
S2275|450|O
S2275|mg|O
S2275|Q|O
S2275|,|O
S2275|and|O
S2275|150|O
S2275|mg|O
S2275|Q|O
S2275|quilizumab|O
S2275|treatment|O
S2275|arms|O
S2275|,|O
S2275|respectively|O
S2275|(|O
S2275|Fig|O
S2275|.|O
S2285|Patient-reported|O
S2285|outcomes|O
S2285|During|O
S2285|the|O
S2285|36-week|O
S2285|treatment|O
S2285|period|O
S2285|,|O
S2285|no|O
S2285|meaningful|O
S2285|differences|O
S2285|were|O
S2285|observed|O
S2285|between|O
S2285|the|O
S2285|quilizumab|O
S2285|dose|O
S2285|groups|O
S2285|compared|O
S2285|with|O
S2285|the|O
S2285|placebo|O
S2285|group|O
S2285|for|O
S2285|the|O
S2285|total|O
S2285|mTASS|O
S2285|,|O
S2285|daytime|O
S2285|mTASS|O
S2285|,|O
S2285|ACQ-5|O
S2285|,|O
S2285|AQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|,|O
S2285|or|O
S2285|RQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|scores|O
S2285|(|O
S2285|Table|O
S2285|3|O
S2285|)|O
S2285|.|O
S2229|The|O
S2229|pharmacokinetic|O
S2229|outcomes|O
S2229|included|O
S2229|:|O
S2229|serum|O
S2229|concentrations|O
S2229|prior|O
S2229|to|O
S2229|dosing|O
S2229|at|O
S2229|Weeks|O
S2229|0|O
S2229|,|O
S2229|4|O
S2229|,|O
S2229|12|O
S2229|,|O
S2229|24|O
S2229|,|O
S2229|and|O
S2229|32|O
S2229|;|O
S2229|serum|O
S2229|concentrations|O
S2229|at|O
S2229|Week|O
S2229|5|O
S2229|and|O
S2229|Week|O
S2229|25|O
S2229|;|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentrations|O
S2229|(|O
S2229|Cmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|time|O
S2229|of|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentration|O
S2229|(|O
S2229|Tmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|and|O
S2229|terminal|O
S2229|elimination|O
S2229|half-life|O
S2229|(|O
S2229|t1/2|O
S2229|)|O
S2229|.|O
S2284|Analysis|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|biomarker|O
S2284|subgroups|O
S2284|demonstrated|O
S2284|no|O
S2284|consistent|O
S2284|or|O
S2284|meaningful|O
S2284|improvements|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|quilizumab-treated|O
S2284|arms|O
S2284|over|O
S2284|placebo|O
S2284|(|O
S2284|see|O
S2284|Additional|O
S2284|file|O
S2284|2|O
S2284|:|O
S2284|Table|O
S2284|S1|O
S2284|and|O
S2284|Additional|O
S2284|file|O
S2284|3|O
S2284|:|O
S2284|Table|O
S2284|S2|O
S2284|)|O
S2284|.|O
S2228|Pharmacokinetics|O
S2228|and|O
S2228|immunogenicity|O
S2228|Serum|O
S2228|levels|O
S2228|of|O
S2228|quilizumab|O
S2228|for|O
S2228|pharmacokinetic|O
S2228|assessments|O
S2228|were|O
S2228|measured|O
S2228|using|O
S2228|a|O
S2228|validated|O
S2228|enzyme-linked|O
S2228|immunosorbent|O
S2228|assay|O
S2228|(|O
S2228|ELISA|O
S2228|;|O
S2228|Genentech|O
S2228|,|O
S2228|Inc.|O
S2228|,|O
S2228|South|O
S2228|San|O
S2228|Francisco|O
S2228|,|O
S2228|CA|O
S2228|)|O
S2228|.|O
S2262|ATA|O
S2262|incidence|O
S2262|for|O
S2262|all|O
S2262|dosing|O
S2262|groups|O
S2262|was|O
S2262|1.6|O
S2262|%|O
S2262|(|O
S2262|7|O
S2262|of|O
S2262|427|O
S2262|quilizumab-dosed|O
S2262|patients|O
S2262|)|O
S2262|.|O
S2283|5|O
S2283|;|O
S2283|see|O
S2283|Additional|O
S2283|file|O
S2283|2|O
S2283|:|O
S2283|Table|O
S2283|S1|O
S2283|and|O
S2283|Additional|O
S2283|file|O
S2283|3|O
S2283|:|O
S2283|Table|O
S2283|S2|O
S2283|)|O
S2283|.|O
S2257|89|B-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|384/433|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|quilizumab|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|and|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|91|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|132/145|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|completed|O
S2257|the|O
S2257|study|O
S2257|treatment|O
S2257|.|O
S2214|Participants|O
S2214|Inclusion|O
S2214|criteria|O
S2214|Adult|O
S2214|asthma|O
S2214|patients|O
S2214|,|O
S2214|aged|O
S2214|18–75|O
S2214|years|O
S2214|,|O
S2214|were|O
S2214|required|O
S2214|to|O
S2214|have|O
S2214|:|O
S2214|bronchodilator|O
S2214|reversibility|O
S2214|of|O
S2214|either|O
S2214|≥12|O
S2214|%|O
S2214|β-agonist|O
S2214|reversibility|O
S2214|using|O
S2214|4|O
S2214|puffs|O
S2214|of|O
S2214|a|O
S2214|short-acting|O
S2214|β|O
S2214|−|O
S2214|agonist|O
S2214|(|O
S2214|SABA|O
S2214|)|O
S2214|or|O
S2214|a|O
S2214|PC20|O
S2214|FEV1|O
S2214|methacholine|O
S2214|(|O
S2214|provocative|O
S2214|concentration|O
S2214|of|O
S2214|methacholine|O
S2214|producing|O
S2214|a|O
S2214|20|O
S2214|%|O
S2214|fall|O
S2214|in|O
S2214|FEV1|O
S2214|(|O
S2214|forced|O
S2214|expiratory|O
S2214|volume|O
S2214|in|O
S2214|1|O
S2214|s|O
S2214|)|O
S2214|)|O
S2214|of|O
S2214|8|O
S2214|mg/mL|O
S2214|or|O
S2214|less|O
S2214|,|O
S2214|within|O
S2214|the|O
S2214|last|O
S2214|2|O
S2214|years|O
S2214|;|O
S2214|a|O
S2214|pre-bronchodilator|O
S2214|FEV1|O
S2214|at|O
S2214|screening|O
S2214|of|O
S2214|40–80|O
S2214|%|O
S2214|predicted|O
S2214|;|O
S2214|daily|O
S2214|use|O
S2214|of|O
S2214|ICS|O
S2214|(|O
S2214|≥400|O
S2214|μg/day|O
S2214|total|O
S2214|daily|O
S2214|dose|O
S2214|of|O
S2214|fluticasone|O
S2214|propionate|O
S2214|or|O
S2214|equivalent|O
S2214|)|O
S2214|and|O
S2214|a|O
S2214|second|O
S2214|controller|O
S2214|for|O
S2214|a|O
S2214|minimum|O
S2214|of|O
S2214|3|O
S2214|consecutive|O
S2214|months|O
S2214|;|O
S2214|inadequately-controlled|O
S2214|asthma|O
S2214|as|O
S2214|documented|O
S2214|by|O
S2214|a|O
S2214|5-item|O
S2214|Asthma|O
S2214|Control|O
S2214|Questionnaire|O
S2214|(|O
S2214|ACQ-5|O
S2214|)|O
S2214|score|O
S2214|≥1.50|O
S2214|at|O
S2214|screening|O
S2214|and|O
S2214|randomization|O
S2214|,|O
S2214|despite|O
S2214|compliance|O
S2214|with|O
S2214|asthma|O
S2214|controller|O
S2214|therapy|O
S2214|;|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|positive|O
S2214|aeroallergen-specific|O
S2214|IgE|O
S2214|(|O
S2214|≥0.35|O
S2214|kU|O
S2214|(|O
S2214|A|O
S2214|)|O
S2214|/L|O
S2214|)|O
S2214|,|O
S2214|or|O
S2214|a|O
S2214|total|O
S2214|serum|O
S2214|IgE|O
S2214|≥75|O
S2214|IU/mL|O
S2214|;|O
S2214|and|O
S2214|a|O
S2214|history|O
S2214|of|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|protocol-defined|O
S2214|asthma|O
S2214|exacerbation|O
S2214|in|O
S2214|the|O
S2214|18|O
S2214|months|O
S2214|prior|O
S2214|to|O
S2214|screening|O
S2214|.|O
S2220|Exploratory|O
S2220|outcome|O
S2220|measures|O
S2220|included|O
S2220|the|O
S2220|change|O
S2220|in|O
S2220|asthma|O
S2220|control|O
S2220|from|O
S2220|baseline|O
S2220|to|O
S2220|Week|O
S2220|36|O
S2220|,|O
S2220|as|O
S2220|measured|O
S2220|by|O
S2220|the|O
S2220|ACQ-5|O
S2220|.|O
S2224|Assessments|O
S2224|The|O
S2224|patient|O
S2224|daily|O
S2224|diary|O
S2224|included|O
S2224|two|O
S2224|sections|O
S2224|in|O
S2224|addition|O
S2224|to|O
S2224|peak|O
S2224|flow|O
S2224|measurements|O
S2224|:|O
S2224|1|O
S2224|)|O
S2224|a|O
S2224|morning|O
S2224|section|O
S2224|capturing|O
S2224|awakenings|O
S2224|and|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|at|O
S2224|night|O
S2224|,|O
S2224|and|O
S2224|symptoms|O
S2224|on|O
S2224|awakening|O
S2224|;|O
S2224|and|O
S2224|2|O
S2224|)|O
S2224|an|O
S2224|evening|O
S2224|section|O
S2224|capturing|O
S2224|daytime|O
S2224|symptom|O
S2224|severity|O
S2224|,|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|,|O
S2224|preventive|O
S2224|inhaler|O
S2224|use|O
S2224|,|O
S2224|activity|O
S2224|impairment|O
S2224|during|O
S2224|the|O
S2224|day|O
S2224|,|O
S2224|and|O
S2224|nasal|O
S2224|symptoms|O
S2224|.|O
S2245|Corresponding|O
S2245|two-sided|O
S2245|p-values|O
S2245|and|O
S2245|90|O
S2245|%|O
S2245|confidence|O
S2245|intervals|O
S2245|(|O
S2245|CI|O
S2245|)|O
S2245|were|O
S2245|reported|O
S2245|.|O
S2209|Patients|B-Blinding_Object_Patients
S2209|and|O
S2209|study|B-Blinding_Object_Care_Providers
S2209|site|I-Blinding_Object_Care_Providers
S2209|personnel|I-Blinding_Object_Care_Providers
S2209|were|O
S2209|blinded|O
S2209|to|O
S2209|treatment|O
S2209|assignments|O
S2209|until|O
S2209|all|O
S2209|follow-up|O
S2209|data|O
S2209|through|O
S2209|Week|O
S2209|84|O
S2209|were|O
S2209|collected|O
S2209|and|O
S2209|verified|O
S2209|.|O
S2233|Specific|O
S2233|IgE|O
S2233|was|O
S2233|measured|O
S2233|for|O
S2233|the|O
S2233|following|O
S2233|allergens|O
S2233|:|O
S2233|cat|O
S2233|,|O
S2233|house|O
S2233|dust|O
S2233|mite|O
S2233|(|O
S2233|HDM|O
S2233|)|O
S2233|Dermatophagoides|O
S2233|farinae|O
S2233|,|O
S2233|HDM|O
S2233|Dermatophagoides|O
S2233|pteronyssinus|O
S2233|,|O
S2233|ragweed|O
S2233|,|O
S2233|aspergillus|O
S2233|,|O
S2233|timothy|O
S2233|grass|O
S2233|,|O
S2233|bermuda|O
S2233|grass|O
S2233|,|O
S2233|oak|O
S2233|,|O
S2233|birch|O
S2233|,|O
S2233|plantain|O
S2233|,|O
S2233|and|O
S2233|orchard|O
S2233|grass|O
S2233|.|O
S2235|Only|O
S2235|observed|O
S2235|values|O
S2235|of|O
S2235|IgE|O
S2235|levels|O
S2235|were|O
S2235|analyzed|O
S2235|,|O
S2235|with|O
S2235|no|O
S2235|imputation|O
S2235|performed|O
S2235|for|O
S2235|missing|O
S2235|IgE|O
S2235|data|O
S2235|.|O
S2249|Missing|O
S2249|values|O
S2249|were|O
S2249|imputed|O
S2249|using|O
S2249|the|O
S2249|last-observation-carried-forward|O
S2249|(|O
S2249|LOCF|O
S2249|)|O
S2249|approach|O
S2249|,|O
S2249|as|O
S2249|prespecified|O
S2249|in|O
S2249|the|O
S2249|statistical|O
S2249|analysis|O
S2249|plan|O
S2249|.|O
S2276|3|O
S2276|)|O
S2276|.|O
S2217|Outcome|O
S2217|measures|O
S2217|The|O
S2217|primary|O
S2217|efficacy|O
S2217|outcome|O
S2217|was|O
S2217|the|O
S2217|annualized|O
S2217|rate|O
S2217|of|O
S2217|protocol-defined|O
S2217|asthma|O
S2217|exacerbations|O
S2217|from|O
S2217|baseline|O
S2217|to|O
S2217|Week|O
S2217|36|O
S2217|.|O
S2266|At|O
S2266|treatment|O
S2266|Weeks|O
S2266|4|O
S2266|,|O
S2266|12|O
S2266|,|O
S2266|and|O
S2266|24|O
S2266|,|O
S2266|the|O
S2266|mean|O
S2266|trough|O
S2266|serum|O
S2266|concentrations|O
S2266|of|O
S2266|quilizumab|O
S2266|were|O
S2266|:|O
S2266|(|O
S2266|150|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|5.7|O
S2266|±|O
S2266|2.3|O
S2266|μg/mL|O
S2266|,|O
S2266|2.6|O
S2266|±|O
S2266|2.0|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|1.3|O
S2266|±|O
S2266|4.6|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|(|O
S2266|450|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|17.1|O
S2266|±|O
S2266|7.0|O
S2266|μg/mL|O
S2266|,|O
S2266|7.2|O
S2266|±|O
S2266|3.8|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|2.3|O
S2266|±|O
S2266|2.2|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|and|O
S2266|(|O
S2266|300|O
S2266|mg|O
S2266|M|O
S2266|)|O
S2266|11.6|O
S2266|±|O
S2266|4.5|O
S2266|μg/mL|O
S2266|,|O
S2266|16.7|O
S2266|±|O
S2266|6.7|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|16.8|O
S2266|±|O
S2266|7.7|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|.|O
S2282|Relative|O
S2282|changes|O
S2282|from|O
S2282|baseline|O
S2282|in|O
S2282|FEV1|O
S2282|compared|O
S2282|to|O
S2282|placebo|O
S2282|were|O
S2282|3.8|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−1.2|O
S2282|to|O
S2282|8.9|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.21|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|5.6|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|0.6|O
S2282|to|O
S2282|10.6|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.07|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|150|O
S2282|mg|O
S2282|Q|O
S2282|treatment|O
S2282|arm|O
S2282|;|O
S2282|2.2|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−2.8|O
S2282|to|O
S2282|7.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.48|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−5.0|O
S2282|to|O
S2282|5.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.98|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|450|O
S2282|mg|O
S2282|Q|O
S2282|arm|O
S2282|;|O
S2282|and|O
S2282|1.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−3.9|O
S2282|to|O
S2282|6.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.72|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−4.9|O
S2282|to|O
S2282|5.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.96|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|300|O
S2282|mg|O
S2282|M|O
S2282|arm|O
S2282|(|O
S2282|Fig|O
S2282|.|O
S2240|Demographic|O
S2240|and|O
S2240|baseline|O
S2240|characteristics|O
S2240|were|O
S2240|summarized|O
S2240|using|O
S2240|descriptive|O
S2240|statistics|O
S2240|.|O
S2221|To|O
S2221|assess|O
S2221|the|O
S2221|change|O
S2221|in|O
S2221|allergy-related|O
S2221|quality-of-life|O
S2221|measures|O
S2221|from|O
S2221|baseline|O
S2221|to|O
S2221|Week|O
S2221|36|O
S2221|,|O
S2221|the|O
S2221|Standardized|O
S2221|Asthma|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|AQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|and|O
S2221|the|O
S2221|Standardized|O
S2221|Rhinoconjunctivitis|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|RQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|were|O
S2221|administered|O
S2221|at|O
S2221|patient|O
S2221|visits|O
S2221|throughout|O
S2221|the|O
S2221|treatment|O
S2221|and|O
S2221|follow-up|O
S2221|periods|O
S2221|.|O
S2206|Trial|O
S2206|design|O
S2206|The|O
S2206|COSTA|O
S2206|trial|O
S2206|of|O
S2206|quilizumab|O
S2206|was|O
S2206|a|O
S2206|Phase|B-Design_Phase_2
S2206|II|I-Design_Phase_2
S2206|,|O
S2206|randomized|O
S2206|,|O
S2206|double-blind|B-Blinding_Double_Blind
S2206|,|O
S2206|placebo-controlled|O
S2206|study|O
S2206|(|O
S2206|including|O
S2206|recruiting|B-Settings_Multicenter
S2206|sites|I-Settings_Multicenter
S2206|from|I-Settings_Multicenter
S2206|14|I-Settings_Multicenter
S2206|countries|I-Settings_Multicenter
S2206|:|O
S2206|Argentina|B-Settings_Location
S2206|,|I-Settings_Location
S2206|Belgium|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Bulgaria|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Canada|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Germany|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Hungary|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Mexico|I-Settings_Location
S2206|,|I-Settings_Location
S2206|New|I-Settings_Location
S2206|Zealand|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Peru|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Poland|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Romania|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Russia|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Ukraine|I-Settings_Location
S2206|,|I-Settings_Location
S2206|and|I-Settings_Location
S2206|the|I-Settings_Location
S2206|United|I-Settings_Location
S2206|States|I-Settings_Location
S2206|)|O
S2206|that|O
S2206|enrolled|O
S2206|578|B-Sample_Size_Actual_at_Enrollment
S2206|adults|O
S2206|with|O
S2206|uncontrolled|O
S2206|allergic|O
S2206|asthma|O
S2206|.|O
S2208|Randomization|O
S2208|was|O
S2208|stratified|B-Randomization_Type_Stratified
S2208|based|O
S2208|on|O
S2208|serum|B-Randomization_Stratified_Criteria
S2208|periostin|I-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|<|I-Randomization_Stratified_Criteria
S2208|50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|≥50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|exacerbation|B-Randomization_Stratified_Criteria
S2208|history|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|number|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|exacerbations|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|requiring|I-Randomization_Stratified_Criteria
S2208|use|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|systemic|I-Randomization_Stratified_Criteria
S2208|corticosteroids|I-Randomization_Stratified_Criteria
S2208|in|I-Randomization_Stratified_Criteria
S2208|the|I-Randomization_Stratified_Criteria
S2208|prior|I-Randomization_Stratified_Criteria
S2208|18|I-Randomization_Stratified_Criteria
S2208|months|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|IgE|B-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|≤75|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|75–200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|and|O
S2208|country|B-Randomization_Stratified_Criteria
S2208|.|O
S2277|Subgroup|O
S2277|analysis|O
S2277|by|O
S2277|baseline|O
S2277|serum|O
S2277|periostin|O
S2277|(|O
S2277|≥50|O
S2277|ng/ml|O
S2277|,|O
S2277|<|O
S2277|50|O
S2277|ng/ml|O
S2277|)|O
S2277|,|O
S2277|blood|O
S2277|eosinophils|O
S2277|(|O
S2277|≥300|O
S2277|cells/μl|O
S2277|,|O
S2277|<|O
S2277|300|O
S2277|cells/μl|O
S2277|)|O
S2277|,|O
S2277|FeNO|O
S2277|(|O
S2277|≥20|O
S2277|ppb|O
S2277|,|O
S2277|<|O
S2277|20|O
S2277|ppb|O
S2277|)|O
S2277|and|O
S2277|serum|O
S2277|total|O
S2277|IgE|O
S2277|(|O
S2277|≥200|O
S2277|IU/mL|O
S2277|,|O
S2277|<|O
S2277|200|O
S2277|IU/mL|O
S2277|)|O
S2277|demonstrated|O
S2277|no|O
S2277|consistent|O
S2277|effect|O
S2277|of|O
S2277|quilizumab|O
S2277|on|O
S2277|the|O
S2277|exacerbation|O
S2277|rate|O
S2277|across|O
S2277|all|O
S2277|doses|O
S2277|when|O
S2277|compared|O
S2277|to|O
S2277|the|O
S2277|ITT|O
S2277|population|O
S2277|(|O
S2277|Fig|O
S2277|.|O
S2234|The|O
S2234|maximum|O
S2234|specific|O
S2234|IgE|O
S2234|was|O
S2234|defined|O
S2234|as|O
S2234|the|O
S2234|specific|O
S2234|IgE|O
S2234|with|O
S2234|the|O
S2234|highest|O
S2234|titer|O
S2234|of|O
S2234|specific|O
S2234|IgEs|O
S2234|pre-dose|O
S2234|in|O
S2234|each|O
S2234|patient|O
S2234|.|O
S2210|Quilizumab|O
S2210|(|O
S2210|Genentech|O
S2210|,|O
S2210|Inc.|O
S2210|,|O
S2210|South|O
S2210|San|O
S2210|Francisco|O
S2210|,|O
S2210|CA|O
S2210|)|O
S2210|was|O
S2210|delivered|O
S2210|subcutaneously|O
S2210|at|O
S2210|nine|O
S2210|monthly|O
S2210|intervals|O
S2210|at|O
S2210|300|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|300|O
S2210|mg|O
S2210|M|O
S2210|)|O
S2210|,|O
S2210|or|O
S2210|at|O
S2210|three|O
S2210|quarterly|O
S2210|intervals|O
S2210|and|O
S2210|at|O
S2210|Week|O
S2210|4|O
S2210|at|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|Q|O
S2210|)|O
S2210|.|O
S2274|Asthma|O
S2274|exacerbation|O
S2274|rates|O
S2274|Quilizumab|O
S2274|treatment|O
S2274|did|O
S2274|not|O
S2274|produce|O
S2274|a|O
S2274|clinically|O
S2274|meaningful|O
S2274|reduction|O
S2274|of|O
S2274|the|O
S2274|rate|O
S2274|of|O
S2274|asthma|O
S2274|exacerbations|O
S2274|over|O
S2274|the|O
S2274|36-week|O
S2274|treatment|O
S2274|period|O
S2274|.|O
S2239|Statistical|O
S2239|methods|O
S2239|All|O
S2239|patients|O
S2239|received|O
S2239|at|O
S2239|least|O
S2239|one|O
S2239|dose|O
S2239|of|O
S2239|study|O
S2239|drug|O
S2239|(|O
S2239|intention-to-treat|O
S2239|,|O
S2239|ITT|O
S2239|population|O
S2239|)|O
S2239|and|O
S2239|were|O
S2239|included|O
S2239|in|O
S2239|all|O
S2239|safety|O
S2239|and|O
S2239|efficacy|O
S2239|analyses|O
S2239|.|O
S2267|For|O
S2267|the|O
S2267|150|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|450|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|and|O
S2267|300|O
S2267|mg|O
S2267|M|O
S2267|doses|O
S2267|,|O
S2267|the|O
S2267|mean|O
S2267|Cmax|O
S2267|,|O
S2267|obs|O
S2267|values|O
S2267|were|O
S2267|18|O
S2267|±|O
S2267|7.8|O
S2267|μg/mL|O
S2267|,|O
S2267|51.6|O
S2267|±|O
S2267|19.5|O
S2267|μg/mL|O
S2267|,|O
S2267|and|O
S2267|34|O
S2267|±|O
S2267|12.6|O
S2267|μg/mL|O
S2267|,|O
S2267|which|O
S2267|occurred|O
S2267|at|O
S2267|Tmax|O
S2267|,|O
S2267|obs|O
S2267|of|O
S2267|36.4|O
S2267|±|O
S2267|4.3|O
S2267|days|O
S2267|,|O
S2267|36.2|O
S2267|±|O
S2267|3.0|O
S2267|days|O
S2267|,|O
S2267|and|O
S2267|36.2|O
S2267|±|O
S2267|3.5|O
S2267|days|O
S2267|,|O
S2267|respectively|O
S2267|,|O
S2267|approximately|O
S2267|7|O
S2267|days|O
S2267|following|O
S2267|the|O
S2267|second|O
S2267|doses|O
S2267|.|O
S2222|We|O
S2222|also|O
S2222|evaluated|O
S2222|the|O
S2222|ability|O
S2222|of|O
S2222|biomarkers|O
S2222|(|O
S2222|serum|O
S2222|periostin|O
S2222|,|O
S2222|blood|O
S2222|eosinophils|O
S2222|,|O
S2222|exhaled|O
S2222|NO|O
S2222|,|O
S2222|and|O
S2222|serum|O
S2222|IgE|O
S2222|)|O
S2222|to|O
S2222|predict|O
S2222|benefit|O
S2222|from|O
S2222|quilizumab|O
S2222|.|O
S2281|The|O
S2281|highest|O
S2281|relative|O
S2281|improvement|O
S2281|compared|O
S2281|to|O
S2281|placebo|O
S2281|occurred|O
S2281|in|O
S2281|the|O
S2281|lowest|O
S2281|dose|O
S2281|arm|O
S2281|(|O
S2281|150|O
S2281|mg|O
S2281|Q|O
S2281|)|O
S2281|,|O
S2281|but|O
S2281|no|O
S2281|meaningful|O
S2281|improvements|O
S2281|were|O
S2281|observed|O
S2281|in|O
S2281|the|O
S2281|higher|O
S2281|dose|O
S2281|arms|O
S2281|(|O
S2281|450|O
S2281|mg|O
S2281|Q|O
S2281|and|O
S2281|300|O
S2281|mg|O
S2281|M|O
S2281|)|O
S2281|.|O
S2247|For|O
S2247|secondary|O
S2247|and|O
S2247|exploratory|O
S2247|end|O
S2247|points|O
S2247|,|O
S2247|the|O
S2247|means|O
S2247|and|O
S2247|standard|O
S2247|deviations|O
S2247|of|O
S2247|all|O
S2247|values|O
S2247|for|O
S2247|relative|O
S2247|change|O
S2247|were|O
S2247|calculated|O
S2247|according|O
S2247|to|O
S2247|study|O
S2247|group|O
S2247|at|O
S2247|Weeks|O
S2247|12|O
S2247|and|O
S2247|36|O
S2247|.|O
S2264|Pharmacokinetics|O
S2264|Quilizumab|O
S2264|displayed|O
S2264|linear|O
S2264|pharmacokinetics|O
S2264|with|O
S2264|a|O
S2264|dose-proportional|O
S2264|increase|O
S2264|in|O
S2264|exposure|O
S2264|as|O
S2264|shown|O
S2264|by|O
S2264|increases|O
S2264|in|O
S2264|Cmax|O
S2264|values|O
S2264|between|O
S2264|the|O
S2264|150|O
S2264|and|O
S2264|450|O
S2264|mg|O
S2264|Q|O
S2264|doses|O
S2264|at|O
S2264|Weeks|O
S2264|5|O
S2264|and|O
S2264|25|O
S2264|.|O
S2237|Serum|O
S2237|periostin|O
S2237|was|O
S2237|measured|O
S2237|by|O
S2237|immunoassay|O
S2237|using|O
S2237|the|O
S2237|Roche|O
S2237|Elecsys|O
S2237|platform|O
S2237|(|O
S2237|Roche|O
S2237|Diagnostics|O
S2237|Ltd.|O
S2237|,|O
S2237|Rotkreuz|O
S2237|,|O
S2237|Switzerland|O
S2237|)|O
S2237|.|O
S2248|The|O
S2248|mean|O
S2248|relative|O
S2248|changes|O
S2248|from|O
S2248|baseline|O
S2248|were|O
S2248|compared|O
S2248|between|O
S2248|the|O
S2248|study|O
S2248|groups|O
S2248|using|O
S2248|the|O
S2248|differences|O
S2248|between|O
S2248|the|O
S2248|means|O
S2248|for|O
S2248|each|O
S2248|group|O
S2248|,|O
S2248|with|O
S2248|the|O
S2248|associated|O
S2248|two-sided|O
S2248|90|O
S2248|%|O
S2248|CIs|O
S2248|.|O
S2269|Pharmacodynamic|O
S2269|biomarkers|O
S2269|Quilizumab|O
S2269|gradually|O
S2269|reduced|O
S2269|mean|O
S2269|serum|O
S2269|total|O
S2269|and|O
S2269|allergen-specific|O
S2269|IgE|O
S2269|,|O
S2269|reaching|O
S2269|a|O
S2269|30–40|O
S2269|%|O
S2269|reduction|O
S2269|at|O
S2269|Week|O
S2269|36|O
S2269|in|O
S2269|all|O
S2269|three|O
S2269|quilizumab|O
S2269|cohorts|O
S2269|(|O
S2269|p|O
S2269|<|O
S2269|0.01|O
S2269|compared|O
S2269|to|O
S2269|placebo|O
S2269|;|O
S2269|Fig|O
S2269|.|O
S2279|Lung|O
S2279|function|O
S2279|No|O
S2279|significant|O
S2279|evidence|O
S2279|of|O
S2279|improved|O
S2279|FEV1|O
S2279|at|O
S2279|Weeks|O
S2279|12|O
S2279|and|O
S2279|36|O
S2279|was|O
S2279|observed|O
S2279|in|O
S2279|quilizumab-treated|O
S2279|patients|O
S2279|compared|O
S2279|to|O
S2279|placebo|O
S2279|(|O
S2279|Fig|O
S2279|.|O
S2252|This|O
S2252|sample|O
S2252|size|O
S2252|provided|O
S2252|approximately|O
S2252|84|B-Sample_Size_Calculation_Power_Value
S2252|%|I-Sample_Size_Calculation_Power_Value
S2252|power|O
S2252|to|O
S2252|detect|O
S2252|a|O
S2252|50|O
S2252|%|O
S2252|reduction|O
S2252|in|O
S2252|average|O
S2252|exacerbation|O
S2252|rates|O
S2252|due|O
S2252|to|O
S2252|quilizumab|O
S2252|,|O
S2252|assuming|O
S2252|0.63|O
S2252|exacerbations|O
S2252|per|O
S2252|patient|O
S2252|in|O
S2252|the|O
S2252|placebo|O
S2252|group|O
S2252|over|O
S2252|a|O
S2252|36-week|O
S2252|treatment|O
S2252|period|O
S2252|,|O
S2252|and|O
S2252|a|O
S2252|significance|O
S2252|level|O
S2252|of|O
S2252|α|O
S2252|=|O
S2252|0.10|B-Sample_Size_Calculation_Alpha_Value
S2252|.|O
S2241|The|O
S2241|primary|O
S2241|endpoint|O
S2241|,|O
S2241|the|O
S2241|annualized|O
S2241|exacerbation|O
S2241|rate|O
S2241|,|O
S2241|was|O
S2241|calculated|O
S2241|by|O
S2241|the|O
S2241|total|O
S2241|number|O
S2241|of|O
S2241|protocol-defined|O
S2241|exacerbations|O
S2241|observed|O
S2241|in|O
S2241|the|O
S2241|group|O
S2241|over|O
S2241|the|O
S2241|treatment|O
S2241|period|O
S2241|divided|O
S2241|by|O
S2241|total|O
S2241|patient-weeks|O
S2241|at|O
S2241|risk|O
S2241|(|O
S2241|number|O
S2241|of|O
S2241|weeks|O
S2241|from|O
S2241|first|O
S2241|study|O
S2241|drug|O
S2241|administration|O
S2241|to|O
S2241|the|O
S2241|earliest|O
S2241|of|O
S2241|Week|O
S2241|36|O
S2241|or|O
S2241|study|O
S2241|discontinuation|O
S2241|)|O
S2241|for|O
S2241|the|O
S2241|group|O
S2241|and|O
S2241|multiplied|O
S2241|by|O
S2241|52|O
S2241|.|O
S2212|Ethics|O
S2212|,|O
S2212|consent|O
S2212|,|O
S2212|and|O
S2212|permissions|O
S2212|Quorum|O
S2212|Review|O
S2212|based|O
S2212|in|O
S2212|Seattle|O
S2212|,|O
S2212|WA|O
S2212|was|O
S2212|the|O
S2212|primary|O
S2212|central|O
S2212|IRB|O
S2212|used|O
S2212|by|O
S2212|sites|O
S2212|in|O
S2212|North|O
S2212|America|O
S2212|,|O
S2212|however|O
S2212|multiple|O
S2212|other|O
S2212|site-specific|O
S2212|institutional|O
S2212|review|O
S2212|boards|O
S2212|at|O
S2212|other|O
S2212|global|O
S2212|sites|O
S2212|approved|O
S2212|the|O
S2212|protocol|O
S2212|and|O
S2212|patients|O
S2212|gave|O
S2212|written|O
S2212|,|O
S2212|informed|O
S2212|consent|O
S2212|.|O
S2213|The|O
S2213|trial|O
S2213|was|O
S2213|conducted|O
S2213|in|O
S2213|full|O
S2213|conformance|O
S2213|with|O
S2213|the|O
S2213|International|O
S2213|Conference|O
S2213|on|O
S2213|Harmonisation|O
S2213|E6|O
S2213|guidelines|O
S2213|and|O
S2213|the|O
S2213|Declaration|O
S2213|of|O
S2213|Helsinki|O
S2213|,|O
S2213|or|O
S2213|laws|O
S2213|and|O
S2213|regulations|O
S2213|of|O
S2213|the|O
S2213|country|O
S2213|where|O
S2213|the|O
S2213|research|O
S2213|was|O
S2213|conducted|O
S2213|,|O
S2213|whichever|O
S2213|afforded|O
S2213|greater|O
S2213|protection|O
S2213|to|O
S2213|the|O
S2213|individual|O
S2213|.|O
S2219|The|O
S2219|diary|O
S2219|was|O
S2219|also|O
S2219|used|O
S2219|to|O
S2219|determine|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|who|O
S2219|had|O
S2219|no|O
S2219|nighttime|O
S2219|awakenings|O
S2219|due|O
S2219|to|O
S2219|asthma|O
S2219|symptoms|O
S2219|and|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|with|O
S2219|fewer|O
S2219|than|O
S2219|2|O
S2219|days|O
S2219|of|O
S2219|SABA|O
S2219|use|O
S2219|per|O
S2219|week|O
S2219|by|O
S2219|Week|O
S2219|36|O
S2219|.|O
S2244|For|O
S2244|biomarker|O
S2244|subgroup|O
S2244|analyses|O
S2244|,|O
S2244|unadjusted|O
S2244|asthma|O
S2244|exacerbation|O
S2244|rates|O
S2244|were|O
S2244|calculated|O
S2244|.|O
S2211|The|O
S2211|treatment|O
S2211|period|O
S2211|ended|O
S2211|36|O
S2211|weeks|O
S2211|after|O
S2211|randomization|O
S2211|and|O
S2211|was|O
S2211|followed|O
S2211|by|O
S2211|a|O
S2211|48-week|O
S2211|period|O
S2211|to|O
S2211|assess|O
S2211|the|O
S2211|sustained|O
S2211|efficacy|O
S2211|and|O
S2211|safety|O
S2211|of|O
S2211|quilizumab|O
S2211|(|O
S2211|see|O
S2211|Additional|O
S2211|file|O
S2211|1|O
S2211|:|O
S2211|Figure|O
S2211|S1|O
S2211|)|O
S2211|.|O
S2238|Fractional|O
S2238|exhaled|O
S2238|nitric|O
S2238|oxide|O
S2238|(|O
S2238|FeNO|O
S2238|)|O
S2238|was|O
S2238|measured|O
S2238|using|O
S2238|a|O
S2238|hand-held|O
S2238|portable|O
S2238|device|O
S2238|,|O
S2238|NIOX|O
S2238|MINO®|O
S2238|(|O
S2238|Niox|O
S2238|;|O
S2238|Morrisville|O
S2238|,|O
S2238|NC|O
S2238|)|O
S2238|,|O
S2238|according|O
S2238|to|O
S2238|American|O
S2238|Thoracic|O
S2238|Society/European|O
S2238|Respiratory|O
S2238|Society|O
S2238|2009|O
S2238|guidelines|O
S2238|.|O
S2271|The|O
S2271|largest|O
S2271|decreases|O
S2271|in|O
S2271|total|O
S2271|and|O
S2271|allergen-specific|O
S2271|IgE|O
S2271|were|O
S2271|observed|O
S2271|at|O
S2271|Week|O
S2271|42|O
S2271|in|O
S2271|the|O
S2271|300|O
S2271|mg|O
S2271|M|O
S2271|treatment|O
S2271|cohort|O
S2271|.|O
S2225|The|O
S2225|modified|O
S2225|total|O
S2225|asthma|O
S2225|symptom|O
S2225|score|O
S2225|(|O
S2225|mTASS|O
S2225|)|O
S2225|was|O
S2225|generated|O
S2225|from|O
S2225|a|O
S2225|subset|O
S2225|of|O
S2225|diary|O
S2225|questions|O
S2225|adapted|O
S2225|from|O
S2225|a|O
S2225|previous|O
S2225|questionnaire|O
S2225|,|O
S2225|scoring|O
S2225|nighttime|O
S2225|awakenings|O
S2225|(|O
S2225|0–3|O
S2225|)|O
S2225|,|O
S2225|symptoms|O
S2225|on|O
S2225|awakening|O
S2225|(|O
S2225|0–1|O
S2225|)|O
S2225|,|O
S2225|and|O
S2225|daytime|O
S2225|symptom|O
S2225|severity|O
S2225|(|O
S2225|0–4|O
S2225|)|O
S2225|,|O
S2225|for|O
S2225|a|O
S2225|total|O
S2225|score|O
S2225|range|O
S2225|of|O
S2225|0–8|O
S2225|.|O
S2261|The|O
S2261|treatment-emergent|O
S2261|ATA|O
S2261|rate|O
S2261|was|O
S2261|1.4|O
S2261|%|O
S2261|in|O
S2261|both|O
S2261|the|O
S2261|150|O
S2261|mg|O
S2261|Q|O
S2261|and|O
S2261|300|O
S2261|mg|O
S2261|M|O
S2261|groups|O
S2261|,|O
S2261|and|O
S2261|2.1|O
S2261|%|O
S2261|in|O
S2261|the|O
S2261|450|O
S2261|mg|O
S2261|Q|O
S2261|group|O
S2261|.|O
S2253|This|O
S2253|sample|O
S2253|size|O
S2253|also|O
S2253|provided|O
S2253|approximately|O
S2253|70|B-Sample_Size_Calculation_Power_Value
S2253|%|I-Sample_Size_Calculation_Power_Value
S2253|power|O
S2253|to|O
S2253|detect|O
S2253|a|O
S2253|50|O
S2253|%|O
S2253|reduction|O
S2253|in|O
S2253|average|O
S2253|exacerbation|O
S2253|rates|O
S2253|in|O
S2253|the|O
S2253|subgroup|O
S2253|of|O
S2253|periostin-high|O
S2253|patients|O
S2253|,|O
S2253|assuming|O
S2253|0.69|O
S2253|exacerbations|O
S2253|per|O
S2253|patient|O
S2253|in|O
S2253|the|O
S2253|placebo|O
S2253|group|O
S2253|over|O
S2253|the|O
S2253|36-week|O
S2253|period|O
S2253|,|O
S2253|a|O
S2253|significance|O
S2253|level|O
S2253|of|O
S2253|0.15|B-Sample_Size_Calculation_Alpha_Value
S2253|,|O
S2253|and|O
S2253|50|O
S2253|%|O
S2253|of|O
S2253|patients|O
S2253|in|O
S2253|each|O
S2253|treatment|O
S2253|arm|O
S2253|to|O
S2253|be|O
S2253|periostin|O
S2253|high|O
S2253|.|O
S2265|(|O
S2265|see|O
S2265|Additional|O
S2265|file|O
S2265|1|O
S2265|:|O
S2265|Figure|O
S2265|S2|O
S2265|)|O
S2265|.|O
S2207|Patients|O
S2207|were|O
S2207|randomly|O
S2207|assigned|O
S2207|(|O
S2207|1:1:1:1|B-Randomization_Ratio
S2207|)|O
S2207|to|O
S2207|one|B-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|three|I-Design_Parallel_Group
S2207|dosing|I-Design_Parallel_Group
S2207|regimens|I-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|quilizumab|I-Design_Parallel_Group
S2207|or|I-Design_Parallel_Group
S2207|placebo|I-Design_Parallel_Group
S2207|using|O
S2207|an|B-Randomization_Sequence_Generation_Method
S2207|interactive|I-Randomization_Sequence_Generation_Method
S2207|web|I-Randomization_Sequence_Generation_Method
S2207|response|I-Randomization_Sequence_Generation_Method
S2207|system|I-Randomization_Sequence_Generation_Method
S2207|.|O
S2286|Treatment|O
S2286|with|O
S2286|quilizumab|O
S2286|failed|O
S2286|to|O
S2286|increase|O
S2286|either|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|used|O
S2286|a|O
S2286|SABA|O
S2286|for|O
S2286|fewer|O
S2286|than|O
S2286|2|O
S2286|days|O
S2286|in|O
S2286|the|O
S2286|prior|O
S2286|week|O
S2286|or|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|did|O
S2286|not|O
S2286|awaken|O
S2286|at|O
S2286|night|O
S2286|due|O
S2286|to|O
S2286|asthma|O
S2286|symptoms|O
S2286|for|O
S2286|all|O
S2286|dosing|O
S2286|levels|O
S2286|relative|O
S2286|to|O
S2286|the|O
S2286|placebo|O
S2286|group|O
S2286|at|O
S2286|Week|O
S2286|36|O
S2286|(|O
S2286|Table|O
S2286|3|O
S2286|)|O
S2286|.|O
S2251|Sample|O
S2251|size|O
S2251|determination|O
S2251|We|O
S2251|planned|O
S2251|to|O
S2251|randomize|O
S2251|560|B-Sample_Size_Required
S2251|patients|O
S2251|to|O
S2251|one|O
S2251|of|O
S2251|three|O
S2251|dose|I-Design_Parallel_Group
S2251|regimens|I-Design_Parallel_Group
S2251|of|I-Design_Parallel_Group
S2251|quilizumab|I-Design_Parallel_Group
S2251|or|I-Design_Parallel_Group
S2251|placebo|I-Design_Parallel_Group
S2251|in|O
S2251|a|O
S2251|1:1:1:1|B-Randomization_Ratio
S2251|ratio|O
S2251|(|O
S2251|140|O
S2251|patients|O
S2251|per|O
S2251|group|O
S2251|)|O
S2251|.|O
S2242|For|O
S2242|patients|O
S2242|who|O
S2242|discontinued|O
S2242|the|O
S2242|study|O
S2242|prematurely|O
S2242|,|O
S2242|there|O
S2242|was|O
S2242|no|O
S2242|imputation|O
S2242|of|O
S2242|additional|O
S2242|exacerbations|O
S2242|.|O
S2263|There|O
S2263|was|O
S2263|no|O
S2263|apparent|O
S2263|impact|O
S2263|of|O
S2263|positive|O
S2263|ATA|O
S2263|results|O
S2263|on|O
S2263|either|O
S2263|pharmacokinetic|O
S2263|profiles|O
S2263|or|O
S2263|safety|O
S2263|.|O
S2250|An|O
S2250|analysis|O
S2250|of|O
S2250|covariance|O
S2250|(|O
S2250|ANCOVA|O
S2250|)|O
S2250|model|O
S2250|with|O
S2250|factors|O
S2250|for|O
S2250|baseline|O
S2250|level|O
S2250|,|O
S2250|periostin|O
S2250|status|O
S2250|(|O
S2250|<|O
S2250|50|O
S2250|ng/mL|O
S2250|,|O
S2250|≥50|O
S2250|ng/mL|O
S2250|)|O
S2250|,|O
S2250|number|O
S2250|of|O
S2250|prior|O
S2250|exacerbations|O
S2250|(|O
S2250|1|O
S2250|,|O
S2250|>|O
S2250|1|O
S2250|)|O
S2250|,|O
S2250|and|O
S2250|IgE|O
S2250|level|O
S2250|(|O
S2250|<|O
S2250|200|O
S2250|IU/mL|O
S2250|,|O
S2250|≥200|O
S2250|IU/mL|O
S2250|)|O
S2250|was|O
S2250|fit|O
S2250|to|O
S2250|assess|O
S2250|the|O
S2250|treatment|O
S2250|effect|O
S2250|.|O
S2272|Serum|O
S2272|total|O
S2272|and|O
S2272|allergen-specific|O
S2272|IgE|O
S2272|in|O
S2272|quilizumab-treated|O
S2272|patients|O
S2272|gradually|O
S2272|increased|O
S2272|throughout|O
S2272|the|O
S2272|safety|O
S2272|follow-up|O
S2272|period|O
S2272|,|O
S2272|but|O
S2272|did|O
S2272|not|O
S2272|return|O
S2272|to|O
S2272|pre-dose|O
S2272|levels|O
S2272|by|O
S2272|the|O
S2272|end|O
S2272|of|O
S2272|the|O
S2272|study|O
S2272|period|O
S2272|(|O
S2272|Week|O
S2272|84|O
S2272|)|O
S2272|.|O
S2230|Serum|O
S2230|anti-therapeutic|O
S2230|antibodies|O
S2230|(|O
S2230|ATAs|O
S2230|)|O
S2230|were|O
S2230|assessed|O
S2230|in|O
S2230|samples|O
S2230|at|O
S2230|Weeks|O
S2230|0|O
S2230|,|O
S2230|4|O
S2230|,|O
S2230|12|O
S2230|,|O
S2230|24|O
S2230|,|O
S2230|36|O
S2230|,|O
S2230|48|O
S2230|,|O
S2230|60|O
S2230|,|O
S2230|and|O
S2230|84|O
S2230|using|O
S2230|a|O
S2230|validated|O
S2230|bridging|O
S2230|ELISA|O
S2230|(|O
S2230|Genentech|O
S2230|,|O
S2230|Inc.|O
S2230|,|O
S2230|South|O
S2230|San|O
S2230|Francisco|O
S2230|,|O
S2230|CA|O
S2230|)|O
S2230|.|O
S149|Results|O
S149|In|O
S149|total|O
S149|,|O
S149|149|B-Sample_Size_Actual_at_Enrollment
S149|patients|O
S149|were|O
S149|randomised|O
S149|and|O
S149|141|B-Sample_Size_Actual_at_Outcome_Analysis
S149|completed|O
S149|the|O
S149|study|O
S149|.|O
S1316|The|O
S1316|corresponding|O
S1316|author|O
S1316|had|O
S1316|full|O
S1316|access|O
S1316|to|O
S1316|all|O
S1316|the|O
S1316|data|O
S1316|in|O
S1316|the|O
S1316|study|O
S1316|and|O
S1316|had|O
S1316|final|O
S1316|responsibility|O
S1316|for|O
S1316|the|O
S1316|decision|O
S1316|to|O
S1316|submit|O
S1316|for|O
S1316|publication|O
S1316|.|O
S1491|Duration|O
S1491|of|O
S1491|illness|O
S1491|before|O
S1491|enrolment|O
S1491|and|O
S1491|antiviral|O
S1491|treatment|O
S1491|before|O
S1491|enrolment|O
S1491|were|O
S1491|not|O
S1491|significant|O
S1491|predictors|O
S1491|in|O
S1491|the|O
S1491|multivariate|O
S1491|model|O
S1491|:|O
S1491|odds|O
S1491|ratio|O
S1491|1.48|O
S1491|(|O
S1491|95|O
S1491|%|O
S1491|confidence|O
S1491|interval|O
S1491|0.79|O
S1491|to|O
S1491|2.80|O
S1491|;|O
S1491|P=0.22|O
S1491|)|O
S1491|for|O
S1491|duration|O
S1491|of|O
S1491|illness|O
S1491|over|O
S1491|two|O
S1491|days|O
S1491|and|O
S1491|1.53|O
S1491|(|O
S1491|0.51|O
S1491|to|O
S1491|4.55|O
S1491|;|O
S1491|P=0.45|O
S1491|)|O
S1491|for|O
S1491|antiviral|O
S1491|treatment|O
S1491|.|O
S813|Vasomotor|O
S813|response|O
S813|Of|O
S813|the|O
S813|26|B-Sample_Size_Actual_at_Enrollment
S813|patients|O
S813|enrolled|O
S813|,|O
S813|15|B-Sample_Size_Actual_at_Outcome_Analysis
S813|underwent|O
S813|vascular|O
S813|assessment|O
S813|(|O
S813|eight|O
S813|randomised|O
S813|to|O
S813|receive|O
S813|etanercept|O
S813|)|O
S813|.|O
S1093|They|O
S1093|independently|O
S1093|assessed|O
S1093|the|O
S1093|photographs|O
S1093|for|O
S1093|each|O
S1093|participant|O
S1093|to|O
S1093|determine|O
S1093|whether|O
S1093|the|O
S1093|plantar|O
S1093|wart|O
S1093|had|O
S1093|cleared|O
S1093|.|O
S6|RESULTS|O
S6|:|O
S6|In|O
S6|REDUCE-1|O
S6|,|O
S6|the|O
S6|primary|O
S6|end|O
S6|point|O
S6|analysis|O
S6|of|O
S6|gastric|O
S6|ulcers|O
S6|at|O
S6|24|O
S6|weeks|O
S6|with|O
S6|HZT-501|O
S6|vs.|O
S6|ibuprofen|O
S6|was|O
S6|12.7|O
S6|%|O
S6|vs.|O
S6|22.9|O
S6|%|O
S6|(|O
S6|P=0.0044|O
S6|)|O
S6|in|O
S6|the|O
S6|post-adjudication|O
S6|analysis|O
S6|.|O
S151|The|O
S151|largest|O
S151|difference|O
S151|from|O
S151|placebo|O
S151|was|O
S151|with|O
S151|tiotropium|O
S151|Respimat®|O
S151|5|O
S151|μg|O
S151|(|O
S151|188|O
S151|mL|O
S151|)|O
S151|.|O
S280|Evidence|O
S280|for|O
S280|the|O
S280|efficacy|O
S280|of|O
S280|colchicine|O
S280|as|O
S280|prophylaxis|O
S280|against|O
S280|flares|O
S280|comes|O
S280|from|O
S280|two|O
S280|small|O
S280|studies|O
S280|and|O
S280|a|O
S280|larger|O
S280|study|O
S280|performed|O
S280|50|O
S280|years|O
S280|ago|O
S280|.|O
S1879|During|O
S1879|the|O
S1879|post-trial|O
S1879|period|O
S1879|,|O
S1879|the|O
S1879|incidence|O
S1879|rates|O
S1879|were|O
S1879|similar|O
S1879|in|O
S1879|both|O
S1879|treatment|O
S1879|groups|O
S1879|(|O
S1879|RR|O
S1879|0·96|O
S1879|[|O
S1879|95|O
S1879|%|O
S1879|CI|O
S1879|0·88–1·04|O
S1879|]|O
S1879|;|O
S1879|p=0·31|O
S1879|)|O
S1879|,|O
S1879|although|O
S1879|a|O
S1879|further|O
S1879|reduction|O
S1879|was|O
S1879|recorded|O
S1879|in|O
S1879|first|O
S1879|non-fatal|O
S1879|myocardial|O
S1879|infarction|O
S1879|(|O
S1879|413|O
S1879|[|O
S1879|4·8|O
S1879|%|O
S1879|]|O
S1879|vs|O
S1879|465|O
S1879|[|O
S1879|5·7|O
S1879|%|O
S1879|]|O
S1879|;|O
S1879|p=0·01|O
S1879|)|O
S1879|.|O
S264|There|O
S264|was|O
S264|a|O
S264|64|O
S264|%|O
S264|to|O
S264|72|O
S264|%|O
S264|reduction|O
S264|in|O
S264|the|O
S264|risk|O
S264|of|O
S264|experiencing|O
S264|≥1|O
S264|flare|O
S264|for|O
S264|canakinumab|O
S264|doses|O
S264|≥50|O
S264|mg|O
S264|versus|O
S264|colchicine|O
S264|at|O
S264|16|O
S264|weeks|O
S264|(|O
S264|hazard|O
S264|ratio|O
S264|(|O
S264|HR|O
S264|)|O
S264|:|O
S264|0.28–0.36|O
S264|,|O
S264|p≤0.05|O
S264|)|O
S264|.|O
S498|This|O
S498|was|O
S498|because|O
S498|the|O
S498|randomisation|O
S498|analyses|O
S498|compared|O
S498|intervention|O
S498|and|O
S498|control|O
S498|groups|O
S498|in|O
S498|which|O
S498|half|O
S498|of|O
S498|each|O
S498|control|O
S498|group|O
S498|had|O
S498|received|O
S498|an|O
S498|effective|O
S498|intervention|O
S498|from|O
S498|the|O
S498|other|O
S498|randomisation|O
S498|,|O
S498|thus|O
S498|reducing|O
S498|the|O
S498|apparent|O
S498|effect|O
S498|size|O
S498|.|O
S1701|Among|O
S1701|45|O
S1701|WHO|O
S1701|stage|O
S1701|3|O
S1701|or|O
S1701|4|O
S1701|events|O
S1701|reported|O
S1701|on|O
S1701|clinically|O
S1701|driven|O
S1701|monitoring|O
S1701|and|O
S1701|21|O
S1701|on|O
S1701|routine|O
S1701|laboratory|O
S1701|monitoring|O
S1701|from|O
S1701|the|O
S1701|second|O
S1701|year|O
S1701|onwards|O
S1701|,|O
S1701|14|O
S1701|versus|O
S1701|one|O
S1701|were|O
S1701|failure-to-thrive|O
S1701|and|O
S1701|15|O
S1701|versus|O
S1701|15|O
S1701|were|O
S1701|extrapulmonary|O
S1701|or|O
S1701|pulmonary|O
S1701|tuberculosis|O
S1701|,|O
S1701|highlighting|O
S1701|the|O
S1701|potential|O
S1701|of|O
S1701|weight|O
S1701|monitoring|O
S1701|to|O
S1701|identify|O
S1701|first-line|O
S1701|CD4|O
S1701|failure|O
S1701|clinically|O
S1701|.|O
S1590|Randomisation|O
S1590|used|O
S1590|computer-generated|B-Randomization_Sequence_Generation_Method
S1590|sequentially|I-Randomization_Sequence_Generation_Method
S1590|numbered|I-Randomization_Sequence_Generation_Method
S1590|tables|I-Randomization_Sequence_Generation_Method
S1590|incorporated|O
S1590|securely|O
S1590|within|O
S1590|the|O
S1590|database|O
S1590|.|O
S2197|Quilizumab|O
S2197|is|O
S2197|a|O
S2197|humanized|O
S2197|,|O
S2197|monoclonal|O
S2197|IgG1|O
S2197|that|O
S2197|binds|O
S2197|to|O
S2197|the|O
S2197|M1-prime|O
S2197|segment|O
S2197|present|O
S2197|only|O
S2197|on|O
S2197|membrane|O
S2197|IgE|O
S2197|,|O
S2197|but|O
S2197|not|O
S2197|on|O
S2197|soluble|O
S2197|IgE|O
S2197|in|O
S2197|serum|O
S2197|.|O
S211|Evaluation|O
S211|of|O
S211|safety|O
S211|and|O
S211|tolerability|O
S211|was|O
S211|performed|O
S211|on|O
S211|the|O
S211|treated|O
S211|set|O
S211|,|O
S211|defined|O
S211|as|O
S211|all|O
S211|randomised|O
S211|patients|O
S211|who|O
S211|received|O
S211|at|O
S211|least|O
S211|one|O
S211|dose|O
S211|of|O
S211|study|O
S211|medication|O
S211|.|O
S1236|Introduction|O
S1236|Each|O
S1236|year|O
S1236|,|O
S1236|about|O
S1236|22|O
S1236|million|O
S1236|people|O
S1236|have|O
S1236|a|O
S1236|stroke|O
S1236|world-wide|O
S1236|,|O
S1236|of|O
S1236|whom|O
S1236|4|O
S1236|million|O
S1236|reside|O
S1236|in|O
S1236|high-income|O
S1236|countries|O
S1236|,|O
S1236|where|O
S1236|thrombolytic|O
S1236|therapy|O
S1236|is|O
S1236|affordable|O
S1236|and|O
S1236|feasible|O
S1236|.|O
S33|In|O
S33|addition|O
S33|,|O
S33|antacids|O
S33|could|O
S33|not|O
S33|be|O
S33|taken|O
S33|for|O
S33|>|O
S33|3|O
S33|days|O
S33|in|O
S33|any|O
S33|2-week|O
S33|period|O
S33|;|O
S33|patients|O
S33|requiring|O
S33|further|O
S33|antacid|O
S33|therapy|O
S33|were|O
S33|to|O
S33|be|O
S33|discontinued|O
S33|from|O
S33|the|O
S33|trial|O
S33|.|O
S1302|The|O
S1302|statistical|O
S1302|analysis|O
S1302|plan|O
S1302|was|O
S1302|published|O
S1302|before|O
S1302|unmasking|O
S1302|of|O
S1302|the|O
S1302|authors|O
S1302|to|O
S1302|the|O
S1302|data|O
S1302|.|O
S1492|Secondary|O
S1492|endpoints|O
S1492|Day|O
S1492|five|O
S1492|clinical|O
S1492|failure|O
S1492|The|O
S1492|criteria|O
S1492|for|O
S1492|clinical|O
S1492|failure|O
S1492|on|O
S1492|day|O
S1492|five|O
S1492|were|O
S1492|met|O
S1492|in|O
S1492|16/161|O
S1492|(|O
S1492|9.9|O
S1492|%|O
S1492|,|O
S1492|95|O
S1492|%|O
S1492|confidence|O
S1492|interval|O
S1492|6.2|O
S1492|%|O
S1492|to|O
S1492|15.5|O
S1492|%|O
S1492|)|O
S1492|patients|O
S1492|in|O
S1492|the|O
S1492|double|O
S1492|dose|O
S1492|and|O
S1492|20/158|O
S1492|(|O
S1492|13|O
S1492|%|O
S1492|,|O
S1492|8.3|O
S1492|%|O
S1492|to|O
S1492|18.7|O
S1492|%|O
S1492|)|O
S1492|in|O
S1492|the|O
S1492|standard|O
S1492|dose|O
S1492|arm|O
S1492|(|O
S1492|P=0.44|O
S1492|)|O
S1492|;|O
S1492|all|O
S1492|received|O
S1492|five|O
S1492|additional|O
S1492|days|O
S1492|of|O
S1492|oseltamivir|O
S1492|.|O
S814|Heart|O
S814|rate|O
S814|and|O
S814|systemic|O
S814|blood|O
S814|pressure|O
S814|were|O
S814|similar|O
S814|in|O
S814|both|O
S814|groups|O
S814|and|O
S814|were|O
S814|unaffected|O
S814|by|O
S814|either|O
S814|treatment|O
S814|(|O
S814|data|O
S814|not|O
S814|shown|O
S814|)|O
S814|.|O
S1450|Statistical|O
S1450|analyses|O
S1450|Data|O
S1450|were|O
S1450|analysed|O
S1450|with|O
S1450|Stata|O
S1450|v10|O
S1450|(|O
S1450|Stata|O
S1450|Corporation|O
S1450|,|O
S1450|Washington|O
S1450|DC|O
S1450|)|O
S1450|.|O
S1050|Conclusions|O
S1050|Salicylic|O
S1050|acid|O
S1050|and|O
S1050|the|O
S1050|cryotherapy|O
S1050|were|O
S1050|equally|O
S1050|effective|O
S1050|for|O
S1050|clearance|O
S1050|of|O
S1050|plantar|O
S1050|warts|O
S1050|.|O
S2259|Safety|O
S2259|Quilizumab|O
S2259|was|O
S2259|well|O
S2259|tolerated|O
S2259|,|O
S2259|and|O
S2259|the|O
S2259|number|O
S2259|of|O
S2259|patients|O
S2259|experiencing|O
S2259|at|O
S2259|least|O
S2259|one|O
S2259|adverse|O
S2259|event|O
S2259|(|O
S2259|AE|O
S2259|)|O
S2259|was|O
S2259|comparable|O
S2259|between|O
S2259|all|O
S2259|treatment|O
S2259|groups|O
S2259|(|O
S2259|Table|O
S2259|2|O
S2259|)|O
S2259|.|O
S864|Participants|O
S864|121|B-Sample_Size_Actual_at_Enrollment
S864|patients|O
S864|(|O
S864|73|O
S864|women|O
S864|,|O
S864|mean|O
S864|age|O
S864|54|O
S864|years|O
S864|)|O
S864|with|O
S864|clinician|O
S864|diagnosed|O
S864|pyoderma|O
S864|gangrenosum|O
S864|.|O
S1272|The|O
S1272|primary|O
S1272|outcome|O
S1272|specified|O
S1272|in|O
S1272|version|O
S1272|1·93|O
S1272|of|O
S1272|the|O
S1272|protocol|O
S1272|and|O
S1272|in|O
S1272|the|O
S1272|published|O
S1272|statistical|O
S1272|analysis|O
S1272|plan|O
S1272|was|O
S1272|the|O
S1272|proportion|O
S1272|of|O
S1272|patients|O
S1272|alive|O
S1272|and|O
S1272|independent|O
S1272|as|O
S1272|measured|O
S1272|by|O
S1272|the|O
S1272|Oxford|O
S1272|Handicap|O
S1272|Score|O
S1272|(|O
S1272|OHS|O
S1272|)|O
S1272|,|O
S1272|a|O
S1272|commonly|O
S1272|used|O
S1272|variant|O
S1272|of|O
S1272|the|O
S1272|modified|O
S1272|Rankin|O
S1272|score|O
S1272|.|O
S1688|There|O
S1688|was|O
S1688|no|O
S1688|evidence|O
S1688|of|O
S1688|interaction|O
S1688|between|O
S1688|monitoring|O
S1688|and|O
S1688|induction-maintenance|O
S1688|ART|O
S1688|strategies|O
S1688|in|O
S1688|primary|O
S1688|or|O
S1688|secondary|O
S1688|outcomes|O
S1688|(|O
S1688|heterogeneity|O
S1688|p|O
S1688|>|O
S1688|0·1|O
S1688|)|O
S1688|except|O
S1688|for|O
S1688|WHO|O
S1688|stage|O
S1688|4|O
S1688|events|O
S1688|or|O
S1688|death|O
S1688|in|O
S1688|the|O
S1688|first|O
S1688|year|O
S1688|on|O
S1688|ART|O
S1688|,|O
S1688|for|O
S1688|which|O
S1688|the|O
S1688|relative|O
S1688|difference|O
S1688|between|O
S1688|clinically|O
S1688|driven|O
S1688|and|O
S1688|routine|O
S1688|laboratory|O
S1688|monitoring|O
S1688|varied|O
S1688|by|O
S1688|first-line|O
S1688|ART|O
S1688|strategy|O
S1688|(|O
S1688|appendix|O
S1688|)|O
S1688|.|O
S77|The|O
S77|results|O
S77|for|O
S77|the|O
S77|primary|O
S77|end|O
S77|point|O
S77|in|O
S77|REDUCE-2|O
S77|showed|O
S77|the|O
S77|proportions|O
S77|of|O
S77|patients|O
S77|with|O
S77|upper|O
S77|GI|O
S77|ulcers|O
S77|of|O
S77|13.0|O
S77|%|O
S77|for|O
S77|HZT-501|O
S77|and|O
S77|20.5|O
S77|%|O
S77|for|O
S77|ibuprofen|O
S77|(|O
S77|P=0.0587|O
S77|)|O
S77|.|O
S1844|In|O
S1844|view|O
S1844|of|O
S1844|the|O
S1844|high|O
S1844|confirmation|O
S1844|rate|O
S1844|(|O
S1844|>|O
S1844|95|O
S1844|%|O
S1844|)|O
S1844|in|O
S1844|central|O
S1844|adjudication|O
S1844|of|O
S1844|cancers|O
S1844|reported|O
S1844|during|O
S1844|the|O
S1844|in-trial|O
S1844|period|O
S1844|,|O
S1844|further|O
S1844|information|O
S1844|was|O
S1844|not|O
S1844|routinely|O
S1844|sought|O
S1844|about|O
S1844|non-fatal|O
S1844|cancers|O
S1844|reported|O
S1844|during|O
S1844|the|O
S1844|post-trial|O
S1844|period|O
S1844|.|O
S1675|Among|O
S1675|151|O
S1675|first-line|O
S1675|drug|O
S1675|changes|O
S1675|,|O
S1675|equal|O
S1675|numbers|O
S1675|were|O
S1675|due|O
S1675|to|O
S1675|adverse|O
S1675|events|O
S1675|and|O
S1675|antituberculosis|O
S1675|therapy|O
S1675|(|O
S1675|both|O
S1675|59|O
S1675|changes|O
S1675|[|O
S1675|39|O
S1675|%|O
S1675|]|O
S1675|;|O
S1675|table|O
S1675|2|O
S1675|)|O
S1675|.|O
S2013|In|O
S2013|an|O
S2013|analysis|O
S2013|of|O
S2013|alkaline|O
S2013|phosphatase|O
S2013|values|O
S2013|,|O
S2013|adjusted|O
S2013|for|O
S2013|baseline|O
S2013|values|O
S2013|,|O
S2013|mean|O
S2013|values|O
S2013|were|O
S2013|marginally|O
S2013|lower|O
S2013|in|O
S2013|the|O
S2013|Ca+D|O
S2013|group|O
S2013|than|O
S2013|the|O
S2013|Ca|O
S2013|group|O
S2013|at|O
S2013|12|O
S2013|weeks|O
S2013|(|O
S2013|p=0.06|O
S2013|)|O
S2013|but|O
S2013|not|O
S2013|at|O
S2013|24|O
S2013|weeks|O
S2013|(|O
S2013|p=0.40|O
S2013|)|O
S2013|.|O
S15|The|O
S15|main|O
S15|factor|O
S15|that|O
S15|limits|O
S15|NSAID|O
S15|use|O
S15|is|O
S15|the|O
S15|development|O
S15|of|O
S15|upper|O
S15|gastrointestinal|O
S15|(|O
S15|GI|O
S15|)|O
S15|adverse|O
S15|effects|O
S15|including|O
S15|ulcers|O
S15|,|O
S15|complications|O
S15|such|O
S15|as|O
S15|bleeding|O
S15|,|O
S15|and|O
S15|dyspepsia|O
S15|.|O
S1691|The|O
S1691|absolute|O
S1691|difference|O
S1691|of|O
S1691|0·32|O
S1691|per|O
S1691|100|O
S1691|child-years|O
S1691|(|O
S1691|95|O
S1691|%|O
S1691|CI|O
S1691|−0·47|O
S1691|to|O
S1691|1·12|O
S1691|)|O
S1691|translated|O
S1691|into|O
S1691|a|O
S1691|relative|O
S1691|HR|O
S1691|of|O
S1691|1·13|O
S1691|(|O
S1691|95|O
S1691|%|O
S1691|CI|O
S1691|0·73–1·73|O
S1691|,|O
S1691|p=0·59|O
S1691|;|O
S1691|figure|O
S1691|3|O
S1691|)|O
S1691|.|O
S79|Assessment|O
S79|of|O
S79|secondary|O
S79|end|O
S79|points|O
S79|in|O
S79|REDUCE-2|O
S79|showed|O
S79|that|O
S79|the|O
S79|6.7|O
S79|%|O
S79|reduction|O
S79|in|O
S79|life|O
S79|table|O
S79|estimate|O
S79|of|O
S79|gastric|O
S79|ulcers|O
S79|was|O
S79|not|O
S79|significant|O
S79|in|O
S79|the|O
S79|initial|O
S79|comparison|O
S79|(|O
S79|P=0.0795|O
S79|)|O
S79|and|O
S79|the|O
S79|5.3|O
S79|%|O
S79|reduction|O
S79|in|O
S79|the|O
S79|post-adjudication|O
S79|analysis|O
S79|was|O
S79|not|O
S79|formally|O
S79|tested|O
S79|based|O
S79|on|O
S79|the|O
S79|predefined|O
S79|hierarchical|O
S79|testing|O
S79|sequence|O
S79|for|O
S79|the|O
S79|analysis|O
S79|.|O
S931|We|O
S931|chose|O
S931|speed|O
S931|of|O
S931|healing|O
S931|for|O
S931|the|O
S931|primary|O
S931|outcome|O
S931|as|O
S931|previous|O
S931|studies|O
S931|have|O
S931|shown|O
S931|it|O
S931|to|O
S931|be|O
S931|a|O
S931|good|O
S931|predictor|O
S931|of|O
S931|healing|O
S931|in|O
S931|patients|O
S931|with|O
S931|leg|O
S931|ulcers|O
S931|,|O
S931|and|O
S931|because|O
S931|blinded|O
S931|outcome|O
S931|assessment|O
S931|was|O
S931|possible|O
S931|using|O
S931|digital|O
S931|images|O
S931|and|O
S931|independent|O
S931|assessors|O
S931|.|O
S239|The|O
S239|other|O
S239|patient|O
S239|was|O
S239|reported|O
S239|with|O
S239|inguinal|O
S239|hernia|O
S239|,|O
S239|which|O
S239|led|O
S239|to|O
S239|hospitalisation|O
S239|.|O
S1319|1617|O
S1319|(|O
S1319|53|O
S1319|%|O
S1319|)|O
S1319|patients|O
S1319|were|O
S1319|older|O
S1319|than|O
S1319|80|O
S1319|years|O
S1319|of|O
S1319|age|O
S1319|.|O
S623|Concomitant|O
S623|use|O
S623|of|O
S623|systemic|O
S623|antibiotics|O
S623|,|O
S623|analgaesics|O
S623|and|O
S623|topical|O
S623|treatments|O
S623|for|O
S623|wound|O
S623|care|O
S623|were|O
S623|allowed|O
S623|,|O
S623|and|O
S623|randomised|O
S623|treatment|O
S623|was|O
S623|administered|O
S623|in|O
S623|addition|O
S623|to|O
S623|the|O
S623|usual|O
S623|,|O
S623|stable|O
S623|(|O
S623|over|O
S623|the|O
S623|previous|O
S623|month|O
S623|)|O
S623|treatment|O
S623|for|O
S623|Raynaud|O
S623|'s|O
S623|phenomenon|O
S623|.|O
S2173|In|O
S2173|patients|O
S2173|with|O
S2173|mild|O
S2173|asthma|O
S2173|,|O
S2173|quilizumab|O
S2173|reduced|O
S2173|serum|O
S2173|IgE|O
S2173|and|O
S2173|attenuated|O
S2173|the|O
S2173|early|O
S2173|and|O
S2173|late|O
S2173|asthmatic|O
S2173|reaction|O
S2173|following|O
S2173|whole|O
S2173|lung|O
S2173|allergen|O
S2173|challenge|O
S2173|.|O
S1895|As|O
S1895|a|O
S1895|result|O
S1895|,|O
S1895|the|O
S1895|absolute|O
S1895|reduction|O
S1895|in|O
S1895|all-cause|O
S1895|mortality|O
S1895|that|O
S1895|emerged|O
S1895|with|O
S1895|simvastatin|O
S1895|allocation|O
S1895|during|O
S1895|the|O
S1895|in-trial|O
S1895|period|O
S1895|persisted|O
S1895|roughly|O
S1895|unchanged|O
S1895|after|O
S1895|11|O
S1895|years|O
S1895|of|O
S1895|follow-up|O
S1895|.|O
S2002|Unlike|O
S2002|classical|O
S2002|vitamin|O
S2002|D-deficiency|O
S2002|rickets|O
S2002|,|O
S2002|all|O
S2002|children|O
S2002|were|O
S2002|over|O
S2002|the|O
S2002|age|O
S2002|of|O
S2002|1|O
S2002|year|O
S2002|at|O
S2002|presentation|O
S2002|and|O
S2002|most|O
S2002|had|O
S2002|regular|O
S2002|sun|O
S2002|exposure|O
S2002|.|O
S2131|With|O
S2131|a|O
S2131|power|O
S2131|of|O
S2131|80|B-Sample_Size_Calculation_Power_Value
S2131|%|I-Sample_Size_Calculation_Power_Value
S2131|and|O
S2131|a|B-Sample_Size_Calculation_Alpha_Value
S2131|type|I-Sample_Size_Calculation_Alpha_Value
S2131|I|I-Sample_Size_Calculation_Alpha_Value
S2131|error|I-Sample_Size_Calculation_Alpha_Value
S2131|of|I-Sample_Size_Calculation_Alpha_Value
S2131|5|I-Sample_Size_Calculation_Alpha_Value
S2131|%|I-Sample_Size_Calculation_Alpha_Value
S2131|,|O
S2131|the|O
S2131|total|O
S2131|sample|O
S2131|size|O
S2131|was|O
S2131|found|O
S2131|to|O
S2131|be|O
S2131|17|B-Sample_Size_Required
S2131|patients|I-Sample_Size_Required
S2131|per|I-Sample_Size_Required
S2131|group|I-Sample_Size_Required
S2131|.|O
S958|Results|O
S958|Of|O
S958|499|O
S958|patients|O
S958|screened|O
S958|from|O
S958|June|O
S958|2009|O
S958|to|O
S958|November|O
S958|2012|O
S958|,|O
S958|121|B-Sample_Size_Actual_at_Enrollment
S958|were|O
S958|eligible|O
S958|and|O
S958|gave|O
S958|written|O
S958|informed|O
S958|consent|O
S958|(|O
S958|86|O
S958|%|O
S958|of|O
S958|target|O
S958|of|O
S958|140|B-Sample_Size_Required
S958|participants|O
S958|)|O
S958|(|O
S958|fig|O
S958|1|O
S958|)|O
S958|.|O
S1856|Role|O
S1856|of|O
S1856|the|O
S1856|funding|O
S1856|source|O
S1856|The|O
S1856|trial|O
S1856|was|O
S1856|designed|O
S1856|,|O
S1856|conducted|O
S1856|,|O
S1856|analysed|O
S1856|,|O
S1856|and|O
S1856|interpreted|O
S1856|by|O
S1856|the|O
S1856|investigators|O
S1856|,|O
S1856|independently|O
S1856|of|O
S1856|all|O
S1856|funding|O
S1856|sources|O
S1856|.|O
S1644|Co-primary|O
S1644|endpoints|O
S1644|for|O
S1644|the|O
S1644|ART-strategy|O
S1644|randomisation|O
S1644|were|O
S1644|change|O
S1644|in|O
S1644|CD4|O
S1644|percentage|O
S1644|from|O
S1644|randomisation|O
S1644|to|O
S1644|72|O
S1644|and|O
S1644|144|O
S1644|weeks|O
S1644|(|O
S1644|efficacy|O
S1644|)|O
S1644|and|O
S1644|grade|O
S1644|3|O
S1644|or|O
S1644|4|O
S1644|adverse|O
S1644|events|O
S1644|(|O
S1644|safety|O
S1644|)|O
S1644|.|O
S1886|The|O
S1886|effects|O
S1886|of|O
S1886|statin|O
S1886|allocation|O
S1886|on|O
S1886|vascular|O
S1886|mortality|O
S1886|in|O
S1886|both|O
S1886|the|O
S1886|in-trial|O
S1886|and|O
S1886|post-trial|O
S1886|periods|O
S1886|were|O
S1886|unaffected|O
S1886|by|O
S1886|age|O
S1886|or|O
S1886|pretreatment|O
S1886|lipid|O
S1886|profiles|O
S1886|(|O
S1886|webappendix|O
S1886|,|O
S1886|p|O
S1886|5|O
S1886|)|O
S1886|.|O
S1340|The|O
S1340|subgroup|O
S1340|analyses|O
S1340|for|O
S1340|a|O
S1340|specific|O
S1340|factor|O
S1340|provide|O
S1340|estimated|O
S1340|effects|O
S1340|within|O
S1340|sub-categories|O
S1340|that|O
S1340|adjust|O
S1340|for|O
S1340|such|O
S1340|imbalances|O
S1340|.|O
S2003|Dietary|O
S2003|calcium|O
S2003|intake|O
S2003|was|O
S2003|uniformly|O
S2003|low|O
S2003|,|O
S2003|reflecting|O
S2003|minimal|O
S2003|dairy|O
S2003|product|O
S2003|intake|O
S2003|.|O
S619|Contraceptive|O
S619|measures|O
S619|and|O
S619|monthly|O
S619|pregnancy|O
S619|testing|O
S619|were|O
S619|required|O
S619|during|O
S619|and|O
S619|for|O
S619|3|O
S619|months|O
S619|after|O
S619|the|O
S619|end|O
S619|of|O
S619|study|O
S619|treatment|O
S619|.|O
S1730|There|O
S1730|were|O
S1730|15|O
S1730|versus|O
S1730|41|O
S1730|versus|O
S1730|31|O
S1730|definitely|O
S1730|,|O
S1730|probably|O
S1730|,|O
S1730|or|O
S1730|uncertainly|O
S1730|ART-related|O
S1730|grade|O
S1730|3|O
S1730|or|O
S1730|4|O
S1730|adverse|O
S1730|events|O
S1730|,|O
S1730|respectively|O
S1730|.|O
S1833|Briefly|O
S1833|,|O
S1833|between|O
S1833|July|O
S1833|,|O
S1833|1994|O
S1833|,|O
S1833|and|O
S1833|May|O
S1833|,|O
S1833|1997|O
S1833|,|O
S1833|20|O
S1833|536|B-Sample_Size_Actual_at_Enrollment
S1833|men|O
S1833|and|O
S1833|women|O
S1833|aged|O
S1833|about|O
S1833|40–80|O
S1833|years|O
S1833|,|O
S1833|who|O
S1833|were|O
S1833|at|O
S1833|increased|O
S1833|risk|O
S1833|of|O
S1833|vascular|O
S1833|events|O
S1833|,|O
S1833|were|O
S1833|randomly|O
S1833|allocated|O
S1833|to|O
S1833|receive|O
S1833|40|B-Design_Parallel_Group
S1833|mg|I-Design_Parallel_Group
S1833|simvastatin|I-Design_Parallel_Group
S1833|daily|I-Design_Parallel_Group
S1833|or|I-Design_Parallel_Group
S1833|matching|I-Design_Parallel_Group
S1833|placebo|I-Design_Parallel_Group
S1833|.|O
S1973|All|O
S1973|children|O
S1973|were|O
S1973|examined|O
S1973|for|O
S1973|clinical|O
S1973|signs|O
S1973|of|O
S1973|rickets|O
S1973|.|O
S899|Oversight|O
S899|of|O
S899|the|O
S899|trial|O
S899|included|O
S899|a|O
S899|trial|O
S899|management|O
S899|group|O
S899|and|O
S899|independent|O
S899|trial|O
S899|steering|O
S899|and|O
S899|data|O
S899|monitoring|O
S899|committees|O
S899|.|O
S1829|It|O
S1829|has|O
S1829|been|O
S1829|suggested|O
S1829|,|O
S1829|therefore|O
S1829|,|O
S1829|that|O
S1829|lowering|O
S1829|LDL|O
S1829|cholesterol|O
S1829|(|O
S1829|particularly|O
S1829|to|O
S1829|low|O
S1829|levels|O
S1829|)|O
S1829|might|O
S1829|produce|O
S1829|increases|O
S1829|in|O
S1829|the|O
S1829|rates|O
S1829|of|O
S1829|cancers|O
S1829|and|O
S1829|other|O
S1829|types|O
S1829|of|O
S1829|adverse|O
S1829|events|O
S1829|that|O
S1829|take|O
S1829|longer|O
S1829|than|O
S1829|5|O
S1829|years|O
S1829|to|O
S1829|emerge|O
S1829|.|O
S1636|Total|O
S1636|lymphocytes|O
S1636|and|O
S1636|CD4|O
S1636|tests|O
S1636|were|O
S1636|never|O
S1636|returned|O
S1636|for|O
S1636|participants|O
S1636|on|O
S1636|clinically|O
S1636|driven|O
S1636|monitoring|O
S1636|,|O
S1636|but|O
S1636|for|O
S1636|all|O
S1636|children|O
S1636|other|O
S1636|investigations|O
S1636|could|O
S1636|be|O
S1636|requested|O
S1636|and|O
S1636|concomitant|O
S1636|drugs|O
S1636|prescribed|O
S1636|,|O
S1636|as|O
S1636|clinically|O
S1636|indicated|O
S1636|.|O
S501|The|O
S501|oxandrolone|O
S501|effect|O
S501|of|O
S501|+4.3|O
S501|cm|O
S501|(|O
S501|P=0.002|O
S501|)|O
S501|was|O
S501|similar|O
S501|to|O
S501|that|O
S501|for|O
S501|final|O
S501|height|O
S501|(|O
S501|+4.6|O
S501|cm|O
S501|)|O
S501|,|O
S501|and|O
S501|the|O
S501|late|O
S501|induction|O
S501|effect|O
S501|of|O
S501|+2.4|O
S501|cm|O
S501|(|O
S501|P=0.2|O
S501|)|O
S501|was|O
S501|appreciably|O
S501|smaller|O
S501|than|O
S501|the|O
S501|+3.8|O
S501|cm|O
S501|for|O
S501|final|O
S501|height|O
S501|.|O
S1431|All|O
S1431|drug|O
S1431|treatments|O
S1431|were|O
S1431|supervised|O
S1431|by|O
S1431|the|O
S1431|research|O
S1431|team|O
S1431|.|O
S73|In|O
S73|the|O
S73|primary|O
S73|population|O
S73|,|O
S73|five|O
S73|patients|O
S73|in|O
S73|REDUCE-1|O
S73|(|O
S73|one|O
S73|HZT-501|O
S73|(|O
S73|no|O
S73|ulcer|O
S73|)|O
S73|,|O
S73|four|O
S73|ibuprofen|O
S73|(|O
S73|four|O
S73|esophageal|O
S73|ulcers|O
S73|)|O
S73|)|O
S73|and|O
S73|seven|O
S73|patients|O
S73|in|O
S73|REDUCE-2|O
S73|(|O
S73|three|O
S73|HZT-501|O
S73|(|O
S73|two|O
S73|no|O
S73|ulcer|O
S73|,|O
S73|one|O
S73|esophageal|O
S73|ulcer|O
S73|)|O
S73|,|O
S73|four|O
S73|ibuprofen|O
S73|(|O
S73|one|O
S73|no|O
S73|ulcer|O
S73|,|O
S73|three|O
S73|esophageal|O
S73|ulcers|O
S73|)|O
S73|)|O
S73|had|O
S73|esophageal|O
S73|ulcers|O
S73|misclassified|O
S73|as|O
S73|gastric|O
S73|ulcers|O
S73|or|O
S73|had|O
S73|no|O
S73|gastric|O
S73|ulcer|O
S73|present|O
S73|;|O
S73|duodenal|O
S73|ulcers|O
S73|were|O
S73|not|O
S73|affected|O
S73|.|O
S2019|At|O
S2019|the|O
S2019|end|O
S2019|of|O
S2019|24|O
S2019|weeks|O
S2019|,|O
S2019|mean|O
S2019|serum|O
S2019|calcium|O
S2019|values|O
S2019|increased|O
S2019|similarly|O
S2019|in|O
S2019|the|O
S2019|two|O
S2019|treatment|O
S2019|groups|O
S2019|,|O
S2019|and|O
S2019|mean|O
S2019|25|O
S2019|(|O
S2019|OH|O
S2019|)|O
S2019|D|O
S2019|values|O
S2019|had|O
S2019|increased|O
S2019|to|O
S2019|55.4±17.0|O
S2019|nmol/L|O
S2019|and|O
S2019|37.9±20.0|O
S2019|nmol/L|O
S2019|in|O
S2019|the|O
S2019|Ca+D|O
S2019|and|O
S2019|the|O
S2019|Ca|O
S2019|groups|O
S2019|,|O
S2019|respectively|O
S2019|,|O
S2019|(|O
S2019|p|O
S2019|<|O
S2019|0.001|O
S2019|;|O
S2019|figure|O
S2019|4|O
S2019|)|O
S2019|.|O
S7|In|O
S7|REDUCE-2|O
S7|,|O
S7|the|O
S7|primary|O
S7|end|O
S7|point|O
S7|analysis|O
S7|of|O
S7|upper|O
S7|gastrointestinal|O
S7|(|O
S7|GI|O
S7|)|O
S7|ulcers|O
S7|was|O
S7|13.0|O
S7|%|O
S7|vs.|O
S7|20.5|O
S7|%|O
S7|(|O
S7|P=0.0587|O
S7|)|O
S7|in|O
S7|the|O
S7|post-adjudication|O
S7|analysis|O
S7|.|O
S1810|Summary|O
S1810|Background|O
S1810|Findings|O
S1810|of|O
S1810|large|O
S1810|randomised|O
S1810|trials|O
S1810|have|O
S1810|shown|O
S1810|that|O
S1810|lowering|O
S1810|LDL|O
S1810|cholesterol|O
S1810|with|O
S1810|statins|O
S1810|reduces|O
S1810|vascular|O
S1810|morbidity|O
S1810|and|O
S1810|mortality|O
S1810|rapidly|O
S1810|,|O
S1810|but|O
S1810|limited|O
S1810|evidence|O
S1810|exists|O
S1810|about|O
S1810|the|O
S1810|long-term|O
S1810|efficacy|O
S1810|and|O
S1810|safety|O
S1810|of|O
S1810|statin|O
S1810|treatment|O
S1810|.|O
S1279|Randomisation|O
S1279|and|O
S1279|masking|O
S1279|To|O
S1279|avoid|O
S1279|predictable|O
S1279|alternation|O
S1279|of|O
S1279|treatment|O
S1279|allocation|O
S1279|,|O
S1279|and|O
S1279|thus|O
S1279|potential|O
S1279|loss|O
S1279|of|O
S1279|allocation|O
S1279|concealment|O
S1279|,|O
S1279|patients|O
S1279|were|O
S1279|allocated|O
S1279|with|O
S1279|a|O
S1279|probability|O
S1279|of|O
S1279|0·80|O
S1279|to|O
S1279|the|O
S1279|treatment|O
S1279|group|O
S1279|that|O
S1279|would|O
S1279|minimise|B-Randomization_Type_Minimization
S1279|the|O
S1279|difference|O
S1279|between|O
S1279|the|O
S1279|groups|O
S1279|on|O
S1279|the|O
S1279|key|O
S1279|prognostic|O
S1279|factors|O
S1279|.|O
S261|Results|O
S261|A|O
S261|dose-response|O
S261|for|O
S261|canakinumab|O
S261|was|O
S261|not|O
S261|apparent|O
S261|with|O
S261|any|O
S261|of|O
S261|the|O
S261|four|O
S261|predefined|O
S261|dose-response|O
S261|models|O
S261|.|O
S1444|We|O
S1444|chose|O
S1444|the|O
S1444|proportion|O
S1444|of|O
S1444|patients|O
S1444|with|O
S1444|viral|O
S1444|RNA|O
S1444|shedding|O
S1444|at|O
S1444|day|O
S1444|five|O
S1444|after|O
S1444|the|O
S1444|start|O
S1444|of|O
S1444|treatment|O
S1444|as|O
S1444|the|O
S1444|primary|O
S1444|endpoint|O
S1444|as|O
S1444|this|O
S1444|represents|O
S1444|the|O
S1444|duration|O
S1444|of|O
S1444|one|O
S1444|standard|O
S1444|course|O
S1444|of|O
S1444|oseltamivir|O
S1444|and|O
S1444|clinical|O
S1444|failure|O
S1444|is|O
S1444|generally|O
S1444|evaluated|O
S1444|after|O
S1444|five|O
S1444|days|O
S1444|of|O
S1444|treatment|O
S1444|.|O
S1324|Among|O
S1324|patients|O
S1324|allocated|O
S1324|to|O
S1324|the|O
S1324|rt-PA|O
S1324|group|O
S1324|,|O
S1324|the|O
S1324|mean|O
S1324|time|O
S1324|from|O
S1324|randomisation|O
S1324|to|O
S1324|injection|O
S1324|of|O
S1324|the|O
S1324|bolus|O
S1324|was|O
S1324|18|O
S1324|min|O
S1324|,|O
S1324|the|O
S1324|mean|O
S1324|time|O
S1324|from|O
S1324|onset|O
S1324|to|O
S1324|treatment|O
S1324|was|O
S1324|4·2|O
S1324|h|O
S1324|(|O
S1324|SD|O
S1324|1·2|O
S1324|)|O
S1324|,|O
S1324|median|O
S1324|4·2|O
S1324|h|O
S1324|(|O
S1324|IQR|O
S1324|3·2–5·2|O
S1324|)|O
S1324|.|O
S2087|However|O
S2087|,|O
S2087|in|O
S2087|the|O
S2087|memantine|O
S2087|group|O
S2087|,|O
S2087|we|O
S2087|observed|O
S2087|significantly|O
S2087|better|O
S2087|results|O
S2087|(|O
S2087|vs|O
S2087|placebo|O
S2087|)|O
S2087|for|O
S2087|the|O
S2087|overall|O
S2087|UPDRS|O
S2087|score|O
S2087|(|O
S2087|F|O
S2087|(|O
S2087|1,21|O
S2087|)|O
S2087|=4.9|O
S2087|;|O
S2087|p=0.039|O
S2087|(|O
S2087|−1|O
S2087|)|O
S2087|)|O
S2087|and|O
S2087|its|O
S2087|axial|O
S2087|subscore|O
S2087|(|O
S2087|F|O
S2087|(|O
S2087|1,21|O
S2087|)|O
S2087|=7.2|O
S2087|;|O
S2087|p=0.014|O
S2087|(|O
S2087|−1.1|O
S2087|)|O
S2087|)|O
S2087|,|O
S2087|axial|O
S2087|hypertonia|O
S2087|,|O
S2087|the|O
S2087|axial|O
S2087|and|O
S2087|overall|O
S2087|DRS|O
S2087|and|O
S2087|axial|O
S2087|strength|O
S2087|.|O
S29|Patients|B-Blinding_Object_Patients
S29|,|O
S29|care|B-Blinding_Object_Care_Providers
S29|providers|I-Blinding_Object_Care_Providers
S29|,|O
S29|and|O
S29|all|B-Blinding_Object_Others
S29|study|I-Blinding_Object_Others
S29|personnel|I-Blinding_Object_Others
S29|were|O
S29|blinded|O
S29|to|O
S29|the|O
S29|treatment|O
S29|.|O
S1452|For|O
S1452|the|O
S1452|virological|O
S1452|endpoints|O
S1452|,|O
S1452|we|O
S1452|included|O
S1452|only|O
S1452|patients|O
S1452|with|O
S1452|RT-PCR|O
S1452|proved|O
S1452|influenza|O
S1452|virus|O
S1452|infection|O
S1452|on|O
S1452|screening|O
S1452|(|O
S1452|day|O
S1452|0|O
S1452|)|O
S1452|.|O
S1939|Population|O
S1939|Nigerian|O
S1939|children|O
S1939|with|O
S1939|active|O
S1939|rickets|O
S1939|treated|O
S1939|with|O
S1939|calcium|O
S1939|carbonate|O
S1939|as|O
S1939|limestone|O
S1939|(|O
S1939|approximately|O
S1939|938|O
S1939|mg|O
S1939|elemental|O
S1939|calcium|O
S1939|twice|O
S1939|daily|O
S1939|)|O
S1939|were|O
S1939|,|O
S1939|in|O
S1939|addition|O
S1939|,|O
S1939|randomised|O
S1939|to|O
S1939|receive|O
S1939|either|B-Design_Parallel_Group
S1939|oral|I-Design_Parallel_Group
S1939|vitamin|I-Design_Parallel_Group
S1939|D2|I-Design_Parallel_Group
S1939|50|I-Design_Parallel_Group
S1939|000|I-Design_Parallel_Group
S1939|IU|I-Design_Parallel_Group
S1939|(|I-Design_Parallel_Group
S1939|Ca+D|I-Design_Parallel_Group
S1939|,|I-Design_Parallel_Group
S1939|n=44|I-Design_Parallel_Group
S1939|)|I-Design_Parallel_Group
S1939|or|I-Design_Parallel_Group
S1939|placebo|I-Design_Parallel_Group
S1939|(|I-Design_Parallel_Group
S1939|Ca|I-Design_Parallel_Group
S1939|,|I-Design_Parallel_Group
S1939|n=28|I-Design_Parallel_Group
S1939|)|I-Design_Parallel_Group
S1939|monthly|I-Design_Parallel_Group
S1939|for|I-Design_Parallel_Group
S1939|24|I-Design_Parallel_Group
S1939|weeks|I-Design_Parallel_Group
S1939|.|O
S769|Subcutaneous|O
S769|etanercept|O
S769|has|O
S769|23|O
S769|%|O
S769|bioavailability|O
S769|and|O
S769|achieves|O
S769|peak|O
S769|plasma|O
S769|concentrations|O
S769|of|O
S769|0.43|O
S769|µg/ml|O
S769|at|O
S769|66|O
S769|h.|O
S769|In|O
S769|contrast|O
S769|,|O
S769|a|O
S769|single|O
S769|intravenous|O
S769|dose|O
S769|of|O
S769|10|O
S769|mg|O
S769|etanercept|O
S769|achieves|O
S769|a|O
S769|maximum|O
S769|concentration|O
S769|of|O
S769|2.32|O
S769|µg/ml|O
S769|at|O
S769|50|O
S769|min|O
S769|.|O
S1609|Trials|O
S1609|in|O
S1609|adults|O
S1609|have|O
S1609|compared|O
S1609|routine|O
S1609|laboratory|O
S1609|with|O
S1609|clinical|O
S1609|monitoring|O
S1609|on|O
S1609|ART|O
S1609|.|O
S1049|There|O
S1049|was|O
S1049|also|O
S1049|no|O
S1049|evidence|O
S1049|of|O
S1049|a|O
S1049|difference|O
S1049|in|O
S1049|the|O
S1049|number|O
S1049|of|O
S1049|plantar|O
S1049|warts|O
S1049|at|O
S1049|12|O
S1049|weeks|O
S1049|(|O
S1049|incident|O
S1049|rate|O
S1049|ratio|O
S1049|1.08|O
S1049|(|O
S1049|0.81|O
S1049|to|O
S1049|1.43|O
S1049|)|O
S1049|,|O
S1049|P=0.62|O
S1049|)|O
S1049|.|O
S780|Vasomotor|O
S780|assessment|O
S780|Assessment|O
S780|of|O
S780|vasomotor|O
S780|function|O
S780|in|O
S780|response|O
S780|to|O
S780|intra-arterial|O
S780|vasodilators|O
S780|was|O
S780|performed|O
S780|as|O
S780|described|O
S780|previously|O
S780|.|O
S1479|In|O
S1479|children|O
S1479|,|O
S1479|the|O
S1479|corresponding|O
S1479|rates|O
S1479|were|O
S1479|71|O
S1479|%|O
S1479|(|O
S1479|85/120|O
S1479|;|O
S1479|62.2|O
S1479|%|O
S1479|to|O
S1479|78.2|O
S1479|%|O
S1479|)|O
S1479|in|O
S1479|the|O
S1479|double|O
S1479|dose|O
S1479|arm|O
S1479|versus|O
S1479|67|O
S1479|%|O
S1479|(|O
S1479|79/118|O
S1479|;|O
S1479|58.0|O
S1479|%|O
S1479|to|O
S1479|74.8|O
S1479|%|O
S1479|)|O
S1479|in|O
S1479|the|O
S1479|standard|O
S1479|dose|O
S1479|arm|O
S1479|(|O
S1479|P=0.52|O
S1479|)|O
S1479|,|O
S1479|and|O
S1479|in|O
S1479|adults|O
S1479|77|O
S1479|%|O
S1479|(|O
S1479|30/39|O
S1479|;|O
S1479|61.7|O
S1479|%|O
S1479|to|O
S1479|87.4|O
S1479|%|O
S1479|)|O
S1479|versus|O
S1479|72|O
S1479|%|O
S1479|(|O
S1479|26/36|O
S1479|;|O
S1479|56.0|O
S1479|%|O
S1479|to|O
S1479|84.2|O
S1479|%|O
S1479|)|O
S1479|,|O
S1479|respectively|O
S1479|(|O
S1479|P=0.64|O
S1479|)|O
S1479|.|O
S573|Bosentan|O
S573|treatment|O
S573|of|O
S573|digital|O
S573|ulcers|O
S573|related|O
S573|to|O
S573|systemic|O
S573|sclerosis|O
S573|:|O
S573|results|O
S573|from|O
S573|the|O
S573|RAPIDS-2|O
S573|randomised|O
S573|,|O
S573|double-blind|B-Blinding_Double_Blind
S573|,|O
S573|placebo-controlled|O
S573|trial|O
S917|Randomisation|O
S917|was|O
S917|stratified|B-Randomization_Type_Stratified
S917|by|O
S917|target|B-Randomization_Stratified_Criteria
S917|lesion|I-Randomization_Stratified_Criteria
S917|size|I-Randomization_Stratified_Criteria
S917|(|I-Randomization_Stratified_Criteria
S917|<|I-Randomization_Stratified_Criteria
S917|20|I-Randomization_Stratified_Criteria
S917|cm2|I-Randomization_Stratified_Criteria
S917|;|I-Randomization_Stratified_Criteria
S917|≥20|I-Randomization_Stratified_Criteria
S917|cm2|I-Randomization_Stratified_Criteria
S917|)|I-Randomization_Stratified_Criteria
S917|and|O
S917|presence|B-Randomization_Stratified_Criteria
S917|or|I-Randomization_Stratified_Criteria
S917|absence|I-Randomization_Stratified_Criteria
S917|of|I-Randomization_Stratified_Criteria
S917|underlying|I-Randomization_Stratified_Criteria
S917|systemic|I-Randomization_Stratified_Criteria
S917|disease|I-Randomization_Stratified_Criteria
S917|.|O
S1296|All|O
S1296|IST-3|O
S1296|monitoring|O
S1296|procedures|O
S1296|were|O
S1296|compliant|O
S1296|with|O
S1296|requirements|O
S1296|of|O
S1296|all|O
S1296|study|O
S1296|sponsors|O
S1296|,|O
S1296|the|O
S1296|national|O
S1296|ethics|O
S1296|committees|O
S1296|and|O
S1296|regulatory|O
S1296|agencies|O
S1296|in|O
S1296|the|O
S1296|12|O
S1296|participating|O
S1296|countries|O
S1296|,|O
S1296|and|O
S1296|they|O
S1296|met|O
S1296|all|O
S1296|appropriate|O
S1296|regulatory|O
S1296|and|O
S1296|Good|O
S1296|Clinical|O
S1296|Practice|O
S1296|requirements|O
S1296|.|O
S608|The|O
S608|present|O
S608|study|O
S608|(|O
S608|RAPIDS-2|O
S608|,|O
S608|for|O
S608|‘|O
S608|RAndomized|O
S608|,|O
S608|double-blind|O
S608|,|O
S608|Placebo-controlled|O
S608|study|O
S608|with|O
S608|bosentan|O
S608|on|O
S608|healing|O
S608|and|O
S608|prevention|O
S608|of|O
S608|Ischemic|O
S608|Digital|O
S608|ulcers|O
S608|in|O
S608|patients|O
S608|with|O
S608|systemic|O
S608|Sclerosis|O
S608|’|O
S608|)|O
S608|was|O
S608|designed|O
S608|to|O
S608|further|O
S608|investigate|O
S608|the|O
S608|effects|O
S608|of|O
S608|bosentan|O
S608|as|O
S608|a|O
S608|treatment|O
S608|for|O
S608|DUs|O
S608|secondary|O
S608|to|O
S608|SSc|O
S608|over|O
S608|a|O
S608|24-week|O
S608|treatment|O
S608|period|O
S608|in|O
S608|a|O
S608|larger|O
S608|population|O
S608|of|O
S608|patients|O
S608|,|O
S608|all|O
S608|of|O
S608|whom|O
S608|had|O
S608|active|O
S608|DUs|O
S608|at|O
S608|study|O
S608|entry|O
S608|.|O
S946|We|O
S946|chose|O
S946|a|O
S946|difference|O
S946|of|O
S946|0.5|O
S946|standard|O
S946|deviations|O
S946|as|O
S946|being|O
S946|a|O
S946|clinically|O
S946|meaningful|O
S946|between|O
S946|group|O
S946|difference|O
S946|,|O
S946|as|O
S946|observational|O
S946|data|O
S946|suggested|O
S946|that|O
S946|ciclosporin|O
S946|was|O
S946|potentially|O
S946|more|O
S946|effective|O
S946|,|O
S946|but|O
S946|at|O
S946|higher|O
S946|cost|O
S946|,|O
S946|than|O
S946|prednisolone|O
S946|.|O
S790|Blood|O
S790|anticoagulated|O
S790|with|O
S790|PPACK|O
S790|was|O
S790|labelled|O
S790|with|O
S790|the|O
S790|appropriate|O
S790|antibodies|O
S790|exactly|O
S790|5|O
S790|min|O
S790|from|O
S790|collection|O
S790|and|O
S790|incubated|O
S790|in|O
S790|the|O
S790|dark|O
S790|for|O
S790|20|O
S790|min|O
S790|at|O
S790|room|O
S790|temperature|O
S790|.|O
S1869|During|O
S1869|the|O
S1869|post-trial|O
S1869|period|O
S1869|,|O
S1869|self-reported|O
S1869|statin|O
S1869|use|O
S1869|was|O
S1869|similar|O
S1869|in|O
S1869|both|O
S1869|groups|O
S1869|,|O
S1869|rising|O
S1869|from|O
S1869|about|O
S1869|59|O
S1869|%|O
S1869|at|O
S1869|the|O
S1869|end|O
S1869|of|O
S1869|the|O
S1869|first|O
S1869|year|O
S1869|to|O
S1869|84|O
S1869|%|O
S1869|by|O
S1869|the|O
S1869|end|O
S1869|of|O
S1869|the|O
S1869|fifth|O
S1869|year|O
S1869|(|O
S1869|table|O
S1869|2|O
S1869|)|O
S1869|.|O
S1677|30|O
S1677|children|O
S1677|in|O
S1677|group|O
S1677|A|O
S1677|,|O
S1677|20|O
S1677|in|O
S1677|group|O
S1677|B|O
S1677|,|O
S1677|and|O
S1677|nine|O
S1677|in|O
S1677|group|O
S1677|C|O
S1677|stopped|O
S1677|nevirapine|O
S1677|because|O
S1677|of|O
S1677|starting|O
S1677|antituberculosis|O
S1677|treatment|O
S1677|.|O
S157|Trial|O
S157|registration|O
S157|ClinicalTrials.gov|O
S157|identifier|O
S157|NCT01233284|O
S157|.|O
S449|Randomisation|O
S449|and|O
S449|masking|O
S449|The|O
S449|British|O
S449|Society|O
S449|for|O
S449|Paediatric|O
S449|Endocrinology|O
S449|and|O
S449|Diabetes|O
S449|Clinical|O
S449|Trials|O
S449|Unit|O
S449|(|O
S449|Cambridge|O
S449|,|O
S449|UK|O
S449|)|O
S449|used|O
S449|minimisation|B-Randomization_Type_Minimization
S449|by|O
S449|weighted|B-Randomization_Minimization_Criteria
S449|randomisation|I-Randomization_Minimization_Criteria
S449|for|O
S449|the|O
S449|study|O
S449|’|O
S449|s|O
S449|two|O
S449|randomisations|O
S449|.|O
S347|No|O
S347|serious|O
S347|infections|O
S347|were|O
S347|reported|O
S347|in|O
S347|patients|O
S347|receiving|O
S347|colchicine|O
S347|.|O
S2232|Allergen-specific|O
S2232|and|O
S2232|total|O
S2232|IgE|O
S2232|were|O
S2232|measured|O
S2232|in|O
S2232|serum|O
S2232|by|O
S2232|ImmunoCAP®|O
S2232|Specific|O
S2232|IgE|O
S2232|blood|O
S2232|tests|O
S2232|(|O
S2232|ViraCor-IBT|O
S2232|Laboratories|O
S2232|,|O
S2232|Lee|O
S2232|’|O
S2232|s|O
S2232|Summit|O
S2232|,|O
S2232|MO|O
S2232|)|O
S2232|.|O
S2101|Patients|O
S2101|and|O
S2101|methods|O
S2101|The|O
S2101|present|O
S2101|randomised|B-Randomization_Type_Simple
S2101|trial|O
S2101|complied|O
S2101|with|O
S2101|the|O
S2101|CONSORT|O
S2101|2010|O
S2101|guidelines|O
S2101|and|O
S2101|was|O
S2101|registered|O
S2101|at|O
S2101|ClinicalTrials.gov|O
S2101|(|O
S2101|identifier|O
S2101|:|O
S2101|NCT01108029|O
S2101|)|O
S2101|.|O
S2005|Children|O
S2005|'s|O
S2005|heights|O
S2005|were|O
S2005|significantly|O
S2005|stunted|O
S2005|,|O
S2005|in|O
S2005|part|O
S2005|reflecting|O
S2005|their|O
S2005|leg|O
S2005|deformities|O
S2005|,|O
S2005|but|O
S2005|their|O
S2005|relatively|O
S2005|normal|O
S2005|weight|O
S2005|for|O
S2005|height|O
S2005|and|O
S2005|serum|O
S2005|albumin|O
S2005|did|O
S2005|not|O
S2005|indicate|O
S2005|acute|O
S2005|malnutrition|O
S2005|.|O
S227|Secondary|O
S227|analyses|O
S227|Trough|O
S227|FEV1|O
S227|,|O
S227|FEV1|O
S227|AUC|O
S227|(|O
S227|0-3h|O
S227|)|O
S227|,|O
S227|peak|O
S227|FVC|O
S227|(|O
S227|0-3h|O
S227|)|O
S227|,|O
S227|trough|O
S227|FVC|O
S227|and|O
S227|FVC|O
S227|AUC|O
S227|(|O
S227|0-3h|O
S227|)|O
S227|responses|O
S227|with|O
S227|all|O
S227|doses|O
S227|of|O
S227|tiotropium|O
S227|Respimat®|O
S227|were|O
S227|larger|O
S227|than|O
S227|the|O
S227|responses|O
S227|observed|O
S227|with|O
S227|placebo|O
S227|Respimat®|O
S227|,|O
S227|and|O
S227|all|O
S227|were|O
S227|statistically|O
S227|significant|O
S227|except|O
S227|for|O
S227|trough|O
S227|FVC|O
S227|in|O
S227|the|O
S227|1.25|O
S227|μg|O
S227|group|O
S227|(|O
S227|Figure|O
S227|3|O
S227|,|O
S227|Additional|O
S227|file|O
S227|1|O
S227|:|O
S227|Table|O
S227|S1|O
S227|)|O
S227|.|O
S612|The|O
S612|study|O
S612|was|O
S612|approved|O
S612|by|O
S612|local|O
S612|ethics|O
S612|committees|O
S612|and|O
S612|conducted|O
S612|in|O
S612|accordance|O
S612|with|O
S612|the|O
S612|amended|O
S612|Declaration|O
S612|of|O
S612|Helsinki|O
S612|.|O
S331|CRP|O
S331|levels|O
S331|An|O
S331|initial|O
S331|decrease|O
S331|in|O
S331|median|O
S331|CRP|O
S331|levels|O
S331|was|O
S331|seen|O
S331|in|O
S331|all|O
S331|treatment|O
S331|groups|O
S331|(|O
S331|figure|O
S331|3|O
S331|)|O
S331|.|O
S1439|Qualitative|O
S1439|RT-PCR|O
S1439|for|O
S1439|detection|O
S1439|of|O
S1439|influenza|O
S1439|A|O
S1439|and|O
S1439|B|O
S1439|viruses|O
S1439|and|O
S1439|for|O
S1439|subtyping|O
S1439|of|O
S1439|influenza|O
S1439|A|O
S1439|viruses|O
S1439|was|O
S1439|done|O
S1439|according|O
S1439|to|O
S1439|WHO/US|O
S1439|CDC|O
S1439|protocols|O
S1439|.|O
S635|Means±SEs|O
S635|are|O
S635|presented|O
S635|for|O
S635|numerical|O
S635|variables|O
S635|and|O
S635|Kaplan–Meier|O
S635|estimates|O
S635|for|O
S635|time-to-event|O
S635|variables|O
S635|.|O
S2231|Biomarkers|O
S2231|Samples|O
S2231|for|O
S2231|biomarker|O
S2231|assessments|O
S2231|were|O
S2231|collected|O
S2231|throughout|O
S2231|the|O
S2231|study|O
S2231|.|O
S97|Gastric|O
S97|erosions|O
S97|were|O
S97|noted|O
S97|at|O
S97|endoscopy|O
S97|in|O
S97|all|O
S97|three|O
S97|patients|O
S97|.|O
S809|Platelet|O
S809|activation|O
S809|PMA|O
S809|and|O
S809|platelet|O
S809|P-selectin|O
S809|expression|O
S809|were|O
S809|similar|O
S809|between|O
S809|the|O
S809|groups|O
S809|at|O
S809|baseline|O
S809|.|O
S164|Further|O
S164|,|O
S164|in|O
S164|patients|O
S164|who|O
S164|fail|O
S164|to|O
S164|gain|O
S164|control|O
S164|with|O
S164|an|O
S164|ICS|O
S164|+|O
S164|LABA|O
S164|fixed-dose|O
S164|combination|O
S164|,|O
S164|the|O
S164|remaining|O
S164|options|O
S164|,|O
S164|such|O
S164|as|O
S164|further|O
S164|upwards|O
S164|titration|O
S164|of|O
S164|ICS|O
S164|,|O
S164|systemic|O
S164|glucocorticosteroids|O
S164|and|O
S164|anti-immunoglobulin|O
S164|E|O
S164|therapy|O
S164|,|O
S164|may|O
S164|have|O
S164|several|O
S164|limitations|O
S164|with|O
S164|respect|O
S164|to|O
S164|side|O
S164|effects|O
S164|,|O
S164|risk|O
S164|:|O
S164|benefit|O
S164|ratio|O
S164|,|O
S164|convenience|O
S164|and|O
S164|efficacy|O
S164|.|O
S1640|During|O
S1640|four-drug|O
S1640|induction|O
S1640|,|O
S1640|a|O
S1640|drug|O
S1640|could|O
S1640|be|O
S1640|dropped|O
S1640|because|O
S1640|of|O
S1640|toxicity|O
S1640|or|O
S1640|drug|O
S1640|interactions|O
S1640|with|O
S1640|antituberculosis|O
S1640|treatment|O
S1640|.|O
S865|Clinical|O
S865|diagnosis|O
S865|was|O
S865|revised|O
S865|in|O
S865|nine|O
S865|participants|O
S865|after|O
S865|randomisation|O
S865|,|O
S865|leaving|O
S865|112|B-Sample_Size_Actual_at_Outcome_Analysis
S865|participants|O
S865|in|O
S865|the|O
S865|analysis|O
S865|set|O
S865|(|O
S865|59|O
S865|ciclosporin|O
S865|;|O
S865|53|O
S865|prednisolone|O
S865|)|O
S865|.|O
S1278|Data|O
S1278|on|O
S1278|potential|O
S1278|reports|O
S1278|of|O
S1278|any|O
S1278|of|O
S1278|these|O
S1278|events|O
S1278|were|O
S1278|extracted|O
S1278|from|O
S1278|the|O
S1278|trial|O
S1278|database|O
S1278|and|O
S1278|presented|O
S1278|to|O
S1278|the|O
S1278|adjudication|O
S1278|committee|O
S1278|who|O
S1278|were|O
S1278|masked|O
S1278|to|O
S1278|treatment|O
S1278|allocation|O
S1278|.|O
S4|Study|O
S4|endoscopies|O
S4|were|O
S4|done|O
S4|at|O
S4|8|O
S4|,|O
S4|16|O
S4|,|O
S4|and|O
S4|24|O
S4|weeks|O
S4|.|O
S203|Pre-dose|O
S203|lung|O
S203|function|O
S203|tests|O
S203|were|O
S203|scheduled|O
S203|between|O
S203|18:00|O
S203|and|O
S203|20:00|O
S203|.|O
S22|For|O
S22|example|O
S22|,|O
S22|van|O
S22|Soest|O
S22|et|O
S22|al|O
S22|.|O
S284|This|O
S284|suggests|O
S284|that|O
S284|selective|O
S284|blockade|O
S284|of|O
S284|IL-1β|O
S284|signalling|O
S284|may|O
S284|provide|O
S284|effective|O
S284|prophylaxis|O
S284|against|O
S284|flares|O
S284|in|O
S284|patients|O
S284|with|O
S284|gouty|O
S284|arthritis|O
S284|and|O
S284|is|O
S284|supported|O
S284|by|O
S284|results|O
S284|showing|O
S284|that|O
S284|IL-1β|O
S284|blockade|O
S284|with|O
S284|canakinumab|O
S284|,|O
S284|a|O
S284|fully|O
S284|human|O
S284|monoclonal|O
S284|antibody|O
S284|to|O
S284|IL-1β|O
S284|with|O
S284|a|O
S284|half-life|O
S284|of|O
S284|3–4|O
S284|weeks|O
S284|,|O
S284|can|O
S284|effectively|O
S284|reduce|O
S284|pain|O
S284|,|O
S284|inflammation|O
S284|and|O
S284|the|O
S284|risk|O
S284|of|O
S284|recurrent|O
S284|flares|O
S284|in|O
S284|patients|O
S284|with|O
S284|acute|O
S284|gouty|O
S284|arthritis|O
S284|.|O
S1722|No|O
S1722|significant|O
S1722|difference|O
S1722|was|O
S1722|seen|O
S1722|in|O
S1722|suppression|O
S1722|less|O
S1722|than|O
S1722|80|O
S1722|copies|O
S1722|per|O
S1722|mL|O
S1722|at|O
S1722|week|O
S1722|24|O
S1722|(|O
S1722|p=0·41|O
S1722|)|O
S1722|;|O
S1722|however|O
S1722|,|O
S1722|suppression|O
S1722|less|O
S1722|than|O
S1722|80|O
S1722|copies|O
S1722|per|O
S1722|mL|O
S1722|was|O
S1722|significantly|O
S1722|greater|O
S1722|in|O
S1722|groups|O
S1722|A|O
S1722|and|O
S1722|B|O
S1722|at|O
S1722|week|O
S1722|144|O
S1722|and|O
S1722|latest|O
S1722|test|O
S1722|(|O
S1722|466|O
S1722|[|O
S1722|79|O
S1722|%|O
S1722|]|O
S1722|in|O
S1722|groups|O
S1722|A|O
S1722|and|O
S1722|B|O
S1722|vs|O
S1722|176|O
S1722|[|O
S1722|57|O
S1722|%|O
S1722|]|O
S1722|in|O
S1722|group|O
S1722|C|O
S1722|;|O
S1722|p|O
S1722|<|O
S1722|0·0001|O
S1722|)|O
S1722|.|O
S1877|Similar|O
S1877|patterns|O
S1877|were|O
S1877|seen|O
S1877|for|O
S1877|each|O
S1877|component|O
S1877|of|O
S1877|major|O
S1877|vascular|O
S1877|events|O
S1877|(|O
S1877|figure|O
S1877|1|O
S1877|)|O
S1877|.|O
S1106|Analyses|O
S1106|were|O
S1106|conducted|O
S1106|in|O
S1106|SAS|O
S1106|version|O
S1106|9.2|O
S1106|(|O
S1106|SAS|O
S1106|Institute|O
S1106|,|O
S1106|NC|O
S1106|,|O
S1106|USA|O
S1106|)|O
S1106|and|O
S1106|SPSS|O
S1106|version|O
S1106|17.0.2|O
S1106|(|O
S1106|SPSS|O
S1106|)|O
S1106|using|O
S1106|two|O
S1106|sided|O
S1106|significance|O
S1106|tests|O
S1106|at|O
S1106|the|O
S1106|5|O
S1106|%|O
S1106|significance|O
S1106|level|O
S1106|for|O
S1106|the|O
S1106|primary|O
S1106|outcome|O
S1106|measure|O
S1106|and|O
S1106|1|O
S1106|%|O
S1106|significance|O
S1106|level|O
S1106|for|O
S1106|secondary|O
S1106|outcome|O
S1106|measures|O
S1106|.|O
S918|It|O
S918|was|O
S918|not|O
S918|possible|O
S918|to|O
S918|blind|O
S918|clinicians|O
S918|and|O
S918|participants|O
S918|to|O
S918|treatment|O
S918|allocation|O
S918|owing|O
S918|to|O
S918|resource|O
S918|limitations|O
S918|and|O
S918|the|O
S918|complexities|O
S918|of|O
S918|different|O
S918|dosing|O
S918|regimens|O
S918|and|O
S918|safety|O
S918|testing|O
S918|of|O
S918|the|O
S918|two|O
S918|drugs|O
S918|.|O
S228|Responses|O
S228|for|O
S228|each|O
S228|of|O
S228|these|O
S228|end|O
S228|points|O
S228|were|O
S228|all|O
S228|largest|O
S228|in|O
S228|the|O
S228|5|O
S228|μg|O
S228|group|O
S228|(|O
S228|Figure|O
S228|3|O
S228|,|O
S228|Additional|O
S228|file|O
S228|1|O
S228|:|O
S228|Table|O
S228|S1|O
S228|)|O
S228|.|O
S509|This|O
S509|effect|O
S509|is|O
S509|seen|O
S509|in|O
S509|figure|O
S509|3|O
S509|(|O
S509|top|O
S509|panel|O
S509|)|O
S509|,|O
S509|which|O
S509|shows|O
S509|SITAR|O
S509|summary|O
S509|curves|O
S509|calculated|O
S509|separately|O
S509|for|O
S509|oxandrolone|O
S509|and|O
S509|placebo|O
S509|.|O
S2227|Baseline|O
S2227|values|O
S2227|were|O
S2227|derived|O
S2227|from|O
S2227|a|O
S2227|minimum|O
S2227|of|O
S2227|10|O
S2227|days|O
S2227|of|O
S2227|patient|O
S2227|diary|O
S2227|entries|O
S2227|during|O
S2227|the|O
S2227|14|O
S2227|days|O
S2227|prior|O
S2227|to|O
S2227|the|O
S2227|first|O
S2227|treatment|O
S2227|.|O
S897|Trial|O
S897|design|O
S897|and|O
S897|oversight|O
S897|We|O
S897|carried|O
S897|out|O
S897|a|O
S897|multicentre|B-Settings_Multicenter
S897|,|O
S897|parallel|B-Design_Parallel_Group
S897|group|I-Design_Parallel_Group
S897|,|O
S897|observer|B-Blinding_Object_Outcome_Assessors
S897|blind|I-Blinding_Single_Blind
S897|randomised|O
S897|controlled|O
S897|trial|O
S897|to|O
S897|compare|O
S897|the|O
S897|efficacy|O
S897|and|O
S897|safety|O
S897|of|O
S897|ciclosporin|O
S897|with|O
S897|that|O
S897|of|O
S897|prednisolone|O
S897|.|O
S1241|As|O
S1241|a|O
S1241|result|O
S1241|of|O
S1241|the|O
S1241|current|O
S1241|European|O
S1241|Union|O
S1241|(|O
S1241|EU|O
S1241|)|O
S1241|approval|O
S1241|criteria|O
S1241|,|O
S1241|treatment|O
S1241|is|O
S1241|only|O
S1241|applicable|O
S1241|to|O
S1241|a|O
S1241|small|O
S1241|proportion|O
S1241|of|O
S1241|patients|O
S1241|with|O
S1241|acute|O
S1241|stroke|O
S1241|.|O
S2023|The|O
S2023|increase|O
S2023|in|O
S2023|height|O
S2023|over|O
S2023|the|O
S2023|course|O
S2023|of|O
S2023|treatment|O
S2023|was|O
S2023|significantly|O
S2023|related|O
S2023|to|O
S2023|the|O
S2023|final|O
S2023|25|O
S2023|(|O
S2023|OH|O
S2023|)|O
S2023|D|O
S2023|concentration|O
S2023|(|O
S2023|r=0.28|O
S2023|;|O
S2023|p=0.02|O
S2023|)|O
S2023|.|O
S643|Safety|O
S643|and|O
S643|baseline|O
S643|data|O
S643|were|O
S643|summarised|O
S643|descriptively|O
S643|,|O
S643|with|O
S643|no|O
S643|statistical|O
S643|testing|O
S643|planned|O
S643|or|O
S643|given|O
S643|.|O
S2122|After|O
S2122|acute|O
S2122|administration|O
S2122|of|O
S2122|L-dopa|O
S2122|at|O
S2122|9:00|O
S2122|,|O
S2122|the|O
S2122|‘|O
S2122|best|O
S2122|on|O
S2122|’|O
S2122|condition|O
S2122|was|O
S2122|assessed|O
S2122|at|O
S2122|between|O
S2122|9:30|O
S2122|and|O
S2122|10:00|O
S2122|on|O
S2122|the|O
S2122|same|O
S2122|morning|O
S2122|.|O
S1038|Objective|O
S1038|To|O
S1038|compare|O
S1038|the|O
S1038|clinical|O
S1038|effectiveness|O
S1038|of|O
S1038|cryotherapy|O
S1038|versus|O
S1038|salicylic|O
S1038|acid|O
S1038|for|O
S1038|the|O
S1038|treatment|O
S1038|of|O
S1038|plantar|O
S1038|warts|O
S1038|.|O
S1996|The|O
S1996|Wilcoxon|O
S1996|test|O
S1996|was|O
S1996|used|O
S1996|to|O
S1996|compare|O
S1996|non-normally|O
S1996|distributed|O
S1996|variables|O
S1996|.|O
S171|Kerstjens|O
S171|and|O
S171|colleagues|O
S171|subsequently|O
S171|reported|O
S171|results|O
S171|from|O
S171|two|O
S171|long-term|O
S171|,|O
S171|replicate|O
S171|,|O
S171|1-year|O
S171|Phase|O
S171|III|O
S171|trials|O
S171|of|O
S171|tiotropium|O
S171|Respimat®|O
S171|5|O
S171|μg|O
S171|,|O
S171|also|O
S171|in|O
S171|patients|O
S171|with|O
S171|symptomatic|O
S171|severe|O
S171|asthma|O
S171|despite|O
S171|using|O
S171|ICS|O
S171|+|O
S171|LABA|O
S171|.|O
S288|The|O
S288|trial|O
S288|was|O
S288|registered|O
S288|with|O
S288|http|O
S288|:|O
S288|//www.clinicaltrials.gov|O
S288|(|O
S288|registration|O
S288|number|O
S288|:|O
S288|NCT00819585|O
S288|)|O
S288|.|O
S1494|Of|O
S1494|17|O
S1494|patients|O
S1494|infected|O
S1494|with|O
S1494|avian|O
S1494|H5N1|O
S1494|virus|O
S1494|,|O
S1494|only|O
S1494|three|O
S1494|survived|O
S1494|to|O
S1494|the|O
S1494|day|O
S1494|five|O
S1494|evaluation|O
S1494|,|O
S1494|all|O
S1494|of|O
S1494|whom|O
S1494|met|O
S1494|the|O
S1494|criteria|O
S1494|for|O
S1494|clinical|O
S1494|failure|O
S1494|.|O
S1483|In|O
S1483|addition|O
S1483|,|O
S1483|no|O
S1483|comparisons|O
S1483|showed|O
S1483|less|O
S1483|frequent|O
S1483|virus|O
S1483|RNA|O
S1483|detection|O
S1483|in|O
S1483|the|O
S1483|double|O
S1483|dose|O
S1483|group|O
S1483|on|O
S1483|treatment|O
S1483|day|O
S1483|one|O
S1483|or|O
S1483|three|O
S1483|in|O
S1483|any|O
S1483|subgroup|O
S1483|of|O
S1483|interest|O
S1483|(|O
S1483|data|O
S1483|not|O
S1483|shown|O
S1483|)|O
S1483|.|O
S1303|All|O
S1303|randomly|O
S1303|assigned|O
S1303|patients|O
S1303|were|O
S1303|included|O
S1303|in|O
S1303|the|O
S1303|analysis|O
S1303|.|O
S1471|The|O
S1471|latter|O
S1471|were|O
S1471|confirmed|O
S1471|as|O
S1471|false|O
S1471|positive|O
S1471|tests|O
S1471|as|O
S1471|there|O
S1471|was|O
S1471|no|O
S1471|rise|O
S1471|in|O
S1471|haemagglutination|O
S1471|inhibition|O
S1471|titers|O
S1471|during|O
S1471|convalescence|O
S1471|.|O
S1683|Overall|O
S1683|,|O
S1683|28|O
S1683|(|O
S1683|5|O
S1683|%|O
S1683|)|O
S1683|children|O
S1683|on|O
S1683|clinically|O
S1683|driven|O
S1683|monitoring|O
S1683|versus|O
S1683|35|O
S1683|(|O
S1683|6|O
S1683|%|O
S1683|)|O
S1683|on|O
S1683|routine|O
S1683|laboratory|O
S1683|monitoring|O
S1683|switched|O
S1683|to|O
S1683|second-line|O
S1683|treatment|O
S1683|(|O
S1683|hazard|O
S1683|ratio|O
S1683|[|O
S1683|HR|O
S1683|]|O
S1683|0·78|O
S1683|,|O
S1683|95|O
S1683|%|O
S1683|CI|O
S1683|0·48–1·29|O
S1683|,|O
S1683|p=0·22|O
S1683|;|O
S1683|table|O
S1683|2|O
S1683|;|O
S1683|figure|O
S1683|2|O
S1683|)|O
S1683|,|O
S1683|after|O
S1683|median|O
S1683|2·8|O
S1683|(|O
S1683|IQR|O
S1683|1·8–3·3|O
S1683|)|O
S1683|years|O
S1683|versus|O
S1683|2·2|O
S1683|(|O
S1683|1·5–3·0|O
S1683|)|O
S1683|years|O
S1683|,|O
S1683|respectively|O
S1683|.|O
S282|There|O
S282|is|O
S282|therefore|O
S282|a|O
S282|need|O
S282|for|O
S282|more|O
S282|rigorous|O
S282|assessment|O
S282|of|O
S282|the|O
S282|efficacy|O
S282|of|O
S282|colchicine|O
S282|as|O
S282|prophylaxis|O
S282|against|O
S282|flares|O
S282|following|O
S282|ULT|O
S282|initiation|O
S282|and|O
S282|the|O
S282|introduction|O
S282|of|O
S282|alternative|O
S282|therapies|O
S282|.|O
S2234|The|O
S2234|maximum|O
S2234|specific|O
S2234|IgE|O
S2234|was|O
S2234|defined|O
S2234|as|O
S2234|the|O
S2234|specific|O
S2234|IgE|O
S2234|with|O
S2234|the|O
S2234|highest|O
S2234|titer|O
S2234|of|O
S2234|specific|O
S2234|IgEs|O
S2234|pre-dose|O
S2234|in|O
S2234|each|O
S2234|patient|O
S2234|.|O
S494|However|O
S494|,|O
S494|the|O
S494|positive|O
S494|effects|O
S494|of|O
S494|oxandrolone|O
S494|and|O
S494|late|O
S494|induction|O
S494|were|O
S494|not|O
S494|additive|O
S494|.|O
S2179|At|O
S2179|Week|O
S2179|36|O
S2179|,|O
S2179|the|O
S2179|300|O
S2179|mg|O
S2179|monthly|O
S2179|quilizumab|O
S2179|group|O
S2179|showed|O
S2179|a|O
S2179|19.6|O
S2179|%|O
S2179|reduction|O
S2179|(|O
S2179|p|O
S2179|=|O
S2179|0.38|O
S2179|)|O
S2179|in|O
S2179|the|O
S2179|asthma|O
S2179|exacerbation|O
S2179|rate|O
S2179|relative|O
S2179|to|O
S2179|placebo|O
S2179|,|O
S2179|but|O
S2179|this|O
S2179|was|O
S2179|neither|O
S2179|statistically|O
S2179|nor|O
S2179|clinically|O
S2179|significant|O
S2179|.|O
S1248|The|O
S1248|eligibility|O
S1248|criteria|O
S1248|can|O
S1248|be|O
S1248|summarised|O
S1248|in|O
S1248|terms|O
S1248|of|O
S1248|the|O
S1248|uncertainty|O
S1248|principle|O
S1248|.|O
S2222|We|O
S2222|also|O
S2222|evaluated|O
S2222|the|O
S2222|ability|O
S2222|of|O
S2222|biomarkers|O
S2222|(|O
S2222|serum|O
S2222|periostin|O
S2222|,|O
S2222|blood|O
S2222|eosinophils|O
S2222|,|O
S2222|exhaled|O
S2222|NO|O
S2222|,|O
S2222|and|O
S2222|serum|O
S2222|IgE|O
S2222|)|O
S2222|to|O
S2222|predict|O
S2222|benefit|O
S2222|from|O
S2222|quilizumab|O
S2222|.|O
S779|Haematocrit|O
S779|and|O
S779|white|O
S779|cell|O
S779|count|O
S779|were|O
S779|determined|O
S779|using|O
S779|an|O
S779|automated|O
S779|Coulter|O
S779|counter|O
S779|(|O
S779|Beckman-Coulter|O
S779|)|O
S779|.|O
S196|Patients|O
S196|were|O
S196|excluded|O
S196|for|O
S196|any|O
S196|of|O
S196|the|O
S196|following|O
S196|reasons|O
S196|:|O
S196|a|O
S196|diagnosis|O
S196|of|O
S196|chronic|O
S196|obstructive|O
S196|pulmonary|O
S196|disease|O
S196|or|O
S196|any|O
S196|respiratory|O
S196|disease|O
S196|other|O
S196|than|O
S196|asthma|O
S196|;|O
S196|myocardial|O
S196|infarction|O
S196|within|O
S196|the|O
S196|last|O
S196|6|O
S196|months|O
S196|;|O
S196|hospitalisation|O
S196|due|O
S196|to|O
S196|cardiac|O
S196|failure|O
S196|or|O
S196|unstable|O
S196|cardiac|O
S196|arrhythmia|O
S196|within|O
S196|the|O
S196|past|O
S196|year|O
S196|;|O
S196|treatment|O
S196|with|O
S196|anti-immunoglobulin|O
S196|E|O
S196|antibodies|O
S196|within|O
S196|6|O
S196|months|O
S196|prior|O
S196|to|O
S196|Visit|O
S196|1|O
S196|.|O
S1329|Patients|O
S1329|recruited|O
S1329|within|O
S1329|1–2|O
S1329|h|O
S1329|of|O
S1329|onset|O
S1329|were|O
S1329|significantly|O
S1329|more|O
S1329|likely|O
S1329|to|O
S1329|have|O
S1329|a|O
S1329|more|O
S1329|severe|O
S1329|neurological|O
S1329|deficit|O
S1329|did|O
S1329|than|O
S1329|those|O
S1329|recruited|O
S1329|at|O
S1329|later|O
S1329|timepoints|O
S1329|after|O
S1329|onset|O
S1329|(|O
S1329|test|O
S1329|for|O
S1329|linear|O
S1329|trend|O
S1329|p|O
S1329|<|O
S1329|0·0001|O
S1329|)|O
S1329|.|O
S1399|Of|O
S1399|these|O
S1399|,|O
S1399|260|O
S1399|(|O
S1399|79.8|O
S1399|%|O
S1399|)|O
S1399|were|O
S1399|infected|O
S1399|with|O
S1399|influenza|O
S1399|virus|O
S1399|A|O
S1399|(|O
S1399|133|O
S1399|(|O
S1399|40.8|O
S1399|%|O
S1399|)|O
S1399|with|O
S1399|A/H3N2|O
S1399|,|O
S1399|72|O
S1399|(|O
S1399|22.1|O
S1399|%|O
S1399|)|O
S1399|with|O
S1399|A/H1N1-pdm09|O
S1399|,|O
S1399|38|O
S1399|(|O
S1399|11.7|O
S1399|%|O
S1399|)|O
S1399|with|O
S1399|seasonal|O
S1399|A/H1N1|O
S1399|,|O
S1399|17|O
S1399|(|O
S1399|5.2|O
S1399|%|O
S1399|)|O
S1399|with|O
S1399|A/H5N1|O
S1399|)|O
S1399|and|O
S1399|53|O
S1399|(|O
S1399|16.2|O
S1399|%|O
S1399|)|O
S1399|with|O
S1399|influenza|O
S1399|virus|O
S1399|B|O
S1399|.|O
S98|No|O
S98|GI|O
S98|complications|O
S98|were|O
S98|reported|O
S98|in|O
S98|REDUCE-2|O
S98|.|O
S789|FACS-Lyse|O
S789|was|O
S789|obtained|O
S789|from|O
S789|Becton-Dickinson|O
S789|(|O
S789|Cowley|O
S789|,|O
S789|UK|O
S789|)|O
S789|.|O
S605|ET|O
S605|receptor|O
S605|antagonists|O
S605|including|O
S605|bosentan|O
S605|are|O
S605|now|O
S605|commonly|O
S605|used|O
S605|for|O
S605|the|O
S605|treatment|O
S605|of|O
S605|PAH|O
S605|in|O
S605|SSc|O
S605|.|O
S770|Given|O
S770|a|O
S770|plasma|O
S770|half-life|O
S770|of|O
S770|approximately|O
S770|70|O
S770|h|O
S770|,|O
S770|we|O
S770|judged|O
S770|that|O
S770|24|O
S770|h|O
S770|would|O
S770|be|O
S770|an|O
S770|appropriate|O
S770|time|O
S770|point|O
S770|to|O
S770|capture|O
S770|any|O
S770|potential|O
S770|beneficial|O
S770|cardiovascular|O
S770|effects|O
S770|of|O
S770|intravenous|O
S770|etanercept|O
S770|.|O
S2191|Th2|O
S2191|cells|O
S2191|produce|O
S2191|interleukin|O
S2191|(|O
S2191|IL|O
S2191|)|O
S2191|-4|O
S2191|,|O
S2191|IL-5|O
S2191|,|O
S2191|IL-13|O
S2191|,|O
S2191|and|O
S2191|other|O
S2191|cytokines|O
S2191|that|O
S2191|promote|O
S2191|immunoglobulin|O
S2191|E|O
S2191|(|O
S2191|IgE|O
S2191|)|O
S2191|class|O
S2191|switching|O
S2191|of|O
S2191|B|O
S2191|cells|O
S2191|,|O
S2191|increased|O
S2191|IgE|O
S2191|synthesis|O
S2191|by|O
S2191|plasma|O
S2191|B|O
S2191|cells|O
S2191|,|O
S2191|and|O
S2191|recruitment|O
S2191|and|O
S2191|activation|O
S2191|of|O
S2191|eosinophils|O
S2191|and|O
S2191|other|O
S2191|inflammatory|O
S2191|cells|O
S2191|.|O
S1629|Randomisation|O
S1629|and|O
S1629|masking|O
S1629|Both|O
S1629|factorial|B-Design_Factorial
S1629|randomisations|O
S1629|were|O
S1629|stratified|B-Randomization_Type_Stratified
S1629|by|O
S1629|centre|B-Randomization_Stratified_Criteria
S1629|and|O
S1629|age|B-Randomization_Stratified_Criteria
S1629|(|I-Randomization_Stratified_Criteria
S1629|<|I-Randomization_Stratified_Criteria
S1629|7|I-Randomization_Stratified_Criteria
S1629|,|I-Randomization_Stratified_Criteria
S1629|7–12|I-Randomization_Stratified_Criteria
S1629|,|I-Randomization_Stratified_Criteria
S1629|≥13|I-Randomization_Stratified_Criteria
S1629|years|I-Randomization_Stratified_Criteria
S1629|)|I-Randomization_Stratified_Criteria
S1629|.|O
S1666|Median|O
S1666|follow-up|O
S1666|to|O
S1666|planned|O
S1666|trial|O
S1666|closure|O
S1666|(|O
S1666|March|O
S1666|16|O
S1666|,|O
S1666|2012|O
S1666|)|O
S1666|was|O
S1666|4·0|O
S1666|(|O
S1666|IQR|O
S1666|3·7–4·4|O
S1666|)|O
S1666|years|O
S1666|in|O
S1666|each|O
S1666|monitoring|O
S1666|and|O
S1666|ART-strategy|O
S1666|group|O
S1666|(|O
S1666|maximum|O
S1666|5·0|O
S1666|years|O
S1666|;|O
S1666|total|O
S1666|4685|O
S1666|child-years|O
S1666|)|O
S1666|.|O
S613|All|O
S613|patients|O
S613|gave|O
S613|written|O
S613|informed|O
S613|consent|O
S613|.|O
S303|Secondary|O
S303|efficacy|O
S303|outcomes|O
S303|included|O
S303|:|O
S303|mean|O
S303|number|O
S303|of|O
S303|flares|O
S303|per|O
S303|patient|O
S303|,|O
S303|proportion|O
S303|of|O
S303|patients|O
S303|with|O
S303|at|O
S303|least|O
S303|one|O
S303|flare|O
S303|,|O
S303|time|O
S303|to|O
S303|first|O
S303|flare|O
S303|,|O
S303|average|O
S303|duration|O
S303|of|O
S303|flares|O
S303|and|O
S303|CRP|O
S303|levels|O
S303|(|O
S303|see|O
S303|supplementary|O
S303|material|O
S303|for|O
S303|further|O
S303|details|O
S303|)|O
S303|.|O
S821|However|O
S821|,|O
S821|dose–response|O
S821|curves|O
S821|were|O
S821|similar|O
S821|at|O
S821|24|O
S821|h|O
S821|and|O
S821|were|O
S821|unaffected|O
S821|by|O
S821|either|O
S821|treatment|O
S821|(|O
S821|p|O
S821|>|O
S821|0.1|O
S821|for|O
S821|all|O
S821|;|O
S821|table|O
S821|2|O
S821|;|O
S821|figure|O
S821|2|O
S821|)|O
S821|.|O
S1678|Whereas|O
S1678|in|O
S1678|group|O
S1678|A|O
S1678|nevirapine|O
S1678|was|O
S1678|mainly|O
S1678|substituted|O
S1678|with|O
S1678|zidovudine|O
S1678|(|O
S1678|<|O
S1678|3|O
S1678|years|O
S1678|)|O
S1678|or|O
S1678|efavirenz|O
S1678|(|O
S1678|>|O
S1678|3|O
S1678|years|O
S1678|)|O
S1678|,|O
S1678|in|O
S1678|the|O
S1678|four-drug|O
S1678|groups|O
S1678|,|O
S1678|about|O
S1678|a|O
S1678|third|O
S1678|(|O
S1678|five|O
S1678|children|O
S1678|in|O
S1678|group|O
S1678|B|O
S1678|and|O
S1678|six|O
S1678|in|O
S1678|C|O
S1678|)|O
S1678|simply|O
S1678|dropped|O
S1678|nevirapine|O
S1678|during|O
S1678|four-drug|O
S1678|induction|O
S1678|to|O
S1678|continue|O
S1678|on|O
S1678|three|O
S1678|NRTIs|O
S1678|.|O
S1681|There|O
S1681|were|O
S1681|small|O
S1681|but|O
S1681|significant|O
S1681|differences|O
S1681|by|O
S1681|ART|O
S1681|strategy|O
S1681|,|O
S1681|with|O
S1681|fewer|O
S1681|reporting|O
S1681|missing|O
S1681|doses|O
S1681|in|O
S1681|the|O
S1681|past|O
S1681|28|O
S1681|days|O
S1681|in|O
S1681|group|O
S1681|A|O
S1681|through|O
S1681|week|O
S1681|36|O
S1681|(|O
S1681|induction|O
S1681|period|O
S1681|;|O
S1681|7·9|O
S1681|%|O
S1681|[|O
S1681|253/2966|O
S1681|]|O
S1681|in|O
S1681|group|O
S1681|A|O
S1681|,|O
S1681|9·8|O
S1681|%|O
S1681|[|O
S1681|326/3014|O
S1681|]|O
S1681|in|O
S1681|group|O
S1681|B|O
S1681|,|O
S1681|9·0|O
S1681|%|O
S1681|[|O
S1681|295/2999|O
S1681|]|O
S1681|in|O
S1681|group|O
S1681|C|O
S1681|;|O
S1681|p=0·02|O
S1681|)|O
S1681|and|O
S1681|overall|O
S1681|(|O
S1681|6·1|O
S1681|%|O
S1681|[|O
S1681|1059/16345|O
S1681|]|O
S1681|,|O
S1681|7·3|O
S1681|%|O
S1681|[|O
S1681|1302/16640|O
S1681|]|O
S1681|,|O
S1681|6·5|O
S1681|%|O
S1681|[|O
S1681|1135/16371|O
S1681|]|O
S1681|,|O
S1681|respectively|O
S1681|;|O
S1681|p|O
S1681|<|O
S1681|0·0001|O
S1681|)|O
S1681|.|O
S1606|Although|O
S1606|not|O
S1606|mandated|O
S1606|when|O
S1606|public|O
S1606|health|O
S1606|ART|O
S1606|rollout|O
S1606|started|O
S1606|,|O
S1606|the|O
S1606|extent|O
S1606|to|O
S1606|which|O
S1606|HIV|O
S1606|treatment|O
S1606|programmes|O
S1606|in|O
S1606|resource-limited|O
S1606|settings|O
S1606|should|O
S1606|provide|O
S1606|routine|O
S1606|laboratory|O
S1606|monitoring|O
S1606|versus|O
S1606|focus|O
S1606|resources|O
S1606|on|O
S1606|expanding|O
S1606|ART|O
S1606|access|O
S1606|for|O
S1606|the|O
S1606|many|O
S1606|in|O
S1606|need|O
S1606|,|O
S1606|remains|O
S1606|an|O
S1606|ongoing|O
S1606|debate|O
S1606|,|O
S1606|particularly|O
S1606|relevant|O
S1606|with|O
S1606|slowing|O
S1606|growth|O
S1606|in|O
S1606|health|O
S1606|assistance|O
S1606|for|O
S1606|resource-limited|O
S1606|countries|O
S1606|in|O
S1606|the|O
S1606|current|O
S1606|economic|O
S1606|crisis|O
S1606|.|O
S1466|The|O
S1466|figure|O
S1466|shows|O
S1466|the|O
S1466|flow|O
S1466|of|O
S1466|patients|O
S1466|through|O
S1466|the|O
S1466|trial|O
S1466|.|O
S23|reported|O
S23|that|O
S23|the|O
S23|risk|O
S23|of|O
S23|an|O
S23|upper|O
S23|GI|O
S23|clinical|O
S23|event|O
S23|(|O
S23|bleeding|O
S23|,|O
S23|perforation|O
S23|,|O
S23|or|O
S23|symptomatic|O
S23|ulcer|O
S23|)|O
S23|in|O
S23|NSAID|O
S23|users|O
S23|at|O
S23|increased|O
S23|GI|O
S23|risk|O
S23|rose|O
S23|16|O
S23|%|O
S23|for|O
S23|every|O
S23|10|O
S23|%|O
S23|decrease|O
S23|in|O
S23|the|O
S23|proportion|O
S23|of|O
S23|time|O
S23|a|O
S23|proton-pump|O
S23|inhibitor|O
S23|or|O
S23|H2RA|O
S23|was|O
S23|prescribed|O
S23|.|O
S805|Inflammatory|O
S805|response|O
S805|and|O
S805|cytokine|O
S805|analyses|O
S805|Consistent|O
S805|with|O
S805|effective|O
S805|conjugation|O
S805|of|O
S805|circulating|O
S805|TNF-α|O
S805|,|O
S805|plasma|O
S805|TNF-α|O
S805|concentrations|O
S805|increased|O
S805|in|O
S805|all|O
S805|patients|O
S805|following|O
S805|etanercept|O
S805|infusion|O
S805|(|O
S805|254±15|O
S805|vs|O
S805|0.12±0.02|O
S805|pg/ml|O
S805|;|O
S805|p|O
S805|<|O
S805|0.0001|O
S805|)|O
S805|.|O
S2223|Safety|O
S2223|outcomes|O
S2223|were|O
S2223|assessed|O
S2223|throughout|O
S2223|the|O
S2223|36-week|O
S2223|treatment|O
S2223|and|O
S2223|48-week|O
S2223|follow-up|O
S2223|periods|O
S2223|.|O
S781|Briefly|O
S781|,|O
S781|studies|O
S781|were|O
S781|performed|O
S781|in|O
S781|a|O
S781|quiet|O
S781|,|O
S781|temperature-controlled|O
S781|environment|O
S781|with|O
S781|the|O
S781|patient|O
S781|in|O
S781|the|O
S781|supine|O
S781|position|O
S781|throughout|O
S781|.|O
S659|Healing|O
S659|of|O
S659|all|O
S659|DUs|O
S659|(|O
S659|baseline|O
S659|and|O
S659|new|O
S659|combined|O
S659|)|O
S659|at|O
S659|week|O
S659|24|O
S659|was|O
S659|observed|O
S659|in|O
S659|35/95|O
S659|(|O
S659|36.8|O
S659|%|O
S659|)|O
S659|and|O
S659|35/89|O
S659|(|O
S659|39.3|O
S659|%|O
S659|)|O
S659|of|O
S659|patients|O
S659|on|O
S659|bosentan|O
S659|and|O
S659|placebo|O
S659|,|O
S659|respectively|O
S659|(|O
S659|RR|O
S659|0.94|O
S659|(|O
S659|95|O
S659|%|O
S659|CI|O
S659|0.65|O
S659|to|O
S659|1.35|O
S659|)|O
S659|,|O
S659|p=0.76|O
S659|)|O
S659|.|O
S1643|Co-primary|O
S1643|endpoints|O
S1643|for|O
S1643|the|O
S1643|monitoring|O
S1643|randomisation|O
S1643|were|O
S1643|progression|O
S1643|to|O
S1643|new|O
S1643|WHO|O
S1643|stage|O
S1643|4|O
S1643|event|O
S1643|or|O
S1643|death|O
S1643|(|O
S1643|efficacy|O
S1643|)|O
S1643|,|O
S1643|and|O
S1643|grade|O
S1643|3|O
S1643|or|O
S1643|4|O
S1643|adverse|O
S1643|events|O
S1643|not|O
S1643|solely|O
S1643|related|O
S1643|to|O
S1643|HIV|O
S1643|(|O
S1643|safety|O
S1643|)|O
S1643|.|O
S2257|89|B-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|384/433|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|quilizumab|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|and|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|91|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|(|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|132/145|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|)|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|of|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|who|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|received|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|placebo|I-Sample_Size_Actual_at_Outcome_Analysis
S2257|completed|O
S2257|the|O
S2257|study|O
S2257|treatment|O
S2257|.|O
S31|In|O
S31|addition|O
S31|to|O
S31|the|O
S31|screening|O
S31|upper|O
S31|endoscopy|O
S31|at|O
S31|baseline|O
S31|,|O
S31|patients|O
S31|had|O
S31|endoscopy|O
S31|at|O
S31|weeks|O
S31|8|O
S31|,|O
S31|16|O
S31|,|O
S31|and|O
S31|24|O
S31|(|O
S31|or|O
S31|earlier|O
S31|if|O
S31|premature|O
S31|study|O
S31|termination|O
S31|)|O
S31|of|O
S31|study|O
S31|therapy|O
S31|.|O
S799|The|O
S799|primary|O
S799|outcome|O
S799|measure|O
S799|was|O
S799|PMA|O
S799|.|O
S1265|Blood|O
S1265|pressure|O
S1265|was|O
S1265|managed|O
S1265|in|O
S1265|the|O
S1265|same|O
S1265|way|O
S1265|in|O
S1265|both|O
S1265|treatment|O
S1265|groups|O
S1265|,|O
S1265|according|O
S1265|to|O
S1265|local|O
S1265|protocol|O
S1265|.|O
S175|The|O
S175|study|O
S175|was|O
S175|conducted|O
S175|in|O
S175|19|B-Settings_Multicenter
S175|sites|I-Settings_Multicenter
S175|in|O
S175|three|O
S175|European|O
S175|countries|O
S175|(|O
S175|Germany|B-Settings_Location
S175|,|I-Settings_Location
S175|Austria|I-Settings_Location
S175|and|I-Settings_Location
S175|Ukraine|I-Settings_Location
S175|;|O
S175|ClinicalTrials.gov|O
S175|identifier|O
S175|NCT01233284|O
S175|)|O
S175|,|O
S175|and|O
S175|was|O
S175|carried|O
S175|out|O
S175|in|O
S175|accordance|O
S175|with|O
S175|the|O
S175|principles|O
S175|of|O
S175|the|O
S175|Declaration|O
S175|of|O
S175|Helsinki|O
S175|and|O
S175|the|O
S175|International|O
S175|Conference|O
S175|on|O
S175|Harmonisation|O
S175|Good|O
S175|Clinical|O
S175|Practice|O
S175|Guidelines|O
S175|.|O
S1406|Conclusions|O
S1406|There|O
S1406|were|O
S1406|no|O
S1406|virological|O
S1406|or|O
S1406|clinical|O
S1406|advantages|O
S1406|with|O
S1406|double|B-Design_Parallel_Group
S1406|dose|I-Design_Parallel_Group
S1406|oseltamivir|I-Design_Parallel_Group
S1406|compared|I-Design_Parallel_Group
S1406|with|I-Design_Parallel_Group
S1406|standard|I-Design_Parallel_Group
S1406|dose|I-Design_Parallel_Group
S1406|in|O
S1406|patients|O
S1406|with|O
S1406|severe|O
S1406|influenza|O
S1406|admitted|O
S1406|to|O
S1406|hospital|O
S1406|.|O
S1304|Masked|O
S1304|analysis|O
S1304|of|O
S1304|the|O
S1304|patients|O
S1304|'|O
S1304|baseline|O
S1304|characteristics|O
S1304|showed|O
S1304|clear|O
S1304|differences|O
S1304|in|O
S1304|key|O
S1304|prognostic|O
S1304|factors|O
S1304|(|O
S1304|age|O
S1304|,|O
S1304|stroke|O
S1304|severity|O
S1304|,|O
S1304|degree|O
S1304|of|O
S1304|ischaemic|O
S1304|change|O
S1304|on|O
S1304|baseline|O
S1304|CT|O
S1304|or|O
S1304|MRI|O
S1304|)|O
S1304|in|O
S1304|patients|O
S1304|randomly|O
S1304|assigned|O
S1304|at|O
S1304|different|O
S1304|times|O
S1304|after|O
S1304|stroke|O
S1304|onset|O
S1304|,|O
S1304|which|O
S1304|might|O
S1304|complicate|O
S1304|the|O
S1304|estimation|O
S1304|of|O
S1304|the|O
S1304|effect|O
S1304|of|O
S1304|treatment|O
S1304|overall|O
S1304|and|O
S1304|in|O
S1304|subgroups|O
S1304|.|O
S808|No|O
S808|significant|O
S808|differences|O
S808|were|O
S808|observed|O
S808|at|O
S808|24|O
S808|h|O
S808|compared|O
S808|with|O
S808|baseline|O
S808|in|O
S808|those|O
S808|patients|O
S808|randomised|O
S808|to|O
S808|placebo|O
S808|(|O
S808|p|O
S808|>|O
S808|0.05|O
S808|for|O
S808|all|O
S808|;|O
S808|table|O
S808|2|O
S808|)|O
S808|.|O
S1851|The|O
S1851|results|O
S1851|of|O
S1851|these|O
S1851|in-trial|O
S1851|analyses|O
S1851|differ|O
S1851|slightly|O
S1851|from|O
S1851|previously|O
S1851|published|O
S1851|findings|O
S1851|because|O
S1851|of|O
S1851|the|O
S1851|inclusion|O
S1851|of|O
S1851|events|O
S1851|taking|O
S1851|place|O
S1851|between|O
S1851|the|O
S1851|participants|O
S1851|'|O
S1851|final|O
S1851|follow-up|O
S1851|visit|O
S1851|and|O
S1851|Nov|O
S1851|11|O
S1851|,|O
S1851|2001|O
S1851|(|O
S1851|mean|O
S1851|extra|O
S1851|follow-up|O
S1851|of|O
S1851|3·5|O
S1851|months|O
S1851|[|O
S1851|SD|O
S1851|1·4|O
S1851|]|O
S1851|)|O
S1851|.|O
S1148|Adverse|O
S1148|events|O
S1148|Data|O
S1148|on|O
S1148|adverse|O
S1148|events|O
S1148|were|O
S1148|collected|O
S1148|by|O
S1148|the|O
S1148|treating|O
S1148|healthcare|O
S1148|professional|O
S1148|,|O
S1148|by|O
S1148|review|O
S1148|of|O
S1148|patients|O
S1148|’|O
S1148|medical|O
S1148|notes|O
S1148|by|O
S1148|the|O
S1148|trial|O
S1148|coordinator|O
S1148|at|O
S1148|site|O
S1148|monitoring|O
S1148|visits|O
S1148|,|O
S1148|or|O
S1148|by|O
S1148|review|O
S1148|of|O
S1148|participant|O
S1148|follow-up|O
S1148|questionnaires|O
S1148|.|O
S578|Methods|O
S578|This|O
S578|double-blind|B-Blinding_Double_Blind
S578|,|O
S578|placebo-controlled|O
S578|trial|O
S578|conducted|O
S578|at|O
S578|41|B-Settings_Multicenter
S578|centres|I-Settings_Multicenter
S578|in|O
S578|Europe|B-Settings_Location
S578|and|I-Settings_Location
S578|North|I-Settings_Location
S578|America|I-Settings_Location
S578|randomised|O
S578|188|B-Sample_Size_Actual_at_Enrollment
S578|patients|O
S578|with|O
S578|SSc|O
S578|with|O
S578|at|O
S578|least|O
S578|1|O
S578|active|O
S578|DU|O
S578|(|O
S578|‘|O
S578|cardinal|O
S578|ulcer|O
S578|’|O
S578|)|O
S578|to|O
S578|bosentan|B-Design_Parallel_Group
S578|62.5|I-Design_Parallel_Group
S578|mg|I-Design_Parallel_Group
S578|twice|I-Design_Parallel_Group
S578|daily|I-Design_Parallel_Group
S578|for|I-Design_Parallel_Group
S578|4|I-Design_Parallel_Group
S578|weeks|I-Design_Parallel_Group
S578|and|I-Design_Parallel_Group
S578|125|I-Design_Parallel_Group
S578|mg|I-Design_Parallel_Group
S578|twice|I-Design_Parallel_Group
S578|daily|I-Design_Parallel_Group
S578|thereafter|I-Design_Parallel_Group
S578|for|I-Design_Parallel_Group
S578|20|I-Design_Parallel_Group
S578|weeks|I-Design_Parallel_Group
S578|(|I-Design_Parallel_Group
S578|n=98|I-Design_Parallel_Group
S578|)|I-Design_Parallel_Group
S578|or|I-Design_Parallel_Group
S578|matching|I-Design_Parallel_Group
S578|placebo|I-Design_Parallel_Group
S578|(|O
S578|n=90|O
S578|;|O
S578|total|O
S578|24|O
S578|weeks|O
S578|)|O
S578|.|O
S1308|The|O
S1308|statistical-analysis-plan|O
S1308|writing|O
S1308|committee|O
S1308|,|O
S1308|which|O
S1308|did|O
S1308|not|O
S1308|have|O
S1308|access|O
S1308|to|O
S1308|the|O
S1308|accumulating|O
S1308|data|O
S1308|,|O
S1308|was|O
S1308|therefore|O
S1308|expanded|O
S1308|to|O
S1308|include|O
S1308|an|O
S1308|independent|O
S1308|statistician|O
S1308|(|O
S1308|Gordon|O
S1308|Murray|O
S1308|,|O
S1308|University|O
S1308|of|O
S1308|Edinburgh|O
S1308|,|O
S1308|Edinburgh|O
S1308|,|O
S1308|UK|O
S1308|)|O
S1308|to|O
S1308|advise|O
S1308|on|O
S1308|the|O
S1308|correct|O
S1308|approach|O
S1308|.|O
S1654|All|O
S1654|comparisons|O
S1654|were|O
S1654|as|O
S1654|randomised|O
S1654|(|O
S1654|intention-to-treat|O
S1654|)|O
S1654|.|O
S667|One|O
S667|patient|O
S667|on|O
S667|placebo|O
S667|died|O
S667|from|O
S667|acute|O
S667|respiratory|O
S667|distress|O
S667|syndrome|O
S667|during|O
S667|the|O
S667|post-treatment|O
S667|follow-up|O
S667|.|O
S199|The|O
S199|following|O
S199|secondary|O
S199|efficacy|O
S199|end|O
S199|points|O
S199|were|O
S199|investigated|O
S199|:|O
S199|trough|O
S199|FEV1|O
S199|;|O
S199|peak|O
S199|forced|O
S199|vital|O
S199|capacity|O
S199|(|O
S199|FVC|O
S199|)|O
S199|within|O
S199|the|O
S199|first|O
S199|3|O
S199|hours|O
S199|after|O
S199|dosing|O
S199|(|O
S199|FVC|O
S199|)|O
S199|(|O
S199|0-3h|O
S199|)|O
S199|;|O
S199|trough|O
S199|FVC|O
S199|;|O
S199|FEV1|O
S199|area|O
S199|under|O
S199|the|O
S199|curve|O
S199|(|O
S199|AUC|O
S199|)|O
S199|within|O
S199|the|O
S199|first|O
S199|3|O
S199|hours|O
S199|after|O
S199|dosing|O
S199|(|O
S199|FEV1|O
S199|AUC|O
S199|(|O
S199|0-3h|O
S199|)|O
S199|)|O
S199|;|O
S199|FVC|O
S199|AUC|O
S199|(|O
S199|0-3h|O
S199|)|O
S199|;|O
S199|pre-dose|O
S199|PEFam|O
S199|and|O
S199|PEFpm|O
S199|using|O
S199|the|O
S199|Asthma|O
S199|Monitor2+|O
S199|device|O
S199|(|O
S199|AM2+®|O
S199|;|O
S199|ERT|O
S199|,|O
S199|Philadelphia|O
S199|,|O
S199|Pennsylvania|O
S199|,|O
S199|USA|O
S199|)|O
S199|based|O
S199|on|O
S199|the|O
S199|mean|O
S199|of|O
S199|the|O
S199|final|O
S199|week|O
S199|of|O
S199|each|O
S199|treatment|O
S199|period|O
S199|.|O
S634|Statistical|O
S634|methods|O
S634|Efficacy|O
S634|analyses|O
S634|were|O
S634|performed|O
S634|on|O
S634|all|O
S634|treated|O
S634|patients|O
S634|using|O
S634|SAS|O
S634|software|O
S634|(|O
S634|SAS|O
S634|Institute|O
S634|,|O
S634|Cary|O
S634|,|O
S634|North|O
S634|Carolina|O
S634|,|O
S634|USA|O
S634|)|O
S634|.|O
S1080|Intervention|O
S1080|Cryotherapy|O
S1080|Participants|O
S1080|randomised|B-Randomization_Type_Simple
S1080|to|O
S1080|cryotherapy|O
S1080|with|O
S1080|liquid|O
S1080|nitrogen|O
S1080|received|O
S1080|a|O
S1080|maximum|O
S1080|of|O
S1080|four|O
S1080|treatments|O
S1080|given|O
S1080|two|O
S1080|to|O
S1080|three|O
S1080|weeks|O
S1080|apart|O
S1080|by|O
S1080|a|O
S1080|healthcare|O
S1080|professional|O
S1080|.|O
S37|Urinalysis|O
S37|was|O
S37|done|O
S37|at|O
S37|baseline|O
S37|and|O
S37|final|O
S37|visit|O
S37|.|O
S1512|There|O
S1512|was|O
S1512|no|O
S1512|difference|O
S1512|between|O
S1512|adults|O
S1512|and|O
S1512|children|O
S1512|in|O
S1512|reported|O
S1512|adverse|O
S1512|events|O
S1512|.|O
S2140|All|O
S2140|statistical|O
S2140|tests|O
S2140|were|O
S2140|two-tailed|O
S2140|and|O
S2140|performed|O
S2140|with|O
S2140|SAS|O
S2140|software|O
S2140|(|O
S2140|V.9.2|O
S2140|,|O
S2140|SAS|O
S2140|Institute|O
S2140|Inc.|O
S2140|,|O
S2140|Cary|O
S2140|,|O
S2140|North|O
S2140|Carolina|O
S2140|,|O
S2140|USA|O
S2140|)|O
S2140|.|O
S1224|The|O
S1224|study|O
S1224|is|O
S1224|registered|O
S1224|,|O
S1224|ISRCTN25765518|O
S1224|.|O
S800|On|O
S800|the|O
S800|basis|O
S800|of|O
S800|previous|O
S800|work|O
S800|examining|O
S800|the|O
S800|effect|O
S800|of|O
S800|clopidogrel|O
S800|on|O
S800|PMA|O
S800|we|O
S800|estimated|O
S800|that|O
S800|a|O
S800|5|O
S800|%|O
S800|absolute|O
S800|change|O
S800|in|O
S800|PMA|O
S800|would|O
S800|be|O
S800|of|O
S800|clinical|O
S800|significance|O
S800|and|O
S800|that|O
S800|at|O
S800|least|O
S800|12|B-Sample_Size_Required
S800|paired|I-Sample_Size_Required
S800|samples|I-Sample_Size_Required
S800|would|O
S800|provide|O
S800|an|O
S800|80|B-Sample_Size_Calculation_Power_Value
S800|%|I-Sample_Size_Calculation_Power_Value
S800|power|O
S800|to|O
S800|detect|O
S800|a|O
S800|10|O
S800|%|O
S800|absolute|O
S800|difference|O
S800|in|O
S800|PMA|O
S800|from|O
S800|baseline|O
S800|at|O
S800|a|O
S800|significance|O
S800|level|O
S800|of|O
S800|5|B-Sample_Size_Calculation_Alpha_Value
S800|%|I-Sample_Size_Calculation_Alpha_Value
S800|.|O
S1889|During|O
S1889|the|O
S1889|post-trial|O
S1889|period|O
S1889|,|O
S1889|non-vascular|O
S1889|mortality|O
S1889|rates|O
S1889|were|O
S1889|similar|O
S1889|in|O
S1889|both|O
S1889|treatment|O
S1889|groups|O
S1889|(|O
S1889|943|O
S1889|[|O
S1889|10·6|O
S1889|%|O
S1889|]|O
S1889|vs|O
S1889|942|O
S1889|[|O
S1889|10·9|O
S1889|%|O
S1889|]|O
S1889|;|O
S1889|RR|O
S1889|0·97|O
S1889|[|O
S1889|95|O
S1889|%|O
S1889|CI|O
S1889|0·89–1·06|O
S1889|]|O
S1889|;|O
S1889|p=0·55|O
S1889|)|O
S1889|,|O
S1889|with|O
S1889|no|O
S1889|differences|O
S1889|reported|O
S1889|in|O
S1889|deaths|O
S1889|from|O
S1889|cancer|O
S1889|,|O
S1889|respiratory|O
S1889|disease|O
S1889|,|O
S1889|or|O
S1889|non-medical|O
S1889|causes|O
S1889|.|O
S1607|90|O
S1607|%|O
S1607|of|O
S1607|children|O
S1607|with|O
S1607|HIV|O
S1607|live|O
S1607|in|O
S1607|sub-Saharan|O
S1607|Africa|O
S1607|;|O
S1607|in|O
S1607|2011|O
S1607|,|O
S1607|only|O
S1607|about|O
S1607|28|O
S1607|%|O
S1607|of|O
S1607|those|O
S1607|needing|O
S1607|ART|O
S1607|were|O
S1607|receiving|O
S1607|it|O
S1607|.|O
S169|A|O
S169|second|O
S169|proof-of-concept|O
S169|study|O
S169|(|O
S169|three-way|O
S169|crossover|O
S169|,|O
S169|8|O
S169|weeks|O
S169|per|O
S169|treatment|O
S169|)|O
S169|in|O
S169|patients|O
S169|with|O
S169|more|O
S169|severe|O
S169|disease|O
S169|–|O
S169|severe|O
S169|persistent|O
S169|asthma|O
S169|,|O
S169|and|O
S169|receiving|O
S169|ICS|O
S169|+|O
S169|LABA|O
S169|–|O
S169|demonstrated|O
S169|that|O
S169|lung|O
S169|function|O
S169|improved|O
S169|significantly|O
S169|with|O
S169|tiotropium|O
S169|Respimat®|O
S169|10|O
S169|μg|O
S169|or|O
S169|5|O
S169|μg|O
S169|.|O
S179|Seven|O
S179|clinic|O
S179|visits|O
S179|were|O
S179|scheduled|O
S179|:|O
S179|at|O
S179|screening|O
S179|(|O
S179|Visit|O
S179|0|O
S179|)|O
S179|;|O
S179|prior|O
S179|to|O
S179|the|O
S179|4-week|O
S179|run-in|O
S179|(|O
S179|Visit|O
S179|1|O
S179|)|O
S179|;|O
S179|at|O
S179|randomisation|O
S179|(|O
S179|after|O
S179|the|O
S179|4-week|O
S179|run-in|O
S179|[|O
S179|Visit|O
S179|2|O
S179|]|O
S179|)|O
S179|;|O
S179|every|O
S179|4|O
S179|weeks|O
S179|at|O
S179|the|O
S179|end|O
S179|of|O
S179|each|O
S179|treatment|O
S179|period|O
S179|(|O
S179|Visits|O
S179|3–6|O
S179|)|O
S179|;|O
S179|and|O
S179|21|O
S179|days|O
S179|following|O
S179|the|O
S179|end|O
S179|of|O
S179|the|O
S179|final|O
S179|treatment|O
S179|period|O
S179|(|O
S179|Visit|O
S179|7|O
S179|)|O
S179|.|O
S2248|The|O
S2248|mean|O
S2248|relative|O
S2248|changes|O
S2248|from|O
S2248|baseline|O
S2248|were|O
S2248|compared|O
S2248|between|O
S2248|the|O
S2248|study|O
S2248|groups|O
S2248|using|O
S2248|the|O
S2248|differences|O
S2248|between|O
S2248|the|O
S2248|means|O
S2248|for|O
S2248|each|O
S2248|group|O
S2248|,|O
S2248|with|O
S2248|the|O
S2248|associated|O
S2248|two-sided|O
S2248|90|O
S2248|%|O
S2248|CIs|O
S2248|.|O
S2279|Lung|O
S2279|function|O
S2279|No|O
S2279|significant|O
S2279|evidence|O
S2279|of|O
S2279|improved|O
S2279|FEV1|O
S2279|at|O
S2279|Weeks|O
S2279|12|O
S2279|and|O
S2279|36|O
S2279|was|O
S2279|observed|O
S2279|in|O
S2279|quilizumab-treated|O
S2279|patients|O
S2279|compared|O
S2279|to|O
S2279|placebo|O
S2279|(|O
S2279|Fig|O
S2279|.|O
S1321|Overall|O
S1321|,|O
S1321|2581|O
S1321|(|O
S1321|95|O
S1321|%|O
S1321|)|O
S1321|of|O
S1321|2714|O
S1321|patients|O
S1321|with|O
S1321|data|O
S1321|(|O
S1321|data|O
S1321|for|O
S1321|some|O
S1321|relevant|O
S1321|variables|O
S1321|were|O
S1321|not|O
S1321|collected|O
S1321|in|O
S1321|the|O
S1321|initial|O
S1321|phase|O
S1321|)|O
S1321|did|O
S1321|not|O
S1321|meet|O
S1321|the|O
S1321|prevailing|O
S1321|EU-licence-approval|O
S1321|criteria|O
S1321|.|O
S321|The|O
S321|estimated|O
S321|canakinumab|O
S321|dose|O
S321|with|O
S321|equivalent|O
S321|efficacy|O
S321|to|O
S321|colchicine|O
S321|was|O
S321|below|O
S321|the|O
S321|range|O
S321|of|O
S321|canakinumab|O
S321|doses|O
S321|tested|O
S321|.|O
S1942|Mean|O
S1942|(|O
S1942|±SD|O
S1942|)|O
S1942|25-hydroxyvitamin|O
S1942|D|O
S1942|(|O
S1942|25|O
S1942|(|O
S1942|OH|O
S1942|)|O
S1942|D|O
S1942|)|O
S1942|was|O
S1942|30.2±13.2|O
S1942|nmol/L|O
S1942|at|O
S1942|baseline|O
S1942|,|O
S1942|and|O
S1942|29|O
S1942|(|O
S1942|43|O
S1942|%|O
S1942|)|O
S1942|had|O
S1942|values|O
S1942|<|O
S1942|30|O
S1942|nmol/L|O
S1942|.|O
S2118|Efficacy|O
S2118|criteria|O
S2118|The|O
S2118|primary|O
S2118|efficacy|O
S2118|criterion|O
S2118|was|O
S2118|the|O
S2118|change|O
S2118|in|O
S2118|stride|O
S2118|length|O
S2118|(|O
S2118|m|O
S2118|)|O
S2118|under|O
S2118|‘|O
S2118|on-L-dopa|O
S2118|’|O
S2118|conditions|O
S2118|.|O
S2255|1|O
S2255|)|O
S2255|from|O
S2255|April|O
S2255|2012|O
S2255|to|O
S2255|September|O
S2255|2013|O
S2255|;|O
S2255|the|O
S2255|study|O
S2255|was|O
S2255|completed|O
S2255|in|O
S2255|November|O
S2255|2014|O
S2255|.|O
S2121|All|O
S2121|measurements|O
S2121|were|O
S2121|recorded|O
S2121|in|O
S2121|a|O
S2121|double-blind|O
S2121|manner|O
S2121|in|O
S2121|our|O
S2121|hospital|O
S2121|'s|O
S2121|gait|O
S2121|laboratory|O
S2121|by|O
S2121|CM|O
S2121|,|O
S2121|AD|O
S2121|and|O
S2121|VT.|O
S2121|Standardised|O
S2121|assessment|O
S2121|Efficacy|O
S2121|criteria|O
S2121|were|O
S2121|assessed|O
S2121|at|O
S2121|8:30|O
S2121|in|O
S2121|the|O
S2121|morning|O
S2121|under|O
S2121|‘|O
S2121|off-L-dopa|O
S2121|’|O
S2121|conditions|O
S2121|,|O
S2121|that|O
S2121|is|O
S2121|,|O
S2121|at|O
S2121|least|O
S2121|8|O
S2121|h|O
S2121|after|O
S2121|the|O
S2121|withdrawal|O
S2121|of|O
S2121|dopaminergic|O
S2121|medications|O
S2121|.|O
S55|The|O
S55|proportion|O
S55|of|O
S55|patients|O
S55|developing|O
S55|ulcers|O
S55|was|O
S55|also|O
S55|prespecified|O
S55|to|O
S55|be|O
S55|assessed|O
S55|in|O
S55|the|O
S55|following|O
S55|subgroups|O
S55|:|O
S55|use|O
S55|of|O
S55|low-dose|O
S55|aspirin|O
S55|and/or|O
S55|anticoagulants|O
S55|,|O
S55|prior|O
S55|ulcer|O
S55|history|O
S55|,|O
S55|age|O
S55|(|O
S55|≥65|O
S55|vs.|O
S55|<|O
S55|65|O
S55|years|O
S55|)|O
S55|,|O
S55|gender|O
S55|,|O
S55|and|O
S55|race|O
S55|.|O
S1853|Secondary|O
S1853|outcomes|O
S1853|were|O
S1853|:|O
S1853|major|O
S1853|vascular|O
S1853|events|O
S1853|during|O
S1853|each|O
S1853|year|O
S1853|of|O
S1853|follow-up|O
S1853|and|O
S1853|in|O
S1853|various|O
S1853|subcategories|O
S1853|of|O
S1853|patients|O
S1853|;|O
S1853|major|O
S1853|coronary|O
S1853|events|O
S1853|(|O
S1853|ie|O
S1853|,|O
S1853|non-fatal|O
S1853|myocardial|O
S1853|infarction|O
S1853|or|O
S1853|coronary|O
S1853|death|O
S1853|)|O
S1853|,|O
S1853|strokes|O
S1853|,|O
S1853|and|O
S1853|revascularisations|O
S1853|separately|O
S1853|;|O
S1853|deaths|O
S1853|from|O
S1853|vascular|O
S1853|and|O
S1853|non-vascular|O
S1853|causes|O
S1853|separately|O
S1853|;|O
S1853|and|O
S1853|cancers|O
S1853|at|O
S1853|all|O
S1853|sites|O
S1853|(|O
S1853|excluding|O
S1853|non-melanoma|O
S1853|skin|O
S1853|cancer|O
S1853|)|O
S1853|.|O
S230|At|O
S230|the|O
S230|end|O
S230|of|O
S230|each|O
S230|4-week|O
S230|treatment|O
S230|period|O
S230|,|O
S230|there|O
S230|was|O
S230|a|O
S230|statistically|O
S230|significant|O
S230|improvement|O
S230|in|O
S230|ACQ-7|O
S230|score|O
S230|with|O
S230|all|O
S230|three|O
S230|tiotropium|O
S230|Respimat®|O
S230|doses|O
S230|(|O
S230|Additional|O
S230|file|O
S230|1|O
S230|:|O
S230|Table|O
S230|S1|O
S230|)|O
S230|.|O
S1510|The|O
S1510|most|O
S1510|common|O
S1510|adverse|O
S1510|events|O
S1510|were|O
S1510|respiratory|O
S1510|failure|O
S1510|(|O
S1510|n=14|O
S1510|)|O
S1510|,|O
S1510|diarrhoea|O
S1510|(|O
S1510|n=11|O
S1510|)|O
S1510|,|O
S1510|and|O
S1510|multi-organ|O
S1510|failure|O
S1510|(|O
S1510|n=6|O
S1510|)|O
S1510|.|O
S2021|Of|O
S2021|the|O
S2021|10|O
S2021|subjects|O
S2021|with|O
S2021|25|O
S2021|(|O
S2021|OH|O
S2021|)|O
S2021|D|O
S2021|<|O
S2021|30|O
S2021|nmol/L|O
S2021|at|O
S2021|24|O
S2021|weeks|O
S2021|,|O
S2021|two|O
S2021|(|O
S2021|20|O
S2021|%|O
S2021|)|O
S2021|attained|O
S2021|the|O
S2021|primary|O
S2021|outcome|O
S2021|compared|O
S2021|with|O
S2021|66|O
S2021|%|O
S2021|of|O
S2021|those|O
S2021|with|O
S2021|25|O
S2021|(|O
S2021|OH|O
S2021|)|O
S2021|D|O
S2021|≥30|O
S2021|nmol/L|O
S2021|(|O
S2021|p=0.006|O
S2021|)|O
S2021|.|O
S65|The|O
S65|REDUCE-1|O
S65|trial|O
S65|took|O
S65|place|O
S65|from|O
S65|March|O
S65|2007|O
S65|through|O
S65|August|O
S65|2008|O
S65|at|O
S65|68|O
S65|centers|O
S65|in|O
S65|the|O
S65|United|O
S65|States|O
S65|and|O
S65|REDUCE-2|O
S65|took|O
S65|place|O
S65|from|O
S65|March|O
S65|2007|O
S65|through|O
S65|September|O
S65|2008|O
S65|at|O
S65|68|B-Settings_Multicenter
S65|centers|I-Settings_Multicenter
S65|in|O
S65|the|O
S65|United|B-Settings_Location
S65|States|I-Settings_Location
S65|.|O
S319|Approximately|O
S319|6|O
S319|%|O
S319|of|O
S319|patients|O
S319|had|O
S319|reduced|O
S319|renal|O
S319|function|O
S319|,|O
S319|defined|O
S319|as|O
S319|having|O
S319|an|O
S319|estimated|O
S319|creatinine|O
S319|clearance|O
S319|rate|O
S319|(|O
S319|CrCl|O
S319|)|O
S319|below|O
S319|the|O
S319|normal|O
S319|range|O
S319|for|O
S319|age|O
S319|and|O
S319|sex|O
S319|(|O
S319|table|O
S319|1|O
S319|)|O
S319|.|O
S1115|Participants|O
S1115|whose|O
S1115|plantar|O
S1115|warts|O
S1115|had|O
S1115|not|O
S1115|cleared|O
S1115|were|O
S1115|treated|O
S1115|as|O
S1115|censored|O
S1115|,|O
S1115|and|O
S1115|we|O
S1115|calculated|O
S1115|their|O
S1115|duration|O
S1115|in|O
S1115|the|O
S1115|trial|O
S1115|from|O
S1115|their|O
S1115|date|O
S1115|of|O
S1115|trial|O
S1115|exit|O
S1115|,|O
S1115|date|O
S1115|of|O
S1115|last|O
S1115|available|O
S1115|assessment|O
S1115|,|O
S1115|or|O
S1115|the|O
S1115|183|O
S1115|days|O
S1115|to|O
S1115|trial|O
S1115|cessation|O
S1115|,|O
S1115|as|O
S1115|appropriate|O
S1115|.|O
S2199|In|O
S2199|animal|O
S2199|studies|O
S2199|,|O
S2199|anti-M1|O
S2199|prime|O
S2199|bound|O
S2199|membrane|O
S2199|IgE|O
S2199|on|O
S2199|IgE-switched|O
S2199|B|O
S2199|cells|O
S2199|and|O
S2199|plasmablasts|O
S2199|and|O
S2199|depleted|O
S2199|them|O
S2199|through|O
S2199|apoptosis|O
S2199|and|O
S2199|antibody-dependent|O
S2199|cell-mediated|O
S2199|cytotoxicity|O
S2199|,|O
S2199|leading|O
S2199|to|O
S2199|fewer|O
S2199|IgE|O
S2199|plasma|O
S2199|cells|O
S2199|and|O
S2199|less|O
S2199|production|O
S2199|of|O
S2199|soluble|O
S2199|IgE|O
S2199|.|O
S283|Several|O
S283|lines|O
S283|of|O
S283|evidence|O
S283|suggest|O
S283|that|O
S283|the|O
S283|proinflammatory|O
S283|cytokine|O
S283|,|O
S283|interleukin|O
S283|1β|O
S283|(|O
S283|IL-1β|O
S283|)|O
S283|,|O
S283|plays|O
S283|a|O
S283|key|O
S283|role|O
S283|in|O
S283|mediating|O
S283|the|O
S283|initiation|O
S283|of|O
S283|inflammation|O
S283|in|O
S283|gouty|O
S283|arthritis|O
S283|in|O
S283|a|O
S283|similar|O
S283|manner|O
S283|to|O
S283|that|O
S283|occurring|O
S283|in|O
S283|the|O
S283|hereditary|O
S283|autoinflammatory|O
S283|syndrome|O
S283|,|O
S283|cryopyrin-associated|O
S283|periodic|O
S283|syndrome|O
S283|(|O
S283|CAPS|O
S283|)|O
S283|,|O
S283|and|O
S283|may|O
S283|also|O
S283|contribute|O
S283|to|O
S283|joint|O
S283|destruction|O
S283|in|O
S283|gouty|O
S283|arthritis|O
S283|.|O
S446|Figure|O
S446|1|O
S446|shows|O
S446|the|O
S446|flow|O
S446|chart|O
S446|of|O
S446|the|O
S446|design|O
S446|and|O
S446|participants|O
S446|.|O
S1696|25|O
S1696|(|O
S1696|4|O
S1696|%|O
S1696|)|O
S1696|children|O
S1696|died|O
S1696|in|O
S1696|the|O
S1696|clinically|O
S1696|driven|O
S1696|monitoring|O
S1696|group|O
S1696|versus|O
S1696|29|O
S1696|(|O
S1696|5|O
S1696|%|O
S1696|)|O
S1696|in|O
S1696|the|O
S1696|routine|O
S1696|laboratory|O
S1696|monitoring|O
S1696|group|O
S1696|(|O
S1696|1·1|O
S1696|vs|O
S1696|1·3|O
S1696|per|O
S1696|100|O
S1696|child-years|O
S1696|,|O
S1696|respectively|O
S1696|;|O
S1696|difference|O
S1696|−0·2|O
S1696|per|O
S1696|100|O
S1696|child-years|O
S1696|,|O
S1696|95|O
S1696|%|O
S1696|CI|O
S1696|−0·82|O
S1696|to|O
S1696|0·41|O
S1696|;|O
S1696|HR|O
S1696|0·84|O
S1696|,|O
S1696|95|O
S1696|%|O
S1696|CI|O
S1696|0·49–1·44|O
S1696|;|O
S1696|p=0·45|O
S1696|;|O
S1696|appendix|O
S1696|)|O
S1696|.|O
S1982|Subjects|O
S1982|returned|O
S1982|every|O
S1982|4|O
S1982|weeks|O
S1982|for|O
S1982|their|O
S1982|supplements|O
S1982|and|O
S1982|assessment|O
S1982|of|O
S1982|adverse|O
S1982|events|O
S1982|.|O
S57|For|O
S57|comparison|O
S57|of|O
S57|subgroups|O
S57|with|O
S57|<|O
S57|100|O
S57|patients|O
S57|across|O
S57|the|O
S57|combined|O
S57|treatment|O
S57|arms|O
S57|,|O
S57|a|O
S57|Fisher|O
S57|'s|O
S57|exact|O
S57|test|O
S57|was|O
S57|used|O
S57|.|O
S633|Safety|O
S633|was|O
S633|continually|O
S633|monitored|O
S633|.|O
S960|Nine|O
S960|were|O
S960|excluded|O
S960|after|O
S960|randomisation|O
S960|because|O
S960|histological|O
S960|findings|O
S960|failed|O
S960|to|O
S960|support|O
S960|a|O
S960|diagnosis|O
S960|of|O
S960|pyoderma|O
S960|gangrenosum|O
S960|.|O
S577|The|O
S577|present|O
S577|study|O
S577|(|O
S577|RAPIDS-2|O
S577|,|O
S577|for|O
S577|‘|O
S577|RAndomized|O
S577|,|O
S577|double-blind|B-Blinding_Double_Blind
S577|,|O
S577|Placebo-controlled|O
S577|study|O
S577|with|O
S577|bosentan|O
S577|on|O
S577|healing|O
S577|and|O
S577|prevention|O
S577|of|O
S577|Ischemic|O
S577|Digital|O
S577|ulcers|O
S577|in|O
S577|patients|O
S577|with|O
S577|systemic|O
S577|Sclerosis|O
S577|’|O
S577|)|O
S577|was|O
S577|conducted|O
S577|to|O
S577|more|O
S577|fully|O
S577|evaluate|O
S577|the|O
S577|effects|O
S577|of|O
S577|bosentan|O
S577|treatment|O
S577|on|O
S577|DUs|O
S577|associated|O
S577|with|O
S577|SSc|O
S577|.|O
S204|At|O
S204|Visits|O
S204|2–6|O
S204|,|O
S204|lung|O
S204|function|O
S204|tests|O
S204|were|O
S204|performed|O
S204|10|O
S204|minutes|O
S204|prior|O
S204|to|O
S204|and|O
S204|up|O
S204|to|O
S204|3|O
S204|hours|O
S204|after|O
S204|dosing|O
S204|of|O
S204|study|O
S204|treatment|O
S204|.|O
S207|Adverse|O
S207|events|O
S207|and|O
S207|concomitant|O
S207|medications|O
S207|were|O
S207|recorded|O
S207|on|O
S207|the|O
S207|electronic|O
S207|case|O
S207|report|O
S207|form|O
S207|at|O
S207|each|O
S207|visit|O
S207|.|O
S1323|Of|O
S1323|those|O
S1323|assigned|O
S1323|to|O
S1323|the|O
S1323|rt-PA|O
S1323|group|O
S1323|,|O
S1323|26|O
S1323|(|O
S1323|2|O
S1323|%|O
S1323|)|O
S1323|did|O
S1323|not|O
S1323|receive|O
S1323|any|O
S1323|rt-PA|O
S1323|treatment|O
S1323|,|O
S1323|and|O
S1323|of|O
S1323|those|O
S1323|assigned|O
S1323|to|O
S1323|the|O
S1323|control|O
S1323|group|O
S1323|,|O
S1323|seven|O
S1323|(|O
S1323|<|O
S1323|1|O
S1323|%|O
S1323|)|O
S1323|received|O
S1323|at|O
S1323|least|O
S1323|some|O
S1323|rt-PA|O
S1323|.|O
S2284|Analysis|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|biomarker|O
S2284|subgroups|O
S2284|demonstrated|O
S2284|no|O
S2284|consistent|O
S2284|or|O
S2284|meaningful|O
S2284|improvements|O
S2284|of|O
S2284|FEV1|O
S2284|in|O
S2284|the|O
S2284|quilizumab-treated|O
S2284|arms|O
S2284|over|O
S2284|placebo|O
S2284|(|O
S2284|see|O
S2284|Additional|O
S2284|file|O
S2284|2|O
S2284|:|O
S2284|Table|O
S2284|S1|O
S2284|and|O
S2284|Additional|O
S2284|file|O
S2284|3|O
S2284|:|O
S2284|Table|O
S2284|S2|O
S2284|)|O
S2284|.|O
S508|This|O
S508|indicated|O
S508|that|O
S508|the|O
S508|developmental|O
S508|age|O
S508|scale|O
S508|in|O
S508|the|O
S508|oxandrolone|O
S508|arm|O
S508|was|O
S508|foreshortened|O
S508|by|O
S508|23|O
S508|%|O
S508|,|O
S508|increasing|O
S508|the|O
S508|velocity|O
S508|and|O
S508|making|O
S508|the|O
S508|oxandrolone|O
S508|curve|O
S508|correspondingly|O
S508|steeper|O
S508|than|O
S508|the|O
S508|placebo|O
S508|curve|O
S508|,|O
S508|although|O
S508|the|O
S508|age|O
S508|of|O
S508|final|O
S508|height|O
S508|was|O
S508|no|O
S508|earlier|O
S508|.|O
S988|Adverse|O
S988|reactions|O
S988|differed|O
S988|between|O
S988|the|O
S988|treatments|O
S988|in|O
S988|line|O
S988|with|O
S988|known|O
S988|side|O
S988|effects|O
S988|of|O
S988|each|O
S988|drug|O
S988|.|O
S1401|Similar|O
S1401|proportions|O
S1401|of|O
S1401|patients|O
S1401|were|O
S1401|negative|O
S1401|for|O
S1401|RT-PCR|O
S1401|on|O
S1401|day|O
S1401|five|O
S1401|of|O
S1401|treatment|O
S1401|:|O
S1401|115/159|O
S1401|(|O
S1401|72.3|O
S1401|%|O
S1401|,|O
S1401|95|O
S1401|%|O
S1401|confidence|O
S1401|interval|O
S1401|64.9|O
S1401|%|O
S1401|to|O
S1401|78.7|O
S1401|%|O
S1401|)|O
S1401|double|O
S1401|dose|O
S1401|recipients|O
S1401|versus|O
S1401|105/154|O
S1401|(|O
S1401|68.2|O
S1401|%|O
S1401|,|O
S1401|60.5|O
S1401|%|O
S1401|to|O
S1401|75.0|O
S1401|%|O
S1401|)|O
S1401|standard|O
S1401|dose|O
S1401|recipients|O
S1401|;|O
S1401|difference|O
S1401|4.2|O
S1401|%|O
S1401|(|O
S1401|−5.9|O
S1401|to|O
S1401|14.2|O
S1401|)|O
S1401|;|O
S1401|P=0.42|O
S1401|.|O
S1390|Effect|O
S1390|of|O
S1390|double|O
S1390|dose|O
S1390|oseltamivir|O
S1390|on|O
S1390|clinical|O
S1390|and|O
S1390|virological|O
S1390|outcomes|O
S1390|in|O
S1390|children|O
S1390|and|O
S1390|adults|O
S1390|admitted|O
S1390|to|O
S1390|hospital|O
S1390|with|O
S1390|severe|O
S1390|influenza|O
S1390|:|O
S1390|double|B-Blinding_Double_Blind
S1390|blind|I-Blinding_Double_Blind
S1390|randomised|O
S1390|controlled|O
S1390|trial|O
S641|For|O
S641|exploratory|O
S641|purposes|O
S641|,|O
S641|statistical|O
S641|tests|O
S641|of|O
S641|treatment|O
S641|difference|O
S641|were|O
S641|provided|O
S641|for|O
S641|planned|O
S641|secondary/exploratory|O
S641|and|O
S641|unplanned|O
S641|post|O
S641|hoc|O
S641|efficacy|O
S641|analyses|O
S641|and|O
S641|included|O
S641|the|O
S641|Pitman|O
S641|permutation|O
S641|(|O
S641|for|O
S641|changes|O
S641|from|O
S641|baseline|O
S641|)|O
S641|,|O
S641|the|O
S641|Fisher|O
S641|exact|O
S641|test|O
S641|(|O
S641|for|O
S641|proportions|O
S641|)|O
S641|and|O
S641|the|O
S641|log-rank|O
S641|test|O
S641|(|O
S641|for|O
S641|times|O
S641|to|O
S641|event|O
S641|)|O
S641|,|O
S641|each|O
S641|performed|O
S641|without|O
S641|correction|O
S641|for|O
S641|multiple|O
S641|testing|O
S641|.|O
S2271|The|O
S2271|largest|O
S2271|decreases|O
S2271|in|O
S2271|total|O
S2271|and|O
S2271|allergen-specific|O
S2271|IgE|O
S2271|were|O
S2271|observed|O
S2271|at|O
S2271|Week|O
S2271|42|O
S2271|in|O
S2271|the|O
S2271|300|O
S2271|mg|O
S2271|M|O
S2271|treatment|O
S2271|cohort|O
S2271|.|O
S1287|In|O
S1287|Portugal|O
S1287|,|O
S1287|patients|O
S1287|were|O
S1287|followed|O
S1287|up|O
S1287|in|O
S1287|clinic|O
S1287|by|O
S1287|clinicians|B-Blinding_Object_Others
S1287|not|O
S1287|involved|O
S1287|in|O
S1287|the|O
S1287|patients|O
S1287|'|O
S1287|initial|O
S1287|treatment|O
S1287|,|O
S1287|again|O
S1287|,|O
S1287|masked|O
S1287|to|O
S1287|treatment|O
S1287|allocation|O
S1287|as|O
S1287|far|O
S1287|as|O
S1287|possible|O
S1287|.|O
S1514|Among|O
S1514|38|O
S1514|patients|O
S1514|infected|O
S1514|with|O
S1514|seasonal|O
S1514|H1N1|O
S1514|viruses|O
S1514|,|O
S1514|32|O
S1514|(|O
S1514|11|O
S1514|in|O
S1514|double|O
S1514|dose|O
S1514|arm|O
S1514|,|O
S1514|21|O
S1514|in|O
S1514|standard|O
S1514|dose|O
S1514|arm|O
S1514|)|O
S1514|could|O
S1514|be|O
S1514|sequenced|O
S1514|and|O
S1514|18|O
S1514|(|O
S1514|56|O
S1514|%|O
S1514|;|O
S1514|six|O
S1514|double|O
S1514|dose|O
S1514|,|O
S1514|12|O
S1514|standard|O
S1514|dose|O
S1514|)|O
S1514|of|O
S1514|these|O
S1514|had|O
S1514|the|O
S1514|H275Y|O
S1514|mutation|O
S1514|at|O
S1514|baseline|O
S1514|.|O
S2280|5|O
S2280|)|O
S2280|.|O
S1140|The|O
S1140|proportional|O
S1140|hazard|O
S1140|assumption|O
S1140|was|O
S1140|tested|O
S1140|and|O
S1140|not|O
S1140|violated|O
S1140|,|O
S1140|either|O
S1140|separately|O
S1140|for|O
S1140|each|O
S1140|covariate|O
S1140|(|O
S1140|cryotherapy|O
S1140|v|O
S1140|salicylic|O
S1140|acid|O
S1140|(|O
S1140|P=0.3107|O
S1140|)|O
S1140|,|O
S1140|age|O
S1140|(|O
S1140|P=0.9508|O
S1140|)|O
S1140|,|O
S1140|type|O
S1140|of|O
S1140|plantar|O
S1140|wart|O
S1140|(|O
S1140|P=0.7024|O
S1140|)|O
S1140|,|O
S1140|previous|O
S1140|treatment|O
S1140|(|O
S1140|P=0.4456|O
S1140|)|O
S1140|)|O
S1140|or|O
S1140|globally|O
S1140|(|O
S1140|P=0.8208|O
S1140|)|O
S1140|.|O
S1427|Oseltamivir|O
S1427|capsules|O
S1427|,|O
S1427|paediatric|O
S1427|oseltamivir|O
S1427|suspensions|O
S1427|,|O
S1427|and|O
S1427|placebo|O
S1427|suspensions|O
S1427|were|O
S1427|provided|O
S1427|by|O
S1427|Roche|O
S1427|(|O
S1427|Basel|O
S1427|,|O
S1427|Switzerland|O
S1427|)|O
S1427|.|O
S504|Figure|O
S504|2|O
S504|shows|O
S504|individual|O
S504|height|O
S504|curves|O
S504|unadjusted|O
S504|(|O
S504|top|O
S504|panel|O
S504|)|O
S504|and|O
S504|SITAR|O
S504|adjusted|O
S504|with|O
S504|the|O
S504|summary|O
S504|curve|O
S504|(|O
S504|bottom|O
S504|panel|O
S504|)|O
S504|.|O
S500|Table|O
S500|3|O
S500|also|O
S500|includes|O
S500|the|O
S500|results|O
S500|for|O
S500|maximum|O
S500|height|O
S500|,|O
S500|based|O
S500|on|O
S500|the|O
S500|92|O
S500|girls|O
S500|still|O
S500|in|O
S500|the|O
S500|trial|O
S500|.|O
S1101|This|O
S1101|difference|O
S1101|of|O
S1101|17|O
S1101|%|O
S1101|was|O
S1101|not|O
S1101|statistically|O
S1101|significant|O
S1101|.|O
S1816|Findings|O
S1816|During|O
S1816|the|O
S1816|in-trial|O
S1816|period|O
S1816|,|O
S1816|allocation|O
S1816|to|O
S1816|simvastatin|O
S1816|yielded|O
S1816|an|O
S1816|average|O
S1816|reduction|O
S1816|in|O
S1816|LDL|O
S1816|cholesterol|O
S1816|of|O
S1816|1·0|O
S1816|mmol/L|O
S1816|and|O
S1816|a|O
S1816|proportional|O
S1816|decrease|O
S1816|in|O
S1816|major|O
S1816|vascular|O
S1816|events|O
S1816|of|O
S1816|23|O
S1816|%|O
S1816|(|O
S1816|95|O
S1816|%|O
S1816|CI|O
S1816|19–28|O
S1816|;|O
S1816|p|O
S1816|<|O
S1816|0·0001|O
S1816|)|O
S1816|,|O
S1816|with|O
S1816|significant|O
S1816|divergence|O
S1816|each|O
S1816|year|O
S1816|after|O
S1816|the|O
S1816|first|O
S1816|.|O
S1594|Findings|O
S1594|1206|B-Sample_Size_Actual_at_Enrollment
S1594|children|I-Sample_Size_Actual_at_Enrollment
S1594|were|O
S1594|randomly|O
S1594|assigned|O
S1594|to|O
S1594|clinically|O
S1594|driven|O
S1594|(|O
S1594|n=606|O
S1594|)|O
S1594|versus|O
S1594|routine|O
S1594|laboratory|O
S1594|monitoring|O
S1594|(|O
S1594|n=600|O
S1594|)|O
S1594|,|O
S1594|and|O
S1594|groups|O
S1594|A|O
S1594|(|O
S1594|n=397|O
S1594|)|O
S1594|,|O
S1594|B|O
S1594|(|O
S1594|n=404|O
S1594|)|O
S1594|,|O
S1594|and|O
S1594|C|O
S1594|(|O
S1594|n=405|O
S1594|)|O
S1594|.|O
S1461|Normally|O
S1461|distributed|O
S1461|continuous|O
S1461|data|O
S1461|were|O
S1461|compared|O
S1461|between|O
S1461|the|O
S1461|two|O
S1461|arms|O
S1461|with|O
S1461|the|O
S1461|unpaired|O
S1461|t|O
S1461|test|O
S1461|;|O
S1461|the|O
S1461|Mann-Whitney|O
S1461|U|O
S1461|or|O
S1461|Kruskal-Wallis|O
S1461|tests|O
S1461|were|O
S1461|used|O
S1461|for|O
S1461|skewed|O
S1461|data|O
S1461|.|O
S2228|Pharmacokinetics|O
S2228|and|O
S2228|immunogenicity|O
S2228|Serum|O
S2228|levels|O
S2228|of|O
S2228|quilizumab|O
S2228|for|O
S2228|pharmacokinetic|O
S2228|assessments|O
S2228|were|O
S2228|measured|O
S2228|using|O
S2228|a|O
S2228|validated|O
S2228|enzyme-linked|O
S2228|immunosorbent|O
S2228|assay|O
S2228|(|O
S2228|ELISA|O
S2228|;|O
S2228|Genentech|O
S2228|,|O
S2228|Inc.|O
S2228|,|O
S2228|South|O
S2228|San|O
S2228|Francisco|O
S2228|,|O
S2228|CA|O
S2228|)|O
S2228|.|O
S1709|Of|O
S1709|1170|O
S1709|adverse|O
S1709|events|O
S1709|(|O
S1709|621|O
S1709|clinically|O
S1709|driven|O
S1709|monitoring|O
S1709|,|O
S1709|549|O
S1709|routine|O
S1709|laboratory|O
S1709|monitoring|O
S1709|)|O
S1709|,|O
S1709|810|O
S1709|(|O
S1709|69|O
S1709|%|O
S1709|)|O
S1709|were|O
S1709|asymptomatic|O
S1709|laboratory|O
S1709|results|O
S1709|,|O
S1709|most|O
S1709|commonly|O
S1709|grade|O
S1709|3|O
S1709|neutropenia|O
S1709|(|O
S1709|171|O
S1709|clinically|O
S1709|driven|O
S1709|monitoring|O
S1709|,|O
S1709|167|O
S1709|routine|O
S1709|laboratory|O
S1709|monitoring|O
S1709|;|O
S1709|appendix|O
S1709|)|O
S1709|;|O
S1709|only|O
S1709|87|O
S1709|(|O
S1709|7|O
S1709|%|O
S1709|)|O
S1709|were|O
S1709|definitely|O
S1709|,|O
S1709|probably|O
S1709|,|O
S1709|or|O
S1709|uncertainly|O
S1709|ART-related|O
S1709|(|O
S1709|41|O
S1709|clinically|O
S1709|driven|O
S1709|monitoring|O
S1709|,|O
S1709|46|O
S1709|routine|O
S1709|laboratory|O
S1709|monitoring|O
S1709|)|O
S1709|.|O
S1608|Infrastructure|O
S1608|,|O
S1608|personnel|O
S1608|,|O
S1608|and|O
S1608|supply|O
S1608|chain|O
S1608|constraints|O
S1608|all|O
S1608|affect|O
S1608|the|O
S1608|ability|O
S1608|to|O
S1608|monitor|O
S1608|,|O
S1608|and|O
S1608|tests|O
S1608|for|O
S1608|detecting|O
S1608|toxicity|O
S1608|and|O
S1608|measuring|O
S1608|efficacy|O
S1608|are|O
S1608|generally|O
S1608|unavailable|O
S1608|,|O
S1608|particularly|O
S1608|at|O
S1608|low-level|O
S1608|facilities|O
S1608|.|O
S257|Objective|O
S257|This|O
S257|study|O
S257|assessed|O
S257|the|O
S257|efficacy|O
S257|and|O
S257|safety|O
S257|of|O
S257|canakinumab|O
S257|,|O
S257|a|O
S257|fully|O
S257|human|O
S257|anti-interleukin|O
S257|1β|O
S257|monoclonal|O
S257|antibody|O
S257|,|O
S257|for|O
S257|prophylaxis|O
S257|against|O
S257|acute|O
S257|gouty|O
S257|arthritis|O
S257|flares|O
S257|in|O
S257|patients|O
S257|initiating|O
S257|urate-lowering|O
S257|treatment|O
S257|.|O
S1999|Results|O
S1999|A|O
S1999|total|O
S1999|of|O
S1999|254|O
S1999|children|O
S1999|presented|O
S1999|with|O
S1999|leg|O
S1999|deformities|O
S1999|,|O
S1999|and|O
S1999|72|B-Sample_Size_Actual_at_Enrollment
S1999|subjects|O
S1999|with|O
S1999|radiographically|O
S1999|active|O
S1999|rickets|O
S1999|were|O
S1999|enrolled|O
S1999|between|O
S1999|February|O
S1999|2004|O
S1999|and|O
S1999|November|O
S1999|2006|O
S1999|(|O
S1999|figure|O
S1999|1|O
S1999|)|O
S1999|.|O
S214|If|O
S214|the|O
S214|previous|O
S214|step|O
S214|was|O
S214|not|O
S214|successful|O
S214|,|O
S214|analysis|O
S214|of|O
S214|the|O
S214|current|O
S214|step|O
S214|was|O
S214|to|O
S214|be|O
S214|considered|O
S214|descriptive|O
S214|.|O
S2017|In|O
S2017|a|O
S2017|logistic|O
S2017|regression|O
S2017|analysis|O
S2017|that|O
S2017|controlled|O
S2017|for|O
S2017|baseline|O
S2017|values|O
S2017|of|O
S2017|alkaline|O
S2017|phosphatase|O
S2017|,|O
S2017|radiographic|O
S2017|score|O
S2017|,|O
S2017|serum|O
S2017|25|O
S2017|(|O
S2017|OH|O
S2017|)|O
S2017|D|O
S2017|and|O
S2017|height|O
S2017|for|O
S2017|age|O
S2017|,|O
S2017|treatment|O
S2017|with|O
S2017|calcium|O
S2017|plus|O
S2017|vitamin|O
S2017|D|O
S2017|was|O
S2017|significantly|O
S2017|superior|O
S2017|to|O
S2017|treatment|O
S2017|with|O
S2017|calcium|O
S2017|alone|O
S2017|(|O
S2017|table|O
S2017|2|O
S2017|)|O
S2017|.|O
S874|By|O
S874|six|O
S874|months|O
S874|,|O
S874|ulcers|O
S874|had|O
S874|healed|O
S874|in|O
S874|28/59|O
S874|(|O
S874|47|O
S874|%|O
S874|)|O
S874|participants|O
S874|in|O
S874|the|O
S874|ciclosporin|O
S874|group|O
S874|compared|O
S874|with|O
S874|25/53|O
S874|(|O
S874|47|O
S874|%|O
S874|)|O
S874|in|O
S874|the|O
S874|prednisolone|O
S874|group|O
S874|.|O
S326|According|O
S326|to|O
S326|this|O
S326|analysis|O
S326|,|O
S326|there|O
S326|was|O
S326|a|O
S326|62|O
S326|%|O
S326|to|O
S326|72|O
S326|%|O
S326|reduction|O
S326|in|O
S326|the|O
S326|mean|O
S326|number|O
S326|of|O
S326|flares|O
S326|per|O
S326|patient|O
S326|for|O
S326|canakinumab|O
S326|doses|O
S326|≥50|O
S326|mg|O
S326|versus|O
S326|colchicine|O
S326|(|O
S326|rate|O
S326|ratio|O
S326|:|O
S326|0.28–0.38|O
S326|,|O
S326|p≤0.0083|O
S326|)|O
S326|(|O
S326|table|O
S326|2|O
S326|)|O
S326|.|O
S956|We|O
S956|analysed|O
S956|adverse|O
S956|reactions|O
S956|that|O
S956|occurred|O
S956|during|O
S956|the|O
S956|trial|O
S956|according|O
S956|to|O
S956|the|O
S956|original|O
S956|randomised|O
S956|allocation|O
S956|,|O
S956|regardless|O
S956|of|O
S956|whether|O
S956|other|O
S956|drugs|O
S956|had|O
S956|been|O
S956|introduced|O
S956|before|O
S956|the|O
S956|adverse|O
S956|reaction|O
S956|.|O
S1612|Children|O
S1612|with|O
S1612|HIV|O
S1612|start|O
S1612|ART|O
S1612|early|O
S1612|and|O
S1612|will|O
S1612|need|O
S1612|to|O
S1612|take|O
S1612|treatment|O
S1612|for|O
S1612|longer|O
S1612|than|O
S1612|adults|O
S1612|.|O
S1126|Participants|O
S1126|applied|O
S1126|salicylic|O
S1126|acid|O
S1126|on|O
S1126|a|O
S1126|mean|O
S1126|of|O
S1126|6.3|O
S1126|days|O
S1126|in|O
S1126|week|O
S1126|1|O
S1126|and|O
S1126|5.4|O
S1126|days|O
S1126|in|O
S1126|week|O
S1126|3|O
S1126|.|O
S186|Permitted|O
S186|medication|O
S186|for|O
S186|the|O
S186|treatment|O
S186|of|O
S186|acute|O
S186|asthma|O
S186|exacerbations|O
S186|included|O
S186|salbutamol|O
S186|hydrofluoroalkane|O
S186|metered-dose|O
S186|inhaler|O
S186|,|O
S186|systemic|O
S186|corticosteroids|O
S186|and|O
S186|short-acting|O
S186|theophylline|O
S186|preparations|O
S186|.|O
S268|Introduction|O
S268|Gouty|O
S268|arthritis|O
S268|is|O
S268|a|O
S268|painful|O
S268|inflammatory|O
S268|arthritis|O
S268|that|O
S268|becomes|O
S268|increasingly|O
S268|prevalent|O
S268|with|O
S268|age|O
S268|,|O
S268|affecting|O
S268|around|O
S268|10|O
S268|%|O
S268|of|O
S268|men|O
S268|and|O
S268|6|O
S268|%|O
S268|of|O
S268|women|O
S268|over|O
S268|70|O
S268|years|O
S268|old|O
S268|.|O
S457|Oral|O
S457|ethinylestradiol|O
S457|(|O
S457|UCB|O
S457|Pharma|O
S457|,|O
S457|Slough|O
S457|,|O
S457|UK|O
S457|)|O
S457|was|O
S457|given|O
S457|daily|O
S457|as|O
S457|follows|O
S457|,|O
S457|regardless|O
S457|of|O
S457|the|O
S457|age|O
S457|at|O
S457|starting|O
S457|:|O
S457|year|O
S457|1|O
S457|,|O
S457|2|O
S457|μg|O
S457|;|O
S457|year|O
S457|2|O
S457|,|O
S457|4|O
S457|μg|O
S457|;|O
S457|year|O
S457|3|O
S457|,|O
S457|four|O
S457|months|O
S457|each|O
S457|of|O
S457|6|O
S457|,|O
S457|8|O
S457|,|O
S457|and|O
S457|10|O
S457|μg|O
S457|.|O
S2241|The|O
S2241|primary|O
S2241|endpoint|O
S2241|,|O
S2241|the|O
S2241|annualized|O
S2241|exacerbation|O
S2241|rate|O
S2241|,|O
S2241|was|O
S2241|calculated|O
S2241|by|O
S2241|the|O
S2241|total|O
S2241|number|O
S2241|of|O
S2241|protocol-defined|O
S2241|exacerbations|O
S2241|observed|O
S2241|in|O
S2241|the|O
S2241|group|O
S2241|over|O
S2241|the|O
S2241|treatment|O
S2241|period|O
S2241|divided|O
S2241|by|O
S2241|total|O
S2241|patient-weeks|O
S2241|at|O
S2241|risk|O
S2241|(|O
S2241|number|O
S2241|of|O
S2241|weeks|O
S2241|from|O
S2241|first|O
S2241|study|O
S2241|drug|O
S2241|administration|O
S2241|to|O
S2241|the|O
S2241|earliest|O
S2241|of|O
S2241|Week|O
S2241|36|O
S2241|or|O
S2241|study|O
S2241|discontinuation|O
S2241|)|O
S2241|for|O
S2241|the|O
S2241|group|O
S2241|and|O
S2241|multiplied|O
S2241|by|O
S2241|52|O
S2241|.|O
S293|Allopurinol|O
S293|treatment|O
S293|(|O
S293|100–300|O
S293|mg|O
S293|)|O
S293|was|O
S293|initiated|O
S293|at|O
S293|baseline|O
S293|or|O
S293|within|O
S293|1|O
S293|month|O
S293|before|O
S293|baseline|O
S293|and|O
S293|was|O
S293|administered|O
S293|to|O
S293|all|O
S293|randomised|O
S293|patients|O
S293|once|O
S293|daily|O
S293|for|O
S293|24|O
S293|weeks|O
S293|(|O
S293|see|O
S293|supplementary|O
S293|material|O
S293|for|O
S293|details|O
S293|)|O
S293|.|O
S1728|157|O
S1728|(|O
S1728|40|O
S1728|%|O
S1728|)|O
S1728|children|O
S1728|in|O
S1728|group|O
S1728|A|O
S1728|,|O
S1728|190|O
S1728|(|O
S1728|47|O
S1728|%|O
S1728|)|O
S1728|in|O
S1728|group|O
S1728|B|O
S1728|,|O
S1728|and|O
S1728|218|O
S1728|(|O
S1728|54|O
S1728|%|O
S1728|)|O
S1728|in|O
S1728|group|O
S1728|C|O
S1728|had|O
S1728|one|O
S1728|or|O
S1728|more|O
S1728|grade|O
S1728|3|O
S1728|or|O
S1728|4|O
S1728|adverse|O
S1728|events|O
S1728|(|O
S1728|co-primary|O
S1728|endpoint|O
S1728|;|O
S1728|HR|O
S1728|[|O
S1728|B|O
S1728|:|O
S1728|A|O
S1728|]|O
S1728|1·32|O
S1728|,|O
S1728|95|O
S1728|%|O
S1728|CI|O
S1728|1·07–1·63|O
S1728|;|O
S1728|HR|O
S1728|[|O
S1728|C|O
S1728|:|O
S1728|A|O
S1728|]|O
S1728|1·58|O
S1728|,|O
S1728|1·29–1·94|O
S1728|;|O
S1728|global|O
S1728|p=0·0001|O
S1728|;|O
S1728|figure|O
S1728|4|O
S1728|)|O
S1728|.|O
S2211|The|O
S2211|treatment|O
S2211|period|O
S2211|ended|O
S2211|36|O
S2211|weeks|O
S2211|after|O
S2211|randomization|O
S2211|and|O
S2211|was|O
S2211|followed|O
S2211|by|O
S2211|a|O
S2211|48-week|O
S2211|period|O
S2211|to|O
S2211|assess|O
S2211|the|O
S2211|sustained|O
S2211|efficacy|O
S2211|and|O
S2211|safety|O
S2211|of|O
S2211|quilizumab|O
S2211|(|O
S2211|see|O
S2211|Additional|O
S2211|file|O
S2211|1|O
S2211|:|O
S2211|Figure|O
S2211|S1|O
S2211|)|O
S2211|.|O
S1226|All|O
S1226|of|O
S1226|these|O
S1226|patients|O
S1226|were|O
S1226|included|O
S1226|in|O
S1226|the|O
S1226|analyses|O
S1226|(|O
S1226|1515|O
S1226|in|O
S1226|the|O
S1226|rt-PA|O
S1226|group|O
S1226|vs|O
S1226|1520|O
S1226|in|O
S1226|the|O
S1226|control|O
S1226|group|O
S1226|)|O
S1226|,|O
S1226|of|O
S1226|whom|O
S1226|1617|O
S1226|(|O
S1226|53|O
S1226|%|O
S1226|)|O
S1226|were|O
S1226|older|O
S1226|than|O
S1226|80|O
S1226|years|O
S1226|of|O
S1226|age|O
S1226|.|O
S615|Recruited|O
S615|patients|O
S615|were|O
S615|≥18|O
S615|years|O
S615|old|O
S615|,|O
S615|with|O
S615|SSc|O
S615|as|O
S615|defined|O
S615|by|O
S615|the|O
S615|preliminary|O
S615|classification|O
S615|criteria|O
S615|of|O
S615|the|O
S615|American|O
S615|College|O
S615|of|O
S615|Rheumatology|O
S615|(|O
S615|ACR|O
S615|)|O
S615|and|O
S615|at|O
S615|least|O
S615|one|O
S615|active|O
S615|DU|O
S615|(|O
S615|onset|O
S615|between|O
S615|1|O
S615|week|O
S615|and|O
S615|3|O
S615|months|O
S615|prior|O
S615|to|O
S615|randomisation|O
S615|)|O
S615|that|O
S615|was|O
S615|selected|O
S615|by|O
S615|the|O
S615|investigator|O
S615|and|O
S615|termed|O
S615|the|O
S615|‘|O
S615|cardinal|O
S615|ulcer|O
S615|’|O
S615|(|O
S615|painful|O
S615|area|O
S615|,|O
S615|≥2|O
S615|mm|O
S615|in|O
S615|diameter|O
S615|with|O
S615|visible|O
S615|depth|O
S615|and|O
S615|loss|O
S615|of|O
S615|dermis|O
S615|,|O
S615|amenable|O
S615|to|O
S615|healing|O
S615|and|O
S615|in|O
S615|a|O
S615|location|O
S615|judged|O
S615|compatible|O
S615|with|O
S615|a|O
S615|vascular|O
S615|aetiology|O
S615|,|O
S615|specified|O
S615|by|O
S615|protocol|O
S615|as|O
S615|volar|O
S615|surface|O
S615|of|O
S615|the|O
S615|digit|O
S615|distal|O
S615|to|O
S615|the|O
S615|proximal|O
S615|interphalangeal|O
S615|digital|O
S615|crease|O
S615|)|O
S615|.|O
S287|The|O
S287|study|O
S287|was|O
S287|performed|O
S287|in|O
S287|accordance|O
S287|with|O
S287|the|O
S287|International|O
S287|Conference|O
S287|on|O
S287|Harmonisation|O
S287|of|O
S287|Technical|O
S287|Requirements|O
S287|for|O
S287|Registration|O
S287|of|O
S287|Pharmaceuticals|O
S287|for|O
S287|Human|O
S287|Use|O
S287|(|O
S287|ICH|O
S287|)|O
S287|Harmonised|O
S287|Tripartite|O
S287|Guidelines|O
S287|for|O
S287|Good|O
S287|Clinical|O
S287|Practice|O
S287|and|O
S287|the|O
S287|ethical|O
S287|principles|O
S287|laid|O
S287|down|O
S287|in|O
S287|the|O
S287|Declaration|O
S287|of|O
S287|Helsinki|O
S287|,|O
S287|and|O
S287|all|O
S287|patients|O
S287|provided|O
S287|written|O
S287|informed|O
S287|consent|O
S287|.|O
S668|The|O
S668|proportions|O
S668|of|O
S668|patients|O
S668|experiencing|O
S668|at|O
S668|least|O
S668|one|O
S668|adverse|O
S668|event|O
S668|were|O
S668|similar|O
S668|in|O
S668|both|O
S668|treatment|O
S668|groups|O
S668|(|O
S668|table|O
S668|4|O
S668|)|O
S668|.|O
S447|A|O
S447|steering|O
S447|committee|O
S447|(|O
S447|British|O
S447|Society|O
S447|for|O
S447|Paediatric|O
S447|Endocrinology|O
S447|and|O
S447|Diabetes|O
S447|Clinical|O
S447|Trials/Audit|O
S447|Group|O
S447|)|O
S447|supervised|O
S447|the|O
S447|study|O
S447|,|O
S447|and|O
S447|an|O
S447|independent|O
S447|data|O
S447|and|O
S447|safety|O
S447|monitoring|O
S447|group|O
S447|was|O
S447|established|O
S447|.|O
S1346|An|O
S1346|analysis|O
S1346|of|O
S1346|the|O
S1346|treatment|O
S1346|effect|O
S1346|in|O
S1346|each|O
S1346|of|O
S1346|three|O
S1346|equal-sized|O
S1346|cohorts|O
S1346|of|O
S1346|patients|O
S1346|(|O
S1346|ie|O
S1346|,|O
S1346|those|O
S1346|recruited|O
S1346|in|O
S1346|2000–06|O
S1346|,|O
S1346|2007–08|O
S1346|,|O
S1346|2009–11|O
S1346|)|O
S1346|did|O
S1346|not|O
S1346|provide|O
S1346|any|O
S1346|evidence|O
S1346|of|O
S1346|period|O
S1346|effects|O
S1346|(|O
S1346|data|O
S1346|not|O
S1346|shown|O
S1346|)|O
S1346|.|O
S1457|Because|O
S1457|we|O
S1457|found|O
S1457|no|O
S1457|heterogeneity|O
S1457|,|O
S1457|we|O
S1457|used|O
S1457|conditional|O
S1457|multiple|O
S1457|logistic|O
S1457|regression|O
S1457|to|O
S1457|investigate|O
S1457|independent|O
S1457|predictors|O
S1457|of|O
S1457|viral|O
S1457|RNA|O
S1457|clearance|O
S1457|on|O
S1457|day|O
S1457|five|O
S1457|,|O
S1457|stratified|O
S1457|by|O
S1457|study|O
S1457|sites|O
S1457|.|O
S817|However|O
S817|,|O
S817|there|O
S817|were|O
S817|no|O
S817|differences|O
S817|in|O
S817|the|O
S817|dose–response|O
S817|curves|O
S817|between|O
S817|etanercept|O
S817|and|O
S817|placebo|O
S817|(|O
S817|p|O
S817|>|O
S817|0.1|O
S817|for|O
S817|all|O
S817|;|O
S817|figure|O
S817|1|O
S817|)|O
S817|.|O
S1488|In|O
S1488|nasal|O
S1488|samples|O
S1488|by|O
S1488|day|O
S1488|10|O
S1488|,|O
S1488|4/138|O
S1488|(|O
S1488|2.9|O
S1488|%|O
S1488|)|O
S1488|and|O
S1488|4/132|O
S1488|(|O
S1488|3.0|O
S1488|%|O
S1488|)|O
S1488|patients|O
S1488|remained|O
S1488|positive|O
S1488|for|O
S1488|viral|O
S1488|RNA|O
S1488|in|O
S1488|double|O
S1488|and|O
S1488|standard|O
S1488|dose|O
S1488|arms|O
S1488|.|O
S973|Similar|O
S973|results|O
S973|were|O
S973|observed|O
S973|for|O
S973|sensitivity|O
S973|analyses|O
S973|in|O
S973|which|O
S973|missing|O
S973|data|O
S973|were|O
S973|imputed|O
S973|(|O
S973|0.001|O
S973|cm2/day|O
S973|,|O
S973|−0.20|O
S973|to|O
S973|0.21|O
S973|;|O
S973|P=0.99|O
S973|)|O
S973|,|O
S973|and|O
S973|separately|O
S973|,|O
S973|after|O
S973|adjusting|O
S973|for|O
S973|additional|O
S973|baseline|O
S973|covariates|O
S973|(|O
S973|−0.10|O
S973|cm2/day|O
S973|,|O
S973|−0.33|O
S973|to|O
S973|0.13|O
S973|;|O
S973|P=0.38|O
S973|)|O
S973|.|O
S334|At|O
S334|16|O
S334|weeks|O
S334|38.9|O
S334|%|O
S334|to|O
S334|53.7|O
S334|%|O
S334|of|O
S334|patients|O
S334|treated|O
S334|with|O
S334|canakinumab|O
S334|and|O
S334|46.3|O
S334|%|O
S334|of|O
S334|patients|O
S334|treated|O
S334|with|O
S334|colchicine|O
S334|achieved|O
S334|SU|O
S334|levels|O
S334|<|O
S334|6|O
S334|mg/dl|O
S334|and|O
S334|similar|O
S334|results|O
S334|were|O
S334|reported|O
S334|for|O
S334|week|O
S334|24|O
S334|(|O
S334|canakinumab|O
S334|,|O
S334|37.0|O
S334|%|O
S334|to|O
S334|50.9|O
S334|%|O
S334|;|O
S334|colchicine|O
S334|,|O
S334|41.7|O
S334|%|O
S334|)|O
S334|.|O
S1615|Whether|O
S1615|addition|O
S1615|of|O
S1615|one|O
S1615|drug|O
S1615|for|O
S1615|a|O
S1615|short|O
S1615|period|O
S1615|in|O
S1615|an|O
S1615|induction-maintenance|O
S1615|approach|O
S1615|might|O
S1615|have|O
S1615|benefits|O
S1615|across|O
S1615|childhood|O
S1615|is|O
S1615|unknown|O
S1615|.|O
S804|No|O
S804|serious|O
S804|adverse|O
S804|events|O
S804|occurred|O
S804|during|O
S804|the|O
S804|study|O
S804|.|O
S153|Peak|O
S153|forced|O
S153|vital|O
S153|capacity|O
S153|(|O
S153|FVC|O
S153|)|O
S153|(|O
S153|0-3h|O
S153|)|O
S153|,|O
S153|trough|O
S153|FVC|O
S153|and|O
S153|FVC|O
S153|AUC|O
S153|(|O
S153|0-3h|O
S153|)|O
S153|responses|O
S153|,|O
S153|versus|O
S153|placebo|O
S153|,|O
S153|were|O
S153|greatest|O
S153|with|O
S153|tiotropium|O
S153|Respimat®|O
S153|5|O
S153|μg|O
S153|(|O
S153|P|O
S153|<|O
S153|0.0001|O
S153|,|O
S153|P|O
S153|=|O
S153|0.0012|O
S153|and|O
S153|P|O
S153|<|O
S153|0.0001|O
S153|,|O
S153|respectively|O
S153|)|O
S153|.|O
S496|The|O
S496|two|O
S496|treatments|O
S496|together|O
S496|were|O
S496|thus|O
S496|no|O
S496|more|O
S496|effective|O
S496|than|O
S496|either|O
S496|one|O
S496|alone|O
S496|,|O
S496|as|O
S496|shown|O
S496|by|O
S496|the|O
S496|substantial|O
S496|and|O
S496|close|O
S496|to|O
S496|significant|O
S496|negative|O
S496|interaction|O
S496|.|O
S665|An|O
S665|analysis|O
S665|of|O
S665|subgroups|O
S665|based|O
S665|on|O
S665|randomisation|O
S665|month|O
S665|(|O
S665|October–February|O
S665|,|O
S665|March–September|O
S665|)|O
S665|confined|O
S665|to|O
S665|the|O
S665|first|O
S665|12|O
S665|weeks|O
S665|of|O
S665|treatment|O
S665|(|O
S665|to|O
S665|avoid|O
S665|overlapping|O
S665|time|O
S665|periods|O
S665|)|O
S665|found|O
S665|no|O
S665|effect|O
S665|of|O
S665|season|O
S665|on|O
S665|the|O
S665|treatment|O
S665|effect|O
S665|(|O
S665|table|O
S665|2|O
S665|)|O
S665|.|O
S1513|Oseltamivir|O
S1513|resistance|O
S1513|No|O
S1513|patients|O
S1513|with|O
S1513|H1N1-pdm09|O
S1513|or|O
S1513|H5N1|O
S1513|had|O
S1513|the|O
S1513|oseltamivir|O
S1513|resistance|O
S1513|associated|O
S1513|mutation|O
S1513|H275Y|O
S1513|at|O
S1513|baseline|O
S1513|or|O
S1513|after|O
S1513|treatment|O
S1513|.|O
S285|Here|O
S285|,|O
S285|we|O
S285|report|O
S285|the|O
S285|results|O
S285|of|O
S285|a|O
S285|dose-ranging|O
S285|,|O
S285|active-controlled|O
S285|phase|O
S285|II|O
S285|trial|O
S285|to|O
S285|assess|O
S285|the|O
S285|efficacy|O
S285|,|O
S285|safety|O
S285|and|O
S285|tolerability|O
S285|of|O
S285|canakinumab|O
S285|as|O
S285|prophylaxis|O
S285|against|O
S285|flares|O
S285|in|O
S285|patients|O
S285|initiating|O
S285|allopurinol|O
S285|treatment|O
S285|.|O
S16|Strategies|O
S16|recommended|O
S16|to|O
S16|decrease|O
S16|GI|O
S16|injury|O
S16|in|O
S16|NSAID|O
S16|users|O
S16|include|O
S16|co-therapy|O
S16|with|O
S16|misoprostol|O
S16|or|O
S16|proton-pump|O
S16|inhibitors|O
S16|and/or|O
S16|use|O
S16|of|O
S16|COX-2|O
S16|selective|O
S16|inhibitors|O
S16|.|O
S2127|The|O
S2127|study|O
S2127|'s|O
S2127|Data|O
S2127|and|O
S2127|Safety|O
S2127|Monitoring|O
S2127|Board|O
S2127|examined|O
S2127|adverse|O
S2127|event|O
S2127|reports|O
S2127|periodically|O
S2127|but|O
S2127|the|O
S2127|blinding|O
S2127|code|O
S2127|was|O
S2127|not|O
S2127|broken|O
S2127|.|O
S1509|Adverse|O
S1509|events|O
S1509|Oseltamivir|O
S1509|was|O
S1509|generally|O
S1509|well|O
S1509|tolerated|O
S1509|;|O
S1509|55|O
S1509|(|O
S1509|16.9|O
S1509|%|O
S1509|)|O
S1509|patients|O
S1509|had|O
S1509|75|O
S1509|treatment|O
S1509|emergent|O
S1509|adverse|O
S1509|events|O
S1509|with|O
S1509|similar|O
S1509|rates|O
S1509|between|O
S1509|the|O
S1509|two|O
S1509|arms|O
S1509|(|O
S1509|table|O
S1509|7|O
S1509|)|O
S1509|.|O
S1434|Study|O
S1434|evaluations|O
S1434|Patients|O
S1434|with|O
S1434|severe|O
S1434|influenza-like|O
S1434|illness|O
S1434|were|O
S1434|screened|O
S1434|with|O
S1434|the|O
S1434|Quickvue|O
S1434|rapid|O
S1434|test|O
S1434|(|O
S1434|Quidel|O
S1434|,|O
S1434|San|O
S1434|Diego|O
S1434|,|O
S1434|CA|O
S1434|,|O
S1434|US|O
S1434|)|O
S1434|and/or|O
S1434|reverse|O
S1434|transcriptase|O
S1434|polymerase|O
S1434|chain|O
S1434|reaction|O
S1434|(|O
S1434|RT-PCR|O
S1434|)|O
S1434|of|O
S1434|throat|O
S1434|and|O
S1434|nose|O
S1434|swabs|O
S1434|.|O
S2217|Outcome|O
S2217|measures|O
S2217|The|O
S2217|primary|O
S2217|efficacy|O
S2217|outcome|O
S2217|was|O
S2217|the|O
S2217|annualized|O
S2217|rate|O
S2217|of|O
S2217|protocol-defined|O
S2217|asthma|O
S2217|exacerbations|O
S2217|from|O
S2217|baseline|O
S2217|to|O
S2217|Week|O
S2217|36|O
S2217|.|O
S161|In|O
S161|accordance|O
S161|with|O
S161|the|O
S161|Global|O
S161|Initiative|O
S161|for|O
S161|Asthma|O
S161|guidelines|O
S161|,|O
S161|for|O
S161|patients|O
S161|with|O
S161|moderate|O
S161|asthma|O
S161|who|O
S161|remain|O
S161|symptomatic|O
S161|despite|O
S161|using|O
S161|ICS|O
S161|,|O
S161|therapy|O
S161|is|O
S161|typically|O
S161|‘|O
S161|stepped|O
S161|up|O
S161|’|O
S161|by|O
S161|increasing|O
S161|the|O
S161|ICS|O
S161|dose|O
S161|and/or|O
S161|adding|O
S161|a|O
S161|long-acting|O
S161|β2-agonist|O
S161|(|O
S161|LABA|O
S161|)|O
S161|to|O
S161|the|O
S161|maintenance|O
S161|treatment|O
S161|regimen|O
S161|.|O
S603|Plasma|O
S603|ET|O
S603|concentrations|O
S603|are|O
S603|increased|O
S603|in|O
S603|patients|O
S603|with|O
S603|SSc|O
S603|,|O
S603|and|O
S603|there|O
S603|is|O
S603|evidence|O
S603|for|O
S603|increased|O
S603|ETB|O
S603|receptor|O
S603|expression|O
S603|in|O
S603|lung|O
S603|,|O
S603|skin|O
S603|and|O
S603|blood|O
S603|vessels|O
S603|in|O
S603|this|O
S603|disease|O
S603|.|O
S38|End|O
S38|points|O
S38|and|O
S38|analysis|O
S38|The|O
S38|primary|O
S38|end|O
S38|point|O
S38|for|O
S38|REDUCE-1|O
S38|was|O
S38|gastric|O
S38|ulcers|O
S38|identified|O
S38|at|O
S38|endoscopy|O
S38|during|O
S38|the|O
S38|24-week|O
S38|study|O
S38|period|O
S38|,|O
S38|with|O
S38|three|O
S38|secondary|O
S38|end|O
S38|points|O
S38|:|O
S38|upper|O
S38|GI|O
S38|ulcers|O
S38|(|O
S38|gastric|O
S38|and|O
S38|duodenal|O
S38|)|O
S38|,|O
S38|duodenal|O
S38|ulcers|O
S38|,|O
S38|and|O
S38|GI|O
S38|complications|O
S38|(|O
S38|bleeding|O
S38|,|O
S38|ulcer|O
S38|perforation|O
S38|,|O
S38|and|O
S38|gastric|O
S38|outlet|O
S38|obstruction|O
S38|due|O
S38|to|O
S38|ulcer|O
S38|)|O
S38|.|O
S647|Primary|O
S647|end|O
S647|points|O
S647|New|O
S647|DUs|O
S647|After|O
S647|24|O
S647|weeks|O
S647|of|O
S647|bosentan|O
S647|treatment|O
S647|there|O
S647|was|O
S647|a|O
S647|30|O
S647|%|O
S647|reduction|O
S647|in|O
S647|the|O
S647|occurrence|O
S647|of|O
S647|new|O
S647|DUs|O
S647|compared|O
S647|with|O
S647|placebo|O
S647|in|O
S647|the|O
S647|study|O
S647|population|O
S647|(|O
S647|1.9|O
S647|(|O
S647|95|O
S647|%|O
S647|CI|O
S647|1.4|O
S647|to|O
S647|2.3|O
S647|)|O
S647|vs|O
S647|2.7|O
S647|(|O
S647|2.0|O
S647|to|O
S647|3.4|O
S647|)|O
S647|new|O
S647|DUs|O
S647|,|O
S647|p=0.0351|O
S647|,|O
S647|figure|O
S647|2|O
S647|)|O
S647|.|O
S58|The|O
S58|independent|O
S58|variables|O
S58|prior|O
S58|ulcer|O
S58|history|O
S58|,|O
S58|gender|O
S58|,|O
S58|age|O
S58|,|O
S58|low-dose|O
S58|aspirin|O
S58|use|O
S58|,|O
S58|baseline|O
S58|erosions|O
S58|,|O
S58|and|O
S58|therapy|O
S58|also|O
S58|were|O
S58|included|O
S58|in|O
S58|a|O
S58|proportional|O
S58|hazards|O
S58|model|O
S58|to|O
S58|determine|O
S58|the|O
S58|effect|O
S58|on|O
S58|the|O
S58|dependent|O
S58|variable|O
S58|of|O
S58|development|O
S58|of|O
S58|upper|O
S58|GI|O
S58|ulcer|O
S58|.|O
S985|Treatment|O
S985|failure|O
S985|was|O
S985|documented|O
S985|in|O
S985|29/59|O
S985|(|O
S985|49|O
S985|%|O
S985|)|O
S985|participants|O
S985|in|O
S985|the|O
S985|ciclosporin|O
S985|group|O
S985|and|O
S985|26/53|O
S985|(|O
S985|49|O
S985|%|O
S985|)|O
S985|in|O
S985|the|O
S985|prednisolone|O
S985|group|O
S985|(|O
S985|P=0.88|O
S985|)|O
S985|.|O
S1138|We|O
S1138|compared|O
S1138|the|O
S1138|time|O
S1138|to|O
S1138|clearance|O
S1138|of|O
S1138|the|O
S1138|plantar|O
S1138|warts|O
S1138|between|O
S1138|the|O
S1138|two|O
S1138|groups|O
S1138|adjusting|O
S1138|for|O
S1138|the|O
S1138|same|O
S1138|covariates|O
S1138|as|O
S1138|above|O
S1138|(|O
S1138|age|O
S1138|,|O
S1138|previous|O
S1138|treatment|O
S1138|,|O
S1138|and|O
S1138|type|O
S1138|of|O
S1138|wart|O
S1138|)|O
S1138|.|O
S1152|Of|O
S1152|the|O
S1152|13|O
S1152|non-serious|O
S1152|adverse|O
S1152|events|O
S1152|in|O
S1152|the|O
S1152|salicylic|O
S1152|acid|O
S1152|group|O
S1152|,|O
S1152|nine|O
S1152|were|O
S1152|unrelated|O
S1152|to|O
S1152|the|O
S1152|trial|O
S1152|treatment|O
S1152|and|O
S1152|four|O
S1152|were|O
S1152|unlikely|O
S1152|to|O
S1152|be|O
S1152|related|O
S1152|to|O
S1152|the|O
S1152|treatment|O
S1152|.|O
S1506|Three|O
S1506|patients|O
S1506|developed|O
S1506|acute|O
S1506|respiratory|O
S1506|distress|O
S1506|syndrome|O
S1506|after|O
S1506|enrolment|O
S1506|across|O
S1506|both|O
S1506|arms|O
S1506|(|O
S1506|two|O
S1506|double|O
S1506|dose|O
S1506|,|O
S1506|one|O
S1506|standard|O
S1506|dose|O
S1506|)|O
S1506|.|O
S1702|CD4|O
S1702|percentage|O
S1702|increased|O
S1702|throughout|O
S1702|the|O
S1702|first|O
S1702|3|O
S1702|years|O
S1702|on|O
S1702|ART|O
S1702|before|O
S1702|plateauing|O
S1702|in|O
S1702|both|O
S1702|groups|O
S1702|(|O
S1702|figure|O
S1702|3|O
S1702|;|O
S1702|p=0·23|O
S1702|)|O
S1702|.|O
S786|Immunostaining|O
S786|and|O
S786|flow|O
S786|cytometry|O
S786|All|O
S786|reagents|O
S786|were|O
S786|obtained|O
S786|from|O
S786|AbD|O
S786|Serotec|O
S786|(|O
S786|Oxford|O
S786|,|O
S786|UK|O
S786|)|O
S786|unless|O
S786|otherwise|O
S786|stated|O
S786|.|O
S1694|After|O
S1694|year|O
S1694|1|O
S1694|,|O
S1694|23|O
S1694|(|O
S1694|4|O
S1694|%|O
S1694|)|O
S1694|children|O
S1694|on|O
S1694|clinically|O
S1694|driven|O
S1694|monitoring|O
S1694|versus|O
S1694|six|O
S1694|(|O
S1694|1|O
S1694|%|O
S1694|)|O
S1694|on|O
S1694|routine|O
S1694|laboratory|O
S1694|monitoring|O
S1694|had|O
S1694|a|O
S1694|first|O
S1694|WHO|O
S1694|stage|O
S1694|4|O
S1694|event|O
S1694|or|O
S1694|died|O
S1694|(|O
S1694|difference|O
S1694|0·99|O
S1694|per|O
S1694|100|O
S1694|child-years|O
S1694|,|O
S1694|95|O
S1694|%|O
S1694|CI|O
S1694|0·37–1·60|O
S1694|,|O
S1694|p=0·002|O
S1694|)|O
S1694|.|O
S205|ACQ-7|O
S205|was|O
S205|self-administered|O
S205|at|O
S205|Visits|O
S205|1–6|O
S205|prior|O
S205|to|O
S205|lung|O
S205|function|O
S205|tests|O
S205|.|O
S423|No|O
S423|cases|O
S423|of|O
S423|virilisation|O
S423|were|O
S423|reported|O
S423|.|O
S2137|Furthermore|O
S2137|,|O
S2137|the|O
S2137|covariance|O
S2137|model|O
S2137|'s|O
S2137|validity|O
S2137|was|O
S2137|checked|O
S2137|by|O
S2137|analysing|O
S2137|the|O
S2137|residuals|O
S2137|and|O
S2137|the|O
S2137|Cook|O
S2137|distances|O
S2137|.|O
S1639|Antiretroviral|O
S1639|drugs|O
S1639|could|O
S1639|be|O
S1639|substituted|O
S1639|,|O
S1639|preferably|O
S1639|within|O
S1639|class|O
S1639|,|O
S1639|after|O
S1639|adverse|O
S1639|events|O
S1639|.|O
S1591|Primary|O
S1591|efficacy|O
S1591|endpoints|O
S1591|were|O
S1591|new|O
S1591|WHO|O
S1591|stage|O
S1591|4|O
S1591|events|O
S1591|or|O
S1591|death|O
S1591|for|O
S1591|monitoring|O
S1591|and|O
S1591|change|O
S1591|in|O
S1591|CD4|O
S1591|percentage|O
S1591|at|O
S1591|72|O
S1591|and|O
S1591|144|O
S1591|weeks|O
S1591|for|O
S1591|ART-strategy|O
S1591|randomisations|O
S1591|;|O
S1591|the|O
S1591|co-primary|O
S1591|toxicity|O
S1591|endpoint|O
S1591|was|O
S1591|grade|O
S1591|3|O
S1591|or|O
S1591|4|O
S1591|adverse|O
S1591|events|O
S1591|.|O
S1965|Approval|O
S1965|for|O
S1965|the|O
S1965|study|O
S1965|was|O
S1965|obtained|O
S1965|from|O
S1965|the|O
S1965|Ethical|O
S1965|Committee|O
S1965|of|O
S1965|the|O
S1965|Jos|O
S1965|University|O
S1965|Teaching|O
S1965|Hospital|O
S1965|and|O
S1965|the|O
S1965|Institutional|O
S1965|Review|O
S1965|Board|O
S1965|of|O
S1965|Mayo|O
S1965|Clinic|O
S1965|,|O
S1965|and|O
S1965|written|O
S1965|informed|O
S1965|consent|O
S1965|was|O
S1965|obtained|O
S1965|from|O
S1965|a|O
S1965|parent|O
S1965|of|O
S1965|each|O
S1965|enrolled|O
S1965|child|O
S1965|.|O
S646|The|O
S646|treatment|O
S646|period|O
S646|was|O
S646|completed|O
S646|by|O
S646|75/98|B-Sample_Size_Actual_at_Outcome_Analysis
S646|(|I-Sample_Size_Actual_at_Outcome_Analysis
S646|76.5|I-Sample_Size_Actual_at_Outcome_Analysis
S646|%|I-Sample_Size_Actual_at_Outcome_Analysis
S646|)|I-Sample_Size_Actual_at_Outcome_Analysis
S646|and|I-Sample_Size_Actual_at_Outcome_Analysis
S646|73/90|I-Sample_Size_Actual_at_Outcome_Analysis
S646|(|I-Sample_Size_Actual_at_Outcome_Analysis
S646|81.1|I-Sample_Size_Actual_at_Outcome_Analysis
S646|%|I-Sample_Size_Actual_at_Outcome_Analysis
S646|)|I-Sample_Size_Actual_at_Outcome_Analysis
S646|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S646|,|O
S646|respectively|O
S646|(|O
S646|figure|O
S646|1|O
S646|)|O
S646|,|O
S646|with|O
S646|9.2|O
S646|%|O
S646|and|O
S646|7.8|O
S646|%|O
S646|,|O
S646|respectively|O
S646|,|O
S646|discontinued|O
S646|due|O
S646|to|O
S646|an|O
S646|adverse|O
S646|event|O
S646|.|O
S1085|Patients|O
S1085|were|O
S1085|directed|O
S1085|to|O
S1085|fix|O
S1085|the|O
S1085|adhesive|O
S1085|ring|O
S1085|with|O
S1085|the|O
S1085|hole|O
S1085|over|O
S1085|the|O
S1085|verruca|O
S1085|and|O
S1085|to|O
S1085|squeeze|O
S1085|a|O
S1085|little|O
S1085|ointment|O
S1085|into|O
S1085|the|O
S1085|hole|O
S1085|and|O
S1085|directly|O
S1085|on|O
S1085|to|O
S1085|the|O
S1085|verruca|O
S1085|.|O
S576|In|O
S576|an|O
S576|earlier|O
S576|trial|O
S576|,|O
S576|treatment|O
S576|with|O
S576|bosentan|O
S576|,|O
S576|an|O
S576|oral|O
S576|endothelin|O
S576|receptor|O
S576|antagonist|O
S576|,|O
S576|reduced|O
S576|the|O
S576|occurrence|O
S576|of|O
S576|new|O
S576|DUs|O
S576|by|O
S576|48|O
S576|%|O
S576|.|O
S296|Key|O
S296|exclusion|O
S296|criteria|O
S296|were|O
S296|:|O
S296|having|O
S296|a|O
S296|gouty|O
S296|arthritis|O
S296|flare|O
S296|within|O
S296|2|O
S296|weeks|O
S296|of|O
S296|screening|O
S296|,|O
S296|present|O
S296|at|O
S296|screening|O
S296|,|O
S296|or|O
S296|having|O
S296|pain|O
S296|associated|O
S296|with|O
S296|a|O
S296|flare|O
S296|at|O
S296|screening|O
S296|;|O
S296|history|O
S296|of|O
S296|allergy|O
S296|,|O
S296|contraindication|O
S296|,|O
S296|or|O
S296|intolerance|O
S296|to|O
S296|allopurinol|O
S296|or|O
S296|colchicine|O
S296|(|O
S296|see|O
S296|supplementary|O
S296|material|O
S296|for|O
S296|further|O
S296|details|O
S296|)|O
S296|.|O
S1977|Powdered|O
S1977|limestone|O
S1977|was|O
S1977|locally|O
S1977|available|O
S1977|at|O
S1977|a|O
S1977|much|O
S1977|lower|O
S1977|cost|O
S1977|than|O
S1977|calcium|O
S1977|tablets|O
S1977|.|O
S1232|Benefit|O
S1232|did|O
S1232|not|O
S1232|seem|O
S1232|to|O
S1232|be|O
S1232|diminished|O
S1232|in|O
S1232|elderly|O
S1232|patients|O
S1232|.|O
S180|Tiotropium|B-Design_Parallel_Group
S180|Respimat®|I-Design_Parallel_Group
S180|(|I-Design_Parallel_Group
S180|two|I-Design_Parallel_Group
S180|puffs|I-Design_Parallel_Group
S180|)|I-Design_Parallel_Group
S180|or|I-Design_Parallel_Group
S180|placebo|I-Design_Parallel_Group
S180|Respimat®|I-Design_Parallel_Group
S180|(|I-Design_Parallel_Group
S180|two|I-Design_Parallel_Group
S180|puffs|I-Design_Parallel_Group
S180|)|I-Design_Parallel_Group
S180|was|O
S180|administered|O
S180|once|O
S180|daily|O
S180|in|O
S180|the|O
S180|evening|O
S180|between|O
S180|18:00|O
S180|and|O
S180|20:00|O
S180|.|O
S1987|Serum|O
S1987|25|O
S1987|(|O
S1987|OH|O
S1987|)|O
S1987|D|O
S1987|was|O
S1987|measured|O
S1987|by|O
S1987|isotope-dilution|O
S1987|liquid|O
S1987|chromatography–tandem|O
S1987|mass|O
S1987|spectrometry|O
S1987|(|O
S1987|LC-MS/MS|O
S1987|)|O
S1987|.|O
S778|Plasma|O
S778|TNF-α|O
S778|and|O
S778|IL-6|O
S778|concentrations|O
S778|were|O
S778|determined|O
S778|as|O
S778|described|O
S778|previously|O
S778|using|O
S778|ELISA|O
S778|(|O
S778|Quantikine|O
S778|human|O
S778|TNF|O
S778|and|O
S778|IL-6|O
S778|immunoassays|O
S778|,|O
S778|R|O
S778|&|O
S778|D|O
S778|Systems|O
S778|;|O
S778|and|O
S778|Dako|O
S778|A/S|O
S778|,|O
S778|respectively|O
S778|)|O
S778|and|O
S778|fibrinolytic|O
S778|activities|O
S778|using|O
S778|a|O
S778|photometric|O
S778|method|O
S778|(|O
S778|Coatest|O
S778|t-PA|O
S778|and|O
S778|PAI-1|O
S778|,|O
S778|Chomogenix|O
S778|AB|O
S778|)|O
S778|.|O
S1459|This|O
S1459|analysis|O
S1459|was|O
S1459|repeated|O
S1459|by|O
S1459|giving|O
S1459|these|O
S1459|samples|O
S1459|the|O
S1459|value|O
S1459|of|O
S1459|0|O
S1459|.|O
S459|Treatment|O
S459|with|O
S459|growth|O
S459|hormone|O
S459|and|O
S459|oxandrolone|O
S459|continued|O
S459|until|O
S459|final|O
S459|height|O
S459|was|O
S459|reached|O
S459|.|O
S2144|The|O
S2144|median|O
S2144|plasma|O
S2144|concentration|O
S2144|of|O
S2144|memantine|O
S2144|was|O
S2144|83|O
S2144|ng/ml|O
S2144|(|O
S2144|76.5–98.3|O
S2144|)|O
S2144|.|O
S596|As|O
S596|a|O
S596|result|O
S596|,|O
S596|no|O
S596|single|O
S596|pharmacological|O
S596|treatment|O
S596|is|O
S596|entirely|O
S596|effective|O
S596|.|O
S1233|Funding|O
S1233|UK|O
S1233|Medical|O
S1233|Research|O
S1233|Council|O
S1233|,|O
S1233|Health|O
S1233|Foundation|O
S1233|UK|O
S1233|,|O
S1233|Stroke|O
S1233|Association|O
S1233|UK|O
S1233|,|O
S1233|Research|O
S1233|Council|O
S1233|of|O
S1233|Norway|O
S1233|,|O
S1233|Arbetsmarknadens|O
S1233|Partners|O
S1233|Forsakringsbolag|O
S1233|(|O
S1233|AFA|O
S1233|)|O
S1233|Insurances|O
S1233|Sweden|O
S1233|,|O
S1233|Swedish|O
S1233|Heart|O
S1233|Lung|O
S1233|Fund|O
S1233|,|O
S1233|The|O
S1233|Foundation|O
S1233|of|O
S1233|Marianne|O
S1233|and|O
S1233|Marcus|O
S1233|Wallenberg|O
S1233|,|O
S1233|Polish|O
S1233|Ministry|O
S1233|of|O
S1233|Science|O
S1233|and|O
S1233|Education|O
S1233|,|O
S1233|the|O
S1233|Australian|O
S1233|Heart|O
S1233|Foundation|O
S1233|,|O
S1233|Australian|O
S1233|National|O
S1233|Health|O
S1233|and|O
S1233|Medical|O
S1233|Research|O
S1233|Council|O
S1233|(|O
S1233|NHMRC|O
S1233|)|O
S1233|,|O
S1233|Swiss|O
S1233|National|O
S1233|Research|O
S1233|Foundation|O
S1233|,|O
S1233|Swiss|O
S1233|Heart|O
S1233|Foundation|O
S1233|,|O
S1233|Assessorato|O
S1233|alla|O
S1233|Sanita|O
S1233|,|O
S1233|Regione|O
S1233|dell'Umbria|O
S1233|,|O
S1233|Italy|O
S1233|,|O
S1233|and|O
S1233|Danube|O
S1233|University|O
S1233|.|O
S2000|The|O
S2000|baseline|O
S2000|characteristics|O
S2000|at|O
S2000|enrolment|O
S2000|are|O
S2000|shown|O
S2000|in|O
S2000|table|O
S2000|1|O
S2000|.|O
S652|Secondary|O
S652|and|O
S652|exploratory|O
S652|end|O
S652|points|O
S652|New|O
S652|DUs|O
S652|The|O
S652|proportion|O
S652|of|O
S652|patients|O
S652|with|O
S652|no|O
S652|new|O
S652|DUs|O
S652|up|O
S652|to|O
S652|week|O
S652|24|O
S652|was|O
S652|similar|O
S652|with|O
S652|bosentan|O
S652|and|O
S652|placebo|O
S652|(|O
S652|observed|O
S652|in|O
S652|32/95|O
S652|(|O
S652|33.7|O
S652|%|O
S652|)|O
S652|and|O
S652|26/89|O
S652|(|O
S652|29.2|O
S652|%|O
S652|)|O
S652|patients|O
S652|,|O
S652|respectively|O
S652|,|O
S652|RR|O
S652|1.15|O
S652|(|O
S652|95|O
S652|%|O
S652|CI|O
S652|0.75|O
S652|to|O
S652|1.77|O
S652|)|O
S652|;|O
S652|p=0.53|O
S652|)|O
S652|.|O
S1610|These|O
S1610|showed|O
S1610|no|O
S1610|benefit|O
S1610|from|O
S1610|routine|O
S1610|toxicity|O
S1610|monitoring|O
S1610|,|O
S1610|small|O
S1610|but|O
S1610|significant|O
S1610|benefits|O
S1610|from|O
S1610|CD4|O
S1610|monitoring|O
S1610|,|O
S1610|and|O
S1610|no|O
S1610|significant|O
S1610|additional|O
S1610|benefit|O
S1610|of|O
S1610|viral|O
S1610|load|O
S1610|over|O
S1610|CD4|O
S1610|monitoring|O
S1610|.|O
S1330|Similarly|O
S1330|,|O
S1330|patients|O
S1330|recruited|O
S1330|at|O
S1330|earlier|O
S1330|time|O
S1330|points|O
S1330|were|O
S1330|significantly|O
S1330|older|O
S1330|than|O
S1330|those|O
S1330|recruited|O
S1330|later|O
S1330|(|O
S1330|test|O
S1330|for|O
S1330|linear|O
S1330|trend|O
S1330|p|O
S1330|<|O
S1330|0·0001|O
S1330|)|O
S1330|.|O
S1426|Patients|O
S1426|with|O
S1426|H5N1|O
S1426|influenza|O
S1426|were|O
S1426|stratified|O
S1426|separately|O
S1426|.|O
S2004|Their|O
S2004|calcium|O
S2004|intakes|O
S2004|were|O
S2004|well|O
S2004|below|O
S2004|the|O
S2004|Institute|O
S2004|of|O
S2004|Medicine|O
S2004|'s|O
S2004|estimated|O
S2004|average|O
S2004|daily|O
S2004|requirements|O
S2004|of|O
S2004|500|O
S2004|mg|O
S2004|and|O
S2004|800|O
S2004|mg|O
S2004|for|O
S2004|children|O
S2004|1–3|O
S2004|years|O
S2004|of|O
S2004|age|O
S2004|and|O
S2004|4–8|O
S2004|years|O
S2004|of|O
S2004|age|O
S2004|,|O
S2004|respectively|O
S2004|.|O
S1295|We|O
S1295|monitored|O
S1295|the|O
S1295|quality|O
S1295|and|O
S1295|integrity|O
S1295|of|O
S1295|the|O
S1295|accumulating|O
S1295|clinical|O
S1295|data|O
S1295|according|O
S1295|to|O
S1295|a|O
S1295|protocol|O
S1295|agreed|O
S1295|with|O
S1295|the|O
S1295|study|O
S1295|sponsors|O
S1295|,|O
S1295|which|O
S1295|involved|O
S1295|central|O
S1295|statistical|O
S1295|monitoring|O
S1295|according|O
S1295|to|O
S1295|the|O
S1295|principles|O
S1295|described|O
S1295|by|O
S1295|Buyse|O
S1295|and|O
S1295|colleagues|O
S1295|,|O
S1295|supplemented|O
S1295|by|O
S1295|onsite|O
S1295|monitoring|O
S1295|and|O
S1295|detailed|O
S1295|source|O
S1295|data|O
S1295|verification|O
S1295|in|O
S1295|a|O
S1295|random|O
S1295|sample|O
S1295|of|O
S1295|10|O
S1295|%|O
S1295|of|O
S1295|records|O
S1295|in|O
S1295|centres|O
S1295|that|O
S1295|had|O
S1295|recruited|O
S1295|more|O
S1295|than|O
S1295|30|O
S1295|patients|O
S1295|,|O
S1295|or|O
S1295|when|O
S1295|patterns|O
S1295|in|O
S1295|the|O
S1295|data|O
S1295|at|O
S1295|a|O
S1295|centre|O
S1295|seemed|O
S1295|anomalous|O
S1295|.|O
S2104|The|O
S2104|research|O
S2104|protocol|O
S2104|was|O
S2104|approved|O
S2104|by|O
S2104|the|O
S2104|local|O
S2104|independent|O
S2104|ethics|O
S2104|committee|O
S2104|(|O
S2104|Protocol|O
S2104|ID|O
S2104|:|O
S2104|2008-008210-38|O
S2104|)|O
S2104|.|O
S1507|Use|O
S1507|of|O
S1507|antibiotics|O
S1507|and|O
S1507|steroids|O
S1507|For|O
S1507|patients|O
S1507|not|O
S1507|taking|O
S1507|antibiotics|O
S1507|at|O
S1507|enrolment|O
S1507|,|O
S1507|antibiotic|O
S1507|prescribing|O
S1507|was|O
S1507|similar|O
S1507|(|O
S1507|P=0.27|O
S1507|)|O
S1507|for|O
S1507|both|O
S1507|arms|O
S1507|after|O
S1507|enrolment|O
S1507|:|O
S1507|31/50|O
S1507|(|O
S1507|62|O
S1507|%|O
S1507|)|O
S1507|in|O
S1507|the|O
S1507|double|O
S1507|dose|O
S1507|and|O
S1507|33/45|O
S1507|(|O
S1507|73|O
S1507|%|O
S1507|)|O
S1507|in|O
S1507|the|O
S1507|standard|O
S1507|dose|O
S1507|arm|O
S1507|.|O
S1130|The|O
S1130|assessors|O
S1130|disagreed|O
S1130|in|O
S1130|51|O
S1130|cases|O
S1130|:|O
S1130|in|O
S1130|three|O
S1130|cases|O
S1130|the|O
S1130|disagreement|O
S1130|was|O
S1130|between|O
S1130|whether|O
S1130|the|O
S1130|plantar|O
S1130|wart|O
S1130|was|O
S1130|“|O
S1130|cleared|O
S1130|”|O
S1130|or|O
S1130|“|O
S1130|not|O
S1130|cleared|O
S1130|,|O
S1130|”|O
S1130|in|O
S1130|five|O
S1130|cases|O
S1130|it|O
S1130|was|O
S1130|between|O
S1130|“|O
S1130|cleared|O
S1130|”|O
S1130|and|O
S1130|“|O
S1130|unable|O
S1130|to|O
S1130|assess|O
S1130|,|O
S1130|”|O
S1130|and|O
S1130|in|O
S1130|the|O
S1130|remaining|O
S1130|43|O
S1130|cases|O
S1130|it|O
S1130|was|O
S1130|between|O
S1130|“|O
S1130|not|O
S1130|cleared|O
S1130|”|O
S1130|and|O
S1130|“|O
S1130|unable|O
S1130|to|O
S1130|assess.|O
S1130|”|O
S1130|This|O
S1130|might|O
S1130|lead|O
S1130|to|O
S1130|an|O
S1130|underestimation|O
S1130|of|O
S1130|the|O
S1130|clearance|O
S1130|rate|O
S1130|,|O
S1130|but|O
S1130|as|O
S1130|the|O
S1130|assessment|O
S1130|was|O
S1130|blind|O
S1130|to|O
S1130|treatment|O
S1130|allocation|O
S1130|it|O
S1130|is|O
S1130|unlikely|O
S1130|to|O
S1130|lead|O
S1130|to|O
S1130|a|O
S1130|difference|O
S1130|between|O
S1130|the|O
S1130|two|O
S1130|treatments|O
S1130|groups|O
S1130|.|O
S1817|During|O
S1817|the|O
S1817|post-trial|O
S1817|period|O
S1817|(|O
S1817|when|O
S1817|statin|O
S1817|use|O
S1817|and|O
S1817|lipid|O
S1817|concentrations|O
S1817|were|O
S1817|similar|O
S1817|in|O
S1817|both|O
S1817|groups|O
S1817|)|O
S1817|,|O
S1817|no|O
S1817|further|O
S1817|significant|O
S1817|reductions|O
S1817|were|O
S1817|noted|O
S1817|in|O
S1817|either|O
S1817|major|O
S1817|vascular|O
S1817|events|O
S1817|(|O
S1817|risk|O
S1817|ratio|O
S1817|[|O
S1817|RR|O
S1817|]|O
S1817|0·95|O
S1817|[|O
S1817|0·89–1·02|O
S1817|]|O
S1817|)|O
S1817|or|O
S1817|vascular|O
S1817|mortality|O
S1817|(|O
S1817|0·98|O
S1817|[|O
S1817|0·90–1·07|O
S1817|]|O
S1817|)|O
S1817|.|O
S743|We|O
S743|conclude|O
S743|that|O
S743|TNF-α|O
S743|antagonism|O
S743|is|O
S743|unlikely|O
S743|to|O
S743|be|O
S743|a|O
S743|beneficial|O
S743|therapeutic|O
S743|strategy|O
S743|in|O
S743|patients|O
S743|with|O
S743|acute|O
S743|myocardial|O
S743|infarction|O
S743|.|O
S970|Primary|O
S970|outcome|O
S970|Of|O
S970|the|O
S970|108|O
S970|participants|O
S970|with|O
S970|data|O
S970|at|O
S970|baseline|O
S970|and|O
S970|six|O
S970|weeks|O
S970|,|O
S970|86|O
S970|(|O
S970|80|O
S970|%|O
S970|)|O
S970|had|O
S970|blinded|O
S970|outcome|O
S970|data|O
S970|based|O
S970|on|O
S970|digital|O
S970|images|O
S970|.|O
S1144|At|O
S1144|week|O
S1144|1|O
S1144|,|O
S1144|more|O
S1144|patients|O
S1144|were|O
S1144|happy|O
S1144|with|O
S1144|salicylic|O
S1144|acid|O
S1144|than|O
S1144|cryotherapy|O
S1144|but|O
S1144|also|O
S1144|more|O
S1144|patients|O
S1144|were|O
S1144|very|O
S1144|happy|O
S1144|with|O
S1144|cryotherapy|O
S1144|than|O
S1144|salicylic|O
S1144|acid|O
S1144|.|O
S942|Number|O
S942|of|O
S942|treatment|O
S942|failures—defined|O
S942|as|O
S942|those|O
S942|who|O
S942|withdrew|O
S942|from|O
S942|their|O
S942|randomised|O
S942|treatment|O
S942|because|O
S942|of|O
S942|treatment|O
S942|intolerance|O
S942|,|O
S942|whose|O
S942|pyoderma|O
S942|gangrenosum|O
S942|worsened|O
S942|,|O
S942|or|O
S942|whose|O
S942|target|O
S942|lesion|O
S942|remained|O
S942|unhealed|O
S942|after|O
S942|six|O
S942|months|O
S942|of|O
S942|follow-up|O
S942|.|O
S2206|Methods|O
S2206|Trial|O
S2206|design|O
S2206|The|O
S2206|COSTA|O
S2206|trial|O
S2206|of|O
S2206|quilizumab|O
S2206|was|O
S2206|a|O
S2206|Phase|B-Design_Phase_2
S2206|II|I-Design_Phase_2
S2206|,|O
S2206|randomized|O
S2206|,|O
S2206|double-blind|B-Blinding_Double_Blind
S2206|,|O
S2206|placebo-controlled|O
S2206|study|O
S2206|(|O
S2206|including|O
S2206|recruiting|B-Settings_Multicenter
S2206|sites|I-Settings_Multicenter
S2206|from|I-Settings_Multicenter
S2206|14|I-Settings_Multicenter
S2206|countries|I-Settings_Multicenter
S2206|:|O
S2206|Argentina|B-Settings_Location
S2206|,|I-Settings_Location
S2206|Belgium|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Bulgaria|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Canada|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Germany|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Hungary|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Mexico|I-Settings_Location
S2206|,|I-Settings_Location
S2206|New|I-Settings_Location
S2206|Zealand|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Peru|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Poland|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Romania|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Russia|I-Settings_Location
S2206|,|I-Settings_Location
S2206|Ukraine|I-Settings_Location
S2206|,|I-Settings_Location
S2206|and|I-Settings_Location
S2206|the|I-Settings_Location
S2206|United|I-Settings_Location
S2206|States|I-Settings_Location
S2206|)|O
S2206|that|O
S2206|enrolled|O
S2206|578|B-Sample_Size_Actual_at_Enrollment
S2206|adults|O
S2206|with|O
S2206|uncontrolled|O
S2206|allergic|O
S2206|asthma|O
S2206|.|O
S221|The|O
S221|treated|O
S221|set|O
S221|comprised|O
S221|all|O
S221|149|O
S221|patients|O
S221|and|O
S221|the|O
S221|full|O
S221|analysis|O
S221|set|O
S221|comprised|O
S221|148|O
S221|patients|O
S221|(|O
S221|one|O
S221|patient|O
S221|had|O
S221|missing|O
S221|efficacy|O
S221|data|O
S221|and|O
S221|was|O
S221|lost|O
S221|to|O
S221|follow-up|O
S221|after|O
S221|Visit|O
S221|2|O
S221|)|O
S221|(|O
S221|Figure|O
S221|2|O
S221|)|O
S221|.|O
S236|Neither|O
S236|was|O
S236|considered|O
S236|to|O
S236|be|O
S236|drug-related|O
S236|.|O
S735|We|O
S735|wished|O
S735|to|O
S735|determine|O
S735|the|O
S735|effects|O
S735|of|O
S735|TNF-α|O
S735|antagonism|O
S735|on|O
S735|endothelial|O
S735|function|O
S735|and|O
S735|platelet|O
S735|activation|O
S735|in|O
S735|patients|O
S735|with|O
S735|acute|O
S735|myocardial|O
S735|infarction|O
S735|.|O
S473|The|O
S473|study|O
S473|was|O
S473|not|O
S473|formally|O
S473|powered|O
S473|to|O
S473|detect|O
S473|a|O
S473|significant|O
S473|interaction|O
S473|between|O
S473|the|O
S473|two|O
S473|randomisations|O
S473|.|O
S663|In|O
S663|both|O
S663|subgroups|O
S663|,|O
S663|the|O
S663|estimated|O
S663|proportion|O
S663|of|O
S663|patients|O
S663|without|O
S663|each|O
S663|subsequent|O
S663|new|O
S663|DU|O
S663|was|O
S663|larger|O
S663|in|O
S663|the|O
S663|bosentan|O
S663|than|O
S663|placebo|O
S663|group|O
S663|except|O
S663|the|O
S663|first|O
S663|new|O
S663|DU|O
S663|(|O
S663|table|O
S663|3|O
S663|)|O
S663|,|O
S663|and|O
S663|the|O
S663|difference|O
S663|between|O
S663|treatment|O
S663|groups|O
S663|was|O
S663|larger|O
S663|among|O
S663|patients|O
S663|with|O
S663|at|O
S663|least|O
S663|four|O
S663|new|O
S663|DUs|O
S663|than|O
S663|in|O
S663|those|O
S663|with|O
S663|fewer|O
S663|than|O
S663|four|O
S663|new|O
S663|DUs|O
S663|.|O
S625|Use|O
S625|of|O
S625|glibenclamide|O
S625|,|O
S625|fluconazole|O
S625|,|O
S625|calcineurin|O
S625|inhibitors|O
S625|or|O
S625|ciclosporin|O
S625|A|O
S625|was|O
S625|not|O
S625|allowed|O
S625|due|O
S625|to|O
S625|potential|O
S625|drug|O
S625|interactions|O
S625|.|O
S1074|Participants|O
S1074|were|O
S1074|excluded|O
S1074|from|O
S1074|the|O
S1074|study|O
S1074|if|O
S1074|they|O
S1074|had|O
S1074|impaired|O
S1074|healing|O
S1074|(|O
S1074|such|O
S1074|as|O
S1074|from|O
S1074|diabetes|O
S1074|or|O
S1074|peripheral|O
S1074|vascular|O
S1074|disease|O
S1074|)|O
S1074|;|O
S1074|were|O
S1074|immunosuppressed|O
S1074|(|O
S1074|such|O
S1074|as|O
S1074|agammaglobulinaemia|O
S1074|)|O
S1074|or|O
S1074|were|O
S1074|taking|O
S1074|immunosuppressant|O
S1074|drugs|O
S1074|(|O
S1074|such|O
S1074|as|O
S1074|oral|O
S1074|corticosteroids|O
S1074|)|O
S1074|;|O
S1074|had|O
S1074|neuropathy|O
S1074|;|O
S1074|were|O
S1074|receiving|O
S1074|renal|O
S1074|dialysis|O
S1074|;|O
S1074|had|O
S1074|cold|O
S1074|intolerance|O
S1074|(|O
S1074|such|O
S1074|as|O
S1074|Raynaud|O
S1074|’|O
S1074|s|O
S1074|syndrome|O
S1074|or|O
S1074|cold|O
S1074|urticaria|O
S1074|)|O
S1074|;|O
S1074|had|O
S1074|any|O
S1074|of|O
S1074|the|O
S1074|following|O
S1074|conditions|O
S1074|(|O
S1074|blood|O
S1074|dyscrasias|O
S1074|of|O
S1074|unknown|O
S1074|origin|O
S1074|,|O
S1074|cryoglobulinaemia|O
S1074|,|O
S1074|cryofibrinogenaemia|O
S1074|,|O
S1074|collagen|O
S1074|or|O
S1074|autoimmune|O
S1074|disease|O
S1074|)|O
S1074|;|O
S1074|were|O
S1074|unable|O
S1074|to|O
S1074|give|O
S1074|informed|O
S1074|consent|O
S1074|;|O
S1074|or|O
S1074|were|O
S1074|currently|O
S1074|in|O
S1074|a|O
S1074|trial|O
S1074|evaluating|O
S1074|other|O
S1074|treatments|O
S1074|for|O
S1074|their|O
S1074|plantar|O
S1074|wart|O
S1074|.|O
S1261|Acute-care|O
S1261|protocols|O
S1261|were|O
S1261|not|O
S1261|specified|O
S1261|by|O
S1261|the|O
S1261|trial|O
S1261|,|O
S1261|but|O
S1261|had|O
S1261|to|O
S1261|include|O
S1261|the|O
S1261|components|O
S1261|of|O
S1261|effective|O
S1261|stroke-unit|O
S1261|care|O
S1261|,|O
S1261|including|O
S1261|,|O
S1261|soon|O
S1261|after|O
S1261|admission|O
S1261|,|O
S1261|intravenous|O
S1261|access|O
S1261|,|O
S1261|monitoring|O
S1261|of|O
S1261|physiological|O
S1261|variables|O
S1261|,|O
S1261|correction|O
S1261|of|O
S1261|any|O
S1261|abnormalities|O
S1261|,|O
S1261|and|O
S1261|where|O
S1261|clinically|O
S1261|appropriate|O
S1261|,|O
S1261|intravenous-fluid|O
S1261|therapy|O
S1261|.|O
S1154|Both|O
S1154|participants|O
S1154|developed|O
S1154|a|O
S1154|blister|O
S1154|that|O
S1154|was|O
S1154|larger|O
S1154|than|O
S1154|expected|O
S1154|in|O
S1154|routine|O
S1154|practice|O
S1154|.|O
S1944|Of|O
S1944|the|O
S1944|68|B-Sample_Size_Actual_at_Outcome_Analysis
S1944|children|I-Sample_Size_Actual_at_Outcome_Analysis
S1944|(|O
S1944|94|O
S1944|%|O
S1944|of|O
S1944|original|O
S1944|cohort|O
S1944|)|O
S1944|who|O
S1944|completed|O
S1944|24|O
S1944|weeks|O
S1944|of|O
S1944|treatment|O
S1944|,|O
S1944|29|O
S1944|(|O
S1944|67|O
S1944|%|O
S1944|)|O
S1944|in|O
S1944|the|O
S1944|Ca+D|O
S1944|group|O
S1944|and|O
S1944|11|O
S1944|(|O
S1944|44|O
S1944|%|O
S1944|)|O
S1944|in|O
S1944|the|O
S1944|Ca|O
S1944|group|O
S1944|achieved|O
S1944|the|O
S1944|primary|O
S1944|outcome|O
S1944|(|O
S1944|p=0.06|O
S1944|)|O
S1944|.|O
S1984|Height|O
S1984|,|O
S1984|weight|O
S1984|,|O
S1984|venous|O
S1984|blood|O
S1984|,|O
S1984|wrist|O
S1984|and|O
S1984|knee|O
S1984|radiographs|O
S1984|,|O
S1984|and|O
S1984|forearm|O
S1984|bone|O
S1984|density|O
S1984|measurements|O
S1984|were|O
S1984|obtained|O
S1984|at|O
S1984|baseline|O
S1984|and|O
S1984|at|O
S1984|12|O
S1984|and|O
S1984|24|O
S1984|weeks|O
S1984|after|O
S1984|enrolment|O
S1984|.|O
S1826|Collectively|O
S1826|,|O
S1826|findings|O
S1826|of|O
S1826|HPS|O
S1826|and|O
S1826|other|O
S1826|major|O
S1826|trials|O
S1826|of|O
S1826|statins|O
S1826|provide|O
S1826|compelling|O
S1826|evidence|O
S1826|that|O
S1826|lowering|O
S1826|LDL|O
S1826|cholesterol|O
S1826|by|O
S1826|about|O
S1826|1|O
S1826|mmol/L|O
S1826|reduces|O
S1826|vascular|O
S1826|mortality|O
S1826|and|O
S1826|morbidity|O
S1826|by|O
S1826|about|O
S1826|a|O
S1826|quarter|O
S1826|in|O
S1826|a|O
S1826|wide|O
S1826|range|O
S1826|of|O
S1826|patients|O
S1826|(|O
S1826|including|O
S1826|elderly|O
S1826|people|O
S1826|and|O
S1826|those|O
S1826|with|O
S1826|low|O
S1826|cholesterol|O
S1826|concentrations|O
S1826|)|O
S1826|,|O
S1826|without|O
S1826|increasing|O
S1826|the|O
S1826|risk|O
S1826|of|O
S1826|non-vascular|O
S1826|mortality|O
S1826|or|O
S1826|morbidity|O
S1826|(|O
S1826|apart|O
S1826|from|O
S1826|a|O
S1826|small|O
S1826|myopathy|O
S1826|excess|O
S1826|)|O
S1826|during|O
S1826|about|O
S1826|5|O
S1826|years|O
S1826|of|O
S1826|treatment|O
S1826|.|O
S2208|Randomization|O
S2208|was|O
S2208|stratified|B-Randomization_Type_Stratified
S2208|based|O
S2208|on|O
S2208|serum|B-Randomization_Stratified_Criteria
S2208|periostin|I-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|<|I-Randomization_Stratified_Criteria
S2208|50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|≥50|I-Randomization_Stratified_Criteria
S2208|ng/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|exacerbation|B-Randomization_Stratified_Criteria
S2208|history|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|number|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|exacerbations|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|1|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|requiring|I-Randomization_Stratified_Criteria
S2208|use|I-Randomization_Stratified_Criteria
S2208|of|I-Randomization_Stratified_Criteria
S2208|systemic|I-Randomization_Stratified_Criteria
S2208|corticosteroids|I-Randomization_Stratified_Criteria
S2208|in|I-Randomization_Stratified_Criteria
S2208|the|I-Randomization_Stratified_Criteria
S2208|prior|I-Randomization_Stratified_Criteria
S2208|18|I-Randomization_Stratified_Criteria
S2208|months|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|IgE|B-Randomization_Stratified_Criteria
S2208|level|I-Randomization_Stratified_Criteria
S2208|(|I-Randomization_Stratified_Criteria
S2208|≤75|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|75–200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|,|I-Randomization_Stratified_Criteria
S2208|>|I-Randomization_Stratified_Criteria
S2208|200|I-Randomization_Stratified_Criteria
S2208|IU/mL|I-Randomization_Stratified_Criteria
S2208|)|I-Randomization_Stratified_Criteria
S2208|,|O
S2208|and|O
S2208|country|B-Randomization_Stratified_Criteria
S2208|.|O
S486|Of|O
S486|the|O
S486|46|O
S486|girls|O
S486|not|O
S486|randomised|O
S486|at|O
S486|12|O
S486|years|O
S486|,|O
S486|21|O
S486|enrolled|O
S486|after|O
S486|12|O
S486|years|O
S486|(|O
S486|the|O
S486|late|O
S486|group|O
S486|)|O
S486|,|O
S486|18|O
S486|had|O
S486|spontaneous|O
S486|puberty|O
S486|,|O
S486|and|O
S486|seven|O
S486|had|O
S486|withdrawn|O
S486|before|O
S486|the|O
S486|age|O
S486|of|O
S486|12|O
S486|years|O
S486|.|O
S335|Safety|O
S335|and|O
S335|tolerability|O
S335|Safety|O
S335|results|O
S335|for|O
S335|the|O
S335|individual|O
S335|dose|O
S335|groups|O
S335|are|O
S335|summarised|O
S335|in|O
S335|table|O
S335|3|O
S335|.|O
S580|Secondary|O
S580|end|O
S580|points|O
S580|included|O
S580|pain|O
S580|,|O
S580|disability|O
S580|and|O
S580|safety|O
S580|.|O
S941|The|O
S941|period|O
S941|of|O
S941|follow-up|O
S941|available|O
S941|varied|O
S941|depending|O
S941|on|O
S941|the|O
S941|time|O
S941|at|O
S941|which|O
S941|participants|O
S941|were|O
S941|randomised|O
S941|into|O
S941|the|O
S941|trial|O
S941|.|O
S1271|All|O
S1271|assessments|O
S1271|were|O
S1271|made|O
S1271|masked|O
S1271|to|O
S1271|all|O
S1271|patient|O
S1271|details|O
S1271|and|O
S1271|treatment|O
S1271|allocation|O
S1271|.|O
S869|Outcomes|O
S869|were|O
S869|assessed|O
S869|at|O
S869|baseline|O
S869|and|O
S869|six|O
S869|weeks|O
S869|and|O
S869|when|O
S869|the|O
S869|ulcer|O
S869|had|O
S869|healed|O
S869|(|O
S869|to|O
S869|a|O
S869|maximum|O
S869|of|O
S869|six|O
S869|months|O
S869|)|O
S869|.|O
S9|Proportional|O
S9|hazards|O
S9|analysis|O
S9|of|O
S9|multiple|O
S9|potential|O
S9|risk|O
S9|factors|O
S9|showed|O
S9|the|O
S9|risk|O
S9|ratio|O
S9|of|O
S9|upper|O
S9|GI|O
S9|ulcers|O
S9|with|O
S9|HZT-501|B-Design_Parallel_Group
S9|vs.|I-Design_Parallel_Group
S9|ibuprofen|I-Design_Parallel_Group
S9|was|O
S9|0.46|O
S9|,|O
S9|95|O
S9|%|O
S9|confidence|O
S9|interval|O
S9|was|O
S9|0.34–0.61|O
S9|.|O
S650|Healing|O
S650|of|O
S650|the|O
S650|cardinal|O
S650|ulcer|O
S650|No|O
S650|difference|O
S650|between|O
S650|bosentan|O
S650|and|O
S650|placebo|O
S650|treatments|O
S650|was|O
S650|observed|O
S650|in|O
S650|the|O
S650|time|O
S650|to|O
S650|healing|O
S650|of|O
S650|the|O
S650|cardinal|O
S650|ulcer|O
S650|(|O
S650|HR|O
S650|0.91|O
S650|(|O
S650|95|O
S650|%|O
S650|CI|O
S650|0.61|O
S650|to|O
S650|1.35|O
S650|)|O
S650|,|O
S650|p=0.63|O
S650|,|O
S650|figure|O
S650|3|O
S650|)|O
S650|.|O
S1822|Funding|O
S1822|UK|O
S1822|Medical|O
S1822|Research|O
S1822|Council|O
S1822|,|O
S1822|British|O
S1822|Heart|O
S1822|Foundation|O
S1822|,|O
S1822|Merck|O
S1822|&|O
S1822|Co|O
S1822|,|O
S1822|Roche|O
S1822|Vitamins|O
S1822|.|O
S604|Other|O
S604|actions|O
S604|of|O
S604|ET|O
S604|relevant|O
S604|to|O
S604|SSc|O
S604|include|O
S604|proinflammatory|O
S604|and|O
S604|proliferative|O
S604|effects|O
S604|as|O
S604|well|O
S604|as|O
S604|mediation|O
S604|of|O
S604|vasoconstriction|O
S604|.|O
S1310|We|O
S1310|therefore|O
S1310|specified|O
S1310|in|O
S1310|the|O
S1310|statistical|O
S1310|analysis|O
S1310|plan|O
S1310|an|O
S1310|ordinal|O
S1310|logistic|O
S1310|regression|O
S1310|analysis|O
S1310|,|O
S1310|as|O
S1310|a|O
S1310|secondary|O
S1310|outcome|O
S1310|,|O
S1310|in|O
S1310|which|O
S1310|the|O
S1310|OHS|O
S1310|as|O
S1310|a|O
S1310|dependent|O
S1310|variable|O
S1310|had|O
S1310|5|O
S1310|levels|O
S1310|:|O
S1310|levels|O
S1310|4|O
S1310|,|O
S1310|5|O
S1310|,|O
S1310|and|O
S1310|6|O
S1310|were|O
S1310|combined|O
S1310|into|O
S1310|a|O
S1310|single|O
S1310|level|O
S1310|and|O
S1310|levels|O
S1310|0|O
S1310|,|O
S1310|1|O
S1310|,|O
S1310|2|O
S1310|,|O
S1310|3|O
S1310|were|O
S1310|retained|O
S1310|as|O
S1310|distinct|O
S1310|.|O
S600|Similarly|O
S600|,|O
S600|a|O
S600|trial|O
S600|in|O
S600|patients|O
S600|with|O
S600|severe|O
S600|PAH|O
S600|associated|O
S600|with|O
S600|SSc|O
S600|indicated|O
S600|there|O
S600|may|O
S600|be|O
S600|a|O
S600|beneficial|O
S600|effect|O
S600|of|O
S600|epoprostenol|O
S600|on|O
S600|the|O
S600|number|O
S600|of|O
S600|DUs|O
S600|.|O
S1715|ART-modifying|O
S1715|adverse|O
S1715|events|O
S1715|occurred|O
S1715|in|O
S1715|31|O
S1715|(|O
S1715|5|O
S1715|%|O
S1715|)|O
S1715|children|O
S1715|on|O
S1715|clinically|O
S1715|driven|O
S1715|monitoring|O
S1715|versus|O
S1715|32|O
S1715|(|O
S1715|5|O
S1715|%|O
S1715|)|O
S1715|on|O
S1715|routine|O
S1715|laboratory|O
S1715|monitoring|O
S1715|(|O
S1715|HR|O
S1715|0·95|O
S1715|,|O
S1715|0·58–1·56|O
S1715|,|O
S1715|p=0·84|O
S1715|)|O
S1715|.|O
S806|At|O
S806|24|O
S806|h|O
S806|,|O
S806|treatment|O
S806|with|O
S806|etanercept|O
S806|was|O
S806|associated|O
S806|with|O
S806|a|O
S806|reduced|O
S806|neutrophil|O
S806|count|O
S806|(|O
S806|8.8±0.6|O
S806|vs|O
S806|7.4±0.5|O
S806|cells|O
S806|109/l|O
S806|;|O
S806|p=0.02|O
S806|)|O
S806|,|O
S806|and|O
S806|a|O
S806|rise|O
S806|in|O
S806|the|O
S806|lymphocyte|O
S806|count|O
S806|(|O
S806|2.3±0.2|O
S806|vs|O
S806|2.7±0.26|O
S806|;|O
S806|p=0.001|O
S806|)|O
S806|,|O
S806|with|O
S806|a|O
S806|reduction|O
S806|in|O
S806|the|O
S806|neutrophil|O
S806|to|O
S806|lymphocyte|O
S806|ratio|O
S806|following|O
S806|etanercept|O
S806|compared|O
S806|with|O
S806|placebo|O
S806|(|O
S806|−1.3±0.4|O
S806|vs|O
S806|0.17±0.2|O
S806|;|O
S806|p=0.001|O
S806|)|O
S806|.|O
S1153|In|O
S1153|the|O
S1153|cryotherapy|O
S1153|group|O
S1153|,|O
S1153|there|O
S1153|were|O
S1153|two|O
S1153|treatment|O
S1153|related|O
S1153|,|O
S1153|non-serious|O
S1153|adverse|O
S1153|events|O
S1153|in|O
S1153|two|O
S1153|participants|O
S1153|.|O
S1094|Any|O
S1094|discrepancies|O
S1094|were|O
S1094|referred|O
S1094|to|O
S1094|a|O
S1094|third|O
S1094|assessor|O
S1094|.|O
S863|Setting|O
S863|39|B-Settings_Multicenter
S863|UK|B-Settings_Location
S863|hospitals|I-Settings_Multicenter
S863|,|O
S863|recruiting|O
S863|from|O
S863|June|O
S863|2009|O
S863|to|O
S863|November|O
S863|2012|O
S863|.|O
S1652|Change|O
S1652|in|O
S1652|CD4|O
S1652|percentage|O
S1652|was|O
S1652|compared|O
S1652|with|O
S1652|normal|O
S1652|linear|O
S1652|regression|O
S1652|adjusted|O
S1652|for|O
S1652|randomisation|O
S1652|stratification|O
S1652|factors|O
S1652|.|O
S948|Statistical|O
S948|analysis|O
S948|We|O
S948|prespecified|O
S948|all|O
S948|analyses|O
S948|in|O
S948|a|O
S948|statistical|O
S948|analysis|O
S948|plan|O
S948|.|O
S452|Girls|O
S452|with|O
S452|a|O
S452|follicle|O
S452|stimulating|O
S452|hormone|O
S452|concentration|O
S452|below|O
S452|10U/L|O
S452|and|O
S452|a|O
S452|karyotype|O
S452|associated|O
S452|with|O
S452|preservation|O
S452|of|O
S452|ovarian|O
S452|function|O
S452|(|O
S452|45|O
S452|,|O
S452|X/46|O
S452|,|O
S452|XX|O
S452|and|O
S452|45|O
S452|,|O
S452|X/47|O
S452|,|O
S452|XXX|O
S452|)|O
S452|(|O
S452|the|O
S452|spontaneous|O
S452|puberty|O
S452|group|O
S452|)|O
S452|were|O
S452|not|O
S452|randomised|O
S452|at|O
S452|randomisation|O
S452|2|O
S452|.|O
S1669|For|O
S1669|children|O
S1669|assigned|O
S1669|to|O
S1669|clinically|O
S1669|driven|O
S1669|monitoring|O
S1669|,|O
S1669|clinicians|O
S1669|could|O
S1669|request|O
S1669|individual|O
S1669|laboratory|O
S1669|toxicity|O
S1669|results|O
S1669|from|O
S1669|routine|O
S1669|haematology|O
S1669|or|O
S1669|biochemistry|O
S1669|panels|O
S1669|for|O
S1669|clinical|O
S1669|reasons|O
S1669|.|O
S425|However|O
S425|,|O
S425|these|O
S425|effects|O
S425|were|O
S425|not|O
S425|additive|O
S425|,|O
S425|so|O
S425|using|O
S425|both|O
S425|had|O
S425|no|O
S425|advantage|O
S425|.|O
S53|Numbers-needed-to-treat|O
S53|(|O
S53|NNTs|O
S53|)|O
S53|and|O
S53|absolute|O
S53|risk|O
S53|reductions|O
S53|were|O
S53|calculated|O
S53|using|O
S53|crude|O
S53|proportions|O
S53|.|O
S2286|Treatment|O
S2286|with|O
S2286|quilizumab|O
S2286|failed|O
S2286|to|O
S2286|increase|O
S2286|either|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|used|O
S2286|a|O
S2286|SABA|O
S2286|for|O
S2286|fewer|O
S2286|than|O
S2286|2|O
S2286|days|O
S2286|in|O
S2286|the|O
S2286|prior|O
S2286|week|O
S2286|or|O
S2286|the|O
S2286|proportion|O
S2286|of|O
S2286|patients|O
S2286|who|O
S2286|did|O
S2286|not|O
S2286|awaken|O
S2286|at|O
S2286|night|O
S2286|due|O
S2286|to|O
S2286|asthma|O
S2286|symptoms|O
S2286|for|O
S2286|all|O
S2286|dosing|O
S2286|levels|O
S2286|relative|O
S2286|to|O
S2286|the|O
S2286|placebo|O
S2286|group|O
S2286|at|O
S2286|Week|O
S2286|36|O
S2286|(|O
S2286|Table|O
S2286|3|O
S2286|)|O
S2286|.|O
S959|Table|O
S959|1|O
S959|summarises|O
S959|the|O
S959|baseline|O
S959|characteristics|O
S959|of|O
S959|the|O
S959|participants|O
S959|.|O
S224|The|O
S224|remainder|O
S224|of|O
S224|the|O
S224|study|O
S224|population|O
S224|had|O
S224|never|O
S224|smoked|O
S224|(|O
S224|80.5|O
S224|%|O
S224|;|O
S224|n|O
S224|=|O
S224|120|O
S224|)|O
S224|(|O
S224|Table|O
S224|1|O
S224|)|O
S224|.|O
S947|As|O
S947|a|O
S947|result|O
S947|,|O
S947|we|O
S947|felt|O
S947|that|O
S947|a|O
S947|substantial|O
S947|treatment|O
S947|effect|O
S947|was|O
S947|necessary|O
S947|to|O
S947|justify|O
S947|a|O
S947|change|O
S947|in|O
S947|clinical|O
S947|practice|O
S947|.|O
S1703|Only|O
S1703|11|O
S1703|(|O
S1703|2|O
S1703|%|O
S1703|)|O
S1703|children|O
S1703|on|O
S1703|clinically|O
S1703|driven|O
S1703|monitoring|O
S1703|versus|O
S1703|two|O
S1703|(|O
S1703|<|O
S1703|1|O
S1703|%|O
S1703|)|O
S1703|on|O
S1703|routine|O
S1703|laboratory|O
S1703|monitoring|O
S1703|had|O
S1703|CD4|O
S1703|less|O
S1703|than|O
S1703|5|O
S1703|%|O
S1703|at|O
S1703|their|O
S1703|last|O
S1703|visit|O
S1703|(|O
S1703|exact|O
S1703|p=0·01|O
S1703|;|O
S1703|appendix|O
S1703|)|O
S1703|.|O
S1711|Although|O
S1711|there|O
S1711|was|O
S1711|no|O
S1711|difference|O
S1711|in|O
S1711|grade|O
S1711|4|O
S1711|adverse|O
S1711|events|O
S1711|,|O
S1711|147|O
S1711|(|O
S1711|24|O
S1711|%|O
S1711|)|O
S1711|children|O
S1711|on|O
S1711|clinically|O
S1711|driven|O
S1711|monitoring|O
S1711|versus|O
S1711|117|O
S1711|(|O
S1711|20|O
S1711|%|O
S1711|)|O
S1711|on|O
S1711|routine|O
S1711|laboratory|O
S1711|monitoring|O
S1711|had|O
S1711|one|O
S1711|or|O
S1711|more|O
S1711|serious|O
S1711|adverse|O
S1711|events|O
S1711|(|O
S1711|any|O
S1711|grade|O
S1711|;|O
S1711|HR|O
S1711|1·30|O
S1711|,|O
S1711|1·02–1·66|O
S1711|,|O
S1711|p=0·04|O
S1711|)|O
S1711|.|O
S272|Long-standing|O
S272|elevated|O
S272|body|O
S272|uric|O
S272|acid|O
S272|pools|O
S272|can|O
S272|lead|O
S272|to|O
S272|increased|O
S272|serum|O
S272|urate|O
S272|(|O
S272|SU|O
S272|)|O
S272|levels|O
S272|and|O
S272|formation|O
S272|of|O
S272|MSU|O
S272|crystals|O
S272|.|O
S1435|Patients|O
S1435|with|O
S1435|positive|O
S1435|results|O
S1435|for|O
S1435|influenza|O
S1435|virus|O
S1435|who|O
S1435|met|O
S1435|the|O
S1435|inclusion|O
S1435|criteria|O
S1435|were|O
S1435|randomised|O
S1435|.|O
S2007|Baseline|O
S2007|alkaline|O
S2007|phosphatase|O
S2007|and|O
S2007|radiographic|O
S2007|scores|O
S2007|were|O
S2007|unrelated|O
S2007|to|O
S2007|25|O
S2007|(|O
S2007|OH|O
S2007|)|O
S2007|D|O
S2007|concentrations|O
S2007|.|O
S2238|Fractional|O
S2238|exhaled|O
S2238|nitric|O
S2238|oxide|O
S2238|(|O
S2238|FeNO|O
S2238|)|O
S2238|was|O
S2238|measured|O
S2238|using|O
S2238|a|O
S2238|hand-held|O
S2238|portable|O
S2238|device|O
S2238|,|O
S2238|NIOX|O
S2238|MINO®|O
S2238|(|O
S2238|Niox|O
S2238|;|O
S2238|Morrisville|O
S2238|,|O
S2238|NC|O
S2238|)|O
S2238|,|O
S2238|according|O
S2238|to|O
S2238|American|O
S2238|Thoracic|O
S2238|Society/European|O
S2238|Respiratory|O
S2238|Society|O
S2238|2009|O
S2238|guidelines|O
S2238|.|O
S2148|Other|O
S2148|than|O
S2148|a|O
S2148|slight|O
S2148|worsening|O
S2148|of|O
S2148|pre-existing|O
S2148|alopecia|O
S2148|in|O
S2148|one|O
S2148|female|O
S2148|patient|O
S2148|,|O
S2148|no|O
S2148|adverse|O
S2148|events|O
S2148|were|O
S2148|reported|O
S2148|.|O
S1663|Results|O
S1663|1210|B-Sample_Size_Actual_at_Enrollment
S1663|children|I-Sample_Size_Actual_at_Enrollment
S1663|were|O
S1663|enrolled|O
S1663|(|O
S1663|March|O
S1663|15|O
S1663|,|O
S1663|2007–Nov|O
S1663|18|O
S1663|,|O
S1663|2008|O
S1663|)|O
S1663|.|O
S1103|This|O
S1103|trial|O
S1103|was|O
S1103|a|O
S1103|superiority|O
S1103|study|O
S1103|of|O
S1103|cryotherapy|O
S1103|compared|O
S1103|with|O
S1103|salicylic|O
S1103|acid|O
S1103|and|O
S1103|was|O
S1103|powered|O
S1103|to|O
S1103|show|O
S1103|a|O
S1103|15|O
S1103|%|O
S1103|difference|O
S1103|in|O
S1103|effectiveness|O
S1103|.|O
S1229|Fatal|O
S1229|or|O
S1229|non-fatal|O
S1229|symptomatic|O
S1229|intracranial|O
S1229|haemorrhage|O
S1229|within|O
S1229|7|O
S1229|days|O
S1229|occurred|O
S1229|in|O
S1229|104|O
S1229|(|O
S1229|7|O
S1229|%|O
S1229|)|O
S1229|patients|O
S1229|in|O
S1229|the|O
S1229|rt-PA|O
S1229|group|O
S1229|versus|O
S1229|16|O
S1229|(|O
S1229|1|O
S1229|%|O
S1229|)|O
S1229|in|O
S1229|the|O
S1229|control|O
S1229|group|O
S1229|(|O
S1229|adjusted|O
S1229|OR|O
S1229|6·94|O
S1229|,|O
S1229|95|O
S1229|%|O
S1229|CI|O
S1229|4·07–11·8|O
S1229|;|O
S1229|absolute|O
S1229|excess|O
S1229|58/1000|O
S1229|,|O
S1229|95|O
S1229|%|O
S1229|CI|O
S1229|44–72|O
S1229|)|O
S1229|.|O
S491|Table|O
S491|3|O
S491|summarises|O
S491|the|O
S491|results|O
S491|of|O
S491|the|O
S491|randomised|O
S491|comparisons|O
S491|.|O
S792|Samples|O
S792|were|O
S792|then|O
S792|fixed|O
S792|and|O
S792|run|O
S792|through|O
S792|a|O
S792|FACSCalibur|O
S792|(|O
S792|Becton-Dickinson|O
S792|)|O
S792|flow|O
S792|cytometer|O
S792|within|O
S792|2|O
S792|h|O
S792|of|O
S792|fixing|O
S792|using|O
S792|an|O
S792|established|O
S792|flow|O
S792|protocol|O
S792|.|O
S80|The|O
S80|combined|O
S80|trial|O
S80|cumulative|O
S80|incidence|O
S80|for|O
S80|crude|O
S80|rate|O
S80|of|O
S80|ulcers|O
S80|by|O
S80|visit|O
S80|is|O
S80|shown|O
S80|in|O
S80|Figure|O
S80|2|O
S80|.|O
S1865|Overall|O
S1865|,|O
S1865|96|O
S1865|784|O
S1865|person-years|O
S1865|of|O
S1865|follow-up|O
S1865|were|O
S1865|available|O
S1865|for|O
S1865|those|O
S1865|originally|O
S1865|allocated|O
S1865|simvastatin|O
S1865|and|O
S1865|95|O
S1865|084|O
S1865|for|O
S1865|those|O
S1865|allocated|O
S1865|placebo|O
S1865|(|O
S1865|ratio|O
S1865|1·02|O
S1865|)|O
S1865|.|O
S40|An|O
S40|endoscopic|O
S40|diagnosis|O
S40|of|O
S40|ulcer|O
S40|required|O
S40|unequivocal|O
S40|depth|O
S40|and|O
S40|diameter|O
S40|of|O
S40|≥3|O
S40|mm|O
S40|.|O
S1843|Further|O
S1843|details|O
S1843|were|O
S1843|sought|O
S1843|from|O
S1843|the|O
S1843|participants|O
S1843|'|O
S1843|family|O
S1843|doctors|O
S1843|(|O
S1843|plus|O
S1843|,|O
S1843|if|O
S1843|necessary|O
S1843|,|O
S1843|hospital|O
S1843|records|O
S1843|)|O
S1843|about|O
S1843|all|O
S1843|reports|O
S1843|that|O
S1843|might|O
S1843|relate|O
S1843|to|O
S1843|major|O
S1843|vascular|O
S1843|events|O
S1843|or|O
S1843|deaths|O
S1843|.|O
S516|No|O
S516|virilisation|O
S516|was|O
S516|reported|O
S516|;|O
S516|in|O
S516|particular|O
S516|,|O
S516|no|O
S516|voice|O
S516|deepening|O
S516|or|O
S516|clitoromegaly|O
S516|was|O
S516|noted|O
S516|.|O
S1721|By|O
S1721|contrast|O
S1721|,|O
S1721|similarly|O
S1721|to|O
S1721|week|O
S1721|144|O
S1721|,|O
S1721|at|O
S1721|the|O
S1721|latest|O
S1721|test|O
S1721|suppression|O
S1721|was|O
S1721|significantly|O
S1721|greater|O
S1721|in|O
S1721|children|O
S1721|receiving|O
S1721|two|O
S1721|NRTIs|O
S1721|plus|O
S1721|an|O
S1721|NNRTI|O
S1721|(|O
S1721|496|O
S1721|[|O
S1721|84|O
S1721|%|O
S1721|]|O
S1721|of|O
S1721|591|O
S1721|in|O
S1721|groups|O
S1721|A|O
S1721|and|O
S1721|B|O
S1721|vs|O
S1721|200|O
S1721|[|O
S1721|65|O
S1721|%|O
S1721|]|O
S1721|of|O
S1721|310|O
S1721|in|O
S1721|group|O
S1721|C|O
S1721|)|O
S1721|.|O
S305|Sample|O
S305|size|O
S305|determination|O
S305|and|O
S305|statistical|O
S305|analysis|O
S305|A|O
S305|sample|O
S305|size|O
S305|of|O
S305|350|B-Sample_Size_Required
S305|patients|O
S305|(|O
S305|50|O
S305|patients|O
S305|in|O
S305|each|O
S305|of|O
S305|the|O
S305|5|O
S305|canakinumab|O
S305|single-dose|O
S305|groups|O
S305|and|O
S305|100|O
S305|patients|O
S305|in|O
S305|the|O
S305|colchicine|O
S305|group|O
S305|)|O
S305|was|O
S305|considered|O
S305|sufficient|O
S305|to|O
S305|give|O
S305|a|O
S305|95|B-Sample_Size_Calculation_Alpha_Value
S305|%|I-Sample_Size_Calculation_Alpha_Value
S305|confidence|I-Sample_Size_Calculation_Alpha_Value
S305|interval|I-Sample_Size_Calculation_Alpha_Value
S305|(|O
S305|CI|O
S305|)|O
S305|of|O
S305|the|O
S305|target|O
S305|dose|O
S305|with|O
S305|reasonable|O
S305|precision|O
S305|.|O
S339|One|O
S339|death|O
S339|occurred|O
S339|in|O
S339|the|O
S339|colchicine|O
S339|group|O
S339|,|O
S339|a|O
S339|possible|O
S339|myocardial|O
S339|infarction|O
S339|,|O
S339|but|O
S339|was|O
S339|not|O
S339|regarded|O
S339|by|O
S339|the|O
S339|investigator|O
S339|as|O
S339|being|O
S339|related|O
S339|to|O
S339|study|O
S339|medication|O
S339|.|O
S497|The|O
S497|mean|O
S497|effect|O
S497|on|O
S497|final|O
S497|height|O
S497|of|O
S497|oxandrolone|O
S497|,|O
S497|late|O
S497|induction|O
S497|of|O
S497|puberty|O
S497|,|O
S497|or|O
S497|both|O
S497|compared|O
S497|with|O
S497|placebo|O
S497|and|O
S497|early|O
S497|induction|O
S497|was|O
S497|+7.1|O
S497|cm|O
S497|(|O
S497|that|O
S497|is|O
S497|,|O
S497|the|O
S497|mean|O
S497|final|O
S497|height|O
S497|in|O
S497|the|O
S497|combined|O
S497|oxandrolone/early|O
S497|,|O
S497|oxandrolone/late|O
S497|,|O
S497|and|O
S497|placebo/late|O
S497|groups|O
S497|compared|O
S497|with|O
S497|the|O
S497|placebo/early|O
S497|group|O
S497|)|O
S497|,|O
S497|which|O
S497|is|O
S497|appreciably|O
S497|larger|O
S497|than|O
S497|the|O
S497|effects|O
S497|for|O
S497|either|O
S497|randomisation|O
S497|alone|O
S497|(|O
S497|table|O
S497|3|O
S497|,|O
S497|combination|O
S497|)|O
S497|.|O
S1647|Statistical|O
S1647|analysis|O
S1647|1200|B-Sample_Size_Required
S1647|children|I-Sample_Size_Required
S1647|followed|O
S1647|up|O
S1647|for|O
S1647|3·5–5·0|O
S1647|years|O
S1647|with|O
S1647|less|O
S1647|than|O
S1647|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S1647|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1647|loss|I-Sample_Size_Calculation_Dropout_Rate_Value
S1647|to|I-Sample_Size_Calculation_Dropout_Rate_Value
S1647|follow-up|I-Sample_Size_Calculation_Dropout_Rate_Value
S1647|provided|O
S1647|90|B-Sample_Size_Calculation_Power_Value
S1647|%|I-Sample_Size_Calculation_Power_Value
S1647|power|O
S1647|to|O
S1647|establish|O
S1647|that|O
S1647|clinically|O
S1647|driven|O
S1647|monitoring|O
S1647|was|O
S1647|not|B-Design_Comparative_Intent_NonInferiority
S1647|inferior|I-Design_Comparative_Intent_NonInferiority
S1647|to|O
S1647|routine|O
S1647|laboratory|O
S1647|monitoring|O
S1647|on|O
S1647|the|O
S1647|primary|O
S1647|efficacy|O
S1647|outcome|O
S1647|,|O
S1647|defined|O
S1647|as|O
S1647|the|O
S1647|upper|O
S1647|95|B-Sample_Size_Calculation_Alpha_Value
S1647|%|I-Sample_Size_Calculation_Alpha_Value
S1647|confidence|I-Sample_Size_Calculation_Alpha_Value
S1647|limit|O
S1647|for|O
S1647|the|O
S1647|difference|O
S1647|(|O
S1647|clinically|O
S1647|driven|O
S1647|minus|O
S1647|routine|O
S1647|laboratory|O
S1647|monitoring|O
S1647|)|O
S1647|in|O
S1647|rate|O
S1647|of|O
S1647|first|O
S1647|new|O
S1647|WHO|O
S1647|stage|O
S1647|4|O
S1647|event|O
S1647|or|O
S1647|deaths|O
S1647|per|O
S1647|100|O
S1647|child-years|O
S1647|being|O
S1647|no|O
S1647|greater|O
S1647|than|O
S1647|1·6|O
S1647|per|O
S1647|100|O
S1647|child-years|O
S1647|(|O
S1647|assumed|O
S1647|rate|O
S1647|for|O
S1647|routine|O
S1647|laboratory|O
S1647|monitoring|O
S1647|of|O
S1647|2·5|O
S1647|per|O
S1647|100|O
S1647|child-years|O
S1647|)|O
S1647|.|O
S593|Of|O
S593|all|O
S593|patients|O
S593|with|O
S593|SSc|O
S593|,|O
S593|32|O
S593|%|O
S593|(|O
S593|666|O
S593|patients|O
S593|)|O
S593|had|O
S593|persistent|O
S593|or|O
S593|recurrent|O
S593|DUs|O
S593|for|O
S593|≥6|O
S593|months|O
S593|;|O
S593|of|O
S593|these|O
S593|,|O
S593|30|O
S593|%|O
S593|(|O
S593|197|O
S593|patients|O
S593|)|O
S593|had|O
S593|severe|O
S593|DUs|O
S593|(|O
S593|complicated|O
S593|by|O
S593|gangrene|O
S593|,|O
S593|or|O
S593|requiring|O
S593|digital|O
S593|sympathectomy|O
S593|or|O
S593|amputation|O
S593|)|O
S593|.|O
S961|Such|O
S961|participants|O
S961|were|O
S961|randomised|O
S961|before|O
S961|confirmation|O
S961|of|O
S961|biopsy|O
S961|results|O
S961|as|O
S961|it|O
S961|was|O
S961|considered|O
S961|unethical|O
S961|to|O
S961|delay|O
S961|treatment|O
S961|for|O
S961|those|O
S961|with|O
S961|painful|O
S961|and|O
S961|rapidly|O
S961|spreading|O
S961|ulcers|O
S961|.|O
S1102|The|O
S1102|overall|O
S1102|cure|O
S1102|rates|O
S1102|from|O
S1102|this|O
S1102|study|O
S1102|are|O
S1102|smaller|O
S1102|than|O
S1102|those|O
S1102|observed|O
S1102|in|O
S1102|two|O
S1102|placebo|O
S1102|controlled|O
S1102|trials|O
S1102|of|O
S1102|salicylic|O
S1102|acid|O
S1102|,|O
S1102|both|O
S1102|of|O
S1102|which|O
S1102|reported|O
S1102|cure|O
S1102|rates|O
S1102|of|O
S1102|85|O
S1102|%|O
S1102|for|O
S1102|active|O
S1102|treatment|O
S1102|,|O
S1102|possibly|O
S1102|because|O
S1102|more|O
S1102|resistant|O
S1102|verrucae|O
S1102|were|O
S1102|included|O
S1102|in|O
S1102|the|O
S1102|study|O
S1102|comparing|O
S1102|cryotherapy|O
S1102|with|O
S1102|salicylic|O
S1102|acid|O
S1102|.|O
S1837|Procedures|O
S1837|and|O
S1837|follow-up|O
S1837|During|O
S1837|the|O
S1837|in-trial|O
S1837|treatment|O
S1837|period|O
S1837|,|O
S1837|routine|O
S1837|follow-up|O
S1837|in|O
S1837|study|O
S1837|clinics|O
S1837|was|O
S1837|at|O
S1837|4|O
S1837|,|O
S1837|8|O
S1837|,|O
S1837|and|O
S1837|12|O
S1837|months|O
S1837|and|O
S1837|then|O
S1837|every|O
S1837|6|O
S1837|months|O
S1837|.|O
S218|The|O
S218|statistical|O
S218|model|O
S218|included|O
S218|‘|O
S218|treatment|O
S218|’|O
S218|and|O
S218|‘|O
S218|period|O
S218|’|O
S218|as|O
S218|fixed|O
S218|effects|O
S218|and|O
S218|‘|O
S218|patient|O
S218|’|O
S218|as|O
S218|a|O
S218|random|O
S218|effect|O
S218|.|O
S965|During|O
S965|the|O
S965|trial|O
S965|,|O
S965|16/112|O
S965|(|O
S965|14|O
S965|%|O
S965|)|O
S965|participants|O
S965|switched|O
S965|to|O
S965|the|O
S965|alternative|O
S965|trial|O
S965|drug|O
S965|and|O
S965|a|O
S965|further|O
S965|eight|O
S965|(|O
S965|7|O
S965|%|O
S965|)|O
S965|received|O
S965|the|O
S965|two|O
S965|drugs|O
S965|together|O
S965|.|O
S1611|No|O
S1611|trials|O
S1611|have|O
S1611|evaluated|O
S1611|monitoring|O
S1611|strategies|O
S1611|in|O
S1611|children|O
S1611|on|O
S1611|ART|O
S1611|;|O
S1611|results|O
S1611|in|O
S1611|adults|O
S1611|might|O
S1611|not|O
S1611|be|O
S1611|generalisable|O
S1611|because|O
S1611|of|O
S1611|differences|O
S1611|in|O
S1611|frequency|O
S1611|of|O
S1611|ART|O
S1611|toxicity|O
S1611|,|O
S1611|predictive|O
S1611|value|O
S1611|of|O
S1611|CD4s|O
S1611|,|O
S1611|and|O
S1611|the|O
S1611|clinical|O
S1611|spectrum|O
S1611|of|O
S1611|paediatric|O
S1611|HIV|O
S1611|and|O
S1611|its|O
S1611|comorbidities|O
S1611|,|O
S1611|particularly|O
S1611|in|O
S1611|Africa|O
S1611|.|O
S638|The|O
S638|worst|O
S638|of|O
S638|either|O
S638|the|O
S638|calculated|O
S638|number|O
S638|or|O
S638|observed|O
S638|values|O
S638|at|O
S638|week|O
S638|24|O
S638|was|O
S638|used|O
S638|for|O
S638|patients|O
S638|who|O
S638|prematurely|O
S638|discontinued|O
S638|study|O
S638|treatment|O
S638|.|O
S2175|Methods|O
S2175|Five|B-Sample_Size_Actual_at_Enrollment
S2175|hundred|I-Sample_Size_Actual_at_Enrollment
S2175|seventy-eight|I-Sample_Size_Actual_at_Enrollment
S2175|patients|O
S2175|were|O
S2175|randomized|O
S2175|to|O
S2175|monthly|B-Design_Parallel_Group
S2175|or|I-Design_Parallel_Group
S2175|quarterly|I-Design_Parallel_Group
S2175|dosing|I-Design_Parallel_Group
S2175|regimens|I-Design_Parallel_Group
S2175|of|I-Design_Parallel_Group
S2175|subcutaneous|I-Design_Parallel_Group
S2175|quilizumab|I-Design_Parallel_Group
S2175|or|I-Design_Parallel_Group
S2175|placebo|I-Design_Parallel_Group
S2175|for|O
S2175|36|O
S2175|weeks|O
S2175|,|O
S2175|with|O
S2175|a|O
S2175|48-week|O
S2175|safety|O
S2175|follow-up|O
S2175|.|O
S10|CONCLUSIONS|O
S10|:|O
S10|Combined|O
S10|results|O
S10|of|O
S10|the|O
S10|REDUCE|O
S10|studies|O
S10|indicate|O
S10|that|O
S10|double-dose|O
S10|famotidine|O
S10|plus|O
S10|ibuprofen|O
S10|,|O
S10|given|O
S10|as|O
S10|a|O
S10|combination|O
S10|tablet|O
S10|,|O
S10|decreases|O
S10|endoscopic|O
S10|upper|O
S10|GI|O
S10|ulcers|O
S10|as|O
S10|compared|O
S10|with|O
S10|ibuprofen|O
S10|alone|O
S10|.|O
S1051|Trial|O
S1051|registration|O
S1051|Current|O
S1051|Controlled|O
S1051|Trials|O
S1051|ISRCTN18994246|O
S1051|,|O
S1051|National|O
S1051|Research|O
S1051|Register|O
S1051|N0484189151|O
S1051|.|O
S2086|The|O
S2086|memantine|O
S2086|and|O
S2086|placebo|O
S2086|group|O
S2086|did|O
S2086|not|O
S2086|differ|O
S2086|significantly|O
S2086|in|O
S2086|terms|O
S2086|of|O
S2086|stride|O
S2086|length|O
S2086|.|O
S329|The|O
S329|average|O
S329|duration|O
S329|(|O
S329|LS|O
S329|mean|O
S329|)|O
S329|for|O
S329|all|O
S329|flares|O
S329|over|O
S329|the|O
S329|16-week|O
S329|period|O
S329|was|O
S329|shorter|O
S329|in|O
S329|all|O
S329|canakinumab|O
S329|groups|O
S329|compared|O
S329|with|O
S329|colchicine|O
S329|0.5|O
S329|mg|O
S329|:|O
S329|2.8–4.6|O
S329|days|O
S329|versus|O
S329|5.1|O
S329|days|O
S329|(|O
S329|table|O
S329|2|O
S329|)|O
S329|.|O
S795|Data|O
S795|and|O
S795|statistical|O
S795|analysis|O
S795|Cytometric|O
S795|data|O
S795|analysis|O
S795|was|O
S795|performed|O
S795|with|O
S795|FlowJo|O
S795|V.7.2.5|O
S795|(|O
S795|Flow|O
S795|Cytometry|O
S795|Analysis|O
S795|Software|O
S795|)|O
S795|.|O
S732|Cardiovascular|O
S732|effects|O
S732|of|O
S732|tumour|O
S732|necrosis|O
S732|factor|O
S732|α|O
S732|antagonism|O
S732|in|O
S732|patients|O
S732|with|O
S732|acute|O
S732|myocardial|O
S732|infarction|O
S732|:|O
S732|a|O
S732|first|O
S732|in|O
S732|human|O
S732|study|O
S968|Data|O
S968|on|O
S968|adherence|O
S968|to|O
S968|study|O
S968|drugs|O
S968|from|O
S968|daily|O
S968|diaries|O
S968|were|O
S968|available|O
S968|for|O
S968|68/112|O
S968|(|O
S968|61|O
S968|%|O
S968|)|O
S968|participants|O
S968|.|O
S2275|In|O
S2275|the|O
S2275|ITT|O
S2275|population|O
S2275|,|O
S2275|the|O
S2275|reduction|O
S2275|in|O
S2275|the|O
S2275|asthma|O
S2275|exacerbation|O
S2275|rate|O
S2275|relative|O
S2275|to|O
S2275|placebo|O
S2275|was|O
S2275|19.6|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−21|O
S2275|to|O
S2275|47|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.38|O
S2275|)|O
S2275|,|O
S2275|−11.2|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−63|O
S2275|to|O
S2275|24|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.65|O
S2275|)|O
S2275|,|O
S2275|and|O
S2275|−5.7|O
S2275|%|O
S2275|(|O
S2275|90|O
S2275|%|O
S2275|CI|O
S2275|:|O
S2275|−55|O
S2275|to|O
S2275|28|O
S2275|;|O
S2275|p|O
S2275|=|O
S2275|0.81|O
S2275|)|O
S2275|in|O
S2275|the|O
S2275|300|O
S2275|mg|O
S2275|M|O
S2275|,|O
S2275|450|O
S2275|mg|O
S2275|Q|O
S2275|,|O
S2275|and|O
S2275|150|O
S2275|mg|O
S2275|Q|O
S2275|quilizumab|O
S2275|treatment|O
S2275|arms|O
S2275|,|O
S2275|respectively|O
S2275|(|O
S2275|Fig|O
S2275|.|O
S17|Histamine2-receptor|O
S17|antagonists|O
S17|(|O
S17|H2RAs|O
S17|)|O
S17|have|O
S17|not|O
S17|been|O
S17|recommended|O
S17|for|O
S17|preventive|O
S17|therapy|O
S17|in|O
S17|NSAID|O
S17|users|O
S17|because|O
S17|,|O
S17|when|O
S17|given|O
S17|in|O
S17|standard|O
S17|doses|O
S17|,|O
S17|they|O
S17|significantly|O
S17|decrease|O
S17|duodenal|O
S17|but|O
S17|not|O
S17|gastric|O
S17|ulcers|O
S17|.|O
S1292|However|O
S1292|,|O
S1292|it|O
S1292|was|O
S1292|clear|O
S1292|by|O
S1292|2007|O
S1292|that|O
S1292|obtaining|O
S1292|a|O
S1292|sample|O
S1292|of|O
S1292|6000|O
S1292|was|O
S1292|no|O
S1292|longer|O
S1292|feasible|O
S1292|,|O
S1292|and|O
S1292|the|O
S1292|Steering|O
S1292|Committee|O
S1292|agreed|O
S1292|a|O
S1292|revised|O
S1292|recruitment|O
S1292|target|O
S1292|.|O
S737|26|B-Sample_Size_Actual_at_Enrollment
S737|patients|O
S737|presenting|O
S737|with|O
S737|acute|O
S737|myocardial|O
S737|infarction|O
S737|randomised|O
S737|to|O
S737|receive|O
S737|an|B-Design_Parallel_Group
S737|intravenous|I-Design_Parallel_Group
S737|infusion|I-Design_Parallel_Group
S737|of|I-Design_Parallel_Group
S737|etanercept|I-Design_Parallel_Group
S737|(|I-Design_Parallel_Group
S737|10|I-Design_Parallel_Group
S737|mg|I-Design_Parallel_Group
S737|)|I-Design_Parallel_Group
S737|or|I-Design_Parallel_Group
S737|saline|I-Design_Parallel_Group
S737|placebo|I-Design_Parallel_Group
S737|.|O
S915|As|O
S915|a|O
S915|result|O
S915|we|O
S915|implemented|O
S915|ceiling|O
S915|doses|O
S915|of|O
S915|75|O
S915|mg/day|O
S915|for|O
S915|prednisolone|O
S915|and|O
S915|400|O
S915|mg/day|O
S915|for|O
S915|ciclosporin|O
S915|.|O
S575|Objectives|O
S575|Ischaemic|O
S575|digital|O
S575|ulcers|O
S575|(|O
S575|DUs|O
S575|)|O
S575|are|O
S575|common|O
S575|in|O
S575|patients|O
S575|with|O
S575|systemic|O
S575|sclerosis|O
S575|(|O
S575|SSc|O
S575|)|O
S575|and|O
S575|are|O
S575|a|O
S575|cause|O
S575|of|O
S575|disease-related|O
S575|morbidity|O
S575|.|O
S861|Objective|O
S861|To|O
S861|determine|O
S861|whether|O
S861|ciclosporin|O
S861|is|O
S861|superior|O
S861|to|O
S861|prednisolone|O
S861|for|O
S861|the|O
S861|treatment|O
S861|of|O
S861|pyoderma|O
S861|gangrenosum|O
S861|,|O
S861|a|O
S861|painful|O
S861|,|O
S861|ulcerating|O
S861|skin|O
S861|disease|O
S861|with|O
S861|a|O
S861|poor|O
S861|evidence|O
S861|base|O
S861|for|O
S861|management|O
S861|.|O
S317|At|O
S317|baseline|O
S317|,|O
S317|many|O
S317|patients|O
S317|had|O
S317|very|O
S317|high|O
S317|SU|O
S317|levels|O
S317|(|O
S317|≥9|O
S317|mg/dl|O
S317|;|O
S317|35|O
S317|%|O
S317|to|O
S317|55|O
S317|%|O
S317|)|O
S317|.|O
S1827|As|O
S1827|a|O
S1827|result|O
S1827|,|O
S1827|many|O
S1827|people|O
S1827|are|O
S1827|now|O
S1827|prescribed|O
S1827|long-term|O
S1827|statin|O
S1827|treatment|O
S1827|to|O
S1827|reduce|O
S1827|their|O
S1827|vascular|O
S1827|risk|O
S1827|.|O
S2253|This|O
S2253|sample|O
S2253|size|O
S2253|also|O
S2253|provided|O
S2253|approximately|O
S2253|70|B-Sample_Size_Calculation_Power_Value
S2253|%|I-Sample_Size_Calculation_Power_Value
S2253|power|O
S2253|to|O
S2253|detect|O
S2253|a|O
S2253|50|O
S2253|%|O
S2253|reduction|O
S2253|in|O
S2253|average|O
S2253|exacerbation|O
S2253|rates|O
S2253|in|O
S2253|the|O
S2253|subgroup|O
S2253|of|O
S2253|periostin-high|O
S2253|patients|O
S2253|,|O
S2253|assuming|O
S2253|0.69|O
S2253|exacerbations|O
S2253|per|O
S2253|patient|O
S2253|in|O
S2253|the|O
S2253|placebo|O
S2253|group|O
S2253|over|O
S2253|the|O
S2253|36-week|O
S2253|period|O
S2253|,|O
S2253|a|O
S2253|significance|O
S2253|level|O
S2253|of|O
S2253|0.15|B-Sample_Size_Calculation_Alpha_Value
S2253|,|O
S2253|and|O
S2253|50|O
S2253|%|O
S2253|of|O
S2253|patients|O
S2253|in|O
S2253|each|O
S2253|treatment|O
S2253|arm|O
S2253|to|O
S2253|be|O
S2253|periostin|O
S2253|high|O
S2253|.|O
S1227|At|O
S1227|6|O
S1227|months|O
S1227|,|O
S1227|554|O
S1227|(|O
S1227|37|O
S1227|%|O
S1227|)|O
S1227|patients|O
S1227|in|O
S1227|the|O
S1227|rt-PA|O
S1227|group|O
S1227|versus|O
S1227|534|O
S1227|(|O
S1227|35|O
S1227|%|O
S1227|)|O
S1227|in|O
S1227|the|O
S1227|control|O
S1227|group|O
S1227|were|O
S1227|alive|O
S1227|and|O
S1227|independent|O
S1227|(|O
S1227|OHS|O
S1227|0–2|O
S1227|;|O
S1227|adjusted|O
S1227|odds|O
S1227|ratio|O
S1227|[|O
S1227|OR|O
S1227|]|O
S1227|1·13|O
S1227|,|O
S1227|95|O
S1227|%|O
S1227|CI|O
S1227|0·95–1·35|O
S1227|,|O
S1227|p=0·181|O
S1227|;|O
S1227|a|O
S1227|non-significant|O
S1227|absolute|O
S1227|increase|O
S1227|of|O
S1227|14/1000|O
S1227|,|O
S1227|95|O
S1227|%|O
S1227|CI|O
S1227|−20|O
S1227|to|O
S1227|48|O
S1227|)|O
S1227|.|O
S2108|The|O
S2108|appearance|O
S2108|of|O
S2108|axial|O
S2108|signs|O
S2108|immediately|O
S2108|after|O
S2108|the|O
S2108|initiation|O
S2108|of|O
S2108|STN|O
S2108|stimulation|O
S2108|was|O
S2108|also|O
S2108|an|O
S2108|exclusion|O
S2108|criterion|O
S2108|.|O
S278|Low-dose|O
S278|colchicine|O
S278|is|O
S278|the|O
S278|most|O
S278|commonly|O
S278|prescribed|O
S278|drug|O
S278|for|O
S278|prophylaxis|O
S278|in|O
S278|patients|O
S278|initiating|O
S278|ULT|O
S278|,|O
S278|but|O
S278|it|O
S278|has|O
S278|significant|O
S278|shortcomings|O
S278|.|O
S867|Main|O
S867|outcome|O
S867|measures|O
S867|The|O
S867|primary|O
S867|outcome|O
S867|was|O
S867|speed|O
S867|of|O
S867|healing|O
S867|over|O
S867|six|O
S867|weeks|O
S867|,|O
S867|captured|O
S867|using|O
S867|digital|O
S867|images|O
S867|and|O
S867|assessed|O
S867|by|O
S867|blinded|O
S867|investigators|O
S867|.|O
S1503|Most|O
S1503|of|O
S1503|these|O
S1503|interventions|O
S1503|occurred|O
S1503|before|O
S1503|or|O
S1503|at|O
S1503|the|O
S1503|time|O
S1503|of|O
S1503|enrolment|O
S1503|.|O
S2109|Other|O
S2109|notable|O
S2109|exclusion|O
S2109|criteria|O
S2109|included|O
S2109|(|O
S2109|i|O
S2109|)|O
S2109|inability|O
S2109|to|O
S2109|walk|O
S2109|unaided|O
S2109|while|O
S2109|on|O
S2109|dopaminergic|O
S2109|treatment|O
S2109|,|O
S2109|(|O
S2109|ii|O
S2109|)|O
S2109|dementia|O
S2109|(|O
S2109|diagnosed|O
S2109|according|O
S2109|to|O
S2109|the|O
S2109|DSM-IV-R|O
S2109|criteria|O
S2109|and|O
S2109|with|O
S2109|a|O
S2109|Mattis|O
S2109|Dementia|O
S2109|Rating|O
S2109|Scale|O
S2109|score|O
S2109|<|O
S2109|130|O
S2109|)|O
S2109|and|O
S2109|(|O
S2109|iii|O
S2109|)|O
S2109|the|O
S2109|ongoing|O
S2109|administration|O
S2109|of|O
S2109|an|O
S2109|NMDA|O
S2109|antagonist|O
S2109|other|O
S2109|than|O
S2109|memantine|O
S2109|.|O
S1451|The|O
S1451|intention|O
S1451|to|O
S1451|treat|O
S1451|population|O
S1451|included|O
S1451|all|O
S1451|patients|O
S1451|randomised|O
S1451|,|O
S1451|whether|O
S1451|or|O
S1451|not|O
S1451|they|O
S1451|received|O
S1451|study|O
S1451|drug|O
S1451|.|O
S454|Participants|O
S454|enrolled|O
S454|after|O
S454|the|O
S454|age|O
S454|of|O
S454|12.25|O
S454|years|O
S454|and|O
S454|without|O
S454|spontaneous|O
S454|puberty|O
S454|(|O
S454|the|O
S454|late|O
S454|group|O
S454|)|O
S454|started|O
S454|ethinylestradiol|O
S454|at|O
S454|14|O
S454|years|O
S454|.|O
S1099|Sample|O
S1099|size|O
S1099|The|O
S1099|Cochrane|O
S1099|systematic|O
S1099|review|O
S1099|found|O
S1099|only|O
S1099|one|O
S1099|small|O
S1099|trial|O
S1099|directly|O
S1099|comparing|O
S1099|the|O
S1099|effectiveness|O
S1099|of|O
S1099|a|O
S1099|chemical|O
S1099|treatment|O
S1099|,|O
S1099|salicylic|O
S1099|acid|O
S1099|,|O
S1099|with|O
S1099|cryotherapy|O
S1099|in|O
S1099|patients|O
S1099|with|O
S1099|warts|O
S1099|on|O
S1099|their|O
S1099|feet|O
S1099|alone|O
S1099|.|O
S489|Table|O
S489|2|O
S489|shows|O
S489|details|O
S489|of|O
S489|final|O
S489|height|O
S489|and|O
S489|maximum|O
S489|height|O
S489|according|O
S489|to|O
S489|the|O
S489|study|O
S489|’|O
S489|s|O
S489|two|O
S489|randomisations|O
S489|.|O
S1277|Other|O
S1277|fatal|O
S1277|and|O
S1277|non-fatal|O
S1277|non-cerebral|O
S1277|events|O
S1277|were|O
S1277|also|O
S1277|recorded|O
S1277|and|O
S1277|coded|O
S1277|.|O
S156|Overall|O
S156|,|O
S156|improvements|O
S156|were|O
S156|largest|O
S156|with|O
S156|tiotropium|O
S156|Respimat®|O
S156|5|O
S156|μg|O
S156|.|O
S481|The|O
S481|effects|O
S481|of|O
S481|the|O
S481|randomisations|O
S481|can|O
S481|be|O
S481|explored|O
S481|by|O
S481|comparing|O
S481|the|O
S481|values|O
S481|of|O
S481|the|O
S481|random|O
S481|effects|O
S481|by|O
S481|trial|O
S481|arm|O
S481|.|O
S2216|Exclusion|O
S2216|criteria|O
S2216|Patients|O
S2216|were|O
S2216|excluded|O
S2216|from|O
S2216|the|O
S2216|study|O
S2216|if|O
S2216|they|O
S2216|had|O
S2216|an|O
S2216|asthma|O
S2216|exacerbation|O
S2216|requiring|O
S2216|systemic|O
S2216|steroids|O
S2216|in|O
S2216|the|O
S2216|30|O
S2216|days|O
S2216|prior|O
S2216|to|O
S2216|screening|O
S2216|,|O
S2216|or|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|a|O
S2216|>|O
S2216|20|O
S2216|%|O
S2216|relative|O
S2216|change|O
S2216|in|O
S2216|FEV1|O
S2216|between|O
S2216|screening|O
S2216|and|O
S2216|randomization|O
S2216|,|O
S2216|any|O
S2216|pre-existing|O
S2216|active|O
S2216|lung|O
S2216|disease|O
S2216|other|O
S2216|than|O
S2216|asthma|O
S2216|,|O
S2216|any|O
S2216|infections|O
S2216|,|O
S2216|elevated|O
S2216|IgE|O
S2216|levels|O
S2216|for|O
S2216|reasons|O
S2216|other|O
S2216|than|O
S2216|allergy|O
S2216|,|O
S2216|or|O
S2216|were|O
S2216|former|O
S2216|or|O
S2216|current|O
S2216|smokers|O
S2216|.|O
S1689|Since|O
S1689|most|O
S1689|variation|O
S1689|was|O
S1689|between|O
S1689|groups|O
S1689|B|O
S1689|and|O
S1689|C|O
S1689|,|O
S1689|who|O
S1689|received|O
S1689|identical|O
S1689|ART|O
S1689|for|O
S1689|the|O
S1689|first|O
S1689|36|O
S1689|weeks|O
S1689|,|O
S1689|this|O
S1689|year|O
S1689|1|O
S1689|interaction|O
S1689|appeared|O
S1689|attributable|O
S1689|to|O
S1689|chance|O
S1689|in|O
S1689|children|O
S1689|initiating|O
S1689|ART|O
S1689|with|O
S1689|severe|O
S1689|immunodeficiency|O
S1689|.|O
S1685|At|O
S1685|switch|O
S1685|,|O
S1685|median|O
S1685|CD4|O
S1685|percentage|O
S1685|was|O
S1685|8·5|O
S1685|%|O
S1685|(|O
S1685|IQR|O
S1685|1·5–22·5|O
S1685|)|O
S1685|in|O
S1685|the|O
S1685|clinically|O
S1685|driven|O
S1685|monitoring|O
S1685|group|O
S1685|and|O
S1685|7|O
S1685|%|O
S1685|(|O
S1685|3–13|O
S1685|)|O
S1685|in|O
S1685|the|O
S1685|routine|O
S1685|laboratory|O
S1685|monitoring|O
S1685|group|O
S1685|;|O
S1685|11|O
S1685|children|O
S1685|(|O
S1685|39|O
S1685|%|O
S1685|)|O
S1685|versus|O
S1685|14|O
S1685|(|O
S1685|40|O
S1685|%|O
S1685|)|O
S1685|had|O
S1685|CD4|O
S1685|percentage|O
S1685|less|O
S1685|than|O
S1685|5|O
S1685|%|O
S1685|and|O
S1685|six|O
S1685|children|O
S1685|(|O
S1685|21|O
S1685|%|O
S1685|)|O
S1685|versus|O
S1685|none|O
S1685|had|O
S1685|CD4|O
S1685|percentage|O
S1685|greater|O
S1685|than|O
S1685|25|O
S1685|%|O
S1685|,|O
S1685|respectively|O
S1685|.|O
S2281|The|O
S2281|highest|O
S2281|relative|O
S2281|improvement|O
S2281|compared|O
S2281|to|O
S2281|placebo|O
S2281|occurred|O
S2281|in|O
S2281|the|O
S2281|lowest|O
S2281|dose|O
S2281|arm|O
S2281|(|O
S2281|150|O
S2281|mg|O
S2281|Q|O
S2281|)|O
S2281|,|O
S2281|but|O
S2281|no|O
S2281|meaningful|O
S2281|improvements|O
S2281|were|O
S2281|observed|O
S2281|in|O
S2281|the|O
S2281|higher|O
S2281|dose|O
S2281|arms|O
S2281|(|O
S2281|450|O
S2281|mg|O
S2281|Q|O
S2281|and|O
S2281|300|O
S2281|mg|O
S2281|M|O
S2281|)|O
S2281|.|O
S1297|All|O
S1297|baseline|O
S1297|data|O
S1297|,|O
S1297|7-day|O
S1297|,|O
S1297|and|O
S1297|6-month|O
S1297|outcome|O
S1297|data|O
S1297|were|O
S1297|subject|O
S1297|to|O
S1297|verification|O
S1297|checks|O
S1297|built|O
S1297|into|O
S1297|the|O
S1297|randomisation|O
S1297|and|O
S1297|data|O
S1297|management|O
S1297|system|O
S1297|.|O
S1334|More|O
S1334|patients|O
S1334|died|O
S1334|within|O
S1334|7|O
S1334|days|O
S1334|in|O
S1334|the|O
S1334|rt-PA|O
S1334|group|O
S1334|than|O
S1334|in|O
S1334|the|O
S1334|control|O
S1334|group|O
S1334|,|O
S1334|but|O
S1334|between|O
S1334|7|O
S1334|days|O
S1334|and|O
S1334|6|O
S1334|months|O
S1334|there|O
S1334|were|O
S1334|correspondingly|O
S1334|fewer|O
S1334|deaths|O
S1334|in|O
S1334|the|O
S1334|rt-PA|O
S1334|group|O
S1334|.|O
S306|In|O
S306|order|O
S306|to|O
S306|increase|O
S306|the|O
S306|precision|O
S306|of|O
S306|the|O
S306|analysis|O
S306|the|O
S306|planned|O
S306|total|O
S306|sample|O
S306|size|O
S306|of|O
S306|400|O
S306|was|O
S306|increased|O
S306|to|O
S306|approximately|O
S306|440|B-Sample_Size_Target
S306|patients|O
S306|(|O
S306|see|O
S306|supplementary|O
S306|material|O
S306|for|O
S306|more|O
S306|details|O
S306|)|O
S306|.|O
S1967|The|O
S1967|percentage|O
S1967|of|O
S1967|unclothed|O
S1967|skin|O
S1967|at|O
S1967|enrolment|O
S1967|was|O
S1967|estimated|O
S1967|with|O
S1967|a|O
S1967|Lund|O
S1967|and|O
S1967|Browder|O
S1967|age-related|O
S1967|burn|O
S1967|chart|O
S1967|.|O
S1086|The|O
S1086|backing|O
S1086|paper|O
S1086|from|O
S1086|the|O
S1086|plaster|O
S1086|was|O
S1086|then|O
S1086|removed|O
S1086|and|O
S1086|the|O
S1086|plaster|O
S1086|applied|O
S1086|to|O
S1086|cover|O
S1086|the|O
S1086|ring|O
S1086|completely|O
S1086|.|O
S2025|However|O
S2025|,|O
S2025|the|O
S2025|increase|O
S2025|in|O
S2025|proximal|O
S2025|1/3|O
S2025|forearm|O
S2025|bone|O
S2025|mineral|O
S2025|in|O
S2025|the|O
S2025|Ca|O
S2025|group|O
S2025|(|O
S2025|least|O
S2025|squares|O
S2025|mean|O
S2025|increase|O
S2025|0.130|O
S2025|g|O
S2025|)|O
S2025|was|O
S2025|similar|O
S2025|to|O
S2025|that|O
S2025|of|O
S2025|the|O
S2025|Ca+D|O
S2025|group|O
S2025|(|O
S2025|least|O
S2025|squares|O
S2025|mean|O
S2025|increase|O
S2025|0.109|O
S2025|g|O
S2025|;|O
S2025|p=0.22|O
S2025|)|O
S2025|.|O
S1876|The|O
S1876|effects|O
S1876|of|O
S1876|statin|O
S1876|allocation|O
S1876|on|O
S1876|major|O
S1876|vascular|O
S1876|events|O
S1876|during|O
S1876|the|O
S1876|in-trial|O
S1876|and|O
S1876|post-trial|O
S1876|periods|O
S1876|were|O
S1876|unaffected|O
S1876|by|O
S1876|age|O
S1876|or|O
S1876|pretreatment|O
S1876|lipid|O
S1876|profiles|O
S1876|(|O
S1876|webappendix|O
S1876|p|O
S1876|3|O
S1876|)|O
S1876|.|O
S1455|We|O
S1455|used|O
S1455|conditional|O
S1455|univariate|O
S1455|logistic|O
S1455|regression|O
S1455|to|O
S1455|calculate|O
S1455|and|O
S1455|compare|O
S1455|the|O
S1455|odds|O
S1455|ratios|O
S1455|of|O
S1455|viral|O
S1455|clearance|O
S1455|for|O
S1455|categorical|O
S1455|data|O
S1455|between|O
S1455|the|O
S1455|treatment|O
S1455|arms|O
S1455|stratified|O
S1455|by|O
S1455|study|O
S1455|site|O
S1455|and|O
S1455|the|O
S1455|Mantel-Haenszel|O
S1455|method|O
S1455|when|O
S1455|the|O
S1455|numbers|O
S1455|of|O
S1455|patients|O
S1455|were|O
S1455|small|O
S1455|.|O
S1333|A|O
S1333|secondary|O
S1333|ordinal|O
S1333|analysis|O
S1333|provided|O
S1333|evidence|O
S1333|of|O
S1333|a|O
S1333|favourable|O
S1333|shift|O
S1333|in|O
S1333|the|O
S1333|distribution|O
S1333|of|O
S1333|OHS|O
S1333|scores|O
S1333|at|O
S1333|6|O
S1333|months|O
S1333|with|O
S1333|treatment|O
S1333|(|O
S1333|p|O
S1333|<|O
S1333|0·001|O
S1333|;|O
S1333|figure|O
S1333|2|O
S1333|)|O
S1333|.|O
S1135|The|O
S1135|findings|O
S1135|from|O
S1135|the|O
S1135|adjusted|O
S1135|analysis|O
S1135|were|O
S1135|similar|O
S1135|to|O
S1135|those|O
S1135|of|O
S1135|the|O
S1135|unadjusted|O
S1135|analysis|O
S1135|(|O
S1135|odds|O
S1135|ratio|O
S1135|1.17|O
S1135|(|O
S1135|0.62|O
S1135|to|O
S1135|2.21|O
S1135|)|O
S1135|,|O
S1135|P=0.62|O
S1135|)|O
S1135|.|O
S787|The|O
S787|following|O
S787|antibodies|O
S787|were|O
S787|used|O
S787|:|O
S787|IgG1-FITC|O
S787|,|O
S787|CD14-PE|O
S787|,|O
S787|CD42a-FITC|O
S787|,|O
S787|IgG2a-PE|O
S787|,|O
S787|CD62P-PE|O
S787|,|O
S787|IgG1-PE|O
S787|(|O
S787|eBioscience|O
S787|Ltd.|O
S787|UK|O
S787|)|O
S787|and|O
S787|CD14-RPE|O
S787|and|O
S787|IgG1-RPE|O
S787|(|O
S787|DakoCytomation|O
S787|,|O
S787|Denmark|O
S787|)|O
S787|.|O
S184|Concomitant|O
S184|use|O
S184|of|O
S184|the|O
S184|following|O
S184|was|O
S184|not|O
S184|permitted|O
S184|for|O
S184|maintenance|O
S184|treatment|O
S184|:|O
S184|systemic|O
S184|oral|O
S184|or|O
S184|depot|O
S184|corticosteroids|O
S184|;|O
S184|anticholinergics|O
S184|other|O
S184|than|O
S184|tiotropium|O
S184|;|O
S184|LABAs|O
S184|;|O
S184|ICS|O
S184|plus|O
S184|short-acting|O
S184|β2-agonist|O
S184|or|O
S184|ICS|O
S184|+|O
S184|LABA|O
S184|fixed-dose|O
S184|combinations|O
S184|;|O
S184|leukotriene|O
S184|modifiers|O
S184|;|O
S184|anti-immunoglobulin|O
S184|E|O
S184|treatment|O
S184|;|O
S184|chromone|O
S184|;|O
S184|methylxanthines|O
S184|;|O
S184|and|O
S184|phosphodiesterase-4|O
S184|inhibitors|O
S184|.|O
S1084|Salicylic|O
S1084|acid|O
S1084|Participants|O
S1084|randomised|B-Randomization_Type_Simple
S1084|to|O
S1084|self|O
S1084|treatment|O
S1084|with|O
S1084|50|O
S1084|%|O
S1084|salicylic|O
S1084|acid|O
S1084|(|O
S1084|Verrugon|O
S1084|,|O
S1084|William|O
S1084|Ransom|O
S1084|and|O
S1084|Son|O
S1084|)|O
S1084|were|O
S1084|instructed|O
S1084|how|O
S1084|to|O
S1084|apply|O
S1084|the|O
S1084|treatment|O
S1084|according|O
S1084|to|O
S1084|the|O
S1084|manufacturer|O
S1084|’|O
S1084|s|O
S1084|instructions|O
S1084|by|O
S1084|the|O
S1084|treating|O
S1084|healthcare|O
S1084|professional|O
S1084|.|O
S775|During|O
S775|vasomotor|O
S775|assessments|O
S775|,|O
S775|venous|O
S775|blood|O
S775|was|O
S775|withdrawn|O
S775|simultaneously|O
S775|from|O
S775|each|O
S775|arm|O
S775|and|O
S775|collected|O
S775|into|O
S775|tubes|O
S775|containing|O
S775|acidified|O
S775|buffered|O
S775|citrate|O
S775|(|O
S775|for|O
S775|t-PA|O
S775|assays|O
S775|)|O
S775|,|O
S775|trisodium|O
S775|citrate|O
S775|(|O
S775|for|O
S775|plasminogen|O
S775|activator|O
S775|inhibitor|O
S775|type|O
S775|1|O
S775|(|O
S775|PAI-1|O
S775|)|O
S775|assays|O
S775|)|O
S775|and|O
S775|potassium|O
S775|EDTA|O
S775|(|O
S775|for|O
S775|cytokine|O
S775|assays|O
S775|)|O
S775|.|O
S2209|Patients|B-Blinding_Object_Patients
S2209|and|O
S2209|study|B-Blinding_Object_Care_Providers
S2209|site|I-Blinding_Object_Care_Providers
S2209|personnel|I-Blinding_Object_Care_Providers
S2209|were|O
S2209|blinded|O
S2209|to|O
S2209|treatment|O
S2209|assignments|O
S2209|until|O
S2209|all|O
S2209|follow-up|O
S2209|data|O
S2209|through|O
S2209|Week|O
S2209|84|O
S2209|were|O
S2209|collected|O
S2209|and|O
S2209|verified|O
S2209|.|O
S474|In|O
S474|the|O
S474|event|O
S474|,|O
S474|more|O
S474|than|O
S474|100|O
S474|patients|O
S474|were|O
S474|recruited|O
S474|,|O
S474|but|O
S474|fewer|O
S474|than|O
S474|100|O
S474|were|O
S474|followed|O
S474|up|O
S474|to|O
S474|final|O
S474|height|O
S474|.|O
S505|The|O
S505|curves|O
S505|are|O
S505|labelled|O
S505|according|O
S505|to|O
S505|randomisation|O
S505|1|O
S505|,|O
S505|and|O
S505|the|O
S505|oxandrolone|O
S505|curves|O
S505|tend|O
S505|to|O
S505|be|O
S505|above|O
S505|and|O
S505|to|O
S505|the|O
S505|left|O
S505|of|O
S505|the|O
S505|placebo|O
S505|curves|O
S505|.|O
S1465|Results|O
S1465|Patients|O
S1465|’|O
S1465|characteristics|O
S1465|Between|O
S1465|April|O
S1465|2007|O
S1465|and|O
S1465|February|O
S1465|2010|O
S1465|,|O
S1465|699|O
S1465|patients|O
S1465|were|O
S1465|screened|O
S1465|and|O
S1465|326|B-Sample_Size_Actual_at_Enrollment
S1465|were|O
S1465|enrolled|O
S1465|and|O
S1465|randomised|O
S1465|:|O
S1465|165|O
S1465|received|O
S1465|double|O
S1465|dose|O
S1465|and|O
S1465|161|O
S1465|standard|O
S1465|dose|O
S1465|oseltamivir|O
S1465|.|O
S1674|At|O
S1674|trial|O
S1674|end|O
S1674|,|O
S1674|578|O
S1674|(|O
S1674|95|O
S1674|%|O
S1674|)|O
S1674|children|O
S1674|on|O
S1674|clinically|O
S1674|driven|O
S1674|monitoring|O
S1674|versus|O
S1674|565|O
S1674|(|O
S1674|94|O
S1674|%|O
S1674|)|O
S1674|on|O
S1674|routine|O
S1674|laboratory|O
S1674|monitoring|O
S1674|were|O
S1674|still|O
S1674|on|O
S1674|first-line|O
S1674|ART|O
S1674|(|O
S1674|table|O
S1674|2|O
S1674|)|O
S1674|;|O
S1674|330|O
S1674|(|O
S1674|83|O
S1674|%|O
S1674|)|O
S1674|children|O
S1674|in|O
S1674|group|O
S1674|A|O
S1674|,|O
S1674|356|O
S1674|(|O
S1674|88|O
S1674|%|O
S1674|)|O
S1674|in|O
S1674|group|O
S1674|B|O
S1674|,|O
S1674|and|O
S1674|367|O
S1674|(|O
S1674|91|O
S1674|%|O
S1674|)|O
S1674|in|O
S1674|group|O
S1674|C|O
S1674|were|O
S1674|still|O
S1674|on|O
S1674|their|O
S1674|original|O
S1674|randomised|O
S1674|regimen|O
S1674|.|O
S986|Adverse|O
S986|reactions|O
S986|Overall|O
S986|,|O
S986|40|O
S986|(|O
S986|68|O
S986|%|O
S986|)|O
S986|participants|O
S986|in|O
S986|the|O
S986|ciclosporin|O
S986|group|O
S986|and|O
S986|35|O
S986|(|O
S986|66|O
S986|%|O
S986|)|O
S986|in|O
S986|the|O
S986|prednisolone|O
S986|group|O
S986|experienced|O
S986|at|O
S986|least|O
S986|one|O
S986|adverse|O
S986|reaction|O
S986|.|O
S592|Among|O
S592|a|O
S592|cohort|O
S592|of|O
S592|2080|O
S592|patients|O
S592|with|O
S592|SSc|O
S592|identified|O
S592|between|O
S592|1972|O
S592|and|O
S592|1995|O
S592|and|O
S592|prospectively|O
S592|followed-up|O
S592|for|O
S592|a|O
S592|mean|O
S592|of|O
S592|10|O
S592|years|O
S592|,|O
S592|58|O
S592|%|O
S592|of|O
S592|patients|O
S592|had|O
S592|a|O
S592|history|O
S592|of|O
S592|DUs|O
S592|.|O
S1974|Dual|O
S1974|energy|O
S1974|X-ray|O
S1974|absorptiometry|O
S1974|of|O
S1974|the|O
S1974|left|O
S1974|distal|O
S1974|and|O
S1974|proximal|O
S1974|1/3|O
S1974|forearm|O
S1974|was|O
S1974|performed|O
S1974|by|O
S1974|a|O
S1974|single|O
S1974|investigator|O
S1974|(|O
S1974|TDT|O
S1974|)|O
S1974|with|O
S1974|a|O
S1974|portable|O
S1974|densitometer|O
S1974|(|O
S1974|Norland|O
S1974|pDEXA|O
S1974|,|O
S1974|Model|O
S1974|476A110|O
S1974|)|O
S1974|.|O
S976|For|O
S976|33|O
S976|participants|O
S976|(|O
S976|14|O
S976|in|O
S976|the|O
S976|prednisolone|O
S976|group|O
S976|;|O
S976|19|O
S976|in|O
S976|the|O
S976|ciclosporin|O
S976|group|O
S976|)|O
S976|the|O
S976|pyoderma|O
S976|gangrenosum|O
S976|worsened|O
S976|(|O
S976|increased|O
S976|in|O
S976|size|O
S976|)|O
S976|between|O
S976|baseline|O
S976|and|O
S976|week|O
S976|2|O
S976|.|O
S96|These|O
S96|were|O
S96|GI|O
S96|bleeding|O
S96|episodes|O
S96|in|O
S96|which|O
S96|hemoglobin|O
S96|dropped|O
S96|1.6|O
S96|,|O
S96|2.1|O
S96|,|O
S96|and|O
S96|3.1|O
S96|g/dl|O
S96|without|O
S96|clinical|O
S96|evidence|O
S96|of|O
S96|overt|O
S96|GI|O
S96|bleeding|O
S96|,|O
S96|transfusions|O
S96|,|O
S96|or|O
S96|hospitalizations|O
S96|.|O
S485|All|O
S485|106|O
S485|participants|O
S485|were|O
S485|randomised|O
S485|at|O
S485|or|O
S485|after|O
S485|9|O
S485|years|O
S485|of|O
S485|age|O
S485|to|O
S485|oxandrolone|O
S485|or|O
S485|placebo|O
S485|(|O
S485|randomisation|O
S485|1|O
S485|)|O
S485|,|O
S485|and|O
S485|60|O
S485|were|O
S485|also|O
S485|randomised|O
S485|at|O
S485|12|O
S485|years|O
S485|to|O
S485|early|O
S485|or|O
S485|late|O
S485|induction|O
S485|of|O
S485|puberty|O
S485|(|O
S485|randomisation|O
S485|2|O
S485|)|O
S485|.|O
S1131|Secondary|O
S1131|outcome|O
S1131|The|O
S1131|primary|O
S1131|analysis|O
S1131|was|O
S1131|repeated|O
S1131|after|O
S1131|controlling|O
S1131|for|O
S1131|age|O
S1131|,|O
S1131|whether|O
S1131|the|O
S1131|plantar|O
S1131|warts|O
S1131|had|O
S1131|been|O
S1131|previously|O
S1131|treated|O
S1131|(|O
S1131|yes|O
S1131|or|O
S1131|no|O
S1131|)|O
S1131|,|O
S1131|and|O
S1131|the|O
S1131|type|O
S1131|of|O
S1131|plantar|O
S1131|wart|O
S1131|(|O
S1131|mosaic|O
S1131|or|O
S1131|non-mosaic|O
S1131|,|O
S1131|where|O
S1131|a|O
S1131|mosaic|O
S1131|was|O
S1131|defined|O
S1131|as|O
S1131|a|O
S1131|group|O
S1131|of|O
S1131|numerous|O
S1131|,|O
S1131|closely|O
S1131|aggregated|O
S1131|plantar|O
S1131|warts|O
S1131|on|O
S1131|the|O
S1131|sole|O
S1131|of|O
S1131|the|O
S1131|foot|O
S1131|)|O
S1131|.|O
S2193|Biomarkers|O
S2193|in|O
S2193|sputum|O
S2193|,|O
S2193|bronchoalveolar|O
S2193|lavage|O
S2193|,|O
S2193|blood|O
S2193|,|O
S2193|and|O
S2193|bronchial|O
S2193|biopsies|O
S2193|may|O
S2193|indicate|O
S2193|a|O
S2193|particular|O
S2193|endotype|O
S2193|and|O
S2193|potentially|O
S2193|identify|O
S2193|patients|O
S2193|with|O
S2193|increased|O
S2193|responsiveness|O
S2193|to|O
S2193|endotype-specific|O
S2193|treatments|O
S2193|.|O
S2125|Safety|O
S2125|criteria|O
S2125|Adverse|O
S2125|events|O
S2125|,|O
S2125|arterial|O
S2125|blood|O
S2125|pressure|O
S2125|values|O
S2125|,|O
S2125|an|O
S2125|electrocardiogram|O
S2125|and|O
S2125|a|O
S2125|standard|O
S2125|blood|O
S2125|biochemistry|O
S2125|profile|O
S2125|were|O
S2125|recorded|O
S2125|monthly|O
S2125|.|O
S1421|The|O
S1421|study|O
S1421|took|O
S1421|place|O
S1421|between|O
S1421|April|O
S1421|2007|O
S1421|and|O
S1421|February|O
S1421|2010|O
S1421|in|O
S1421|13|B-Settings_Multicenter
S1421|hospitals|I-Settings_Multicenter
S1421|in|O
S1421|Indonesia|B-Settings_Location
S1421|,|I-Settings_Location
S1421|Singapore|I-Settings_Location
S1421|,|I-Settings_Location
S1421|Thailand|I-Settings_Location
S1421|,|I-Settings_Location
S1421|and|I-Settings_Location
S1421|Vietnam|I-Settings_Location
S1421|.|O
S1695|The|O
S1695|most|O
S1695|common|O
S1695|WHO|O
S1695|stage|O
S1695|4|O
S1695|events|O
S1695|were|O
S1695|oesophageal|O
S1695|candidiasis|O
S1695|(|O
S1695|eight|O
S1695|on|O
S1695|clinically|O
S1695|driven|O
S1695|and|O
S1695|five|O
S1695|on|O
S1695|routine|O
S1695|laboratory|O
S1695|monitoring|O
S1695|)|O
S1695|and|O
S1695|severe|O
S1695|unexplained|O
S1695|failure-to-thrive|O
S1695|(|O
S1695|nine|O
S1695|on|O
S1695|clinically|O
S1695|driven|O
S1695|and|O
S1695|three|O
S1695|on|O
S1695|routine|O
S1695|laboratory|O
S1695|monitoring|O
S1695|)|O
S1695|.|O
S1727|There|O
S1727|was|O
S1727|no|O
S1727|evidence|O
S1727|of|O
S1727|differences|O
S1727|in|O
S1727|weight|O
S1727|for|O
S1727|age|O
S1727|(|O
S1727|p=0·58|O
S1727|)|O
S1727|or|O
S1727|height|O
S1727|for|O
S1727|age|O
S1727|(|O
S1727|p=0·90|O
S1727|)|O
S1727|across|O
S1727|ART|O
S1727|strategies|O
S1727|(|O
S1727|appendix|O
S1727|)|O
S1727|.|O
S477|In|O
S477|addition|O
S477|,|O
S477|we|O
S477|applied|O
S477|SITAR|O
S477|(|O
S477|superimposition|O
S477|by|O
S477|translation|O
S477|and|O
S477|rotation|O
S477|)|O
S477|,|O
S477|a|O
S477|novel|O
S477|method|O
S477|of|O
S477|growth|O
S477|curve|O
S477|analysis|O
S477|,|O
S477|to|O
S477|the|O
S477|data|O
S477|.|O
S1347|We|O
S1347|also|O
S1347|undertook|O
S1347|a|O
S1347|sensitivity|O
S1347|analysis|O
S1347|restricted|O
S1347|to|O
S1347|the|O
S1347|2939|O
S1347|(|O
S1347|96|O
S1347|%|O
S1347|)|O
S1347|patients|O
S1347|with|O
S1347|known|O
S1347|6-month|O
S1347|vital|O
S1347|and|O
S1347|disability|O
S1347|status|O
S1347|(|O
S1347|appendix|O
S1347|pp|O
S1347|4–5|O
S1347|)|O
S1347|,|O
S1347|and|O
S1347|the|O
S1347|results|O
S1347|were|O
S1347|not|O
S1347|qualitatively|O
S1347|different|O
S1347|from|O
S1347|those|O
S1347|in|O
S1347|table|O
S1347|2|O
S1347|.|O
S1082|The|O
S1082|treatment|O
S1082|was|O
S1082|delivered|O
S1082|according|O
S1082|to|O
S1082|the|O
S1082|site|O
S1082|’|O
S1082|s|O
S1082|usual|O
S1082|practice|O
S1082|(|O
S1082|such|O
S1082|as|O
S1082|debridement|O
S1082|before|O
S1082|treatment|O
S1082|,|O
S1082|masking|O
S1082|of|O
S1082|the|O
S1082|surrounding|O
S1082|area|O
S1082|,|O
S1082|and|O
S1082|padding|O
S1082|after|O
S1082|treatment|O
S1082|)|O
S1082|.|O
S1420|Study|O
S1420|design|O
S1420|and|O
S1420|sites|O
S1420|This|O
S1420|was|O
S1420|a|O
S1420|prospective|O
S1420|,|O
S1420|multicentre|B-Settings_Multicenter
S1420|,|O
S1420|double|B-Blinding_Double_Blind
S1420|blinded|I-Blinding_Double_Blind
S1420|,|O
S1420|randomised|O
S1420|trial|O
S1420|of|O
S1420|standard|B-Design_Parallel_Group
S1420|dose|I-Design_Parallel_Group
S1420|oseltamivir|I-Design_Parallel_Group
S1420|(|I-Design_Parallel_Group
S1420|75|I-Design_Parallel_Group
S1420|mg|I-Design_Parallel_Group
S1420|twice|I-Design_Parallel_Group
S1420|a|I-Design_Parallel_Group
S1420|day|I-Design_Parallel_Group
S1420|or|I-Design_Parallel_Group
S1420|paediatric|I-Design_Parallel_Group
S1420|equivalent|I-Design_Parallel_Group
S1420|)|I-Design_Parallel_Group
S1420|versus|I-Design_Parallel_Group
S1420|double|I-Design_Parallel_Group
S1420|dose|I-Design_Parallel_Group
S1420|(|I-Design_Parallel_Group
S1420|150|I-Design_Parallel_Group
S1420|mg|I-Design_Parallel_Group
S1420|twice|I-Design_Parallel_Group
S1420|a|I-Design_Parallel_Group
S1420|day|I-Design_Parallel_Group
S1420|or|I-Design_Parallel_Group
S1420|paediatric|I-Design_Parallel_Group
S1420|equivalent|I-Design_Parallel_Group
S1420|)|I-Design_Parallel_Group
S1420|for|O
S1420|treating|O
S1420|severe|O
S1420|influenza|O
S1420|.|O
S482|Equally|O
S482|,|O
S482|separate|O
S482|summary|O
S482|curves|O
S482|can|O
S482|be|O
S482|constructed|O
S482|for|O
S482|each|O
S482|trial|O
S482|arm|O
S482|.|O
S666|Safety|O
S666|and|O
S666|tolerability|O
S666|Serious|O
S666|adverse|O
S666|events|O
S666|occurred|O
S666|in|O
S666|9.4|O
S666|%|O
S666|and|O
S666|16.7|O
S666|%|O
S666|of|O
S666|patients|O
S666|on|O
S666|bosentan|O
S666|and|O
S666|placebo|O
S666|,|O
S666|respectively|O
S666|(|O
S666|table|O
S666|4|O
S666|)|O
S666|,|O
S666|with|O
S666|only|O
S666|one|O
S666|serious|O
S666|event|O
S666|(|O
S666|pneumonia|O
S666|)|O
S666|reported|O
S666|for|O
S666|more|O
S666|than|O
S666|one|O
S666|patient|O
S666|on|O
S666|bosentan|O
S666|.|O
S1867|All|O
S1867|but|O
S1867|74|O
S1867|participants|O
S1867|(|O
S1867|42|O
S1867|simvastatin|O
S1867|and|O
S1867|32|O
S1867|placebo|O
S1867|)|O
S1867|could|O
S1867|be|O
S1867|followed|O
S1867|up|O
S1867|for|O
S1867|cancer|O
S1867|reports|O
S1867|and|O
S1867|death|O
S1867|certification|O
S1867|through|O
S1867|national|O
S1867|registries|O
S1867|.|O
S1325|Appendix|O
S1325|pp|O
S1325|2–3|O
S1325|documents|O
S1325|deviations|O
S1325|from|O
S1325|the|O
S1325|protocol|O
S1325|and|O
S1325|the|O
S1325|background|O
S1325|treatments|O
S1325|that|O
S1325|were|O
S1325|given|O
S1325|during|O
S1325|the|O
S1325|first|O
S1325|7|O
S1325|days|O
S1325|.|O
S1811|The|O
S1811|aim|O
S1811|of|O
S1811|the|O
S1811|extended|O
S1811|follow-up|O
S1811|of|O
S1811|the|O
S1811|Heart|O
S1811|Protection|O
S1811|Study|O
S1811|(|O
S1811|HPS|O
S1811|)|O
S1811|is|O
S1811|to|O
S1811|assess|O
S1811|long-term|O
S1811|efficacy|O
S1811|and|O
S1811|safety|O
S1811|of|O
S1811|lowering|O
S1811|LDL|O
S1811|cholesterol|O
S1811|with|O
S1811|statins|O
S1811|,|O
S1811|and|O
S1811|here|O
S1811|we|O
S1811|report|O
S1811|cause-specific|O
S1811|mortality|O
S1811|and|O
S1811|major|O
S1811|morbidity|O
S1811|in|O
S1811|the|O
S1811|in-trial|O
S1811|and|O
S1811|post-trial|O
S1811|periods|O
S1811|.|O
S1686|2|O
S1686|%|O
S1686|of|O
S1686|follow-up|O
S1686|(|O
S1686|40/2373|O
S1686|child-years|O
S1686|)|O
S1686|was|O
S1686|spent|O
S1686|on|O
S1686|second-line|O
S1686|treatment|O
S1686|in|O
S1686|children|O
S1686|on|O
S1686|clinically|O
S1686|driven|O
S1686|monitoring|O
S1686|versus|O
S1686|3|O
S1686|%|O
S1686|(|O
S1686|67/2311|O
S1686|child-years|O
S1686|)|O
S1686|in|O
S1686|those|O
S1686|on|O
S1686|routine|O
S1686|laboratory|O
S1686|monitoring|O
S1686|.|O
S1815|This|O
S1815|trial|O
S1815|is|O
S1815|registered|O
S1815|with|O
S1815|ISRCTN|O
S1815|,|O
S1815|number|O
S1815|48489393|O
S1815|.|O
S1840|Post-trial|O
S1840|follow-up|O
S1840|of|O
S1840|serious|O
S1840|adverse|O
S1840|events|O
S1840|was|O
S1840|conducted|O
S1840|by|O
S1840|mailing|O
S1840|questionnaires|O
S1840|to|O
S1840|all|O
S1840|surviving|O
S1840|participants|O
S1840|in|O
S1840|late|O
S1840|November|O
S1840|,|O
S1840|2001|O
S1840|,|O
S1840|and|O
S1840|then|O
S1840|annually|O
S1840|until|O
S1840|November|O
S1840|,|O
S1840|2006|O
S1840|,|O
S1840|with|O
S1840|a|O
S1840|reminder|O
S1840|mailed|O
S1840|about|O
S1840|2|O
S1840|months|O
S1840|later|O
S1840|.|O
S1270|Images|O
S1270|were|O
S1270|assessed|O
S1270|with|O
S1270|all|O
S1270|original|O
S1270|identifiers|O
S1270|stripped|O
S1270|from|O
S1270|the|O
S1270|record|O
S1270|,|O
S1270|and|O
S1270|then|O
S1270|viewed|O
S1270|via|O
S1270|a|O
S1270|secure|O
S1270|web-based|O
S1270|image|O
S1270|viewing|O
S1270|system|O
S1270|by|O
S1270|an|O
S1270|international|O
S1270|panel|O
S1270|of|O
S1270|expert|O
S1270|radiologists|O
S1270|.|O
S451|Randomisation|O
S451|2|O
S451|took|O
S451|place|O
S451|at|O
S451|age|O
S451|12|O
S451|years|O
S451|in|O
S451|girls|O
S451|with|O
S451|ovarian|O
S451|failure|O
S451|(|O
S451|basal|O
S451|serum|O
S451|follicle|O
S451|stimulating|O
S451|hormone|O
S451|concentration|O
S451|>|O
S451|10|O
S451|U/L|O
S451|)|O
S451|,|O
S451|with|O
S451|additional|O
S451|minimisation|B-Randomization_Type_Minimization
S451|for|O
S451|randomisation|O
S451|1|O
S451|,|O
S451|to|O
S451|begin|O
S451|oral|O
S451|ethinylestradiol|O
S451|or|O
S451|placebo|O
S451|at|O
S451|12|O
S451|years|O
S451|;|O
S451|the|O
S451|placebo|O
S451|group|O
S451|subsequently|O
S451|started|O
S451|ethinylestradiol|O
S451|at|O
S451|14|O
S451|years|O
S451|.|O
S2146|Memantine|O
S2146|'s|O
S2146|effects|O
S2146|in|O
S2146|the|O
S2146|‘|O
S2146|on-L-dopa|O
S2146|’|O
S2146|condition|O
S2146|are|O
S2146|presented|O
S2146|in|O
S2146|the|O
S2146|table|O
S2146|2|O
S2146|.|O
S1698|Similar|O
S1698|variation|O
S1698|over|O
S1698|time|O
S1698|(|O
S1698|heterogeneity|O
S1698|p=0·03|O
S1698|;|O
S1698|appendix|O
S1698|)|O
S1698|was|O
S1698|observed|O
S1698|for|O
S1698|deaths|O
S1698|alone|O
S1698|as|O
S1698|for|O
S1698|the|O
S1698|combined|O
S1698|endpoint|O
S1698|of|O
S1698|WHO|O
S1698|stage|O
S1698|4|O
S1698|or|O
S1698|death|O
S1698|(|O
S1698|13|O
S1698|deaths|O
S1698|on|O
S1698|clinically|O
S1698|driven|O
S1698|and|O
S1698|27|O
S1698|on|O
S1698|routine|O
S1698|laboratory|O
S1698|monitoring|O
S1698|in|O
S1698|first|O
S1698|year|O
S1698|,|O
S1698|12|O
S1698|vs|O
S1698|two|O
S1698|subsequently|O
S1698|;|O
S1698|difference|O
S1698|0·56|O
S1698|per|O
S1698|100|O
S1698|child-years|O
S1698|,|O
S1698|95|O
S1698|%|O
S1698|CI|O
S1698|0·15–0·97|O
S1698|,|O
S1698|with|O
S1698|12|O
S1698|of|O
S1698|the|O
S1698|14|O
S1698|deaths|O
S1698|after|O
S1698|1|O
S1698|year|O
S1698|in|O
S1698|children|O
S1698|aged|O
S1698|>|O
S1698|8|O
S1698|years|O
S1698|)|O
S1698|.|O
S2138|Numerical|O
S2138|safety|O
S2138|data|O
S2138|for|O
S2138|all|O
S2138|randomised|O
S2138|patients|O
S2138|were|O
S2138|assessed|O
S2138|in|O
S2138|an|O
S2138|analysis|O
S2138|of|O
S2138|variance|O
S2138|.|O
S952|A|O
S952|linear|O
S952|regression|O
S952|model|O
S952|was|O
S952|used|O
S952|to|O
S952|analyse|O
S952|differences|O
S952|between|O
S952|treatment|O
S952|groups|O
S952|for|O
S952|the|O
S952|primary|O
S952|outcome|O
S952|at|O
S952|six|O
S952|weeks|O
S952|,|O
S952|adjusting|O
S952|for|O
S952|the|O
S952|stratification|O
S952|variables|O
S952|.|O
S1447|.|O
S925|For|O
S925|participants|O
S925|whose|O
S925|pyoderma|O
S925|gangrenosum|O
S925|had|O
S925|healed|O
S925|,|O
S925|we|O
S925|assessed|O
S925|recurrence|O
S925|and|O
S925|time|O
S925|to|O
S925|recurrence|O
S925|from|O
S925|medical|O
S925|notes|O
S925|.|O
S2278|4|O
S2278|)|O
S2278|.|O
S1125|Table|O
S1125|4|O
S1125|summarises|O
S1125|the|O
S1125|treatment|O
S1125|details|O
S1125|for|O
S1125|the|O
S1125|salicylic|O
S1125|acid|O
S1125|group|O
S1125|.|O
S421|Both|O
S421|oxandrolone|O
S421|and|O
S421|late|O
S421|pubertal|O
S421|induction|O
S421|increased|O
S421|final|O
S421|height|O
S421|:|O
S421|by|O
S421|4.6|O
S421|(|O
S421|95|O
S421|%|O
S421|confidence|O
S421|interval|O
S421|1.9|O
S421|to|O
S421|7.2|O
S421|)|O
S421|cm|O
S421|(|O
S421|P=0.001|O
S421|,|O
S421|n=82|O
S421|)|O
S421|for|O
S421|oxandrolone|O
S421|and|O
S421|3.8|O
S421|(|O
S421|0.0|O
S421|to|O
S421|7.5|O
S421|)|O
S421|cm|O
S421|(|O
S421|P=0.05|O
S421|,|O
S421|n=48|O
S421|)|O
S421|for|O
S421|late|O
S421|pubertal|O
S421|induction|O
S421|with|O
S421|ethinylestradiol|O
S421|.|O
S1857|The|O
S1857|writing|O
S1857|committee|O
S1857|had|O
S1857|full|O
S1857|access|O
S1857|to|O
S1857|the|O
S1857|study|O
S1857|data|O
S1857|and|O
S1857|had|O
S1857|final|O
S1857|responsibility|O
S1857|for|O
S1857|the|O
S1857|decision|O
S1857|to|O
S1857|submit|O
S1857|for|O
S1857|publication|O
S1857|.|O
S766|Study|O
S766|design|O
S766|In|O
S766|a|O
S766|randomised|O
S766|,|O
S766|double-blind|B-Blinding_Double_Blind
S766|,|O
S766|parallel|B-Design_Parallel_Group
S766|group|I-Design_Parallel_Group
S766|design|O
S766|,|O
S766|patients|O
S766|were|O
S766|evaluated|O
S766|on|O
S766|two|O
S766|occasions|O
S766|:|O
S766|before|O
S766|and|O
S766|24|O
S766|h|O
S766|after|O
S766|intravenous|O
S766|administration|B-Design_Parallel_Group
S766|of|I-Design_Parallel_Group
S766|the|I-Design_Parallel_Group
S766|TNF-α|I-Design_Parallel_Group
S766|antagonist|I-Design_Parallel_Group
S766|,|I-Design_Parallel_Group
S766|etanercept|I-Design_Parallel_Group
S766|(|I-Design_Parallel_Group
S766|10|I-Design_Parallel_Group
S766|mg|I-Design_Parallel_Group
S766|)|I-Design_Parallel_Group
S766|,|I-Design_Parallel_Group
S766|or|I-Design_Parallel_Group
S766|saline|I-Design_Parallel_Group
S766|placebo|I-Design_Parallel_Group
S766|.|O
S1500|Mortality|O
S1500|rates|O
S1500|for|O
S1500|H5N1|O
S1500|by|O
S1500|country|O
S1500|were|O
S1500|similar|O
S1500|,|O
S1500|with|O
S1500|10/11|O
S1500|(|O
S1500|90|O
S1500|%|O
S1500|)|O
S1500|in|O
S1500|Indonesia|O
S1500|and|O
S1500|5/6|O
S1500|(|O
S1500|83|O
S1500|%|O
S1500|)|O
S1500|in|O
S1500|Vietnam|O
S1500|.|O
S490|By|O
S490|twice|O
S490|randomised|O
S490|group|O
S490|,|O
S490|the|O
S490|mean|O
S490|final|O
S490|heights|O
S490|were|O
S490|placebo/early|O
S490|induction|O
S490|147.0|O
S490|cm|O
S490|,|O
S490|placebo/late|O
S490|induction|O
S490|153.1|O
S490|cm|O
S490|,|O
S490|oxandrolone/early|O
S490|induction|O
S490|154.4|O
S490|cm|O
S490|,|O
S490|and|O
S490|oxandrolone/late|O
S490|induction|O
S490|155.1|O
S490|cm|O
S490|(|O
S490|table|O
S490|1|O
S490|)|O
S490|.|O
S1239|The|O
S1239|review|O
S1239|also|O
S1239|suggested|O
S1239|that|O
S1239|treatment|O
S1239|might|O
S1239|be|O
S1239|beneficial|O
S1239|up|O
S1239|to|O
S1239|6|O
S1239|h.|O
S1239|An|O
S1239|individual|O
S1239|patient|O
S1239|data|O
S1239|meta-analysis|O
S1239|of|O
S1239|a|O
S1239|subset|O
S1239|of|O
S1239|intravenous|O
S1239|rt-PA|O
S1239|trials|O
S1239|further|O
S1239|showed|O
S1239|that|O
S1239|the|O
S1239|earlier|O
S1239|treatment|O
S1239|was|O
S1239|given|O
S1239|,|O
S1239|the|O
S1239|greater|O
S1239|the|O
S1239|chance|O
S1239|of|O
S1239|a|O
S1239|favourable|O
S1239|outcome|O
S1239|.|O
S620|Randomisation|O
S620|and|O
S620|interventions|O
S620|After|O
S620|screening|O
S620|,|O
S620|patients|O
S620|were|O
S620|randomised|O
S620|to|O
S620|bosentan|B-Design_Parallel_Group
S620|or|I-Design_Parallel_Group
S620|placebo|I-Design_Parallel_Group
S620|(|O
S620|1:1|B-Randomization_Ratio
S620|ratio|O
S620|)|O
S620|by|O
S620|sequential|B-Randomization_Sequence_Generation_Method
S620|allocation|I-Randomization_Sequence_Generation_Method
S620|of|I-Randomization_Sequence_Generation_Method
S620|randomisation|I-Randomization_Sequence_Generation_Method
S620|numbers|I-Randomization_Sequence_Generation_Method
S620|distributed|O
S620|to|O
S620|each|O
S620|centre|O
S620|in|O
S620|blocks|B-Randomization_Type_Block
S620|of|O
S620|four|B-Randomization_Block_Size
S620|.|O
S1228|An|O
S1228|ordinal|O
S1228|analysis|O
S1228|showed|O
S1228|a|O
S1228|significant|O
S1228|shift|O
S1228|in|O
S1228|OHS|O
S1228|scores|O
S1228|;|O
S1228|common|O
S1228|OR|O
S1228|1·27|O
S1228|(|O
S1228|95|O
S1228|%|O
S1228|CI|O
S1228|1·10–1·47|O
S1228|,|O
S1228|p=0·001|O
S1228|)|O
S1228|.|O
S1645|Secondary|O
S1645|endpoints|O
S1645|for|O
S1645|both|O
S1645|randomisations|O
S1645|(|O
S1645|if|O
S1645|not|O
S1645|co-primary|O
S1645|)|O
S1645|were|O
S1645|:|O
S1645|mortality|O
S1645|;|O
S1645|new|O
S1645|(|O
S1645|or|O
S1645|new|O
S1645|or|O
S1645|recurrent|O
S1645|)|O
S1645|WHO|O
S1645|stage|O
S1645|4|O
S1645|event|O
S1645|or|O
S1645|death|O
S1645|;|O
S1645|new|O
S1645|(|O
S1645|or|O
S1645|new|O
S1645|or|O
S1645|recurrent|O
S1645|)|O
S1645|WHO|O
S1645|stage|O
S1645|3|O
S1645|or|O
S1645|4|O
S1645|event|O
S1645|or|O
S1645|death|O
S1645|;|O
S1645|grade|O
S1645|3|O
S1645|or|O
S1645|4|O
S1645|adverse|O
S1645|events|O
S1645|definitely|O
S1645|,|O
S1645|probably|O
S1645|,|O
S1645|or|O
S1645|uncertainly|O
S1645|ART-related|O
S1645|;|O
S1645|serious|O
S1645|adverse|O
S1645|events|O
S1645|not|O
S1645|solely|O
S1645|HIV-related|O
S1645|;|O
S1645|ART-modifying|O
S1645|adverse|O
S1645|events|O
S1645|;|O
S1645|admissions|O
S1645|to|O
S1645|hospital|O
S1645|;|O
S1645|height|O
S1645|,|O
S1645|weight|O
S1645|,|O
S1645|and|O
S1645|body-mass|O
S1645|index|O
S1645|for|O
S1645|age|O
S1645|;|O
S1645|CD4|O
S1645|;|O
S1645|number|O
S1645|and|O
S1645|class|O
S1645|of|O
S1645|antiretrovirals|O
S1645|received|O
S1645|;|O
S1645|switch|O
S1645|to|O
S1645|second-line|O
S1645|regimen|O
S1645|;|O
S1645|adherence|O
S1645|;|O
S1645|viral|O
S1645|load|O
S1645|and|O
S1645|resistance|O
S1645|(|O
S1645|done|O
S1645|retrospectively|O
S1645|;|O
S1645|see|O
S1645|appendix|O
S1645|)|O
S1645|.|O
S1299|An|B-Blinding_Object_Outcome_Assessors
S1299|expert|I-Blinding_Object_Outcome_Assessors
S1299|radiologist|I-Blinding_Object_Outcome_Assessors
S1299|checked|O
S1299|all|O
S1299|scans|O
S1299|,|O
S1299|masked|O
S1299|to|O
S1299|clinical|O
S1299|details|O
S1299|and|O
S1299|treatment|O
S1299|allocation|O
S1299|,|O
S1299|immediately|O
S1299|on|O
S1299|receipt|O
S1299|at|O
S1299|the|O
S1299|trial|O
S1299|office|O
S1299|,|O
S1299|for|O
S1299|evidence|O
S1299|of|O
S1299|adverse|O
S1299|events|O
S1299|and|O
S1299|protocol|O
S1299|deviations|O
S1299|.|O
S933|In|O
S933|cases|O
S933|where|O
S933|digital|O
S933|images|O
S933|were|O
S933|unavailable|O
S933|,|O
S933|or|O
S933|of|O
S933|poor|O
S933|quality|O
S933|,|O
S933|we|O
S933|used|O
S933|physical|O
S933|measurements|O
S933|of|O
S933|the|O
S933|ulcer|O
S933|taken|O
S933|by|O
S933|non-blinded|O
S933|clinicians|O
S933|at|O
S933|baseline|O
S933|and|O
S933|six|O
S933|weeks|O
S933|.|O
S86|Patients|O
S86|≥65|O
S86|years|O
S86|had|O
S86|a|O
S86|significantly|O
S86|higher|O
S86|risk|O
S86|ratio|O
S86|of|O
S86|upper|O
S86|GI|O
S86|ulcer|O
S86|formation|O
S86|(|O
S86|initial|O
S86|:|O
S86|1.47|O
S86|,|O
S86|1.06–2.05|O
S86|;|O
S86|post-adjudication|O
S86|:|O
S86|1.54|O
S86|,|O
S86|1.10–2.17|O
S86|)|O
S86|than|O
S86|those|O
S86|<|O
S86|65|O
S86|years|O
S86|.|O
S2016|At|O
S2016|the|O
S2016|intermediate|O
S2016|time|O
S2016|point|O
S2016|of|O
S2016|12|O
S2016|weeks|O
S2016|,|O
S2016|11|O
S2016|(|O
S2016|26|O
S2016|%|O
S2016|)|O
S2016|in|O
S2016|the|O
S2016|Ca+D|O
S2016|group|O
S2016|and|O
S2016|1|O
S2016|(|O
S2016|4.2|O
S2016|%|O
S2016|)|O
S2016|in|O
S2016|the|O
S2016|Ca|O
S2016|group|O
S2016|had|O
S2016|achieved|O
S2016|the|O
S2016|combined|O
S2016|outcome|O
S2016|(|O
S2016|p=0.03|O
S2016|)|O
S2016|.|O
S1136|The|O
S1136|median|O
S1136|number|O
S1136|of|O
S1136|plantar|O
S1136|warts|O
S1136|at|O
S1136|12|O
S1136|weeks|O
S1136|in|O
S1136|the|O
S1136|salicylic|O
S1136|acid|O
S1136|group|O
S1136|was|O
S1136|two|O
S1136|(|O
S1136|range|O
S1136|0–20|O
S1136|)|O
S1136|and|O
S1136|in|O
S1136|the|O
S1136|cryotherapy|O
S1136|group|O
S1136|was|O
S1136|one|O
S1136|(|O
S1136|0–40|O
S1136|)|O
S1136|,|O
S1136|and|O
S1136|no|O
S1136|significant|O
S1136|difference|O
S1136|between|O
S1136|the|O
S1136|two|O
S1136|groups|O
S1136|(|O
S1136|incident|O
S1136|rate|O
S1136|ratio|O
S1136|1.08|O
S1136|(|O
S1136|0.81|O
S1136|to|O
S1136|1.43|O
S1136|)|O
S1136|,|O
S1136|P=0.62|O
S1136|)|O
S1136|.|O
S1620|Children|O
S1620|with|O
S1620|acute|O
S1620|infections|O
S1620|,|O
S1620|on|O
S1620|drugs|O
S1620|contraindicated|O
S1620|with|O
S1620|ART|O
S1620|,|O
S1620|unlikely|O
S1620|to|O
S1620|adhere|O
S1620|or|O
S1620|to|O
S1620|attend|O
S1620|regularly|O
S1620|,|O
S1620|with|O
S1620|laboratory|O
S1620|abnormalities|O
S1620|contraindicating|O
S1620|ART|O
S1620|,|O
S1620|pregnant|O
S1620|or|O
S1620|breastfeeding|O
S1620|,|O
S1620|or|O
S1620|perinatally|O
S1620|exposed|O
S1620|to|O
S1620|ART|O
S1620|(|O
S1620|if|O
S1620|<|O
S1620|6|O
S1620|months|O
S1620|old|O
S1620|)|O
S1620|were|O
S1620|excluded|O
S1620|.|O
S969|Of|O
S969|these|O
S969|,|O
S969|36/37|O
S969|(|O
S969|97|O
S969|%|O
S969|)|O
S969|in|O
S969|the|O
S969|ciclosporin|O
S969|group|O
S969|and|O
S969|29/31|O
S969|(|O
S969|94|O
S969|%|O
S969|)|O
S969|in|O
S969|the|O
S969|prednisolone|O
S969|group|O
S969|took|O
S969|their|O
S969|treatment|O
S969|every|O
S969|day|O
S969|throughout|O
S969|the|O
S969|first|O
S969|six|O
S969|weeks|O
S969|of|O
S969|the|O
S969|trial|O
S969|.|O
S1446|Sample|O
S1446|size|O
S1446|calculations|O
S1446|Based|O
S1446|on|O
S1446|previous|O
S1446|studies|O
S1446|,|O
S1446|we|O
S1446|assumed|O
S1446|that|O
S1446|children|O
S1446|and|O
S1446|adults|O
S1446|admitted|O
S1446|to|O
S1446|hospital|O
S1446|with|O
S1446|influenza|O
S1446|would|O
S1446|have|O
S1446|detectable|O
S1446|virus|O
S1446|for|O
S1446|an|O
S1446|average|O
S1446|of|O
S1446|6.3|O
S1446|days|O
S1446|(|O
S1446|plus|O
S1446|or|O
S1446|minus|O
S1446|1.5|O
S1446|days|O
S1446|)|O
S1446|and|O
S1446|4|O
S1446|days|O
S1446|after|O
S1446|onset|O
S1446|of|O
S1446|treatment|O
S1446|,|O
S1446|respectively|O
S1446|.|O
S2|OBJECTIVES|O
S2|:|O
S2|We|O
S2|performed|O
S2|two|O
S2|24-week|O
S2|double-blind|B-Blinding_Double_Blind
S2|trials|O
S2|(|O
S2|REDUCE-1|O
S2|and|O
S2|-2|O
S2|(|O
S2|Registration|O
S2|Endoscopic|O
S2|Studies|O
S2|to|O
S2|Determine|O
S2|Ulcer|O
S2|Formation|O
S2|of|O
S2|HZT-501|O
S2|Compared|O
S2|with|O
S2|Ibuprofen|O
S2|:|O
S2|Efficacy|O
S2|and|O
S2|Safety|O
S2|Studies|O
S2|)|O
S2|)|O
S2|to|O
S2|assess|O
S2|whether|O
S2|double-dose|O
S2|famotidine|O
S2|given|O
S2|in|O
S2|a|O
S2|single-tablet|O
S2|combination|O
S2|with|O
S2|ibuprofen|O
S2|(|O
S2|HZT-501|O
S2|)|O
S2|significantly|O
S2|reduces|O
S2|gastric|O
S2|and|O
S2|duodenal|O
S2|ulcers|O
S2|as|O
S2|compared|O
S2|with|O
S2|ibuprofen|O
S2|.|O
S1631|Randomisation|O
S1631|was|O
S1631|undertaken|O
S1631|by|O
S1631|clinicians|B-Randomization_Personnel
S1631|phoning|O
S1631|the|O
S1631|local|O
S1631|trials|O
S1631|centre|O
S1631|.|O
S294|Patients|O
S294|could|O
S294|receive|O
S294|rescue|O
S294|medication|O
S294|as|O
S294|needed|O
S294|(|O
S294|see|O
S294|supplementary|O
S294|material|O
S294|for|O
S294|details|O
S294|)|O
S294|.|O
S1978|The|O
S1978|content|O
S1978|of|O
S1978|elemental|O
S1978|calcium|O
S1978|in|O
S1978|1.0|O
S1978|g|O
S1978|of|O
S1978|limestone|O
S1978|was|O
S1978|268|O
S1978|mg|O
S1978|(|O
S1978|courtesy|O
S1978|of|O
S1978|Michael|O
S1978|Gruzak|O
S1978|,|O
S1978|USDA/ARS|O
S1978|Children|O
S1978|'s|O
S1978|Nutrition|O
S1978|Research|O
S1978|Center|O
S1978|,|O
S1978|Houston|O
S1978|,|O
S1978|Texas|O
S1978|,|O
S1978|USA|O
S1978|)|O
S1978|.|O
S462|The|O
S462|study|O
S462|’|O
S462|s|O
S462|central|O
S462|pharmacy|O
S462|(|O
S462|Royal|O
S462|Hospital|O
S462|for|O
S462|Sick|O
S462|Children|O
S462|,|O
S462|Glasgow|O
S462|,|O
S462|UK|O
S462|)|O
S462|supplied|O
S462|all|O
S462|tablets|O
S462|in|O
S462|a|O
S462|double|O
S462|blind|O
S462|,|O
S462|placebo|O
S462|controlled|O
S462|fashion|O
S462|;|O
S462|only|O
S462|staff|O
S462|at|O
S462|the|O
S462|British|O
S462|Society|O
S462|for|O
S462|Paediatric|O
S462|Endocrinology|O
S462|and|O
S462|Diabetes|O
S462|Clinical|O
S462|Trials|O
S462|Unit|O
S462|and|O
S462|the|O
S462|central|O
S462|distributing|O
S462|pharmacy|O
S462|were|O
S462|not|O
S462|blinded|O
S462|to|O
S462|treatment|O
S462|allocations|O
S462|.|O
S1493|There|O
S1493|were|O
S1493|also|O
S1493|no|O
S1493|differences|O
S1493|in|O
S1493|clinical|O
S1493|failure|O
S1493|in|O
S1493|the|O
S1493|subgroup|O
S1493|of|O
S1493|patients|O
S1493|with|O
S1493|seasonal|O
S1493|influenza|O
S1493|viruses|O
S1493|(|O
S1493|see|O
S1493|above|O
S1493|)|O
S1493|:|O
S1493|3/114|O
S1493|(|O
S1493|2.6|O
S1493|%|O
S1493|,|O
S1493|0.9|O
S1493|%|O
S1493|to|O
S1493|7.5|O
S1493|%|O
S1493|)|O
S1493|patients|O
S1493|in|O
S1493|the|O
S1493|double|O
S1493|dose|O
S1493|and|O
S1493|5/110|O
S1493|(|O
S1493|4.5|O
S1493|%|O
S1493|,|O
S1493|2.0|O
S1493|%|O
S1493|to|O
S1493|10.2|O
S1493|%|O
S1493|)|O
S1493|in|O
S1493|the|O
S1493|standard|O
S1493|dose|O
S1493|arm|O
S1493|(|O
S1493|P=0.50|O
S1493|)|O
S1493|.|O
S2274|Asthma|O
S2274|exacerbation|O
S2274|rates|O
S2274|Quilizumab|O
S2274|treatment|O
S2274|did|O
S2274|not|O
S2274|produce|O
S2274|a|O
S2274|clinically|O
S2274|meaningful|O
S2274|reduction|O
S2274|of|O
S2274|the|O
S2274|rate|O
S2274|of|O
S2274|asthma|O
S2274|exacerbations|O
S2274|over|O
S2274|the|O
S2274|36-week|O
S2274|treatment|O
S2274|period|O
S2274|.|O
S955|Sensitivity|O
S955|analysis|O
S955|of|O
S955|the|O
S955|primary|O
S955|outcome|O
S955|and|O
S955|time|O
S955|to|O
S955|healing|O
S955|were|O
S955|further|O
S955|adjusted|O
S955|for|O
S955|additional|O
S955|baseline|O
S955|variables|O
S955|including|O
S955|age|O
S955|,|O
S955|sex|O
S955|,|O
S955|weight|O
S955|,|O
S955|size|O
S955|of|O
S955|recruiting|O
S955|centre|O
S955|and|O
S955|geographical|O
S955|region|O
S955|;|O
S955|missing|O
S955|data|O
S955|;|O
S955|and|O
S955|participants|O
S955|who|O
S955|switched|O
S955|randomised|O
S955|treatments|O
S955|or|O
S955|received|O
S955|the|O
S955|trial|O
S955|drugs|O
S955|in|O
S955|combination|O
S955|during|O
S955|the|O
S955|period|O
S955|of|O
S955|the|O
S955|trial|O
S955|.|O
S2252|This|O
S2252|sample|O
S2252|size|O
S2252|provided|O
S2252|approximately|O
S2252|84|B-Sample_Size_Calculation_Power_Value
S2252|%|I-Sample_Size_Calculation_Power_Value
S2252|power|O
S2252|to|O
S2252|detect|O
S2252|a|O
S2252|50|O
S2252|%|O
S2252|reduction|O
S2252|in|O
S2252|average|O
S2252|exacerbation|O
S2252|rates|O
S2252|due|O
S2252|to|O
S2252|quilizumab|O
S2252|,|O
S2252|assuming|O
S2252|0.63|O
S2252|exacerbations|O
S2252|per|O
S2252|patient|O
S2252|in|O
S2252|the|O
S2252|placebo|O
S2252|group|O
S2252|over|O
S2252|a|O
S2252|36-week|O
S2252|treatment|O
S2252|period|O
S2252|,|O
S2252|and|O
S2252|a|O
S2252|significance|O
S2252|level|O
S2252|of|O
S2252|α|O
S2252|=|O
S2252|0.10|B-Sample_Size_Calculation_Alpha_Value
S2252|.|O
S1087|The|O
S1087|plaster|O
S1087|was|O
S1087|then|O
S1087|sealed|O
S1087|into|O
S1087|position|O
S1087|.|O
S1617|A|O
S1617|triple|O
S1617|NRTI|O
S1617|regimen|O
S1617|after|O
S1617|four-drug|O
S1617|NRTI|O
S1617|plus|O
S1617|NNRTI|O
S1617|induction|O
S1617|also|O
S1617|avoids|O
S1617|challenges|O
S1617|of|O
S1617|managing|O
S1617|interactions|O
S1617|with|O
S1617|antituberculosis|O
S1617|drugs|O
S1617|,|O
S1617|particularly|O
S1617|for|O
S1617|young|O
S1617|children|O
S1617|unable|O
S1617|to|O
S1617|take|O
S1617|efavirenz|O
S1617|.|O
S313|Therefore|O
S313|a|O
S313|post|O
S313|hoc|O
S313|analysis|O
S313|using|O
S313|a|O
S313|negative|O
S313|binomial|O
S313|model|O
S313|with|O
S313|treatment|O
S313|group|O
S313|,|O
S313|allopurinol|O
S313|dose|O
S313|at|O
S313|baseline|O
S313|and|O
S313|BMI|O
S313|at|O
S313|baseline|O
S313|as|O
S313|covariates|O
S313|and|O
S313|log|O
S313|(|O
S313|time|O
S313|on|O
S313|study|O
S313|)|O
S313|as|O
S313|an|O
S313|offset|O
S313|was|O
S313|performed|O
S313|with|O
S313|an|O
S313|adjustment|O
S313|made|O
S313|for|O
S313|multiplicity|O
S313|(|O
S313|see|O
S313|supplementary|O
S313|material|O
S313|for|O
S313|further|O
S313|details|O
S313|of|O
S313|analyses|O
S313|for|O
S313|secondary|O
S313|outcomes|O
S313|)|O
S313|.|O
S289|At|O
S289|screening|O
S289|,|O
S289|patients|O
S289|indicated|O
S289|which|O
S289|of|O
S289|their|O
S289|joints|O
S289|was|O
S289|most|O
S289|affected|O
S289|by|O
S289|previous|O
S289|gouty|O
S289|arthritis|O
S289|flares|O
S289|.|O
S859|Comparison|O
S859|of|O
S859|the|O
S859|two|O
S859|most|O
S859|commonly|O
S859|used|O
S859|treatments|O
S859|for|O
S859|pyoderma|O
S859|gangrenosum|O
S859|:|O
S859|results|O
S859|of|O
S859|the|O
S859|STOP|O
S859|GAP|O
S859|randomised|O
S859|controlled|O
S859|trial|O
S2107|Patients|O
S2107|receiving|O
S2107|STN|O
S2107|stimulation|O
S2107|had|O
S2107|to|O
S2107|have|O
S2107|shown|O
S2107|an|O
S2107|improvement|O
S2107|of|O
S2107|at|O
S2107|least|O
S2107|50|O
S2107|%|O
S2107|in|O
S2107|motor|O
S2107|symptoms|O
S2107|during|O
S2107|the|O
S2107|first|O
S2107|year|O
S2107|of|O
S2107|this|O
S2107|treatment|O
S2107|(|O
S2107|without|O
S2107|a|O
S2107|worsening|O
S2107|in|O
S2107|gait|O
S2107|and|O
S2107|posture|O
S2107|)|O
S2107|.|O
S1463|All|O
S1463|P|O
S1463|values|O
S1463|are|O
S1463|two|O
S1463|tailed|O
S1463|.|O
S1733|ART-modifying|O
S1733|adverse|O
S1733|events|O
S1733|occurred|O
S1733|in|O
S1733|eight|O
S1733|(|O
S1733|2|O
S1733|%|O
S1733|)|O
S1733|children|O
S1733|in|O
S1733|group|O
S1733|A|O
S1733|versus|O
S1733|30|O
S1733|(|O
S1733|7|O
S1733|%|O
S1733|)|O
S1733|in|O
S1733|group|O
S1733|B|O
S1733|and|O
S1733|25|O
S1733|(|O
S1733|6|O
S1733|%|O
S1733|)|O
S1733|in|O
S1733|group|O
S1733|C|O
S1733|(|O
S1733|HR|O
S1733|[|O
S1733|B|O
S1733|:|O
S1733|A|O
S1733|]|O
S1733|3·80|O
S1733|,|O
S1733|95|O
S1733|%|O
S1733|CI|O
S1733|1·74–8·29|O
S1733|;|O
S1733|HR|O
S1733|(|O
S1733|C|O
S1733|:|O
S1733|A|O
S1733|)|O
S1733|3·09|O
S1733|,|O
S1733|1·39–6·85|O
S1733|;|O
S1733|global|O
S1733|p=0·002|O
S1733|;|O
S1733|figure|O
S1733|4|O
S1733|)|O
S1733|.|O
S1893|The|O
S1893|14|O
S1893|%|O
S1893|(|O
S1893|SE|O
S1893|3|O
S1893|)|O
S1893|proportional|O
S1893|reduction|O
S1893|in|O
S1893|all-cause|O
S1893|mortality|O
S1893|(|O
S1893|p=0·0001|O
S1893|)|O
S1893|seen|O
S1893|during|O
S1893|the|O
S1893|in-trial|O
S1893|period|O
S1893|reflects|O
S1893|the|O
S1893|combination|O
S1893|of|O
S1893|an|O
S1893|18|O
S1893|%|O
S1893|(|O
S1893|SE|O
S1893|4|O
S1893|)|O
S1893|proportional|O
S1893|reduction|O
S1893|in|O
S1893|vascular|O
S1893|mortality|O
S1893|and|O
S1893|little|O
S1893|effect|O
S1893|on|O
S1893|non-vascular|O
S1893|mortality|O
S1893|(|O
S1893|webappendix|O
S1893|p|O
S1893|4|O
S1893|)|O
S1893|.|O
S1072|This|O
S1072|multicentre|B-Settings_Multicenter
S1072|,|O
S1072|two|O
S1072|arm|O
S1072|,|O
S1072|randomised|B-Randomization_Type_Simple
S1072|,|O
S1072|controlled|O
S1072|,|O
S1072|open|B-Blinding_Open_Label
S1072|trial|O
S1072|was|O
S1072|carried|O
S1072|out|O
S1072|in|O
S1072|13|B-Settings_Multicenter
S1072|centres|I-Settings_Multicenter
S1072|in|O
S1072|the|O
S1072|United|B-Settings_Location
S1072|Kingdom|I-Settings_Location
S1072|and|O
S1072|one|O
S1072|in|O
S1072|the|B-Settings_Location
S1072|Republic|I-Settings_Location
S1072|of|I-Settings_Location
S1072|Ireland|I-Settings_Location
S1072|.|O
S1508|Twenty|O
S1508|children|O
S1508|(|O
S1508|10|O
S1508|in|O
S1508|each|O
S1508|arm|O
S1508|)|O
S1508|and|O
S1508|10|O
S1508|adults|O
S1508|(|O
S1508|five|O
S1508|in|O
S1508|each|O
S1508|arm|O
S1508|)|O
S1508|were|O
S1508|given|O
S1508|inhaled|O
S1508|steroids|O
S1508|for|O
S1508|bronchospasm|O
S1508|.|O
S147|Long-acting|O
S147|β2-agonists|O
S147|were|O
S147|not|O
S147|permitted|O
S147|during|O
S147|the|O
S147|treatment|O
S147|phase|O
S147|.|O
S1397|Main|O
S1397|outcome|O
S1397|measure|O
S1397|Viral|O
S1397|status|O
S1397|according|O
S1397|to|O
S1397|reverse|O
S1397|transcriptase|O
S1397|polymerase|O
S1397|chain|O
S1397|reaction|O
S1397|(|O
S1397|RT-PCR|O
S1397|)|O
S1397|for|O
S1397|influenza|O
S1397|RNA|O
S1397|in|O
S1397|nasal|O
S1397|and|O
S1397|throat|O
S1397|swabs|O
S1397|on|O
S1397|day|O
S1397|five|O
S1397|.|O
S1605|Introduction|O
S1605|In|O
S1605|high-income|O
S1605|countries|O
S1605|,|O
S1605|routine|O
S1605|laboratory|O
S1605|tests|O
S1605|are|O
S1605|done|O
S1605|(|O
S1605|typically|O
S1605|every|O
S1605|3–4|O
S1605|months|O
S1605|)|O
S1605|to|O
S1605|monitor|O
S1605|efficacy|O
S1605|(|O
S1605|HIV|O
S1605|viral|O
S1605|load|O
S1605|,|O
S1605|CD4|O
S1605|counts|O
S1605|)|O
S1605|and|O
S1605|toxicity|O
S1605|(|O
S1605|haematology|O
S1605|or|O
S1605|biochemistry|O
S1605|panels|O
S1605|)|O
S1605|in|O
S1605|patients|O
S1605|with|O
S1605|HIV|O
S1605|on|O
S1605|antiretroviral|O
S1605|therapy|O
S1605|(|O
S1605|ART|O
S1605|)|O
S1605|.|O
S1873|Among|O
S1873|event-free|O
S1873|survivors|O
S1873|at|O
S1873|the|O
S1873|start|O
S1873|of|O
S1873|the|O
S1873|post-trial|O
S1873|period|O
S1873|,|O
S1873|1636|O
S1873|(|O
S1873|21·7|O
S1873|%|O
S1873|)|O
S1873|first|O
S1873|events|O
S1873|arose|O
S1873|in|O
S1873|patients|O
S1873|previously|O
S1873|allocated|O
S1873|simvastatin|O
S1873|versus|O
S1873|1566|O
S1873|(|O
S1873|22·5|O
S1873|%|O
S1873|)|O
S1873|in|O
S1873|those|O
S1873|previously|O
S1873|allocated|O
S1873|placebo|O
S1873|(|O
S1873|risk|O
S1873|ratio|O
S1873|[|O
S1873|RR|O
S1873|]|O
S1873|0·95|O
S1873|[|O
S1873|95|O
S1873|%|O
S1873|CI|O
S1873|0·89–1·02|O
S1873|]|O
S1873|;|O
S1873|p=0·17|O
S1873|)|O
S1873|.|O
S291|In|O
S291|order|O
S291|to|O
S291|achieve|O
S291|blinding|O
S291|for|O
S291|patients|B-Blinding_Object_Patients
S291|and|O
S291|investigators|B-Blinding_Object_Investigators
S291|,|O
S291|all|O
S291|patients|O
S291|received|O
S291|subcutaneous|O
S291|injections|O
S291|of|O
S291|canakinumab|O
S291|or|O
S291|canakinumab|O
S291|placebo|O
S291|on|O
S291|day|O
S291|1|O
S291|,|O
S291|and|O
S291|at|O
S291|weeks|O
S291|4|O
S291|,|O
S291|8|O
S291|and|O
S291|12|O
S291|,|O
S291|and|O
S291|took|O
S291|capsules|O
S291|of|O
S291|colchicine|O
S291|or|O
S291|colchicine|O
S291|placebo|O
S291|daily|O
S291|for|O
S291|16|O
S291|weeks|O
S291|(|O
S291|see|O
S291|supplementary|O
S291|material|O
S291|for|O
S291|details|O
S291|)|O
S291|.|O
S812|Platelet|O
S812|P-selectin|O
S812|expression|O
S812|was|O
S812|not|O
S812|affected|O
S812|by|O
S812|either|O
S812|treatment|O
S812|(|O
S812|p|O
S812|>|O
S812|0.05|O
S812|for|O
S812|both|O
S812|;|O
S812|table|O
S812|2|O
S812|)|O
S812|.|O
S1589|Children|O
S1589|switched|O
S1589|to|O
S1589|second-line|O
S1589|ART|O
S1589|for|O
S1589|WHO|O
S1589|stage|O
S1589|3|O
S1589|or|O
S1589|4|O
S1589|events|O
S1589|or|O
S1589|(|O
S1589|routine|O
S1589|laboratory|O
S1589|monitoring|O
S1589|only|O
S1589|)|O
S1589|age-dependent|O
S1589|WHO|O
S1589|CD4|O
S1589|criteria|O
S1589|.|O
S657|(|O
S657|95|O
S657|%|O
S657|CI|O
S657|−2.3|O
S657|to|O
S657|−1.0|O
S657|)|O
S657|and|O
S657|−1.5|O
S657|(|O
S657|−2.3|O
S657|to|O
S657|−0.7|O
S657|)|O
S657|DUs|O
S657|,|O
S657|respectively|O
S657|;|O
S657|p=0.76|O
S657|)|O
S657|.|O
S617|Patients|O
S617|were|O
S617|also|O
S617|excluded|O
S617|if|O
S617|they|O
S617|received|O
S617|systemic|O
S617|antibiotics|O
S617|to|O
S617|treat|O
S617|infected|O
S617|DUs|O
S617|within|O
S617|2|O
S617|weeks|O
S617|prior|O
S617|to|O
S617|randomisation|O
S617|.|O
S906|Participants|O
S906|Recruitment|O
S906|took|O
S906|place|O
S906|at|O
S906|39|B-Settings_Multicenter
S906|hospitals|I-Settings_Multicenter
S906|in|O
S906|the|O
S906|United|B-Settings_Location
S906|Kingdom|I-Settings_Location
S906|.|O
S1884|Vascular|O
S1884|mortality|O
S1884|during|O
S1884|the|O
S1884|in-trial|O
S1884|period|O
S1884|accounted|O
S1884|for|O
S1884|826|O
S1884|(|O
S1884|8·0|O
S1884|%|O
S1884|)|O
S1884|deaths|O
S1884|in|O
S1884|participants|O
S1884|allocated|O
S1884|simvastatin|O
S1884|versus|O
S1884|998|O
S1884|(|O
S1884|9·7|O
S1884|%|O
S1884|)|O
S1884|in|O
S1884|those|O
S1884|allocated|O
S1884|placebo|O
S1884|,|O
S1884|corresponding|O
S1884|to|O
S1884|an|O
S1884|18|O
S1884|%|O
S1884|(|O
S1884|SE|O
S1884|4|O
S1884|)|O
S1884|proportional|O
S1884|reduction|O
S1884|(|O
S1884|p|O
S1884|<|O
S1884|0·0001|O
S1884|,|O
S1884|figure|O
S1884|4|O
S1884|;|O
S1884|webappendix|O
S1884|,|O
S1884|p|O
S1884|4|O
S1884|)|O
S1884|.|O
S1613|Challenges|O
S1613|in|O
S1613|treatment|O
S1613|of|O
S1613|young|O
S1613|children|O
S1613|,|O
S1613|in|O
S1613|whom|O
S1613|viral|O
S1613|loads|O
S1613|are|O
S1613|higher|O
S1613|,|O
S1613|pharmacokinetics|O
S1613|more|O
S1613|variable|O
S1613|,|O
S1613|and|O
S1613|adherence|O
S1613|more|O
S1613|challenging|O
S1613|,|O
S1613|might|O
S1613|account|O
S1613|for|O
S1613|the|O
S1613|lower|O
S1613|virological|O
S1613|suppression|O
S1613|rates|O
S1613|in|O
S1613|children|O
S1613|compared|O
S1613|with|O
S1613|adults|O
S1613|in|O
S1613|similar|O
S1613|calendar|O
S1613|periods|O
S1613|.|O
S1283|6|O
S1283|months|O
S1283|after|O
S1283|randomisation|O
S1283|,|O
S1283|general|O
S1283|practitioners|O
S1283|(|O
S1283|or|O
S1283|hospital|O
S1283|coordinators|O
S1283|)|O
S1283|were|O
S1283|contacted|O
S1283|by|O
S1283|the|O
S1283|IST-3|O
S1283|trial|O
S1283|office|O
S1283|staff|O
S1283|to|O
S1283|check|O
S1283|that|O
S1283|the|O
S1283|patient|O
S1283|was|O
S1283|alive|O
S1283|and|O
S1283|inform|O
S1283|them|O
S1283|that|O
S1283|they|O
S1283|might|O
S1283|be|O
S1283|approached|O
S1283|for|O
S1283|follow-up|O
S1283|.|O
S1089|Outcome|O
S1089|measurements|O
S1089|Primary|O
S1089|outcome|O
S1089|The|O
S1089|primary|O
S1089|outcome|O
S1089|was|O
S1089|complete|O
S1089|clearance|O
S1089|of|O
S1089|all|O
S1089|plantar|O
S1089|warts|O
S1089|at|O
S1089|12|O
S1089|weeks|O
S1089|after|O
S1089|randomisation|O
S1089|.|O
S170|Slightly|O
S170|higher|O
S170|peak|O
S170|forced|O
S170|expiratory|O
S170|volume|O
S170|in|O
S170|1|O
S170|second|O
S170|(|O
S170|FEV1|O
S170|)|O
S170|responses|O
S170|were|O
S170|observed|O
S170|in|O
S170|the|O
S170|10|O
S170|μg|O
S170|arm|O
S170|,|O
S170|and|O
S170|there|O
S170|were|O
S170|statistically|O
S170|significant|O
S170|improvements|O
S170|in|O
S170|pre-dose|O
S170|morning|O
S170|and|O
S170|evening|O
S170|peak|O
S170|expiratory|O
S170|flow|O
S170|(|O
S170|PEFam|O
S170|and|O
S170|PEFpm|O
S170|)|O
S170|with|O
S170|10|O
S170|μg|O
S170|versus|O
S170|5|O
S170|μg|O
S170|.|O
S427|Trial|O
S427|registration|O
S427|Current|O
S427|Controlled|O
S427|Trials|O
S427|ISRCTN50343149|O
S427|.|O
S1634|Screening|O
S1634|results|O
S1634|were|O
S1634|used|O
S1634|to|O
S1634|assess|O
S1634|eligibility|O
S1634|.|O
S811|PMA|O
S811|was|O
S811|however|O
S811|unaffected|O
S811|by|O
S811|saline|O
S811|placebo|O
S811|infusion|O
S811|(|O
S811|28±5|O
S811|vs|O
S811|33±6|O
S811|%|O
S811|;|O
S811|p=0.23|O
S811|)|O
S811|.|O
S621|Patients|O
S621|received|O
S621|bosentan|B-Design_Parallel_Group
S621|62.5|I-Design_Parallel_Group
S621|mg|I-Design_Parallel_Group
S621|twice|I-Design_Parallel_Group
S621|daily|I-Design_Parallel_Group
S621|for|I-Design_Parallel_Group
S621|4|I-Design_Parallel_Group
S621|weeks|I-Design_Parallel_Group
S621|and|I-Design_Parallel_Group
S621|then|I-Design_Parallel_Group
S621|125|I-Design_Parallel_Group
S621|mg|I-Design_Parallel_Group
S621|twice|I-Design_Parallel_Group
S621|daily|I-Design_Parallel_Group
S621|for|I-Design_Parallel_Group
S621|the|I-Design_Parallel_Group
S621|remainder|I-Design_Parallel_Group
S621|of|I-Design_Parallel_Group
S621|the|I-Design_Parallel_Group
S621|treatment|I-Design_Parallel_Group
S621|period|I-Design_Parallel_Group
S621|or|I-Design_Parallel_Group
S621|matching|I-Design_Parallel_Group
S621|placebo|I-Design_Parallel_Group
S621|.|O
S742|Conclusions|O
S742|Following|O
S742|acute|O
S742|myocardial|O
S742|infarction|O
S742|,|O
S742|etanercept|O
S742|reduces|O
S742|systemic|O
S742|inflammation|O
S742|but|O
S742|increases|O
S742|platelet|O
S742|activation|O
S742|without|O
S742|affecting|O
S742|peripheral|O
S742|vasomotor|O
S742|or|O
S742|fibrinolytic|O
S742|function|O
S742|.|O
S1096|If|O
S1096|neither|O
S1096|of|O
S1096|these|O
S1096|were|O
S1096|available|O
S1096|for|O
S1096|a|O
S1096|participant|O
S1096|,|O
S1096|the|O
S1096|patient|O
S1096|’|O
S1096|s|O
S1096|self|O
S1096|reported|O
S1096|outcome|O
S1096|recorded|O
S1096|in|O
S1096|the|O
S1096|week|O
S1096|12|O
S1096|patient|O
S1096|questionnaire|O
S1096|or|O
S1096|on|O
S1096|the|O
S1096|“|O
S1096|Verrucae|O
S1096|gone|O
S1096|form|O
S1096|”|O
S1096|was|O
S1096|used|O
S1096|.|O
S1963|Subjects|O
S1963|Children|O
S1963|with|O
S1963|active|O
S1963|rickets|O
S1963|were|O
S1963|identified|O
S1963|using|O
S1963|radiographs|O
S1963|of|O
S1963|the|O
S1963|wrists|O
S1963|and|O
S1963|the|O
S1963|knees|O
S1963|from|O
S1963|among|O
S1963|children|O
S1963|who|O
S1963|presented|O
S1963|with|O
S1963|leg|O
S1963|deformities|O
S1963|to|O
S1963|the|O
S1963|primary|O
S1963|care|O
S1963|setting|O
S1963|of|O
S1963|the|O
S1963|Family|O
S1963|Medicine|O
S1963|Department|O
S1963|of|O
S1963|the|O
S1963|Jos|B-Settings_Single_Center
S1963|University|I-Settings_Single_Center
S1963|Teaching|I-Settings_Single_Center
S1963|Hospital|I-Settings_Single_Center
S1963|in|O
S1963|the|O
S1963|geographic|O
S1963|centre|O
S1963|of|O
S1963|Nigeria|B-Settings_Location
S1963|(|O
S1963|10°|O
S1963|north|O
S1963|latitude|O
S1963|)|O
S1963|.|O
S94|However|O
S94|,|O
S94|the|O
S94|proportion|O
S94|of|O
S94|patients|O
S94|with|O
S94|one|O
S94|or|O
S94|more|O
S94|predefined|O
S94|symptoms|O
S94|consistent|O
S94|with|O
S94|dyspepsia|O
S94|was|O
S94|not|O
S94|significantly|O
S94|different|O
S94|between|O
S94|HZT-501|O
S94|and|O
S94|ibuprofen|O
S94|(|O
S94|12.3|O
S94|%|O
S94|vs.|O
S94|14.9|O
S94|%|O
S94|)|O
S94|.|O
S279|Some|O
S279|patients|O
S279|have|O
S279|contraindications|O
S279|to|O
S279|colchicine|O
S279|whereas|O
S279|others|O
S279|do|O
S279|not|O
S279|tolerate|O
S279|colchicine|O
S279|or|O
S279|still|O
S279|experience|O
S279|flares|O
S279|.|O
S2260|Through|O
S2260|Week|O
S2260|36|O
S2260|,|O
S2260|the|O
S2260|most|O
S2260|frequent|O
S2260|AEs|O
S2260|across|O
S2260|all|O
S2260|quilizumab|O
S2260|dose|O
S2260|groups|O
S2260|were|O
S2260|worsening|O
S2260|of|O
S2260|asthma|O
S2260|(|O
S2260|27|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|nasopharyngitis|O
S2260|(|O
S2260|15|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|upper|O
S2260|respiratory|O
S2260|tract|O
S2260|infection|O
S2260|(|O
S2260|7|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|bronchitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|sinusitis|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|,|O
S2260|and|O
S2260|injection|O
S2260|site|O
S2260|pain|O
S2260|(|O
S2260|5|O
S2260|%|O
S2260|)|O
S2260|.|O
S872|The|O
S872|mean|O
S872|(|O
S872|SD|O
S872|)|O
S872|speed|O
S872|of|O
S872|healing|O
S872|at|O
S872|six|O
S872|weeks|O
S872|was|O
S872|−0.21|O
S872|(|O
S872|1.00|O
S872|)|O
S872|cm2/day|O
S872|in|O
S872|the|O
S872|ciclosporin|O
S872|group|O
S872|compared|O
S872|with|O
S872|−0.14|O
S872|(|O
S872|0.42|O
S872|)|O
S872|cm2/day|O
S872|in|O
S872|the|O
S872|prednisolone|O
S872|group|O
S872|.|O
S13|INTRODUCTION|O
S13|Non-steroidal|O
S13|anti-inflammatory|O
S13|drugs|O
S13|(|O
S13|NSAIDs|O
S13|)|O
S13|are|O
S13|widely|O
S13|used|O
S13|as|O
S13|analgesics|O
S13|.|O
S1713|The|O
S1713|excess|O
S1713|malaria|O
S1713|serious|O
S1713|adverse|O
S1713|events|O
S1713|in|O
S1713|the|O
S1713|clinically|O
S1713|driven|O
S1713|monitoring|O
S1713|group|O
S1713|were|O
S1713|mostly|O
S1713|in|O
S1713|children|O
S1713|with|O
S1713|parasite|O
S1713|counts|O
S1713|less|O
S1713|than|O
S1713|500|O
S1713|per|O
S1713|200|O
S1713|white|O
S1713|blood|O
S1713|cells|O
S1713|,|O
S1713|or|O
S1713|were|O
S1713|not|O
S1713|diagnostically|O
S1713|confirmed|O
S1713|(|O
S1713|figure|O
S1713|3|O
S1713|)|O
S1713|.|O
S927|Two|O
S927|trained|O
S927|assessors|O
S927|mapped|O
S927|the|O
S927|circumference|O
S927|of|O
S927|the|O
S927|lesion|O
S927|using|O
S927|VERG|O
S927|Videometry|O
S927|VEV|O
S927|MD|O
S927|software|O
S927|(|O
S927|Vista|O
S927|Medical|O
S927|,|O
S927|Winnipeg|O
S927|,|O
S927|Canada|O
S927|)|O
S927|.|O
S488|At|O
S488|the|O
S488|time|O
S488|of|O
S488|writing|O
S488|,|O
S488|82|O
S488|participants|O
S488|had|O
S488|attained|O
S488|a|O
S488|mean|O
S488|final|O
S488|height|O
S488|of|O
S488|151.8|O
S488|(|O
S488|SD|O
S488|6.4|O
S488|)|O
S488|cm|O
S488|,|O
S488|and|O
S488|10|O
S488|others|O
S488|continued|O
S488|growing|O
S488|.|O
S1989|Concentrations|O
S1989|of|O
S1989|25|O
S1989|(|O
S1989|OH|O
S1989|)|O
S1989|D|O
S1989|below|O
S1989|the|O
S1989|limit|O
S1989|of|O
S1989|detection|O
S1989|(|O
S1989|5|O
S1989|nmol/L|O
S1989|for|O
S1989|25|O
S1989|(|O
S1989|OH|O
S1989|)|O
S1989|D3|O
S1989|and|O
S1989|10|O
S1989|nmol/L|O
S1989|for|O
S1989|25|O
S1989|(|O
S1989|OH|O
S1989|)|O
S1989|D2|O
S1989|)|O
S1989|were|O
S1989|designated|O
S1989|as|O
S1989|zero|O
S1989|for|O
S1989|the|O
S1989|data|O
S1989|analysis|O
S1989|.|O
S1274|The|O
S1274|statistical|O
S1274|analysis|O
S1274|plan|O
S1274|specified|O
S1274|an|O
S1274|ordinal|O
S1274|analysis|O
S1274|of|O
S1274|the|O
S1274|OHS|O
S1274|score|O
S1274|at|O
S1274|6|O
S1274|months|O
S1274|.|O
S1585|Summary|O
S1585|Background|O
S1585|No|O
S1585|trials|O
S1585|have|O
S1585|investigated|O
S1585|routine|O
S1585|laboratory|O
S1585|monitoring|O
S1585|for|O
S1585|children|O
S1585|with|O
S1585|HIV|O
S1585|,|O
S1585|nor|O
S1585|four-drug|O
S1585|induction|O
S1585|strategies|O
S1585|to|O
S1585|increase|O
S1585|durability|O
S1585|of|O
S1585|first-line|O
S1585|antiretroviral|O
S1585|therapy|O
S1585|(|O
S1585|ART|O
S1585|)|O
S1585|.|O
S1145|At|O
S1145|week|O
S1145|3|O
S1145|,|O
S1145|more|O
S1145|patients|O
S1145|were|O
S1145|unhappy|O
S1145|with|O
S1145|salicylic|O
S1145|acid|O
S1145|than|O
S1145|with|O
S1145|cryotherapy|O
S1145|(|O
S1145|none|O
S1145|)|O
S1145|,|O
S1145|and|O
S1145|more|O
S1145|patients|O
S1145|were|O
S1145|very|O
S1145|happy|O
S1145|with|O
S1145|cryotherapy|O
S1145|than|O
S1145|salicylic|O
S1145|acid|O
S1145|.|O
S1839|Participants|O
S1839|unable|O
S1839|or|O
S1839|unwilling|O
S1839|to|O
S1839|attend|O
S1839|were|O
S1839|contacted|O
S1839|by|O
S1839|telephone|O
S1839|,|O
S1839|or|O
S1839|follow-up|O
S1839|was|O
S1839|sought|O
S1839|from|O
S1839|their|O
S1839|family|O
S1839|doctors|O
S1839|.|O
S1263|Patients|O
S1263|allocated|O
S1263|to|O
S1263|the|O
S1263|control|O
S1263|group|O
S1263|were|O
S1263|to|O
S1263|avoid|O
S1263|treatment|O
S1263|with|O
S1263|rt-PA|O
S1263|and|O
S1263|received|O
S1263|stroke|O
S1263|care|O
S1263|in|O
S1263|the|O
S1263|same|O
S1263|clinical|O
S1263|environment|O
S1263|as|O
S1263|those|O
S1263|allocated|O
S1263|to|O
S1263|the|O
S1263|rt-PA|O
S1263|group|O
S1263|.|O
S487|Final|O
S487|and|O
S487|maximum|O
S487|height|O
S487|Table|O
S487|1|O
S487|shows|O
S487|participants|O
S487|’|O
S487|characteristics|O
S487|at|O
S487|enrolment|O
S487|,|O
S487|at|O
S487|maximum|O
S487|height|O
S487|,|O
S487|and|O
S487|at|O
S487|final|O
S487|height|O
S487|by|O
S487|treatment|O
S487|group|O
S487|.|O
S2128|In|O
S2128|order|O
S2128|to|O
S2128|estimate|O
S2128|the|O
S2128|final|O
S2128|plasma|O
S2128|concentration|O
S2128|of|O
S2128|memantine|O
S2128|,|O
S2128|a|O
S2128|blood|O
S2128|sample|O
S2128|was|O
S2128|taken|O
S2128|from|O
S2128|all|O
S2128|patients|O
S2128|(|O
S2128|ie|O
S2128|,|O
S2128|both|O
S2128|groups|O
S2128|,|O
S2128|to|O
S2128|maintain|O
S2128|blinding|O
S2128|)|O
S2128|before|O
S2128|the|O
S2128|morning|O
S2128|administration|O
S2128|of|O
S2128|study|O
S2128|medication|O
S2128|at|O
S2128|7:00|O
S2128|on|O
S2128|the|O
S2128|last|O
S2128|day|O
S2128|of|O
S2128|treatment|O
S2128|.|O
S475|We|O
S475|estimated|O
S475|the|O
S475|effects|O
S475|of|O
S475|the|O
S475|two|O
S475|randomisations|O
S475|separately|O
S475|by|O
S475|using|O
S475|multiple|O
S475|regression|O
S475|.|O
S981|By|O
S981|six|O
S981|months|O
S981|,|O
S981|ulcers|O
S981|had|O
S981|healed|O
S981|in|O
S981|28/59|O
S981|(|O
S981|47|O
S981|%|O
S981|)|O
S981|participants|O
S981|in|O
S981|the|O
S981|ciclosporin|O
S981|group|O
S981|and|O
S981|25/53|O
S981|(|O
S981|47|O
S981|%|O
S981|)|O
S981|in|O
S981|the|O
S981|prednisolone|O
S981|group|O
S981|.|O
S1587|Randomisation|O
S1587|was|O
S1587|to|O
S1587|either|O
S1587|clinically|O
S1587|driven|O
S1587|monitoring|O
S1587|or|O
S1587|routine|O
S1587|laboratory|O
S1587|and|O
S1587|clinical|O
S1587|monitoring|O
S1587|for|O
S1587|toxicity|O
S1587|(|O
S1587|haematology|O
S1587|and|O
S1587|biochemistry|O
S1587|)|O
S1587|and|O
S1587|efficacy|O
S1587|(|O
S1587|CD4|O
S1587|cell|O
S1587|counts|O
S1587|;|O
S1587|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1587|monitoring|O
S1587|randomisation|O
S1587|)|O
S1587|;|O
S1587|and|O
S1587|simultaneously|O
S1587|to|O
S1587|standard|O
S1587|three-drug|O
S1587|or|O
S1587|to|O
S1587|four-drug|O
S1587|induction|O
S1587|first-line|O
S1587|ART|O
S1587|,|O
S1587|in|O
S1587|three|O
S1587|groups|O
S1587|:|O
S1587|three-drug|O
S1587|treatment|O
S1587|(|O
S1587|non-nucleoside|O
S1587|reverse|O
S1587|transcriptase|O
S1587|inhibitor|O
S1587|[|O
S1587|NNRTI|O
S1587|]|O
S1587|,|O
S1587|lamivudine|O
S1587|,|O
S1587|abacavir|O
S1587|;|O
S1587|group|O
S1587|A|O
S1587|)|O
S1587|versus|O
S1587|four-drug|O
S1587|induction|O
S1587|(|O
S1587|NNRTI|O
S1587|,|O
S1587|lamivudine|O
S1587|,|O
S1587|abacavir|O
S1587|,|O
S1587|zidovudine|O
S1587|;|O
S1587|groups|O
S1587|B|O
S1587|and|O
S1587|C|O
S1587|)|O
S1587|,|O
S1587|decreasing|O
S1587|after|O
S1587|week|O
S1587|36|O
S1587|to|O
S1587|three-drug|O
S1587|NNRTI|O
S1587|,|O
S1587|lamivudine|O
S1587|,|O
S1587|plus|O
S1587|abacavir|O
S1587|(|O
S1587|group|O
S1587|B|O
S1587|)|O
S1587|or|O
S1587|lamivudine|O
S1587|,|O
S1587|abacavir|O
S1587|,|O
S1587|plus|O
S1587|zidovudine|O
S1587|(|O
S1587|group|O
S1587|C|O
S1587|;|O
S1587|superiority|O
S1587|ART-strategy|O
S1587|randomisation|O
S1587|)|O
S1587|.|O
S277|Therefore|O
S277|,|O
S277|when|O
S277|initiating|O
S277|a|O
S277|patient|O
S277|on|O
S277|ULT|O
S277|,|O
S277|prophylactic|O
S277|low-dose|O
S277|anti-inflammatory|O
S277|treatment|O
S277|is|O
S277|recommended|O
S277|to|O
S277|prevent|O
S277|flares|O
S277|and|O
S277|foster|O
S277|compliance|O
S277|with|O
S277|ULT|O
S277|.|O
S2081|Background|O
S2081|Given|O
S2081|that|O
S2081|memantine|O
S2081|is|O
S2081|thought|O
S2081|to|O
S2081|decrease|O
S2081|N-methyl-D-aspartic-acid-related|O
S2081|(|O
S2081|NMDA|O
S2081|)|O
S2081|glutamatergic|O
S2081|hyperactivity|O
S2081|and|O
S2081|improve|O
S2081|locomotion|O
S2081|in|O
S2081|rats|O
S2081|,|O
S2081|we|O
S2081|sought|O
S2081|to|O
S2081|assess|O
S2081|the|O
S2081|drug|O
S2081|'s|O
S2081|impact|O
S2081|on|O
S2081|axial|O
S2081|symptoms|O
S2081|in|O
S2081|advanced|O
S2081|Parkinson|O
S2081|'s|O
S2081|disease|O
S2081|(|O
S2081|PD|O
S2081|)|O
S2081|.|O
S611|Patients|O
S611|and|O
S611|methods|O
S611|Study|O
S611|design|O
S611|This|O
S611|double-blind|B-Blinding_Double_Blind
S611|,|O
S611|randomised|O
S611|,|O
S611|parallel-group|B-Design_Parallel_Group
S611|,|O
S611|placebo-controlled|O
S611|study|O
S611|consisted|O
S611|of|O
S611|a|O
S611|≤2-week|O
S611|screening|O
S611|period|O
S611|,|O
S611|a|O
S611|24-week|O
S611|treatment|O
S611|period|O
S611|and|O
S611|an|O
S611|8-week|O
S611|post-treatment|O
S611|follow-up|O
S611|period|O
S611|.|O
S862|Design|O
S862|Multicentre|B-Settings_Multicenter
S862|,|O
S862|parallel|B-Design_Parallel_Group
S862|group|I-Design_Parallel_Group
S862|,|O
S862|observer|B-Blinding_Object_Outcome_Assessors
S862|blind|I-Blinding_Single_Blind
S862|,|O
S862|randomised|O
S862|controlled|O
S862|trial|O
S862|.|O
S1725|In|O
S1725|particular|O
S1725|,|O
S1725|there|O
S1725|was|O
S1725|no|O
S1725|evidence|O
S1725|that|O
S1725|greater|O
S1725|initial|O
S1725|CD4|O
S1725|increases|O
S1725|in|O
S1725|groups|O
S1725|B|O
S1725|or|O
S1725|C|O
S1725|significantly|O
S1725|reduced|O
S1725|disease|O
S1725|progression|O
S1725|risks|O
S1725|in|O
S1725|the|O
S1725|first|O
S1725|year|O
S1725|(|O
S1725|13|O
S1725|deaths|O
S1725|in|O
S1725|group|O
S1725|A|O
S1725|vs|O
S1725|nine|O
S1725|in|O
S1725|group|O
S1725|B|O
S1725|vs|O
S1725|18|O
S1725|in|O
S1725|group|O
S1725|C|O
S1725|;|O
S1725|22|O
S1725|vs|O
S1725|19|O
S1725|vs|O
S1725|24|O
S1725|WHO|O
S1725|stage|O
S1725|4|O
S1725|events|O
S1725|or|O
S1725|deaths|O
S1725|;|O
S1725|36|O
S1725|vs|O
S1725|35|O
S1725|vs|O
S1725|37|O
S1725|WHO|O
S1725|stage|O
S1725|3|O
S1725|or|O
S1725|4|O
S1725|events|O
S1725|or|O
S1725|deaths|O
S1725|)|O
S1725|.|O
S472|Assuming|O
S472|a|O
S472|standard|O
S472|deviation|O
S472|of|O
S472|5|O
S472|cm|O
S472|,|O
S472|we|O
S472|needed|O
S472|50|B-Sample_Size_Required
S472|girls|I-Sample_Size_Required
S472|in|I-Sample_Size_Required
S472|each|I-Sample_Size_Required
S472|group|I-Sample_Size_Required
S472|to|O
S472|detect|O
S472|a|O
S472|difference|O
S472|between|O
S472|groups|O
S472|in|O
S472|mean|O
S472|final|O
S472|height|O
S472|of|O
S472|2.8|O
S472|cm|O
S472|with|O
S472|80|B-Sample_Size_Calculation_Power_Value
S472|%|I-Sample_Size_Calculation_Power_Value
S472|power|O
S472|at|O
S472|5|B-Sample_Size_Calculation_Alpha_Value
S472|%|I-Sample_Size_Calculation_Alpha_Value
S472|significance—a|O
S472|total|O
S472|of|O
S472|100|B-Sample_Size_Required
S472|patients|O
S472|.|O
S937|Resolution|O
S937|of|O
S937|inflammation—this|O
S937|was|O
S937|recorded|O
S937|by|O
S937|clinicians|O
S937|and|O
S937|participants|O
S937|using|O
S937|a|O
S937|scale|O
S937|reported|O
S937|by|O
S937|Foss|O
S937|.|O
S1880|For|O
S1880|strokes|O
S1880|,|O
S1880|a|O
S1880|24|O
S1880|%|O
S1880|(|O
S1880|SE|O
S1880|5|O
S1880|)|O
S1880|reduction|O
S1880|was|O
S1880|seen|O
S1880|during|O
S1880|the|O
S1880|in-trial|O
S1880|period|O
S1880|(|O
S1880|p|O
S1880|<|O
S1880|0·0001|O
S1880|)|O
S1880|,|O
S1880|reflecting|O
S1880|a|O
S1880|29|O
S1880|%|O
S1880|(|O
S1880|SE|O
S1880|6|O
S1880|)|O
S1880|reduction|O
S1880|in|O
S1880|definite|O
S1880|ischaemic|O
S1880|stroke|O
S1880|and|O
S1880|no|O
S1880|difference|O
S1880|in|O
S1880|haemorrhagic|O
S1880|stroke|O
S1880|(|O
S1880|51|O
S1880|[|O
S1880|0·5|O
S1880|%|O
S1880|]|O
S1880|vs|O
S1880|56|O
S1880|[|O
S1880|0·5|O
S1880|%|O
S1880|]|O
S1880|;|O
S1880|p=0·59|O
S1880|)|O
S1880|.|O
S325|Therefore|O
S325|a|O
S325|post|O
S325|hoc|O
S325|analysis|O
S325|using|O
S325|a|O
S325|negative|O
S325|binomial|O
S325|model|O
S325|(|O
S325|the|O
S325|model|O
S325|used|O
S325|for|O
S325|the|O
S325|primary|O
S325|outcome|O
S325|)|O
S325|was|O
S325|performed|O
S325|after|O
S325|unblinding|O
S325|at|O
S325|16|O
S325|weeks|O
S325|.|O
S1846|During|O
S1846|the|O
S1846|in-trial|O
S1846|period|O
S1846|,|O
S1846|compliance|O
S1846|with|O
S1846|study|O
S1846|treatment|O
S1846|was|O
S1846|assessed|O
S1846|at|O
S1846|each|O
S1846|follow-up|O
S1846|by|O
S1846|questioning|O
S1846|the|O
S1846|participant|O
S1846|and|O
S1846|reviewing|O
S1846|their|O
S1846|remaining|O
S1846|calendar-packed|O
S1846|tablets|O
S1846|.|O
S93|The|O
S93|rates|O
S93|for|O
S93|HZT-501|O
S93|vs.|O
S93|ibuprofen|O
S93|in|O
S93|the|O
S93|pooled|O
S93|results|O
S93|were|O
S93|4.7|O
S93|%|O
S93|vs.|O
S93|8.0|O
S93|%|O
S93|for|O
S93|dyspepsia|O
S93|and|O
S93|5.8|O
S93|%|O
S93|vs.|O
S93|4.7|O
S93|%|O
S93|for|O
S93|nausea|O
S93|.|O
S233|No|O
S233|significant|O
S233|differences|O
S233|in|O
S233|PEFam|O
S233|or|O
S233|PEFpm|O
S233|responses|O
S233|were|O
S233|observed|O
S233|between|O
S233|the|O
S233|different|O
S233|tiotropium|O
S233|Respimat®|O
S233|doses|O
S233|.|O
S41|The|O
S41|predefined|O
S41|primary|O
S41|population|O
S41|for|O
S41|analysis|O
S41|included|O
S41|all|O
S41|patients|O
S41|who|O
S41|were|O
S41|randomized|O
S41|,|O
S41|received|O
S41|a|O
S41|dose|O
S41|of|O
S41|study|O
S41|medication|O
S41|,|O
S41|and|O
S41|had|O
S41|at|O
S41|least|O
S41|one|O
S41|study-mandated|O
S41|follow-up|O
S41|endoscopy|O
S41|.|O
S801|Results|O
S801|26|B-Sample_Size_Actual_at_Enrollment
S801|patients|O
S801|hospitalised|O
S801|with|O
S801|type|O
S801|1|O
S801|acute|O
S801|non-ST|O
S801|elevation|O
S801|myocardial|O
S801|infarction|O
S801|were|O
S801|recruited|O
S801|into|O
S801|the|O
S801|study|O
S801|.|O
S465|Study|O
S465|procedures|O
S465|At|O
S465|clinic|O
S465|visits|O
S465|every|O
S465|four|O
S465|to|O
S465|six|O
S465|months|O
S465|,|O
S465|height|O
S465|was|O
S465|measured|O
S465|with|O
S465|a|O
S465|Harpenden|O
S465|stadiometer|O
S465|to|O
S465|the|O
S465|last|O
S465|completed|O
S465|1|O
S465|mm|O
S465|and|O
S465|converted|O
S465|to|O
S465|an|O
S465|SD|O
S465|score|O
S465|by|O
S465|using|O
S465|the|O
S465|British|O
S465|1990|O
S465|reference|O
S465|.|O
S1285|Non-responders|O
S1285|were|O
S1285|contacted|O
S1285|by|O
S1285|telephone|O
S1285|,|O
S1285|and|O
S1285|follow-up|O
S1285|data|O
S1285|was|O
S1285|obtained|O
S1285|by|O
S1285|telephone|O
S1285|interview|O
S1285|.|O
S1651|Categorical|O
S1651|variables|O
S1651|were|O
S1651|compared|O
S1651|with|O
S1651|χ2|O
S1651|or|O
S1651|exact|O
S1651|(|O
S1651|if|O
S1651|indicated|O
S1651|)|O
S1651|tests|O
S1651|.|O
S764|Patients|O
S764|were|O
S764|excluded|O
S764|in|O
S764|the|O
S764|event|O
S764|of|O
S764|significant|O
S764|comorbidity|O
S764|,|O
S764|including|O
S764|active|O
S764|systemic|O
S764|inflammatory|O
S764|disorders|O
S764|,|O
S764|insulin-dependent|O
S764|diabetes|O
S764|mellitus|O
S764|and|O
S764|the|O
S764|use|O
S764|of|O
S764|anti-inflammatory|O
S764|drugs|O
S764|other|O
S764|than|O
S764|aspirin|O
S764|.|O
S2219|The|O
S2219|diary|O
S2219|was|O
S2219|also|O
S2219|used|O
S2219|to|O
S2219|determine|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|who|O
S2219|had|O
S2219|no|O
S2219|nighttime|O
S2219|awakenings|O
S2219|due|O
S2219|to|O
S2219|asthma|O
S2219|symptoms|O
S2219|and|O
S2219|the|O
S2219|proportion|O
S2219|of|O
S2219|patients|O
S2219|with|O
S2219|fewer|O
S2219|than|O
S2219|2|O
S2219|days|O
S2219|of|O
S2219|SABA|O
S2219|use|O
S2219|per|O
S2219|week|O
S2219|by|O
S2219|Week|O
S2219|36|O
S2219|.|O
S471|Secondary|O
S471|outcomes|O
S471|were|O
S471|maximum|O
S471|height|O
S471|(|O
S471|that|O
S471|is|O
S471|,|O
S471|the|O
S471|most|O
S471|recently|O
S471|available|O
S471|height|O
S471|)|O
S471|,|O
S471|age|O
S471|of|O
S471|attaining|O
S471|final|O
S471|height|O
S471|,|O
S471|and|O
S471|the|O
S471|three|O
S471|summary|O
S471|growth|O
S471|parameters|O
S471|from|O
S471|the|O
S471|SITAR|O
S471|analysis|O
S471|described|O
S471|below|O
S471|.|O
S2214|Participants|O
S2214|Inclusion|O
S2214|criteria|O
S2214|Adult|O
S2214|asthma|O
S2214|patients|O
S2214|,|O
S2214|aged|O
S2214|18–75|O
S2214|years|O
S2214|,|O
S2214|were|O
S2214|required|O
S2214|to|O
S2214|have|O
S2214|:|O
S2214|bronchodilator|O
S2214|reversibility|O
S2214|of|O
S2214|either|O
S2214|≥12|O
S2214|%|O
S2214|β-agonist|O
S2214|reversibility|O
S2214|using|O
S2214|4|O
S2214|puffs|O
S2214|of|O
S2214|a|O
S2214|short-acting|O
S2214|β|O
S2214|−|O
S2214|agonist|O
S2214|(|O
S2214|SABA|O
S2214|)|O
S2214|or|O
S2214|a|O
S2214|PC20|O
S2214|FEV1|O
S2214|methacholine|O
S2214|(|O
S2214|provocative|O
S2214|concentration|O
S2214|of|O
S2214|methacholine|O
S2214|producing|O
S2214|a|O
S2214|20|O
S2214|%|O
S2214|fall|O
S2214|in|O
S2214|FEV1|O
S2214|(|O
S2214|forced|O
S2214|expiratory|O
S2214|volume|O
S2214|in|O
S2214|1|O
S2214|s|O
S2214|)|O
S2214|)|O
S2214|of|O
S2214|8|O
S2214|mg/mL|O
S2214|or|O
S2214|less|O
S2214|,|O
S2214|within|O
S2214|the|O
S2214|last|O
S2214|2|O
S2214|years|O
S2214|;|O
S2214|a|O
S2214|pre-bronchodilator|O
S2214|FEV1|O
S2214|at|O
S2214|screening|O
S2214|of|O
S2214|40–80|O
S2214|%|O
S2214|predicted|O
S2214|;|O
S2214|daily|O
S2214|use|O
S2214|of|O
S2214|ICS|O
S2214|(|O
S2214|≥400|O
S2214|μg/day|O
S2214|total|O
S2214|daily|O
S2214|dose|O
S2214|of|O
S2214|fluticasone|O
S2214|propionate|O
S2214|or|O
S2214|equivalent|O
S2214|)|O
S2214|and|O
S2214|a|O
S2214|second|O
S2214|controller|O
S2214|for|O
S2214|a|O
S2214|minimum|O
S2214|of|O
S2214|3|O
S2214|consecutive|O
S2214|months|O
S2214|;|O
S2214|inadequately-controlled|O
S2214|asthma|O
S2214|as|O
S2214|documented|O
S2214|by|O
S2214|a|O
S2214|5-item|O
S2214|Asthma|O
S2214|Control|O
S2214|Questionnaire|O
S2214|(|O
S2214|ACQ-5|O
S2214|)|O
S2214|score|O
S2214|≥1.50|O
S2214|at|O
S2214|screening|O
S2214|and|O
S2214|randomization|O
S2214|,|O
S2214|despite|O
S2214|compliance|O
S2214|with|O
S2214|asthma|O
S2214|controller|O
S2214|therapy|O
S2214|;|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|positive|O
S2214|aeroallergen-specific|O
S2214|IgE|O
S2214|(|O
S2214|≥0.35|O
S2214|kU|O
S2214|(|O
S2214|A|O
S2214|)|O
S2214|/L|O
S2214|)|O
S2214|,|O
S2214|or|O
S2214|a|O
S2214|total|O
S2214|serum|O
S2214|IgE|O
S2214|≥75|O
S2214|IU/mL|O
S2214|;|O
S2214|and|O
S2214|a|O
S2214|history|O
S2214|of|O
S2214|at|O
S2214|least|O
S2214|one|O
S2214|protocol-defined|O
S2214|asthma|O
S2214|exacerbation|O
S2214|in|O
S2214|the|O
S2214|18|O
S2214|months|O
S2214|prior|O
S2214|to|O
S2214|screening|O
S2214|.|O
S1121|The|O
S1121|figure|O
S1121|shows|O
S1121|the|O
S1121|flow|O
S1121|of|O
S1121|participants|O
S1121|through|O
S1121|the|O
S1121|trial|O
S1121|,|O
S1121|and|O
S1121|table|O
S1121|1|O
S1121|summarises|O
S1121|their|O
S1121|baseline|O
S1121|characteristics|O
S1121|.|O
S1818|During|O
S1818|the|O
S1818|combined|O
S1818|in-trial|O
S1818|and|O
S1818|post-trial|O
S1818|periods|O
S1818|,|O
S1818|no|O
S1818|significant|O
S1818|differences|O
S1818|were|O
S1818|recorded|O
S1818|in|O
S1818|cancer|O
S1818|incidence|O
S1818|at|O
S1818|all|O
S1818|sites|O
S1818|(|O
S1818|0·98|O
S1818|[|O
S1818|0·92–1·05|O
S1818|]|O
S1818|)|O
S1818|or|O
S1818|any|O
S1818|particular|O
S1818|site|O
S1818|,|O
S1818|or|O
S1818|in|O
S1818|mortality|O
S1818|attributed|O
S1818|to|O
S1818|cancer|O
S1818|(|O
S1818|1·01|O
S1818|[|O
S1818|0·92–1·11|O
S1818|]|O
S1818|)|O
S1818|or|O
S1818|to|O
S1818|non-vascular|O
S1818|causes|O
S1818|(|O
S1818|0·96|O
S1818|[|O
S1818|0·89–1·03|O
S1818|]|O
S1818|)|O
S1818|.|O
S810|Following|O
S810|etanercept|O
S810|infusion|O
S810|,|O
S810|there|O
S810|was|O
S810|a|O
S810|50|O
S810|%|O
S810|relative|O
S810|increase|O
S810|in|O
S810|PMA|O
S810|(|O
S810|30±5|O
S810|vs|O
S810|20±3|O
S810|%|O
S810|;|O
S810|p=0.02|O
S810|)|O
S810|compared|O
S810|with|O
S810|baseline|O
S810|.|O
S215|To|O
S215|detect|O
S215|a|O
S215|treatment|O
S215|difference|O
S215|of|O
S215|80|O
S215|mL|O
S215|for|O
S215|peak|O
S215|FEV1|O
S215|(|O
S215|0-3h|O
S215|)|O
S215|with|O
S215|90|B-Sample_Size_Calculation_Power_Value
S215|%|I-Sample_Size_Calculation_Power_Value
S215|power|O
S215|,|O
S215|and|O
S215|assuming|O
S215|a|O
S215|standard|O
S215|deviation|O
S215|of|O
S215|228|O
S215|mL|O
S215|,|O
S215|it|O
S215|was|O
S215|calculated|O
S215|that|O
S215|88|B-Sample_Size_Required
S215|completed|O
S215|patients|O
S215|were|O
S215|required|O
S215|.|O
S88|Baseline|O
S88|erosions|O
S88|did|O
S88|not|O
S88|show|O
S88|a|O
S88|significant|O
S88|association|O
S88|with|O
S88|upper|O
S88|GI|O
S88|ulcer|O
S88|formation|O
S88|(|O
S88|initial|O
S88|:|O
S88|1.20|O
S88|,|O
S88|0.86–1.67|O
S88|;|O
S88|post-adjudication|O
S88|:|O
S88|1.15|O
S88|,|O
S88|0.82–1.62|O
S88|)|O
S88|.|O
S1592|Analysis|O
S1592|was|O
S1592|by|O
S1592|intention|O
S1592|to|O
S1592|treat|O
S1592|.|O
S476|We|O
S476|also|O
S476|adjusted|O
S476|randomisation|O
S476|2|O
S476|(|O
S476|timing|O
S476|of|O
S476|pubertal|O
S476|induction|O
S476|)|O
S476|for|O
S476|randomisation|O
S476|1|O
S476|(|O
S476|oxandrolone|O
S476|)|O
S476|and|O
S476|tested|O
S476|for|O
S476|an|O
S476|interaction|O
S476|.|O
S658|DU|O
S658|healing|O
S658|No|O
S658|treatment|O
S658|effects|O
S658|were|O
S658|observed|O
S658|in|O
S658|the|O
S658|times|O
S658|to|O
S658|healing|O
S658|up|O
S658|to|O
S658|week|O
S658|24|O
S658|for|O
S658|all|O
S658|baseline|O
S658|DUs|O
S658|(|O
S658|HR|O
S658|0.94|O
S658|(|O
S658|95|O
S658|%|O
S658|CI|O
S658|0.65|O
S658|to|O
S658|1.37|O
S658|)|O
S658|,|O
S658|p=0.74|O
S658|)|O
S658|or|O
S658|of|O
S658|all|O
S658|new|O
S658|DUs|O
S658|(|O
S658|HR|O
S658|1.40|O
S658|(|O
S658|0.78|O
S658|to|O
S658|2.51|O
S658|)|O
S658|,|O
S658|p=0.26|O
S658|)|O
S658|.|O
S2273|Peripheral|O
S2273|blood|O
S2273|eosinophils|O
S2273|and|O
S2273|FeNO|O
S2273|levels|O
S2273|were|O
S2273|not|O
S2273|modified|O
S2273|following|O
S2273|quilizumab|O
S2273|treatment|O
S2273|(|O
S2273|see|O
S2273|Additional|O
S2273|file|O
S2273|1|O
S2273|:|O
S2273|Figure|O
S2273|S3|O
S2273|)|O
S2273|.|O
S1682|No|O
S1682|child|O
S1682|switched|O
S1682|to|O
S1682|second-line|O
S1682|treatment|O
S1682|during|O
S1682|their|O
S1682|first|O
S1682|year|O
S1682|on|O
S1682|ART|O
S1682|.|O
S1141|Hence|O
S1141|all|O
S1141|hazard|O
S1141|ratios|O
S1141|were|O
S1141|assumed|O
S1141|constant|O
S1141|during|O
S1141|the|O
S1141|follow-up|O
S1141|period|O
S1141|.|O
S980|Secondary|O
S980|outcomes|O
S980|Time|O
S980|to|O
S980|healing|O
S980|At|O
S980|six|O
S980|weeks|O
S980|,|O
S980|ulcers|O
S980|had|O
S980|healed|O
S980|in|O
S980|nine|O
S980|(|O
S980|15|O
S980|%|O
S980|)|O
S980|participants|O
S980|in|O
S980|the|O
S980|ciclosporin|O
S980|group|O
S980|and|O
S980|11|O
S980|(|O
S980|21|O
S980|%|O
S980|)|O
S980|in|O
S980|the|O
S980|prednisolone|O
S980|group|O
S980|.|O
S290|Eligible|O
S290|patients|O
S290|were|O
S290|subsequently|O
S290|randomised|B-Randomization_Type_Simple
S290|1:1:1:1:1:1:2|B-Randomization_Ratio
S290|to|O
S290|receive|O
S290|a|B-Design_Parallel_Group
S290|single|I-Design_Parallel_Group
S290|dose|I-Design_Parallel_Group
S290|of|I-Design_Parallel_Group
S290|canakinumab|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|25|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|50|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|100|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|200|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|or|I-Design_Parallel_Group
S290|300|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|on|I-Design_Parallel_Group
S290|day|I-Design_Parallel_Group
S290|1|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|or|I-Design_Parallel_Group
S290|four|I-Design_Parallel_Group
S290|canakinumab|I-Design_Parallel_Group
S290|doses|I-Design_Parallel_Group
S290|administered|I-Design_Parallel_Group
S290|at|I-Design_Parallel_Group
S290|4-weekly|I-Design_Parallel_Group
S290|intervals|I-Design_Parallel_Group
S290|(|I-Design_Parallel_Group
S290|50|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|on|I-Design_Parallel_Group
S290|day|I-Design_Parallel_Group
S290|1|I-Design_Parallel_Group
S290|and|I-Design_Parallel_Group
S290|at|I-Design_Parallel_Group
S290|week|I-Design_Parallel_Group
S290|4|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|and|I-Design_Parallel_Group
S290|25|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|at|I-Design_Parallel_Group
S290|weeks|I-Design_Parallel_Group
S290|8|I-Design_Parallel_Group
S290|and|I-Design_Parallel_Group
S290|12|I-Design_Parallel_Group
S290|)|I-Design_Parallel_Group
S290|,|I-Design_Parallel_Group
S290|or|I-Design_Parallel_Group
S290|daily|I-Design_Parallel_Group
S290|oral|I-Design_Parallel_Group
S290|doses|I-Design_Parallel_Group
S290|of|I-Design_Parallel_Group
S290|colchicine|I-Design_Parallel_Group
S290|0.5|I-Design_Parallel_Group
S290|mg|I-Design_Parallel_Group
S290|given|I-Design_Parallel_Group
S290|for|I-Design_Parallel_Group
S290|16|I-Design_Parallel_Group
S290|weeks|I-Design_Parallel_Group
S290|.|O
S1821|These|O
S1821|findings|O
S1821|provide|O
S1821|further|O
S1821|support|O
S1821|for|O
S1821|the|O
S1821|prompt|O
S1821|initiation|O
S1821|and|O
S1821|long-term|O
S1821|continuation|O
S1821|of|O
S1821|statin|O
S1821|treatment|O
S1821|.|O
S926|Digital|O
S926|image|O
S926|assessments|O
S926|A|O
S926|template|O
S926|was|O
S926|photographed|O
S926|alongside|O
S926|the|O
S926|target|O
S926|ulcer|O
S926|to|O
S926|calibrate|O
S926|the|O
S926|image|O
S926|in|O
S926|the|O
S926|image|O
S926|analysis|O
S926|software|O
S926|(|O
S926|see|O
S926|supplementary|O
S926|figure|O
S926|)|O
S926|.|O
S453|Girls|O
S453|with|O
S453|other|O
S453|karyotypes|O
S453|were|O
S453|tested|O
S453|for|O
S453|concentrations|O
S453|of|O
S453|gonadotrophin|O
S453|releasing|O
S453|hormone|O
S453|and|O
S453|were|O
S453|randomised|O
S453|at|O
S453|randomisation|O
S453|2|O
S453|if|O
S453|the|O
S453|peak|O
S453|follicle|O
S453|stimulating|O
S453|hormone|O
S453|concentration|O
S453|was|O
S453|above|O
S453|30|O
S453|U/L|O
S453|.|O
S1247|We|O
S1247|have|O
S1247|published|O
S1247|reports|O
S1247|of|O
S1247|the|O
S1247|rationale|O
S1247|for|O
S1247|the|O
S1247|trial|O
S1247|,|O
S1247|the|O
S1247|protocol|O
S1247|,|O
S1247|an|O
S1247|update|O
S1247|on|O
S1247|recruitment|O
S1247|,|O
S1247|amendments|O
S1247|to|O
S1247|the|O
S1247|protocol|O
S1247|and|O
S1247|the|O
S1247|baseline|O
S1247|characteristics|O
S1247|of|O
S1247|the|O
S1247|patients|O
S1247|recruited|O
S1247|,|O
S1247|and|O
S1247|the|O
S1247|statistical|O
S1247|analysis|O
S1247|plan|O
S1247|.|O
S1142|Satisfaction|O
S1142|with|O
S1142|treatment|O
S1142|Patients|O
S1142|were|O
S1142|asked|O
S1142|to|O
S1142|rate|O
S1142|their|O
S1142|satisfaction|O
S1142|with|O
S1142|their|O
S1142|treatment|O
S1142|on|O
S1142|a|O
S1142|five|O
S1142|point|O
S1142|scale|O
S1142|from|O
S1142|“|O
S1142|very|O
S1142|happy|O
S1142|”|O
S1142|to|O
S1142|“|O
S1142|very|O
S1142|unhappy|O
S1142|”|O
S1142|on|O
S1142|a|O
S1142|postal|O
S1142|or|O
S1142|web|O
S1142|based|O
S1142|questionnaire|O
S1142|at|O
S1142|one|O
S1142|,|O
S1142|three|O
S1142|,|O
S1142|and|O
S1142|12|O
S1142|weeks|O
S1142|(|O
S1142|see|O
S1142|table|O
S1142|5|O
S1142|)|O
S1142|.|O
S2237|Serum|O
S2237|periostin|O
S2237|was|O
S2237|measured|O
S2237|by|O
S2237|immunoassay|O
S2237|using|O
S2237|the|O
S2237|Roche|O
S2237|Elecsys|O
S2237|platform|O
S2237|(|O
S2237|Roche|O
S2237|Diagnostics|O
S2237|Ltd.|O
S2237|,|O
S2237|Rotkreuz|O
S2237|,|O
S2237|Switzerland|O
S2237|)|O
S2237|.|O
S1998|p|O
S1998|Values|O
S1998|less|O
S1998|than|O
S1998|0.05|O
S1998|were|O
S1998|considered|O
S1998|significant|O
S1998|.|O
S1151|The|O
S1151|remaining|O
S1151|27|O
S1151|were|O
S1151|assessed|O
S1151|as|O
S1151|non-serious|O
S1151|,|O
S1151|13|O
S1151|of|O
S1151|which|O
S1151|were|O
S1151|in|O
S1151|the|O
S1151|salicylic|O
S1151|acid|O
S1151|group|O
S1151|and|O
S1151|14|O
S1151|in|O
S1151|the|O
S1151|cryotherapy|O
S1151|group|O
S1151|.|O
S1042|Interventions|O
S1042|Cryotherapy|O
S1042|with|O
S1042|liquid|O
S1042|nitrogen|O
S1042|delivered|O
S1042|by|O
S1042|a|O
S1042|healthcare|O
S1042|professional|O
S1042|,|O
S1042|up|O
S1042|to|O
S1042|four|O
S1042|treatments|O
S1042|two|O
S1042|to|O
S1042|three|O
S1042|weeks|O
S1042|apart|O
S1042|.|O
S1266|Additionally|O
S1266|,|O
S1266|all|O
S1266|centres|O
S1266|were|O
S1266|asked|O
S1266|for|O
S1266|their|O
S1266|pretrial|O
S1266|experience|O
S1266|of|O
S1266|thrombolysis|O
S1266|for|O
S1266|treatment|O
S1266|of|O
S1266|stroke|O
S1266|,|O
S1266|and|O
S1266|if|O
S1266|the|O
S1266|centre|O
S1266|had|O
S1266|,|O
S1266|before|O
S1266|joining|O
S1266|the|O
S1266|trial|O
S1266|,|O
S1266|a|O
S1266|protocol|O
S1266|for|O
S1266|open-label|O
S1266|use|O
S1266|of|O
S1266|rt-PA|O
S1266|and|O
S1266|had|O
S1266|treated|O
S1266|at|O
S1266|least|O
S1266|three|O
S1266|people|O
S1266|in|O
S1266|the|O
S1266|12|O
S1266|months|O
S1266|before|O
S1266|joining|O
S1266|the|O
S1266|trial|O
S1266|,|O
S1266|the|O
S1266|centre|O
S1266|was|O
S1266|classed|O
S1266|as|O
S1266|experienced|O
S1266|.|O
S1289|All|O
S1289|follow-up|O
S1289|done|O
S1289|by|O
S1289|patient|O
S1289|contact|O
S1289|for|O
S1289|these|O
S1289|analyses|O
S1289|ceased|O
S1289|on|O
S1289|March|O
S1289|31|O
S1289|,|O
S1289|2012|O
S1289|,|O
S1289|but|O
S1289|recording|O
S1289|of|O
S1289|deaths|O
S1289|from|O
S1289|national|O
S1289|registries|O
S1289|of|O
S1289|deaths|O
S1289|continues|O
S1289|in|O
S1289|UK|O
S1289|,|O
S1289|Norway|O
S1289|,|O
S1289|and|O
S1289|Sweden|O
S1289|.|O
S654|The|O
S654|maximum|O
S654|number|O
S654|of|O
S654|new|O
S654|DUs|O
S654|per|O
S654|patient|O
S654|was|O
S654|10|O
S654|on|O
S654|bosentan|O
S654|and|O
S654|16|O
S654|on|O
S654|placebo|O
S654|.|O
S34|The|O
S34|study|O
S34|medication|O
S34|was|O
S34|dispensed|O
S34|in|O
S34|an|O
S34|8-week|O
S34|supply|O
S34|at|O
S34|0|O
S34|,|O
S34|8|O
S34|,|O
S34|and|O
S34|16|O
S34|weeks|O
S34|.|O
S197|Study|O
S197|end|O
S197|points|O
S197|All|O
S197|end|O
S197|points|O
S197|were|O
S197|determined|O
S197|at|O
S197|the|O
S197|end|O
S197|of|O
S197|each|O
S197|4-week|O
S197|treatment|O
S197|period|O
S197|(|O
S197|Visits|O
S197|3–6|O
S197|)|O
S197|and|O
S197|analysed|O
S197|as|O
S197|a|O
S197|response|O
S197|defined|O
S197|as|O
S197|change|O
S197|from|O
S197|study|O
S197|baseline|O
S197|(|O
S197|pre-treatment|O
S197|value|O
S197|measured|O
S197|at|O
S197|Visit|O
S197|2|O
S197|in|O
S197|the|O
S197|evening|O
S197|)|O
S197|.|O
S2106|The|O
S2106|main|O
S2106|exclusion|O
S2106|criterion|O
S2106|was|O
S2106|the|O
S2106|presence|O
S2106|of|O
S2106|axial|O
S2106|disorders|O
S2106|related|O
S2106|to|O
S2106|insufficient|O
S2106|doses|O
S2106|of|O
S2106|L-dopa|O
S2106|or|O
S2106|off-periods|O
S2106|of|O
S2106|motor|O
S2106|fluctuation|O
S2106|or|O
S2106|those|O
S2106|induced|O
S2106|by|O
S2106|STN|O
S2106|stimulation|O
S2106|.|O
S2244|For|O
S2244|biomarker|O
S2244|subgroup|O
S2244|analyses|O
S2244|,|O
S2244|unadjusted|O
S2244|asthma|O
S2244|exacerbation|O
S2244|rates|O
S2244|were|O
S2244|calculated|O
S2244|.|O
S1707|49|O
S1707|(|O
S1707|9|O
S1707|%|O
S1707|)|O
S1707|children|O
S1707|on|O
S1707|clinically|O
S1707|driven|O
S1707|monitoring|O
S1707|versus|O
S1707|29|O
S1707|(|O
S1707|5|O
S1707|%|O
S1707|)|O
S1707|on|O
S1707|routine|O
S1707|laboratory|O
S1707|monitoring|O
S1707|had|O
S1707|weight-for-age|O
S1707|Z|O
S1707|score|O
S1707|less|O
S1707|than|O
S1707|−3|O
S1707|(|O
S1707|approximate|O
S1707|one|O
S1707|thousandth|O
S1707|percentile|O
S1707|of|O
S1707|normal|O
S1707|UK|O
S1707|weight|O
S1707|)|O
S1707|at|O
S1707|last|O
S1707|visit|O
S1707|(|O
S1707|global|O
S1707|p=0·12|O
S1707|)|O
S1707|.|O
S1245|The|O
S1245|initial|O
S1245|pilot|O
S1245|phase|O
S1245|was|O
S1245|double-blinded|B-Blinding_Double_Blind
S1245|and|O
S1245|placebo-controlled|O
S1245|.|O
S2024|The|O
S2024|incremental|O
S2024|increase|O
S2024|in|O
S2024|the|O
S2024|distal|O
S2024|forearm|O
S2024|bone|O
S2024|mineral|O
S2024|content|O
S2024|in|O
S2024|the|O
S2024|Ca|O
S2024|group|O
S2024|(|O
S2024|least|O
S2024|squares|O
S2024|mean|O
S2024|increase|O
S2024|0.093|O
S2024|g|O
S2024|)|O
S2024|was|O
S2024|nearly|O
S2024|twice|O
S2024|that|O
S2024|of|O
S2024|the|O
S2024|Ca+D|O
S2024|group|O
S2024|(|O
S2024|least|O
S2024|squares|O
S2024|mean|O
S2024|increase|O
S2024|0.053|O
S2024|g|O
S2024|;|O
S2024|p=0.02|O
S2024|)|O
S2024|in|O
S2024|a|O
S2024|model|O
S2024|adjusting|O
S2024|for|O
S2024|baseline|O
S2024|bone|O
S2024|mineral|O
S2024|content|O
S2024|and|O
S2024|height|O
S2024|.|O
S49|However|O
S49|,|O
S49|the|O
S49|FDA|O
S49|generally|O
S49|has|O
S49|approved|O
S49|antisecretory|O
S49|medications|O
S49|for|O
S49|prevention|O
S49|of|O
S49|gastric|O
S49|ulcers|O
S49|(|O
S49|e.g.|O
S49|,|O
S49|lansoprazole|O
S49|and|O
S49|esomeprazole|O
S49|)|O
S49|.|O
S1478|Primary|O
S1478|virological|O
S1478|efficacy|O
S1478|endpoint|O
S1478|Day|O
S1478|five|O
S1478|negative|O
S1478|viral|O
S1478|RNA|O
S1478|by|O
S1478|RT-PCR|O
S1478|At|O
S1478|day|O
S1478|five|O
S1478|,|O
S1478|the|O
S1478|proportions|O
S1478|of|O
S1478|all|O
S1478|patients|O
S1478|negative|O
S1478|for|O
S1478|viral|O
S1478|RNA|O
S1478|in|O
S1478|the|O
S1478|nasal|O
S1478|and|O
S1478|throat|O
S1478|swabs|O
S1478|were|O
S1478|similar|O
S1478|between|O
S1478|the|O
S1478|double|O
S1478|(|O
S1478|115/159|O
S1478|;|O
S1478|72.3|O
S1478|%|O
S1478|,|O
S1478|95|O
S1478|%|O
S1478|confidence|O
S1478|interval|O
S1478|64.9|O
S1478|%|O
S1478|to|O
S1478|78.7|O
S1478|%|O
S1478|)|O
S1478|and|O
S1478|standard|O
S1478|dose|O
S1478|arms|O
S1478|(|O
S1478|105/154|O
S1478|;|O
S1478|68.2|O
S1478|%|O
S1478|,|O
S1478|60.5|O
S1478|%|O
S1478|to|O
S1478|75.0|O
S1478|%|O
S1478|)|O
S1478|,|O
S1478|with|O
S1478|a|O
S1478|difference|O
S1478|of|O
S1478|4.2|O
S1478|%|O
S1478|(|O
S1478|−5.9|O
S1478|%|O
S1478|to|O
S1478|14.2|O
S1478|%|O
S1478|;|O
S1478|P=0.42|O
S1478|)|O
S1478|.|O
S200|Control|O
S200|of|O
S200|asthma|O
S200|,|O
S200|as|O
S200|assessed|O
S200|by|O
S200|ACQ-7|O
S200|self-administered|O
S200|at|O
S200|the|O
S200|end|O
S200|of|O
S200|each|O
S200|4-week|O
S200|treatment|O
S200|period|O
S200|,|O
S200|was|O
S200|an|O
S200|additional|O
S200|exploratory|O
S200|end|O
S200|point|O
S200|.|O
S300|Safety|O
S300|assessments|O
S300|were|O
S300|performed|O
S300|at|O
S300|scheduled|O
S300|visits|O
S300|(|O
S300|2|O
S300|,|O
S300|4|O
S300|,|O
S300|8|O
S300|,|O
S300|12|O
S300|,|O
S300|16|O
S300|,|O
S300|20|O
S300|and|O
S300|24|O
S300|weeks|O
S300|)|O
S300|and|O
S300|included|O
S300|collection|O
S300|of|O
S300|blood|O
S300|samples|O
S300|for|O
S300|assessment|O
S300|of|O
S300|the|O
S300|inflammatory|O
S300|marker|O
S300|,|O
S300|C|O
S300|reactive|O
S300|protein|O
S300|(|O
S300|CRP|O
S300|)|O
S300|,|O
S300|haematology|O
S300|and|O
S300|immunogenicity|O
S300|(|O
S300|at|O
S300|baseline|O
S300|and|O
S300|weeks|O
S300|8|O
S300|,|O
S300|16|O
S300|and|O
S300|24|O
S300|)|O
S300|and|O
S300|doctor|O
S300|'s|O
S300|assessments|O
S300|of|O
S300|local|O
S300|tolerability|O
S300|at|O
S300|sites|O
S300|of|O
S300|subcutaneous|O
S300|injections|O
S300|.|O
S903|During|O
S903|the|O
S903|trial|O
S903|,|O
S903|a|O
S903|patient|O
S903|joined|O
S903|the|O
S903|independent|O
S903|trial|O
S903|steering|O
S903|committee|O
S903|.|O
S1990|Statistical|O
S1990|analysis|O
S1990|The|O
S1990|primary|O
S1990|outcome|O
S1990|was|O
S1990|the|O
S1990|combined|O
S1990|attainment|O
S1990|of|O
S1990|a|O
S1990|radiographic|O
S1990|score|O
S1990|of|O
S1990|1.5|O
S1990|or|O
S1990|less|O
S1990|and|O
S1990|a|O
S1990|serum|O
S1990|alkaline|O
S1990|phosphatase|O
S1990|concentration|O
S1990|of|O
S1990|350|O
S1990|U/L|O
S1990|or|O
S1990|less|O
S1990|.|O
S1036|Cryotherapy|O
S1036|versus|O
S1036|salicylic|O
S1036|acid|O
S1036|for|O
S1036|the|O
S1036|treatment|O
S1036|of|O
S1036|plantar|O
S1036|warts|O
S1036|(|O
S1036|verrucae|O
S1036|)|O
S1036|:|O
S1036|a|O
S1036|randomised|B-Randomization_Type_Simple
S1036|controlled|O
S1036|trial|O
S2178|Results|O
S2178|Quilizumab|O
S2178|was|O
S2178|well|O
S2178|tolerated|O
S2178|and|O
S2178|reduced|O
S2178|serum|O
S2178|total|O
S2178|and|O
S2178|allergen-specific|O
S2178|IgE|O
S2178|by|O
S2178|30–40|O
S2178|%|O
S2178|,|O
S2178|but|O
S2178|had|O
S2178|no|O
S2178|impact|O
S2178|on|O
S2178|asthma|O
S2178|exacerbations|O
S2178|,|O
S2178|lung|O
S2178|function|O
S2178|,|O
S2178|or|O
S2178|patient-reported|O
S2178|symptom|O
S2178|measures|O
S2178|.|O
S301|Adverse|O
S301|events|O
S301|(|O
S301|AEs|O
S301|)|O
S301|were|O
S301|reported|O
S301|throughout|O
S301|the|O
S301|study|O
S301|.|O
S929|Outcomes|O
S929|Primary|O
S929|outcome|O
S929|The|O
S929|main|O
S929|outcome|O
S929|measure|O
S929|was|O
S929|speed|O
S929|of|O
S929|healing|O
S929|over|O
S929|six|O
S929|weeks|O
S929|,|O
S929|captured|O
S929|for|O
S929|a|O
S929|single|O
S929|target|O
S929|lesion|O
S929|for|O
S929|each|O
S929|patient|O
S929|.|O
S902|During|O
S902|the|O
S902|feasibility|O
S902|stage|O
S902|,|O
S902|priority|O
S902|of|O
S902|the|O
S902|research|O
S902|question|O
S902|,|O
S902|choice|O
S902|of|O
S902|outcome|O
S902|measures|O
S902|,|O
S902|and|O
S902|methods|O
S902|of|O
S902|recruitment|O
S902|were|O
S902|informed|O
S902|by|O
S902|discussions|O
S902|with|O
S902|patients|O
S902|through|O
S902|a|O
S902|focus|O
S902|group|O
S902|session|O
S902|and|O
S902|two|O
S902|structured|O
S902|interviews|O
S902|.|O
S2263|There|O
S2263|was|O
S2263|no|O
S2263|apparent|O
S2263|impact|O
S2263|of|O
S2263|positive|O
S2263|ATA|O
S2263|results|O
S2263|on|O
S2263|either|O
S2263|pharmacokinetic|O
S2263|profiles|O
S2263|or|O
S2263|safety|O
S2263|.|O
S1462|For|O
S1462|all|O
S1462|comparative|O
S1462|analyses|O
S1462|,|O
S1462|P|O
S1462|<|O
S1462|0.05|O
S1462|was|O
S1462|considered|O
S1462|significant|O
S1462|.|O
S2187|Some|O
S2187|patients|O
S2187|have|O
S2187|persistent|O
S2187|symptoms|O
S2187|despite|O
S2187|the|O
S2187|use|O
S2187|of|O
S2187|steroids|O
S2187|and|O
S2187|other|O
S2187|therapies|O
S2187|.|O
S741|Vasodilatation|O
S741|in|O
S741|response|O
S741|to|O
S741|substance|O
S741|P|O
S741|,|O
S741|acetylcholine|O
S741|and|O
S741|sodium|O
S741|nitroprusside|O
S741|,|O
S741|and|O
S741|acute|O
S741|tissue|O
S741|plasminogen|O
S741|activator|O
S741|release|O
S741|were|O
S741|unaffected|O
S741|by|O
S741|either|O
S741|treatment|O
S741|(|O
S741|p|O
S741|>|O
S741|0.1|O
S741|for|O
S741|all|O
S741|)|O
S741|.|O
S235|Serious|O
S235|adverse|O
S235|events|O
S235|were|O
S235|reported|O
S235|for|O
S235|two|O
S235|patients|O
S235|(|O
S235|in|O
S235|the|O
S235|tiotropium|O
S235|Respimat®|O
S235|5|O
S235|μg|O
S235|group|O
S235|)|O
S235|.|O
S1900|The|O
S1900|incidence|O
S1900|of|O
S1900|genitourinary|O
S1900|,|O
S1900|gastrointestinal|O
S1900|,|O
S1900|respiratory|O
S1900|,|O
S1900|haematological|O
S1900|,|O
S1900|or|O
S1900|any|O
S1900|other|O
S1900|malignant|O
S1900|disease|O
S1900|did|O
S1900|not|O
S1900|differ|O
S1900|significantly|O
S1900|(|O
S1900|figure|O
S1900|6|O
S1900|)|O
S1900|,|O
S1900|even|O
S1900|in|O
S1900|patients|O
S1900|aged|O
S1900|70|O
S1900|years|O
S1900|or|O
S1900|older|O
S1900|at|O
S1900|baseline|O
S1900|or|O
S1900|with|O
S1900|below-average|O
S1900|pretreatment|O
S1900|cholesterol|O
S1900|concentrations|O
S1900|(|O
S1900|webappendix|O
S1900|,|O
S1900|p|O
S1900|7|O
S1900|)|O
S1900|.|O
S1616|A|O
S1616|key|O
S1616|advantage|O
S1616|might|O
S1616|be|O
S1616|more|O
S1616|rapid|O
S1616|reduction|O
S1616|of|O
S1616|high|O
S1616|viral|O
S1616|loads|O
S1616|in|O
S1616|ART-naive|O
S1616|children|O
S1616|,|O
S1616|which|O
S1616|could|O
S1616|have|O
S1616|long-term|O
S1616|benefits|O
S1616|.|O
S14|Ibuprofen|O
S14|is|O
S14|the|O
S14|most|O
S14|commonly|O
S14|used|O
S14|non-aspirin|O
S14|NSAID|O
S14|,|O
S14|with|O
S14|about|O
S14|one|O
S14|quarter|O
S14|of|O
S14|the|O
S14|US|O
S14|population|O
S14|aged|O
S14|17|O
S14|years|O
S14|or|O
S14|older|O
S14|reporting|O
S14|ibuprofen|O
S14|intake|O
S14|in|O
S14|the|O
S14|past|O
S14|month|O
S14|.|O
S670|These|O
S670|adverse|O
S670|events|O
S670|resulted|O
S670|in|O
S670|premature|O
S670|discontinuation|O
S670|of|O
S670|bosentan|O
S670|treatment|O
S670|in|O
S670|2.1|O
S670|%|O
S670|and|O
S670|5.2|O
S670|%|O
S670|of|O
S670|patients|O
S670|,|O
S670|respectively|O
S670|(|O
S670|vs|O
S670|none|O
S670|on|O
S670|placebo|O
S670|)|O
S670|.|O
S1991|All|O
S1991|radiographs|O
S1991|were|O
S1991|scored|O
S1991|independently|O
S1991|by|O
S1991|two|O
S1991|of|O
S1991|the|O
S1991|authors|O
S1991|(|O
S1991|TDT|O
S1991|and|O
S1991|PRF|O
S1991|)|O
S1991|and|O
S1991|the|O
S1991|mean|O
S1991|score|O
S1991|was|O
S1991|used|O
S1991|for|O
S1991|analysis|O
S1991|.|O
S415|Setting|O
S415|36|B-Settings_Multicenter
S415|paediatric|I-Settings_Multicenter
S415|endocrinology|I-Settings_Multicenter
S415|departments|I-Settings_Multicenter
S415|in|O
S415|UK|B-Settings_Location
S415|hospitals|O
S415|.|O
S60|A|O
S60|post|O
S60|hoc|O
S60|fixed|O
S60|effect|O
S60|meta-analysis|O
S60|of|O
S60|the|O
S60|results|O
S60|of|O
S60|the|O
S60|two|O
S60|studies|O
S60|for|O
S60|end|O
S60|points|O
S60|of|O
S60|upper|O
S60|GI|O
S60|,|O
S60|gastric|O
S60|,|O
S60|and|O
S60|duodenal|O
S60|ulcers|O
S60|was|O
S60|also|O
S60|performed|O
S60|(|O
S60|Review|O
S60|Manager|O
S60|5.1|O
S60|,|O
S60|Cochrane|O
S60|Collaboration|O
S60|,|O
S60|Copenhagen|O
S60|,|O
S60|Denmark|O
S60|)|O
S60|.|O
S765|Given|O
S765|the|O
S765|immunosuppressive|O
S765|effects|O
S765|of|O
S765|etanercept|O
S765|,|O
S765|exclusion|O
S765|criteria|O
S765|also|O
S765|included|O
S765|any|O
S765|history|O
S765|of|O
S765|recent|O
S765|or|O
S765|recurrent|O
S765|infection|O
S765|,|O
S765|tuberculosis|O
S765|or|O
S765|any|O
S765|opportunistic|O
S765|infection|O
S765|within|O
S765|the|O
S765|previous|O
S765|6|O
S765|months|O
S765|.|O
S461|White|O
S461|,|O
S461|uncoated|O
S461|,|O
S461|flat|O
S461|bevelled|O
S461|edge|O
S461|placebo|O
S461|tablets|O
S461|(|O
S461|7|O
S461|and|O
S461|5|O
S461|mm|O
S461|in|O
S461|diameter|O
S461|)|O
S461|(|O
S461|Essential|O
S461|Nutrition|O
S461|,|O
S461|Brough|O
S461|,|O
S461|UK|O
S461|)|O
S461|were|O
S461|specially|O
S461|manufactured|O
S461|to|O
S461|match|O
S461|the|O
S461|size|O
S461|,|O
S461|weight|O
S461|,|O
S461|and|O
S461|appearance|O
S461|of|O
S461|oxandrolone|O
S461|2.5|O
S461|mg|O
S461|and|O
S461|ethinylestradiol|O
S461|2|O
S461|µg|O
S461|tablets|O
S461|respectively|O
S461|.|O
S1664|One|O
S1664|was|O
S1664|randomly|O
S1664|assigned|O
S1664|twice|O
S1664|at|O
S1664|different|O
S1664|centres|O
S1664|(|O
S1664|second|O
S1664|randomisation|O
S1664|was|O
S1664|excluded|O
S1664|)|O
S1664|,|O
S1664|and|O
S1664|three|O
S1664|had|O
S1664|major|O
S1664|eligibility|O
S1664|violations|O
S1664|,|O
S1664|leaving|O
S1664|600|O
S1664|children|O
S1664|assigned|O
S1664|to|O
S1664|routine|O
S1664|laboratory|O
S1664|and|O
S1664|606|O
S1664|to|O
S1664|clinically|O
S1664|driven|O
S1664|monitoring|O
S1664|,|O
S1664|and|O
S1664|397|O
S1664|to|O
S1664|group|O
S1664|A|O
S1664|,|O
S1664|404|O
S1664|to|O
S1664|group|O
S1664|B|O
S1664|,|O
S1664|and|O
S1664|405|O
S1664|to|O
S1664|group|O
S1664|C|O
S1664|(|O
S1664|figure|O
S1664|1|O
S1664|)|O
S1664|.|O
S1808|Effects|O
S1808|on|O
S1808|11-year|O
S1808|mortality|O
S1808|and|O
S1808|morbidity|O
S1808|of|O
S1808|lowering|O
S1808|LDL|O
S1808|cholesterol|O
S1808|with|O
S1808|simvastatin|O
S1808|for|O
S1808|about|O
S1808|5|O
S1808|years|O
S1808|in|O
S1808|20|O
S1808|536|O
S1808|high-risk|O
S1808|individuals|O
S1808|:|O
S1808|a|O
S1808|randomised|O
S1808|controlled|O
S1808|trial|O
S448|All|O
S448|participants|O
S448|’|O
S448|parents|O
S448|gave|O
S448|written|O
S448|informed|O
S448|consent|O
S448|.|O
S286|Methods|O
S286|Study|O
S286|design|O
S286|This|O
S286|was|O
S286|a|O
S286|24-week|O
S286|,|O
S286|dose-ranging|O
S286|,|O
S286|multicentre|B-Settings_Multicenter
S286|,|O
S286|double-blind|B-Blinding_Double_Blind
S286|,|O
S286|double-dummy|O
S286|,|O
S286|active-controlled|O
S286|study|O
S286|and|O
S286|was|O
S286|approved|O
S286|by|O
S286|all|O
S286|responsible|O
S286|independent|O
S286|ethics|O
S286|committees|O
S286|.|O
S426|Oxandrolone|O
S426|could|O
S426|,|O
S426|therefore|O
S426|,|O
S426|be|O
S426|offered|O
S426|as|O
S426|an|O
S426|alternative|O
S426|to|O
S426|late|O
S426|pubertal|O
S426|induction|O
S426|for|O
S426|increasing|O
S426|final|O
S426|height|O
S426|in|O
S426|Turner|O
S426|’|O
S426|s|O
S426|syndrome|O
S426|.|O
S797|Continuous|O
S797|variables|O
S797|are|O
S797|reported|O
S797|as|O
S797|means±SEM|O
S797|.|O
S2251|Sample|O
S2251|size|O
S2251|determination|O
S2251|We|O
S2251|planned|O
S2251|to|O
S2251|randomize|O
S2251|560|B-Sample_Size_Required
S2251|patients|O
S2251|to|O
S2251|one|O
S2251|of|O
S2251|three|O
S2251|dose|I-Design_Parallel_Group
S2251|regimens|I-Design_Parallel_Group
S2251|of|I-Design_Parallel_Group
S2251|quilizumab|I-Design_Parallel_Group
S2251|or|I-Design_Parallel_Group
S2251|placebo|I-Design_Parallel_Group
S2251|in|O
S2251|a|O
S2251|1:1:1:1|B-Randomization_Ratio
S2251|ratio|O
S2251|(|O
S2251|140|O
S2251|patients|O
S2251|per|O
S2251|group|O
S2251|)|O
S2251|.|O
S636|Treatment|O
S636|effects|O
S636|for|O
S636|the|O
S636|primary|O
S636|end|O
S636|points|O
S636|were|O
S636|evaluated|O
S636|using|O
S636|the|O
S636|Pitman|O
S636|permutation|O
S636|(|O
S636|new|O
S636|DUs|O
S636|)|O
S636|and|O
S636|log-rank|O
S636|test|O
S636|with|O
S636|asymptotic|O
S636|approximation|O
S636|(|O
S636|time|O
S636|to|O
S636|healing|O
S636|of|O
S636|the|O
S636|cardinal|O
S636|ulcer|O
S636|)|O
S636|.|O
S1075|Recruitment|O
S1075|and|O
S1075|randomisation|O
S1075|of|O
S1075|participants|O
S1075|Participants|O
S1075|were|O
S1075|recruited|O
S1075|between|O
S1075|November|O
S1075|2006|O
S1075|and|O
S1075|January|O
S1075|2010|O
S1075|(|O
S1075|end|O
S1075|of|O
S1075|extended|O
S1075|recruitment|O
S1075|period|O
S1075|)|O
S1075|from|O
S1075|university|B-Settings_Multicenter
S1075|podiatry|I-Settings_Multicenter
S1075|school|I-Settings_Multicenter
S1075|clinics|I-Settings_Multicenter
S1075|,|I-Settings_Multicenter
S1075|NHS|I-Settings_Multicenter
S1075|podiatry|I-Settings_Multicenter
S1075|clinics|I-Settings_Multicenter
S1075|,|I-Settings_Multicenter
S1075|and|I-Settings_Multicenter
S1075|primary|I-Settings_Multicenter
S1075|care|I-Settings_Multicenter
S1075|.|O
S1716|The|O
S1716|most|O
S1716|common|O
S1716|modification|O
S1716|(|O
S1716|14|O
S1716|clinically|O
S1716|driven|O
S1716|,|O
S1716|13|O
S1716|routine|O
S1716|laboratory|O
S1716|monitoring|O
S1716|)|O
S1716|was|O
S1716|to|O
S1716|stop|O
S1716|(|O
S1716|on|O
S1716|four-drug|O
S1716|regimen|O
S1716|)|O
S1716|or|O
S1716|substitute|O
S1716|zidovudine|O
S1716|.|O
S1255|This|O
S1255|study|O
S1255|is|O
S1255|registered|O
S1255|,|O
S1255|ISRCTN25765518|O
S1255|.|O
S936|Pyoderma|O
S936|gangrenosum|O
S936|specific|O
S936|global|O
S936|treatment|O
S936|response—to|O
S936|assess|O
S936|treatment|O
S936|response|O
S936|we|O
S936|used|O
S936|a|O
S936|seven|O
S936|point|O
S936|Likert|O
S936|scale|O
S936|ranging|O
S936|from|O
S936|completely|O
S936|clear|O
S936|through|O
S936|to|O
S936|worse|O
S936|(|O
S936|assessed|O
S936|by|O
S936|clinicians|O
S936|and|O
S936|participants|O
S936|and|O
S936|from|O
S936|digital|O
S936|images|O
S936|for|O
S936|blinded|O
S936|assessment|O
S936|)|O
S936|.|O
S2233|Specific|O
S2233|IgE|O
S2233|was|O
S2233|measured|O
S2233|for|O
S2233|the|O
S2233|following|O
S2233|allergens|O
S2233|:|O
S2233|cat|O
S2233|,|O
S2233|house|O
S2233|dust|O
S2233|mite|O
S2233|(|O
S2233|HDM|O
S2233|)|O
S2233|Dermatophagoides|O
S2233|farinae|O
S2233|,|O
S2233|HDM|O
S2233|Dermatophagoides|O
S2233|pteronyssinus|O
S2233|,|O
S2233|ragweed|O
S2233|,|O
S2233|aspergillus|O
S2233|,|O
S2233|timothy|O
S2233|grass|O
S2233|,|O
S2233|bermuda|O
S2233|grass|O
S2233|,|O
S2233|oak|O
S2233|,|O
S2233|birch|O
S2233|,|O
S2233|plantain|O
S2233|,|O
S2233|and|O
S2233|orchard|O
S2233|grass|O
S2233|.|O
S1048|There|O
S1048|was|O
S1048|no|O
S1048|evidence|O
S1048|of|O
S1048|a|O
S1048|difference|O
S1048|between|O
S1048|the|O
S1048|salicylic|O
S1048|acid|O
S1048|and|O
S1048|cryotherapy|O
S1048|groups|O
S1048|in|O
S1048|self|O
S1048|reported|O
S1048|clearance|O
S1048|of|O
S1048|plantar|O
S1048|warts|O
S1048|at|O
S1048|six|O
S1048|months|O
S1048|(|O
S1048|29/95|O
S1048|(|O
S1048|31|O
S1048|%|O
S1048|)|O
S1048|v|O
S1048|33/98|O
S1048|(|O
S1048|34|O
S1048|%|O
S1048|)|O
S1048|,|O
S1048|difference|O
S1048|–3.15|O
S1048|%|O
S1048|(|O
S1048|–16.31|O
S1048|to|O
S1048|10.02|O
S1048|)|O
S1048|,|O
S1048|P=0.64|O
S1048|)|O
S1048|or|O
S1048|in|O
S1048|time|O
S1048|to|O
S1048|clearance|O
S1048|(|O
S1048|hazard|O
S1048|ratio|O
S1048|0.80|O
S1048|(|O
S1048|95|O
S1048|%|O
S1048|CI|O
S1048|0.51|O
S1048|to|O
S1048|1.25|O
S1048|)|O
S1048|,|O
S1048|P=0.33|O
S1048|)|O
S1048|.|O
S1081|The|O
S1081|liquid|O
S1081|nitrogen|O
S1081|was|O
S1081|applied|O
S1081|with|O
S1081|a|O
S1081|spray|O
S1081|(|O
S1081|method|O
S1081|of|O
S1081|choice|O
S1081|if|O
S1081|available|O
S1081|)|O
S1081|or|O
S1081|a|O
S1081|probe|O
S1081|.|O
S1875|As|O
S1875|a|O
S1875|result|O
S1875|,|O
S1875|the|O
S1875|cumulative|O
S1875|proportions|O
S1875|of|O
S1875|participants|O
S1875|who|O
S1875|had|O
S1875|major|O
S1875|vascular|O
S1875|events|O
S1875|diverged|O
S1875|throughout|O
S1875|the|O
S1875|in-trial|O
S1875|period|O
S1875|,|O
S1875|and|O
S1875|this|O
S1875|separation|O
S1875|then|O
S1875|persisted|O
S1875|roughly|O
S1875|unchanged|O
S1875|throughout|O
S1875|the|O
S1875|post-trial|O
S1875|period|O
S1875|(|O
S1875|figure|O
S1875|3|O
S1875|)|O
S1875|.|O
S651|At|O
S651|week|O
S651|24|O
S651|,|O
S651|more|O
S651|than|O
S651|50|O
S651|%|O
S651|of|O
S651|patients|O
S651|in|O
S651|both|O
S651|groups|O
S651|had|O
S651|healing|O
S651|of|O
S651|the|O
S651|cardinal|O
S651|ulcer|O
S651|maintained|O
S651|for|O
S651|at|O
S651|least|O
S651|12|O
S651|weeks|O
S651|.|O
S82|When|O
S82|a|O
S82|fixed|O
S82|effect|O
S82|meta-analysis|O
S82|of|O
S82|the|O
S82|two|O
S82|studies|O
S82|was|O
S82|performed|O
S82|,|O
S82|the|O
S82|differences|O
S82|and|O
S82|95|O
S82|%|O
S82|confidence|O
S82|intervals|O
S82|were|O
S82|identical|O
S82|to|O
S82|those|O
S82|shown|O
S82|in|O
S82|Table|O
S82|2|O
S82|for|O
S82|the|O
S82|pooled|O
S82|analyses|O
S82|of|O
S82|upper|O
S82|GI|O
S82|,|O
S82|gastric|O
S82|,|O
S82|and|O
S82|duodenal|O
S82|ulcers|O
S82|without|O
S82|evidence|O
S82|of|O
S82|heterogeneity|O
S82|(|O
S82|I2=0|O
S82|for|O
S82|upper|O
S82|GI|O
S82|,|O
S82|gastric|O
S82|,|O
S82|and|O
S82|duodenal|O
S82|ulcer|O
S82|analyses|O
S82|)|O
S82|.|O
S1467|Most|O
S1467|patients|O
S1467|were|O
S1467|children|O
S1467|(|O
S1467|246/326|O
S1467|,|O
S1467|75.5|O
S1467|%|O
S1467|)|O
S1467|aged|O
S1467|1-13.5|O
S1467|,|O
S1467|median|O
S1467|2|O
S1467|years|O
S1467|(|O
S1467|table|O
S1467|1|O
S1467|)|O
S1467|.|O
S2020|In|O
S2020|the|O
S2020|Ca+D|O
S2020|and|O
S2020|Ca|O
S2020|groups|O
S2020|,|O
S2020|the|O
S2020|response|O
S2020|to|O
S2020|treatment|O
S2020|was|O
S2020|associated|O
S2020|with|O
S2020|an|O
S2020|increase|O
S2020|in|O
S2020|25|O
S2020|(|O
S2020|OH|O
S2020|)|O
S2020|D|O
S2020|concentration|O
S2020|.|O
S939|Health|O
S939|related|O
S939|quality|O
S939|of|O
S939|life—assessed|O
S939|using|O
S939|the|O
S939|dermatology|O
S939|life|O
S939|quality|O
S939|index|O
S939|and|O
S939|European|O
S939|quality|O
S939|of|O
S939|life-5|O
S939|dimensions|O
S939|,|O
S939|three|O
S939|levels|O
S939|(|O
S939|EQ-5D-3L|O
S939|and|O
S939|EQ|O
S939|VAS|O
S939|)|O
S939|.|O
S1395|Participants|O
S1395|Patients|O
S1395|aged|O
S1395|≥1|O
S1395|year|O
S1395|admitted|O
S1395|to|O
S1395|hospital|O
S1395|with|O
S1395|confirmed|O
S1395|severe|O
S1395|influenza|O
S1395|.|O
S2262|ATA|O
S2262|incidence|O
S2262|for|O
S2262|all|O
S2262|dosing|O
S2262|groups|O
S2262|was|O
S2262|1.6|O
S2262|%|O
S2262|(|O
S2262|7|O
S2262|of|O
S2262|427|O
S2262|quilizumab-dosed|O
S2262|patients|O
S2262|)|O
S2262|.|O
S796|Plethysmographic|O
S796|data|O
S796|and|O
S796|net|O
S796|t-PA|O
S796|release|O
S796|were|O
S796|determined|O
S796|as|O
S796|described|O
S796|previously|O
S796|,|O
S796|as|O
S796|the|O
S796|product|O
S796|of|O
S796|the|O
S796|infused|O
S796|forearm|O
S796|plasma|O
S796|ﬂow|O
S796|(|O
S796|based|O
S796|on|O
S796|the|O
S796|mean|O
S796|haematocrit|O
S796|and|O
S796|the|O
S796|infused|O
S796|FBF|O
S796|)|O
S796|and|O
S796|the|O
S796|concentration|O
S796|difference|O
S796|between|O
S796|the|O
S796|infused|O
S796|(|O
S796|[|O
S796|t-PA|O
S796|]|O
S796|inf|O
S796|)|O
S796|and|O
S796|non-infused|O
S796|(|O
S796|[|O
S796|t-PA|O
S796|]|O
S796|non-inf|O
S796|)|O
S796|arms|O
S796|:|O
S796|estimated|O
S796|net|O
S796|t-PA|O
S796|release=FBF×|O
S796|(|O
S796|1−Hct|O
S796|)|O
S796|×|O
S796|(|O
S796|[|O
S796|tPA|O
S796|]|O
S796|inf−|O
S796|[|O
S796|tPA|O
S796|]|O
S796|non-inf|O
S796|)|O
S796|.|O
S609|The|O
S609|primary|O
S609|objectives|O
S609|were|O
S609|to|O
S609|evaluate|O
S609|the|O
S609|effect|O
S609|of|O
S609|bosentan|O
S609|on|O
S609|the|O
S609|reduction|O
S609|of|O
S609|new|O
S609|DUs|O
S609|and|O
S609|healing|O
S609|of|O
S609|DUs|O
S609|in|O
S609|patients|O
S609|with|O
S609|SSc|O
S609|.|O
S420|Results|O
S420|106|B-Sample_Size_Actual_at_Enrollment
S420|participants|O
S420|were|O
S420|recruited|O
S420|,|O
S420|of|O
S420|whom|O
S420|14|B-Sample_Size_Calculation_Dropout_Rate_Value
S420|withdrew|I-Sample_Size_Calculation_Dropout_Rate_Value
S420|and|O
S420|82/92|O
S420|reached|O
S420|final|O
S420|height|O
S420|.|O
S1312|For|O
S1312|patients|O
S1312|known|O
S1312|to|O
S1312|be|O
S1312|alive|O
S1312|at|O
S1312|6|O
S1312|months|O
S1312|,|O
S1312|but|O
S1312|with|O
S1312|an|O
S1312|unknown|O
S1312|OHS|O
S1312|,|O
S1312|we|O
S1312|used|O
S1312|the|O
S1312|level|O
S1312|of|O
S1312|function|O
S1312|recorded|O
S1312|on|O
S1312|the|O
S1312|7-day|O
S1312|form|O
S1312|(|O
S1312|ie|O
S1312|,|O
S1312|measured|O
S1312|at|O
S1312|7|O
S1312|days|O
S1312|or|O
S1312|before|O
S1312|discharge|O
S1312|from|O
S1312|hospital|O
S1312|)|O
S1312|to|O
S1312|impute|O
S1312|6-month|O
S1312|functional|O
S1312|status|O
S1312|.|O
S2120|Secondary|O
S2120|efficacy|O
S2120|criteria|O
S2120|included|O
S2120|(|O
S2120|i|O
S2120|)|O
S2120|gait|O
S2120|velocity|O
S2120|(|O
S2120|m/s|O
S2120|)|O
S2120|and|O
S2120|cadence|O
S2120|(|O
S2120|steps/min|O
S2120|)|O
S2120|;|O
S2120|(|O
S2120|ii|O
S2120|)|O
S2120|motor|O
S2120|handicap|O
S2120|,|O
S2120|assessed|O
S2120|as|O
S2120|the|O
S2120|overall|O
S2120|UPDRS|O
S2120|motor|O
S2120|score|O
S2120|and|O
S2120|its|O
S2120|axial|O
S2120|subscore|O
S2120|(|O
S2120|the|O
S2120|sum|O
S2120|of|O
S2120|items|O
S2120|18|O
S2120|(|O
S2120|speech|O
S2120|)|O
S2120|,|O
S2120|19|O
S2120|(|O
S2120|facial|O
S2120|expression|O
S2120|)|O
S2120|,|O
S2120|22|O
S2120|(|O
S2120|neck|O
S2120|rigidity|O
S2120|)|O
S2120|,|O
S2120|27|O
S2120|(|O
S2120|arising|O
S2120|from|O
S2120|a|O
S2120|chair|O
S2120|)|O
S2120|,|O
S2120|28|O
S2120|(|O
S2120|posture|O
S2120|)|O
S2120|,|O
S2120|29|O
S2120|(|O
S2120|gait|O
S2120|)|O
S2120|and|O
S2120|30|O
S2120|(|O
S2120|postural|O
S2120|stability|O
S2120|)|O
S2120|)|O
S2120|;|O
S2120|(|O
S2120|iii|O
S2120|)|O
S2120|LID|O
S2120|,|O
S2120|assessed|O
S2120|as|O
S2120|the|O
S2120|overall|O
S2120|Dyskinesia|O
S2120|Rating|O
S2120|Scale|O
S2120|score|O
S2120|and|O
S2120|its|O
S2120|axial|O
S2120|subscore|O
S2120|;|O
S2120|(|O
S2120|iv|O
S2120|)|O
S2120|hypertonia|O
S2120|of|O
S2120|axial|O
S2120|flexors|O
S2120|and|O
S2120|extensors|O
S2120|,|O
S2120|assessed|O
S2120|as|O
S2120|the|O
S2120|mean|O
S2120|work|O
S2120|(|O
S2120|in|O
S2120|joules|O
S2120|)|O
S2120|performed|O
S2120|during|O
S2120|10|O
S2120|passive|O
S2120|trunk|O
S2120|movements|O
S2120|at|O
S2120|30°/s|O
S2120|on|O
S2120|a|O
S2120|CON-TREX|O
S2120|isokinetic|O
S2120|dynamometer|O
S2120|(|O
S2120|CMV|O
S2120|AG|O
S2120|,|O
S2120|Dübendorf|O
S2120|,|O
S2120|Switzerland|O
S2120|)|O
S2120|;|O
S2120|(|O
S2120|v|O
S2120|)|O
S2120|trunk|O
S2120|flexor|O
S2120|and|O
S2120|extensor|O
S2120|strength|O
S2120|,|O
S2120|measured|O
S2120|as|O
S2120|the|O
S2120|mean|O
S2120|work|O
S2120|(|O
S2120|in|O
S2120|joules|O
S2120|)|O
S2120|performed|O
S2120|over|O
S2120|three|O
S2120|repetitions|O
S2120|at|O
S2120|30°/s|O
S2120|in|O
S2120|active|O
S2120|flexion|O
S2120|and|O
S2120|extension|O
S2120|mode|O
S2120|on|O
S2120|the|O
S2120|isokinetic|O
S2120|dynamometer|O
S2120|.|O
S1937|Design|O
S1937|Randomised|B-Randomization_Type_Simple
S1937|controlled|O
S1937|trial|O
S1937|.|O
S1442|Data|O
S1442|analysis|O
S1442|Endpoints|O
S1442|The|O
S1442|primary|O
S1442|efficacy|O
S1442|endpoint|O
S1442|was|O
S1442|the|O
S1442|proportion|O
S1442|of|O
S1442|all|O
S1442|patients|O
S1442|with|O
S1442|no|O
S1442|detectable|O
S1442|viral|O
S1442|RNA|O
S1442|by|O
S1442|RT-PCR|O
S1442|in|O
S1442|a|O
S1442|combined|O
S1442|nasal|O
S1442|and|O
S1442|throat|O
S1442|swab|O
S1442|sample|O
S1442|on|O
S1442|day|O
S1442|five|O
S1442|.|O
S2133|Statistical|O
S2133|analysis|O
S2133|Descriptive|O
S2133|analyses|O
S2133|and|O
S2133|the|O
S2133|Shapiro-Wilk|O
S2133|test|O
S2133|were|O
S2133|used|O
S2133|to|O
S2133|check|O
S2133|whether|O
S2133|data|O
S2133|were|O
S2133|normally|O
S2133|distributed|O
S2133|.|O
S1218|The|O
S1218|benefits|O
S1218|and|O
S1218|harms|O
S1218|of|O
S1218|intravenous|O
S1218|thrombolysis|O
S1218|with|O
S1218|recombinant|O
S1218|tissue|O
S1218|plasminogen|O
S1218|activator|O
S1218|within|O
S1218|6|O
S1218|h|O
S1218|of|O
S1218|acute|O
S1218|ischaemic|O
S1218|stroke|O
S1218|(|O
S1218|the|O
S1218|third|O
S1218|international|O
S1218|stroke|O
S1218|trial|O
S1218|[|O
S1218|IST-3|O
S1218|]|O
S1218|)|O
S1218|:|O
S1218|a|O
S1218|randomised|O
S1218|controlled|O
S1218|trial|O
S601|In|O
S601|a|O
S601|recent|O
S601|small|O
S601|placebo-controlled|O
S601|study|O
S601|,|O
S601|atorvastatin|O
S601|reduced|O
S601|the|O
S601|number|O
S601|of|O
S601|new|O
S601|DUs|O
S601|in|O
S601|association|O
S601|with|O
S601|improvement|O
S601|in|O
S601|markers|O
S601|of|O
S601|endothelial|O
S601|function|O
S601|.|O
S2098|By|O
S2098|decreasing|O
S2098|NMDA-dependant|O
S2098|glutamatergic|O
S2098|hyperactivity|O
S2098|,|O
S2098|memantine|O
S2098|reduces|O
S2098|akinesia|O
S2098|and|O
S2098|rigidity|O
S2098|in|O
S2098|the|O
S2098|MPTP|O
S2098|(|O
S2098|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|O
S2098|)|O
S2098|rat|O
S2098|model|O
S2098|and|O
S2098|improves|O
S2098|locomotion|O
S2098|in|O
S2098|rats|O
S2098|treated|O
S2098|with|O
S2098|reserpine|O
S2098|and|O
S2098|α-methyl-p-tyrosine|O
S2098|.|O
S2204|Quilizumab|O
S2204|may|O
S2204|reset|O
S2204|the|O
S2204|IgE|O
S2204|repertoire|O
S2204|by|O
S2204|targeting|O
S2204|IgE|O
S2204|production|O
S2204|and|O
S2204|provide|O
S2204|a|O
S2204|more|O
S2204|sustained|O
S2204|effect|O
S2204|with|O
S2204|a|O
S2204|lower|O
S2204|dose|O
S2204|frequency|O
S2204|then|O
S2204|omalizumab|O
S2204|.|O
S2112|The|O
S2112|1|B-Randomization_Ratio
S2112|:|I-Randomization_Ratio
S2112|1|I-Randomization_Ratio
S2112|assignment|O
S2112|sequence|O
S2112|(|O
S2112|based|O
S2112|on|O
S2112|a|B-Randomization_Sequence_Generation_Method
S2112|computer|I-Randomization_Sequence_Generation_Method
S2112|random-number|I-Randomization_Sequence_Generation_Method
S2112|generator|I-Randomization_Sequence_Generation_Method
S2112|)|O
S2112|was|O
S2112|produced|O
S2112|by|O
S2112|our|O
S2112|Department|B-Randomization_Personnel
S2112|of|I-Randomization_Personnel
S2112|Biostatistics|I-Randomization_Personnel
S2112|.|O
S2249|Missing|O
S2249|values|O
S2249|were|O
S2249|imputed|O
S2249|using|O
S2249|the|O
S2249|last-observation-carried-forward|O
S2249|(|O
S2249|LOCF|O
S2249|)|O
S2249|approach|O
S2249|,|O
S2249|as|O
S2249|prespecified|O
S2249|in|O
S2249|the|O
S2249|statistical|O
S2249|analysis|O
S2249|plan|O
S2249|.|O
S1425|Treatment|O
S1425|Patients|O
S1425|were|O
S1425|randomised|O
S1425|to|O
S1425|receive|O
S1425|double|B-Design_Parallel_Group
S1425|or|I-Design_Parallel_Group
S1425|standard|I-Design_Parallel_Group
S1425|dose|I-Design_Parallel_Group
S1425|oseltamivir|I-Design_Parallel_Group
S1425|based|O
S1425|on|O
S1425|a|B-Randomization_Sequence_Generation_Method
S1425|computer|I-Randomization_Sequence_Generation_Method
S1425|generated|I-Randomization_Sequence_Generation_Method
S1425|list|I-Randomization_Sequence_Generation_Method
S1425|that|O
S1425|was|O
S1425|stratified|B-Randomization_Type_Stratified
S1425|by|O
S1425|site|B-Randomization_Stratified_Criteria
S1425|and|O
S1425|age|B-Randomization_Stratified_Criteria
S1425|group|I-Randomization_Stratified_Criteria
S1425|.|O
S1890|The|O
S1890|apparent|O
S1890|reduction|O
S1890|in|O
S1890|deaths|O
S1890|attributed|O
S1890|to|O
S1890|other|O
S1890|medical|O
S1890|causes|O
S1890|in|O
S1890|participants|O
S1890|originally|O
S1890|allocated|O
S1890|simvastatin|O
S1890|(|O
S1890|200|O
S1890|[|O
S1890|2·3|O
S1890|%|O
S1890|]|O
S1890|vs|O
S1890|239|O
S1890|[|O
S1890|2·8|O
S1890|%|O
S1890|]|O
S1890|)|O
S1890|was|O
S1890|only|O
S1890|marginally|O
S1890|significant|O
S1890|(|O
S1890|p=0·03|O
S1890|)|O
S1890|and|O
S1890|involved|O
S1890|no|O
S1890|material|O
S1890|differences|O
S1890|in|O
S1890|deaths|O
S1890|due|O
S1890|to|O
S1890|renal|O
S1890|or|O
S1890|hepatic|O
S1890|disease|O
S1890|and|O
S1890|only|O
S1890|a|O
S1890|non-significant|O
S1890|difference|O
S1890|in|O
S1890|a|O
S1890|miscellaneous|O
S1890|group|O
S1890|of|O
S1890|other|O
S1890|non-vascular|O
S1890|causes|O
S1890|.|O
S1291|A|O
S1291|trial|O
S1291|of|O
S1291|that|O
S1291|size|O
S1291|could|O
S1291|detect|O
S1291|a|O
S1291|clinically|O
S1291|worthwhile|O
S1291|net|O
S1291|benefit|O
S1291|of|O
S1291|as|O
S1291|little|O
S1291|as|O
S1291|3|O
S1291|%|O
S1291|absolute|O
S1291|difference|O
S1291|in|O
S1291|the|O
S1291|primary|O
S1291|outcome|O
S1291|(|O
S1291|80|B-Sample_Size_Calculation_Power_Value
S1291|%|I-Sample_Size_Calculation_Power_Value
S1291|power|O
S1291|,|O
S1291|α=0·05|O
S1291|)|O
S1291|.|O
S81|Results|O
S81|of|O
S81|the|O
S81|pooled|O
S81|analysis|O
S81|of|O
S81|the|O
S81|two|O
S81|studies|O
S81|are|O
S81|also|O
S81|shown|O
S81|in|O
S81|Table|O
S81|2|O
S81|.|O
S2126|In|O
S2126|view|O
S2126|of|O
S2126|a|O
S2126|possible|O
S2126|antagonistic|O
S2126|effect|O
S2126|of|O
S2126|memantine|O
S2126|on|O
S2126|nicotinic|O
S2126|acetylcholine|O
S2126|receptors|O
S2126|,|O
S2126|drowsiness|O
S2126|was|O
S2126|assessed|O
S2126|on|O
S2126|the|O
S2126|Epworth|O
S2126|Sleepiness|O
S2126|Scale|O
S2126|.|O
S456|Oral|O
S456|oxandrolone|O
S456|(|O
S456|SPA|O
S456|,|O
S456|Milan|O
S456|,|O
S456|Italy|O
S456|)|O
S456|was|O
S456|given|O
S456|at|O
S456|0.05|O
S456|mg/kg/day|O
S456|,|O
S456|with|O
S456|a|O
S456|maximum|O
S456|daily|O
S456|dose|O
S456|of|O
S456|2.5|O
S456|mg|O
S456|.|O
S242|No|O
S242|clinically|O
S242|relevant|O
S242|change|O
S242|in|O
S242|mean|O
S242|vital|O
S242|sign|O
S242|values|O
S242|was|O
S242|associated|O
S242|with|O
S242|tiotropium|O
S242|Respimat®|O
S242|.|O
S2254|Results|O
S2254|Patient|O
S2254|demographics|O
S2254|and|O
S2254|study|O
S2254|flow|O
S2254|1212|O
S2254|patients|O
S2254|were|O
S2254|screened|O
S2254|for|O
S2254|eligibility|O
S2254|and|O
S2254|578|B-Sample_Size_Actual_at_Enrollment
S2254|adult|O
S2254|asthma|O
S2254|patients|O
S2254|(|O
S2254|18–75|O
S2254|years|O
S2254|old|O
S2254|)|O
S2254|were|O
S2254|enrolled|O
S2254|(|O
S2254|Fig|O
S2254|.|O
S648|Fewer|O
S648|new|O
S648|DUs|O
S648|were|O
S648|observed|O
S648|with|O
S648|bosentan|O
S648|than|O
S648|placebo|O
S648|in|O
S648|all|O
S648|subgroups|O
S648|except|O
S648|among|O
S648|current|O
S648|smokers|O
S648|(|O
S648|table|O
S648|2|O
S648|,|O
S648|subgroup|O
S648|analyses|O
S648|)|O
S648|.|O
S642|Placebo-corrected|O
S642|changes|O
S642|from|O
S642|baseline|O
S642|,|O
S642|RR|O
S642|and|O
S642|HRs|O
S642|from|O
S642|Cox|O
S642|modelling|O
S642|were|O
S642|each|O
S642|reported|O
S642|with|O
S642|95|O
S642|%|O
S642|CIs|O
S642|where|O
S642|appropriate|O
S642|.|O
S1864|Of|O
S1864|20|B-Sample_Size_Actual_at_Enrollment
S1864|536|I-Sample_Size_Actual_at_Enrollment
S1864|participants|O
S1864|,|O
S1864|17|B-Sample_Size_Actual_at_Outcome_Analysis
S1864|519|I-Sample_Size_Actual_at_Outcome_Analysis
S1864|were|O
S1864|still|O
S1864|alive|O
S1864|at|O
S1864|the|O
S1864|start|O
S1864|of|O
S1864|the|O
S1864|post-trial|O
S1864|follow-up|O
S1864|period|O
S1864|:|O
S1864|8863|O
S1864|allocated|O
S1864|simvastatin|O
S1864|versus|O
S1864|8656|O
S1864|placebo|O
S1864|(|O
S1864|ratio|O
S1864|1·02|O
S1864|;|O
S1864|because|O
S1864|simvastatin|O
S1864|reduced|O
S1864|mortality|O
S1864|)|O
S1864|.|O
S1337|To|O
S1337|assess|O
S1337|the|O
S1337|effect|O
S1337|of|O
S1337|treatment|O
S1337|on|O
S1337|the|O
S1337|primary|O
S1337|outcome|O
S1337|,|O
S1337|the|O
S1337|statistical|O
S1337|analysis|O
S1337|plan|O
S1337|predefined|O
S1337|a|O
S1337|small|O
S1337|subset|O
S1337|of|O
S1337|key|O
S1337|prognostic|O
S1337|subgroups|O
S1337|(|O
S1337|figure|O
S1337|3|O
S1337|)|O
S1337|.|O
S328|In|O
S328|addition|O
S328|,|O
S328|time|O
S328|to|O
S328|first|O
S328|new|O
S328|gouty|O
S328|arthritis|O
S328|flare|O
S328|was|O
S328|longer|O
S328|with|O
S328|all|O
S328|canakinumab|O
S328|groups|O
S328|compared|O
S328|with|O
S328|colchicine|O
S328|0.5|O
S328|mg|O
S328|(|O
S328|figure|O
S328|2|O
S328|)|O
S328|and|O
S328|there|O
S328|was|O
S328|a|O
S328|64|O
S328|%|O
S328|to|O
S328|72|O
S328|%|O
S328|reduction|O
S328|in|O
S328|the|O
S328|risk|O
S328|of|O
S328|experiencing|O
S328|at|O
S328|least|O
S328|one|O
S328|flare|O
S328|for|O
S328|canakinumab|O
S328|doses|O
S328|≥50|O
S328|mg|O
S328|versus|O
S328|colchicine|O
S328|at|O
S328|16|O
S328|weeks|O
S328|(|O
S328|HR|O
S328|:|O
S328|0.28–0.36|O
S328|,|O
S328|p≤0.05|O
S328|)|O
S328|(|O
S328|table|O
S328|2|O
S328|)|O
S328|.|O
S463|Oxandrolone|O
S463|supplies|O
S463|In|O
S463|2004|O
S463|and|O
S463|2008|O
S463|,|O
S463|the|O
S463|sole|O
S463|European|O
S463|manufacturer|O
S463|of|O
S463|oxandrolone|O
S463|2.5|O
S463|mg|O
S463|ceased|O
S463|production|O
S463|,|O
S463|resulting|O
S463|in|O
S463|34|O
S463|participants|O
S463|in|O
S463|2004|O
S463|and|O
S463|11|O
S463|in|O
S463|2008|O
S463|temporarily|O
S463|suspending|O
S463|active|O
S463|oxandrolone|O
S463|treatment|O
S463|(|O
S463|mean|O
S463|duration|O
S463|:|O
S463|2004|O
S463|,|O
S463|52|O
S463|days|O
S463|;|O
S463|2008|O
S463|,|O
S463|163|O
S463|days|O
S463|)|O
S463|.|O
S1300|The|O
S1300|independent|O
S1300|data|O
S1300|monitoring|O
S1300|committee|O
S1300|met|O
S1300|at|O
S1300|least|O
S1300|annually|O
S1300|to|O
S1300|review|O
S1300|the|O
S1300|unmasked|O
S1300|data|O
S1300|on|O
S1300|major|O
S1300|outcome|O
S1300|events|O
S1300|in|O
S1300|the|O
S1300|trial|O
S1300|,|O
S1300|on|O
S1300|the|O
S1300|background|O
S1300|stroke-unit|O
S1300|care|O
S1300|received|O
S1300|by|O
S1300|trial|O
S1300|patients|O
S1300|(|O
S1300|to|O
S1300|ensure|O
S1300|it|O
S1300|was|O
S1300|equal|O
S1300|in|O
S1300|both|O
S1300|treatment|O
S1300|groups|O
S1300|)|O
S1300|,|O
S1300|relevant|O
S1300|external|O
S1300|data|O
S1300|(|O
S1300|including|O
S1300|updates|O
S1300|of|O
S1300|the|O
S1300|Cochrane|O
S1300|systematic|O
S1300|review|O
S1300|and|O
S1300|reports|O
S1300|from|O
S1300|large-scale|O
S1300|registries|O
S1300|of|O
S1300|rt-PA|O
S1300|use|O
S1300|)|O
S1300|in|O
S1300|strict|O
S1300|confidence|O
S1300|throughout|O
S1300|the|O
S1300|course|O
S1300|of|O
S1300|the|O
S1300|trial|O
S1300|.|O
S624|Patients|O
S624|who|O
S624|required|O
S624|parenteral|O
S624|,|O
S624|oral|O
S624|or|O
S624|inhaled|O
S624|prostanoid|O
S624|treatment|O
S624|during|O
S624|the|O
S624|study|O
S624|were|O
S624|first|O
S624|discontinued|O
S624|from|O
S624|study|O
S624|treatment|O
S624|.|O
S1498|Most|O
S1498|deaths|O
S1498|(|O
S1498|15/21|O
S1498|,|O
S1498|71|O
S1498|%|O
S1498|)|O
S1498|were|O
S1498|in|O
S1498|patients|O
S1498|with|O
S1498|avian|O
S1498|H5N1|O
S1498|virus|O
S1498|.|O
S1282|Hospital|O
S1282|staff|O
S1282|completed|O
S1282|an|O
S1282|early|O
S1282|outcome|O
S1282|form|O
S1282|at|O
S1282|7|O
S1282|days|O
S1282|,|O
S1282|death|O
S1282|,|O
S1282|or|O
S1282|hospital|O
S1282|discharge|O
S1282|,|O
S1282|whichever|O
S1282|occured|O
S1282|first|O
S1282|,|O
S1282|recording|O
S1282|details|O
S1282|of|O
S1282|events|O
S1282|occurring|O
S1282|in|O
S1282|hospital|O
S1282|within|O
S1282|7|O
S1282|days|O
S1282|,|O
S1282|details|O
S1282|of|O
S1282|background|O
S1282|treatments|O
S1282|given|O
S1282|and|O
S1282|functional|O
S1282|status|O
S1282|.|O
S1679|Adverse|O
S1679|events|O
S1679|resulted|O
S1679|in|O
S1679|a|O
S1679|drug|O
S1679|being|O
S1679|substituted|O
S1679|or|O
S1679|dropped|O
S1679|in|O
S1679|five|O
S1679|children|O
S1679|in|O
S1679|group|O
S1679|A|O
S1679|,|O
S1679|28|O
S1679|in|O
S1679|group|O
S1679|B|O
S1679|,|O
S1679|and|O
S1679|26|O
S1679|in|O
S1679|group|O
S1679|C|O
S1679|;|O
S1679|most|O
S1679|changes|O
S1679|were|O
S1679|zidovudine-related|O
S1679|(|O
S1679|16|O
S1679|in|O
S1679|B|O
S1679|,|O
S1679|20|O
S1679|in|O
S1679|C|O
S1679|;|O
S1679|table|O
S1679|2|O
S1679|)|O
S1679|.|O
S346|Only|O
S346|the|O
S346|case|O
S346|of|O
S346|erysipelas|O
S346|was|O
S346|considered|O
S346|to|O
S346|be|O
S346|possibly|O
S346|related|O
S346|to|O
S346|study|O
S346|medication|O
S346|.|O
S962|As|O
S962|such|O
S962|,|O
S962|the|O
S962|intention|O
S962|to|O
S962|treat|O
S962|population|O
S962|was|O
S962|112|B-Sample_Size_Actual_at_Outcome_Analysis
S962|participants|O
S962|(|O
S962|59|O
S962|ciclosporin|O
S962|;|O
S962|53|O
S962|prednisolone|O
S962|)|O
S962|.|O
S622|The|O
S622|dose|O
S622|could|O
S622|remain|O
S622|at|O
S622|or|O
S622|be|O
S622|decreased|O
S622|to|O
S622|the|O
S622|starting|O
S622|dose|O
S622|due|O
S622|to|O
S622|intolerance|O
S622|,|O
S622|with|O
S622|possible|O
S622|subsequent|O
S622|increase|O
S622|to|O
S622|the|O
S622|target|O
S622|dose|O
S622|.|O
S1454|For|O
S1454|patients|O
S1454|with|O
S1454|missing|O
S1454|results|O
S1454|on|O
S1454|day|O
S1454|five|O
S1454|,|O
S1454|we|O
S1454|carried|O
S1454|forward|O
S1454|the|O
S1454|last|O
S1454|available|O
S1454|results|O
S1454|.|O
S583|There|O
S583|was|O
S583|no|O
S583|difference|O
S583|between|O
S583|treatments|O
S583|in|O
S583|healing|O
S583|rate|O
S583|of|O
S583|the|O
S583|cardinal|O
S583|ulcer|O
S583|or|O
S583|secondary|O
S583|end|O
S583|points|O
S583|of|O
S583|pain|O
S583|and|O
S583|disability|O
S583|.|O
S630|Secondary|O
S630|and|O
S630|exploratory|O
S630|end|O
S630|points|O
S630|included|O
S630|:|O
S630|(|O
S630|1|O
S630|)|O
S630|reduction|O
S630|of|O
S630|new|O
S630|DUs|O
S630|and|O
S630|overall|O
S630|DU|O
S630|number|O
S630|(|O
S630|proportions|O
S630|of|O
S630|patients|O
S630|with|O
S630|no|O
S630|new|O
S630|DUs|O
S630|and|O
S630|with|O
S630|each|O
S630|number|O
S630|of|O
S630|new|O
S630|DUs|O
S630|up|O
S630|to|O
S630|week|O
S630|24|O
S630|,|O
S630|time|O
S630|to|O
S630|onset|O
S630|of|O
S630|each|O
S630|number|O
S630|of|O
S630|new|O
S630|DUs|O
S630|up|O
S630|to|O
S630|week|O
S630|24|O
S630|and|O
S630|change|O
S630|from|O
S630|baseline|O
S630|to|O
S630|week|O
S630|24|O
S630|in|O
S630|total|O
S630|number|O
S630|of|O
S630|all|O
S630|DUs|O
S630|)|O
S630|,|O
S630|(|O
S630|2|O
S630|)|O
S630|healing|O
S630|(|O
S630|time|O
S630|to|O
S630|healing|O
S630|of|O
S630|all|O
S630|baseline|O
S630|DUs|O
S630|and|O
S630|of|O
S630|all|O
S630|new|O
S630|DUs|O
S630|through|O
S630|week|O
S630|24|O
S630|,|O
S630|and|O
S630|proportions|O
S630|of|O
S630|patients|O
S630|with|O
S630|healing|O
S630|of|O
S630|all|O
S630|DUs|O
S630|by|O
S630|the|O
S630|end|O
S630|of|O
S630|week|O
S630|24|O
S630|)|O
S630|and|O
S630|(|O
S630|3|O
S630|)|O
S630|pain|O
S630|and|O
S630|disability|O
S630|parameters|O
S630|(|O
S630|changes|O
S630|from|O
S630|baseline|O
S630|to|O
S630|week|O
S630|24|O
S630|:|O
S630|in|O
S630|pain|O
S630|of|O
S630|the|O
S630|cardinal|O
S630|ulcer|O
S630|and|O
S630|overall|O
S630|hand|O
S630|pain|O
S630|assessed|O
S630|on|O
S630|visual|O
S630|analogue|O
S630|scales|O
S630|;|O
S630|hand|O
S630|disability|O
S630|index|O
S630|(|O
S630|an|O
S630|averaged|O
S630|score|O
S630|from|O
S630|the|O
S630|three|O
S630|Health|O
S630|Assessment|O
S630|Questionnaire|O
S630|(|O
S630|HAQ|O
S630|)|O
S630|domains|O
S630|of|O
S630|dressing/grooming|O
S630|,|O
S630|grip|O
S630|and|O
S630|hygiene|O
S630|)|O
S630|;|O
S630|and|O
S630|HAQ|O
S630|disability|O
S630|index|O
S630|)|O
S630|.|O
S1659|All|O
S1659|p|O
S1659|values|O
S1659|are|O
S1659|two-sided|O
S1659|.|O
S1079|Randomisation|O
S1079|was|O
S1079|simple|B-Randomization_Type_Simple
S1079|(|O
S1079|that|O
S1079|is|O
S1079|,|O
S1079|it|O
S1079|was|O
S1079|not|O
S1079|restricted|O
S1079|in|O
S1079|any|O
S1079|way|O
S1079|such|O
S1079|as|O
S1079|by|O
S1079|stratification|O
S1079|or|O
S1079|blocked|O
S1079|allocation|O
S1079|with|O
S1079|the|O
S1079|allocation|O
S1079|sequence|O
S1079|being|O
S1079|computer|O
S1079|generated|O
S1079|)|O
S1079|.|O
S1863|Results|O
S1863|Mean|O
S1863|follow-up|O
S1863|during|O
S1863|the|O
S1863|in-trial|O
S1863|period|O
S1863|for|O
S1863|all|O
S1863|randomised|O
S1863|participants|O
S1863|was|O
S1863|5·3|O
S1863|years|O
S1863|(|O
S1863|SD|O
S1863|1·2|O
S1863|)|O
S1863|,|O
S1863|and|O
S1863|the|O
S1863|mean|O
S1863|total|O
S1863|follow-up|O
S1863|for|O
S1863|participants|O
S1863|who|O
S1863|survived|O
S1863|to|O
S1863|the|O
S1863|end|O
S1863|of|O
S1863|the|O
S1863|post-trial|O
S1863|period|O
S1863|was|O
S1863|11·0|O
S1863|years|O
S1863|(|O
S1863|SD|O
S1863|0·6|O
S1863|)|O
S1863|.|O
S2246|The|O
S2246|relative|O
S2246|change|O
S2246|in|O
S2246|pre-bronchodilator|O
S2246|FEV1|O
S2246|from|O
S2246|baseline|O
S2246|was|O
S2246|calculated|O
S2246|as|O
S2246|the|O
S2246|absolute|O
S2246|change|O
S2246|in|O
S2246|FEV1|O
S2246|(|O
S2246|volume|O
S2246|in|O
S2246|liters|O
S2246|)|O
S2246|from|O
S2246|baseline|O
S2246|divided|O
S2246|by|O
S2246|the|O
S2246|FEV1|O
S2246|at|O
S2246|baseline|O
S2246|.|O
S784|Forearm|O
S784|blood|O
S784|flow|O
S784|was|O
S784|measured|O
S784|in|O
S784|both|O
S784|arms|O
S784|by|O
S784|venous|O
S784|occlusion|O
S784|plethysmography|O
S784|with|O
S784|the|O
S784|use|O
S784|of|O
S784|mercury-in-silastic|O
S784|strain|O
S784|gauges|O
S784|.|O
S1668|Completeness|O
S1668|of|O
S1668|nurse|O
S1668|visits|O
S1668|every|O
S1668|4–6|O
S1668|weeks|O
S1668|and|O
S1668|doctor|O
S1668|visits|O
S1668|every|O
S1668|12|O
S1668|weeks|O
S1668|was|O
S1668|more|O
S1668|than|O
S1668|95|O
S1668|%|O
S1668|(|O
S1668|46|O
S1668|531/48|O
S1668|461|O
S1668|nurse|O
S1668|,|O
S1668|19|O
S1668|088/19|O
S1668|765|O
S1668|doctor|O
S1668|visits|O
S1668|)|O
S1668|and|O
S1668|was|O
S1668|similar|O
S1668|in|O
S1668|all|O
S1668|groups|O
S1668|.|O
S1819|Interpretation|O
S1819|More|O
S1819|prolonged|O
S1819|LDL-lowering|O
S1819|statin|O
S1819|treatment|O
S1819|produces|O
S1819|larger|O
S1819|absolute|O
S1819|reductions|O
S1819|in|O
S1819|vascular|O
S1819|events|O
S1819|.|O
S920|Treatment|O
S920|allocation|O
S920|was|O
S920|concealed|O
S920|from|O
S920|the|O
S920|statistician|B-Blinding_Object_Others
S920|and|O
S920|blinded|O
S920|assessors|B-Blinding_Object_Outcome_Assessors
S920|of|O
S920|the|O
S920|digital|O
S920|images|O
S920|until|O
S920|interventions|O
S920|were|O
S920|all|O
S920|assigned|O
S920|and|O
S920|recruitment|O
S920|,|O
S920|data|O
S920|collection|O
S920|,|O
S920|data|O
S920|cleaning|O
S920|,|O
S920|and|O
S920|blind|O
S920|analysis|O
S920|were|O
S920|complete|O
S920|.|O
S671|Overall|O
S671|,|O
S671|adverse|O
S671|events|O
S671|led|O
S671|to|O
S671|the|O
S671|discontinuation|O
S671|of|O
S671|study|O
S671|treatment|O
S671|in|O
S671|15.6|O
S671|%|O
S671|of|O
S671|patients|O
S671|on|O
S671|bosentan|O
S671|and|O
S671|12.2|O
S671|%|O
S671|on|O
S671|placebo|O
S671|.|O
S595|The|O
S595|pathogenesis|O
S595|of|O
S595|DUs|O
S595|is|O
S595|thought|O
S595|to|O
S595|include|O
S595|many|O
S595|of|O
S595|the|O
S595|hallmark|O
S595|processes|O
S595|of|O
S595|critical|O
S595|tissue|O
S595|ischaemia|O
S595|,|O
S595|such|O
S595|as|O
S595|impaired|O
S595|afferent|O
S595|vasomotion|O
S595|,|O
S595|microvascular|O
S595|disruption|O
S595|,|O
S595|reduced|O
S595|venous|O
S595|drainage|O
S595|,|O
S595|increased|O
S595|local|O
S595|platelet|O
S595|activation|O
S595|and|O
S595|increased|O
S595|leucocyte|O
S595|adherence|O
S595|.|O
S1650|Randomised|O
S1650|groups|O
S1650|were|O
S1650|compared|O
S1650|with|O
S1650|Kaplan-Meier|O
S1650|plots|O
S1650|,|O
S1650|log-rank|O
S1650|tests|O
S1650|,|O
S1650|and|O
S1650|proportional|O
S1650|hazards|O
S1650|models|O
S1650|,|O
S1650|stratified|O
S1650|by|O
S1650|randomisation|O
S1650|stratification|O
S1650|factors|O
S1650|(|O
S1650|including|O
S1650|the|O
S1650|other|O
S1650|factorial|O
S1650|)|O
S1650|for|O
S1650|time-to-event|O
S1650|disease|O
S1650|progression|O
S1650|,|O
S1650|ART|O
S1650|,|O
S1650|and|O
S1650|adverse|O
S1650|event|O
S1650|outcomes|O
S1650|,|O
S1650|censoring|O
S1650|at|O
S1650|the|O
S1650|earlier|O
S1650|of|O
S1650|trial|O
S1650|closure|O
S1650|or|O
S1650|last|O
S1650|follow-up|O
S1650|.|O
S974|Excluding|O
S974|the|O
S974|five|O
S974|patients|O
S974|who|O
S974|either|O
S974|swapped|O
S974|to|O
S974|the|O
S974|alternative|O
S974|trial|O
S974|drug|O
S974|or|O
S974|used|O
S974|both|O
S974|drugs|O
S974|in|O
S974|combination|O
S974|before|O
S974|the|O
S974|six|O
S974|week|O
S974|visit|O
S974|,|O
S974|did|O
S974|not|O
S974|change|O
S974|the|O
S974|overall|O
S974|treatment|O
S974|effect|O
S974|(|O
S974|−0.036|O
S974|,|O
S974|−0.21|O
S974|to|O
S974|0.14|O
S974|;|O
S974|P=0.68|O
S974|)|O
S974|.|O
S1269|All|O
S1269|scans|O
S1269|were|O
S1269|sent|O
S1269|to|O
S1269|the|O
S1269|trial|O
S1269|centre|O
S1269|in|O
S1269|Edinburgh|O
S1269|for|O
S1269|masked|O
S1269|central|O
S1269|rating|O
S1269|of|O
S1269|any|O
S1269|signs|O
S1269|of|O
S1269|visible|O
S1269|early|O
S1269|ischaemia|O
S1269|(|O
S1269|presence|O
S1269|and|O
S1269|extent|O
S1269|of|O
S1269|hypo-attenuation|O
S1269|,|O
S1269|swelling|O
S1269|,|O
S1269|hyperattenuated|O
S1269|artery|O
S1269|)|O
S1269|,|O
S1269|haemorrhage|O
S1269|,|O
S1269|and|O
S1269|background|O
S1269|brain|O
S1269|changes|O
S1269|(|O
S1269|leukoaraiosis|O
S1269|,|O
S1269|atrophy|O
S1269|,|O
S1269|prior|O
S1269|stroke|O
S1269|lesions|O
S1269|,|O
S1269|non-stroke|O
S1269|lesions|O
S1269|)|O
S1269|with|O
S1269|validated|O
S1269|rating|O
S1269|methods|O
S1269|.|O
S639|Patients|O
S639|with|O
S639|no|O
S639|valid|O
S639|assessment|O
S639|post|O
S639|baseline|O
S639|(|O
S639|three|O
S639|patients|O
S639|on|O
S639|bosentan|O
S639|,|O
S639|one|O
S639|on|O
S639|placebo|O
S639|)|O
S639|were|O
S639|excluded|O
S639|from|O
S639|the|O
S639|main|O
S639|analysis|O
S639|.|O
S1598|Mean|O
S1598|CD4|O
S1598|percentage|O
S1598|change|O
S1598|did|O
S1598|not|O
S1598|differ|O
S1598|between|O
S1598|ART|O
S1598|groups|O
S1598|at|O
S1598|week|O
S1598|72|O
S1598|(|O
S1598|16·5|O
S1598|%|O
S1598|[|O
S1598|SD|O
S1598|8·6|O
S1598|]|O
S1598|vs|O
S1598|17·1|O
S1598|%|O
S1598|[|O
S1598|8·5|O
S1598|]|O
S1598|vs|O
S1598|17·3|O
S1598|%|O
S1598|[|O
S1598|8·0|O
S1598|]|O
S1598|,|O
S1598|p=0·33|O
S1598|)|O
S1598|or|O
S1598|week|O
S1598|144|O
S1598|(|O
S1598|p=0·69|O
S1598|)|O
S1598|,|O
S1598|but|O
S1598|four-drug|O
S1598|groups|O
S1598|(|O
S1598|B|O
S1598|,|O
S1598|C|O
S1598|)|O
S1598|were|O
S1598|superior|O
S1598|to|O
S1598|three-drug|O
S1598|group|O
S1598|A|O
S1598|at|O
S1598|week|O
S1598|36|O
S1598|(|O
S1598|12·4|O
S1598|%|O
S1598|[|O
S1598|7·2|O
S1598|]|O
S1598|vs|O
S1598|14·1|O
S1598|%|O
S1598|[|O
S1598|7·1|O
S1598|]|O
S1598|vs|O
S1598|14·6|O
S1598|%|O
S1598|[|O
S1598|7·3|O
S1598|]|O
S1598|,|O
S1598|p|O
S1598|<|O
S1598|0·0001|O
S1598|)|O
S1598|.|O
S910|We|O
S910|excluded|O
S910|patients|O
S910|with|O
S910|pustular|O
S910|or|O
S910|granulomatous|O
S910|variants|O
S910|of|O
S910|pyoderma|O
S910|gangrenosum|O
S910|(|O
S910|as|O
S910|they|O
S910|may|O
S910|respond|O
S910|differently|O
S910|to|O
S910|treatment|O
S910|,|O
S910|and|O
S910|measurement|O
S910|of|O
S910|a|O
S910|single|O
S910|ulcer|O
S910|was|O
S910|not|O
S910|possible|O
S910|)|O
S910|;|O
S910|patients|O
S910|receiving|O
S910|oral|O
S910|prednisolone|O
S910|,|O
S910|ciclosporin|O
S910|,|O
S910|or|O
S910|intravenous|O
S910|immunoglobulin|O
S910|in|O
S910|the|O
S910|previous|O
S910|month|O
S910|;|O
S910|patients|O
S910|participating|O
S910|in|O
S910|another|O
S910|clinical|O
S910|trial|O
S910|;|O
S910|women|O
S910|who|O
S910|were|O
S910|pregnant|O
S910|,|O
S910|lactating|O
S910|,|O
S910|or|O
S910|at|O
S910|risk|O
S910|of|O
S910|pregnancy|O
S910|;|O
S910|patients|O
S910|with|O
S910|known|O
S910|hypersensitivity|O
S910|to|O
S910|either|O
S910|of|O
S910|the|O
S910|study|O
S910|treatments|O
S910|;|O
S910|patients|O
S910|with|O
S910|clinically|O
S910|important|O
S910|renal|O
S910|impairment|O
S910|or|O
S910|other|O
S910|pretreatment|O
S910|findings|O
S910|that|O
S910|would|O
S910|result|O
S910|in|O
S910|the|O
S910|investigator|O
S910|not|O
S910|using|O
S910|either|O
S910|of|O
S910|the|O
S910|study|O
S910|drugs|O
S910|;|O
S910|patients|O
S910|with|O
S910|malignant|O
S910|or|O
S910|premalignant|O
S910|disease|O
S910|;|O
S910|patients|O
S910|with|O
S910|a|O
S910|concurrent|O
S910|medical|O
S910|condition|O
S910|for|O
S910|which|O
S910|treatments|O
S910|might|O
S910|interfere|O
S910|with|O
S910|ongoing|O
S910|treatment|O
S910|or|O
S910|cause|O
S910|harm|O
S910|;|O
S910|and|O
S910|patients|O
S910|taking|O
S910|rosuvastatin|O
S910|or|O
S910|those|O
S910|who|O
S910|had|O
S910|received|O
S910|a|O
S910|live|O
S910|vaccine|O
S910|in|O
S910|the|O
S910|two|O
S910|weeks|O
S910|before|O
S910|randomisation|O
S910|.|O
S1626|The|O
S1626|NNRTI|O
S1626|(|O
S1626|nevirapine|O
S1626|or|O
S1626|efavirenz|O
S1626|)|O
S1626|was|O
S1626|chosen|O
S1626|by|O
S1626|clinicians|O
S1626|according|O
S1626|to|O
S1626|local|O
S1626|availability|O
S1626|and|O
S1626|age|O
S1626|.|O
S144|Each|O
S144|treatment|O
S144|was|O
S144|administered|O
S144|for|O
S144|4|O
S144|weeks|O
S144|,|O
S144|without|O
S144|washout|O
S144|between|O
S144|treatment|O
S144|periods|O
S144|.|O
S739|Results|O
S739|Consistent|O
S739|with|O
S739|effective|O
S739|conjugation|O
S739|of|O
S739|circulating|O
S739|TNF-α|O
S739|,|O
S739|plasma|O
S739|TNF-α|O
S739|concentrations|O
S739|increased|O
S739|in|O
S739|all|O
S739|patients|O
S739|following|O
S739|etanercept|O
S739|(|O
S739|254±15|O
S739|vs|O
S739|0.12±0.02|O
S739|pg/ml|O
S739|;|O
S739|p|O
S739|<|O
S739|0.0001|O
S739|)|O
S739|,|O
S739|but|O
S739|not|O
S739|saline|O
S739|infusion|O
S739|.|O
S1405|No|O
S1405|important|O
S1405|differences|O
S1405|in|O
S1405|tolerability|O
S1405|were|O
S1405|found|O
S1405|.|O
S1474|A|O
S1474|minority|O
S1474|of|O
S1474|patients|O
S1474|,|O
S1474|76/326|O
S1474|(|O
S1474|23.3|O
S1474|%|O
S1474|)|O
S1474|had|O
S1474|been|O
S1474|prescribed|O
S1474|oseltamivir|O
S1474|or|O
S1474|zanamivir|O
S1474|before|O
S1474|enrolment|O
S1474|,|O
S1474|and|O
S1474|most|O
S1474|231/326|O
S1474|(|O
S1474|70.8|O
S1474|%|O
S1474|)|O
S1474|had|O
S1474|received|O
S1474|antibiotics|O
S1474|.|O
S314|Results|O
S314|Baseline|O
S314|demographics|O
S314|and|O
S314|disease|O
S314|characteristics|O
S314|Between|O
S314|December|O
S314|2008|O
S314|and|O
S314|August|O
S314|2009|O
S314|,|O
S314|432|B-Sample_Size_Actual_at_Enrollment
S314|patients|O
S314|from|O
S314|75|B-Settings_Multicenter
S314|centres|I-Settings_Multicenter
S314|in|O
S314|16|B-Settings_Location
S314|countries|I-Settings_Location
S314|were|O
S314|randomised|O
S314|to|O
S314|treatment|O
S314|;|O
S314|391|B-Sample_Size_Actual_at_Outcome_Analysis
S314|patients|O
S314|(|O
S314|90.5|O
S314|%|O
S314|)|O
S314|completed|O
S314|the|O
S314|study|O
S314|(|O
S314|figure|O
S314|1|O
S314|)|O
S314|.|O
S163|Despite|O
S163|this|O
S163|range|O
S163|of|O
S163|therapeutic|O
S163|choices|O
S163|,|O
S163|at|O
S163|least|O
S163|40|O
S163|%|O
S163|of|O
S163|patients|O
S163|with|O
S163|asthma|O
S163|have|O
S163|poorly|O
S163|controlled|O
S163|disease|O
S163|.|O
S2201|In|O
S2201|these|O
S2201|studies|O
S2201|,|O
S2201|quilizumab|O
S2201|reduced|O
S2201|serum|O
S2201|total|O
S2201|IgE|O
S2201|by|O
S2201|approximately|O
S2201|25|O
S2201|%|O
S2201|.|O
S1866|Response|O
S1866|rates|O
S1866|to|O
S1866|mailed|O
S1866|questionnaires|O
S1866|and|O
S1866|from|O
S1866|family|O
S1866|doctors|O
S1866|during|O
S1866|the|O
S1866|post-trial|O
S1866|period|O
S1866|were|O
S1866|high|O
S1866|and|O
S1866|did|O
S1866|not|O
S1866|differ|O
S1866|by|O
S1866|previous|O
S1866|statin|O
S1866|allocation|O
S1866|(|O
S1866|table|O
S1866|1|O
S1866|)|O
S1866|.|O
S237|One|O
S237|patient|O
S237|was|O
S237|reported|O
S237|with|O
S237|alcohol|O
S237|abuse|O
S237|and|O
S237|panic|O
S237|attack|O
S237|,|O
S237|which|O
S237|led|O
S237|to|O
S237|hospitalisation|O
S237|.|O
S1432|All|O
S1432|patients|O
S1432|received|O
S1432|five|O
S1432|days|O
S1432|of|O
S1432|oseltamivir|O
S1432|.|O
S2243|The|O
S2243|rates|O
S2243|of|O
S2243|asthma|O
S2243|exacerbations|O
S2243|were|O
S2243|compared|O
S2243|between|O
S2243|study|O
S2243|groups|O
S2243|using|O
S2243|a|O
S2243|Poisson|O
S2243|regression|O
S2243|with|O
S2243|overdispersion|O
S2243|model|O
S2243|,|O
S2243|including|O
S2243|terms|O
S2243|for|O
S2243|periostin|O
S2243|status|O
S2243|(|O
S2243|<|O
S2243|50|O
S2243|,|O
S2243|≥50|O
S2243|ng/mL|O
S2243|)|O
S2243|,|O
S2243|number|O
S2243|of|O
S2243|prior|O
S2243|exacerbations|O
S2243|(|O
S2243|1|O
S2243|,|O
S2243|>|O
S2243|1|O
S2243|)|O
S2243|,|O
S2243|and|O
S2243|IgE|O
S2243|level|O
S2243|(|O
S2243|<|O
S2243|200|O
S2243|,|O
S2243|≥200|O
S2243|IU/mL|O
S2243|)|O
S2243|.|O
S193|A|O
S193|diagnosis|O
S193|of|O
S193|asthma|O
S193|confirmed|O
S193|at|O
S193|Visit|O
S193|1|O
S193|was|O
S193|required|O
S193|,|O
S193|with|O
S193|bronchodilator|O
S193|reversibility|O
S193|(|O
S193|15–30|O
S193|minutes|O
S193|after|O
S193|400|O
S193|μg|O
S193|salbutamol|O
S193|)|O
S193|of|O
S193|≥12|O
S193|%|O
S193|and|O
S193|≥200|O
S193|mL|O
S193|.|O
S2147|Safety|O
S2147|criteria|O
S2147|There|O
S2147|were|O
S2147|no|O
S2147|significant|O
S2147|safety|O
S2147|differences|O
S2147|between|O
S2147|the|O
S2147|memantine|O
S2147|and|O
S2147|placebo|O
S2147|groups|O
S2147|.|O
S188|Eligible|O
S188|patients|O
S188|were|O
S188|randomly|O
S188|allocated|O
S188|to|O
S188|one|O
S188|of|O
S188|the|O
S188|four|O
S188|treatment|O
S188|sequences|O
S188|at|O
S188|Visit|O
S188|2|O
S188|(|O
S188|Figure|O
S188|1|O
S188|)|O
S188|.|O
S907|Participants|O
S907|were|O
S907|aged|O
S907|18|O
S907|years|O
S907|or|O
S907|more|O
S907|,|O
S907|with|O
S907|a|O
S907|diagnosis|O
S907|of|O
S907|pyoderma|O
S907|gangrenosum|O
S907|made|O
S907|by|O
S907|a|O
S907|recruiting|O
S907|dermatologist|O
S907|.|O
S1290|Statistical|O
S1290|analysis|O
S1290|At|O
S1290|the|O
S1290|outset|O
S1290|of|O
S1290|the|O
S1290|trial|O
S1290|in|O
S1290|2000|O
S1290|,|O
S1290|we|O
S1290|estimated|O
S1290|that|O
S1290|,|O
S1290|among|O
S1290|the|O
S1290|type|O
S1290|of|O
S1290|patients|O
S1290|likely|O
S1290|to|O
S1290|be|O
S1290|recruited|O
S1290|at|O
S1290|the|O
S1290|time|O
S1290|,|O
S1290|to|O
S1290|detect|O
S1290|both|O
S1290|an|O
S1290|absolute|O
S1290|difference|O
S1290|of|O
S1290|10|O
S1290|%|O
S1290|in|O
S1290|the|O
S1290|proportion|O
S1290|of|O
S1290|patients|O
S1290|alive|O
S1290|and|O
S1290|independent|O
S1290|at|O
S1290|6|O
S1290|months|O
S1290|after|O
S1290|treatment|O
S1290|and|O
S1290|to|O
S1290|have|O
S1290|sufficient|O
S1290|power|O
S1290|to|O
S1290|permit|O
S1290|reliable|O
S1290|analyses|O
S1290|of|O
S1290|the|O
S1290|prespecified|O
S1290|subgroups|O
S1290|,|O
S1290|a|O
S1290|sample|O
S1290|of|O
S1290|6000|O
S1290|patients|O
S1290|would|O
S1290|be|O
S1290|needed|O
S1290|.|O
S1331|The|O
S1331|proportion|O
S1331|of|O
S1331|patients|O
S1331|with|O
S1331|a|O
S1331|definitely|O
S1331|visible|O
S1331|ischaemic|O
S1331|lesion|O
S1331|(|O
S1331|vs|O
S1331|only|O
S1331|possible|O
S1331|or|O
S1331|no|O
S1331|early|O
S1331|ischaemic|O
S1331|change|O
S1331|)|O
S1331|on|O
S1331|baseline|O
S1331|imaging|O
S1331|rose|O
S1331|with|O
S1331|time|O
S1331|(|O
S1331|test|O
S1331|for|O
S1331|linear|O
S1331|trend|O
S1331|p=0·0045|O
S1331|)|O
S1331|.|O
S584|Peripheral|O
S584|oedema|O
S584|and|O
S584|elevated|O
S584|aminotransferases|O
S584|were|O
S584|associated|O
S584|with|O
S584|bosentan|O
S584|treatment|O
S584|.|O
S1134|Overall|O
S1134|,|O
S1134|62|O
S1134|(|O
S1134|32|O
S1134|%|O
S1134|)|O
S1134|of|O
S1134|the|O
S1134|patients|O
S1134|had|O
S1134|complete|O
S1134|clearance|O
S1134|of|O
S1134|all|O
S1134|plantar|O
S1134|warts|O
S1134|at|O
S1134|six|O
S1134|months—29/95|O
S1134|(|O
S1134|31|O
S1134|%|O
S1134|)|O
S1134|of|O
S1134|patients|O
S1134|in|O
S1134|the|O
S1134|salicylic|O
S1134|acid|O
S1134|group|O
S1134|and|O
S1134|33/98|O
S1134|(|O
S1134|34|O
S1134|%|O
S1134|)|O
S1134|in|O
S1134|the|O
S1134|cryotherapy|O
S1134|group|O
S1134|,|O
S1134|with|O
S1134|no|O
S1134|significant|O
S1134|difference|O
S1134|between|O
S1134|the|O
S1134|groups|O
S1134|(|O
S1134|difference|O
S1134|–3.15|O
S1134|%|O
S1134|(|O
S1134|–16.31|O
S1134|to|O
S1134|10.02|O
S1134|)|O
S1134|,|O
S1134|P=0.64|O
S1134|)|O
S1134|.|O
S1850|Endpoints|O
S1850|and|O
S1850|statistical|O
S1850|analysis|O
S1850|The|O
S1850|main|O
S1850|comparisons|O
S1850|entail|O
S1850|log-rank|O
S1850|analyses|O
S1850|of|O
S1850|the|O
S1850|first|O
S1850|post-randomisation|O
S1850|occurrence|O
S1850|of|O
S1850|particular|O
S1850|events|O
S1850|during|O
S1850|the|O
S1850|in-trial|O
S1850|period|O
S1850|(|O
S1850|defined|O
S1850|as|O
S1850|events|O
S1850|occurring|O
S1850|up|O
S1850|to|O
S1850|Nov|O
S1850|11|O
S1850|,|O
S1850|2001|O
S1850|)|O
S1850|and|O
S1850|during|O
S1850|the|O
S1850|post-trial|O
S1850|period|O
S1850|(|O
S1850|defined|O
S1850|as|O
S1850|events|O
S1850|occurring|O
S1850|from|O
S1850|Nov|O
S1850|11|O
S1850|,|O
S1850|2001|O
S1850|,|O
S1850|until|O
S1850|March|O
S1850|31|O
S1850|,|O
S1850|2007|O
S1850|)|O
S1850|among|O
S1850|all|O
S1850|those|O
S1850|originally|O
S1850|allocated|O
S1850|40|O
S1850|mg|O
S1850|simvastatin|O
S1850|daily|O
S1850|versus|O
S1850|all|O
S1850|those|O
S1850|allocated|O
S1850|matching|O
S1850|placebo|O
S1850|tablets|O
S1850|(|O
S1850|ie|O
S1850|,|O
S1850|intention-to-treat|O
S1850|analyses|O
S1850|)|O
S1850|.|O
S160|Background|O
S160|Currently|O
S160|,|O
S160|inhaled|O
S160|corticosteroids|O
S160|(|O
S160|ICS|O
S160|)|O
S160|are|O
S160|the|O
S160|de|O
S160|facto|O
S160|first-line|O
S160|therapy|O
S160|for|O
S160|the|O
S160|management|O
S160|of|O
S160|poorly|O
S160|controlled|O
S160|,|O
S160|persistent|O
S160|asthma|O
S160|.|O
S2213|The|O
S2213|trial|O
S2213|was|O
S2213|conducted|O
S2213|in|O
S2213|full|O
S2213|conformance|O
S2213|with|O
S2213|the|O
S2213|International|O
S2213|Conference|O
S2213|on|O
S2213|Harmonisation|O
S2213|E6|O
S2213|guidelines|O
S2213|and|O
S2213|the|O
S2213|Declaration|O
S2213|of|O
S2213|Helsinki|O
S2213|,|O
S2213|or|O
S2213|laws|O
S2213|and|O
S2213|regulations|O
S2213|of|O
S2213|the|O
S2213|country|O
S2213|where|O
S2213|the|O
S2213|research|O
S2213|was|O
S2213|conducted|O
S2213|,|O
S2213|whichever|O
S2213|afforded|O
S2213|greater|O
S2213|protection|O
S2213|to|O
S2213|the|O
S2213|individual|O
S2213|.|O
S1874|A|O
S1874|further|O
S1874|decrease|O
S1874|of|O
S1874|14|O
S1874|%|O
S1874|(|O
S1874|[|O
S1874|0–26|O
S1874|]|O
S1874|;|O
S1874|p=0·05|O
S1874|)|O
S1874|was|O
S1874|recorded|O
S1874|in|O
S1874|the|O
S1874|first|O
S1874|post-trial|O
S1874|year|O
S1874|in|O
S1874|patients|O
S1874|originally|O
S1874|allocated|O
S1874|simvastatin|O
S1874|,|O
S1874|but|O
S1874|little|O
S1874|difference|O
S1874|was|O
S1874|seen|O
S1874|between|O
S1874|treatment|O
S1874|groups|O
S1874|thereafter|O
S1874|.|O
S478|SITAR|O
S478|transforms|O
S478|individual|O
S478|growth|O
S478|curves|O
S478|so|O
S478|that|O
S478|they|O
S478|become|O
S478|essentially|O
S478|the|O
S478|same|O
S478|as|O
S478|each|O
S478|other|O
S478|and|O
S478|,|O
S478|when|O
S478|superimposed|O
S478|,|O
S478|define|O
S478|the|O
S478|average|O
S478|summary|O
S478|curve|O
S478|.|O
S83|In|O
S83|addition|O
S83|,|O
S83|when|O
S83|the|O
S83|Cochran–Mantel–Haenszel|O
S83|analysis|O
S83|was|O
S83|re-run|O
S83|with|O
S83|study|O
S83|(|O
S83|REDUCE-1|O
S83|or|O
S83|-2|O
S83|)|O
S83|included|O
S83|in|O
S83|the|O
S83|model|O
S83|,|O
S83|the|O
S83|P|O
S83|values|O
S83|for|O
S83|comparisons|O
S83|of|O
S83|all|O
S83|three|O
S83|end|O
S83|points|O
S83|remained|O
S83|<|O
S83|0.0001|O
S83|.|O
S48|In|O
S48|clinical|O
S48|practice|O
S48|,|O
S48|physicians|O
S48|and|O
S48|patients|O
S48|are|O
S48|concerned|O
S48|about|O
S48|preventing|O
S48|ulcers|O
S48|,|O
S48|whether|O
S48|they|O
S48|are|O
S48|gastric|O
S48|or|O
S48|duodenal|O
S48|,|O
S48|and|O
S48|many|O
S48|clinical|O
S48|trials|O
S48|use|O
S48|this|O
S48|primary|O
S48|end|O
S48|point|O
S48|.|O
S56|In|O
S56|addition|O
S56|,|O
S56|post|O
S56|hoc|O
S56|subgroup|O
S56|analysis|O
S56|included|O
S56|use|O
S56|of|O
S56|low-dose|O
S56|aspirin|O
S56|alone|O
S56|,|O
S56|and|O
S56|presence|O
S56|or|O
S56|absence|O
S56|of|O
S56|erosions|O
S56|at|O
S56|screening|O
S56|endoscopy|O
S56|.|O
S967|Nine|O
S967|participants|O
S967|(|O
S967|8|O
S967|%|O
S967|)|O
S967|increased|O
S967|their|O
S967|dose|O
S967|of|O
S967|randomised|O
S967|drug|O
S967|during|O
S967|the|O
S967|trial|O
S967|:|O
S967|four|O
S967|in|O
S967|the|O
S967|prednisolone|O
S967|group|O
S967|,|O
S967|with|O
S967|increases|O
S967|ranging|O
S967|from|O
S967|0.067|O
S967|mg/kg|O
S967|daily|O
S967|to|O
S967|0.6|O
S967|mg/kg|O
S967|daily|O
S967|;|O
S967|and|O
S967|five|O
S967|in|O
S967|the|O
S967|ciclosporin|O
S967|group|O
S967|,|O
S967|with|O
S967|increases|O
S967|ranging|O
S967|from|O
S967|0.36|O
S967|mg/kg|O
S967|daily|O
S967|to|O
S967|0.98|O
S967|mg/kg|O
S967|daily|O
S967|.|O
S1593|This|O
S1593|trial|O
S1593|is|O
S1593|registered|O
S1593|,|O
S1593|ISRCTN24791884|O
S1593|.|O
S39|The|O
S39|primary|O
S39|end|O
S39|point|O
S39|for|O
S39|REDUCE-2|O
S39|was|O
S39|upper|O
S39|GI|O
S39|(|O
S39|gastric|O
S39|or|O
S39|duodenal|O
S39|)|O
S39|ulcers|O
S39|identified|O
S39|at|O
S39|endoscopy|O
S39|during|O
S39|the|O
S39|24-week|O
S39|study|O
S39|period|O
S39|,|O
S39|with|O
S39|three|O
S39|secondary|O
S39|end|O
S39|points|O
S39|:|O
S39|gastric|O
S39|ulcers|O
S39|,|O
S39|duodenal|O
S39|ulcers|O
S39|,|O
S39|and|O
S39|GI|O
S39|complications|O
S39|.|O
S672|Laboratory|O
S672|tests|O
S672|identified|O
S672|increased|O
S672|aminotransferases|O
S672|to|O
S672|>|O
S672|3×ULN|O
S672|in|O
S672|10/95|O
S672|(|O
S672|10.5|O
S672|%|O
S672|)|O
S672|patients|O
S672|on|O
S672|bosentan|O
S672|(|O
S672|which|O
S672|included|O
S672|one|O
S672|patient|O
S672|with|O
S672|an|O
S672|elevation|O
S672|to|O
S672|>|O
S672|8×ULN|O
S672|)|O
S672|and|O
S672|1/88|O
S672|(|O
S672|1.1|O
S672|%|O
S672|)|O
S672|patients|O
S672|on|O
S672|placebo|O
S672|.|O
S1656|Baseline|O
S1656|values|O
S1656|were|O
S1656|those|O
S1656|nearest|O
S1656|to|O
S1656|but|O
S1656|before|O
S1656|and|O
S1656|within|O
S1656|42|O
S1656|days|O
S1656|of|O
S1656|randomisation|O
S1656|.|O
S202|Study|O
S202|assessments|O
S202|Spirometric|O
S202|lung|O
S202|function|O
S202|tests|O
S202|were|O
S202|conducted|O
S202|at|O
S202|all|O
S202|in-clinic|O
S202|visits|O
S202|(|O
S202|Visits|O
S202|1–6|O
S202|)|O
S202|.|O
S794|For|O
S794|platelet|O
S794|expression|O
S794|of|O
S794|P-selectin|O
S794|7500|O
S794|events|O
S794|were|O
S794|collected|O
S794|in|O
S794|the|O
S794|platelet|O
S794|gate|O
S794|.|O
S1975|The|O
S1975|densitometer|O
S1975|had|O
S1975|a|O
S1975|short-term|O
S1975|in|O
S1975|vivo|O
S1975|precision|O
S1975|of|O
S1975|6.4|O
S1975|%|O
S1975|for|O
S1975|areal|O
S1975|bone|O
S1975|density|O
S1975|at|O
S1975|the|O
S1975|distal|O
S1975|radius|O
S1975|and|O
S1975|ulna|O
S1975|,|O
S1975|and|O
S1975|7.2|O
S1975|%|O
S1975|at|O
S1975|the|O
S1975|proximal|O
S1975|1/3|O
S1975|radius|O
S1975|and|O
S1975|ulna|O
S1975|,|O
S1975|and|O
S1975|a|O
S1975|long-term|O
S1975|in|O
S1975|vitro|O
S1975|precision|O
S1975|of|O
S1975|1.1|O
S1975|%|O
S1975|.|O
S935|We|O
S935|identified|O
S935|this|O
S935|outcome|O
S935|as|O
S935|the|O
S935|most|O
S935|important|O
S935|of|O
S935|the|O
S935|secondary|O
S935|outcomes|O
S935|.|O
S2282|Relative|O
S2282|changes|O
S2282|from|O
S2282|baseline|O
S2282|in|O
S2282|FEV1|O
S2282|compared|O
S2282|to|O
S2282|placebo|O
S2282|were|O
S2282|3.8|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−1.2|O
S2282|to|O
S2282|8.9|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.21|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|5.6|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|0.6|O
S2282|to|O
S2282|10.6|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.07|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|150|O
S2282|mg|O
S2282|Q|O
S2282|treatment|O
S2282|arm|O
S2282|;|O
S2282|2.2|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−2.8|O
S2282|to|O
S2282|7.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.48|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−5.0|O
S2282|to|O
S2282|5.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.98|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|450|O
S2282|mg|O
S2282|Q|O
S2282|arm|O
S2282|;|O
S2282|and|O
S2282|1.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−3.9|O
S2282|to|O
S2282|6.1|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.72|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|12|O
S2282|and|O
S2282|0.1|O
S2282|%|O
S2282|(|O
S2282|90|O
S2282|%|O
S2282|CI|O
S2282|:|O
S2282|−4.9|O
S2282|to|O
S2282|5.2|O
S2282|,|O
S2282|p|O
S2282|=|O
S2282|0.96|O
S2282|)|O
S2282|at|O
S2282|Week|O
S2282|36|O
S2282|in|O
S2282|the|O
S2282|300|O
S2282|mg|O
S2282|M|O
S2282|arm|O
S2282|(|O
S2282|Fig|O
S2282|.|O
S416|Participants|O
S416|Girls|O
S416|with|O
S416|Turner|O
S416|’|O
S416|s|O
S416|syndrome|O
S416|aged|O
S416|7-13|O
S416|years|O
S416|at|O
S416|recruitment|O
S416|,|O
S416|receiving|O
S416|recombinant|O
S416|growth|O
S416|hormone|O
S416|therapy|O
S416|(|O
S416|10|O
S416|mg/m2/week|O
S416|)|O
S416|.|O
S1899|The|O
S1899|large|O
S1899|numbers|O
S1899|of|O
S1899|incident|O
S1899|cancers|O
S1899|recorded|O
S1899|during|O
S1899|the|O
S1899|combined|O
S1899|in-trial|O
S1899|and|O
S1899|post-trial|O
S1899|periods|O
S1899|allow|O
S1899|reliable|O
S1899|assessment|O
S1899|of|O
S1899|the|O
S1899|effects|O
S1899|of|O
S1899|a|O
S1899|substantial|O
S1899|5-year|O
S1899|reduction|O
S1899|in|O
S1899|cholesterol|O
S1899|on|O
S1899|11-year|O
S1899|risks|O
S1899|of|O
S1899|the|O
S1899|commoner|O
S1899|types|O
S1899|of|O
S1899|cancer|O
S1899|.|O
S1601|CD4|O
S1601|benefits|O
S1601|from|O
S1601|four-drug|O
S1601|induction|O
S1601|were|O
S1601|not|O
S1601|durable|O
S1601|,|O
S1601|but|O
S1601|three-NRTI|O
S1601|long-term|O
S1601|maintenance|O
S1601|was|O
S1601|immunologically|O
S1601|and|O
S1601|clinically|O
S1601|similar|O
S1601|to|O
S1601|NNRTI-based|O
S1601|ART|O
S1601|and|O
S1601|could|O
S1601|be|O
S1601|valuable|O
S1601|during|O
S1601|tuberculosis|O
S1601|co-treatment|O
S1601|.|O
S1835|Participants|O
S1835|were|O
S1835|advised|O
S1835|to|O
S1835|discuss|O
S1835|with|O
S1835|their|O
S1835|doctors|O
S1835|,|O
S1835|in|O
S1835|light|O
S1835|of|O
S1835|those|O
S1835|results|O
S1835|,|O
S1835|whether|O
S1835|non-trial|O
S1835|statin|O
S1835|treatment|O
S1835|should|O
S1835|be|O
S1835|prescribed|O
S1835|(|O
S1835|and|O
S1835|study|O
S1835|treatment|O
S1835|stopped|O
S1835|)|O
S1835|.|O
S1221|The|O
S1221|third|O
S1221|International|O
S1221|Stroke|O
S1221|Trial|O
S1221|(|O
S1221|IST-3|O
S1221|)|O
S1221|sought|O
S1221|to|O
S1221|determine|O
S1221|whether|O
S1221|a|O
S1221|wider|O
S1221|range|O
S1221|of|O
S1221|patients|O
S1221|might|O
S1221|benefit|O
S1221|up|O
S1221|to|O
S1221|6|O
S1221|h|O
S1221|from|O
S1221|stroke|O
S1221|onset|O
S1221|.|O
S2205|The|O
S2205|primary|O
S2205|purpose|O
S2205|of|O
S2205|this|O
S2205|study|O
S2205|was|O
S2205|to|O
S2205|evaluate|O
S2205|the|O
S2205|efficacy|O
S2205|,|O
S2205|safety|O
S2205|,|O
S2205|and|O
S2205|pharmacokinetics|O
S2205|of|O
S2205|quilizumab|O
S2205|after|O
S2205|36|O
S2205|weeks|O
S2205|of|O
S2205|treatment|O
S2205|in|O
S2205|adults|O
S2205|with|O
S2205|allergic|O
S2205|asthma|O
S2205|inadequately|O
S2205|controlled|O
S2205|despite|O
S2205|high-dose|O
S2205|inhaled|O
S2205|corticosteroids|O
S2205|(|O
S2205|ICS|O
S2205|)|O
S2205|and|O
S2205|a|O
S2205|second|O
S2205|controller|O
S2205|.|O
S1859|These|O
S1859|previous|O
S1859|reports|O
S1859|included|O
S1859|limited|O
S1859|numbers|O
S1859|of|O
S1859|major|O
S1859|vascular|O
S1859|events|O
S1859|,|O
S1859|incident|O
S1859|cancers|O
S1859|,|O
S1859|and|O
S1859|non-vascular|O
S1859|deaths|O
S1859|during|O
S1859|prolonged|O
S1859|post-trial|O
S1859|follow-up|O
S1859|,|O
S1859|making|O
S1859|reliable|O
S1859|assessment|O
S1859|of|O
S1859|persistence|O
S1859|of|O
S1859|benefit|O
S1859|or|O
S1859|emergence|O
S1859|of|O
S1859|any|O
S1859|hazard|O
S1859|difficult|O
S1859|.|O
S1980|One|O
S1980|level|O
S1980|teaspoon|O
S1980|of|O
S1980|powdered|O
S1980|limestone|O
S1980|(|O
S1980|approximately|O
S1980|3.5|O
S1980|g=938|O
S1980|mg|O
S1980|of|O
S1980|elemental|O
S1980|calcium|O
S1980|)|O
S1980|was|O
S1980|mixed|O
S1980|with|O
S1980|the|O
S1980|child|O
S1980|'s|O
S1980|food|O
S1980|or|O
S1980|porridge|O
S1980|twice|O
S1980|daily|O
S1980|.|O
S2115|After|O
S2115|a|O
S2115|30-day|O
S2115|dose|O
S2115|titration|O
S2115|phase|O
S2115|(|O
S2115|with|O
S2115|an|O
S2115|increase|O
S2115|of|O
S2115|5|O
S2115|mg|O
S2115|of|O
S2115|memantine|O
S2115|per|O
S2115|week|O
S2115|or|O
S2115|a|O
S2115|placebo|O
S2115|)|O
S2115|,|O
S2115|the|O
S2115|patients|O
S2115|received|O
S2115|a|B-Design_Parallel_Group
S2115|daily|I-Design_Parallel_Group
S2115|dose|I-Design_Parallel_Group
S2115|(|I-Design_Parallel_Group
S2115|at|I-Design_Parallel_Group
S2115|7:00|I-Design_Parallel_Group
S2115|)|I-Design_Parallel_Group
S2115|of|I-Design_Parallel_Group
S2115|20|I-Design_Parallel_Group
S2115|mg|I-Design_Parallel_Group
S2115|of|I-Design_Parallel_Group
S2115|memantine|I-Design_Parallel_Group
S2115|(|I-Design_Parallel_Group
S2115|ie|I-Design_Parallel_Group
S2115|,|I-Design_Parallel_Group
S2115|the|I-Design_Parallel_Group
S2115|usual|I-Design_Parallel_Group
S2115|recommended|I-Design_Parallel_Group
S2115|dose|I-Design_Parallel_Group
S2115|)|I-Design_Parallel_Group
S2115|or|I-Design_Parallel_Group
S2115|placebo|I-Design_Parallel_Group
S2115|for|O
S2115|a|O
S2115|further|O
S2115|60|O
S2115|days|O
S2115|.|O
S266|Conclusions|O
S266|Single|O
S266|canakinumab|O
S266|doses|O
S266|≥50|O
S266|mg|O
S266|or|O
S266|four|O
S266|4-weekly|O
S266|doses|O
S266|provided|O
S266|superior|O
S266|prophylaxis|O
S266|against|O
S266|flares|O
S266|compared|O
S266|with|O
S266|daily|O
S266|colchicine|O
S266|0.5|O
S266|mg.|O
S983|Sensitivity|O
S983|analyses|O
S983|adjusting|O
S983|for|O
S983|additional|O
S983|baseline|O
S983|covariates|O
S983|was|O
S983|consistent|O
S983|with|O
S983|the|O
S983|main|O
S983|result|O
S983|(|O
S983|hazard|O
S983|ratio|O
S983|1.01|O
S983|,|O
S983|95|O
S983|%|O
S983|confidence|O
S983|interval|O
S983|0.57|O
S983|to|O
S983|1.79|O
S983|;|O
S983|P=0.98|O
S983|)|O
S983|,|O
S983|as|O
S983|was|O
S983|censoring|O
S983|the|O
S983|16|O
S983|participants|O
S983|who|O
S983|changed|O
S983|their|O
S983|treatment|O
S983|(|O
S983|hazard|O
S983|ratio|O
S983|0.86|O
S983|,|O
S983|95|O
S983|%|O
S983|confidence|O
S983|interval|O
S983|0.49|O
S983|to|O
S983|1.52|O
S983|;|O
S983|P=0.60|O
S983|)|O
S983|.|O
S2014|Similarly|O
S2014|,|O
S2014|adjusted|O
S2014|mean|O
S2014|radiographic|O
S2014|scores|O
S2014|were|O
S2014|lower|O
S2014|in|O
S2014|the|O
S2014|Ca+D|O
S2014|group|O
S2014|at|O
S2014|12|O
S2014|weeks|O
S2014|(|O
S2014|p=0.01|O
S2014|)|O
S2014|but|O
S2014|not|O
S2014|at|O
S2014|24|O
S2014|weeks|O
S2014|(|O
S2014|p=0.12|O
S2014|)|O
S2014|.|O
S1043|Patient|O
S1043|self|O
S1043|treatment|O
S1043|with|O
S1043|50|O
S1043|%|O
S1043|salicylic|O
S1043|acid|O
S1043|(|O
S1043|Verrugon|O
S1043|)|O
S1043|daily|O
S1043|up|O
S1043|to|O
S1043|a|O
S1043|maximum|O
S1043|of|O
S1043|eight|O
S1043|weeks|O
S1043|.|O
S1298|We|O
S1298|monitored|O
S1298|all|O
S1298|baseline|O
S1298|and|O
S1298|postrandomisation|O
S1298|imaging|O
S1298|,|O
S1298|which|O
S1298|provided|O
S1298|additional|O
S1298|cross-checks|O
S1298|on|O
S1298|recruited|O
S1298|patients|O
S1298|and|O
S1298|centre|O
S1298|performance|O
S1298|.|O
S84|The|O
S84|combined|O
S84|trial|O
S84|data|O
S84|of|O
S84|the|O
S84|primary|O
S84|population|O
S84|was|O
S84|used|O
S84|in|O
S84|a|O
S84|proportional|O
S84|hazards|O
S84|analysis|O
S84|to|O
S84|examine|O
S84|multiple|O
S84|risk|O
S84|factors|O
S84|in|O
S84|relation|O
S84|to|O
S84|development|O
S84|of|O
S84|upper|O
S84|GI|O
S84|ulcers|O
S84|.|O
S2182|However|O
S2182|,|O
S2182|targeting|O
S2182|the|O
S2182|IgE|O
S2182|pathway|O
S2182|via|O
S2182|depletion|O
S2182|of|O
S2182|IgE-switched|O
S2182|and|O
S2182|memory|O
S2182|B|O
S2182|cells|O
S2182|was|O
S2182|not|O
S2182|sufficient|O
S2182|for|O
S2182|a|O
S2182|clinically|O
S2182|meaningful|O
S2182|benefit|O
S2182|for|O
S2182|adults|O
S2182|with|O
S2182|allergic|O
S2182|asthma|O
S2182|uncontrolled|O
S2182|by|O
S2182|standard|O
S2182|therapy|O
S2182|.|O
S1969|Two|O
S1969|24-h|O
S1969|dietary|O
S1969|recalls|O
S1969|were|O
S1969|obtained|O
S1969|on|O
S1969|separate|O
S1969|days|O
S1969|to|O
S1969|determine|O
S1969|energy|O
S1969|,|O
S1969|phosphorus|O
S1969|and|O
S1969|calcium|O
S1969|intake|O
S1969|.|O
S626|Outcomes|O
S626|The|O
S626|two|O
S626|primary|O
S626|end|O
S626|points|O
S626|were|O
S626|(|O
S626|1|O
S626|)|O
S626|the|O
S626|mean|O
S626|number|O
S626|of|O
S626|new|O
S626|DUs|O
S626|per|O
S626|patient|O
S626|assessed|O
S626|by|O
S626|the|O
S626|investigator|O
S626|up|O
S626|to|O
S626|week|O
S626|24|O
S626|and|O
S626|(|O
S626|2|O
S626|)|O
S626|the|O
S626|time|O
S626|to|O
S626|healing|O
S626|of|O
S626|the|O
S626|cardinal|O
S626|ulcer|O
S626|up|O
S626|to|O
S626|week|O
S626|24|O
S626|in|O
S626|patients|O
S626|with|O
S626|cardinal|O
S626|ulcer|O
S626|healing|O
S626|maintained|O
S626|for|O
S626|12|O
S626|or|O
S626|more|O
S626|weeks|O
S626|.|O
S1107|Primary|O
S1107|analysis|O
S1107|The|O
S1107|primary|O
S1107|analysis|O
S1107|compared|O
S1107|the|O
S1107|clearance|O
S1107|rate|O
S1107|of|O
S1107|all|O
S1107|plantar|O
S1107|warts|O
S1107|at|O
S1107|12|O
S1107|weeks|O
S1107|between|O
S1107|the|O
S1107|two|O
S1107|randomised|O
S1107|groups|O
S1107|using|O
S1107|a|O
S1107|χ2|O
S1107|test|O
S1107|.|O
S210|Data|O
S210|are|O
S210|presented|O
S210|as|O
S210|adjusted|O
S210|mean|O
S210|change|O
S210|from|O
S210|baseline|O
S210|after|O
S210|4|O
S210|weeks|O
S210|of|O
S210|treatment|O
S210|(|O
S210|defined|O
S210|as|O
S210|response|O
S210|)|O
S210|,|O
S210|unless|O
S210|noted|O
S210|otherwise|O
S210|.|O
S2117|Patients|O
S2117|were|O
S2117|not|O
S2117|allowed|O
S2117|to|O
S2117|change|O
S2117|their|O
S2117|medication|O
S2117|regimen|O
S2117|or|O
S2117|STN|O
S2117|stimulation|O
S2117|settings|O
S2117|in|O
S2117|the|O
S2117|3|O
S2117|months|O
S2117|prior|O
S2117|to|O
S2117|the|O
S2117|study|O
S2117|or|O
S2117|during|O
S2117|the|O
S2117|study|O
S2117|itself|O
S2117|.|O
S2220|Exploratory|O
S2220|outcome|O
S2220|measures|O
S2220|included|O
S2220|the|O
S2220|change|O
S2220|in|O
S2220|asthma|O
S2220|control|O
S2220|from|O
S2220|baseline|O
S2220|to|O
S2220|Week|O
S2220|36|O
S2220|,|O
S2220|as|O
S2220|measured|O
S2220|by|O
S2220|the|O
S2220|ACQ-5|O
S2220|.|O
S340|Five|O
S340|further|O
S340|patients|O
S340|discontinued|O
S340|due|O
S340|to|O
S340|SAEs|O
S340|(|O
S340|canakinumab|O
S340|,|O
S340|n=4|O
S340|(|O
S340|1.2|O
S340|%|O
S340|)|O
S340|;|O
S340|colchicine|O
S340|,|O
S340|n=1|O
S340|(|O
S340|0.9|O
S340|%|O
S340|)|O
S340|)|O
S340|.|O
S2212|Ethics|O
S2212|,|O
S2212|consent|O
S2212|,|O
S2212|and|O
S2212|permissions|O
S2212|Quorum|O
S2212|Review|O
S2212|based|O
S2212|in|O
S2212|Seattle|O
S2212|,|O
S2212|WA|O
S2212|was|O
S2212|the|O
S2212|primary|O
S2212|central|O
S2212|IRB|O
S2212|used|O
S2212|by|O
S2212|sites|O
S2212|in|O
S2212|North|O
S2212|America|O
S2212|,|O
S2212|however|O
S2212|multiple|O
S2212|other|O
S2212|site-specific|O
S2212|institutional|O
S2212|review|O
S2212|boards|O
S2212|at|O
S2212|other|O
S2212|global|O
S2212|sites|O
S2212|approved|O
S2212|the|O
S2212|protocol|O
S2212|and|O
S2212|patients|O
S2212|gave|O
S2212|written|O
S2212|,|O
S2212|informed|O
S2212|consent|O
S2212|.|O
S1623|HLA|O
S1623|testing|O
S1623|was|O
S1623|not|O
S1623|done|O
S1623|.|O
S1122|Table|O
S1122|2|O
S1122|summarises|O
S1122|the|O
S1122|baseline|O
S1122|characteristics|O
S1122|of|O
S1122|their|O
S1122|plantar|O
S1122|warts|O
S1122|.|O
S1964|Children|O
S1964|were|O
S1964|eligible|O
S1964|for|O
S1964|enrolment|O
S1964|if|O
S1964|they|O
S1964|had|O
S1964|a|O
S1964|radiographic|O
S1964|score|O
S1964|of|O
S1964|at|O
S1964|least|O
S1964|2.5|O
S1964|on|O
S1964|a|O
S1964|validated|O
S1964|10-point|O
S1964|scoring|O
S1964|method|O
S1964|that|O
S1964|assessed|O
S1964|the|O
S1964|severity|O
S1964|of|O
S1964|rickets|O
S1964|in|O
S1964|the|O
S1964|growth|O
S1964|plates|O
S1964|of|O
S1964|the|O
S1964|distal|O
S1964|radius|O
S1964|and|O
S1964|ulna|O
S1964|and|O
S1964|around|O
S1964|the|O
S1964|knee|O
S1964|.|O
S1887|Non-vascular|O
S1887|mortality|O
S1887|during|O
S1887|the|O
S1887|in-trial|O
S1887|period|O
S1887|accounted|O
S1887|for|O
S1887|580|O
S1887|(|O
S1887|5·6|O
S1887|%|O
S1887|)|O
S1887|deaths|O
S1887|in|O
S1887|participants|O
S1887|allocated|O
S1887|simvastatin|O
S1887|versus|O
S1887|613|O
S1887|(|O
S1887|6·0|O
S1887|%|O
S1887|)|O
S1887|in|O
S1887|those|O
S1887|allocated|O
S1887|placebo|O
S1887|(|O
S1887|p=0·25|O
S1887|;|O
S1887|figure|O
S1887|4|O
S1887|)|O
S1887|.|O
S2084|The|O
S2084|following|O
S2084|parameters|O
S2084|were|O
S2084|analysed|O
S2084|under|O
S2084|standardised|O
S2084|conditions|O
S2084|before|O
S2084|and|O
S2084|after|O
S2084|acute|O
S2084|administration|O
S2084|of|O
S2084|L-dopa|O
S2084|:|O
S2084|gait|O
S2084|(|O
S2084|stride|O
S2084|length|O
S2084|as|O
S2084|primary|O
S2084|criterion|O
S2084|)|O
S2084|,|O
S2084|the|O
S2084|United-Parkinson's-Disease-Rating-Scale|O
S2084|(|O
S2084|UPDRS|O
S2084|)|O
S2084|motor|O
S2084|score|O
S2084|and|O
S2084|its|O
S2084|axial|O
S2084|subscore|O
S2084|,|O
S2084|the|O
S2084|hypertonia|O
S2084|and|O
S2084|strength|O
S2084|of|O
S2084|the|O
S2084|axial|O
S2084|extensors|O
S2084|and|O
S2084|flexors|O
S2084|(|O
S2084|isokinetic|O
S2084|dynamometer|O
S2084|)|O
S2084|,|O
S2084|the|O
S2084|Dyskinesia|O
S2084|Rating|O
S2084|Scale|O
S2084|score|O
S2084|(|O
S2084|DRS|O
S2084|)|O
S2084|and|O
S2084|its|O
S2084|axial|O
S2084|subscore|O
S2084|.|O
S419|Main|O
S419|outcome|O
S419|measure|O
S419|Final|O
S419|height|O
S419|.|O
S1223|The|O
S1223|primary|O
S1223|analysis|O
S1223|was|O
S1223|of|O
S1223|the|O
S1223|proportion|O
S1223|of|O
S1223|patients|O
S1223|alive|O
S1223|and|O
S1223|independent|O
S1223|,|O
S1223|as|O
S1223|defined|O
S1223|by|O
S1223|an|O
S1223|Oxford|O
S1223|Handicap|O
S1223|Score|O
S1223|(|O
S1223|OHS|O
S1223|)|O
S1223|of|O
S1223|0–2|O
S1223|at|O
S1223|6|O
S1223|months|O
S1223|.|O
S1254|The|O
S1254|protocol|O
S1254|was|O
S1254|approved|O
S1254|by|O
S1254|the|O
S1254|Multi-centre|O
S1254|Research|O
S1254|Ethics|O
S1254|Committees|O
S1254|,|O
S1254|Scotland|O
S1254|(|O
S1254|reference|O
S1254|MREC/99/0/78|O
S1254|)|O
S1254|,|O
S1254|and|O
S1254|by|O
S1254|local|O
S1254|ethical|O
S1254|committees|O
S1254|.|O
S1588|For|O
S1588|patients|O
S1588|assigned|O
S1588|to|O
S1588|routine|O
S1588|laboratory|O
S1588|monitoring|O
S1588|,|O
S1588|results|O
S1588|were|O
S1588|returned|O
S1588|every|O
S1588|12|O
S1588|weeks|O
S1588|to|O
S1588|clinicians|O
S1588|;|O
S1588|for|O
S1588|clinically|O
S1588|driven|O
S1588|monitoring|O
S1588|,|O
S1588|toxicity|O
S1588|results|O
S1588|were|O
S1588|only|O
S1588|returned|O
S1588|for|O
S1588|requested|O
S1588|clinical|O
S1588|reasons|O
S1588|or|O
S1588|if|O
S1588|grade|O
S1588|4|O
S1588|.|O
S1891|Despite|O
S1891|previous|O
S1891|concerns|O
S1891|about|O
S1891|the|O
S1891|safety|O
S1891|of|O
S1891|lipid-lowering|O
S1891|treatment|O
S1891|in|O
S1891|elderly|O
S1891|people|O
S1891|and|O
S1891|those|O
S1891|with|O
S1891|below-average|O
S1891|cholesterol|O
S1891|concentrations|O
S1891|,|O
S1891|there|O
S1891|was|O
S1891|no|O
S1891|evidence|O
S1891|of|O
S1891|any|O
S1891|adverse|O
S1891|effect|O
S1891|on|O
S1891|non-vascular|O
S1891|mortality|O
S1891|in|O
S1891|statin-allocated|O
S1891|participants|O
S1891|aged|O
S1891|70|O
S1891|or|O
S1891|older|O
S1891|at|O
S1891|baseline|O
S1891|,|O
S1891|or|O
S1891|those|O
S1891|with|O
S1891|pretreatment|O
S1891|total|O
S1891|cholesterol|O
S1891|concentrations|O
S1891|less|O
S1891|than|O
S1891|5·0|O
S1891|mmol/L|O
S1891|(|O
S1891|webappendix|O
S1891|,|O
S1891|p|O
S1891|6|O
S1891|)|O
S1891|.|O
S870|Results|O
S870|Of|O
S870|the|O
S870|112|B-Sample_Size_Actual_at_Outcome_Analysis
S870|participants|O
S870|,|O
S870|108|O
S870|had|O
S870|complete|O
S870|primary|O
S870|outcome|O
S870|data|O
S870|at|O
S870|baseline|O
S870|and|O
S870|six|O
S870|weeks|O
S870|(|O
S870|57|O
S870|ciclosporin|O
S870|;|O
S870|51|O
S870|prednisolone|O
S870|)|O
S870|.|O
S871|Groups|O
S871|were|O
S871|balanced|O
S871|at|O
S871|baseline|O
S871|.|O
S1718|However|O
S1718|,|O
S1718|at|O
S1718|week|O
S1718|36|O
S1718|(|O
S1718|when|O
S1718|all|O
S1718|children|O
S1718|moved|O
S1718|to|O
S1718|three|O
S1718|drugs|O
S1718|)|O
S1718|,|O
S1718|CD4|O
S1718|percentage|O
S1718|responses|O
S1718|were|O
S1718|significantly|O
S1718|greater|O
S1718|in|O
S1718|the|O
S1718|four-drug|O
S1718|induction|O
S1718|groups|O
S1718|(|O
S1718|p|O
S1718|<|O
S1718|0·0001|O
S1718|;|O
S1718|figure|O
S1718|4|O
S1718|;|O
S1718|appendix|O
S1718|)|O
S1718|.|O
S21|In|O
S21|addition|O
S21|,|O
S21|patients|O
S21|may|O
S21|not|O
S21|take|O
S21|their|O
S21|protective|O
S21|co-therapy|O
S21|along|O
S21|with|O
S21|their|O
S21|NSAID|O
S21|,|O
S21|especially|O
S21|if|O
S21|they|O
S21|are|O
S21|not|O
S21|experiencing|O
S21|any|O
S21|symptoms|O
S21|,|O
S21|and|O
S21|decreased|O
S21|adherence|O
S21|is|O
S21|associated|O
S21|with|O
S21|a|O
S21|significantly|O
S21|increased|O
S21|risk|O
S21|of|O
S21|developing|O
S21|upper|O
S21|GI|O
S21|ulcers|O
S21|or|O
S21|bleeding|O
S21|.|O
S875|In|O
S875|those|O
S875|with|O
S875|healed|O
S875|ulcers|O
S875|,|O
S875|eight|O
S875|(|O
S875|30|O
S875|%|O
S875|)|O
S875|receiving|O
S875|ciclosporin|O
S875|and|O
S875|seven|O
S875|(|O
S875|28|O
S875|%|O
S875|)|O
S875|receiving|O
S875|prednisolone|O
S875|had|O
S875|a|O
S875|recurrence|O
S875|.|O
S231|Higher|O
S231|mean|O
S231|pre-dose|O
S231|PEFam|O
S231|responses|O
S231|(|O
S231|measured|O
S231|with|O
S231|the|O
S231|AM2+®|O
S231|device|O
S231|)|O
S231|were|O
S231|observed|O
S231|with|O
S231|all|O
S231|three|O
S231|tiotropium|O
S231|Respimat®|O
S231|treatments|O
S231|compared|O
S231|with|O
S231|placebo|O
S231|Respimat®|O
S231|(|O
S231|difference|O
S231|from|O
S231|placebo|O
S231|:|O
S231|5|O
S231|μg|O
S231|,|O
S231|20.846|O
S231|L/min|O
S231|;|O
S231|2.5|O
S231|μg|O
S231|,|O
S231|17.895|O
S231|L/min|O
S231|;|O
S231|1.25|O
S231|μg|O
S231|,|O
S231|18.550|O
S231|L/min|O
S231|;|O
S231|all|O
S231|P|O
S231|<|O
S231|0.0001|O
S231|)|O
S231|.|O
S820|Compared|O
S820|with|O
S820|the|O
S820|non-infused|O
S820|arm|O
S820|,|O
S820|substance|O
S820|P|O
S820|caused|O
S820|dose-dependent|O
S820|increases|O
S820|in|O
S820|plasma|O
S820|t-PA|O
S820|activity|O
S820|(|O
S820|ANOVA|O
S820|:|O
S820|p=0.001|O
S820|)|O
S820|.|O
S1220|Summary|O
S1220|Background|O
S1220|Thrombolysis|O
S1220|is|O
S1220|of|O
S1220|net|O
S1220|benefit|O
S1220|in|O
S1220|patients|O
S1220|with|O
S1220|acute|O
S1220|ischaemic|O
S1220|stroke|O
S1220|,|O
S1220|who|O
S1220|are|O
S1220|younger|O
S1220|than|O
S1220|80|O
S1220|years|O
S1220|of|O
S1220|age|O
S1220|and|O
S1220|are|O
S1220|treated|O
S1220|within|O
S1220|4·5|O
S1220|h|O
S1220|of|O
S1220|onset|O
S1220|.|O
S1345|Benefit|O
S1345|was|O
S1345|greatest|O
S1345|in|O
S1345|patients|O
S1345|treated|O
S1345|within|O
S1345|3|O
S1345|h|O
S1345|,|O
S1345|but|O
S1345|there|O
S1345|was|O
S1345|insufficient|O
S1345|power|O
S1345|to|O
S1345|examine|O
S1345|decay|O
S1345|of|O
S1345|benefit|O
S1345|with|O
S1345|time|O
S1345|.|O
S69|The|O
S69|initial|O
S69|results|O
S69|after|O
S69|data|O
S69|lock|O
S69|and|O
S69|unblinding|O
S69|in|O
S69|REDUCE-1|O
S69|for|O
S69|the|O
S69|primary|O
S69|end|O
S69|point|O
S69|of|O
S69|proportion|O
S69|of|O
S69|patients|O
S69|with|O
S69|gastric|O
S69|ulcers|O
S69|at|O
S69|24|O
S69|weeks|O
S69|was|O
S69|12.9|O
S69|%|O
S69|for|O
S69|HZT-501|O
S69|and|O
S69|25.3|O
S69|%|O
S69|for|O
S69|ibuprofen|O
S69|(|O
S69|P=0.0009|O
S69|;|O
S69|NNT=11|O
S69|)|O
S69|.|O
S2102|Patients|O
S2102|Consecutive|O
S2102|patients|O
S2102|(|O
S2102|diagnosed|O
S2102|according|O
S2102|to|O
S2102|Gibb|O
S2102|'s|O
S2102|criteria|O
S2102|and|O
S2102|monitored|O
S2102|at|O
S2102|Lille|B-Settings_Location
S2102|University|I-Settings_Single_Center
S2102|Hospital|I-Settings_Single_Center
S2102|'s|I-Settings_Single_Center
S2102|PD|I-Settings_Single_Center
S2102|clinic|I-Settings_Single_Center
S2102|)|O
S2102|were|O
S2102|invited|O
S2102|to|O
S2102|participate|O
S2102|in|O
S2102|the|O
S2102|study|O
S2102|by|O
S2102|CM|O
S2102|,|O
S2102|AD|O
S2102|,|O
S2102|LD|O
S2102|and|O
S2102|DD|O
S2102|until|O
S2102|the|O
S2102|required|O
S2102|number|O
S2102|of|O
S2102|participants|O
S2102|was|O
S2102|obtained|O
S2102|.|O
S1812|Methods|O
S1812|20|B-Sample_Size_Actual_at_Enrollment
S1812|536|I-Sample_Size_Actual_at_Enrollment
S1812|patients|O
S1812|at|O
S1812|high|O
S1812|risk|O
S1812|of|O
S1812|vascular|O
S1812|and|O
S1812|non-vascular|O
S1812|outcomes|O
S1812|were|O
S1812|allocated|O
S1812|either|O
S1812|40|B-Design_Parallel_Group
S1812|mg|I-Design_Parallel_Group
S1812|simvastatin|I-Design_Parallel_Group
S1812|daily|I-Design_Parallel_Group
S1812|or|I-Design_Parallel_Group
S1812|placebo|I-Design_Parallel_Group
S1812|,|O
S1812|using|O
S1812|minimised|B-Randomization_Type_Minimization
S1812|randomisation|I-Randomization_Type_Minimization
S1812|.|O
S332|For|O
S332|all|O
S332|canakinumab|O
S332|doses|O
S332|≥50|O
S332|mg|O
S332|,|O
S332|median|O
S332|CRP|O
S332|values|O
S332|remained|O
S332|consistently|O
S332|lower|O
S332|than|O
S332|in|O
S332|the|O
S332|colchicine|O
S332|group|O
S332|throughout|O
S332|the|O
S332|study|O
S332|and|O
S332|were|O
S332|below|O
S332|the|O
S332|upper|O
S332|limit|O
S332|of|O
S332|the|O
S332|normal|O
S332|range|O
S332|(|O
S332|ULN|O
S332|,|O
S332|3.0|O
S332|mg/dl|O
S332|)|O
S332|up|O
S332|to|O
S332|week|O
S332|24|O
S332|.|O
S637|Missing|O
S637|data|O
S637|on|O
S637|new|O
S637|DUs|O
S637|were|O
S637|imputed|O
S637|using|O
S637|extrapolation|O
S637|,|O
S637|with|O
S637|the|O
S637|incidence|O
S637|rate|O
S637|of|O
S637|new|O
S637|DUs|O
S637|at|O
S637|the|O
S637|last|O
S637|assessment|O
S637|corrected|O
S637|for|O
S637|the|O
S637|missing|O
S637|time|O
S637|period|O
S637|.|O
S1734|The|O
S1734|most|O
S1734|common|O
S1734|modification|O
S1734|(|O
S1734|13|O
S1734|children|O
S1734|in|O
S1734|group|O
S1734|B|O
S1734|,|O
S1734|14|O
S1734|in|O
S1734|C|O
S1734|)|O
S1734|was|O
S1734|to|O
S1734|stop|O
S1734|(|O
S1734|on|O
S1734|four-drug|O
S1734|regimen|O
S1734|)|O
S1734|or|O
S1734|substitute|O
S1734|zidovudine|O
S1734|because|O
S1734|of|O
S1734|anaemia|O
S1734|,|O
S1734|even|O
S1734|though|O
S1734|grade|O
S1734|3|O
S1734|and|O
S1734|4|O
S1734|anaemias|O
S1734|occurred|O
S1734|similarly|O
S1734|across|O
S1734|all|O
S1734|three|O
S1734|groups|O
S1734|.|O
S269|It|O
S269|results|O
S269|from|O
S269|deposition|O
S269|of|O
S269|monosodium|O
S269|urate|O
S269|(|O
S269|MSU|O
S269|)|O
S269|crystals|O
S269|in|O
S269|joints|O
S269|,|O
S269|which|O
S269|leads|O
S269|to|O
S269|painful|O
S269|inflammatory|O
S269|acute|O
S269|gouty|O
S269|arthritis|O
S269|flares|O
S269|.|O
S877|Conclusion|O
S877|Prednisolone|O
S877|and|O
S877|ciclosporin|O
S877|did|O
S877|not|O
S877|differ|O
S877|across|O
S877|a|O
S877|range|O
S877|of|O
S877|objective|O
S877|and|O
S877|patient|O
S877|reported|O
S877|outcomes|O
S877|.|O
S2242|For|O
S2242|patients|O
S2242|who|O
S2242|discontinued|O
S2242|the|O
S2242|study|O
S2242|prematurely|O
S2242|,|O
S2242|there|O
S2242|was|O
S2242|no|O
S2242|imputation|O
S2242|of|O
S2242|additional|O
S2242|exacerbations|O
S2242|.|O
S1599|Excess|O
S1599|grade|O
S1599|3|O
S1599|or|O
S1599|4|O
S1599|events|O
S1599|in|O
S1599|groups|O
S1599|B|O
S1599|(|O
S1599|one|O
S1599|or|O
S1599|more|O
S1599|events|O
S1599|reported|O
S1599|by|O
S1599|157|O
S1599|[|O
S1599|40|O
S1599|%|O
S1599|]|O
S1599|children|O
S1599|in|O
S1599|A|O
S1599|,|O
S1599|190|O
S1599|[|O
S1599|47|O
S1599|%|O
S1599|]|O
S1599|in|O
S1599|B|O
S1599|;|O
S1599|HR|O
S1599|[|O
S1599|B|O
S1599|:|O
S1599|A|O
S1599|]|O
S1599|1·32|O
S1599|,|O
S1599|1·07–1·63|O
S1599|)|O
S1599|and|O
S1599|C|O
S1599|(|O
S1599|218|O
S1599|[|O
S1599|54|O
S1599|%|O
S1599|]|O
S1599|children|O
S1599|in|O
S1599|C|O
S1599|;|O
S1599|HR|O
S1599|[|O
S1599|C|O
S1599|:|O
S1599|A|O
S1599|]|O
S1599|1·58|O
S1599|,|O
S1599|1·29–1·94|O
S1599|;|O
S1599|global|O
S1599|p=0·0001|O
S1599|)|O
S1599|were|O
S1599|driven|O
S1599|by|O
S1599|asymptomatic|O
S1599|neutropenia|O
S1599|in|O
S1599|zidovudine-containing|O
S1599|groups|O
S1599|(|O
S1599|B|O
S1599|,|O
S1599|C|O
S1599|;|O
S1599|86|O
S1599|group|O
S1599|A|O
S1599|,|O
S1599|133|O
S1599|group|O
S1599|B|O
S1599|,|O
S1599|184|O
S1599|group|O
S1599|C|O
S1599|)|O
S1599|,|O
S1599|but|O
S1599|resulted|O
S1599|in|O
S1599|drug|O
S1599|substitutions|O
S1599|in|O
S1599|only|O
S1599|zero|O
S1599|versus|O
S1599|two|O
S1599|versus|O
S1599|four|O
S1599|children|O
S1599|,|O
S1599|respectively|O
S1599|.|O
S1638|Children|O
S1638|were|O
S1638|reviewed|O
S1638|every|O
S1638|4–6|O
S1638|weeks|O
S1638|by|O
S1638|a|O
S1638|nurse|O
S1638|using|O
S1638|a|O
S1638|standard|O
S1638|symptom|O
S1638|checklist|O
S1638|.|O
S1237|The|O
S1237|burden|O
S1237|of|O
S1237|ischaemic|O
S1237|stroke|O
S1237|among|O
S1237|the|O
S1237|elderly|O
S1237|is|O
S1237|large|O
S1237|and|O
S1237|increasing|O
S1237|;|O
S1237|and|O
S1237|we|O
S1237|estimate|O
S1237|that|O
S1237|annually|O
S1237|ischaemic|O
S1237|stroke|O
S1237|affects|O
S1237|about|O
S1237|a|O
S1237|million|O
S1237|people|O
S1237|older|O
S1237|than|O
S1237|80|O
S1237|years|O
S1237|of|O
S1237|age|O
S1237|in|O
S1237|high-income|O
S1237|countries|O
S1237|and|O
S1237|about|O
S1237|3|O
S1237|million|O
S1237|in|O
S1237|low-income|O
S1237|and|O
S1237|middle-income|O
S1237|countries|O
S1237|.|O
S238|Both|O
S238|of|O
S238|this|O
S238|patient|O
S238|’|O
S238|s|O
S238|adverse|O
S238|events|O
S238|accounted|O
S238|for|O
S238|discontinuation|O
S238|of|O
S238|the|O
S238|study|O
S238|drug|O
S238|(|O
S238|the|O
S238|only|O
S238|case|O
S238|of|O
S238|discontinuation|O
S238|during|O
S238|the|O
S238|trial|O
S238|)|O
S238|.|O
S1693|Although|O
S1693|overall|O
S1693|progression|O
S1693|was|O
S1693|similar|O
S1693|,|O
S1693|a|O
S1693|prespecified|O
S1693|subgroup|O
S1693|analysis|O
S1693|showed|O
S1693|children|O
S1693|on|O
S1693|routine|O
S1693|laboratory|O
S1693|monitoring|O
S1693|had|O
S1693|higher|O
S1693|event|O
S1693|rates|O
S1693|during|O
S1693|the|O
S1693|first|O
S1693|3|O
S1693|months|O
S1693|on|O
S1693|ART|O
S1693|and|O
S1693|lower|O
S1693|rates|O
S1693|from|O
S1693|the|O
S1693|second|O
S1693|year|O
S1693|on|O
S1693|ART|O
S1693|compared|O
S1693|with|O
S1693|those|O
S1693|on|O
S1693|clinically|O
S1693|driven|O
S1693|monitoring|O
S1693|(|O
S1693|heterogeneity|O
S1693|p=0·045|O
S1693|;|O
S1693|appendix|O
S1693|)|O
S1693|.|O
S2092|Introduction|O
S2092|In|O
S2092|late-stage|O
S2092|Parkinson|O
S2092|'s|O
S2092|disease|O
S2092|(|O
S2092|PD|O
S2092|)|O
S2092|,|O
S2092|axial|O
S2092|signs|O
S2092|(|O
S2092|notably|O
S2092|with|O
S2092|gait|O
S2092|disorders|O
S2092|,|O
S2092|such|O
S2092|as|O
S2092|hypokinesia|O
S2092|)|O
S2092|,|O
S2092|abnormal|O
S2092|posture|O
S2092|,|O
S2092|falls|O
S2092|and|O
S2092|poor|O
S2092|balance|O
S2092|reduce|O
S2092|personal|O
S2092|independence|O
S2092|and|O
S2092|may|O
S2092|prompt|O
S2092|institutionalisation|O
S2092|.|O
S1116|A|O
S1116|Cox|O
S1116|proportional|O
S1116|hazards|O
S1116|model|O
S1116|was|O
S1116|used|O
S1116|to|O
S1116|compare|O
S1116|the|O
S1116|time|O
S1116|to|O
S1116|clearance|O
S1116|of|O
S1116|plantar|O
S1116|warts|O
S1116|between|O
S1116|the|O
S1116|two|O
S1116|groups|O
S1116|adjusting|O
S1116|for|O
S1116|the|O
S1116|same|O
S1116|covariates|O
S1116|as|O
S1116|for|O
S1116|the|O
S1116|primary|O
S1116|outcome|O
S1116|.|O
S270|An|O
S270|increasing|O
S270|number|O
S270|of|O
S270|patients|O
S270|have|O
S270|comorbidities|O
S270|which|O
S270|make|O
S270|standard|O
S270|therapies|O
S270|inappropriate|O
S270|.|O
S1714|Differences|O
S1714|in|O
S1714|time|O
S1714|to|O
S1714|first|O
S1714|hospital|O
S1714|admission|O
S1714|were|O
S1714|smaller|O
S1714|(|O
S1714|HR|O
S1714|1·18|O
S1714|,|O
S1714|0·99–1·41|O
S1714|,|O
S1714|p=0·07|O
S1714|)|O
S1714|,|O
S1714|with|O
S1714|no|O
S1714|difference|O
S1714|in|O
S1714|duration|O
S1714|of|O
S1714|admission|O
S1714|(|O
S1714|median|O
S1714|5|O
S1714|[|O
S1714|IQR|O
S1714|3–6|O
S1714|]|O
S1714|days|O
S1714|in|O
S1714|clinically|O
S1714|driven|O
S1714|and|O
S1714|routine|O
S1714|laboratory|O
S1714|monitoring|O
S1714|;|O
S1714|rank-sum|O
S1714|p=0·54|O
S1714|)|O
S1714|.|O
S493|Similarly|O
S493|,|O
S493|for|O
S493|randomisation|O
S493|2|O
S493|,|O
S493|final|O
S493|height|O
S493|was|O
S493|significantly|O
S493|greater|O
S493|with|O
S493|pubertal|O
S493|induction|O
S493|at|O
S493|14|O
S493|years|O
S493|than|O
S493|at|O
S493|12|O
S493|years|O
S493|(|O
S493|3.8|O
S493|cm|O
S493|,|O
S493|0.0|O
S493|to|O
S493|7.5|O
S493|;|O
S493|P=0.05|O
S493|)|O
S493|.|O
S1699|Progression|O
S1699|to|O
S1699|new|O
S1699|WHO|O
S1699|stage|O
S1699|3|O
S1699|or|O
S1699|4|O
S1699|events|O
S1699|or|O
S1699|death|O
S1699|gave|O
S1699|similar|O
S1699|results|O
S1699|(|O
S1699|HR|O
S1699|[|O
S1699|clinically|O
S1699|driven|O
S1699|:|O
S1699|routine|O
S1699|laboratory|O
S1699|monitoring|O
S1699|]|O
S1699|1·00|O
S1699|,|O
S1699|0·73–1·38|O
S1699|;|O
S1699|p=0·98|O
S1699|;|O
S1699|appendix|O
S1699|)|O
S1699|.|O
S1706|Weight|O
S1706|for|O
S1706|age|O
S1706|and|O
S1706|height|O
S1706|for|O
S1706|age|O
S1706|did|O
S1706|not|O
S1706|differ|O
S1706|significantly|O
S1706|between|O
S1706|groups|O
S1706|(|O
S1706|p=0·71|O
S1706|,|O
S1706|p=0·07|O
S1706|;|O
S1706|appendix|O
S1706|)|O
S1706|.|O
S502|The|O
S502|age|O
S502|of|O
S502|attainment|O
S502|of|O
S502|final|O
S502|height|O
S502|was|O
S502|similar|O
S502|for|O
S502|oxandrolone|O
S502|and|O
S502|placebo|O
S502|(|O
S502|16.2|O
S502|v|O
S502|16.7|O
S502|years|O
S502|;|O
S502|P=0.1|O
S502|)|O
S502|and|O
S502|later|O
S502|,|O
S502|by|O
S502|design|O
S502|,|O
S502|for|O
S502|late|O
S502|versus|O
S502|early|O
S502|induction|O
S502|(|O
S502|16.9|O
S502|v|O
S502|16.1|O
S502|years|O
S502|;|O
S502|P=0.009|O
S502|)|O
S502|.|O
S1110|We|O
S1110|also|O
S1110|extended|O
S1110|the|O
S1110|primary|O
S1110|outcome|O
S1110|model|O
S1110|to|O
S1110|explore|O
S1110|the|O
S1110|effect|O
S1110|of|O
S1110|patient|O
S1110|preferences|O
S1110|by|O
S1110|including|O
S1110|preference|O
S1110|and|O
S1110|an|O
S1110|interaction|O
S1110|term|O
S1110|between|O
S1110|preferred|O
S1110|treatment|O
S1110|and|O
S1110|randomised|O
S1110|treatment|O
S1110|.|O
S469|Data|O
S469|collection|O
S469|ceased|O
S469|if|O
S469|participants|O
S469|withdrew|O
S469|consent|O
S469|,|O
S469|although|O
S469|we|O
S469|included|O
S469|previously|O
S469|collected|O
S469|data|O
S469|in|O
S469|the|O
S469|analysis|O
S469|.|O
S165|Tiotropium|O
S165|,|O
S165|a|O
S165|once-daily|O
S165|long-acting|O
S165|anticholinergic|O
S165|bronchodilator|O
S165|,|O
S165|is|O
S165|the|O
S165|established|O
S165|first-line|O
S165|maintenance|O
S165|bronchodilator|O
S165|for|O
S165|the|O
S165|management|O
S165|of|O
S165|chronic|O
S165|obstructive|O
S165|pulmonary|O
S165|disease|O
S165|.|O
S923|Assessments|O
S923|Clinic|O
S923|visits|O
S923|took|O
S923|place|O
S923|at|O
S923|baseline|O
S923|,|O
S923|week|O
S923|2|O
S923|,|O
S923|and|O
S923|week|O
S923|6|O
S923|(|O
S923|primary|O
S923|outcome|O
S923|)|O
S923|and|O
S923|when|O
S923|the|O
S923|ulcer|O
S923|had|O
S923|healed|O
S923|(|O
S923|up|O
S923|to|O
S923|a|O
S923|maximum|O
S923|of|O
S923|six|O
S923|months|O
S923|)|O
S923|.|O
S1825|Introduction|O
S1825|The|O
S1825|Medical|O
S1825|Research|O
S1825|Council|O
S1825|and|O
S1825|British|O
S1825|Heart|O
S1825|Foundation|O
S1825|(|O
S1825|MRC/BHF|O
S1825|)|O
S1825|Heart|O
S1825|Protection|O
S1825|Study|O
S1825|(|O
S1825|HPS|O
S1825|)|O
S1825|,|O
S1825|among|O
S1825|20|O
S1825|000|O
S1825|patients|O
S1825|at|O
S1825|high|O
S1825|risk|O
S1825|of|O
S1825|vascular|O
S1825|and|O
S1825|non-vascular|O
S1825|outcomes|O
S1825|,|O
S1825|was|O
S1825|established|O
S1825|to|O
S1825|assess|O
S1825|the|O
S1825|long-term|O
S1825|efficacy|O
S1825|and|O
S1825|safety|O
S1825|of|O
S1825|lowering|O
S1825|LDL|O
S1825|cholesterol|O
S1825|concentrations|O
S1825|substantially|O
S1825|with|O
S1825|statin|O
S1825|treatment|O
S1825|.|O
S2265|(|O
S2265|see|O
S2265|Additional|O
S2265|file|O
S2265|1|O
S2265|:|O
S2265|Figure|O
S2265|S2|O
S2265|)|O
S2265|.|O
S1993|Data|O
S1993|analysis|O
S1993|was|O
S1993|performed|O
S1993|with|O
S1993|Excel|O
S1993|2003|O
S1993|(|O
S1993|Microsoft|O
S1993|Corp.|O
S1993|,|O
S1993|Redmond|O
S1993|,|O
S1993|Washington|O
S1993|,|O
S1993|USA|O
S1993|)|O
S1993|and|O
S1993|JMP|O
S1993|V.9.0.1|O
S1993|(|O
S1993|SAS|O
S1993|Institute|O
S1993|Inc.|O
S1993|,|O
S1993|Cary|O
S1993|,|O
S1993|North|O
S1993|Carolina|O
S1993|,|O
S1993|USA|O
S1993|)|O
S1993|.|O
S1700|Pulmonary|O
S1700|tuberculosis|O
S1700|was|O
S1700|the|O
S1700|commonest|O
S1700|WHO|O
S1700|stage|O
S1700|3|O
S1700|event|O
S1700|(|O
S1700|25|O
S1700|clinically|O
S1700|driven|O
S1700|monitoring|O
S1700|,|O
S1700|28|O
S1700|routine|O
S1700|laboratory|O
S1700|monitoring|O
S1700|)|O
S1700|.|O
S645|All|O
S645|188|B-Sample_Size_Actual_at_Enrollment
S645|randomised|O
S645|patients|O
S645|received|O
S645|study|O
S645|treatment|O
S645|,|O
S645|with|O
S645|mean|O
S645|exposures|O
S645|of|O
S645|22.7±0.9|O
S645|and|O
S645|24.5±0.9|O
S645|weeks|O
S645|in|O
S645|the|O
S645|bosentan|O
S645|and|O
S645|placebo|O
S645|groups|O
S645|,|O
S645|respectively|O
S645|.|O
S1090|Clearance|O
S1090|of|O
S1090|plantar|O
S1090|wart|O
S1090|was|O
S1090|defined|O
S1090|as|O
S1090|the|O
S1090|restoration|O
S1090|of|O
S1090|normal|O
S1090|skin|O
S1090|on|O
S1090|close|O
S1090|inspection|O
S1090|.|O
S1259|The|O
S1259|system|O
S1259|used|O
S1259|a|O
S1259|minimisation|B-Randomization_Type_Minimization
S1259|algorithm|O
S1259|to|O
S1259|achieve|O
S1259|optimum|O
S1259|balance|O
S1259|for|O
S1259|key|B-Randomization_Minimization_Criteria
S1259|prognostic|I-Randomization_Minimization_Criteria
S1259|factors|I-Randomization_Minimization_Criteria
S1259|(|O
S1259|table|O
S1259|1|O
S1259|)|O
S1259|,|O
S1259|and|O
S1259|from|O
S1259|January|O
S1259|,|O
S1259|2006|O
S1259|,|O
S1259|minimisation|B-Randomization_Type_Minimization
S1259|was|O
S1259|additionally|O
S1259|stratified|B-Randomization_Type_Stratified
S1259|by|O
S1259|world|B-Randomization_Stratified_Criteria
S1259|region|I-Randomization_Stratified_Criteria
S1259|and|O
S1259|then|O
S1259|minimised|B-Randomization_Type_Minimization
S1259|on|O
S1259|all|B-Randomization_Minimization_Criteria
S1259|the|I-Randomization_Minimization_Criteria
S1259|other|I-Randomization_Minimization_Criteria
S1259|key|I-Randomization_Minimization_Criteria
S1259|factors|I-Randomization_Minimization_Criteria
S1259|within|I-Randomization_Minimization_Criteria
S1259|regions|I-Randomization_Minimization_Criteria
S1259|.|O
S1501|Median|O
S1501|(|O
S1501|range|O
S1501|)|O
S1501|times|O
S1501|to|O
S1501|death|O
S1501|were|O
S1501|2|O
S1501|days|O
S1501|(|O
S1501|1-12|O
S1501|)|O
S1501|in|O
S1501|those|O
S1501|with|O
S1501|avian|O
S1501|H5N1|O
S1501|and|O
S1501|5.5|O
S1501|days|O
S1501|(|O
S1501|1-13|O
S1501|)|O
S1501|days|O
S1501|in|O
S1501|those|O
S1501|with|O
S1501|other|O
S1501|influenza|O
S1501|viruses|O
S1501|(|O
S1501|table|O
S1501|5|O
S1501|)|O
S1501|.|O
S2096|The|O
S2096|N-methyl-D-aspartic-acid-related|O
S2096|(|O
S2096|NMDA|O
S2096|)|O
S2096|receptor|O
S2096|antagonist|O
S2096|MK-801|O
S2096|was|O
S2096|found|O
S2096|to|O
S2096|facilitate|O
S2096|locomotion|O
S2096|in|O
S2096|a|O
S2096|rat|O
S2096|model|O
S2096|of|O
S2096|PD|O
S2096|with|O
S2096|bilateral|O
S2096|PPN|O
S2096|lesions|O
S2096|.|O
S262|The|O
S262|estimated|O
S262|canakinumab|O
S262|dose|O
S262|with|O
S262|equivalent|O
S262|efficacy|O
S262|to|O
S262|colchicine|O
S262|was|O
S262|below|O
S262|the|O
S262|range|O
S262|of|O
S262|doses|O
S262|tested|O
S262|.|O
S777|Platelet-free|O
S777|plasma|O
S777|was|O
S777|decanted|O
S777|and|O
S777|stored|O
S777|at|O
S777|-80°C|O
S777|before|O
S777|assay|O
S777|.|O
S1943|Baseline|O
S1943|alkaline|O
S1943|phosphatase|O
S1943|and|O
S1943|radiographic|O
S1943|scores|O
S1943|were|O
S1943|unrelated|O
S1943|to|O
S1943|vitamin|O
S1943|D|O
S1943|status|O
S1943|.|O
S740|Etanercept|O
S740|treatment|O
S740|reduced|O
S740|neutrophil|O
S740|(|O
S740|7.4±0.6|O
S740|vs|O
S740|8.8±0.6×109|O
S740|cells/l|O
S740|;|O
S740|p=0.03|O
S740|)|O
S740|and|O
S740|plasma|O
S740|interleukin-6|O
S740|concentrations|O
S740|(|O
S740|5.8±2.0|O
S740|vs|O
S740|10.6±4.0|O
S740|pg/ml|O
S740|;|O
S740|p=0.012|O
S740|)|O
S740|at|O
S740|24|O
S740|h|O
S740|but|O
S740|increased|O
S740|platelet–monocyte|O
S740|aggregation|O
S740|(|O
S740|30±5|O
S740|vs|O
S740|20±3|O
S740|%|O
S740|;|O
S740|p=0.02|O
S740|)|O
S740|.|O
S216|Testing|O
S216|was|O
S216|performed|O
S216|with|O
S216|α|O
S216|=|O
S216|0.025|B-Sample_Size_Calculation_Alpha_Value
S216|(|I-Sample_Size_Calculation_Alpha_Value
S216|one-sided|I-Sample_Size_Calculation_Alpha_Value
S216|)|I-Sample_Size_Calculation_Alpha_Value
S216|.|O
S2124|The|O
S2124|L-dopa|O
S2124|dose|O
S2124|used|O
S2124|in|O
S2124|the|O
S2124|assessment|O
S2124|was|O
S2124|150|O
S2124|%|O
S2124|of|O
S2124|the|O
S2124|usual|O
S2124|,|O
S2124|first|O
S2124|morning|O
S2124|dose|O
S2124|taken|O
S2124|by|O
S2124|patients|O
S2124|to|O
S2124|relieve|O
S2124|their|O
S2124|symptoms|O
S2124|(|O
S2124|table|O
S2124|1|O
S2124|)|O
S2124|.|O
S422|In|O
S422|the|O
S422|48|O
S422|children|O
S422|who|O
S422|were|O
S422|randomised|O
S422|twice|O
S422|,|O
S422|the|O
S422|effects|O
S422|on|O
S422|final|O
S422|height|O
S422|(|O
S422|compared|O
S422|with|O
S422|placebo|O
S422|and|O
S422|early|O
S422|induction|O
S422|of|O
S422|puberty|O
S422|)|O
S422|of|O
S422|oxandrolone|O
S422|alone|O
S422|,|O
S422|late|O
S422|induction|O
S422|alone|O
S422|,|O
S422|and|O
S422|oxandrolone|O
S422|plus|O
S422|late|O
S422|induction|O
S422|were|O
S422|similar|O
S422|,|O
S422|averaging|O
S422|7.1|O
S422|(|O
S422|3.4|O
S422|to|O
S422|10.8|O
S422|)|O
S422|cm|O
S422|(|O
S422|P|O
S422|<|O
S422|0.001|O
S422|)|O
S422|.|O
S1813|Mean|O
S1813|in-trial|O
S1813|follow-up|O
S1813|was|O
S1813|5·3|O
S1813|years|O
S1813|(|O
S1813|SD|O
S1813|1·2|O
S1813|)|O
S1813|,|O
S1813|and|O
S1813|post-trial|O
S1813|follow-up|O
S1813|of|O
S1813|surviving|O
S1813|patients|O
S1813|yielded|O
S1813|a|O
S1813|mean|O
S1813|total|O
S1813|duration|O
S1813|of|O
S1813|11·0|O
S1813|years|O
S1813|(|O
S1813|SD|O
S1813|0·6|O
S1813|)|O
S1813|.|O
S1073|Study|O
S1073|population|O
S1073|Participants|O
S1073|were|O
S1073|eligible|O
S1073|for|O
S1073|the|O
S1073|study|O
S1073|if|O
S1073|they|O
S1073|were|O
S1073|aged|O
S1073|12|O
S1073|years|O
S1073|or|O
S1073|over|O
S1073|and|O
S1073|had|O
S1073|a|O
S1073|plantar|O
S1073|wart|O
S1073|(|O
S1073|verruca|O
S1073|)|O
S1073|that|O
S1073|,|O
S1073|in|O
S1073|the|O
S1073|opinion|O
S1073|of|O
S1073|a|O
S1073|healthcare|O
S1073|professional|O
S1073|,|O
S1073|was|O
S1073|suitable|O
S1073|for|O
S1073|treatment|O
S1073|with|O
S1073|both|O
S1073|salicylic|O
S1073|acid|O
S1073|and|O
S1073|cryotherapy|O
S1073|.|O
S928|Two|O
S928|dermatologists|O
S928|independently|O
S928|reviewed|O
S928|all|O
S928|images|O
S928|to|O
S928|ensure|O
S928|that|O
S928|the|O
S928|lesions|O
S928|were|O
S928|consistent|O
S928|with|O
S928|a|O
S928|diagnosis|O
S928|of|O
S928|pyoderma|O
S928|gangrenosum|O
S928|and|O
S928|that|O
S928|the|O
S928|measurements|O
S928|taken|O
S928|by|O
S928|the|O
S928|trained|O
S928|assessors|O
S928|were|O
S928|an|O
S928|accurate|O
S928|representation|O
S928|of|O
S928|the|O
S928|ulcer|O
S928|’|O
S928|s|O
S928|size|O
S928|.|O
S2207|Patients|O
S2207|were|O
S2207|randomly|O
S2207|assigned|O
S2207|(|O
S2207|1:1:1:1|B-Randomization_Ratio
S2207|)|O
S2207|to|O
S2207|one|B-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|three|I-Design_Parallel_Group
S2207|dosing|I-Design_Parallel_Group
S2207|regimens|I-Design_Parallel_Group
S2207|of|I-Design_Parallel_Group
S2207|quilizumab|I-Design_Parallel_Group
S2207|or|I-Design_Parallel_Group
S2207|placebo|I-Design_Parallel_Group
S2207|using|O
S2207|an|B-Randomization_Sequence_Generation_Method
S2207|interactive|I-Randomization_Sequence_Generation_Method
S2207|web|I-Randomization_Sequence_Generation_Method
S2207|response|I-Randomization_Sequence_Generation_Method
S2207|system|I-Randomization_Sequence_Generation_Method
S2207|.|O
S1139|There|O
S1139|was|O
S1139|no|O
S1139|evidence|O
S1139|of|O
S1139|a|O
S1139|difference|O
S1139|in|O
S1139|the|O
S1139|time|O
S1139|to|O
S1139|clearance|O
S1139|between|O
S1139|cryotherapy|O
S1139|and|O
S1139|salicylic|O
S1139|acid|O
S1139|in|O
S1139|the|O
S1139|Cox|O
S1139|proportional|O
S1139|hazards|O
S1139|model|O
S1139|(|O
S1139|hazard|O
S1139|ratio|O
S1139|0.80|O
S1139|(|O
S1139|0.51|O
S1139|to|O
S1139|1.25|O
S1139|)|O
S1139|,|O
S1139|P=0.33|O
S1139|)|O
S1139|.|O
S1472|All|O
S1472|patients|O
S1472|with|O
S1472|H5N1|O
S1472|met|O
S1472|criteria|O
S1472|for|O
S1472|severe|O
S1472|influenza|O
S1472|and|O
S1472|were|O
S1472|therefore|O
S1472|analysed|O
S1472|as|O
S1472|such|O
S1472|.|O
S1949|Trial|O
S1949|registration|O
S1949|number|O
S1949|ClinicalTrials.gov|O
S1949|NCT00949832|O
S1949|.|O
S944|Sample|O
S944|size|O
S944|This|O
S944|was|O
S944|a|O
S944|superiority|B-Design_Comparative_Intent_Superiority
S944|trial|O
S944|,|O
S944|with|O
S944|prednisolone|O
S944|as|O
S944|the|O
S944|control|O
S944|intervention|O
S944|.|O
S1946|At|O
S1946|the|O
S1946|end|O
S1946|of|O
S1946|24|O
S1946|weeks|O
S1946|,|O
S1946|25|O
S1946|(|O
S1946|OH|O
S1946|)|O
S1946|D|O
S1946|values|O
S1946|were|O
S1946|55.4±17.0|O
S1946|nmol/L|O
S1946|and|O
S1946|37.9±20.0|O
S1946|nmol/L|O
S1946|in|O
S1946|the|O
S1946|Ca+D|O
S1946|and|O
S1946|Ca|O
S1946|groups|O
S1946|,|O
S1946|respectively|O
S1946|,|O
S1946|(|O
S1946|p|O
S1946|<|O
S1946|0.001|O
S1946|)|O
S1946|.|O
S1680|Adherence|O
S1680|by|O
S1680|self-reported|O
S1680|questionnaire|O
S1680|was|O
S1680|similar|O
S1680|in|O
S1680|both|O
S1680|monitoring|O
S1680|groups|O
S1680|:|O
S1680|mean|O
S1680|6·7|O
S1680|%|O
S1680|(|O
S1680|1813/26|O
S1680|917|O
S1680|)|O
S1680|of|O
S1680|children|O
S1680|on|O
S1680|clinically|O
S1680|driven|O
S1680|monitoring|O
S1680|reported|O
S1680|missing|O
S1680|doses|O
S1680|in|O
S1680|the|O
S1680|past|O
S1680|28|O
S1680|days|O
S1680|versus|O
S1680|6·5|O
S1680|%|O
S1680|(|O
S1680|1683/25|O
S1680|935|O
S1680|)|O
S1680|on|O
S1680|routine|O
S1680|laboratory|O
S1680|monitoring|O
S1680|(|O
S1680|p=0·26|O
S1680|)|O
S1680|.|O
S348|Injection-site|O
S348|reactions|O
S348|were|O
S348|reported|O
S348|in|O
S348|20|O
S348|(|O
S348|6.2|O
S348|%|O
S348|)|O
S348|patients|O
S348|treated|O
S348|with|O
S348|canakinumab|O
S348|and|O
S348|4|O
S348|(|O
S348|3.7|O
S348|%|O
S348|)|O
S348|patients|O
S348|in|O
S348|the|O
S348|colchicine|O
S348|group|O
S348|.|O
S507|Comparison|O
S507|of|O
S507|the|O
S507|mean|O
S507|values|O
S507|of|O
S507|the|O
S507|parameters|O
S507|by|O
S507|trial|O
S507|arm|O
S507|showed|O
S507|differences|O
S507|in|O
S507|size|O
S507|(|O
S507|oxandrolone|O
S507|v|O
S507|placebo|O
S507|+2.6|O
S507|cm|O
S507|;|O
S507|P=0.02|O
S507|)|O
S507|but|O
S507|not|O
S507|tempo|O
S507|(|O
S507|−0.3|O
S507|years|O
S507|;|O
S507|P=0.1|O
S507|)|O
S507|,|O
S507|and|O
S507|the|O
S507|mean|O
S507|velocity|O
S507|was|O
S507|dramatically|O
S507|greater|O
S507|for|O
S507|oxandrolone|O
S507|(|O
S507|difference|O
S507|+23|O
S507|%|O
S507|,|O
S507|SE|O
S507|4|O
S507|%|O
S507|;|O
S507|P|O
S507|<|O
S507|0.001|O
S507|)|O
S507|.|O
S297|Assessments|O
S297|Flares|O
S297|were|O
S297|patient|O
S297|reported|O
S297|.|O
S273|An|O
S273|important|O
S273|goal|O
S273|in|O
S273|the|O
S273|long-term|O
S273|management|O
S273|of|O
S273|gouty|O
S273|arthritis|O
S273|is|O
S273|the|O
S273|reduction|O
S273|of|O
S273|SU|O
S273|levels|O
S273|to|O
S273|below|O
S273|6|O
S273|mg/dl|O
S273|so|O
S273|as|O
S273|to|O
S273|prevent|O
S273|formation|O
S273|of|O
S273|new|O
S273|crystals|O
S273|,|O
S273|dissolve|O
S273|existing|O
S273|crystals|O
S273|and|O
S273|ultimately|O
S273|decrease|O
S273|the|O
S273|incidence|O
S273|of|O
S273|flares|O
S273|.|O
S2267|For|O
S2267|the|O
S2267|150|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|450|O
S2267|mg|O
S2267|Q|O
S2267|,|O
S2267|and|O
S2267|300|O
S2267|mg|O
S2267|M|O
S2267|doses|O
S2267|,|O
S2267|the|O
S2267|mean|O
S2267|Cmax|O
S2267|,|O
S2267|obs|O
S2267|values|O
S2267|were|O
S2267|18|O
S2267|±|O
S2267|7.8|O
S2267|μg/mL|O
S2267|,|O
S2267|51.6|O
S2267|±|O
S2267|19.5|O
S2267|μg/mL|O
S2267|,|O
S2267|and|O
S2267|34|O
S2267|±|O
S2267|12.6|O
S2267|μg/mL|O
S2267|,|O
S2267|which|O
S2267|occurred|O
S2267|at|O
S2267|Tmax|O
S2267|,|O
S2267|obs|O
S2267|of|O
S2267|36.4|O
S2267|±|O
S2267|4.3|O
S2267|days|O
S2267|,|O
S2267|36.2|O
S2267|±|O
S2267|3.0|O
S2267|days|O
S2267|,|O
S2267|and|O
S2267|36.2|O
S2267|±|O
S2267|3.5|O
S2267|days|O
S2267|,|O
S2267|respectively|O
S2267|,|O
S2267|approximately|O
S2267|7|O
S2267|days|O
S2267|following|O
S2267|the|O
S2267|second|O
S2267|doses|O
S2267|.|O
S417|Interventions|O
S417|Participants|O
S417|were|O
S417|randomised|O
S417|to|O
S417|oxandrolone|B-Design_Parallel_Group
S417|(|I-Design_Parallel_Group
S417|0.05|I-Design_Parallel_Group
S417|mg/kg/day|I-Design_Parallel_Group
S417|,|I-Design_Parallel_Group
S417|maximum|I-Design_Parallel_Group
S417|2.5|I-Design_Parallel_Group
S417|mg/day|I-Design_Parallel_Group
S417|)|I-Design_Parallel_Group
S417|or|I-Design_Parallel_Group
S417|placebo|I-Design_Parallel_Group
S417|from|O
S417|9|O
S417|years|O
S417|of|O
S417|age|O
S417|.|O
S2139|The|O
S2139|threshold|O
S2139|for|O
S2139|statistical|O
S2139|significance|O
S2139|was|O
S2139|set|O
S2139|to|O
S2139|p=0.05|O
S2139|in|O
S2139|all|O
S2139|cases|O
S2139|.|O
S2258|The|O
S2258|sponsor|O
S2258|terminated|O
S2258|the|O
S2258|trial|O
S2258|early|O
S2258|because|O
S2258|of|O
S2258|the|O
S2258|lack|O
S2258|of|O
S2258|efficacy|O
S2258|for|O
S2258|the|O
S2258|primary|O
S2258|end-point|O
S2258|(|O
S2258|asthma|O
S2258|exacerbations|O
S2258|)|O
S2258|at|O
S2258|Week|O
S2258|36|O
S2258|,|O
S2258|with|O
S2258|the|O
S2258|median|O
S2258|time|O
S2258|in|O
S2258|the|O
S2258|study|O
S2258|at|O
S2258|72|O
S2258|weeks|O
S2258|.|O
S1870|This|O
S1870|similarity|O
S1870|in|O
S1870|statin|O
S1870|use|O
S1870|between|O
S1870|groups|O
S1870|was|O
S1870|supported|O
S1870|by|O
S1870|similar|O
S1870|LDL|O
S1870|cholesterol|O
S1870|concentrations|O
S1870|(|O
S1870|2·6|O
S1870|[|O
S1870|SE|O
S1870|0·03|O
S1870|]|O
S1870|vs|O
S1870|2·6|O
S1870|[|O
S1870|0·03|O
S1870|]|O
S1870|mmol/L|O
S1870|;|O
S1870|p=0·7|O
S1870|:|O
S1870|table|O
S1870|3|O
S1870|)|O
S1870|after|O
S1870|3·2|O
S1870|years|O
S1870|of|O
S1870|post-trial|O
S1870|follow-up|O
S1870|.|O
S51|Comparison|O
S51|between|O
S51|treatment|O
S51|arms|O
S51|of|O
S51|the|O
S51|crude|O
S51|proportions|O
S51|of|O
S51|patients|O
S51|with|O
S51|ulcers|O
S51|at|O
S51|24|O
S51|weeks|O
S51|with|O
S51|a|O
S51|Cochran–Mantel–Haenszel|O
S51|test|O
S51|stratified|O
S51|by|O
S51|the|O
S51|two|O
S51|randomization|O
S51|risk|O
S51|factor|O
S51|strata|O
S51|(|O
S51|use|O
S51|of|O
S51|low-dose|O
S51|aspirin|O
S51|and|O
S51|other|O
S51|anticoagulants|O
S51|,|O
S51|prior|O
S51|ulcer|O
S51|history|O
S51|)|O
S51|was|O
S51|specified|O
S51|as|O
S51|the|O
S51|primary|O
S51|statistical|O
S51|analysis|O
S51|at|O
S51|the|O
S51|time|O
S51|of|O
S51|sample|O
S51|size|O
S51|calculation|O
S51|and|O
S51|study|O
S51|initiation|O
S51|.|O
S1143|There|O
S1143|was|O
S1143|a|O
S1143|significant|O
S1143|association|O
S1143|between|O
S1143|patient|O
S1143|satisfaction|O
S1143|with|O
S1143|treatment|O
S1143|and|O
S1143|randomised|O
S1143|treatment|O
S1143|at|O
S1143|each|O
S1143|of|O
S1143|the|O
S1143|three|O
S1143|time|O
S1143|points|O
S1143|(|O
S1143|Fisher|O
S1143|’|O
S1143|s|O
S1143|exact|O
S1143|test|O
S1143|P=0.0336|O
S1143|for|O
S1143|week|O
S1143|1|O
S1143|,|O
S1143|P=0.0020|O
S1143|for|O
S1143|week|O
S1143|3|O
S1143|,|O
S1143|P=0.0065|O
S1143|for|O
S1143|week|O
S1143|12|O
S1143|)|O
S1143|.|O
S614|Settings|O
S614|and|O
S614|participants|O
S614|The|O
S614|study|O
S614|was|O
S614|conducted|O
S614|from|O
S614|October|O
S614|2003|O
S614|to|O
S614|May|O
S614|2005|O
S614|at|O
S614|41|B-Settings_Multicenter
S614|centres|I-Settings_Multicenter
S614|in|O
S614|Europe|B-Settings_Location
S614|and|I-Settings_Location
S614|North|I-Settings_Location
S614|America|I-Settings_Location
S614|.|O
S653|The|O
S653|proportion|O
S653|of|O
S653|patients|O
S653|with|O
S653|one|O
S653|or|O
S653|more|O
S653|new|O
S653|DU|O
S653|was|O
S653|66.3|O
S653|%|O
S653|(|O
S653|63/95|O
S653|)|O
S653|on|O
S653|bosentan|O
S653|compared|O
S653|with|O
S653|70.8|O
S653|%|O
S653|(|O
S653|63/89|O
S653|)|O
S653|on|O
S653|placebo|O
S653|;|O
S653|the|O
S653|difference|O
S653|in|O
S653|observed|O
S653|proportions|O
S653|between|O
S653|treatments|O
S653|was|O
S653|greater|O
S653|in|O
S653|patients|O
S653|with|O
S653|multiple|O
S653|new|O
S653|DUs|O
S653|(|O
S653|18.9|O
S653|%|O
S653|vs|O
S653|29.2|O
S653|%|O
S653|with|O
S653|≥4|O
S653|,|O
S653|10.5|O
S653|%|O
S653|vs|O
S653|29.8|O
S653|%|O
S653|with|O
S653|≥5|O
S653|,|O
S653|etc|O
S653|;|O
S653|figure|O
S653|4|O
S653|)|O
S653|.|O
S954|All|O
S954|analyses|O
S954|were|O
S954|adjusted|O
S954|for|O
S954|the|O
S954|stratification|O
S954|variables|O
S954|.|O
S598|Few|O
S598|studies|O
S598|have|O
S598|been|O
S598|specifically|O
S598|designed|O
S598|to|O
S598|examine|O
S598|efficacy|O
S598|in|O
S598|the|O
S598|prevention|O
S598|or|O
S598|treatment|O
S598|of|O
S598|DUs|O
S598|.|O
S1619|Methods|O
S1619|Trial|O
S1619|design|O
S1619|ARROW|O
S1619|was|O
S1619|an|O
S1619|open-label|B-Blinding_Open_Label
S1619|randomised|O
S1619|parallel-group|B-Design_Parallel_Group
S1619|trial|O
S1619|in|O
S1619|untreated|O
S1619|(|O
S1619|except|O
S1619|for|O
S1619|ART|O
S1619|to|O
S1619|prevent|O
S1619|mother-to-child-transmission|O
S1619|)|O
S1619|children|O
S1619|or|O
S1619|adolescents|O
S1619|(|O
S1619|aged|O
S1619|3|O
S1619|months|O
S1619|to|O
S1619|17|O
S1619|years|O
S1619|)|O
S1619|with|O
S1619|HIV|O
S1619|who|O
S1619|met|O
S1619|WHO|O
S1619|2006|O
S1619|criteria|O
S1619|for|O
S1619|ART|O
S1619|initiation|O
S1619|from|O
S1619|three|B-Settings_Multicenter
S1619|centres|I-Settings_Multicenter
S1619|in|O
S1619|Uganda|B-Settings_Location
S1619|(|O
S1619|Joint|O
S1619|Clinical|O
S1619|Research|O
S1619|Centre|O
S1619|,|O
S1619|Kampala|O
S1619|;|O
S1619|Baylor-Uganda|O
S1619|,|O
S1619|Mulago|O
S1619|;|O
S1619|MRC/UVRI|O
S1619|Uganda|O
S1619|Research|O
S1619|Unit|O
S1619|on|O
S1619|AIDS|O
S1619|,|O
S1619|Entebbe|O
S1619|)|O
S1619|,|O
S1619|and|O
S1619|one|O
S1619|in|O
S1619|Zimbabwe|B-Settings_Location
S1619|(|O
S1619|University|O
S1619|of|O
S1619|Zimbabwe|O
S1619|,|O
S1619|Harare|O
S1619|)|O
S1619|.|O
S167|In|O
S167|the|O
S167|investigator-led|O
S167|TALC|O
S167|trial|O
S167|(|O
S167|Tiotropium|O
S167|Bromide|O
S167|as|O
S167|an|O
S167|Alternative|O
S167|to|O
S167|Increased|O
S167|Inhaled|O
S167|Glucocorticoid|O
S167|in|O
S167|Patients|O
S167|Inadequately|O
S167|Controlled|O
S167|on|O
S167|a|O
S167|Lower|O
S167|Dose|O
S167|of|O
S167|Inhaled|O
S167|Corticosteroid|O
S167|;|O
S167|three-way|O
S167|crossover|O
S167|,|O
S167|14|O
S167|weeks|O
S167|per|O
S167|treatment|O
S167|,|O
S167|210|O
S167|patients|O
S167|)|O
S167|,|O
S167|improvements|O
S167|in|O
S167|lung|O
S167|function|O
S167|in|O
S167|patients|O
S167|with|O
S167|asthma|O
S167|treated|O
S167|with|O
S167|tiotropium|O
S167|(|O
S167|via|O
S167|HandiHaler®|O
S167|;|O
S167|Boehringer|O
S167|Ingelheim|O
S167|Pharma|O
S167|GmbH|O
S167|&|O
S167|Co.|O
S167|KG|O
S167|,|O
S167|Ingelheim|O
S167|am|O
S167|Rhein|O
S167|,|O
S167|Germany|O
S167|)|O
S167|plus|O
S167|beclomethasone|O
S167|(|O
S167|two|O
S167|puffs|O
S167|of|O
S167|40|O
S167|μg|O
S167|,|O
S167|twice|O
S167|daily|O
S167|)|O
S167|were|O
S167|shown|O
S167|to|O
S167|be|O
S167|superior|O
S167|to|O
S167|a|O
S167|doubling|O
S167|of|O
S167|the|O
S167|ICS|O
S167|dose|O
S167|and|O
S167|similar|O
S167|to|O
S167|the|O
S167|addition|O
S167|of|O
S167|salmeterol|O
S167|.|O
S1940|Main|O
S1940|outcome|O
S1940|measure|O
S1940|Achievement|O
S1940|of|O
S1940|a|O
S1940|10-point|O
S1940|radiographic|O
S1940|severity|O
S1940|score|O
S1940|≤1.5|O
S1940|and|O
S1940|serum|O
S1940|alkaline|O
S1940|phosphatase|O
S1940|≤350|O
S1940|U/L|O
S1940|.|O
S85|Treatment|O
S85|with|O
S85|HZT-501|O
S85|(|O
S85|vs.|O
S85|ibuprofen|O
S85|)|O
S85|was|O
S85|associated|O
S85|with|O
S85|a|O
S85|significantly|O
S85|lower|O
S85|risk|O
S85|ratio|O
S85|(|O
S85|RR|O
S85|)|O
S85|for|O
S85|upper|O
S85|GI|O
S85|ulcer|O
S85|formation|O
S85|in|O
S85|the|O
S85|initial|O
S85|(|O
S85|RR=0.44|O
S85|,|O
S85|0.33–0.58|O
S85|)|O
S85|and|O
S85|post-adjudication|O
S85|analyses|O
S85|(|O
S85|RR=0.46|O
S85|,|O
S85|0.34–0.61|O
S85|)|O
S85|.|O
S1658|All|O
S1658|analyses|O
S1658|were|O
S1658|done|O
S1658|with|O
S1658|Stata|O
S1658|12.1|O
S1658|.|O
S1888|A|O
S1888|marginally|O
S1888|significant|O
S1888|reduction|O
S1888|in|O
S1888|deaths|O
S1888|attributed|O
S1888|to|O
S1888|respiratory|O
S1888|disease|O
S1888|was|O
S1888|noted|O
S1888|in|O
S1888|simvastatin-allocated|O
S1888|participants|O
S1888|(|O
S1888|95|O
S1888|[|O
S1888|0·9|O
S1888|%|O
S1888|]|O
S1888|vs|O
S1888|124|O
S1888|[|O
S1888|1·2|O
S1888|%|O
S1888|]|O
S1888|;|O
S1888|p=0·04|O
S1888|)|O
S1888|,|O
S1888|but|O
S1888|deaths|O
S1888|from|O
S1888|cancer|O
S1888|,|O
S1888|or|O
S1888|other|O
S1888|prespecified|O
S1888|categories|O
S1888|of|O
S1888|non-vascular|O
S1888|death|O
S1888|,|O
S1888|did|O
S1888|not|O
S1888|differ|O
S1888|significantly|O
S1888|(|O
S1888|webappendix|O
S1888|,|O
S1888|p|O
S1888|4|O
S1888|)|O
S1888|.|O
S990|Nine|O
S990|serious|O
S990|adverse|O
S990|reactions|O
S990|occurred|O
S990|:|O
S990|two|O
S990|in|O
S990|the|O
S990|ciclosporin|O
S990|group|O
S990|(|O
S990|ruptured|O
S990|abdominal|O
S990|aortic|O
S990|aneurysm|O
S990|and|O
S990|acute|O
S990|kidney|O
S990|injury|O
S990|with|O
S990|increased|O
S990|serum|O
S990|creatinine|O
S990|(|O
S990|212|O
S990|µmol/L|O
S990|)|O
S990|levels|O
S990|)|O
S990|and|O
S990|seven|O
S990|in|O
S990|the|O
S990|prednisolone|O
S990|group|O
S990|(|O
S990|a|O
S990|bowel|O
S990|perforation|O
S990|;|O
S990|five|O
S990|serious|O
S990|infections|O
S990|(|O
S990|one|O
S990|resulted|O
S990|in|O
S990|death|O
S990|)|O
S990|that|O
S990|required|O
S990|admission|O
S990|to|O
S990|hospital|O
S990|or|O
S990|parenteral|O
S990|antibiotics|O
S990|;|O
S990|and|O
S990|one|O
S990|other|O
S990|infection|O
S990|)|O
S990|.|O
S1994|Unless|O
S1994|otherwise|O
S1994|noted|O
S1994|,|O
S1994|means|O
S1994|and|O
S1994|SDs|O
S1994|are|O
S1994|reported|O
S1994|for|O
S1994|continuous|O
S1994|variables|O
S1994|with|O
S1994|normal|O
S1994|distributions|O
S1994|,|O
S1994|and|O
S1994|medians|O
S1994|are|O
S1994|reported|O
S1994|for|O
S1994|non-normally|O
S1994|distributed|O
S1994|variables|O
S1994|.|O
S581|Results|O
S581|Over|O
S581|24|O
S581|weeks|O
S581|,|O
S581|bosentan|O
S581|treatment|O
S581|was|O
S581|associated|O
S581|with|O
S581|a|O
S581|30|O
S581|%|O
S581|reduction|O
S581|in|O
S581|the|O
S581|number|O
S581|of|O
S581|new|O
S581|DUs|O
S581|compared|O
S581|with|O
S581|placebo|O
S581|(|O
S581|mean±standard|O
S581|error|O
S581|:|O
S581|1.9±0.2|O
S581|vs|O
S581|2.7±0.3|O
S581|new|O
S581|ulcers|O
S581|;|O
S581|p=0.04|O
S581|)|O
S581|.|O
S1117|The|O
S1117|Cox|O
S1117|proportional|O
S1117|hazard|O
S1117|assumption|O
S1117|was|O
S1117|tested|O
S1117|globally|O
S1117|by|O
S1117|the|O
S1117|correlation|O
S1117|of|O
S1117|Schoenfeld|O
S1117|residuals|O
S1117|and|O
S1117|survival|O
S1117|time|O
S1117|(|O
S1117|or|O
S1117|ranked|O
S1117|survival|O
S1117|time|O
S1117|)|O
S1117|and|O
S1117|separately|O
S1117|for|O
S1117|each|O
S1117|covariate|O
S1117|through|O
S1117|the|O
S1117|correlation|O
S1117|of|O
S1117|Schoenfeld|O
S1117|scaled|O
S1117|residuals|O
S1117|and|O
S1117|survival|O
S1117|time|O
S1117|(|O
S1117|or|O
S1117|ranked|O
S1117|survival|O
S1117|time|O
S1117|)|O
S1117|.|O
S95|GI|O
S95|complications|O
S95|were|O
S95|reported|O
S95|by|O
S95|investigators|O
S95|for|O
S95|three|O
S95|patients|O
S95|(|O
S95|0.6|O
S95|%|O
S95|)|O
S95|given|O
S95|HZT-501|O
S95|and|O
S95|zero|O
S95|given|O
S95|ibuprofen|O
S95|in|O
S95|REDUCE-1|O
S95|.|O
S1628|The|O
S1628|trial|O
S1628|was|O
S1628|approved|O
S1628|by|O
S1628|research|O
S1628|ethics|O
S1628|committees|O
S1628|in|O
S1628|Uganda|B-Settings_Location
S1628|,|I-Settings_Location
S1628|Zimbabwe|I-Settings_Location
S1628|,|O
S1628|and|O
S1628|the|O
S1628|UK|O
S1628|.|O
S1732|There|O
S1732|were|O
S1732|also|O
S1732|no|O
S1732|significant|O
S1732|differences|O
S1732|in|O
S1732|the|O
S1732|numbers|O
S1732|of|O
S1732|children|O
S1732|with|O
S1732|one|O
S1732|or|O
S1732|more|O
S1732|grade|O
S1732|4|O
S1732|adverse|O
S1732|events|O
S1732|(|O
S1732|63|O
S1732|[|O
S1732|16|O
S1732|%|O
S1732|]|O
S1732|vs|O
S1732|81|O
S1732|[|O
S1732|20|O
S1732|%|O
S1732|]|O
S1732|vs|O
S1732|76|O
S1732|[|O
S1732|19|O
S1732|%|O
S1732|]|O
S1732|;|O
S1732|HR|O
S1732|[|O
S1732|B|O
S1732|:|O
S1732|A|O
S1732|]|O
S1732|1·27|O
S1732|,|O
S1732|0·91–1·76|O
S1732|;|O
S1732|HR|O
S1732|[|O
S1732|C|O
S1732|:|O
S1732|A|O
S1732|]|O
S1732|1·20|O
S1732|,|O
S1732|0·86–1·68|O
S1732|;|O
S1732|global|O
S1732|p=0·34|O
S1732|)|O
S1732|or|O
S1732|serious|O
S1732|adverse|O
S1732|events|O
S1732|(|O
S1732|87|O
S1732|[|O
S1732|22|O
S1732|%|O
S1732|]|O
S1732|vs|O
S1732|82|O
S1732|[|O
S1732|20|O
S1732|%|O
S1732|]|O
S1732|vs|O
S1732|95|O
S1732|[|O
S1732|23|O
S1732|%|O
S1732|]|O
S1732|;|O
S1732|HR|O
S1732|[|O
S1732|B|O
S1732|:|O
S1732|A|O
S1732|]|O
S1732|0·92|O
S1732|,|O
S1732|0·68–1·25|O
S1732|;|O
S1732|HR|O
S1732|[|O
S1732|C|O
S1732|:|O
S1732|A|O
S1732|]|O
S1732|1·09|O
S1732|,|O
S1732|0·81–1·46|O
S1732|;|O
S1732|global|O
S1732|p=0·53|O
S1732|)|O
S1732|.|O
S2113|The|O
S2113|randomisation|O
S2113|list|O
S2113|was|O
S2113|sent|O
S2113|to|O
S2113|an|O
S2113|independent|O
S2113|contract|O
S2113|research|O
S2113|organisation|O
S2113|(|O
S2113|LC2|O
S2113|,|O
S2113|Lentilly|O
S2113|,|O
S2113|France|O
S2113|)|O
S2113|for|O
S2113|preparation|O
S2113|and|O
S2113|distribution|O
S2113|of|O
S2113|identical|O
S2113|capsules|O
S2113|of|O
S2113|memantine|B-Design_Parallel_Group
S2113|and|I-Design_Parallel_Group
S2113|placebo|I-Design_Parallel_Group
S2113|.|I-Design_Parallel_Group
S873|The|O
S873|adjusted|O
S873|mean|O
S873|difference|O
S873|showed|O
S873|no|O
S873|between|O
S873|group|O
S873|difference|O
S873|(|O
S873|0.003|O
S873|cm2/day|O
S873|,|O
S873|95|O
S873|%|O
S873|confidence|O
S873|interval|O
S873|−0.20|O
S873|to|O
S873|0.21|O
S873|;|O
S873|P=0.97|O
S873|)|O
S873|.|O
S1437|Study|O
S1437|swabs|O
S1437|were|O
S1437|collected|O
S1437|and|O
S1437|eluted|O
S1437|in|O
S1437|M4|O
S1437|media|O
S1437|(|O
S1437|Remel|O
S1437|,|O
S1437|Lenexa|O
S1437|,|O
S1437|KS|O
S1437|,|O
S1437|US|O
S1437|)|O
S1437|before|O
S1437|storage|O
S1437|at|O
S1437|−70|O
S1437|°C|O
S1437|.|O
S1098|Questionnaires|O
S1098|were|O
S1098|administered|O
S1098|by|O
S1098|post|O
S1098|or|O
S1098|were|O
S1098|completed|O
S1098|on|O
S1098|line|O
S1098|at|O
S1098|one|O
S1098|,|O
S1098|three|O
S1098|,|O
S1098|and|O
S1098|12|O
S1098|weeks|O
S1098|and|O
S1098|six|O
S1098|months|O
S1098|.|O
S803|No|O
S803|additional|O
S803|medical|O
S803|therapy|O
S803|was|O
S803|instituted|O
S803|during|O
S803|the|O
S803|study|O
S803|period|O
S803|.|O
S868|Secondary|O
S868|outcomes|O
S868|were|O
S868|time|O
S868|to|O
S868|healing|O
S868|,|O
S868|global|O
S868|treatment|O
S868|response|O
S868|,|O
S868|resolution|O
S868|of|O
S868|inflammation|O
S868|,|O
S868|self|O
S868|reported|O
S868|pain|O
S868|,|O
S868|quality|O
S868|of|O
S868|life|O
S868|,|O
S868|number|O
S868|of|O
S868|treatment|O
S868|failures|O
S868|,|O
S868|adverse|O
S868|reactions|O
S868|,|O
S868|and|O
S868|time|O
S868|to|O
S868|recurrence|O
S868|.|O
S1482|There|O
S1482|were|O
S1482|no|O
S1482|significant|O
S1482|differences|O
S1482|between|O
S1482|the|O
S1482|arms|O
S1482|in|O
S1482|any|O
S1482|of|O
S1482|the|O
S1482|subgroups|O
S1482|on|O
S1482|day|O
S1482|five|O
S1482|(|O
S1482|tables|O
S1482|2|O
S1482|and|O
S1482|3|O
S1482|)|O
S1482|.|O
S206|Measurement|O
S206|of|O
S206|PEFam|O
S206|and|O
S206|PEFpm|O
S206|was|O
S206|to|O
S206|be|O
S206|performed|O
S206|prior|O
S206|to|O
S206|ICS|O
S206|and|O
S206|study|O
S206|treatment|O
S206|inhalation|O
S206|,|O
S206|at|O
S206|approximately|O
S206|the|O
S206|same|O
S206|time|O
S206|each|O
S206|day|O
S206|,|O
S206|from|O
S206|06:00|O
S206|to|O
S206|08:00|O
S206|for|O
S206|PEFam|O
S206|and|O
S206|from|O
S206|18:00|O
S206|to|O
S206|20:00|O
S206|for|O
S206|PEFpm|O
S206|.|O
S1489|In|O
S1489|throat|O
S1489|samples|O
S1489|these|O
S1489|proportions|O
S1489|were|O
S1489|13/137|O
S1489|(|O
S1489|9.5|O
S1489|%|O
S1489|)|O
S1489|and|O
S1489|15/130|O
S1489|(|O
S1489|12|O
S1489|%|O
S1489|)|O
S1489|,|O
S1489|respectively|O
S1489|(|O
S1489|P=1.00|O
S1489|for|O
S1489|nose|O
S1489|and|O
S1489|P=0.59|O
S1489|for|O
S1489|throat|O
S1489|for|O
S1489|comparison|O
S1489|between|O
S1489|arms|O
S1489|)|O
S1489|;|O
S1489|corresponding|O
S1489|proportions|O
S1489|for|O
S1489|day|O
S1489|14|O
S1489|were|O
S1489|0/15|O
S1489|and|O
S1489|0/13|O
S1489|for|O
S1489|nose|O
S1489|and|O
S1489|1/15|O
S1489|and|O
S1489|1/13|O
S1489|for|O
S1489|throat|O
S1489|.|O
S819|Following|O
S819|etanercept|O
S819|,|O
S819|plasma|O
S819|t-PA|O
S819|activity|O
S819|concentrations|O
S819|were|O
S819|reduced|O
S819|at|O
S819|24|O
S819|h|O
S819|(|O
S819|0.8±0.1|O
S819|vs|O
S819|0.5±0.1|O
S819|IU/ml|O
S819|;|O
S819|p=0.001|O
S819|)|O
S819|.|O
S1515|Among|O
S1515|the|O
S1515|14|O
S1515|patients|O
S1515|(|O
S1515|five|O
S1515|in|O
S1515|double|O
S1515|dose|O
S1515|arm|O
S1515|,|O
S1515|nine|O
S1515|in|O
S1515|standard|O
S1515|dose|O
S1515|arm|O
S1515|)|O
S1515|with|O
S1515|an|O
S1515|H1N1|O
S1515|virus|O
S1515|without|O
S1515|this|O
S1515|mutation|O
S1515|,|O
S1515|four|O
S1515|out|O
S1515|of|O
S1515|seven|O
S1515|(|O
S1515|two|O
S1515|double|O
S1515|dose|O
S1515|,|O
S1515|five|O
S1515|standard|O
S1515|dose|O
S1515|)|O
S1515|that|O
S1515|could|O
S1515|be|O
S1515|sequenced|O
S1515|after|O
S1515|day|O
S1515|0|O
S1515|developed|O
S1515|the|O
S1515|H275Y|O
S1515|mutation|O
S1515|during|O
S1515|treatment|O
S1515|(|O
S1515|four|O
S1515|standard|O
S1515|dose|O
S1515|)|O
S1515|.|O
S2261|The|O
S2261|treatment-emergent|O
S2261|ATA|O
S2261|rate|O
S2261|was|O
S2261|1.4|O
S2261|%|O
S2261|in|O
S2261|both|O
S2261|the|O
S2261|150|O
S2261|mg|O
S2261|Q|O
S2261|and|O
S2261|300|O
S2261|mg|O
S2261|M|O
S2261|groups|O
S2261|,|O
S2261|and|O
S2261|2.1|O
S2261|%|O
S2261|in|O
S2261|the|O
S2261|450|O
S2261|mg|O
S2261|Q|O
S2261|group|O
S2261|.|O
S66|The|O
S66|trials|O
S66|continued|O
S66|until|O
S66|their|O
S66|planned|O
S66|completion|O
S66|based|O
S66|on|O
S66|the|O
S66|prespecified|O
S66|sample|O
S66|sizes|O
S66|.|O
S1293|The|O
S1293|sample|O
S1293|size|O
S1293|,|O
S1293|re-estimated|O
S1293|in|O
S1293|2007|O
S1293|on|O
S1293|the|O
S1293|basis|O
S1293|of|O
S1293|event|O
S1293|rates|O
S1293|in|O
S1293|both|O
S1293|treatment|O
S1293|groups|O
S1293|combined|O
S1293|,|O
S1293|was|O
S1293|3100|B-Sample_Size_Target
S1293|.|O
S1690|47|O
S1690|(|O
S1690|8|O
S1690|%|O
S1690|)|O
S1690|children|O
S1690|on|O
S1690|clinically|O
S1690|driven|O
S1690|monitoring|O
S1690|versus|O
S1690|39|O
S1690|(|O
S1690|7|O
S1690|%|O
S1690|)|O
S1690|on|O
S1690|routine|O
S1690|laboratory|O
S1690|monitoring|O
S1690|had|O
S1690|a|O
S1690|new|O
S1690|WHO|O
S1690|stage|O
S1690|4|O
S1690|event|O
S1690|or|O
S1690|died|O
S1690|(|O
S1690|2·0|O
S1690|vs|O
S1690|1·7|O
S1690|per|O
S1690|100|O
S1690|child-years|O
S1690|,|O
S1690|respectively|O
S1690|)|O
S1690|.|O
S1400|A|O
S1400|further|O
S1400|3.9|O
S1400|%|O
S1400|(|O
S1400|13|O
S1400|)|O
S1400|were|O
S1400|false|O
S1400|positive|O
S1400|by|O
S1400|rapid|O
S1400|antigen|O
S1400|test|O
S1400|(|O
S1400|negative|O
S1400|by|O
S1400|RT-PCR|O
S1400|and|O
S1400|no|O
S1400|rise|O
S1400|in|O
S1400|convalescent|O
S1400|haemagglutination|O
S1400|inhibition|O
S1400|titers|O
S1400|)|O
S1400|.|O
S1344|Significant|O
S1344|trends|O
S1344|towards|O
S1344|larger|O
S1344|effects|O
S1344|of|O
S1344|treatment|O
S1344|in|O
S1344|more|O
S1344|severe|O
S1344|strokes|O
S1344|were|O
S1344|also|O
S1344|seen|O
S1344|(|O
S1344|as|O
S1344|assessed|O
S1344|by|O
S1344|the|O
S1344|NIHSS|O
S1344|and|O
S1344|by|O
S1344|the|O
S1344|predicted|O
S1344|probability|O
S1344|of|O
S1344|a|O
S1344|poor|O
S1344|outcome|O
S1344|)|O
S1344|.|O
S1602|Funding|O
S1602|UK|O
S1602|Medical|O
S1602|Research|O
S1602|Council|O
S1602|,|O
S1602|the|O
S1602|UK|O
S1602|Department|O
S1602|for|O
S1602|International|O
S1602|Development|O
S1602|;|O
S1602|drugs|O
S1602|donated|O
S1602|and|O
S1602|viral|O
S1602|load|O
S1602|assays|O
S1602|funded|O
S1602|by|O
S1602|ViiV|O
S1602|Healthcare|O
S1602|and|O
S1602|GlaxoSmithKline|O
S1602|.|O
S333|SU|O
S333|levels|O
S333|At|O
S333|baseline|O
S333|,|O
S333|85.2|O
S333|%|O
S333|to|O
S333|92.6|O
S333|%|O
S333|of|O
S333|patients|O
S333|had|O
S333|SU|O
S333|levels|O
S333|≥6|O
S333|mg/dl|O
S333|(|O
S333|table|O
S333|1|O
S333|)|O
S333|.|O
S1855|Allowances|O
S1855|for|O
S1855|multiple|O
S1855|comparisons|O
S1855|and|O
S1855|for|O
S1855|the|O
S1855|post-hoc|O
S1855|nature|O
S1855|of|O
S1855|such|O
S1855|analyses|O
S1855|were|O
S1855|made|O
S1855|in|O
S1855|their|O
S1855|interpretation|O
S1855|.|O
S168|In|O
S168|a|O
S168|16-week|O
S168|proof-of-concept|O
S168|trial|O
S168|in|O
S168|B16-Arg/Arg|O
S168|patients|O
S168|with|O
S168|symptomatic|O
S168|moderate|O
S168|asthma|O
S168|already|O
S168|receiving|O
S168|ICS|O
S168|,|O
S168|tiotropium|O
S168|5|O
S168|μg|O
S168|(|O
S168|administered|O
S168|via|O
S168|the|O
S168|Respimat®|O
S168|SoftMist™|O
S168|inhaler|O
S168|[|O
S168|hereinafter|O
S168|referred|O
S168|to|O
S168|as|O
S168|tiotropium|O
S168|Respimat®|O
S168|;|O
S168|Boehringer|O
S168|Ingelheim|O
S168|Pharma|O
S168|GmbH|O
S168|&|O
S168|Co.|O
S168|KG|O
S168|]|O
S168|)|O
S168|was|O
S168|superior|O
S168|to|O
S168|placebo|O
S168|Respimat®|O
S168|and|O
S168|non-inferior|O
S168|to|O
S168|salmeterol|O
S168|.|O
S1301|The|O
S1301|committee|O
S1301|judged|O
S1301|these|O
S1301|data|O
S1301|never|O
S1301|met|O
S1301|the|O
S1301|protocol-specified|O
S1301|criteria|O
S1301|to|O
S1301|recommend|O
S1301|modification|O
S1301|of|O
S1301|the|O
S1301|protocol|O
S1301|or|O
S1301|halt|O
S1301|recruitment|O
S1301|to|O
S1301|the|O
S1301|study|O
S1301|.|O
S1487|After|O
S1487|day|O
S1487|five|O
S1487|,|O
S1487|the|O
S1487|proportions|O
S1487|of|O
S1487|patients|O
S1487|positive|O
S1487|for|O
S1487|RNA|O
S1487|in|O
S1487|the|O
S1487|double|O
S1487|and|O
S1487|standard|O
S1487|dose|O
S1487|arms|O
S1487|declined|O
S1487|but|O
S1487|were|O
S1487|similar|O
S1487|.|O
S1469|In|O
S1469|total|O
S1469|,|O
S1469|260|O
S1469|(|O
S1469|79.8|O
S1469|%|O
S1469|)|O
S1469|patients|O
S1469|were|O
S1469|infected|O
S1469|with|O
S1469|influenza|O
S1469|virus|O
S1469|A|O
S1469|(|O
S1469|133|O
S1469|(|O
S1469|40.8|O
S1469|%|O
S1469|)|O
S1469|with|O
S1469|A/H3N2|O
S1469|,|O
S1469|72|O
S1469|(|O
S1469|22.1|O
S1469|%|O
S1469|)|O
S1469|with|O
S1469|A/H1N1-pdm09|O
S1469|,|O
S1469|38|O
S1469|(|O
S1469|11.7|O
S1469|%|O
S1469|)|O
S1469|with|O
S1469|seasonal|O
S1469|A/H1N1|O
S1469|,|O
S1469|and|O
S1469|17|O
S1469|(|O
S1469|5.2|O
S1469|%|O
S1469|)|O
S1469|with|O
S1469|A/H5N1|O
S1469|)|O
S1469|and|O
S1469|53|O
S1469|(|O
S1469|16.2|O
S1469|%|O
S1469|)|O
S1469|with|O
S1469|influenza|O
S1469|virus|O
S1469|B|O
S1469|.|O
S1280|Additional|O
S1280|details|O
S1280|of|O
S1280|the|O
S1280|procedures|O
S1280|used|O
S1280|in|O
S1280|the|O
S1280|double-blinded|B-Blinding_Double_Blind
S1280|phase|O
S1280|of|O
S1280|the|O
S1280|study|O
S1280|are|O
S1280|reported|O
S1280|elsewhere|O
S1280|.|O
S68|Reason|O
S68|for|O
S68|NSAID|O
S68|use|O
S68|across|O
S68|both|O
S68|trials|O
S68|included|O
S68|pain|O
S68|(|O
S68|37.9|O
S68|%|O
S68|)|O
S68|,|O
S68|osteoarthritis|O
S68|(|O
S68|50.6|O
S68|%|O
S68|)|O
S68|,|O
S68|rheumatoid|O
S68|arthritis|O
S68|(|O
S68|3.5|O
S68|%|O
S68|)|O
S68|,|O
S68|and|O
S68|other|O
S68|(|O
S68|7.8|O
S68|%|O
S68|)|O
S68|.|O
S661|The|O
S661|changes|O
S661|from|O
S661|baseline|O
S661|in|O
S661|the|O
S661|HAQ|O
S661|disability|O
S661|index|O
S661|and|O
S661|hand|O
S661|disability|O
S661|index|O
S661|at|O
S661|week|O
S661|24|O
S661|were|O
S661|also|O
S661|similar|O
S661|in|O
S661|both|O
S661|treatment|O
S661|groups|O
S661|(|O
S661|−0.04|O
S661|(|O
S661|95|O
S661|%|O
S661|CI|O
S661|−0.15|O
S661|to|O
S661|0.08|O
S661|)|O
S661|,|O
S661|p=0.51|O
S661|and|O
S661|−0.04|O
S661|(|O
S661|−0.20|O
S661|to|O
S661|0.12|O
S661|)|O
S661|,|O
S661|p=0.62|O
S661|,|O
S661|respectively|O
S661|)|O
S661|.|O
S1119|Data|O
S1119|on|O
S1119|patient|O
S1119|satisfaction|O
S1119|with|O
S1119|the|O
S1119|treatment|O
S1119|and|O
S1119|adverse|O
S1119|events|O
S1119|were|O
S1119|summarised|O
S1119|by|O
S1119|treatment|O
S1119|group|O
S1119|but|O
S1119|no|O
S1119|statistical|O
S1119|analyses|O
S1119|were|O
S1119|performed|O
S1119|.|O
S2194|For|O
S2194|example|O
S2194|,|O
S2194|elevated|O
S2194|levels|O
S2194|of|O
S2194|serum|O
S2194|periostin|O
S2194|,|O
S2194|an|O
S2194|extracellular|O
S2194|matrix|O
S2194|protein|O
S2194|induced|O
S2194|by|O
S2194|IL-4|O
S2194|and|O
S2194|IL-13|O
S2194|in|O
S2194|airway|O
S2194|epithelium|O
S2194|,|O
S2194|identified|O
S2194|a|O
S2194|subset|O
S2194|of|O
S2194|asthma|O
S2194|patients|O
S2194|who|O
S2194|responded|O
S2194|better|O
S2194|to|O
S2194|lebrikizumab|O
S2194|,|O
S2194|an|O
S2194|anti-IL-13|O
S2194|monoclonal|O
S2194|antibody|O
S2194|.|O
S1047|The|O
S1047|results|O
S1047|did|O
S1047|not|O
S1047|change|O
S1047|when|O
S1047|the|O
S1047|analysis|O
S1047|was|O
S1047|repeated|O
S1047|but|O
S1047|with|O
S1047|adjustment|O
S1047|for|O
S1047|age|O
S1047|,|O
S1047|whether|O
S1047|the|O
S1047|wart|O
S1047|had|O
S1047|been|O
S1047|treated|O
S1047|previously|O
S1047|,|O
S1047|and|O
S1047|type|O
S1047|of|O
S1047|plantar|O
S1047|wart|O
S1047|or|O
S1047|for|O
S1047|patients|O
S1047|’|O
S1047|preferences|O
S1047|at|O
S1047|baseline|O
S1047|.|O
S72|An|O
S72|adjudication|O
S72|committee|O
S72|of|O
S72|two|O
S72|independent|O
S72|gastroenterologists|O
S72|then|O
S72|reviewed|O
S72|all|O
S72|positive|O
S72|endoscopy|O
S72|reports|O
S72|to|O
S72|determine|O
S72|how|O
S72|many|O
S72|ulcers|O
S72|had|O
S72|been|O
S72|misclassified|O
S72|.|O
S2011|The|O
S2011|median|O
S2011|adherence|O
S2011|to|O
S2011|calcium|O
S2011|supplementation|O
S2011|,|O
S2011|based|O
S2011|on|O
S2011|the|O
S2011|weight|O
S2011|of|O
S2011|unused|O
S2011|limestone|O
S2011|,|O
S2011|was|O
S2011|99|O
S2011|%|O
S2011|in|O
S2011|the|O
S2011|Ca|O
S2011|group|O
S2011|and|O
S2011|96|O
S2011|%|O
S2011|in|O
S2011|the|O
S2011|Ca+D|O
S2011|group|O
S2011|(|O
S2011|p=0.54|O
S2011|)|O
S2011|.|O
S1831|We|O
S1831|aimed|O
S1831|to|O
S1831|assess|O
S1831|the|O
S1831|effects|O
S1831|of|O
S1831|lowering|O
S1831|LDL|O
S1831|cholesterol|O
S1831|on|O
S1831|cause-specific|O
S1831|mortality|O
S1831|and|O
S1831|major|O
S1831|morbidity|O
S1831|,|O
S1831|not|O
S1831|only|O
S1831|during|O
S1831|the|O
S1831|study|O
S1831|treatment|O
S1831|period|O
S1831|in|O
S1831|HPS|O
S1831|but|O
S1831|also|O
S1831|in|O
S1831|the|O
S1831|longer|O
S1831|term|O
S1831|,|O
S1831|post-trial|O
S1831|.|O
S467|Biochemical|O
S467|analyses|O
S467|followed|O
S467|local|O
S467|protocols|O
S467|,|O
S467|and|O
S467|the|O
S467|results|O
S467|were|O
S467|reported|O
S467|centrally|O
S467|.|O
S1244|Methods|O
S1244|Study|O
S1244|design|O
S1244|and|O
S1244|patients|O
S1244|IST-3|O
S1244|was|O
S1244|a|O
S1244|pragmatic|O
S1244|international|B-Settings_Location
S1244|,|O
S1244|multicentre|B-Settings_Multicenter
S1244|,|O
S1244|randomised-controlled|O
S1244|,|O
S1244|open-treatment|B-Blinding_Open_Label
S1244|trial|O
S1244|.|O
S1735|Despite|O
S1735|substantial|O
S1735|numbers|O
S1735|of|O
S1735|grade|O
S1735|3|O
S1735|neutropenias|O
S1735|,|O
S1735|only|O
S1735|six|O
S1735|children|O
S1735|(|O
S1735|two|O
S1735|in|O
S1735|group|O
S1735|B|O
S1735|,|O
S1735|four|O
S1735|in|O
S1735|group|O
S1735|C|O
S1735|)|O
S1735|modified|O
S1735|ART|O
S1735|(|O
S1735|zidovudine|O
S1735|)|O
S1735|for|O
S1735|this|O
S1735|reason|O
S1735|.|O
S2105|The|O
S2105|main|O
S2105|inclusion|O
S2105|criterion|O
S2105|was|O
S2105|the|O
S2105|presence|O
S2105|of|O
S2105|a|O
S2105|severe|O
S2105|gait|O
S2105|disorder|O
S2105|(|O
S2105|defined|O
S2105|as|O
S2105|a|O
S2105|score|O
S2105|≥2|O
S2105|for|O
S2105|UPDRS|O
S2105|part|O
S2105|III|O
S2105|item|O
S2105|29|O
S2105|)|O
S2105|and|O
S2105|an|O
S2105|abnormal|O
S2105|,|O
S2105|forward-leaning|O
S2105|stance|O
S2105|(|O
S2105|a|O
S2105|score|O
S2105|≥2|O
S2105|for|O
S2105|item|O
S2105|28|O
S2105|)|O
S2105|despite|O
S2105|optimal|O
S2105|L-dopa|O
S2105|treatment|O
S2105|.|O
S1635|All|O
S1635|subsequent|O
S1635|results|O
S1635|for|O
S1635|participants|O
S1635|assigned|O
S1635|to|O
S1635|routine|O
S1635|laboratory|O
S1635|monitoring|O
S1635|were|O
S1635|returned|O
S1635|to|O
S1635|clinicians|O
S1635|,|O
S1635|whereas|O
S1635|results|O
S1635|at|O
S1635|and|O
S1635|after|O
S1635|randomisation|O
S1635|for|O
S1635|participants|O
S1635|allocated|O
S1635|clinically|O
S1635|driven|O
S1635|monitoring|O
S1635|were|O
S1635|only|O
S1635|returned|O
S1635|if|O
S1635|requested|O
S1635|for|O
S1635|clinical|O
S1635|management|O
S1635|(|O
S1635|authorised|O
S1635|by|O
S1635|centre|O
S1635|project|O
S1635|leaders|O
S1635|)|O
S1635|;|O
S1635|haemoglobin|O
S1635|results|O
S1635|at|O
S1635|week|O
S1635|8|O
S1635|were|O
S1635|automatically|O
S1635|returned|O
S1635|on|O
S1635|the|O
S1635|basis|O
S1635|of|O
S1635|early|O
S1635|anaemia|O
S1635|in|O
S1635|DART|O
S1635|,|O
S1635|as|O
S1635|were|O
S1635|grade|O
S1635|4|O
S1635|laboratory|O
S1635|toxicities|O
S1635|(|O
S1635|protocol|O
S1635|safety|O
S1635|criteria|O
S1635|;|O
S1635|grades|O
S1635|defined|O
S1635|apart|O
S1635|from|O
S1635|neutrophils|O
S1635|)|O
S1635|.|O
S2198|Membrane|O
S2198|IgE|O
S2198|is|O
S2198|expressed|O
S2198|on|O
S2198|IgE-switched|O
S2198|B|O
S2198|cells|O
S2198|,|O
S2198|IgE|O
S2198|memory|O
S2198|B|O
S2198|cells|O
S2198|,|O
S2198|and|O
S2198|IgE|O
S2198|plasmablasts|O
S2198|,|O
S2198|but|O
S2198|not|O
S2198|on|O
S2198|IgE|O
S2198|plasma|O
S2198|cells|O
S2198|.|O
S2250|An|O
S2250|analysis|O
S2250|of|O
S2250|covariance|O
S2250|(|O
S2250|ANCOVA|O
S2250|)|O
S2250|model|O
S2250|with|O
S2250|factors|O
S2250|for|O
S2250|baseline|O
S2250|level|O
S2250|,|O
S2250|periostin|O
S2250|status|O
S2250|(|O
S2250|<|O
S2250|50|O
S2250|ng/mL|O
S2250|,|O
S2250|≥50|O
S2250|ng/mL|O
S2250|)|O
S2250|,|O
S2250|number|O
S2250|of|O
S2250|prior|O
S2250|exacerbations|O
S2250|(|O
S2250|1|O
S2250|,|O
S2250|>|O
S2250|1|O
S2250|)|O
S2250|,|O
S2250|and|O
S2250|IgE|O
S2250|level|O
S2250|(|O
S2250|<|O
S2250|200|O
S2250|IU/mL|O
S2250|,|O
S2250|≥200|O
S2250|IU/mL|O
S2250|)|O
S2250|was|O
S2250|fit|O
S2250|to|O
S2250|assess|O
S2250|the|O
S2250|treatment|O
S2250|effect|O
S2250|.|O
S1257|After|O
S1257|the|O
S1257|system|O
S1257|had|O
S1257|recorded|O
S1257|and|O
S1257|checked|O
S1257|the|O
S1257|data|O
S1257|,|O
S1257|patients|O
S1257|were|O
S1257|allocated|O
S1257|either|O
S1257|immediate|O
S1257|thrombolysis|O
S1257|with|O
S1257|0·9|B-Design_Parallel_Group
S1257|mg/kg|I-Design_Parallel_Group
S1257|of|I-Design_Parallel_Group
S1257|intravenous|I-Design_Parallel_Group
S1257|rt-PA|I-Design_Parallel_Group
S1257|to|I-Design_Parallel_Group
S1257|a|I-Design_Parallel_Group
S1257|maximum|I-Design_Parallel_Group
S1257|of|I-Design_Parallel_Group
S1257|90|I-Design_Parallel_Group
S1257|mg|I-Design_Parallel_Group
S1257|(|I-Design_Parallel_Group
S1257|10|I-Design_Parallel_Group
S1257|%|I-Design_Parallel_Group
S1257|bolus|I-Design_Parallel_Group
S1257|with|I-Design_Parallel_Group
S1257|the|I-Design_Parallel_Group
S1257|remainder|I-Design_Parallel_Group
S1257|over|I-Design_Parallel_Group
S1257|1|I-Design_Parallel_Group
S1257|h|I-Design_Parallel_Group
S1257|)|I-Design_Parallel_Group
S1257|or|I-Design_Parallel_Group
S1257|control|I-Design_Parallel_Group
S1257|treatment|I-Design_Parallel_Group
S1257|.|O
S1456|The|O
S1456|Breslow-Day|O
S1456|test|O
S1456|was|O
S1456|used|O
S1456|to|O
S1456|test|O
S1456|the|O
S1456|heterogeneity|O
S1456|of|O
S1456|the|O
S1456|results|O
S1456|between|O
S1456|study|O
S1456|sites|O
S1456|.|O
S662|Post|O
S662|hoc|O
S662|analyses|O
S662|of|O
S662|new|O
S662|DUs|O
S662|In|O
S662|unplanned|O
S662|post|O
S662|hoc|O
S662|analyses|O
S662|in|O
S662|subgroups|O
S662|defined|O
S662|by|O
S662|the|O
S662|number|O
S662|of|O
S662|DUs|O
S662|at|O
S662|baseline|O
S662|,|O
S662|the|O
S662|mean|O
S662|treatment|O
S662|effect|O
S662|with|O
S662|bosentan|O
S662|was|O
S662|−2.1|O
S662|(|O
S662|95|O
S662|%|O
S662|CI|O
S662|−3.8|O
S662|to|O
S662|−0.4|O
S662|)|O
S662|new|O
S662|DUs|O
S662|(|O
S662|p=0.02|O
S662|)|O
S662|in|O
S662|patients|O
S662|with|O
S662|at|O
S662|least|O
S662|four|O
S662|DUs|O
S662|at|O
S662|baseline|O
S662|and|O
S662|−0.3|O
S662|(|O
S662|−1.1|O
S662|to|O
S662|0.4|O
S662|)|O
S662|new|O
S662|DUs|O
S662|(|O
S662|p=0.39|O
S662|)|O
S662|in|O
S662|patients|O
S662|with|O
S662|less|O
S662|than|O
S662|four|O
S662|DUs|O
S662|at|O
S662|baseline|O
S662|(|O
S662|table|O
S662|2|O
S662|)|O
S662|.|O
S1313|We|O
S1313|chose|O
S1313|this|O
S1313|simple|O
S1313|form|O
S1313|of|O
S1313|imputation|O
S1313|because|O
S1313|it|O
S1313|effectively|O
S1313|classified|O
S1313|6-month|O
S1313|outcomes|O
S1313|in|O
S1313|patients|O
S1313|for|O
S1313|whom|O
S1313|both|O
S1313|7-day|O
S1313|and|O
S1313|6-month|O
S1313|data|O
S1313|were|O
S1313|known|O
S1313|(|O
S1313|data|O
S1313|not|O
S1313|shown|O
S1313|)|O
S1313|.|O
S762|Subjects|O
S762|The|O
S762|study|O
S762|was|O
S762|performed|O
S762|with|O
S762|the|O
S762|approval|O
S762|of|O
S762|the|O
S762|local|O
S762|research|O
S762|ethics|O
S762|committee|O
S762|in|O
S762|accordance|O
S762|with|O
S762|the|O
S762|Declaration|O
S762|of|O
S762|Helsinki|O
S762|and|O
S762|with|O
S762|the|O
S762|written|O
S762|informed|O
S762|consent|O
S762|of|O
S762|all|O
S762|participants|O
S762|.|O
S1648|For|O
S1648|the|O
S1648|ART-strategy|O
S1648|randomisation|O
S1648|,|O
S1648|1200|B-Sample_Size_Required
S1648|children|I-Sample_Size_Required
S1648|provided|O
S1648|80|B-Sample_Size_Calculation_Power_Value
S1648|%|I-Sample_Size_Calculation_Power_Value
S1648|power|O
S1648|to|O
S1648|detect|O
S1648|differences|O
S1648|in|O
S1648|change|O
S1648|in|O
S1648|CD4|O
S1648|percentage|O
S1648|of|O
S1648|more|O
S1648|than|O
S1648|2·5|O
S1648|%|O
S1648|across|O
S1648|the|O
S1648|three|O
S1648|groups|O
S1648|(|O
S1648|F|O
S1648|test|O
S1648|,|O
S1648|two-sided|B-Sample_Size_Calculation_Alpha_Value
S1648|α=0·05|I-Sample_Size_Calculation_Alpha_Value
S1648|)|O
S1648|assuming|O
S1648|20|B-Sample_Size_Calculation_Dropout_Rate_Value
S1648|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S1648|missing|I-Sample_Size_Calculation_Dropout_Rate_Value
S1648|data|I-Sample_Size_Calculation_Dropout_Rate_Value
S1648|(|O
S1648|loss|O
S1648|to|O
S1648|follow-up|O
S1648|,|O
S1648|missed|O
S1648|visit|O
S1648|or|O
S1648|test|O
S1648|)|O
S1648|and|O
S1648|standard|O
S1648|deviation|O
S1648|10|O
S1648|%|O
S1648|.|O
S1468|Enrolment|O
S1468|differed|O
S1468|by|O
S1468|country|O
S1468|:|O
S1468|235|O
S1468|(|O
S1468|72.1|O
S1468|%|O
S1468|)|O
S1468|were|O
S1468|from|O
S1468|Vietnam|O
S1468|,|O
S1468|71|O
S1468|(|O
S1468|21.8|O
S1468|%|O
S1468|)|O
S1468|from|O
S1468|Thailand|O
S1468|,|O
S1468|15|O
S1468|(|O
S1468|4.6|O
S1468|%|O
S1468|)|O
S1468|from|O
S1468|Indonesia|O
S1468|,|O
S1468|and|O
S1468|five|O
S1468|(|O
S1468|1.5|O
S1468|%|O
S1468|)|O
S1468|from|O
S1468|Singapore|O
S1468|.|O
S2221|To|O
S2221|assess|O
S2221|the|O
S2221|change|O
S2221|in|O
S2221|allergy-related|O
S2221|quality-of-life|O
S2221|measures|O
S2221|from|O
S2221|baseline|O
S2221|to|O
S2221|Week|O
S2221|36|O
S2221|,|O
S2221|the|O
S2221|Standardized|O
S2221|Asthma|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|AQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|and|O
S2221|the|O
S2221|Standardized|O
S2221|Rhinoconjunctivitis|O
S2221|Quality|O
S2221|of|O
S2221|Life|O
S2221|Questionnaire|O
S2221|(|O
S2221|RQLQ|O
S2221|(|O
S2221|S|O
S2221|)|O
S2221|)|O
S2221|were|O
S2221|administered|O
S2221|at|O
S2221|patient|O
S2221|visits|O
S2221|throughout|O
S2221|the|O
S2221|treatment|O
S2221|and|O
S2221|follow-up|O
S2221|periods|O
S2221|.|O
S1948|Conclusions|O
S1948|In|O
S1948|children|O
S1948|with|O
S1948|calcium-deficiency|O
S1948|rickets|O
S1948|,|O
S1948|there|O
S1948|is|O
S1948|a|O
S1948|trend|O
S1948|for|O
S1948|vitamin|O
S1948|D|O
S1948|to|O
S1948|improve|O
S1948|the|O
S1948|response|O
S1948|to|O
S1948|treatment|O
S1948|with|O
S1948|calcium|O
S1948|carbonate|O
S1948|as|O
S1948|limestone|O
S1948|,|O
S1948|independent|O
S1948|of|O
S1948|baseline|O
S1948|25|O
S1948|(|O
S1948|OH|O
S1948|)|O
S1948|D|O
S1948|concentrations|O
S1948|.|O
S1249|Inclusion|O
S1249|and|O
S1249|exclusion|O
S1249|criteria|O
S1249|are|O
S1249|listed|O
S1249|in|O
S1249|detail|O
S1249|in|O
S1249|the|O
S1249|protocol|O
S1249|.|O
S1315|Role|O
S1315|of|O
S1315|the|O
S1315|funding|O
S1315|source|O
S1315|The|O
S1315|sponsors|O
S1315|of|O
S1315|the|O
S1315|study|O
S1315|had|O
S1315|no|O
S1315|role|O
S1315|in|O
S1315|design|O
S1315|,|O
S1315|data|O
S1315|collection|O
S1315|,|O
S1315|data|O
S1315|analysis|O
S1315|,|O
S1315|data|O
S1315|interpretation|O
S1315|,|O
S1315|or|O
S1315|writing|O
S1315|of|O
S1315|the|O
S1315|report|O
S1315|.|O
S1422|Participants|O
S1422|The|O
S1422|inclusion|O
S1422|criteria|O
S1422|were|O
S1422|age|O
S1422|≥1|O
S1422|year|O
S1422|,|O
S1422|respiratory|O
S1422|illness|O
S1422|with|O
S1422|duration|O
S1422|of|O
S1422|symptoms|O
S1422|≤10|O
S1422|days|O
S1422|,|O
S1422|laboratory|O
S1422|confirmed|O
S1422|influenza|O
S1422|,|O
S1422|and|O
S1422|either|O
S1422|evidence|O
S1422|of|O
S1422|severe|O
S1422|influenza|O
S1422|(|O
S1422|defined|O
S1422|below|O
S1422|)|O
S1422|or|O
S1422|positive|O
S1422|result|O
S1422|of|O
S1422|a|O
S1422|diagnostic|O
S1422|test|O
S1422|for|O
S1422|H5N1|O
S1422|.|O
S1039|Design|O
S1039|A|O
S1039|multicentre|B-Settings_Multicenter
S1039|,|O
S1039|open|B-Blinding_Open_Label
S1039|,|O
S1039|two|O
S1039|arm|O
S1039|randomised|B-Randomization_Type_Simple
S1039|controlled|O
S1039|trial|O
S1039|.|O
S1988|Unless|O
S1988|otherwise|O
S1988|indicated|O
S1988|by|O
S1988|subscript|O
S1988|notation|O
S1988|for|O
S1988|individual|O
S1988|metabolites|O
S1988|,|O
S1988|25|O
S1988|(|O
S1988|OH|O
S1988|)|O
S1988|D|O
S1988|refers|O
S1988|to|O
S1988|the|O
S1988|total|O
S1988|concentrations|O
S1988|of|O
S1988|25|O
S1988|(|O
S1988|OH|O
S1988|)|O
S1988|D2|O
S1988|and|O
S1988|25|O
S1988|(|O
S1988|OH|O
S1988|)|O
S1988|D3|O
S1988|.|O
S152|Trough|O
S152|FEV1|O
S152|and|O
S152|FEV1|O
S152|area|O
S152|under|O
S152|the|O
S152|curve|O
S152|(|O
S152|AUC|O
S152|)|O
S152|(|O
S152|0-3h|O
S152|)|O
S152|responses|O
S152|were|O
S152|greater|O
S152|with|O
S152|each|O
S152|tiotropium|O
S152|Respimat®|O
S152|dose|O
S152|than|O
S152|with|O
S152|placebo|O
S152|(|O
S152|all|O
S152|P|O
S152|<|O
S152|0.0001|O
S152|)|O
S152|,|O
S152|and|O
S152|both|O
S152|were|O
S152|greatest|O
S152|with|O
S152|5|O
S152|μg|O
S152|.|O
S32|The|O
S32|following|O
S32|medications|O
S32|were|O
S32|proscribed|O
S32|during|O
S32|the|O
S32|study|O
S32|:|O
S32|medications|O
S32|that|O
S32|may|O
S32|reduce|O
S32|ulcers|O
S32|(|O
S32|e.g.|O
S32|,|O
S32|misoprostol|O
S32|,|O
S32|proton-pump|O
S32|inhibitors|O
S32|,|O
S32|and|O
S32|non-study|O
S32|H2RAs|O
S32|)|O
S32|,|O
S32|non-study|O
S32|NSAIDs|O
S32|other|O
S32|than|O
S32|low-dose|O
S32|aspirin|O
S32|taken|O
S32|for|O
S32|cardiovascular|O
S32|prophylaxis|O
S32|.|O
S90|The|O
S90|forest|O
S90|plot|O
S90|of|O
S90|these|O
S90|is|O
S90|shown|O
S90|in|O
S90|Figure|O
S90|3|O
S90|.|O
S1341|Overall|O
S1341|,|O
S1341|little|O
S1341|variation|O
S1341|occurred|O
S1341|in|O
S1341|the|O
S1341|adjusted|O
S1341|effects|O
S1341|of|O
S1341|treatment|O
S1341|in|O
S1341|different|O
S1341|subgroups|O
S1341|.|O
S1100|This|O
S1100|poor|O
S1100|quality|O
S1100|study|O
S1100|found|O
S1100|a|O
S1100|58|O
S1100|%|O
S1100|cure|O
S1100|rate|O
S1100|among|O
S1100|the|O
S1100|patients|O
S1100|allocated|O
S1100|to|O
S1100|cryotherapy|O
S1100|,|O
S1100|compared|O
S1100|with|O
S1100|41|O
S1100|%|O
S1100|among|O
S1100|those|O
S1100|treated|O
S1100|with|O
S1100|salicylic|O
S1100|acid|O
S1100|.|O
S50|These|O
S50|two|O
S50|trials|O
S50|were|O
S50|designed|O
S50|to|O
S50|be|O
S50|used|O
S50|for|O
S50|registration|O
S50|,|O
S50|and|O
S50|,|O
S50|in|O
S50|pretrial|O
S50|meetings|O
S50|,|O
S50|the|O
S50|FDA|O
S50|agreed|O
S50|to|O
S50|the|O
S50|use|O
S50|of|O
S50|the|O
S50|different|O
S50|end|O
S50|points|O
S50|in|O
S50|the|O
S50|two|O
S50|trials|O
S50|.|O
S2270|2|O
S2270|)|O
S2270|.|O
S618|Also|O
S618|excluded|O
S618|were|O
S618|patients|O
S618|with|O
S618|body|O
S618|weight|O
S618|<|O
S618|40|O
S618|kg|O
S618|,|O
S618|severe|O
S618|PAH|O
S618|(|O
S618|WHO|O
S618|class|O
S618|III/IV|O
S618|)|O
S618|,|O
S618|moderate|O
S618|to|O
S618|severe|O
S618|hepatic|O
S618|impairment|O
S618|or|O
S618|serum|O
S618|aminotransferase|O
S618|levels|O
S618|>|O
S618|3|O
S618|times|O
S618|the|O
S618|upper|O
S618|limit|O
S618|of|O
S618|the|O
S618|normal|O
S618|range|O
S618|(|O
S618|ULN|O
S618|)|O
S618|.|O
S1077|They|O
S1077|were|O
S1077|then|O
S1077|randomised|B-Randomization_Ratio
S1077|equally|I-Randomization_Ratio
S1077|to|O
S1077|receive|O
S1077|cryotherapy|B-Design_Parallel_Group
S1077|with|I-Design_Parallel_Group
S1077|liquid|I-Design_Parallel_Group
S1077|nitrogen|I-Design_Parallel_Group
S1077|or|I-Design_Parallel_Group
S1077|daily|I-Design_Parallel_Group
S1077|self|I-Design_Parallel_Group
S1077|treatment|I-Design_Parallel_Group
S1077|with|I-Design_Parallel_Group
S1077|an|I-Design_Parallel_Group
S1077|over|I-Design_Parallel_Group
S1077|the|I-Design_Parallel_Group
S1077|counter|I-Design_Parallel_Group
S1077|50|I-Design_Parallel_Group
S1077|%|I-Design_Parallel_Group
S1077|salicylic|I-Design_Parallel_Group
S1077|acid|I-Design_Parallel_Group
S1077|treatment|I-Design_Parallel_Group
S1077|.|O
S1438|Virology|O
S1438|Testing|O
S1438|of|O
S1438|the|O
S1438|combined|O
S1438|nasal|O
S1438|and|O
S1438|throat|O
S1438|swab|O
S1438|specimens|O
S1438|on|O
S1438|day|O
S1438|five|O
S1438|,|O
S1438|which|O
S1438|was|O
S1438|the|O
S1438|primary|O
S1438|virological|O
S1438|study|O
S1438|endpoint|O
S1438|,|O
S1438|was|O
S1438|done|O
S1438|under|O
S1438|blinded|O
S1438|conditions|O
S1438|in|O
S1438|the|O
S1438|SEAICRN|O
S1438|reference|O
S1438|laboratories|O
S1438|in|O
S1438|Vietnam|O
S1438|and|O
S1438|Indonesia|O
S1438|.|O
S957|All|O
S957|statistical|O
S957|analyses|O
S957|were|O
S957|conducted|O
S957|using|O
S957|SAS|O
S957|software|O
S957|,|O
S957|version|O
S957|9.2|O
S957|and|O
S957|R|O
S957|version|O
S957|2.10.1|O
S957|.|O
S2015|At|O
S2015|the|O
S2015|end|O
S2015|of|O
S2015|24|O
S2015|weeks|O
S2015|,|O
S2015|29|O
S2015|(|O
S2015|67|O
S2015|%|O
S2015|;|O
S2015|95|O
S2015|%|O
S2015|CI|O
S2015|53|O
S2015|%|O
S2015|to|O
S2015|80|O
S2015|%|O
S2015|)|O
S2015|in|O
S2015|the|O
S2015|Ca+D|O
S2015|group|O
S2015|and|O
S2015|11|O
S2015|(|O
S2015|44|O
S2015|%|O
S2015|;|O
S2015|95|O
S2015|%|O
S2015|CI|O
S2015|27|O
S2015|%|O
S2015|to|O
S2015|63|O
S2015|%|O
S2015|)|O
S2015|in|O
S2015|the|O
S2015|Ca|O
S2015|group|O
S2015|achieved|O
S2015|the|O
S2015|primary|O
S2015|combined|O
S2015|outcome|O
S2015|of|O
S2015|radiographic|O
S2015|and|O
S2015|alkaline|O
S2015|phosphatase|O
S2015|endpoints|O
S2015|,|O
S2015|and|O
S2015|this|O
S2015|difference|O
S2015|was|O
S2015|marginally|O
S2015|significant|O
S2015|(|O
S2015|p=0.06|O
S2015|)|O
S2015|.|O
S1320|Vital|O
S1320|status|O
S1320|at|O
S1320|6|O
S1320|months|O
S1320|was|O
S1320|known|O
S1320|for|O
S1320|99|O
S1320|%|O
S1320|(|O
S1320|3011|O
S1320|of|O
S1320|3035|O
S1320|)|O
S1320|of|O
S1320|patients|O
S1320|.|O
S1046|Results|O
S1046|There|O
S1046|was|O
S1046|no|O
S1046|evidence|O
S1046|of|O
S1046|a|O
S1046|difference|O
S1046|between|O
S1046|the|O
S1046|salicylic|O
S1046|acid|O
S1046|and|O
S1046|cryotherapy|O
S1046|groups|O
S1046|in|O
S1046|the|O
S1046|proportions|O
S1046|of|O
S1046|participants|O
S1046|with|O
S1046|complete|O
S1046|clearance|O
S1046|of|O
S1046|all|O
S1046|plantar|O
S1046|warts|O
S1046|at|O
S1046|12|O
S1046|weeks|O
S1046|(|O
S1046|17/119|O
S1046|(|O
S1046|14|O
S1046|%|O
S1046|)|O
S1046|v|O
S1046|15/110|O
S1046|(|O
S1046|14|O
S1046|%|O
S1046|)|O
S1046|,|O
S1046|difference|O
S1046|0.65|O
S1046|%|O
S1046|(|O
S1046|95|O
S1046|%|O
S1046|CI|O
S1046|–8.33|O
S1046|to|O
S1046|9.63|O
S1046|)|O
S1046|,|O
S1046|P=0.89|O
S1046|)|O
S1046|.|O
S1424|Exclusion|O
S1424|criteria|O
S1424|were|O
S1424|pregnancy|O
S1424|or|O
S1424|positive|O
S1424|for|O
S1424|chorionic|O
S1424|gonadotrophin|O
S1424|(|O
S1424|hCG|O
S1424|)|O
S1424|in|O
S1424|urine|O
S1424|,|O
S1424|women|O
S1424|who|O
S1424|were|O
S1424|actively|O
S1424|breast|O
S1424|feeding|O
S1424|,|O
S1424|a|O
S1424|delay|O
S1424|of|O
S1424|more|O
S1424|than|O
S1424|72|O
S1424|hours|O
S1424|before|O
S1424|treatment|O
S1424|with|O
S1424|oseltamivir|O
S1424|,|O
S1424|and|O
S1424|severe|O
S1424|renal|O
S1424|impairment|O
S1424|defined|O
S1424|by|O
S1424|creatinine|O
S1424|clearance|O
S1424|<|O
S1424|10|O
S1424|mL/min|O
S1424|(|O
S1424|Cockcroft-Gault|O
S1424|equation|O
S1424|)|O
S1424|.|O
S669|Adverse|O
S669|events|O
S669|occurring|O
S669|in|O
S669|more|O
S669|patients|O
S669|on|O
S669|bosentan|O
S669|than|O
S669|placebo|O
S669|included|O
S669|peripheral|O
S669|oedema|O
S669|(|O
S669|18.8|O
S669|%|O
S669|vs|O
S669|4.4|O
S669|%|O
S669|)|O
S669|and|O
S669|events|O
S669|denoting|O
S669|elevated|O
S669|aminotransferases|O
S669|(|O
S669|12.5|O
S669|%|O
S669|vs|O
S669|2.2|O
S669|%|O
S669|)|O
S669|.|O
S1490|In|O
S1490|the|O
S1490|conditional|O
S1490|multiple|O
S1490|logistic|O
S1490|regression|O
S1490|analysis|O
S1490|(|O
S1490|table|O
S1490|4|O
S1490|)|O
S1490|,|O
S1490|patients|O
S1490|who|O
S1490|had|O
S1490|no|O
S1490|viral|O
S1490|RNA|O
S1490|detected|O
S1490|on|O
S1490|day|O
S1490|five|O
S1490|were|O
S1490|more|O
S1490|likely|O
S1490|to|O
S1490|have|O
S1490|lower|O
S1490|nasal|O
S1490|viral|O
S1490|loads|O
S1490|at|O
S1490|baseline|O
S1490|,|O
S1490|human|O
S1490|(|O
S1490|non-avian|O
S1490|H5N1|O
S1490|)|O
S1490|influenza|O
S1490|virus|O
S1490|infection|O
S1490|,|O
S1490|and|O
S1490|a|O
S1490|higher|O
S1490|Karnofsky|O
S1490|score|O
S1490|(|O
S1490|≥50|O
S1490|)|O
S1490|.|O
S1128|Overall|O
S1128|,|O
S1128|32|O
S1128|of|O
S1128|the|O
S1128|229|O
S1128|(|O
S1128|14|O
S1128|%|O
S1128|)|O
S1128|had|O
S1128|complete|O
S1128|clearance|O
S1128|of|O
S1128|all|O
S1128|plantar|O
S1128|warts|O
S1128|at|O
S1128|12|O
S1128|weeks|O
S1128|,|O
S1128|corresponding|O
S1128|to|O
S1128|17/119|O
S1128|(|O
S1128|14|O
S1128|%|O
S1128|)|O
S1128|patients|O
S1128|in|O
S1128|the|O
S1128|salicylic|O
S1128|acid|O
S1128|group|O
S1128|and|O
S1128|15/110|O
S1128|(|O
S1128|14|O
S1128|%|O
S1128|)|O
S1128|patients|O
S1128|in|O
S1128|the|O
S1128|cryotherapy|O
S1128|group|O
S1128|,|O
S1128|with|O
S1128|no|O
S1128|significant|O
S1128|difference|O
S1128|between|O
S1128|the|O
S1128|two|O
S1128|groups|O
S1128|(|O
S1128|difference|O
S1128|0.65|O
S1128|%|O
S1128|(|O
S1128|95|O
S1128|%|O
S1128|confidence|O
S1128|interval|O
S1128|–8.33|O
S1128|to|O
S1128|9.63|O
S1128|)|O
S1128|,|O
S1128|P=0.89|O
S1128|)|O
S1128|.|O
S320|Primary|O
S320|outcome|O
S320|:|O
S320|determination|O
S320|of|O
S320|canakinumab|O
S320|target|O
S320|dose|O
S320|No|O
S320|evidence|O
S320|of|O
S320|a|O
S320|dose-response|O
S320|was|O
S320|seen|O
S320|in|O
S320|any|O
S320|of|O
S320|the|O
S320|four|O
S320|predefined|O
S320|dose|O
S320|response|O
S320|models|O
S320|.|O
S1724|There|O
S1724|was|O
S1724|no|O
S1724|evidence|O
S1724|of|O
S1724|differences|O
S1724|between|O
S1724|ART-strategy|O
S1724|groups|O
S1724|in|O
S1724|progression|O
S1724|to|O
S1724|new|O
S1724|WHO|O
S1724|stage|O
S1724|4|O
S1724|event|O
S1724|or|O
S1724|death|O
S1724|(|O
S1724|HR|O
S1724|[|O
S1724|B|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·89|O
S1724|,|O
S1724|95|O
S1724|%|O
S1724|CI|O
S1724|0·53–1·48|O
S1724|;|O
S1724|HR|O
S1724|[|O
S1724|C|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·91|O
S1724|,|O
S1724|0·54–1·52|O
S1724|;|O
S1724|global|O
S1724|p=0·89|O
S1724|)|O
S1724|,|O
S1724|WHO|O
S1724|stage|O
S1724|3|O
S1724|or|O
S1724|4|O
S1724|event|O
S1724|or|O
S1724|death|O
S1724|(|O
S1724|HR|O
S1724|[|O
S1724|B|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·82|O
S1724|,|O
S1724|0·55–1·20|O
S1724|;|O
S1724|HR|O
S1724|[|O
S1724|C|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·80|O
S1724|,|O
S1724|0·54–1·17|O
S1724|;|O
S1724|global|O
S1724|p=0·44|O
S1724|)|O
S1724|,|O
S1724|or|O
S1724|mortality|O
S1724|overall|O
S1724|(|O
S1724|HR|O
S1724|[|O
S1724|B|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·66|O
S1724|,|O
S1724|0·33–1·31|O
S1724|;|O
S1724|HR|O
S1724|[|O
S1724|C|O
S1724|:|O
S1724|A|O
S1724|]|O
S1724|0·97|O
S1724|,|O
S1724|0·52–1·81|O
S1724|;|O
S1724|global|O
S1724|p=0·43|O
S1724|;|O
S1724|figure|O
S1724|4|O
S1724|;|O
S1724|appendix|O
S1724|)|O
S1724|.|O
S2006|The|O
S2006|baseline|O
S2006|mean|O
S2006|(|O
S2006|±SD|O
S2006|)|O
S2006|25|O
S2006|(|O
S2006|OH|O
S2006|)|O
S2006|D|O
S2006|concentration|O
S2006|was|O
S2006|30.2±13.2|O
S2006|nmol/L|O
S2006|,|O
S2006|and|O
S2006|29|O
S2006|(|O
S2006|40|O
S2006|%|O
S2006|)|O
S2006|had|O
S2006|values|O
S2006|below|O
S2006|30|O
S2006|nmol/L|O
S2006|.|O
S1938|Setting|O
S1938|Jos|B-Settings_Single_Center
S1938|University|I-Settings_Single_Center
S1938|Teaching|I-Settings_Single_Center
S1938|Hospital|I-Settings_Single_Center
S1938|,|O
S1938|Jos|B-Settings_Location
S1938|,|I-Settings_Location
S1938|Nigeria|I-Settings_Location
S1938|.|O
S1484|Specifically|O
S1484|,|O
S1484|at|O
S1484|day|O
S1484|five|O
S1484|,|O
S1484|in|O
S1484|the|O
S1484|224|O
S1484|patients|O
S1484|infected|O
S1484|with|O
S1484|seasonal|O
S1484|influenza|O
S1484|(|O
S1484|excluding|O
S1484|H5N1|O
S1484|and|O
S1484|H1N1-pdm09|O
S1484|infections|O
S1484|)|O
S1484|the|O
S1484|proportions|O
S1484|of|O
S1484|patients|O
S1484|with|O
S1484|negative|O
S1484|results|O
S1484|for|O
S1484|viral|O
S1484|RNA|O
S1484|in|O
S1484|the|O
S1484|nasal|O
S1484|and|O
S1484|throat|O
S1484|swabs|O
S1484|were|O
S1484|similar|O
S1484|(|O
S1484|P=0.45|O
S1484|)|O
S1484|between|O
S1484|the|O
S1484|double|O
S1484|(|O
S1484|82/114|O
S1484|,|O
S1484|72|O
S1484|%|O
S1484|)|O
S1484|and|O
S1484|standard|O
S1484|dose|O
S1484|arms|O
S1484|(|O
S1484|74/110|O
S1484|,|O
S1484|67|O
S1484|%|O
S1484|)|O
S1484|.|O
S1665|Baseline|O
S1665|characteristics|O
S1665|were|O
S1665|similar|O
S1665|across|O
S1665|randomised|O
S1665|groups|O
S1665|(|O
S1665|table|O
S1665|1|O
S1665|)|O
S1665|.|O
S302|The|O
S302|primary|O
S302|outcome|O
S302|was|O
S302|determination|O
S302|of|O
S302|the|O
S302|canakinumab|O
S302|dose|O
S302|producing|O
S302|equivalent|O
S302|efficacy|O
S302|to|O
S302|that|O
S302|achieved|O
S302|with|O
S302|colchicine|O
S302|0.5|O
S302|mg|O
S302|,|O
S302|with|O
S302|respect|O
S302|to|O
S302|the|O
S302|mean|O
S302|number|O
S302|of|O
S302|flares|O
S302|per|O
S302|patient|O
S302|occurring|O
S302|within|O
S302|16|O
S302|weeks|O
S302|post|O
S302|randomisation|O
S302|(|O
S302|ie|O
S302|,|O
S302|the|O
S302|target|O
S302|dose|O
S302|)|O
S302|.|O
S1852|The|O
S1852|primary|O
S1852|outcome|O
S1852|for|O
S1852|analyses|O
S1852|of|O
S1852|prolonged|O
S1852|follow-up|O
S1852|was|O
S1852|prespecified|O
S1852|to|O
S1852|be|O
S1852|the|O
S1852|first|O
S1852|post-randomisation|O
S1852|major|O
S1852|vascular|O
S1852|event|O
S1852|(|O
S1852|defined|O
S1852|as|O
S1852|non-fatal|O
S1852|myocardial|O
S1852|infarction|O
S1852|or|O
S1852|coronary|O
S1852|death|O
S1852|,|O
S1852|fatal|O
S1852|or|O
S1852|non-fatal|O
S1852|stroke|O
S1852|,|O
S1852|coronary|O
S1852|or|O
S1852|non-coronary|O
S1852|revascularisation|O
S1852|)|O
S1852|.|O
S1133|We|O
S1133|received|O
S1133|patient|O
S1133|self|O
S1133|reported|O
S1133|data|O
S1133|on|O
S1133|presence|O
S1133|or|O
S1133|absence|O
S1133|of|O
S1133|plantar|O
S1133|warts|O
S1133|at|O
S1133|six|O
S1133|months|O
S1133|from|O
S1133|193|O
S1133|participants|O
S1133|.|O
S1476|Baseline|O
S1476|rates|O
S1476|of|O
S1476|positivity|O
S1476|for|O
S1476|RNA|O
S1476|influenza|O
S1476|were|O
S1476|similar|O
S1476|for|O
S1476|the|O
S1476|nasal|O
S1476|(|O
S1476|239/317|O
S1476|,|O
S1476|75.4|O
S1476|%|O
S1476|)|O
S1476|and|O
S1476|throat|O
S1476|(|O
S1476|242/312|O
S1476|,|O
S1476|77.6|O
S1476|%|O
S1476|)|O
S1476|swabs|O
S1476|.|O
S220|Results|O
S220|Baseline|O
S220|demographics|O
S220|and|O
S220|disposition|O
S220|A|O
S220|total|O
S220|of|O
S220|149|B-Sample_Size_Actual_at_Enrollment
S220|patients|O
S220|were|O
S220|randomised|O
S220|to|O
S220|the|O
S220|study|O
S220|,|O
S220|and|O
S220|141|B-Sample_Size_Actual_at_Outcome_Analysis
S220|patients|O
S220|completed|O
S220|the|O
S220|study|O
S220|.|O
S1849|About|O
S1849|1100|O
S1849|blood|O
S1849|samples|O
S1849|were|O
S1849|obtained|O
S1849|by|O
S1849|participants|O
S1849|'|O
S1849|family|O
S1849|doctors|O
S1849|and|O
S1849|were|O
S1849|mailed|O
S1849|to|O
S1849|a|O
S1849|central|O
S1849|laboratory|O
S1849|for|O
S1849|assay|O
S1849|using|O
S1849|previously|O
S1849|validated|O
S1849|methods|O
S1849|.|O
S1458|In|O
S1458|these|O
S1458|regression|O
S1458|models|O
S1458|,|O
S1458|the|O
S1458|quantifiable|O
S1458|viral|O
S1458|load|O
S1458|data|O
S1458|were|O
S1458|used|O
S1458|(|O
S1458|that|O
S1458|is|O
S1458|,|O
S1458|≥103|O
S1458|cDNA|O
S1458|copies/mL|O
S1458|)|O
S1458|and|O
S1458|data|O
S1458|from|O
S1458|samples|O
S1458|positive|O
S1458|by|O
S1458|qualitative|O
S1458|RT-PCR|O
S1458|but|O
S1458|not|O
S1458|quantifiable|O
S1458|were|O
S1458|given|O
S1458|a|O
S1458|value|O
S1458|of|O
S1458|103|O
S1458|cDNA|O
S1458|copies|O
S1458|(|O
S1458|c|O
S1458|)|O
S1458|/mL|O
S1458|,|O
S1458|the|O
S1458|lower|O
S1458|limit|O
S1458|of|O
S1458|detection|O
S1458|of|O
S1458|the|O
S1458|quantitative|O
S1458|RT-PCR|O
S1458|.|O
S222|In|O
S222|the|O
S222|treated|O
S222|set|O
S222|,|O
S222|slightly|O
S222|more|O
S222|patients|O
S222|were|O
S222|female|O
S222|(|O
S222|55.0|O
S222|%|O
S222|)|O
S222|than|O
S222|male|O
S222|(|O
S222|45.0|O
S222|%|O
S222|)|O
S222|,|O
S222|mean|O
S222|age|O
S222|was|O
S222|49.3|O
S222|years|O
S222|and|O
S222|mean|O
S222|body|O
S222|mass|O
S222|index|O
S222|was|O
S222|26.9|O
S222|kg/m2|O
S222|(|O
S222|Table|O
S222|1|O
S222|)|O
S222|.|O
S3|METHODS|O
S3|:|O
S3|Patients|O
S3|(|O
S3|40–80|O
S3|years|O
S3|)|O
S3|requiring|O
S3|daily|O
S3|non-steroidal|O
S3|anti-inflammatory|O
S3|drugs|O
S3|(|O
S3|NSAIDs|O
S3|)|O
S3|for|O
S3|≥6|O
S3|months|O
S3|with|O
S3|no|O
S3|prior|O
S3|ulcer|O
S3|complications|O
S3|,|O
S3|negative|O
S3|H.|O
S3|pylori|O
S3|stool|O
S3|test|O
S3|,|O
S3|and|O
S3|baseline|O
S3|endoscopy|O
S3|showing|O
S3|no|O
S3|ulcers|O
S3|and|O
S3|<|O
S3|5|O
S3|erosions|O
S3|were|O
S3|randomly|O
S3|assigned|O
S3|in|O
S3|a|O
S3|2:1|B-Randomization_Ratio
S3|ratio|O
S3|to|O
S3|HZT-501|B-Design_Parallel_Group
S3|or|I-Design_Parallel_Group
S3|identical-appearing|I-Design_Parallel_Group
S3|ibuprofen|I-Design_Parallel_Group
S3|800|I-Design_Parallel_Group
S3|mg|I-Design_Parallel_Group
S3|tablets|I-Design_Parallel_Group
S3|thrice|O
S3|daily|O
S3|.|O
S1404|No|O
S1404|differences|O
S1404|were|O
S1404|found|O
S1404|between|O
S1404|double|O
S1404|and|O
S1404|standard|O
S1404|dose|O
S1404|arms|O
S1404|in|O
S1404|median|O
S1404|days|O
S1404|on|O
S1404|supplemental|O
S1404|oxygen|O
S1404|(|O
S1404|3|O
S1404|(|O
S1404|interquartile|O
S1404|range|O
S1404|2-5|O
S1404|)|O
S1404|v|O
S1404|3.5|O
S1404|(|O
S1404|2-7|O
S1404|)|O
S1404|)|O
S1404|,|O
S1404|in|O
S1404|intensive|O
S1404|care|O
S1404|(|O
S1404|4.5|O
S1404|(|O
S1404|3-6|O
S1404|)|O
S1404|v|O
S1404|5|O
S1404|(|O
S1404|2-11|O
S1404|)|O
S1404|,|O
S1404|and|O
S1404|on|O
S1404|mechanical|O
S1404|ventilation|O
S1404|(|O
S1404|2.5|O
S1404|(|O
S1404|1-16|O
S1404|)|O
S1404|v|O
S1404|8|O
S1404|(|O
S1404|1-16|O
S1404|)|O
S1404|)|O
S1404|,|O
S1404|respectively|O
S1404|.|O
S1109|Secondary|O
S1109|analysis|O
S1109|A|O
S1109|logistic|O
S1109|regression|O
S1109|model|O
S1109|was|O
S1109|used|O
S1109|to|O
S1109|adjust|O
S1109|the|O
S1109|primary|O
S1109|analysis|O
S1109|for|O
S1109|important|O
S1109|prognostic|O
S1109|variables|O
S1109|(|O
S1109|age|O
S1109|,|O
S1109|whether|O
S1109|the|O
S1109|plantar|O
S1109|wart|O
S1109|had|O
S1109|been|O
S1109|previously|O
S1109|treated|O
S1109|,|O
S1109|and|O
S1109|type|O
S1109|of|O
S1109|wart|O
S1109|)|O
S1109|.|O
S1286|In|O
S1286|Italy|O
S1286|and|O
S1286|Austria|O
S1286|,|O
S1286|all|O
S1286|follow-ups|O
S1286|were|O
S1286|done|O
S1286|as|O
S1286|telephone|O
S1286|interviews|O
S1286|by|O
S1286|a|O
S1286|clinician|B-Blinding_Object_Others
S1286|,|O
S1286|who|O
S1286|was|O
S1286|masked|O
S1286|to|O
S1286|treatment|O
S1286|allocation|O
S1286|and|O
S1286|was|O
S1286|highly|O
S1286|experienced|O
S1286|in|O
S1286|outcome|O
S1286|assessment|O
S1286|.|O
S900|Patients|O
S900|suitable|O
S900|for|O
S900|topical|O
S900|treatment|O
S900|were|O
S900|entered|O
S900|into|O
S900|a|O
S900|parallel|O
S900|observational|O
S900|study|O
S900|,|O
S900|the|O
S900|results|O
S900|of|O
S900|which|O
S900|will|O
S900|be|O
S900|reported|O
S900|separately|O
S900|.|O
S1230|More|O
S1230|deaths|O
S1230|occurred|O
S1230|within|O
S1230|7|O
S1230|days|O
S1230|in|O
S1230|the|O
S1230|rt-PA|O
S1230|group|O
S1230|(|O
S1230|163|O
S1230|[|O
S1230|11|O
S1230|%|O
S1230|]|O
S1230|)|O
S1230|than|O
S1230|in|O
S1230|the|O
S1230|control|O
S1230|group|O
S1230|(|O
S1230|107|O
S1230|[|O
S1230|7|O
S1230|%|O
S1230|]|O
S1230|,|O
S1230|adjusted|O
S1230|OR|O
S1230|1·60|O
S1230|,|O
S1230|95|O
S1230|%|O
S1230|CI|O
S1230|1·22–2·08|O
S1230|,|O
S1230|p=0·001|O
S1230|;|O
S1230|absolute|O
S1230|increase|O
S1230|37/1000|O
S1230|,|O
S1230|95|O
S1230|%|O
S1230|CI|O
S1230|17–57|O
S1230|)|O
S1230|,|O
S1230|but|O
S1230|between|O
S1230|7|O
S1230|days|O
S1230|and|O
S1230|6|O
S1230|months|O
S1230|there|O
S1230|were|O
S1230|fewer|O
S1230|deaths|O
S1230|in|O
S1230|the|O
S1230|rt-PA|O
S1230|group|O
S1230|than|O
S1230|in|O
S1230|the|O
S1230|control|O
S1230|group|O
S1230|,|O
S1230|so|O
S1230|that|O
S1230|by|O
S1230|6|O
S1230|months|O
S1230|,|O
S1230|similar|O
S1230|numbers|O
S1230|,|O
S1230|in|O
S1230|total|O
S1230|,|O
S1230|had|O
S1230|died|O
S1230|(|O
S1230|408|O
S1230|[|O
S1230|27|O
S1230|%|O
S1230|]|O
S1230|in|O
S1230|the|O
S1230|rt-PA|O
S1230|group|O
S1230|vs|O
S1230|407|O
S1230|[|O
S1230|27|O
S1230|%|O
S1230|]|O
S1230|in|O
S1230|the|O
S1230|control|O
S1230|group|O
S1230|)|O
S1230|.|O
S2196|These|O
S2196|data|O
S2196|suggest|O
S2196|that|O
S2196|IgE|O
S2196|may|O
S2196|drive|O
S2196|allergic|O
S2196|asthma|O
S2196|in|O
S2196|a|O
S2196|subset|O
S2196|of|O
S2196|patients|O
S2196|.|O
S1630|The|O
S1630|computer-generated|B-Randomization_Sequence_Generation_Method
S1630|sequentially|I-Randomization_Sequence_Generation_Method
S1630|numbered|I-Randomization_Sequence_Generation_Method
S1630|randomisation|I-Randomization_Sequence_Generation_Method
S1630|list|I-Randomization_Sequence_Generation_Method
S1630|(|O
S1630|with|O
S1630|variable|O
S1630|block|B-Randomization_Type_Block
S1630|sizes|O
S1630|)|O
S1630|containing|O
S1630|both|O
S1630|allocations|O
S1630|was|O
S1630|pre-prepared|O
S1630|by|O
S1630|the|O
S1630|trial|O
S1630|statistician|B-Randomization_Personnel
S1630|and|O
S1630|incorporated|O
S1630|within|O
S1630|the|O
S1630|secure|O
S1630|database|O
S1630|at|O
S1630|each|O
S1630|trial|O
S1630|centre|O
S1630|,|O
S1630|connected|O
S1630|to|O
S1630|but|O
S1630|not|O
S1630|located|O
S1630|within|O
S1630|each|O
S1630|clinical|O
S1630|centre|O
S1630|,|O
S1630|allowing|O
S1630|trial|O
S1630|managers|O
S1630|to|O
S1630|access|O
S1630|the|O
S1630|next|O
S1630|number|O
S1630|,|O
S1630|but|O
S1630|not|O
S1630|the|O
S1630|whole|O
S1630|list|O
S1630|.|O
S1276|Events|O
S1276|occurring|O
S1276|within|O
S1276|7|O
S1276|days|O
S1276|of|O
S1276|stroke|O
S1276|were|O
S1276|recorded|O
S1276|by|O
S1276|the|O
S1276|local|O
S1276|trial|O
S1276|clinician|O
S1276|on|O
S1276|the|O
S1276|7-day|O
S1276|form|O
S1276|:|O
S1276|deaths|O
S1276|subdivided|O
S1276|by|O
S1276|cause|O
S1276|(|O
S1276|swelling|O
S1276|of|O
S1276|the|O
S1276|initial|O
S1276|infarct|O
S1276|,|O
S1276|intracranial|O
S1276|haemorrhage|O
S1276|,|O
S1276|other|O
S1276|deaths|O
S1276|from|O
S1276|the|O
S1276|initial|O
S1276|stroke|O
S1276|,|O
S1276|recurrent|O
S1276|ischaemic|O
S1276|stroke|O
S1276|,|O
S1276|recurrent|O
S1276|stroke|O
S1276|of|O
S1276|unknown|O
S1276|type|O
S1276|,|O
S1276|any|O
S1276|other|O
S1276|cause|O
S1276|)|O
S1276|;|O
S1276|symptomatic|O
S1276|intracranial|O
S1276|haemorrhage|O
S1276|;|O
S1276|recurrent|O
S1276|ischaemic|O
S1276|stroke|O
S1276|;|O
S1276|recurrent|O
S1276|stroke|O
S1276|of|O
S1276|unknown|O
S1276|type|O
S1276|;|O
S1276|neurological|O
S1276|deterioration|O
S1276|attributed|O
S1276|to|O
S1276|swelling|O
S1276|of|O
S1276|the|O
S1276|initial|O
S1276|ischaemic|O
S1276|stroke|O
S1276|;|O
S1276|neurological|O
S1276|deterioration|O
S1276|not|O
S1276|attributable|O
S1276|to|O
S1276|swelling|O
S1276|of|O
S1276|the|O
S1276|initial|O
S1276|ischaemic|O
S1276|stroke|O
S1276|or|O
S1276|haemorrhage|O
S1276|;|O
S1276|and|O
S1276|major|O
S1276|extracranial|O
S1276|haemorrhage|O
S1276|(|O
S1276|operational|O
S1276|definitions|O
S1276|of|O
S1276|each|O
S1276|of|O
S1276|these|O
S1276|events|O
S1276|are|O
S1276|provided|O
S1276|in|O
S1276|the|O
S1276|published|O
S1276|protocol|O
S1276|and|O
S1276|statistical|O
S1276|analysis|O
S1276|plan|O
S1276|)|O
S1276|.|O
S911|Interventions|O
S911|Participants|O
S911|received|O
S911|oral|O
S911|prednisolone|O
S911|(|O
S911|brand|O
S911|chosen|O
S911|according|O
S911|to|O
S911|local|O
S911|practice|O
S911|)|O
S911|0.75|O
S911|mg/kg/day|O
S911|in|O
S911|a|O
S911|single|O
S911|dose|O
S911|or|O
S911|ciclosporin|O
S911|(|O
S911|Neoral|O
S911|;|O
S911|Novartis|O
S911|)|O
S911|4|O
S911|mg/kg/day|O
S911|in|O
S911|two|O
S911|divided|O
S911|doses|O
S911|.|O
S1971|Weight|O
S1971|was|O
S1971|measured|O
S1971|with|O
S1971|a|O
S1971|hanging|O
S1971|weighing|O
S1971|scale|O
S1971|.|O
S1076|Eligible|O
S1076|participants|O
S1076|gave|O
S1076|written|O
S1076|informed|O
S1076|consent|O
S1076|.|O
S782|Venous|O
S782|17-gauge|O
S782|cannulae|O
S782|were|O
S782|inserted|O
S782|into|O
S782|each|O
S782|forearm|O
S782|for|O
S782|blood|O
S782|sampling|O
S782|and|O
S782|a|O
S782|27-standard|O
S782|wire|O
S782|gauge|O
S782|steel|O
S782|needle|O
S782|placed|O
S782|in|O
S782|the|O
S782|brachial|O
S782|artery|O
S782|of|O
S782|the|O
S782|non-dominant|O
S782|forearm|O
S782|for|O
S782|vasodilator|O
S782|infusions|O
S782|.|O
S1896|The|O
S1896|incidence|O
S1896|of|O
S1896|a|O
S1896|first|O
S1896|diagnosis|O
S1896|of|O
S1896|any|O
S1896|type|O
S1896|of|O
S1896|cancer|O
S1896|(|O
S1896|excluding|O
S1896|,|O
S1896|as|O
S1896|prespecified|O
S1896|,|O
S1896|non-melanoma|O
S1896|skin|O
S1896|cancer|O
S1896|)|O
S1896|was|O
S1896|similar|O
S1896|throughout|O
S1896|the|O
S1896|in-trial|O
S1896|and|O
S1896|post-trial|O
S1896|periods|O
S1896|combined|O
S1896|(|O
S1896|1749|O
S1896|[|O
S1896|17·0|O
S1896|%|O
S1896|]|O
S1896|allocated|O
S1896|simvastatin|O
S1896|vs|O
S1896|1744|O
S1896|[|O
S1896|17·0|O
S1896|%|O
S1896|]|O
S1896|allocated|O
S1896|placebo|O
S1896|;|O
S1896|RR|O
S1896|0·98|O
S1896|[|O
S1896|0·92–1·05|O
S1896|]|O
S1896|;|O
S1896|p=0·60|O
S1896|;|O
S1896|figure|O
S1896|5|O
S1896|)|O
S1896|.|O
S1477|Median|O
S1477|baseline|O
S1477|quantitative|O
S1477|viral|O
S1477|loads|O
S1477|were|O
S1477|similar|O
S1477|between|O
S1477|the|O
S1477|two|O
S1477|arms|O
S1477|for|O
S1477|nose|O
S1477|(|O
S1477|9.6×10e4|O
S1477|copies|O
S1477|in|O
S1477|the|O
S1477|double|O
S1477|dose|O
S1477|(|O
S1477|n=99|O
S1477|)|O
S1477|and|O
S1477|1.5×10e5|O
S1477|copies|O
S1477|in|O
S1477|the|O
S1477|standard|O
S1477|dose|O
S1477|arm|O
S1477|(|O
S1477|n=96|O
S1477|)|O
S1477|)|O
S1477|and|O
S1477|throat|O
S1477|(|O
S1477|4.1×10e4|O
S1477|copies|O
S1477|in|O
S1477|the|O
S1477|double|O
S1477|dose|O
S1477|(|O
S1477|n=85|O
S1477|)|O
S1477|and|O
S1477|6.3×10e4|O
S1477|copies|O
S1477|in|O
S1477|the|O
S1477|standard|O
S1477|dose|O
S1477|arm|O
S1477|(|O
S1477|n=95|O
S1477|)|O
S1477|;|O
S1477|see|O
S1477|supplementary|O
S1477|figure|O
S1477|in|O
S1477|appendix|O
S1477|)|O
S1477|.|O
S785|Heart|O
S785|rate|O
S785|and|O
S785|blood|O
S785|pressure|O
S785|in|O
S785|the|O
S785|non-infused|O
S785|arm|O
S785|were|O
S785|monitored|O
S785|at|O
S785|intervals|O
S785|throughout|O
S785|with|O
S785|the|O
S785|use|O
S785|of|O
S785|a|O
S785|semiautomated|O
S785|,|O
S785|non-invasive|O
S785|oscillometric|O
S785|sphygmomanometer|O
S785|.|O
S1983|The|O
S1983|weight|O
S1983|of|O
S1983|limestone|O
S1983|remaining|O
S1983|at|O
S1983|each|O
S1983|visit|O
S1983|was|O
S1983|recorded|O
S1983|to|O
S1983|assess|O
S1983|adherence|O
S1983|.|O
S2099|We|O
S2099|hypothesised|O
S2099|that|O
S2099|decreasing|O
S2099|excessive|O
S2099|,|O
S2099|NMDA-dependant|O
S2099|,|O
S2099|glutamatergic|O
S2099|transmission|O
S2099|might|O
S2099|partly|O
S2099|restore|O
S2099|gait|O
S2099|and|O
S2099|posture|O
S2099|control|O
S2099|.|O
S2224|Assessments|O
S2224|The|O
S2224|patient|O
S2224|daily|O
S2224|diary|O
S2224|included|O
S2224|two|O
S2224|sections|O
S2224|in|O
S2224|addition|O
S2224|to|O
S2224|peak|O
S2224|flow|O
S2224|measurements|O
S2224|:|O
S2224|1|O
S2224|)|O
S2224|a|O
S2224|morning|O
S2224|section|O
S2224|capturing|O
S2224|awakenings|O
S2224|and|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|at|O
S2224|night|O
S2224|,|O
S2224|and|O
S2224|symptoms|O
S2224|on|O
S2224|awakening|O
S2224|;|O
S2224|and|O
S2224|2|O
S2224|)|O
S2224|an|O
S2224|evening|O
S2224|section|O
S2224|capturing|O
S2224|daytime|O
S2224|symptom|O
S2224|severity|O
S2224|,|O
S2224|rescue|O
S2224|medication|O
S2224|use|O
S2224|,|O
S2224|preventive|O
S2224|inhaler|O
S2224|use|O
S2224|,|O
S2224|activity|O
S2224|impairment|O
S2224|during|O
S2224|the|O
S2224|day|O
S2224|,|O
S2224|and|O
S2224|nasal|O
S2224|symptoms|O
S2224|.|O
S166|Recently|O
S166|,|O
S166|a|O
S166|number|O
S166|of|O
S166|clinical|O
S166|trials|O
S166|have|O
S166|investigated|O
S166|tiotropium|O
S166|as|O
S166|add-on|O
S166|to|O
S166|at|O
S166|least|O
S166|ICS|O
S166|for|O
S166|the|O
S166|long-term|O
S166|control|O
S166|of|O
S166|asthma|O
S166|,|O
S166|across|O
S166|a|O
S166|range|O
S166|of|O
S166|severities|O
S166|.|O
S2268|Based|O
S2268|on|O
S2268|non-compartmental|O
S2268|analysis|O
S2268|,|O
S2268|the|O
S2268|mean|O
S2268|t1/2|O
S2268|values|O
S2268|of|O
S2268|quilizumab|O
S2268|across|O
S2268|the|O
S2268|dose|O
S2268|groups|O
S2268|ranged|O
S2268|from|O
S2268|16.4|O
S2268|to|O
S2268|18.7|O
S2268|days|O
S2268|,|O
S2268|which|O
S2268|suggests|O
S2268|that|O
S2268|steady-state|O
S2268|was|O
S2268|attained|O
S2268|by|O
S2268|the|O
S2268|time|O
S2268|the|O
S2268|final|O
S2268|doses|O
S2268|were|O
S2268|administered|O
S2268|for|O
S2268|both|O
S2268|monthly|O
S2268|and|O
S2268|quarterly|O
S2268|regimens|O
S2268|.|O
S64|RESULTS|O
S64|The|O
S64|progress|O
S64|of|O
S64|the|O
S64|studies|O
S64|from|O
S64|enrollment|O
S64|through|O
S64|analysis|O
S64|is|O
S64|shown|O
S64|in|O
S64|the|O
S64|CONSORT|O
S64|diagrams|O
S64|in|O
S64|Figure|O
S64|1|O
S64|.|O
S201|Safety|O
S201|and|O
S201|tolerability|O
S201|were|O
S201|assessed|O
S201|based|O
S201|on|O
S201|the|O
S201|incidence|O
S201|and|O
S201|intensity|O
S201|of|O
S201|adverse|O
S201|events|O
S201|,|O
S201|and|O
S201|on|O
S201|changes|O
S201|in|O
S201|vital|O
S201|signs|O
S201|.|O
S1317|Results|O
S1317|Between|O
S1317|May|O
S1317|,|O
S1317|2000|O
S1317|,|O
S1317|and|O
S1317|July|O
S1317|,|O
S1317|2011|O
S1317|,|O
S1317|3035|B-Sample_Size_Actual_at_Enrollment
S1317|patients|O
S1317|were|O
S1317|enrolled|O
S1317|in|O
S1317|156|B-Settings_Multicenter
S1317|centres|I-Settings_Multicenter
S1317|in|O
S1317|12|B-Settings_Multicenter
S1317|countries|I-Settings_Multicenter
S1317|.|O
S295|Patients|O
S295|Inclusion|O
S295|criteria|O
S295|were|O
S295|:|O
S295|age|O
S295|18–80|O
S295|years|O
S295|,|O
S295|diagnosis|O
S295|of|O
S295|gouty|O
S295|arthritis|O
S295|as|O
S295|defined|O
S295|by|O
S295|the|O
S295|American|O
S295|College|O
S295|of|O
S295|Rheumatology|O
S295|1977|O
S295|preliminary|O
S295|criteria|O
S295|,|O
S295|having|O
S295|had|O
S295|at|O
S295|least|O
S295|two|O
S295|gouty|O
S295|arthritis|O
S295|flares|O
S295|in|O
S295|the|O
S295|previous|O
S295|year|O
S295|,|O
S295|body|O
S295|mass|O
S295|index|O
S295|(|O
S295|BMI|O
S295|)|O
S295|of|O
S295|≤40|O
S295|kg/m2|O
S295|and|O
S295|willingness|O
S295|to|O
S295|initiate|O
S295|allopurinol|O
S295|treatment|O
S295|or|O
S295|having|O
S295|initiated|O
S295|allopurinol|O
S295|treatment|O
S295|within|O
S295|1|O
S295|month|O
S295|of|O
S295|screening|O
S295|.|O
S1997|Logistic|O
S1997|regression|O
S1997|was|O
S1997|used|O
S1997|to|O
S1997|assess|O
S1997|the|O
S1997|effect|O
S1997|of|O
S1997|treatment|O
S1997|group|O
S1997|on|O
S1997|the|O
S1997|primary|O
S1997|outcome|O
S1997|while|O
S1997|controlling|O
S1997|for|O
S1997|baseline|O
S1997|group|O
S1997|differences|O
S1997|and|O
S1997|to|O
S1997|test|O
S1997|for|O
S1997|interactions|O
S1997|between|O
S1997|variables|O
S1997|.|O
S145|Eligibility|O
S145|criteria|O
S145|included|O
S145|≥60|O
S145|%|O
S145|and|O
S145|≤90|O
S145|%|O
S145|of|O
S145|predicted|O
S145|normal|O
S145|forced|O
S145|expiratory|O
S145|volume|O
S145|in|O
S145|1|O
S145|second|O
S145|(|O
S145|FEV1|O
S145|)|O
S145|and|O
S145|seven-question|O
S145|Asthma|O
S145|Control|O
S145|Questionnaire|O
S145|mean|O
S145|score|O
S145|of|O
S145|≥1.5|O
S145|.|O
S1307|The|O
S1307|trial|O
S1307|did|O
S1307|not|O
S1307|meet|O
S1307|its|O
S1307|original|O
S1307|target|O
S1307|of|O
S1307|6000|O
S1307|patients|O
S1307|,|O
S1307|and|O
S1307|so|O
S1307|was|O
S1307|no|O
S1307|longer|O
S1307|adequately|O
S1307|powered|O
S1307|to|O
S1307|detect|O
S1307|a|O
S1307|3|O
S1307|%|O
S1307|absolute|O
S1307|difference|O
S1307|in|O
S1307|the|O
S1307|primary|O
S1307|outcome|O
S1307|(|O
S1307|with|O
S1307|80|B-Sample_Size_Calculation_Power_Value
S1307|%|I-Sample_Size_Calculation_Power_Value
S1307|power|O
S1307|and|O
S1307|α=0·05|B-Sample_Size_Calculation_Alpha_Value
S1307|)|O
S1307|.|O
S480|Size|O
S480|,|O
S480|tempo|O
S480|,|O
S480|and|O
S480|velocity|O
S480|are|O
S480|thus|O
S480|participant|O
S480|specific|O
S480|random|O
S480|effects|O
S480|summarising|O
S480|how|O
S480|each|O
S480|girl|O
S480|’|O
S480|s|O
S480|curve|O
S480|differs|O
S480|from|O
S480|the|O
S480|average|O
S480|curve|O
S480|.|O
S271|Such|O
S271|patients|O
S271|may|O
S271|develop|O
S271|difficult-to-treat|O
S271|disease|O
S271|,|O
S271|characterised|O
S271|by|O
S271|frequent|O
S271|flares|O
S271|and|O
S271|persistent|O
S271|inflammation|O
S271|between|O
S271|flares|O
S271|which|O
S271|contribute|O
S271|to|O
S271|joint|O
S271|damage|O
S271|and|O
S271|have|O
S271|a|O
S271|major|O
S271|impact|O
S271|on|O
S271|health-related|O
S271|quality|O
S271|of|O
S271|life|O
S271|and|O
S271|an|O
S271|individual|O
S271|'s|O
S271|ability|O
S271|to|O
S271|work|O
S271|.|O
S1845|Events|O
S1845|were|O
S1845|coded|O
S1845|according|O
S1845|to|O
S1845|prespecified|O
S1845|criteria|O
S1845|by|O
S1845|clinical|B-Blinding_Object_Others
S1845|staff|I-Blinding_Object_Others
S1845|in|O
S1845|the|O
S1845|coordinating|O
S1845|centre|O
S1845|,|O
S1845|who|O
S1845|were|O
S1845|unaware|O
S1845|of|O
S1845|the|O
S1845|study|O
S1845|treatment|O
S1845|allocation|O
S1845|.|O
S177|Study|O
S177|design|O
S177|After|O
S177|an|O
S177|initial|O
S177|screening|O
S177|visit|O
S177|and|O
S177|a|O
S177|4-week|O
S177|run-in|O
S177|period|O
S177|,|O
S177|patients|O
S177|were|O
S177|randomised|O
S177|to|O
S177|one|O
S177|of|O
S177|four|O
S177|treatment|O
S177|sequences|O
S177|,|O
S177|during|O
S177|which|O
S177|they|O
S177|received|O
S177|each|O
S177|of|O
S177|the|O
S177|four|O
S177|treatments|O
S177|(|O
S177|tiotropium|B-Design_Parallel_Group
S177|5|I-Design_Parallel_Group
S177|μg|I-Design_Parallel_Group
S177|,|I-Design_Parallel_Group
S177|2.5|I-Design_Parallel_Group
S177|μg|I-Design_Parallel_Group
S177|or|I-Design_Parallel_Group
S177|1.25|I-Design_Parallel_Group
S177|μg|I-Design_Parallel_Group
S177|or|I-Design_Parallel_Group
S177|placebo|I-Design_Parallel_Group
S177|,|O
S177|all|O
S177|delivered|O
S177|via|O
S177|the|O
S177|Respimat®|O
S177|SoftMist™|O
S177|inhaler|O
S177|)|O
S177|(|O
S177|Figure|O
S177|1|O
S177|)|O
S177|.|O
S67|Selected|O
S67|baseline|O
S67|characteristics|O
S67|of|O
S67|the|O
S67|primary|O
S67|population|O
S67|analyzed|O
S67|in|O
S67|the|O
S67|two|O
S67|study|O
S67|groups|O
S67|for|O
S67|each|O
S67|trial|O
S67|are|O
S67|shown|O
S67|in|O
S67|Table|O
S67|1|O
S67|.|O
S2142|Three|B-Sample_Size_Calculation_Dropout_Rate_Value
S2142|patients|I-Sample_Size_Calculation_Dropout_Rate_Value
S2142|dropped|I-Sample_Size_Calculation_Dropout_Rate_Value
S2142|out|I-Sample_Size_Calculation_Dropout_Rate_Value
S2142|due|O
S2142|to|O
S2142|lack|O
S2142|of|O
S2142|efficacy|O
S2142|(|O
S2142|placebo|O
S2142|:|O
S2142|n=2|O
S2142|;|O
S2142|memantine|O
S2142|:|O
S2142|n=1|O
S2142|)|O
S2142|but|O
S2142|two|O
S2142|of|O
S2142|the|O
S2142|latter|O
S2142|(|O
S2142|one|O
S2142|in|O
S2142|each|O
S2142|group|O
S2142|)|O
S2142|were|O
S2142|included|O
S2142|in|O
S2142|the|O
S2142|final|O
S2142|efficacy|O
S2142|analysis|O
S2142|because|O
S2142|they|O
S2142|had|O
S2142|dropped|O
S2142|out|O
S2142|shortly|O
S2142|before|O
S2142|the|O
S2142|end|O
S2142|of|O
S2142|the|O
S2142|study|O
S2142|(|O
S2142|see|O
S2142|the|O
S2142|see|O
S2142|online|O
S2142|supplementary|O
S2142|figure|O
S2142|(|O
S2142|flowchart|O
S2142|)|O
S2142|and|O
S2142|supplementary|O
S2142|data|O
S2142|on|O
S2142|the|O
S2142|criteria|O
S2142|for|O
S2142|ending|O
S2142|recruitment|O
S2142|)|O
S2142|.|O
S1878|For|O
S1878|major|O
S1878|coronary|O
S1878|events|O
S1878|,|O
S1878|a|O
S1878|27|O
S1878|%|O
S1878|(|O
S1878|SE|O
S1878|4|O
S1878|)|O
S1878|reduction|O
S1878|was|O
S1878|noted|O
S1878|during|O
S1878|the|O
S1878|in-trial|O
S1878|period|O
S1878|(|O
S1878|p|O
S1878|<|O
S1878|0·0001|O
S1878|)|O
S1878|.|O
S914|A|O
S914|change|O
S914|to|O
S914|the|O
S914|protocol|O
S914|was|O
S914|made|O
S914|in|O
S914|August|O
S914|2011|O
S914|(|O
S914|after|O
S914|82|O
S914|participants|O
S914|had|O
S914|been|O
S914|enrolled|O
S914|)|O
S914|as|O
S914|bowel|O
S914|perforation|O
S914|was|O
S914|experienced|O
S914|by|O
S914|a|O
S914|participant|O
S914|receiving|O
S914|prednisolone|O
S914|110|O
S914|mg/day|O
S914|.|O
S1692|The|O
S1692|upper|O
S1692|95|O
S1692|%|O
S1692|confidence|O
S1692|limit|O
S1692|for|O
S1692|the|O
S1692|absolute|O
S1692|difference|O
S1692|was|O
S1692|below|O
S1692|the|O
S1692|non-inferiority|O
S1692|margin|O
S1692|of|O
S1692|1·6|O
S1692|.|O
S1726|However|O
S1726|,|O
S1726|there|O
S1726|was|O
S1726|also|O
S1726|no|O
S1726|suggestion|O
S1726|of|O
S1726|higher|O
S1726|event|O
S1726|rates|O
S1726|in|O
S1726|group|O
S1726|C|O
S1726|receiving|O
S1726|long-term|O
S1726|three-NRTI|O
S1726|maintenance|O
S1726|,|O
S1726|despite|O
S1726|lower|O
S1726|long-term|O
S1726|viral|O
S1726|load|O
S1726|suppression|O
S1726|;|O
S1726|if|O
S1726|anything|O
S1726|,|O
S1726|fewer|O
S1726|events|O
S1726|occurred|O
S1726|after|O
S1726|1|O
S1726|year|O
S1726|(|O
S1726|seven|O
S1726|deaths|O
S1726|in|O
S1726|group|O
S1726|A|O
S1726|vs|O
S1726|five|O
S1726|in|O
S1726|group|O
S1726|B|O
S1726|vs|O
S1726|two|O
S1726|in|O
S1726|group|O
S1726|C|O
S1726|;|O
S1726|18|O
S1726|vs|O
S1726|13|O
S1726|vs|O
S1726|eight|O
S1726|WHO|O
S1726|stage|O
S1726|4|O
S1726|events|O
S1726|or|O
S1726|deaths|O
S1726|;|O
S1726|37|O
S1726|vs|O
S1726|26|O
S1726|vs|O
S1726|17|O
S1726|WHO|O
S1726|stage|O
S1726|3|O
S1726|or|O
S1726|4|O
S1726|events|O
S1726|or|O
S1726|deaths|O
S1726|)|O
S1726|.|O
S788|All|O
S788|antibodies|O
S788|were|O
S788|diluted|O
S788|1:20|O
S788|with|O
S788|flow|O
S788|buffer|O
S788|.|O
S1637|All|O
S1637|children|O
S1637|received|O
S1637|ART|O
S1637|as|O
S1637|syrups|O
S1637|or|O
S1637|tablets|O
S1637|dosed|O
S1637|according|O
S1637|to|O
S1637|WHO|O
S1637|weight-band|O
S1637|tables|O
S1637|.|O
S1137|The|O
S1137|number|O
S1137|of|O
S1137|plantar|O
S1137|warts|O
S1137|at|O
S1137|the|O
S1137|start|O
S1137|of|O
S1137|the|O
S1137|study|O
S1137|was|O
S1137|not|O
S1137|found|O
S1137|to|O
S1137|be|O
S1137|an|O
S1137|important|O
S1137|predictor|O
S1137|of|O
S1137|outcome|O
S1137|(|O
S1137|odds|O
S1137|ratio|O
S1137|0.81|O
S1137|(|O
S1137|0.65|O
S1137|to|O
S1137|1.01|O
S1137|)|O
S1137|)|O
S1137|.|O
S1449|To|O
S1449|allow|O
S1449|for|O
S1449|study|O
S1449|withdrawals|O
S1449|,|O
S1449|our|O
S1449|target|O
S1449|sample|O
S1449|size|O
S1449|was|O
S1449|300|B-Sample_Size_Target
S1449|patients|O
S1449|.|O
S644|Results|O
S644|The|O
S644|two|O
S644|treatment|O
S644|groups|O
S644|were|O
S644|well|O
S644|matched|O
S644|with|O
S644|respect|O
S644|to|O
S644|demographic|O
S644|features|O
S644|,|O
S644|baseline|O
S644|disease|O
S644|characteristics|O
S644|and|O
S644|concomitant|O
S644|treatment|O
S644|for|O
S644|DUs|O
S644|at|O
S644|baseline|O
S644|(|O
S644|table|O
S644|1|O
S644|)|O
S644|.|O
S2230|Serum|O
S2230|anti-therapeutic|O
S2230|antibodies|O
S2230|(|O
S2230|ATAs|O
S2230|)|O
S2230|were|O
S2230|assessed|O
S2230|in|O
S2230|samples|O
S2230|at|O
S2230|Weeks|O
S2230|0|O
S2230|,|O
S2230|4|O
S2230|,|O
S2230|12|O
S2230|,|O
S2230|24|O
S2230|,|O
S2230|36|O
S2230|,|O
S2230|48|O
S2230|,|O
S2230|60|O
S2230|,|O
S2230|and|O
S2230|84|O
S2230|using|O
S2230|a|O
S2230|validated|O
S2230|bridging|O
S2230|ELISA|O
S2230|(|O
S2230|Genentech|O
S2230|,|O
S2230|Inc.|O
S2230|,|O
S2230|South|O
S2230|San|O
S2230|Francisco|O
S2230|,|O
S2230|CA|O
S2230|)|O
S2230|.|O
S1332|At|O
S1332|6|O
S1332|months|O
S1332|,|O
S1332|554|O
S1332|(|O
S1332|37|O
S1332|%|O
S1332|)|O
S1332|in|O
S1332|the|O
S1332|rt-PA|O
S1332|group|O
S1332|versus|O
S1332|534|O
S1332|(|O
S1332|35|O
S1332|%|O
S1332|)|O
S1332|in|O
S1332|the|O
S1332|control|O
S1332|group|O
S1332|were|O
S1332|alive|O
S1332|and|O
S1332|independent|O
S1332|in|O
S1332|activities|O
S1332|of|O
S1332|daily|O
S1332|living|O
S1332|(|O
S1332|OHS|O
S1332|0–2|O
S1332|;|O
S1332|table|O
S1332|2|O
S1332|)|O
S1332|.|O
S2269|Pharmacodynamic|O
S2269|biomarkers|O
S2269|Quilizumab|O
S2269|gradually|O
S2269|reduced|O
S2269|mean|O
S2269|serum|O
S2269|total|O
S2269|and|O
S2269|allergen-specific|O
S2269|IgE|O
S2269|,|O
S2269|reaching|O
S2269|a|O
S2269|30–40|O
S2269|%|O
S2269|reduction|O
S2269|at|O
S2269|Week|O
S2269|36|O
S2269|in|O
S2269|all|O
S2269|three|O
S2269|quilizumab|O
S2269|cohorts|O
S2269|(|O
S2269|p|O
S2269|<|O
S2269|0.01|O
S2269|compared|O
S2269|to|O
S2269|placebo|O
S2269|;|O
S2269|Fig|O
S2269|.|O
S1655|Subgroups|O
S1655|specified|O
S1655|in|O
S1655|the|O
S1655|analysis|O
S1655|plan|O
S1655|were|O
S1655|the|O
S1655|factorial|O
S1655|randomisations|O
S1655|,|O
S1655|time|O
S1655|on|O
S1655|ART|O
S1655|,|O
S1655|sex|O
S1655|,|O
S1655|age|O
S1655|,|O
S1655|centre|O
S1655|,|O
S1655|CD4|O
S1655|,|O
S1655|weight|O
S1655|for|O
S1655|age|O
S1655|,|O
S1655|randomisation|O
S1655|year|O
S1655|,|O
S1655|and|O
S1655|previous|O
S1655|ART|O
S1655|for|O
S1655|prevention|O
S1655|of|O
S1655|mother-to-child|O
S1655|transmission|O
S1655|.|O
S343|The|O
S343|only|O
S343|infections|O
S343|occurring|O
S343|in|O
S343|more|O
S343|than|O
S343|1|O
S343|%|O
S343|of|O
S343|patients|O
S343|receiving|O
S343|canakinumab|O
S343|were|O
S343|upper|O
S343|respiratory|O
S343|tract|O
S343|infections|O
S343|(|O
S343|3.7|O
S343|%|O
S343|)|O
S343|,|O
S343|nasopharyngitis|O
S343|(|O
S343|3.7|O
S343|%|O
S343|)|O
S343|and|O
S343|influenza|O
S343|(|O
S343|1.2|O
S343|%|O
S343|)|O
S343|.|O
S2186|Background|O
S2186|Asthma|O
S2186|,|O
S2186|a|O
S2186|chronic|O
S2186|inflammatory|O
S2186|disorder|O
S2186|of|O
S2186|the|O
S2186|airways|O
S2186|,|O
S2186|affects|O
S2186|over|O
S2186|300|O
S2186|million|O
S2186|people|O
S2186|worldwide|O
S2186|.|O
S582|This|O
S582|effect|O
S582|was|O
S582|greater|O
S582|in|O
S582|patients|O
S582|who|O
S582|entered|O
S582|the|O
S582|trial|O
S582|with|O
S582|more|O
S582|DUs|O
S582|.|O
S274|This|O
S274|is|O
S274|achieved|O
S274|with|O
S274|urate|O
S274|lowering|O
S274|therapies|O
S274|(|O
S274|ULT|O
S274|)|O
S274|.|O
S2093|These|O
S2093|symptoms|O
S2093|represent|O
S2093|a|O
S2093|public|O
S2093|health|O
S2093|issue|O
S2093|for|O
S2093|which|O
S2093|a|O
S2093|specific|O
S2093|treatment|O
S2093|is|O
S2093|currently|O
S2093|lacking|O
S2093|.|O
S470|Statistical|O
S470|methods|O
S470|The|O
S470|primary|O
S470|outcome|O
S470|was|O
S470|final|O
S470|height|O
S470|,|O
S470|defined|O
S470|as|O
S470|height|O
S470|velocity|O
S470|less|O
S470|than|O
S470|1|O
S470|cm/year|O
S470|and|O
S470|bone|O
S470|age|O
S470|at|O
S470|least|O
S470|15.5|O
S470|years|O
S470|.|O
S1729|The|O
S1729|difference|O
S1729|was|O
S1729|almost|O
S1729|exclusively|O
S1729|driven|O
S1729|by|O
S1729|excess|O
S1729|asymptomatic|O
S1729|neutropenia|O
S1729|(|O
S1729|86|O
S1729|vs|O
S1729|133|O
S1729|vs|O
S1729|184|O
S1729|events|O
S1729|;|O
S1729|appendix|O
S1729|)|O
S1729|.|O
S1705|At|O
S1705|the|O
S1705|latest|O
S1705|test|O
S1705|,|O
S1705|median|O
S1705|3·7|O
S1705|(|O
S1705|IQR|O
S1705|3·0–4·1|O
S1705|)|O
S1705|years|O
S1705|after|O
S1705|ART|O
S1705|initiation|O
S1705|,|O
S1705|351|O
S1705|(|O
S1705|77|O
S1705|%|O
S1705|)|O
S1705|of|O
S1705|458|O
S1705|children|O
S1705|on|O
S1705|clinically|O
S1705|driven|O
S1705|monitoring|O
S1705|versus|O
S1705|345|O
S1705|(|O
S1705|78|O
S1705|%|O
S1705|)|O
S1705|of|O
S1705|443|O
S1705|on|O
S1705|routine|O
S1705|laboratory|O
S1705|monitoring|O
S1705|had|O
S1705|viral|O
S1705|load|O
S1705|less|O
S1705|than|O
S1705|400|O
S1705|copies|O
S1705|per|O
S1705|mL|O
S1705|(|O
S1705|p=0·66|O
S1705|)|O
S1705|,|O
S1705|similar|O
S1705|across|O
S1705|ages|O
S1705|(|O
S1705|heterogeneity|O
S1705|p=0·25|O
S1705|)|O
S1705|;|O
S1705|329|O
S1705|(|O
S1705|72|O
S1705|%|O
S1705|)|O
S1705|on|O
S1705|clinically|O
S1705|driven|O
S1705|monitoring|O
S1705|versus|O
S1705|313|O
S1705|(|O
S1705|71|O
S1705|%|O
S1705|)|O
S1705|on|O
S1705|routine|O
S1705|laboratory|O
S1705|monitoring|O
S1705|had|O
S1705|viral|O
S1705|load|O
S1705|less|O
S1705|than|O
S1705|80|O
S1705|copies|O
S1705|per|O
S1705|mL|O
S1705|(|O
S1705|p=0·70|O
S1705|)|O
S1705|.|O
S1268|Although|O
S1268|CT|O
S1268|scanning|O
S1268|was|O
S1268|preferred|O
S1268|,|O
S1268|MRI|O
S1268|was|O
S1268|allowed|O
S1268|.|O
S2247|For|O
S2247|secondary|O
S2247|and|O
S2247|exploratory|O
S2247|end|O
S2247|points|O
S2247|,|O
S2247|the|O
S2247|means|O
S2247|and|O
S2247|standard|O
S2247|deviations|O
S2247|of|O
S2247|all|O
S2247|values|O
S2247|for|O
S2247|relative|O
S2247|change|O
S2247|were|O
S2247|calculated|O
S2247|according|O
S2247|to|O
S2247|study|O
S2247|group|O
S2247|at|O
S2247|Weeks|O
S2247|12|O
S2247|and|O
S2247|36|O
S2247|.|O
S586|Bosentan|O
S586|was|O
S586|well|O
S586|tolerated|O
S586|and|O
S586|may|O
S586|be|O
S586|a|O
S586|useful|O
S586|adjunct|O
S586|in|O
S586|the|O
S586|management|O
S586|of|O
S586|patients|O
S586|with|O
S586|SSc|O
S586|with|O
S586|recurrent|O
S586|DUs|O
S586|.|O
S898|Participants|O
S898|gave|O
S898|written|O
S898|informed|O
S898|consent|O
S898|.|O
S2195|Similarly|O
S2195|,|O
S2195|patients|O
S2195|with|O
S2195|high|O
S2195|levels|O
S2195|of|O
S2195|exhaled|O
S2195|nitric|O
S2195|oxide|O
S2195|(|O
S2195|NO|O
S2195|)|O
S2195|,|O
S2195|blood|O
S2195|eosinophils|O
S2195|,|O
S2195|or|O
S2195|serum|O
S2195|periostin|O
S2195|,|O
S2195|had|O
S2195|fewer|O
S2195|asthma|O
S2195|exacerbations|O
S2195|following|O
S2195|treatment|O
S2195|with|O
S2195|omalizumab|O
S2195|,|O
S2195|a|O
S2195|neutralizing|O
S2195|anti-IgE|O
S2195|antibody|O
S2195|,|O
S2195|than|O
S2195|patients|O
S2195|with|O
S2195|low|O
S2195|biomarker|O
S2195|levels|O
S2195|.|O
S1481|Given|O
S1481|the|O
S1481|heterogeneity|O
S1481|of|O
S1481|the|O
S1481|enrolled|O
S1481|population|O
S1481|,|O
S1481|we|O
S1481|performed|O
S1481|post|O
S1481|hoc|O
S1481|exploratory|O
S1481|analyses|O
S1481|to|O
S1481|evaluate|O
S1481|detection|O
S1481|and|O
S1481|quantification|O
S1481|(|O
S1481|copy|O
S1481|numbers|O
S1481|)|O
S1481|of|O
S1481|virus|O
S1481|RNA|O
S1481|on|O
S1481|day|O
S1481|one|O
S1481|,|O
S1481|three|O
S1481|,|O
S1481|and|O
S1481|five|O
S1481|of|O
S1481|treatment|O
S1481|in|O
S1481|several|O
S1481|subgroups|O
S1481|of|O
S1481|interest|O
S1481|(|O
S1481|age|O
S1481|,|O
S1481|virus|O
S1481|,|O
S1481|days|O
S1481|of|O
S1481|illness|O
S1481|before|O
S1481|enrolment|O
S1481|)|O
S1481|.|O
S255|Canakinumab|O
S255|reduces|O
S255|the|O
S255|risk|O
S255|of|O
S255|acute|O
S255|gouty|O
S255|arthritis|O
S255|flares|O
S255|during|O
S255|initiation|O
S255|of|O
S255|allopurinol|O
S255|treatment|O
S255|:|O
S255|results|O
S255|of|O
S255|a|O
S255|double-blind|B-Blinding_Double_Blind
S255|,|O
S255|randomised|B-Randomization_Type_Simple
S255|study|O
S495|Among|O
S495|girls|O
S495|previously|O
S495|randomised|O
S495|to|O
S495|oxandrolone|O
S495|,|O
S495|the|O
S495|effect|O
S495|of|O
S495|late|O
S495|induction|O
S495|compared|O
S495|with|O
S495|early|O
S495|induction|O
S495|was|O
S495|clinically|O
S495|insignificant|O
S495|(|O
S495|+0.7|O
S495|cm|O
S495|)|O
S495|;|O
S495|in|O
S495|the|O
S495|placebo|O
S495|group|O
S495|,|O
S495|however|O
S495|,|O
S495|late|O
S495|induction|O
S495|added|O
S495|6.2|O
S495|cm|O
S495|compared|O
S495|with|O
S495|early|O
S495|induction|O
S495|(|O
S495|table|O
S495|3|O
S495|,|O
S495|interaction|O
S495|)|O
S495|.|O
S1671|However|O
S1671|,|O
S1671|most|O
S1671|were|O
S1671|done|O
S1671|at|O
S1671|routine|O
S1671|visits|O
S1671|(|O
S1671|10|O
S1671|805|O
S1671|[|O
S1671|92|O
S1671|%|O
S1671|]|O
S1671|haematology|O
S1671|and|O
S1671|10|O
S1671|778|O
S1671|[|O
S1671|94|O
S1671|%|O
S1671|]|O
S1671|biochemistry|O
S1671|;|O
S1671|appendix|O
S1671|)|O
S1671|.|O
S1112|We|O
S1112|used|O
S1112|negative|O
S1112|binomial|O
S1112|regression|O
S1112|to|O
S1112|compare|O
S1112|the|O
S1112|number|O
S1112|of|O
S1112|plantar|O
S1112|warts|O
S1112|at|O
S1112|12|O
S1112|weeks|O
S1112|between|O
S1112|the|O
S1112|two|O
S1112|treatment|O
S1112|groups|O
S1112|with|O
S1112|adjustment|O
S1112|for|O
S1112|the|O
S1112|number|O
S1112|of|O
S1112|plantar|O
S1112|warts|O
S1112|at|O
S1112|baseline|O
S1112|.|O
S916|Randomisation|O
S916|and|O
S916|blinding|O
S916|Participants|O
S916|were|O
S916|randomised|O
S916|(|O
S916|1:1|B-Randomization_Ratio
S916|)|O
S916|to|O
S916|treatment|O
S916|allocation|O
S916|using|O
S916|a|B-Allocation_Concealment_Method
S916|web|I-Allocation_Concealment_Method
S916|based|I-Allocation_Concealment_Method
S916|randomisation|I-Allocation_Concealment_Method
S916|system|I-Allocation_Concealment_Method
S916|hosted|O
S916|by|O
S916|Nottingham|B-Randomization_Sequence_Generation_Method
S916|Clinical|I-Randomization_Sequence_Generation_Method
S916|Trials|I-Randomization_Sequence_Generation_Method
S916|Unit|I-Randomization_Sequence_Generation_Method
S916|,|O
S916|using|O
S916|a|B-Randomization_Sequence_Generation_Method
S916|computer|I-Randomization_Sequence_Generation_Method
S916|generated|I-Randomization_Sequence_Generation_Method
S916|pseudorandom|I-Randomization_Sequence_Generation_Method
S916|list|I-Randomization_Sequence_Generation_Method
S916|,|O
S916|with|O
S916|permuted|B-Randomization_Type_Block
S916|blocks|I-Randomization_Type_Block
S916|of|O
S916|randomly|O
S916|varying|B-Randomization_Block_Size
S916|size|I-Randomization_Block_Size
S916|between|I-Randomization_Block_Size
S916|two|I-Randomization_Block_Size
S916|and|I-Randomization_Block_Size
S916|six|I-Randomization_Block_Size
S916|(|O
S916|RALLOC|O
S916|add-on|O
S916|for|O
S916|Stata|O
S916|,|O
S916|TX|O
S916|)|O
S916|.|O
S1516|No|O
S1516|differences|O
S1516|in|O
S1516|viral|O
S1516|RNA|O
S1516|detection|O
S1516|rates|O
S1516|or|O
S1516|outcome|O
S1516|were|O
S1516|associated|O
S1516|with|O
S1516|presence|O
S1516|of|O
S1516|the|O
S1516|H275Y|O
S1516|mutation|O
S1516|at|O
S1516|day|O
S1516|0|O
S1516|or|O
S1516|day|O
S1516|five|O
S1516|among|O
S1516|patients|O
S1516|infected|O
S1516|with|O
S1516|seasonal|O
S1516|H1N1|O
S1516|viruses|O
S1516|,|O
S1516|but|O
S1516|numbers|O
S1516|were|O
S1516|small|O
S1516|.|O
S2012|Alkaline|O
S2012|phosphatase|O
S2012|values|O
S2012|and|O
S2012|radiographic|O
S2012|scores|O
S2012|improved|O
S2012|in|O
S2012|both|O
S2012|groups|O
S2012|(|O
S2012|figures|O
S2012|2|O
S2012|and|O
S2012|3|O
S2012|)|O
S2012|.|O
S1641|Switching|O
S1641|to|O
S1641|second-line|O
S1641|ART|O
S1641|(|O
S1641|including|O
S1641|a|O
S1641|ritonavir-boosted|O
S1641|protease|O
S1641|inhibitor|O
S1641|)|O
S1641|was|O
S1641|based|O
S1641|on|O
S1641|clinical|O
S1641|criteria|O
S1641|in|O
S1641|all|O
S1641|participants|O
S1641|(|O
S1641|new|O
S1641|or|O
S1641|recurrent|O
S1641|WHO|O
S1641|stage|O
S1641|4|O
S1641|event|O
S1641|;|O
S1641|or|O
S1641|WHO|O
S1641|stage|O
S1641|3|O
S1641|event|O
S1641|or|O
S1641|events|O
S1641|at|O
S1641|clinician|O
S1641|discretion|O
S1641|,|O
S1641|particularly|O
S1641|if|O
S1641|recurrent|O
S1641|or|O
S1641|persistent|O
S1641|)|O
S1641|,|O
S1641|or|O
S1641|on|O
S1641|laboratory|O
S1641|criteria|O
S1641|for|O
S1641|routine|O
S1641|laboratory|O
S1641|monitoring|O
S1641|(|O
S1641|confirmed|O
S1641|on-ART|O
S1641|CD4|O
S1641|of|O
S1641|<|O
S1641|15|O
S1641|%|O
S1641|at|O
S1641|age|O
S1641|1–2|O
S1641|years|O
S1641|,|O
S1641|<|O
S1641|10|O
S1641|%|O
S1641|at|O
S1641|3–4|O
S1641|years|O
S1641|,|O
S1641|<|O
S1641|100|O
S1641|cells/mL|O
S1641|at|O
S1641|≥5|O
S1641|years|O
S1641|)|O
S1641|.|O
S275|Allopurinol|O
S275|is|O
S275|the|O
S275|most|O
S275|commonly|O
S275|used|O
S275|ULT|O
S275|and|O
S275|the|O
S275|current|O
S275|standard|O
S275|of|O
S275|care|O
S275|.|O
S194|Patients|O
S194|were|O
S194|required|O
S194|to|O
S194|have|O
S194|a|O
S194|seven-question|O
S194|Asthma|O
S194|Control|O
S194|Questionnaire|O
S194|(|O
S194|ACQ-7|O
S194|)|O
S194|mean|O
S194|score|O
S194|of|O
S194|≥1.5|O
S194|at|O
S194|Visits|O
S194|1|O
S194|and|O
S194|2|O
S194|,|O
S194|to|O
S194|have|O
S194|a|O
S194|pre-bronchodilator|O
S194|FEV1|O
S194|of|O
S194|≥60|O
S194|%|O
S194|and|O
S194|≤90|O
S194|%|O
S194|of|O
S194|predicted|O
S194|normal|O
S194|FEV1|O
S194|at|O
S194|Visit|O
S194|1|O
S194|,|O
S194|and|O
S194|to|O
S194|demonstrate|O
S194|absolute|O
S194|FEV1|O
S194|variability|O
S194|within|O
S194|30|O
S194|%|O
S194|between|O
S194|Visits|O
S194|1|O
S194|and|O
S194|2|O
S194|.|O
S953|Secondary|O
S953|outcomes|O
S953|were|O
S953|analysed|O
S953|using|O
S953|Cox|O
S953|regression|O
S953|models|O
S953|(|O
S953|for|O
S953|time|O
S953|to|O
S953|event|O
S953|outcomes|O
S953|)|O
S953|;|O
S953|linear|O
S953|regression|O
S953|models|O
S953|for|O
S953|dermatology|O
S953|life|O
S953|quality|O
S953|index|O
S953|,|O
S953|EQ-5D|O
S953|,|O
S953|and|O
S953|EQ-VAS|O
S953|(|O
S953|adjusted|O
S953|for|O
S953|baseline|O
S953|values|O
S953|)|O
S953|,|O
S953|and|O
S953|for|O
S953|self|O
S953|reported|O
S953|pain|O
S953|(|O
S953|which|O
S953|were|O
S953|summarised|O
S953|using|O
S953|area|O
S953|under|O
S953|the|O
S953|curve|O
S953|)|O
S953|;|O
S953|proportional|O
S953|odds|O
S953|models|O
S953|for|O
S953|ordered|O
S953|categorical|O
S953|outcomes|O
S953|;|O
S953|and|O
S953|logistic|O
S953|regression|O
S953|models|O
S953|for|O
S953|binary|O
S953|outcomes|O
S953|.|O
S1445|This|O
S1445|is|O
S1445|also|O
S1445|consistent|O
S1445|with|O
S1445|the|O
S1445|2010|O
S1445|position|O
S1445|paper|O
S1445|by|O
S1445|Ison|O
S1445|and|O
S1445|colleagues|O
S1445|on|O
S1445|the|O
S1445|choice|O
S1445|of|O
S1445|efficacy|O
S1445|endpoints|O
S1445|in|O
S1445|severe|O
S1445|influenza|O
S1445|studies|O
S1445|.|O
S2245|Corresponding|O
S2245|two-sided|O
S2245|p-values|O
S2245|and|O
S2245|90|O
S2245|%|O
S2245|confidence|O
S2245|intervals|O
S2245|(|O
S2245|CI|O
S2245|)|O
S2245|were|O
S2245|reported|O
S2245|.|O
S1111|The|O
S1111|complete|O
S1111|clearance|O
S1111|of|O
S1111|all|O
S1111|plantar|O
S1111|warts|O
S1111|at|O
S1111|six|O
S1111|months|O
S1111|was|O
S1111|analysed|O
S1111|in|O
S1111|the|O
S1111|same|O
S1111|way|O
S1111|as|O
S1111|the|O
S1111|primary|O
S1111|outcome|O
S1111|with|O
S1111|adjustments|O
S1111|for|O
S1111|the|O
S1111|same|O
S1111|covariates|O
S1111|.|O
S1881|During|O
S1881|the|O
S1881|post-trial|O
S1881|period|O
S1881|,|O
S1881|the|O
S1881|incidence|O
S1881|rates|O
S1881|were|O
S1881|similar|O
S1881|in|O
S1881|both|O
S1881|treatment|O
S1881|groups|O
S1881|(|O
S1881|0·98|O
S1881|[|O
S1881|0·86–1·12|O
S1881|]|O
S1881|;|O
S1881|p=0·77|O
S1881|)|O
S1881|,|O
S1881|with|O
S1881|no|O
S1881|adverse|O
S1881|effect|O
S1881|on|O
S1881|haemorrhagic|O
S1881|stroke|O
S1881|(|O
S1881|38|O
S1881|[|O
S1881|0·4|O
S1881|%|O
S1881|]|O
S1881|vs|O
S1881|51|O
S1881|[|O
S1881|0·6|O
S1881|%|O
S1881|]|O
S1881|;|O
S1881|p=0·13|O
S1881|)|O
S1881|.|O
S1392|Objective|O
S1392|To|O
S1392|investigate|O
S1392|the|O
S1392|validity|O
S1392|of|O
S1392|recommendations|O
S1392|in|O
S1392|treatment|O
S1392|guidelines|O
S1392|to|O
S1392|use|O
S1392|higher|O
S1392|than|O
S1392|approved|O
S1392|doses|O
S1392|of|O
S1392|oseltamivir|O
S1392|in|O
S1392|patients|O
S1392|with|O
S1392|severe|O
S1392|influenza|O
S1392|.|O
S2276|3|O
S2276|)|O
S2276|.|O
S2177|Exploratory|O
S2177|analyses|O
S2177|were|O
S2177|conducted|O
S2177|on|O
S2177|biomarker|O
S2177|subgroups|O
S2177|(|O
S2177|periostin|O
S2177|,|O
S2177|blood|O
S2177|eosinophils|O
S2177|,|O
S2177|serum|O
S2177|IgE|O
S2177|,|O
S2177|and|O
S2177|exhaled|O
S2177|nitric|O
S2177|oxide|O
S2177|)|O
S2177|.|O
S1146|At|O
S1146|week|O
S1146|12|O
S1146|,|O
S1146|more|O
S1146|patients|O
S1146|were|O
S1146|unhappy|O
S1146|with|O
S1146|salicylic|O
S1146|acid|O
S1146|than|O
S1146|with|O
S1146|cryotherapy|O
S1146|,|O
S1146|and|O
S1146|more|O
S1146|were|O
S1146|very|O
S1146|happy|O
S1146|with|O
S1146|cryotherapy|O
S1146|than|O
S1146|with|O
S1146|salicylic|O
S1146|acid|O
S1146|.|O
S1934|Vitamin|O
S1934|D|O
S1934|treatment|O
S1934|in|O
S1934|calcium-deficiency|O
S1934|rickets|O
S1934|:|O
S1934|a|O
S1934|randomised|B-Randomization_Type_Simple
S1934|controlled|O
S1934|trial|O
S1129|Cohen|O
S1129|’|O
S1129|s|O
S1129|κ|O
S1129|measure|O
S1129|,|O
S1129|used|O
S1129|to|O
S1129|assess|O
S1129|the|O
S1129|agreement|O
S1129|between|O
S1129|the|O
S1129|two|O
S1129|assessors|O
S1129|of|O
S1129|the|O
S1129|photographs|O
S1129|,|O
S1129|was|O
S1129|estimated|O
S1129|to|O
S1129|be|O
S1129|0.45|O
S1129|(|O
S1129|95|O
S1129|%|O
S1129|confidence|O
S1129|interval|O
S1129|0.35|O
S1129|to|O
S1129|0.55|O
S1129|)|O
S1129|,|O
S1129|which|O
S1129|indicates|O
S1129|a|O
S1129|moderate|O
S1129|level|O
S1129|of|O
S1129|agreement|O
S1129|.|O
S1394|Setting|O
S1394|Thirteen|B-Settings_Multicenter
S1394|hospitals|I-Settings_Multicenter
S1394|in|O
S1394|Indonesia|B-Settings_Location
S1394|,|I-Settings_Location
S1394|Singapore|I-Settings_Location
S1394|,|I-Settings_Location
S1394|Thailand|I-Settings_Location
S1394|,|I-Settings_Location
S1394|and|I-Settings_Location
S1394|Vietnam|I-Settings_Location
S1394|.|O
S1132|Logistic|O
S1132|regression|O
S1132|analysis|O
S1132|showed|O
S1132|no|O
S1132|evidence|O
S1132|of|O
S1132|a|O
S1132|difference|O
S1132|between|O
S1132|the|O
S1132|salicylic|O
S1132|acid|O
S1132|and|O
S1132|cryotherapy|O
S1132|groups|O
S1132|(|O
S1132|odds|O
S1132|ratio|O
S1132|0.96|O
S1132|(|O
S1132|95|O
S1132|%|O
S1132|confidence|O
S1132|interval|O
S1132|0.44|O
S1132|to|O
S1132|2.11|O
S1132|)|O
S1132|,|O
S1132|P=0.92|O
S1132|which|O
S1132|favours|O
S1132|the|O
S1132|salicylic|O
S1132|group|O
S1132|)|O
S1132|.|O
S26|METHODS|O
S26|Patients|O
S26|Male|O
S26|and|O
S26|female|O
S26|patients|O
S26|aged|O
S26|40–80|O
S26|years|O
S26|expected|O
S26|to|O
S26|require|O
S26|daily|O
S26|NSAID|O
S26|therapy|O
S26|for|O
S26|at|O
S26|least|O
S26|6|O
S26|months|O
S26|for|O
S26|pain|O
S26|and/or|O
S26|inflammatory|O
S26|conditions|O
S26|were|O
S26|eligible|O
S26|.|O
S2110|Experimental|O
S2110|design|O
S2110|We|O
S2110|performed|O
S2110|a|O
S2110|90-day|O
S2110|,|O
S2110|double-blind|B-Blinding_Double_Blind
S2110|,|O
S2110|placebo-controlled|O
S2110|pilot|O
S2110|study|O
S2110|.|O
S2239|Statistical|O
S2239|methods|O
S2239|All|O
S2239|patients|O
S2239|received|O
S2239|at|O
S2239|least|O
S2239|one|O
S2239|dose|O
S2239|of|O
S2239|study|O
S2239|drug|O
S2239|(|O
S2239|intention-to-treat|O
S2239|,|O
S2239|ITT|O
S2239|population|O
S2239|)|O
S2239|and|O
S2239|were|O
S2239|included|O
S2239|in|O
S2239|all|O
S2239|safety|O
S2239|and|O
S2239|efficacy|O
S2239|analyses|O
S2239|.|O
S1123|Treatment|O
S1123|details|O
S1123|Table|O
S1123|3|O
S1123|summarises|O
S1123|the|O
S1123|cryotherapy|O
S1123|treatment|O
S1123|details|O
S1123|reported|O
S1123|by|O
S1123|the|O
S1123|treating|O
S1123|healthcare|O
S1123|professional|O
S1123|.|O
S1273|Patients|O
S1273|with|O
S1273|an|O
S1273|OHS|O
S1273|of|O
S1273|0|O
S1273|,|O
S1273|1|O
S1273|,|O
S1273|or|O
S1273|2|O
S1273|were|O
S1273|classed|O
S1273|as|O
S1273|independent|O
S1273|.|O
S2141|Results|O
S2141|We|O
S2141|prospectively|O
S2141|enrolled|O
S2141|25|B-Sample_Size_Actual_at_Enrollment
S2141|patients|O
S2141|with|O
S2141|a|O
S2141|severe|O
S2141|gait|O
S2141|disorder|O
S2141|and|O
S2141|an|O
S2141|abnormal|O
S2141|,|O
S2141|forward-leaning|O
S2141|stance|O
S2141|.|O
S1396|Interventions|O
S1396|Oral|B-Design_Parallel_Group
S1396|oseltamivir|I-Design_Parallel_Group
S1396|at|I-Design_Parallel_Group
S1396|double|I-Design_Parallel_Group
S1396|dose|I-Design_Parallel_Group
S1396|(|I-Design_Parallel_Group
S1396|150|I-Design_Parallel_Group
S1396|mg|I-Design_Parallel_Group
S1396|twice|I-Design_Parallel_Group
S1396|a|I-Design_Parallel_Group
S1396|day/paediatric|I-Design_Parallel_Group
S1396|equivalent|I-Design_Parallel_Group
S1396|)|I-Design_Parallel_Group
S1396|versus|I-Design_Parallel_Group
S1396|standard|I-Design_Parallel_Group
S1396|dose|I-Design_Parallel_Group
S1396|(|I-Design_Parallel_Group
S1396|75|I-Design_Parallel_Group
S1396|mg|I-Design_Parallel_Group
S1396|twice|I-Design_Parallel_Group
S1396|a|I-Design_Parallel_Group
S1396|day/paediatric|I-Design_Parallel_Group
S1396|equivalent|I-Design_Parallel_Group
S1396|)|I-Design_Parallel_Group
S1396|.|O
S1614|However|O
S1614|,|O
S1614|four-drug|O
S1614|combinations|O
S1614|(|O
S1614|generally|O
S1614|three|O
S1614|nucleoside|O
S1614|reverse|O
S1614|transcriptase|O
S1614|inhibitors|O
S1614|[|O
S1614|NRTIs|O
S1614|]|O
S1614|plus|O
S1614|one|O
S1614|non-nucleoside|O
S1614|reverse|O
S1614|transcriptase|O
S1614|inhibitor|O
S1614|[|O
S1614|NNRTI|O
S1614|]|O
S1614|)|O
S1614|have|O
S1614|been|O
S1614|reported|O
S1614|to|O
S1614|show|O
S1614|superior|O
S1614|virological|O
S1614|and|O
S1614|immunological|O
S1614|responses|O
S1614|compared|O
S1614|with|O
S1614|three-drug|O
S1614|ART|O
S1614|(|O
S1614|two|O
S1614|NRTIs|O
S1614|plus|O
S1614|one|O
S1614|NNRTI|O
S1614|or|O
S1614|protease|O
S1614|inhibitor|O
S1614|)|O
S1614|in|O
S1614|an|O
S1614|observational|O
S1614|study|O
S1614|in|O
S1614|infants|O
S1614|.|O
S2174|This|O
S2174|study|O
S2174|evaluated|O
S2174|the|O
S2174|efficacy|O
S2174|and|O
S2174|safety|O
S2174|of|O
S2174|quilizumab|O
S2174|in|O
S2174|adults|O
S2174|with|O
S2174|allergic|O
S2174|asthma|O
S2174|,|O
S2174|inadequately|O
S2174|controlled|O
S2174|despite|O
S2174|high-dose|O
S2174|inhaled|O
S2174|corticosteroids|O
S2174|(|O
S2174|ICS|O
S2174|)|O
S2174|and|O
S2174|a|O
S2174|second|O
S2174|controller|O
S2174|.|O
S28|Study|O
S28|design|O
S28|Patients|O
S28|were|O
S28|randomly|O
S28|assigned|O
S28|,|O
S28|using|O
S28|a|B-Randomization_Sequence_Generation_Method
S28|computer-generated|I-Randomization_Sequence_Generation_Method
S28|randomization|I-Randomization_Sequence_Generation_Method
S28|schedule|I-Randomization_Sequence_Generation_Method
S28|,|O
S28|from|O
S28|a|O
S28|central|O
S28|location|O
S28|utilizing|O
S28|an|B-Randomization_Sequence_Generation_Method
S28|interactive|I-Randomization_Sequence_Generation_Method
S28|voice|I-Randomization_Sequence_Generation_Method
S28|response|I-Randomization_Sequence_Generation_Method
S28|system|I-Randomization_Sequence_Generation_Method
S28|with|O
S28|blinded|O
S28|medication|O
S28|kit|O
S28|number|O
S28|allocation|O
S28|in|O
S28|a|O
S28|2:1|B-Randomization_Ratio
S28|ratio|O
S28|to|O
S28|identical-appearing|B-Design_Parallel_Group
S28|tablets|I-Design_Parallel_Group
S28|of|I-Design_Parallel_Group
S28|HZT-501|I-Design_Parallel_Group
S28|(|I-Design_Parallel_Group
S28|800|I-Design_Parallel_Group
S28|mg|I-Design_Parallel_Group
S28|ibuprofen|I-Design_Parallel_Group
S28|and|I-Design_Parallel_Group
S28|26.6|I-Design_Parallel_Group
S28|mg|I-Design_Parallel_Group
S28|famotidine|I-Design_Parallel_Group
S28|)|I-Design_Parallel_Group
S28|or|I-Design_Parallel_Group
S28|ibuprofen|I-Design_Parallel_Group
S28|(|I-Design_Parallel_Group
S28|800|I-Design_Parallel_Group
S28|mg|I-Design_Parallel_Group
S28|)|I-Design_Parallel_Group
S28|thrice|O
S28|daily|O
S28|for|O
S28|24|O
S28|weeks|O
S28|.|O
S802|Patients|O
S802|were|O
S802|well|O
S802|matched|O
S802|with|O
S802|respect|O
S802|to|O
S802|all|O
S802|relevant|O
S802|baseline|O
S802|characteristics|O
S802|(|O
S802|table|O
S802|1|O
S802|)|O
S802|.|O
S411|Effect|O
S411|of|O
S411|oxandrolone|O
S411|and|O
S411|timing|O
S411|of|O
S411|pubertal|O
S411|induction|O
S411|on|O
S411|final|O
S411|height|O
S411|in|O
S411|Turner|O
S411|’|O
S411|s|O
S411|syndrome|O
S411|:|O
S411|randomised|O
S411|,|O
S411|double|B-Blinding_Double_Blind
S411|blind|I-Blinding_Double_Blind
S411|,|O
S411|placebo|O
S411|controlled|O
S411|trial|O
S455|Treatment|O
S455|All|O
S455|participants|O
S455|received|O
S455|the|O
S455|growth|O
S455|hormone|O
S455|preparation|O
S455|of|O
S455|their|O
S455|choice|O
S455|at|O
S455|10|O
S455|mg/m2/week|O
S455|in|O
S455|daily|O
S455|subcutaneous|O
S455|injections|O
S455|.|O
S905|Once|O
S905|the|O
S905|trial|O
S905|has|O
S905|been|O
S905|published|O
S905|,|O
S905|participants|O
S905|will|O
S905|be|O
S905|informed|O
S905|of|O
S905|the|O
S905|results|O
S905|through|O
S905|a|O
S905|dedicated|O
S905|website|O
S905|(|O
S905|www.stopgaptrial.co.uk|O
S905|)|O
S905|and|O
S905|will|O
S905|be|O
S905|sent|O
S905|details|O
S905|of|O
S905|the|O
S905|results|O
S905|in|O
S905|a|O
S905|study|O
S905|newsletter|O
S905|suitable|O
S905|for|O
S905|a|O
S905|non-specialist|O
S905|audience|O
S905|.|O
S1676|Changes|O
S1676|to|O
S1676|first-line|O
S1676|therapy|O
S1676|occurred|O
S1676|at|O
S1676|rates|O
S1676|of|O
S1676|3·3|O
S1676|per|O
S1676|100|O
S1676|child-years|O
S1676|in|O
S1676|routine|O
S1676|laboratory|O
S1676|monitoring|O
S1676|versus|O
S1676|3·2|O
S1676|per|O
S1676|100|O
S1676|child-years|O
S1676|in|O
S1676|clinically|O
S1676|driven|O
S1676|monitoring|O
S1676|(|O
S1676|p=0·94|O
S1676|)|O
S1676|;|O
S1676|and|O
S1676|3·5|O
S1676|,|O
S1676|3·7|O
S1676|,|O
S1676|and|O
S1676|2·6|O
S1676|per|O
S1676|100|O
S1676|child-years|O
S1676|in|O
S1676|groups|O
S1676|A|O
S1676|,|O
S1676|B|O
S1676|,|O
S1676|and|O
S1676|C|O
S1676|,|O
S1676|respectively|O
S1676|(|O
S1676|p=0·25|O
S1676|)|O
S1676|.|O
S1868|During|O
S1868|the|O
S1868|in-trial|O
S1868|period|O
S1868|,|O
S1868|the|O
S1868|average|O
S1868|difference|O
S1868|in|O
S1868|statin|O
S1868|use|O
S1868|between|O
S1868|simvastatin-allocated|O
S1868|versus|O
S1868|placebo-allocated|O
S1868|patients|O
S1868|was|O
S1868|67|O
S1868|%|O
S1868|(|O
S1868|85|O
S1868|%|O
S1868|vs|O
S1868|17|O
S1868|%|O
S1868|)|O
S1868|,|O
S1868|resulting|O
S1868|in|O
S1868|an|O
S1868|average|O
S1868|LDL|O
S1868|cholesterol|O
S1868|difference|O
S1868|of|O
S1868|1·0|O
S1868|mmol/L|O
S1868|(|O
S1868|SE|O
S1868|0·02|O
S1868|)|O
S1868|.|O
S589|Introduction|O
S589|Intimal|O
S589|hyperplasia|O
S589|,|O
S589|endothelial|O
S589|dysfunction|O
S589|and|O
S589|occlusive|O
S589|vasculopathy|O
S589|are|O
S589|ubiquitous|O
S589|features|O
S589|of|O
S589|systemic|O
S589|sclerosis|O
S589|(|O
S589|SSc|O
S589|)|O
S589|.|O
S2235|Only|O
S2235|observed|O
S2235|values|O
S2235|of|O
S2235|IgE|O
S2235|levels|O
S2235|were|O
S2235|analyzed|O
S2235|,|O
S2235|with|O
S2235|no|O
S2235|imputation|O
S2235|performed|O
S2235|for|O
S2235|missing|O
S2235|IgE|O
S2235|data|O
S2235|.|O
S1441|Virus|O
S1441|culture|O
S1441|and|O
S1441|genotypic|O
S1441|screening|O
S1441|for|O
S1441|oseltamivir|O
S1441|resistance|O
S1441|mutations|O
S1441|were|O
S1441|performed|O
S1441|as|O
S1441|described|O
S1441|previously|O
S1441|on|O
S1441|day|O
S1441|0|O
S1441|samples|O
S1441|for|O
S1441|all|O
S1441|enrolled|O
S1441|patients|O
S1441|and|O
S1441|on|O
S1441|day|O
S1441|five|O
S1441|samples|O
S1441|for|O
S1441|patients|O
S1441|with|O
S1441|positive|O
S1441|results|O
S1441|on|O
S1441|RT-PCR|O
S1441|.|O
S1970|Energy|O
S1970|and|O
S1970|mineral|O
S1970|intakes|O
S1970|were|O
S1970|calculated|O
S1970|using|O
S1970|food|O
S1970|composition|O
S1970|tables|O
S1970|for|O
S1970|African|O
S1970|foods|O
S1970|.|O
S2009|However|O
S2009|,|O
S2009|total|O
S2009|dietary|O
S2009|calcium|O
S2009|intake|O
S2009|was|O
S2009|positively|O
S2009|related|O
S2009|to|O
S2009|weight|O
S2009|for|O
S2009|height|O
S2009|(|O
S2009|r=0.29|O
S2009|;|O
S2009|p=0.01|O
S2009|)|O
S2009|,|O
S2009|25|O
S2009|(|O
S2009|OH|O
S2009|)|O
S2009|D|O
S2009|concentration|O
S2009|(|O
S2009|r=0.24|O
S2009|;|O
S2009|p=0.04|O
S2009|)|O
S2009|and|O
S2009|total|O
S2009|energy|O
S2009|intake|O
S2009|(|O
S2009|r=0.59|O
S2009|;|O
S2009|p|O
S2009|<|O
S2009|0.001|O
S2009|)|O
S2009|.|O
S1430|These|O
S1430|doses|O
S1430|were|O
S1430|halved|O
S1430|for|O
S1430|patients|O
S1430|with|O
S1430|a|O
S1430|creatinine|O
S1430|clearance|O
S1430|≥10|O
S1430|and|O
S1430|<|O
S1430|30|O
S1430|mL/min|O
S1430|.|O
S61|Statistical|O
S61|comparison|O
S61|between|O
S61|the|O
S61|study|O
S61|groups|O
S61|in|O
S61|the|O
S61|population|O
S61|of|O
S61|all|O
S61|patients|O
S61|randomized|O
S61|was|O
S61|also|O
S61|prespecified|O
S61|for|O
S61|common|O
S61|adverse|O
S61|events|O
S61|(|O
S61|occurring|O
S61|in|O
S61|>|O
S61|5|O
S61|%|O
S61|of|O
S61|patients|O
S61|)|O
S61|with|O
S61|a|O
S61|Cochran–Mantel–Haenszel|O
S61|test|O
S61|.|O
S162|Leukotriene|O
S162|modifiers|O
S162|or|O
S162|sustained-release|O
S162|theophylline|O
S162|,|O
S162|added|O
S162|on|O
S162|to|O
S162|low-dose|O
S162|ICS|O
S162|,|O
S162|are|O
S162|alternative|O
S162|options|O
S162|for|O
S162|these|O
S162|patients|O
S162|.|O
S1717|There|O
S1717|was|O
S1717|no|O
S1717|significant|O
S1717|difference|O
S1717|between|O
S1717|the|O
S1717|three|O
S1717|ART|O
S1717|strategy|O
S1717|randomisation|O
S1717|groups|O
S1717|in|O
S1717|mean|O
S1717|CD4|O
S1717|percentage|O
S1717|change|O
S1717|at|O
S1717|week|O
S1717|72|O
S1717|(|O
S1717|p=0·33|O
S1717|)|O
S1717|or|O
S1717|144|O
S1717|(|O
S1717|p=0·69|O
S1717|;|O
S1717|figure|O
S1717|4|O
S1717|)|O
S1717|.|O
S1045|Secondary|O
S1045|outcomes|O
S1045|were|O
S1045|(|O
S1045|a|O
S1045|)|O
S1045|complete|O
S1045|clearance|O
S1045|of|O
S1045|all|O
S1045|plantar|O
S1045|warts|O
S1045|at|O
S1045|12|O
S1045|weeks|O
S1045|controlling|O
S1045|for|O
S1045|age|O
S1045|,|O
S1045|whether|O
S1045|the|O
S1045|wart|O
S1045|had|O
S1045|been|O
S1045|treated|O
S1045|previously|O
S1045|,|O
S1045|and|O
S1045|type|O
S1045|of|O
S1045|wart|O
S1045|,|O
S1045|(|O
S1045|b|O
S1045|)|O
S1045|patient|O
S1045|self|O
S1045|reported|O
S1045|clearance|O
S1045|of|O
S1045|plantar|O
S1045|warts|O
S1045|at|O
S1045|six|O
S1045|months|O
S1045|,|O
S1045|(|O
S1045|c|O
S1045|)|O
S1045|time|O
S1045|to|O
S1045|clearance|O
S1045|of|O
S1045|plantar|O
S1045|wart|O
S1045|,|O
S1045|(|O
S1045|d|O
S1045|)|O
S1045|number|O
S1045|of|O
S1045|plantar|O
S1045|warts|O
S1045|at|O
S1045|12|O
S1045|weeks|O
S1045|,|O
S1045|and|O
S1045|(|O
S1045|e|O
S1045|)|O
S1045|patient|O
S1045|satisfaction|O
S1045|with|O
S1045|the|O
S1045|treatment|O
S1045|.|O
S484|The|O
S484|breakdown|O
S484|of|O
S484|karyotypes|O
S484|was|O
S484|45|O
S484|,|O
S484|X|O
S484|(|O
S484|39|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/46|O
S484|,|O
S484|XX|O
S484|(|O
S484|18|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/46|O
S484|,|O
S484|XrX|O
S484|(|O
S484|9|O
S484|)|O
S484|,|O
S484|complex|O
S484|mosaics|O
S484|containing|O
S484|three|O
S484|or|O
S484|more|O
S484|cell|O
S484|lines|O
S484|(|O
S484|8|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/46|O
S484|,|O
S484|XiX|O
S484|(|O
S484|7|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/45|O
S484|,|O
S484|XY|O
S484|(|O
S484|7|O
S484|)|O
S484|,|O
S484|46|O
S484|,|O
S484|XX|O
S484|including|O
S484|a|O
S484|structural|O
S484|abnormality|O
S484|of|O
S484|second|O
S484|X|O
S484|(|O
S484|7|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/46|O
S484|,|O
S484|XY|O
S484|including|O
S484|a|O
S484|structural|O
S484|abnormality|O
S484|of|O
S484|Y|O
S484|(|O
S484|3|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/46|O
S484|,|O
S484|XX|O
S484|including|O
S484|a|O
S484|structural|O
S484|abnormality|O
S484|of|O
S484|second|O
S484|X|O
S484|(|O
S484|3|O
S484|)|O
S484|,|O
S484|45|O
S484|,|O
S484|X/47|O
S484|,|O
S484|XXX|O
S484|(|O
S484|2|O
S484|)|O
S484|,|O
S484|and|O
S484|other|O
S484|(|O
S484|3|O
S484|)|O
S484|.|O
S71|After|O
S71|unblinding|O
S71|and|O
S71|performance|O
S71|of|O
S71|the|O
S71|statistical|O
S71|analyses|O
S71|,|O
S71|a|O
S71|review|O
S71|of|O
S71|endoscopy|O
S71|reports|O
S71|revealed|O
S71|that|O
S71|some|O
S71|patients|O
S71|with|O
S71|esophageal|O
S71|ulcers|O
S71|had|O
S71|been|O
S71|incorrectly|O
S71|assigned|O
S71|as|O
S71|having|O
S71|gastric|O
S71|ulcers|O
S71|.|O
S943|Adverse|O
S943|reactions|O
S943|to|O
S943|study|O
S943|drugs—adverse|O
S943|events|O
S943|that|O
S943|were|O
S943|possibly|O
S943|,|O
S943|probably|O
S943|,|O
S943|or|O
S943|definitely|O
S943|related|O
S943|to|O
S943|the|O
S943|study|O
S943|drug|O
S943|.|O
S1832|Methods|O
S1832|Patients|O
S1832|and|O
S1832|randomisation|O
S1832|Details|O
S1832|of|O
S1832|HPS|O
S1832|have|O
S1832|been|O
S1832|reported|O
S1832|previously|O
S1832|.|O
S1044|Main|O
S1044|outcome|O
S1044|measures|O
S1044|Complete|O
S1044|clearance|O
S1044|of|O
S1044|all|O
S1044|plantar|O
S1044|warts|O
S1044|at|O
S1044|12|O
S1044|weeks|O
S1044|.|O
S2210|Quilizumab|O
S2210|(|O
S2210|Genentech|O
S2210|,|O
S2210|Inc.|O
S2210|,|O
S2210|South|O
S2210|San|O
S2210|Francisco|O
S2210|,|O
S2210|CA|O
S2210|)|O
S2210|was|O
S2210|delivered|O
S2210|subcutaneously|O
S2210|at|O
S2210|nine|O
S2210|monthly|O
S2210|intervals|O
S2210|at|O
S2210|300|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|300|O
S2210|mg|O
S2210|M|O
S2210|)|O
S2210|,|O
S2210|or|O
S2210|at|O
S2210|three|O
S2210|quarterly|O
S2210|intervals|O
S2210|and|O
S2210|at|O
S2210|Week|O
S2210|4|O
S2210|at|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|per|O
S2210|dose|O
S2210|(|O
S2210|150|O
S2210|or|O
S2210|450|O
S2210|mg|O
S2210|Q|O
S2210|)|O
S2210|.|O
S63|All|O
S63|study|O
S63|patients|O
S63|provided|O
S63|written|O
S63|informed|O
S63|consent|O
S63|and|O
S63|the|O
S63|study|O
S63|was|O
S63|approved|O
S63|by|O
S63|institutional|O
S63|review|O
S63|boards|O
S63|for|O
S63|all|O
S63|participating|O
S63|centers|O
S63|.|O
S1992|Based|O
S1992|on|O
S1992|the|O
S1992|primary|O
S1992|outcome|O
S1992|measures|O
S1992|of|O
S1992|radiographic|O
S1992|score|O
S1992|and|O
S1992|serum|O
S1992|alkaline|O
S1992|phosphatase|O
S1992|values|O
S1992|and|O
S1992|SDs|O
S1992|based|O
S1992|on|O
S1992|previous|O
S1992|studies|O
S1992|(|O
S1992|1.6|O
S1992|for|O
S1992|radiographic|O
S1992|score|O
S1992|and|O
S1992|150|O
S1992|U/L|O
S1992|in|O
S1992|alkaline|O
S1992|phosphatase|O
S1992|)|O
S1992|,|O
S1992|40|B-Sample_Size_Required
S1992|subjects|I-Sample_Size_Required
S1992|in|I-Sample_Size_Required
S1992|each|I-Sample_Size_Required
S1992|treatment|I-Sample_Size_Required
S1992|group|I-Sample_Size_Required
S1992|would|O
S1992|provide|O
S1992|80|B-Sample_Size_Calculation_Power_Value
S1992|%|I-Sample_Size_Calculation_Power_Value
S1992|power|O
S1992|and|O
S1992|95|B-Sample_Size_Calculation_Alpha_Value
S1992|%|I-Sample_Size_Calculation_Alpha_Value
S1992|CI|I-Sample_Size_Calculation_Alpha_Value
S1992|to|O
S1992|detect|O
S1992|a|O
S1992|difference|O
S1992|between|O
S1992|groups|O
S1992|of|O
S1992|1.0|O
S1992|in|O
S1992|final|O
S1992|radiographic|O
S1992|score|O
S1992|and|O
S1992|100|O
S1992|U/L|O
S1992|in|O
S1992|alkaline|O
S1992|phosphatase|O
S1992|.|O
S2285|Patient-reported|O
S2285|outcomes|O
S2285|During|O
S2285|the|O
S2285|36-week|O
S2285|treatment|O
S2285|period|O
S2285|,|O
S2285|no|O
S2285|meaningful|O
S2285|differences|O
S2285|were|O
S2285|observed|O
S2285|between|O
S2285|the|O
S2285|quilizumab|O
S2285|dose|O
S2285|groups|O
S2285|compared|O
S2285|with|O
S2285|the|O
S2285|placebo|O
S2285|group|O
S2285|for|O
S2285|the|O
S2285|total|O
S2285|mTASS|O
S2285|,|O
S2285|daytime|O
S2285|mTASS|O
S2285|,|O
S2285|ACQ-5|O
S2285|,|O
S2285|AQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|,|O
S2285|or|O
S2285|RQLQ|O
S2285|(|O
S2285|S|O
S2285|)|O
S2285|scores|O
S2285|(|O
S2285|Table|O
S2285|3|O
S2285|)|O
S2285|.|O
S2256|There|O
S2256|were|O
S2256|no|O
S2256|major|O
S2256|imbalances|O
S2256|between|O
S2256|treatment|O
S2256|groups|O
S2256|,|O
S2256|but|O
S2256|the|O
S2256|300|O
S2256|mg|O
S2256|monthly|O
S2256|quilizumab|O
S2256|group|O
S2256|had|O
S2256|a|O
S2256|lower|O
S2256|mean|O
S2256|age|O
S2256|(|O
S2256|45|O
S2256|versus|O
S2256|47–48|O
S2256|years|O
S2256|)|O
S2256|and|O
S2256|a|O
S2256|lower|O
S2256|median|O
S2256|IgE|O
S2256|level|O
S2256|(|O
S2256|190|O
S2256|versus|O
S2256|234–254|O
S2256|IU/mL|O
S2256|)|O
S2256|compared|O
S2256|to|O
S2256|the|O
S2256|other|O
S2256|treatment|O
S2256|arms|O
S2256|(|O
S2256|Table|O
S2256|1|O
S2256|)|O
S2256|.|O
S315|Demographic|O
S315|and|O
S315|baseline|O
S315|disease|O
S315|characteristics|O
S315|were|O
S315|generally|O
S315|well|O
S315|balanced|O
S315|across|O
S315|treatment|O
S315|groups|O
S315|(|O
S315|table|O
S315|1|O
S315|)|O
S315|.|O
S78|Assessment|O
S78|of|O
S78|the|O
S78|secondary|O
S78|ulcer|O
S78|end|O
S78|points|O
S78|in|O
S78|REDUCE-1|O
S78|revealed|O
S78|that|O
S78|significantly|O
S78|fewer|O
S78|patients|O
S78|receiving|O
S78|HZT-501|O
S78|developed|O
S78|upper|O
S78|GI|O
S78|ulcers|O
S78|in|O
S78|both|O
S78|the|O
S78|initial|O
S78|(|O
S78|NNT=9|O
S78|)|O
S78|and|O
S78|post-adjudication|O
S78|analysis|O
S78|(|O
S78|NNT=10|O
S78|)|O
S78|,|O
S78|and|O
S78|significantly|O
S78|fewer|O
S78|patients|O
S78|developed|O
S78|duodenal|O
S78|ulcers|O
S78|(|O
S78|NNT=25|O
S78|)|O
S78|.|O
S514|Ten|O
S514|were|O
S514|classified|O
S514|as|O
S514|serious|O
S514|adverse|O
S514|events|O
S514|,|O
S514|as|O
S514|they|O
S514|involved|O
S514|admission|O
S514|to|O
S514|hospital|O
S514|for|O
S514|procedures|O
S514|including|O
S514|appendicectomy|O
S514|and|O
S514|ear|O
S514|,|O
S514|nose|O
S514|,|O
S514|and|O
S514|throat|O
S514|surgery|O
S514|(|O
S514|for|O
S514|example|O
S514|,|O
S514|grommet|O
S514|(|O
S514|ventilation|O
S514|tube|O
S514|)|O
S514|insertion|O
S514|)|O
S514|.|O
S1246|At|O
S1246|the|O
S1246|end|O
S1246|of|O
S1246|the|O
S1246|pilot|O
S1246|phase|O
S1246|,|O
S1246|since|O
S1246|the|O
S1246|main|O
S1246|phase|O
S1246|compared|O
S1246|treatment|O
S1246|with|O
S1246|open|B-Blinding_Open_Label
S1246|control|I-Blinding_Open_Label
S1246|,|O
S1246|several|O
S1246|additional|O
S1246|measures|O
S1246|were|O
S1246|introduced|O
S1246|to|O
S1246|minimise|O
S1246|bias|O
S1246|in|O
S1246|the|O
S1246|assessment|O
S1246|of|O
S1246|early|O
S1246|and|O
S1246|late|O
S1246|outcomes|O
S1246|.|O
S172|In|O
S172|this|O
S172|cohort|O
S172|of|O
S172|912|O
S172|patients|O
S172|,|O
S172|tiotropium|O
S172|Respimat®|O
S172|5|O
S172|μg|O
S172|,|O
S172|administered|O
S172|as|O
S172|add-on|O
S172|to|O
S172|ICS|O
S172|+|O
S172|LABA|O
S172|,|O
S172|significantly|O
S172|reduced|O
S172|the|O
S172|risk|O
S172|of|O
S172|severe|O
S172|exacerbations|O
S172|and|O
S172|improved|O
S172|lung|O
S172|function|O
S172|,|O
S172|compared|O
S172|with|O
S172|placebo|O
S172|Respimat®|O
S172|as|O
S172|add-on|O
S172|to|O
S172|ICS|O
S172|+|O
S172|LABA|O
S172|.|O
S1657|Z|O
S1657|scores|O
S1657|were|O
S1657|determined|O
S1657|with|O
S1657|the|O
S1657|British|O
S1657|reference|O
S1657|because|O
S1657|it|O
S1657|covers|O
S1657|the|O
S1657|full|O
S1657|age|O
S1657|range|O
S1657|of|O
S1657|ARROW|O
S1657|children|O
S1657|.|O
S1848|During|O
S1848|the|O
S1848|post-trial|O
S1848|period|O
S1848|,|O
S1848|participants|O
S1848|were|O
S1848|asked|O
S1848|each|O
S1848|year|O
S1848|about|O
S1848|their|O
S1848|current|O
S1848|statin|O
S1848|use|O
S1848|,|O
S1848|and|O
S1848|post-trial|O
S1848|lipid|O
S1848|profile|O
S1848|assays|O
S1848|were|O
S1848|sought|O
S1848|from|O
S1848|1500|O
S1848|randomly|O
S1848|selected|O
S1848|surviving|O
S1848|participants|O
S1848|between|O
S1848|May|O
S1848|,|O
S1848|2004|O
S1848|,|O
S1848|and|O
S1848|August|O
S1848|,|O
S1848|2004|O
S1848|(|O
S1848|ie|O
S1848|,|O
S1848|about|O
S1848|3|O
S1848|years|O
S1848|after|O
S1848|the|O
S1848|scheduled|O
S1848|treatment|O
S1848|period|O
S1848|)|O
S1848|.|O
S1861|Reassuringly|O
S1861|,|O
S1861|no|O
S1861|adverse|O
S1861|effects|O
S1861|on|O
S1861|particular|O
S1861|causes|O
S1861|of|O
S1861|non-vascular|O
S1861|mortality|O
S1861|or|O
S1861|major|O
S1861|morbidity|O
S1861|(|O
S1861|including|O
S1861|site-specific|O
S1861|cancers|O
S1861|)|O
S1861|were|O
S1861|seen|O
S1861|to|O
S1861|emerge|O
S1861|during|O
S1861|prolonged|O
S1861|follow-up|O
S1861|.|O
S940|Time|O
S940|to|O
S940|recurrence—defined|O
S940|as|O
S940|the|O
S940|interval|O
S940|between|O
S940|the|O
S940|target|O
S940|lesion|O
S940|healing|O
S940|and|O
S940|a|O
S940|further|O
S940|episode|O
S940|of|O
S940|pyoderma|O
S940|gangrenosum|O
S940|(|O
S940|at|O
S940|any|O
S940|site|O
S940|)|O
S940|.|O
S75|These|O
S75|post-adjudication|O
S75|results|O
S75|are|O
S75|presented|O
S75|in|O
S75|Table|O
S75|2|O
S75|.|O
S2218|Secondary|O
S2218|efficacy|O
S2218|outcomes|O
S2218|included|O
S2218|assessments|O
S2218|of|O
S2218|lung|O
S2218|function|O
S2218|using|O
S2218|the|O
S2218|relative|O
S2218|change|O
S2218|in|O
S2218|pre-bronchodilator|O
S2218|FEV1|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Weeks|O
S2218|12|O
S2218|and|O
S2218|36|O
S2218|and|O
S2218|the|O
S2218|change|O
S2218|in|O
S2218|asthma|O
S2218|symptoms|O
S2218|from|O
S2218|baseline|O
S2218|to|O
S2218|Week|O
S2218|36|O
S2218|,|O
S2218|using|O
S2218|total|O
S2218|and|O
S2218|daytime|O
S2218|symptom|O
S2218|severity|O
S2218|scores|O
S2218|derived|O
S2218|from|O
S2218|a|O
S2218|daily|O
S2218|patient|O
S2218|diary|O
S2218|.|O
S1704|Viral|O
S1704|load|O
S1704|suppression|O
S1704|was|O
S1704|similar|O
S1704|in|O
S1704|both|O
S1704|monitoring|O
S1704|groups|O
S1704|(|O
S1704|figure|O
S1704|3|O
S1704|;|O
S1704|global|O
S1704|p|O
S1704|>|O
S1704|0·7|O
S1704|)|O
S1704|.|O
S99|One|O
S99|death|O
S99|occurred|O
S99|in|O
S99|the|O
S99|two|O
S99|studies|O
S99|:|O
S99|a|O
S99|48-year-old|O
S99|female|O
S99|in|O
S99|the|O
S99|ibuprofen|O
S99|group|O
S99|died|O
S99|of|O
S99|cardiorespiratory|O
S99|arrest|O
S99|and|O
S99|multiorgan|O
S99|system|O
S99|failure|O
S99|attributed|O
S99|to|O
S99|acetaminophen|O
S99|toxicity|O
S99|.|O
S458|The|O
S458|code|O
S458|for|O
S458|randomisation|O
S458|2|O
S458|was|O
S458|broken|O
S458|at|O
S458|15|O
S458|years|O
S458|to|O
S458|allow|O
S458|introduction|O
S458|of|O
S458|progesterone|O
S458|therapy|O
S458|:|O
S458|oral|O
S458|norethisterone|O
S458|(|O
S458|CP|O
S458|Pharmaceuticals|O
S458|,|O
S458|Wrexham|O
S458|,|O
S458|UK|O
S458|)|O
S458|5|O
S458|mg|O
S458|daily|O
S458|for|O
S458|five|O
S458|days|O
S458|each|O
S458|month|O
S458|.|O
S1240|Older|O
S1240|people|O
S1240|have|O
S1240|been|O
S1240|under-represented|O
S1240|in|O
S1240|stroke|O
S1240|trials|O
S1240|in|O
S1240|general|O
S1240|,|O
S1240|and|O
S1240|in|O
S1240|stroke|O
S1240|thrombolysis|O
S1240|trials|O
S1240|in|O
S1240|particular|O
S1240|(|O
S1240|only|O
S1240|79|O
S1240|people|O
S1240|aged|O
S1240|older|O
S1240|than|O
S1240|80|O
S1240|years|O
S1240|had|O
S1240|been|O
S1240|included|O
S1240|in|O
S1240|trials|O
S1240|of|O
S1240|rt-PA|O
S1240|)|O
S1240|.|O
S189|The|O
S189|randomisation|O
S189|list|O
S189|was|O
S189|generated|O
S189|by|O
S189|Boehringer|B-Randomization_Personnel
S189|Ingelheim|I-Randomization_Personnel
S189|Pharma|I-Randomization_Personnel
S189|GmbH|I-Randomization_Personnel
S189|&|I-Randomization_Personnel
S189|Co.|O
S189|KG|O
S189|,|O
S189|Biberach|O
S189|an|O
S189|der|O
S189|Riss|O
S189|,|O
S189|Germany|O
S189|,|O
S189|using|O
S189|a|B-Randomization_Sequence_Generation_Method
S189|validated|I-Randomization_Sequence_Generation_Method
S189|pseudo-random|I-Randomization_Sequence_Generation_Method
S189|number|I-Randomization_Sequence_Generation_Method
S189|generator|I-Randomization_Sequence_Generation_Method
S189|and|I-Randomization_Sequence_Generation_Method
S189|a|I-Randomization_Sequence_Generation_Method
S189|supplied|I-Randomization_Sequence_Generation_Method
S189|seed|I-Randomization_Sequence_Generation_Method
S189|number|I-Randomization_Sequence_Generation_Method
S189|.|O
S1673|More|O
S1673|additional|O
S1673|haematology|O
S1673|tests|O
S1673|were|O
S1673|requested|O
S1673|during|O
S1673|nurse|O
S1673|visits|O
S1673|or|O
S1673|extra|O
S1673|visits|O
S1673|in|O
S1673|routine|O
S1673|laboratory|O
S1673|than|O
S1673|in|O
S1673|clinically|O
S1673|driven|O
S1673|monitoring|O
S1673|(|O
S1673|p|O
S1673|<|O
S1673|0·0001|O
S1673|)|O
S1673|;|O
S1673|there|O
S1673|were|O
S1673|no|O
S1673|significant|O
S1673|differences|O
S1673|in|O
S1673|requests|O
S1673|for|O
S1673|additional|O
S1673|biochemistry|O
S1673|tests|O
S1673|(|O
S1673|p=0·17|O
S1673|)|O
S1673|or|O
S1673|other|O
S1673|non-routine|O
S1673|(|O
S1673|eg|O
S1673|,|O
S1673|electrolytes|O
S1673|)|O
S1673|tests|O
S1673|(|O
S1673|p=0·97|O
S1673|)|O
S1673|.|O
S950|We|O
S950|included|O
S950|all|O
S950|participants|O
S950|with|O
S950|available|O
S950|data|O
S950|at|O
S950|both|O
S950|the|O
S950|baseline|O
S950|and|O
S950|the|O
S950|six|O
S950|week|O
S950|visit|O
S950|in|O
S950|the|O
S950|primary|O
S950|analysis|O
S950|.|O
S2143|On|O
S2143|the|O
S2143|basis|O
S2143|of|O
S2143|interviews|O
S2143|with|O
S2143|the|O
S2143|patients|O
S2143|and|O
S2143|caregivers|O
S2143|and|O
S2143|a|O
S2143|monthly|O
S2143|pill|O
S2143|count|O
S2143|,|O
S2143|the|O
S2143|treatment|O
S2143|compliance|O
S2143|was|O
S2143|above|O
S2143|90|B-Sample_Size_Actual_at_Outcome_Analysis
S2143|%|I-Sample_Size_Actual_at_Outcome_Analysis
S2143|for|I-Sample_Size_Actual_at_Outcome_Analysis
S2143|all|I-Sample_Size_Actual_at_Outcome_Analysis
S2143|patients|I-Sample_Size_Actual_at_Outcome_Analysis
S2143|.|O
S1264|Both|O
S1264|treatment|O
S1264|groups|O
S1264|had|O
S1264|blood|O
S1264|pressure|O
S1264|monitored|O
S1264|closely|O
S1264|over|O
S1264|the|O
S1264|first|O
S1264|24|O
S1264|h.|O
S1264|In|O
S1264|the|O
S1264|double-blinded|B-Blinding_Double_Blind
S1264|phase|O
S1264|,|O
S1264|both|O
S1264|groups|O
S1264|were|O
S1264|to|O
S1264|avoid|O
S1264|antiplatelet|O
S1264|or|O
S1264|anticoagulant|O
S1264|therapy|O
S1264|for|O
S1264|24|O
S1264|h.|O
S1264|In|O
S1264|the|O
S1264|open|B-Blinding_Open_Label
S1264|phase|O
S1264|,|O
S1264|patients|O
S1264|allocated|O
S1264|to|O
S1264|the|O
S1264|control|O
S1264|group|O
S1264|were|O
S1264|to|O
S1264|start|O
S1264|aspirin|O
S1264|immediately|O
S1264|.|O
S1267|All|O
S1267|patients|O
S1267|had|O
S1267|a|O
S1267|CT|O
S1267|or|O
S1267|MRI|O
S1267|brain|O
S1267|scan|O
S1267|before|O
S1267|randomisation|O
S1267|and|O
S1267|a|O
S1267|follow-up|O
S1267|scan|O
S1267|at|O
S1267|24–48|O
S1267|h.|O
S1267|A|O
S1267|repeat|O
S1267|brain|O
S1267|scan|O
S1267|was|O
S1267|required|O
S1267|if|O
S1267|the|O
S1267|patient|O
S1267|deteriorated|O
S1267|neurologically|O
S1267|or|O
S1267|intracranial|O
S1267|haemorrhage|O
S1267|was|O
S1267|suspected|O
S1267|for|O
S1267|any|O
S1267|reason|O
S1267|.|O
S1243|The|O
S1243|primary|O
S1243|trial|O
S1243|hypothesis|O
S1243|was|O
S1243|that|O
S1243|0·9|O
S1243|mg/kg|O
S1243|rt-PA|O
S1243|(|O
S1243|maximum|O
S1243|90|O
S1243|mg|O
S1243|)|O
S1243|given|O
S1243|to|O
S1243|adult|O
S1243|patients|O
S1243|of|O
S1243|all|O
S1243|ages|O
S1243|with|O
S1243|acute|O
S1243|ischaemic|O
S1243|stroke|O
S1243|,|O
S1243|within|O
S1243|6|O
S1243|h|O
S1243|of|O
S1243|symptom|O
S1243|onset|O
S1243|,|O
S1243|increased|O
S1243|the|O
S1243|proportion|O
S1243|of|O
S1243|people|O
S1243|who|O
S1243|were|O
S1243|alive|O
S1243|and|O
S1243|independent|O
S1243|at|O
S1243|6|O
S1243|months|O
S1243|.|O
S1497|The|O
S1497|21|O
S1497|deaths|O
S1497|occurred|O
S1497|at|O
S1497|similar|O
S1497|rates|O
S1497|in|O
S1497|the|O
S1497|double|O
S1497|(|O
S1497|n=12|O
S1497|;|O
S1497|7.3|O
S1497|%|O
S1497|,|O
S1497|4.2|O
S1497|%|O
S1497|to|O
S1497|12.3|O
S1497|%|O
S1497|)|O
S1497|and|O
S1497|standard|O
S1497|dose|O
S1497|(|O
S1497|n=9|O
S1497|;|O
S1497|5.6|O
S1497|%|O
S1497|,|O
S1497|3.0|O
S1497|%|O
S1497|to|O
S1497|10.3|O
S1497|%|O
S1497|)|O
S1497|arms|O
S1497|(|O
S1497|P=0.54|O
S1497|)|O
S1497|.|O
S1040|Setting|O
S1040|University|B-Settings_Multicenter
S1040|podiatry|I-Settings_Multicenter
S1040|school|I-Settings_Multicenter
S1040|clinics|I-Settings_Multicenter
S1040|,|I-Settings_Multicenter
S1040|NHS|I-Settings_Multicenter
S1040|podiatry|I-Settings_Multicenter
S1040|clinics|I-Settings_Multicenter
S1040|,|I-Settings_Multicenter
S1040|and|I-Settings_Multicenter
S1040|primary|I-Settings_Multicenter
S1040|care|I-Settings_Multicenter
S1040|in|O
S1040|England|B-Settings_Location
S1040|,|I-Settings_Location
S1040|Scotland|I-Settings_Location
S1040|,|I-Settings_Location
S1040|and|I-Settings_Location
S1040|Ireland|I-Settings_Location
S1040|.|O
S2079|Memantine|O
S2079|for|O
S2079|axial|O
S2079|signs|O
S2079|in|O
S2079|Parkinson|O
S2079|'s|O
S2079|disease|O
S2079|:|O
S2079|a|O
S2079|randomised|B-Randomization_Type_Simple
S2079|,|O
S2079|double-blind|B-Blinding_Double_Blind
S2079|,|O
S2079|placebo-controlled|O
S2079|pilot|O
S2079|study|O
S1814|The|O
S1814|primary|O
S1814|outcome|O
S1814|of|O
S1814|the|O
S1814|long-term|O
S1814|follow-up|O
S1814|of|O
S1814|HPS|O
S1814|was|O
S1814|first|O
S1814|post-randomisation|O
S1814|major|O
S1814|vascular|O
S1814|event|O
S1814|,|O
S1814|and|O
S1814|analysis|O
S1814|was|O
S1814|by|O
S1814|intention|O
S1814|to|O
S1814|treat|O
S1814|.|O
S87|RRs|O
S87|of|O
S87|upper|O
S87|GI|O
S87|ulcer|O
S87|formation|O
S87|for|O
S87|low-dose|O
S87|aspirin|O
S87|use|O
S87|were|O
S87|1.40|O
S87|(|O
S87|0.97–2.02|O
S87|)|O
S87|for|O
S87|initial|O
S87|and|O
S87|1.46|O
S87|(|O
S87|1.004–2.11|O
S87|)|O
S87|for|O
S87|post-adjudication|O
S87|analyses|O
S87|and|O
S87|for|O
S87|prior|O
S87|ulcer|O
S87|history|O
S87|they|O
S87|were|O
S87|1.55|O
S87|(|O
S87|0.95–2.53|O
S87|)|O
S87|for|O
S87|initial|O
S87|and|O
S87|1.65|O
S87|(|O
S87|1.01–2.69|O
S87|)|O
S87|for|O
S87|post-adjudication|O
S87|analyses|O
S87|.|O
S1258|The|O
S1258|system|O
S1258|would|O
S1258|not|O
S1258|accept|O
S1258|patients|O
S1258|with|O
S1258|blood|O
S1258|pressure|O
S1258|or|O
S1258|glucose|O
S1258|levels|O
S1258|outside|O
S1258|protocol-defined|O
S1258|criteria|O
S1258|(|O
S1258|appendix|O
S1258|pp|O
S1258|4–5|O
S1258|)|O
S1258|or|O
S1258|other|O
S1258|data|O
S1258|inconsistencies|O
S1258|.|O
S515|Four|O
S515|adverse|O
S515|events|O
S515|could|O
S515|have|O
S515|been|O
S515|related|O
S515|to|O
S515|oxandrolone|O
S515|or|O
S515|ethinylestradiol|O
S515|:|O
S515|acne|O
S515|in|O
S515|a|O
S515|15|O
S515|year|O
S515|old|O
S515|(|O
S515|all|O
S515|study|O
S515|drugs|O
S515|were|O
S515|continued|O
S515|,|O
S515|and|O
S515|randomisation|O
S515|was|O
S515|later|O
S515|revealed|O
S515|as|O
S515|oxandrolone|O
S515|and|O
S515|pubertal|O
S515|induction|O
S515|at|O
S515|14|O
S515|years|O
S515|)|O
S515|;|O
S515|persistent|O
S515|hypertension|O
S515|in|O
S515|a|O
S515|13|O
S515|year|O
S515|old|O
S515|(|O
S515|oxandrolone/placebo|O
S515|was|O
S515|stopped|O
S515|and|O
S515|antihypertensive|O
S515|treatment|O
S515|started|O
S515|,|O
S515|blood|O
S515|pressure|O
S515|normalised|O
S515|,|O
S515|and|O
S515|oxandrolone/placebo|O
S515|treatment|O
S515|was|O
S515|restarted|O
S515|;|O
S515|the|O
S515|randomisation|O
S515|was|O
S515|later|O
S515|revealed|O
S515|as|O
S515|oxandrolone|O
S515|and|O
S515|pubertal|O
S515|induction|O
S515|at|O
S515|12|O
S515|years|O
S515|)|O
S515|;|O
S515|abnormal|O
S515|liver|O
S515|function|O
S515|in|O
S515|a|O
S515|16|O
S515|year|O
S515|old|O
S515|(|O
S515|the|O
S515|participant|O
S515|was|O
S515|at|O
S515|near|O
S515|final|O
S515|height|O
S515|and|O
S515|elected|O
S515|to|O
S515|stop|O
S515|growth|O
S515|promoting|O
S515|treatment|O
S515|;|O
S515|randomisation|O
S515|was|O
S515|later|O
S515|revealed|O
S515|as|O
S515|oxandrolone|O
S515|and|O
S515|pubertal|O
S515|induction|O
S515|at|O
S515|14|O
S515|years|O
S515|)|O
S515|;|O
S515|and|O
S515|episodic|O
S515|“|O
S515|hot|O
S515|flushes|O
S515|”|O
S515|in|O
S515|a|O
S515|15|O
S515|year|O
S515|old|O
S515|(|O
S515|all|O
S515|study|O
S515|drugs|O
S515|were|O
S515|continued|O
S515|;|O
S515|randomisation|O
S515|was|O
S515|later|O
S515|revealed|O
S515|as|O
S515|placebo|O
S515|and|O
S515|pubertal|O
S515|induction|O
S515|at|O
S515|14|O
S515|years|O
S515|)|O
S515|.|O
S260|The|O
S260|study|O
S260|aimed|O
S260|to|O
S260|determine|O
S260|the|O
S260|canakinumab|O
S260|dose|O
S260|having|O
S260|equivalent|O
S260|efficacy|O
S260|to|O
S260|colchicine|O
S260|0.5|O
S260|mg|O
S260|at|O
S260|16|O
S260|weeks|O
S260|.|O
S2264|Pharmacokinetics|O
S2264|Quilizumab|O
S2264|displayed|O
S2264|linear|O
S2264|pharmacokinetics|O
S2264|with|O
S2264|a|O
S2264|dose-proportional|O
S2264|increase|O
S2264|in|O
S2264|exposure|O
S2264|as|O
S2264|shown|O
S2264|by|O
S2264|increases|O
S2264|in|O
S2264|Cmax|O
S2264|values|O
S2264|between|O
S2264|the|O
S2264|150|O
S2264|and|O
S2264|450|O
S2264|mg|O
S2264|Q|O
S2264|doses|O
S2264|at|O
S2264|Weeks|O
S2264|5|O
S2264|and|O
S2264|25|O
S2264|.|O
S1127|Primary|O
S1127|outcome|O
S1127|In|O
S1127|total|O
S1127|,|O
S1127|229|B-Sample_Size_Actual_at_Outcome_Analysis
S1127|participants|O
S1127|had|O
S1127|a|O
S1127|response|O
S1127|for|O
S1127|whether|O
S1127|there|O
S1127|was|O
S1127|complete|O
S1127|clearance|O
S1127|of|O
S1127|all|O
S1127|plantar|O
S1127|warts|O
S1127|at|O
S1127|12|O
S1127|weeks|O
S1127|after|O
S1127|randomisation|O
S1127|,|O
S1127|with|O
S1127|206|O
S1127|(|O
S1127|90|O
S1127|%|O
S1127|)|O
S1127|having|O
S1127|a|O
S1127|blinded|O
S1127|outcome|O
S1127|assessment|O
S1127|:|O
S1127|159|O
S1127|(|O
S1127|69|O
S1127|%|O
S1127|)|O
S1127|had|O
S1127|a|O
S1127|blinded|O
S1127|outcome|O
S1127|assessment|O
S1127|from|O
S1127|a|O
S1127|digital|O
S1127|photograph|O
S1127|(|O
S1127|cryotherapy=80|O
S1127|,|O
S1127|salicylic|O
S1127|acid=79|O
S1127|)|O
S1127|,|O
S1127|47|O
S1127|(|O
S1127|21|O
S1127|%|O
S1127|)|O
S1127|had|O
S1127|a|O
S1127|blinded|O
S1127|outcome|O
S1127|assessment|O
S1127|from|O
S1127|a|O
S1127|healthcare|O
S1127|professional|O
S1127|(|O
S1127|cryotherapy=22|O
S1127|,|O
S1127|salicylic|O
S1127|acid=25|O
S1127|)|O
S1127|,|O
S1127|four|O
S1127|(|O
S1127|2|O
S1127|%|O
S1127|)|O
S1127|had|O
S1127|an|O
S1127|unblinded|O
S1127|outcome|O
S1127|assessment|O
S1127|from|O
S1127|a|O
S1127|healthcare|O
S1127|professional|O
S1127|(|O
S1127|cryotherapy=1|O
S1127|,|O
S1127|salicylic|O
S1127|acid=3|O
S1127|)|O
S1127|,|O
S1127|and|O
S1127|19|O
S1127|(|O
S1127|8|O
S1127|%|O
S1127|)|O
S1127|had|O
S1127|patient|O
S1127|self|O
S1127|assessment|O
S1127|(|O
S1127|cryotherapy=7|O
S1127|,|O
S1127|salicylic|O
S1127|acid=12|O
S1127|)|O
S1127|.|O
S1976|Intervention|O
S1976|All|O
S1976|children|O
S1976|were|O
S1976|treated|O
S1976|with|O
S1976|calcium|O
S1976|carbonate|O
S1976|as|O
S1976|powdered|O
S1976|limestone|O
S1976|.|O
S2114|Intervention|O
S2114|Patients|B-Blinding_Object_Patients
S2114|,|O
S2114|study|B-Blinding_Object_Others
S2114|staff|I-Blinding_Object_Others
S2114|and|O
S2114|investigators|B-Blinding_Object_Investigators
S2114|were|O
S2114|blinded|O
S2114|to|O
S2114|the|O
S2114|assignment|O
S2114|.|O
S987|Table|O
S987|7|O
S987|presents|O
S987|the|O
S987|specific|O
S987|events|O
S987|that|O
S987|occurred|O
S987|in|O
S987|at|O
S987|least|O
S987|3|O
S987|%|O
S987|of|O
S987|patients|O
S987|in|O
S987|either|O
S987|treatment|O
S987|group|O
S987|.|O
S1309|The|O
S1309|writing|O
S1309|group|O
S1309|was|O
S1309|persuaded|O
S1309|by|O
S1309|the|O
S1309|recent|O
S1309|empirical|O
S1309|evidence|O
S1309|that|O
S1309|the|O
S1309|ordinal|O
S1309|method|O
S1309|was|O
S1309|both|O
S1309|statistically|O
S1309|more|O
S1309|efficient|O
S1309|(|O
S1309|effectively|O
S1309|reducing|O
S1309|the|O
S1309|sample|O
S1309|size|O
S1309|required|O
S1309|in|O
S1309|stroke|O
S1309|trials|O
S1309|)|O
S1309|and|O
S1309|robust|O
S1309|against|O
S1309|substantial|O
S1309|deviations|O
S1309|from|O
S1309|the|O
S1309|proportional|O
S1309|assumption|O
S1309|.|O
S1150|Of|O
S1150|these|O
S1150|,|O
S1150|one|O
S1150|event|O
S1150|(|O
S1150|a|O
S1150|ruptured|O
S1150|Achilles|O
S1150|tendon|O
S1150|requiring|O
S1150|hospitalisation|O
S1150|)|O
S1150|was|O
S1150|classed|O
S1150|as|O
S1150|serious|O
S1150|and|O
S1150|unrelated|O
S1150|to|O
S1150|the|O
S1150|trial|O
S1150|treatment|O
S1150|(|O
S1150|salicylic|O
S1150|acid|O
S1150|)|O
S1150|.|O
S1120|Results|O
S1120|Between|O
S1120|November|O
S1120|2006|O
S1120|and|O
S1120|January|O
S1120|2010|O
S1120|,|O
S1120|284|O
S1120|individuals|O
S1120|were|O
S1120|screened|O
S1120|as|O
S1120|potential|O
S1120|participants|O
S1120|,|O
S1120|and|O
S1120|242|B-Sample_Size_Actual_at_Enrollment
S1120|(|O
S1120|85|O
S1120|%|O
S1120|)|O
S1120|were|O
S1120|randomised—124|O
S1120|to|O
S1120|salicylic|O
S1120|acid|O
S1120|and|O
S1120|118|O
S1120|to|O
S1120|cryotherapy|O
S1120|.|O
S1883|During|O
S1883|the|O
S1883|post-trial|O
S1883|period|O
S1883|,|O
S1883|the|O
S1883|incidence|O
S1883|rates|O
S1883|were|O
S1883|similar|O
S1883|in|O
S1883|both|O
S1883|treatment|O
S1883|groups|O
S1883|(|O
S1883|0·93|O
S1883|[|O
S1883|0·84–1·04|O
S1883|]|O
S1883|;|O
S1883|p=0·20|O
S1883|)|O
S1883|.|O
S1147|This|O
S1147|is|O
S1147|not|O
S1147|expected|O
S1147|if|O
S1147|satisfaction|O
S1147|with|O
S1147|treatment|O
S1147|was|O
S1147|independent|O
S1147|of|O
S1147|treatment|O
S1147|randomised|O
S1147|.|O
S1311|In|O
S1311|this|O
S1311|model|O
S1311|the|O
S1311|treatment|O
S1311|odds|O
S1311|ratios|O
S1311|between|O
S1311|one|O
S1311|level|O
S1311|and|O
S1311|the|O
S1311|next|O
S1311|were|O
S1311|assumed|O
S1311|to|O
S1311|be|O
S1311|constant|O
S1311|,|O
S1311|so|O
S1311|a|O
S1311|single|O
S1311|parameter|O
S1311|summarises|O
S1311|the|O
S1311|shift|O
S1311|in|O
S1311|outcome|O
S1311|distribution|O
S1311|between|O
S1311|treatment|O
S1311|and|O
S1311|control|O
S1311|groups|O
S1311|.|O
S631|Post|O
S631|hoc|O
S631|analyses|O
S631|included|O
S631|:|O
S631|(|O
S631|1|O
S631|)|O
S631|the|O
S631|number|O
S631|of|O
S631|new|O
S631|DUs|O
S631|up|O
S631|to|O
S631|week|O
S631|12|O
S631|in|O
S631|the|O
S631|overall|O
S631|patient|O
S631|population|O
S631|and|O
S631|in|O
S631|subgroups|O
S631|defined|O
S631|by|O
S631|randomisation|O
S631|month|O
S631|(|O
S631|October–February|O
S631|or|O
S631|autumn–winter|O
S631|and|O
S631|March–September|O
S631|or|O
S631|spring–summer|O
S631|)|O
S631|and|O
S631|(|O
S631|2|O
S631|)|O
S631|number|O
S631|of|O
S631|new|O
S631|DUs|O
S631|,|O
S631|time|O
S631|to|O
S631|each|O
S631|successive|O
S631|new|O
S631|DU|O
S631|and|O
S631|total|O
S631|number|O
S631|of|O
S631|DUs|O
S631|through|O
S631|week|O
S631|24|O
S631|in|O
S631|subgroups|O
S631|defined|O
S631|by|O
S631|the|O
S631|number|O
S631|of|O
S631|DUs|O
S631|at|O
S631|baseline|O
S631|(|O
S631|<|O
S631|4|O
S631|and|O
S631|≥4|O
S631|)|O
S631|.|O
S2236|Peripheral|O
S2236|blood|O
S2236|eosinophil|O
S2236|counts|O
S2236|were|O
S2236|obtained|O
S2236|from|O
S2236|standard|O
S2236|complete|O
S2236|blood|O
S2236|counts|O
S2236|.|O
S879|Trial|O
S879|registration|O
S879|Current|O
S879|Controlled|O
S879|Trials|O
S879|ISRCTN35898459|O
S879|.|O
S1486|Given|O
S1486|the|O
S1486|detected|O
S1486|rates|O
S1486|of|O
S1486|viral|O
S1486|shedding|O
S1486|at|O
S1486|day|O
S1486|five|O
S1486|this|O
S1486|sample|O
S1486|of|O
S1486|224|O
S1486|patients|O
S1486|has|O
S1486|more|O
S1486|than|O
S1486|85|O
S1486|%|O
S1486|power|O
S1486|to|O
S1486|show|O
S1486|a|O
S1486|20|O
S1486|%|O
S1486|absolute|O
S1486|improvement|O
S1486|in|O
S1486|cessation|O
S1486|of|O
S1486|viral|O
S1486|shedding|O
S1486|at|O
S1486|two|O
S1486|sided|O
S1486|α|O
S1486|of|O
S1486|0.05|O
S1486|.|O
S1941|Results|O
S1941|The|O
S1941|median|O
S1941|(|O
S1941|range|O
S1941|)|O
S1941|age|O
S1941|of|O
S1941|enrolled|O
S1941|children|O
S1941|was|O
S1941|46|O
S1941|(|O
S1941|15–102|O
S1941|)|O
S1941|months|O
S1941|,|O
S1941|and|O
S1941|baseline|O
S1941|characteristics|O
S1941|were|O
S1941|similar|O
S1941|in|O
S1941|the|O
S1941|two|O
S1941|groups|O
S1941|.|O
S506|The|O
S506|SITAR|O
S506|adjustment|O
S506|process|O
S506|estimated|O
S506|the|O
S506|size|O
S506|,|O
S506|tempo|O
S506|,|O
S506|and|O
S506|velocity|O
S506|parameters|O
S506|for|O
S506|each|O
S506|participant|O
S506|,|O
S506|which|O
S506|when|O
S506|applied|O
S506|to|O
S506|their|O
S506|curves|O
S506|made|O
S506|them|O
S506|all|O
S506|very|O
S506|similar|O
S506|,|O
S506|with|O
S506|a|O
S506|residual|O
S506|standard|O
S506|deviation|O
S506|of|O
S506|0.6|O
S506|mm|O
S506|around|O
S506|the|O
S506|summary|O
S506|curve|O
S506|(|O
S506|fig|O
S506|2|O
S506|,|O
S506|bottom|O
S506|panel|O
S506|)|O
S506|.|O
S773|Venous|O
S773|sampling|O
S773|and|O
S773|cytokine|O
S773|analysis|O
S773|Patients|O
S773|abstained|O
S773|from|O
S773|food|O
S773|and|O
S773|caffeine|O
S773|containing|O
S773|drinks|O
S773|for|O
S773|4|O
S773|h|O
S773|,|O
S773|and|O
S773|24|O
S773|h|O
S773|from|O
S773|ingestion|O
S773|of|O
S773|alcohol|O
S773|prior|O
S773|to|O
S773|phlebotomy|O
S773|.|O
S1118|Non-significant|O
S1118|correlation|O
S1118|indicates|O
S1118|that|O
S1118|there|O
S1118|is|O
S1118|not|O
S1118|enough|O
S1118|evidence|O
S1118|that|O
S1118|the|O
S1118|proportional|O
S1118|hazard|O
S1118|assumption|O
S1118|has|O
S1118|been|O
S1118|violated|O
S1118|.|O
S629|To|O
S629|verify|O
S629|that|O
S629|the|O
S629|effect|O
S629|of|O
S629|treatment|O
S629|would|O
S629|not|O
S629|vary|O
S629|substantially|O
S629|across|O
S629|relevant|O
S629|baseline|O
S629|subgroups|O
S629|,|O
S629|the|O
S629|number|O
S629|of|O
S629|new|O
S629|DUs|O
S629|up|O
S629|to|O
S629|week|O
S629|24|O
S629|was|O
S629|additionally|O
S629|analysed|O
S629|in|O
S629|subgroups|O
S629|based|O
S629|on|O
S629|predefined|O
S629|baseline|O
S629|factors|O
S629|associated|O
S629|with|O
S629|disease|O
S629|severity|O
S629|.|O
S2283|5|O
S2283|;|O
S2283|see|O
S2283|Additional|O
S2283|file|O
S2283|2|O
S2283|:|O
S2283|Table|O
S2283|S1|O
S2283|and|O
S2283|Additional|O
S2283|file|O
S2283|3|O
S2283|:|O
S2283|Table|O
S2283|S2|O
S2283|)|O
S2283|.|O
S640|Treatment|O
S640|effects|O
S640|for|O
S640|new|O
S640|DUs|O
S640|in|O
S640|predefined|O
S640|subgroups|O
S640|were|O
S640|presented|O
S640|as|O
S640|point|O
S640|estimates|O
S640|and|O
S640|95|O
S640|%|O
S640|two-sided|O
S640|CIs|O
S640|.|O
S1398|Results|O
S1398|Of|O
S1398|326|B-Sample_Size_Actual_at_Enrollment
S1398|patients|O
S1398|(|O
S1398|including|O
S1398|246|O
S1398|(|O
S1398|75.5|O
S1398|%|O
S1398|)|O
S1398|children|O
S1398|aged|O
S1398|<|O
S1398|15|O
S1398|)|O
S1398|,|O
S1398|165|O
S1398|and|O
S1398|161|O
S1398|were|O
S1398|randomised|O
S1398|to|O
S1398|double|B-Design_Parallel_Group
S1398|or|I-Design_Parallel_Group
S1398|standard|I-Design_Parallel_Group
S1398|dose|I-Design_Parallel_Group
S1398|oseltamivir|I-Design_Parallel_Group
S1398|,|O
S1398|respectively|O
S1398|.|O
S418|Those|O
S418|with|O
S418|evidence|O
S418|of|O
S418|ovarian|O
S418|failure|O
S418|at|O
S418|12|O
S418|years|O
S418|were|O
S418|further|O
S418|randomised|O
S418|to|O
S418|oral|B-Design_Parallel_Group
S418|ethinylestradiol|I-Design_Parallel_Group
S418|(|I-Design_Parallel_Group
S418|year|I-Design_Parallel_Group
S418|1|I-Design_Parallel_Group
S418|,|I-Design_Parallel_Group
S418|2|I-Design_Parallel_Group
S418|µg|I-Design_Parallel_Group
S418|daily|I-Design_Parallel_Group
S418|;|I-Design_Parallel_Group
S418|year|I-Design_Parallel_Group
S418|2|I-Design_Parallel_Group
S418|,|I-Design_Parallel_Group
S418|4|I-Design_Parallel_Group
S418|μg|I-Design_Parallel_Group
S418|daily|I-Design_Parallel_Group
S418|;|I-Design_Parallel_Group
S418|year|I-Design_Parallel_Group
S418|3|I-Design_Parallel_Group
S418|,|I-Design_Parallel_Group
S418|4|I-Design_Parallel_Group
S418|months|I-Design_Parallel_Group
S418|each|I-Design_Parallel_Group
S418|of|I-Design_Parallel_Group
S418|6|I-Design_Parallel_Group
S418|,|I-Design_Parallel_Group
S418|8|I-Design_Parallel_Group
S418|,|I-Design_Parallel_Group
S418|and|I-Design_Parallel_Group
S418|10|I-Design_Parallel_Group
S418|μg|I-Design_Parallel_Group
S418|daily|I-Design_Parallel_Group
S418|)|I-Design_Parallel_Group
S418|or|I-Design_Parallel_Group
S418|placebo|I-Design_Parallel_Group
S418|;|O
S418|participants|O
S418|who|O
S418|received|O
S418|placebo|O
S418|and|O
S418|those|O
S418|recruited|O
S418|after|O
S418|the|O
S418|age|O
S418|of|O
S418|12.25|O
S418|years|O
S418|started|O
S418|ethinylestradiol|O
S418|at|O
S418|age|O
S418|14|O
S418|.|O
S1736|Three|O
S1736|children|O
S1736|substituted|O
S1736|zidovudine|O
S1736|because|O
S1736|of|O
S1736|lipoatrophy|O
S1736|in|O
S1736|group|O
S1736|C|O
S1736|;|O
S1736|two|O
S1736|children|O
S1736|in|O
S1736|group|O
S1736|A|O
S1736|and|O
S1736|three|O
S1736|in|O
S1736|group|O
S1736|B|O
S1736|substituted|O
S1736|efavirenz|O
S1736|because|O
S1736|of|O
S1736|lipodystrophy|O
S1736|or|O
S1736|gynaecomastia|O
S1736|.|O
S767|A|O
S767|single|O
S767|subcutaneous|O
S767|25|O
S767|mg|O
S767|dose|O
S767|of|O
S767|etanercept|O
S767|improves|O
S767|endothelium-dependent|O
S767|vasodilatation|O
S767|within|O
S767|6|O
S767|h|O
S767|of|O
S767|administration|O
S767|in|O
S767|patients|O
S767|with|O
S767|heart|O
S767|failure|O
S767|.|O
S258|Methods|O
S258|In|O
S258|this|O
S258|double-blind|B-Blinding_Double_Blind
S258|,|O
S258|double-dummy|O
S258|,|O
S258|dose-ranging|O
S258|study|O
S258|,|O
S258|432|B-Sample_Size_Actual_at_Enrollment
S258|patients|O
S258|with|O
S258|gouty|O
S258|arthritis|O
S258|initiating|O
S258|allopurinol|O
S258|treatment|O
S258|were|O
S258|randomised|B-Randomization_Type_Simple
S258|1:1:1:1:1:1:2|B-Randomization_Ratio
S258|to|O
S258|receive|O
S258|:|O
S258|a|B-Design_Parallel_Group
S258|single|I-Design_Parallel_Group
S258|dose|I-Design_Parallel_Group
S258|of|I-Design_Parallel_Group
S258|canakinumab|I-Design_Parallel_Group
S258|,|I-Design_Parallel_Group
S258|25|I-Design_Parallel_Group
S258|,|I-Design_Parallel_Group
S258|50|I-Design_Parallel_Group
S258|,|I-Design_Parallel_Group
S258|100|I-Design_Parallel_Group
S258|,|I-Design_Parallel_Group
S258|200|I-Design_Parallel_Group
S258|,|I-Design_Parallel_Group
S258|or|I-Design_Parallel_Group
S258|300|I-Design_Parallel_Group
S258|mg|I-Design_Parallel_Group
S258|subcutaneously|I-Design_Parallel_Group
S258|;|I-Design_Parallel_Group
S258|4×4-weekly|I-Design_Parallel_Group
S258|doses|I-Design_Parallel_Group
S258|of|I-Design_Parallel_Group
S258|canakinumab|I-Design_Parallel_Group
S258|(|I-Design_Parallel_Group
S258|50+50+25+25|I-Design_Parallel_Group
S258|mg|I-Design_Parallel_Group
S258|subcutaneously|I-Design_Parallel_Group
S258|)|I-Design_Parallel_Group
S258|;|I-Design_Parallel_Group
S258|or|I-Design_Parallel_Group
S258|daily|I-Design_Parallel_Group
S258|colchicine|I-Design_Parallel_Group
S258|0.5|I-Design_Parallel_Group
S258|mg|I-Design_Parallel_Group
S258|orally|I-Design_Parallel_Group
S258|for|I-Design_Parallel_Group
S258|16|I-Design_Parallel_Group
S258|weeks|I-Design_Parallel_Group
S258|.|O
S2170|A|O
S2170|randomized|O
S2170|trial|O
S2170|of|O
S2170|the|O
S2170|efficacy|O
S2170|and|O
S2170|safety|O
S2170|of|O
S2170|quilizumab|O
S2170|in|O
S2170|adults|O
S2170|with|O
S2170|inadequately|O
S2170|controlled|O
S2170|allergic|O
S2170|asthma|O
S1238|Thrombolytic|O
S1238|therapy|O
S1238|with|O
S1238|intravenous|O
S1238|recombinant|O
S1238|tissue|O
S1238|plasminogen|O
S1238|activator|O
S1238|(|O
S1238|rt-PA|O
S1238|)|O
S1238|,|O
S1238|when|O
S1238|approved|O
S1238|in|O
S1238|Europe|O
S1238|,|O
S1238|was|O
S1238|restricted|O
S1238|to|O
S1238|the|O
S1238|treatment|O
S1238|of|O
S1238|patients|O
S1238|younger|O
S1238|than|O
S1238|80|O
S1238|years|O
S1238|of|O
S1238|age|O
S1238|with|O
S1238|acute|O
S1238|ischaemic|O
S1238|stroke|O
S1238|who|O
S1238|could|O
S1238|be|O
S1238|treated|O
S1238|within|O
S1238|3|O
S1238|h.|O
S1238|A|O
S1238|Cochrane|O
S1238|systematic|O
S1238|review|O
S1238|of|O
S1238|the|O
S1238|11|O
S1238|completed|O
S1238|trials|O
S1238|of|O
S1238|thrombolysis|O
S1238|(|O
S1238|including|O
S1238|3977|O
S1238|patients|O
S1238|)|O
S1238|with|O
S1238|intravenous|O
S1238|rt-PA|O
S1238|for|O
S1238|acute|O
S1238|ischaemic|O
S1238|stroke|O
S1238|showed|O
S1238|that|O
S1238|treatment|O
S1238|was|O
S1238|associated|O
S1238|with|O
S1238|a|O
S1238|significant|O
S1238|increase|O
S1238|in|O
S1238|survival|O
S1238|free|O
S1238|of|O
S1238|disability|O
S1238|,|O
S1238|despite|O
S1238|an|O
S1238|early|O
S1238|3|O
S1238|%|O
S1238|excess|O
S1238|of|O
S1238|fatal|O
S1238|intracranial|O
S1238|haemorrhage|O
S1238|.|O
S930|If|O
S930|multiple|O
S930|lesions|O
S930|were|O
S930|present|O
S930|,|O
S930|we|O
S930|designated|O
S930|the|O
S930|largest|O
S930|lesion|O
S930|that|O
S930|could|O
S930|be|O
S930|photographed|O
S930|on|O
S930|a|O
S930|single|O
S930|plane|O
S930|as|O
S930|the|O
S930|target|O
S930|lesion|O
S930|.|O
S1632|Once|O
S1632|randomised|O
S1632|,|O
S1632|allocation|B-Blinding_Open_Label
S1632|was|I-Blinding_Open_Label
S1632|open—ie|O
S1632|,|O
S1632|physicians|B-Blinding_Open_Label
S1632|and|I-Blinding_Open_Label
S1632|carers|I-Blinding_Open_Label
S1632|were|I-Blinding_Open_Label
S1632|aware|I-Blinding_Open_Label
S1632|of|I-Blinding_Open_Label
S1632|group|I-Blinding_Open_Label
S1632|assignment|I-Blinding_Open_Label
S1632|.|O
S2172|Background|O
S2172|Quilizumab|O
S2172|,|O
S2172|a|O
S2172|humanized|O
S2172|IgG1|O
S2172|monoclonal|O
S2172|antibody|O
S2172|,|O
S2172|targets|O
S2172|the|O
S2172|M1-prime|O
S2172|segment|O
S2172|of|O
S2172|membrane-expressed|O
S2172|IgE|O
S2172|,|O
S2172|leading|O
S2172|to|O
S2172|depletion|O
S2172|of|O
S2172|IgE-switched|O
S2172|and|O
S2172|memory|O
S2172|B|O
S2172|cells|O
S2172|.|O
S1428|Placebo|O
S1428|capsules|O
S1428|were|O
S1428|manufactured|O
S1428|by|O
S1428|the|O
S1428|pharmaceutical|O
S1428|development|O
S1428|section|O
S1428|at|O
S1428|the|O
S1428|National|O
S1428|Institutes|O
S1428|of|O
S1428|Health|O
S1428|Clinical|O
S1428|Center|O
S1428|(|O
S1428|Bethesda|O
S1428|,|O
S1428|MD|O
S1428|,|O
S1428|US|O
S1428|)|O
S1428|.|O
S512|The|O
S512|differences|O
S512|here|O
S512|were|O
S512|smaller|O
S512|,|O
S512|the|O
S512|curves|O
S512|diverging|O
S512|only|O
S512|after|O
S512|14|O
S512|years|O
S512|;|O
S512|the|O
S512|late|O
S512|versus|O
S512|early|O
S512|comparisons|O
S512|for|O
S512|size|O
S512|(|O
S512|+2.2|O
S512|cm|O
S512|)|O
S512|and|O
S512|velocity|O
S512|(|O
S512|−9|O
S512|%|O
S512|)|O
S512|were|O
S512|statistically|O
S512|insignificant|O
S512|(|O
S512|P|O
S512|>|O
S512|0.1|O
S512|)|O
S512|,|O
S512|whereas|O
S512|tempo|O
S512|was|O
S512|slightly|O
S512|delayed|O
S512|in|O
S512|the|O
S512|late|O
S512|induction|O
S512|arm|O
S512|(|O
S512|+0.4|O
S512|years|O
S512|;|O
S512|P=0.06|O
S512|)|O
S512|.|O
S1882|For|O
S1882|revascularisation|O
S1882|procedures|O
S1882|,|O
S1882|a|O
S1882|significant|O
S1882|24|O
S1882|%|O
S1882|(|O
S1882|SE|O
S1882|4|O
S1882|)|O
S1882|reduction|O
S1882|was|O
S1882|seen|O
S1882|during|O
S1882|the|O
S1882|in-trial|O
S1882|period|O
S1882|(|O
S1882|p|O
S1882|<|O
S1882|0·0001|O
S1882|)|O
S1882|.|O
S783|A|O
S783|baseline|O
S783|30|O
S783|min|O
S783|intra-arterial|O
S783|infusion|O
S783|of|O
S783|saline|O
S783|was|O
S783|followed|O
S783|by|O
S783|intra-arterial|O
S783|infusion|O
S783|of|O
S783|substance|O
S783|P|O
S783|at|O
S783|2|O
S783|,|O
S783|4|O
S783|and|O
S783|8|O
S783|pmol/min|O
S783|;|O
S783|then|O
S783|acetylcholine|O
S783|at|O
S783|5|O
S783|,|O
S783|10|O
S783|and|O
S783|20|O
S783|µg/min|O
S783|;|O
S783|and|O
S783|finally|O
S783|sodium|O
S783|nitroprusside|O
S783|at|O
S783|2|O
S783|,|O
S783|4|O
S783|and|O
S783|8|O
S783|μg/min|O
S783|,|O
S783|infused|O
S783|for|O
S783|10|O
S783|min|O
S783|at|O
S783|each|O
S783|dose|O
S783|with|O
S783|each|O
S783|agonist|O
S783|separated|O
S783|by|O
S783|a|O
S783|20|O
S783|min|O
S783|saline|O
S783|infusion|O
S783|.|O
S2266|At|O
S2266|treatment|O
S2266|Weeks|O
S2266|4|O
S2266|,|O
S2266|12|O
S2266|,|O
S2266|and|O
S2266|24|O
S2266|,|O
S2266|the|O
S2266|mean|O
S2266|trough|O
S2266|serum|O
S2266|concentrations|O
S2266|of|O
S2266|quilizumab|O
S2266|were|O
S2266|:|O
S2266|(|O
S2266|150|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|5.7|O
S2266|±|O
S2266|2.3|O
S2266|μg/mL|O
S2266|,|O
S2266|2.6|O
S2266|±|O
S2266|2.0|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|1.3|O
S2266|±|O
S2266|4.6|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|(|O
S2266|450|O
S2266|mg|O
S2266|Q|O
S2266|)|O
S2266|17.1|O
S2266|±|O
S2266|7.0|O
S2266|μg/mL|O
S2266|,|O
S2266|7.2|O
S2266|±|O
S2266|3.8|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|2.3|O
S2266|±|O
S2266|2.2|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|;|O
S2266|and|O
S2266|(|O
S2266|300|O
S2266|mg|O
S2266|M|O
S2266|)|O
S2266|11.6|O
S2266|±|O
S2266|4.5|O
S2266|μg/mL|O
S2266|,|O
S2266|16.7|O
S2266|±|O
S2266|6.7|O
S2266|μg/mL|O
S2266|,|O
S2266|and|O
S2266|16.8|O
S2266|±|O
S2266|7.7|O
S2266|μg/mL|O
S2266|,|O
S2266|respectively|O
S2266|.|O
S822|Plasma|O
S822|PAI-1|O
S822|antigen|O
S822|concentrations|O
S822|were|O
S822|similar|O
S822|between|O
S822|the|O
S822|groups|O
S822|at|O
S822|baseline|O
S822|and|O
S822|did|O
S822|not|O
S822|differ|O
S822|following|O
S822|either|O
S822|treatment|O
S822|(|O
S822|p|O
S822|>|O
S822|0.1|O
S822|)|O
S822|.|O
S2202|These|O
S2202|decreases|O
S2202|were|O
S2202|sustained|O
S2202|for|O
S2202|at|O
S2202|least|O
S2202|6|O
S2202|months|O
S2202|after|O
S2202|the|O
S2202|last|O
S2202|dose|O
S2202|,|O
S2202|in|O
S2202|contrast|O
S2202|to|O
S2202|omalizumab|O
S2202|,|O
S2202|which|O
S2202|must|O
S2202|be|O
S2202|administered|O
S2202|every|O
S2202|2–4|O
S2202|weeks|O
S2202|to|O
S2202|maintain|O
S2202|reduced|O
S2202|IgE|O
S2202|levels|O
S2202|.|O
S92|Only|O
S92|two|O
S92|adverse|O
S92|event|O
S92|terms|O
S92|were|O
S92|reported|O
S92|in|O
S92|either|O
S92|study|O
S92|at|O
S92|a|O
S92|rate|O
S92|of|O
S92|≥5|O
S92|%|O
S92|:|O
S92|dyspepsia|O
S92|and|O
S92|nausea|O
S92|.|O
S776|Citrate|O
S776|and|O
S776|acidified|O
S776|buffered|O
S776|citrate|O
S776|samples|O
S776|were|O
S776|centrifuged|O
S776|at|O
S776|2000|O
S776|g|O
S776|for|O
S776|30|O
S776|min|O
S776|at|O
S776|4°C|O
S776|and|O
S776|EDTA|O
S776|samples|O
S776|at|O
S776|1000|O
S776|g|O
S776|for|O
S776|10|O
S776|min|O
S776|at|O
S776|20°C|O
S776|.|O
S513|Adverse|O
S513|events|O
S513|Between|O
S513|1999|O
S513|and|O
S513|2009|O
S513|,|O
S513|197|O
S513|adverse|O
S513|events|O
S513|were|O
S513|reported|O
S513|;|O
S513|none|O
S513|of|O
S513|them|O
S513|were|O
S513|suspected|O
S513|to|O
S513|be|O
S513|unexpected|O
S513|serious|O
S513|adverse|O
S513|reactions|O
S513|.|O
S919|As|O
S919|a|O
S919|result|O
S919|,|O
S919|clinicians|O
S919|and|O
S919|participants|O
S919|were|O
S919|informed|O
S919|of|O
S919|their|O
S919|treatment|O
S919|allocation|O
S919|once|O
S919|data|O
S919|had|O
S919|been|O
S919|irrevocably|O
S919|entered|O
S919|into|O
S919|the|O
S919|randomisation|O
S919|database|O
S919|.|O
S1470|A|O
S1470|further|O
S1470|13|O
S1470|(|O
S1470|3.9|O
S1470|%|O
S1470|)|O
S1470|were|O
S1470|positive|O
S1470|by|O
S1470|rapid|O
S1470|antigen|O
S1470|test|O
S1470|but|O
S1470|negative|O
S1470|by|O
S1470|RT-PCR|O
S1470|.|O
S1995|A|O
S1995|paired|O
S1995|t-test|O
S1995|was|O
S1995|used|O
S1995|to|O
S1995|compare|O
S1995|values|O
S1995|of|O
S1995|continuous|O
S1995|normally|O
S1995|distributed|O
S1995|variables|O
S1995|with|O
S1995|baseline|O
S1995|values|O
S1995|,|O
S1995|and|O
S1995|an|O
S1995|unpaired|O
S1995|t-test|O
S1995|was|O
S1995|used|O
S1995|to|O
S1995|compare|O
S1995|values|O
S1995|of|O
S1995|continuous|O
S1995|variables|O
S1995|between|O
S1995|groups|O
S1995|.|O
S2095|The|O
S2095|PPN|O
S2095|is|O
S2095|particularly|O
S2095|involved|O
S2095|in|O
S2095|posture|O
S2095|and|O
S2095|gait|O
S2095|control|O
S2095|.|O
S24|Mechanisms|O
S24|that|O
S24|ensure|O
S24|adherence|O
S24|to|O
S24|protective|O
S24|therapy|O
S24|,|O
S24|such|O
S24|as|O
S24|the|O
S24|combination|O
S24|of|O
S24|an|O
S24|NSAID|O
S24|and|O
S24|a|O
S24|protective|O
S24|agent|O
S24|in|O
S24|one|O
S24|pill|O
S24|,|O
S24|theoretically|O
S24|should|O
S24|decrease|O
S24|the|O
S24|GI|O
S24|risk|O
S24|associated|O
S24|with|O
S24|the|O
S24|NSAID|O
S24|therapy|O
S24|.|O
S1294|This|O
S1294|sample|O
S1294|size|O
S1294|gave|O
S1294|80|B-Sample_Size_Calculation_Power_Value
S1294|%|I-Sample_Size_Calculation_Power_Value
S1294|power|O
S1294|to|O
S1294|detect|O
S1294|an|O
S1294|absolute|O
S1294|difference|O
S1294|of|O
S1294|4·7|O
S1294|%|O
S1294|in|O
S1294|the|O
S1294|primary|O
S1294|outcome|O
S1294|.|O
S1231|Interpretation|O
S1231|For|O
S1231|the|O
S1231|types|O
S1231|of|O
S1231|patient|O
S1231|recruited|O
S1231|in|O
S1231|IST-3|O
S1231|,|O
S1231|despite|O
S1231|the|O
S1231|early|O
S1231|hazards|O
S1231|,|O
S1231|thrombolysis|O
S1231|within|O
S1231|6|O
S1231|h|O
S1231|improved|O
S1231|functional|O
S1231|outcome|O
S1231|.|O
S2010|Of|O
S2010|those|O
S2010|enrolled|O
S2010|,|O
S2010|68|O
S2010|(|O
S2010|94|O
S2010|%|O
S2010|)|O
S2010|completed|O
S2010|24|O
S2010|weeks|O
S2010|of|O
S2010|treatment|O
S2010|.|O
S1834|At|O
S1834|the|O
S1834|final|O
S1834|follow-up|O
S1834|(|O
S1834|May–October|O
S1834|,|O
S1834|2001|O
S1834|)|O
S1834|,|O
S1834|participants|O
S1834|were|O
S1834|encouraged|O
S1834|to|O
S1834|continue|O
S1834|their|O
S1834|allocated|O
S1834|study|O
S1834|treatment|O
S1834|(|O
S1834|unless|O
S1834|it|O
S1834|was|O
S1834|contraindicated|O
S1834|)|O
S1834|until|O
S1834|the|O
S1834|study|O
S1834|results|O
S1834|were|O
S1834|sent|O
S1834|to|O
S1834|them|O
S1834|and|O
S1834|their|O
S1834|family|O
S1834|doctors|O
S1834|on|O
S1834|Nov|O
S1834|11|O
S1834|,|O
S1834|2001|O
S1834|.|O
S2089|These|O
S2089|benefits|O
S2089|must|O
S2089|be|O
S2089|confirmed|O
S2089|in|O
S2089|a|O
S2089|broader|O
S2089|population|O
S2089|of|O
S2089|patients|O
S2089|.|O
S142|To|O
S142|further|O
S142|explore|O
S142|the|O
S142|dose–response|O
S142|curve|O
S142|in|O
S142|asthma|O
S142|,|O
S142|we|O
S142|investigated|O
S142|the|O
S142|efficacy|O
S142|and|O
S142|safety|O
S142|of|O
S142|three|O
S142|different|O
S142|doses|O
S142|of|O
S142|tiotropium|O
S142|Respimat®|O
S142|as|O
S142|add-on|O
S142|to|O
S142|ICS|O
S142|in|O
S142|symptomatic|O
S142|patients|O
S142|with|O
S142|moderate|O
S142|persistent|O
S142|asthma|O
S142|.|O
S310|The|O
S310|main|O
S310|secondary|O
S310|outcome|O
S310|was|O
S310|the|O
S310|mean|O
S310|number|O
S310|of|O
S310|flares|O
S310|per|O
S310|patient|O
S310|at|O
S310|16|O
S310|weeks|O
S310|.|O
S1436|Swabs|O
S1436|were|O
S1436|obtained|O
S1436|for|O
S1436|virus|O
S1436|detection|O
S1436|in|O
S1436|the|O
S1436|nose|O
S1436|and|O
S1436|throat|O
S1436|on|O
S1436|days|O
S1436|0|O
S1436|to|O
S1436|10|O
S1436|and|O
S1436|day|O
S1436|14|O
S1436|.|O
S226|The|O
S226|largest|O
S226|adjusted|O
S226|mean|O
S226|difference|O
S226|from|O
S226|placebo|O
S226|Respimat®|O
S226|was|O
S226|observed|O
S226|with|O
S226|tiotropium|O
S226|Respimat®|O
S226|5|O
S226|μg|O
S226|(|O
S226|188|O
S226|mL|O
S226|,|O
S226|95|O
S226|%|O
S226|confidence|O
S226|interval|O
S226|:|O
S226|140|O
S226|,|O
S226|236|O
S226|)|O
S226|.|O
S1986|Serum|O
S1986|calcium|O
S1986|,|O
S1986|phosphorus|O
S1986|,|O
S1986|alkaline|O
S1986|phosphatase|O
S1986|and|O
S1986|albumin|O
S1986|were|O
S1986|measured|O
S1986|with|O
S1986|standard|O
S1986|methods|O
S1986|.|O
S1242|The|O
S1242|Third|O
S1242|International|O
S1242|Stroke|O
S1242|Trial|O
S1242|(|O
S1242|IST-3|O
S1242|)|O
S1242|,|O
S1242|therefore|O
S1242|,|O
S1242|had|O
S1242|the|O
S1242|following|O
S1242|objectives|O
S1242|:|O
S1242|to|O
S1242|establish|O
S1242|the|O
S1242|balance|O
S1242|of|O
S1242|benefits|O
S1242|and|O
S1242|harms|O
S1242|of|O
S1242|thrombolytic|O
S1242|therapy|O
S1242|with|O
S1242|rt-PA|O
S1242|in|O
S1242|patients|O
S1242|who|O
S1242|did|O
S1242|not|O
S1242|exactly|O
S1242|meet|O
S1242|the|O
S1242|licence|O
S1242|criteria|O
S1242|(|O
S1242|especially|O
S1242|elderly|O
S1242|patients|O
S1242|)|O
S1242|;|O
S1242|determine|O
S1242|whether|O
S1242|a|O
S1242|wider|O
S1242|range|O
S1242|of|O
S1242|patients|O
S1242|might|O
S1242|benefit|O
S1242|from|O
S1242|this|O
S1242|treatment|O
S1242|;|O
S1242|assess|O
S1242|which|O
S1242|categories|O
S1242|of|O
S1242|patients|O
S1242|were|O
S1242|most|O
S1242|likely|O
S1242|to|O
S1242|benefit|O
S1242|by|O
S1242|investigating|O
S1242|possible|O
S1242|interactions|O
S1242|between|O
S1242|treatment|O
S1242|effect|O
S1242|and|O
S1242|various|O
S1242|factors|O
S1242|(|O
S1242|including|O
S1242|age|O
S1242|,|O
S1242|stroke|O
S1242|severity|O
S1242|,|O
S1242|and|O
S1242|early|O
S1242|brain|O
S1242|imaging|O
S1242|results|O
S1242|)|O
S1242|;|O
S1242|refine|O
S1242|current|O
S1242|estimates|O
S1242|of|O
S1242|the|O
S1242|duration|O
S1242|of|O
S1242|the|O
S1242|therapeutic|O
S1242|time|O
S1242|window|O
S1242|;|O
S1242|and|O
S1242|to|O
S1242|improve|O
S1242|the|O
S1242|external|O
S1242|validity|O
S1242|and|O
S1242|precision|O
S1242|of|O
S1242|the|O
S1242|existing|O
S1242|estimates|O
S1242|of|O
S1242|the|O
S1242|overall|O
S1242|treat-ment|O
S1242|effects|O
S1242|(|O
S1242|benefits|O
S1242|and|O
S1242|harms|O
S1242|)|O
S1242|.|O
S1667|Only|O
S1667|33|O
S1667|(|O
S1667|3|O
S1667|%|O
S1667|)|O
S1667|children|O
S1667|(|O
S1667|median|O
S1667|follow-up|O
S1667|150|O
S1667|[|O
S1667|IQR|O
S1667|46–169|O
S1667|]|O
S1667|weeks|O
S1667|)|O
S1667|not|O
S1667|known|O
S1667|to|O
S1667|have|O
S1667|died|O
S1667|were|O
S1667|not|O
S1667|seen|O
S1667|after|O
S1667|trial|O
S1667|closure|O
S1667|(|O
S1667|figure|O
S1667|1|O
S1667|)|O
S1667|.|O
S1322|Additional|O
S1322|baseline|O
S1322|characteristics|O
S1322|are|O
S1322|shown|O
S1322|in|O
S1322|appendix|O
S1322|pp|O
S1322|2–3|O
S1322|.|O
S345|Six|O
S345|serious|O
S345|infections|O
S345|(|O
S345|erysipelas|O
S345|,|O
S345|gangrene|O
S345|,|O
S345|sepsis|O
S345|,|O
S345|tonsillitis|O
S345|,|O
S345|ear|O
S345|infection|O
S345|and|O
S345|pneumonia|O
S345|)|O
S345|were|O
S345|reported|O
S345|in|O
S345|four|O
S345|patients|O
S345|receiving|O
S345|canakinumab|O
S345|(|O
S345|table|O
S345|3|O
S345|)|O
S345|.|O
S176|All|O
S176|patients|O
S176|provided|O
S176|written|O
S176|,|O
S176|informed|O
S176|consent|O
S176|.|O
S984|Secondary|O
S984|outcomes|O
S984|did|O
S984|not|O
S984|differ|O
S984|significantly|O
S984|between|O
S984|the|O
S984|treatment|O
S984|groups|O
S984|,|O
S984|including|O
S984|global|O
S984|assessments|O
S984|of|O
S984|efficacy|O
S984|(|O
S984|fig|O
S984|3|O
S984|)|O
S984|,|O
S984|resolution|O
S984|of|O
S984|inflammation|O
S984|(|O
S984|tables|O
S984|4|O
S984|and|O
S984|5|O
S984|)|O
S984|,|O
S984|self|O
S984|reported|O
S984|pain|O
S984|in|O
S984|the|O
S984|first|O
S984|six|O
S984|weeks|O
S984|,|O
S984|quality|O
S984|of|O
S984|life|O
S984|over|O
S984|the|O
S984|duration|O
S984|of|O
S984|the|O
S984|study|O
S984|(|O
S984|table|O
S984|6|O
S984|)|O
S984|,|O
S984|health|O
S984|related|O
S984|quality|O
S984|of|O
S984|life|O
S984|(|O
S984|table|O
S984|6|O
S984|)|O
S984|,|O
S984|and|O
S984|time|O
S984|to|O
S984|recurrence|O
S984|(|O
S984|table|O
S984|3|O
S984|)|O
S984|.|O
S1318|Baseline|O
S1318|characteristics|O
S1318|were|O
S1318|well|O
S1318|balanced|O
S1318|between|O
S1318|treatment|O
S1318|groups|O
S1318|(|O
S1318|figure|O
S1318|1|O
S1318|,|O
S1318|table|O
S1318|1|O
S1318|)|O
S1318|.|O
S1854|Analyses|O
S1854|are|O
S1854|presented|O
S1854|of|O
S1854|other|O
S1854|outcomes|O
S1854|,|O
S1854|some|O
S1854|of|O
S1854|which|O
S1854|(|O
S1854|eg|O
S1854|,|O
S1854|site-specific|O
S1854|cancer|O
S1854|,|O
S1854|cerebral|O
S1854|haemorrhage|O
S1854|)|O
S1854|were|O
S1854|prespecified|O
S1854|for|O
S1854|the|O
S1854|in-trial|O
S1854|period|O
S1854|whereas|O
S1854|some|O
S1854|were|O
S1854|not|O
S1854|(|O
S1854|eg|O
S1854|,|O
S1854|cancer|O
S1854|incidence|O
S1854|each|O
S1854|year|O
S1854|)|O
S1854|.|O
S312|However|O
S312|,|O
S312|as|O
S312|the|O
S312|distribution|O
S312|of|O
S312|flares|O
S312|per|O
S312|patient|O
S312|was|O
S312|observed|O
S312|to|O
S312|be|O
S312|skewed|O
S312|,|O
S312|the|O
S312|preplanned|O
S312|ANCOVA|O
S312|was|O
S312|considered|O
S312|inappropriate|O
S312|for|O
S312|these|O
S312|data|O
S312|.|O
S36|Serum|O
S36|chemistries|O
S36|,|O
S36|complete|O
S36|blood|O
S36|count|O
S36|,|O
S36|and|O
S36|prothrombin|O
S36|time|O
S36|were|O
S36|performed|O
S36|at|O
S36|screening|O
S36|,|O
S36|week|O
S36|8|O
S36|,|O
S36|week|O
S36|16|O
S36|,|O
S36|and|O
S36|the|O
S36|final|O
S36|study|O
S36|visit|O
S36|(|O
S36|week|O
S36|24|O
S36|or|O
S36|earlier|O
S36|if|O
S36|early|O
S36|termination|O
S36|)|O
S36|.|O
S191|Study|O
S191|patients|O
S191|Male|O
S191|or|O
S191|female|O
S191|patients|O
S191|aged|O
S191|18–75|O
S191|years|O
S191|,|O
S191|with|O
S191|at|O
S191|least|O
S191|a|O
S191|3-month|O
S191|history|O
S191|of|O
S191|asthma|O
S191|at|O
S191|the|O
S191|time|O
S191|of|O
S191|enrolment|O
S191|and|O
S191|an|O
S191|initial|O
S191|diagnosis|O
S191|of|O
S191|asthma|O
S191|made|O
S191|before|O
S191|the|O
S191|age|O
S191|of|O
S191|40|O
S191|years|O
S191|,|O
S191|were|O
S191|included|O
S191|in|O
S191|the|O
S191|study|O
S191|.|O
S1649|Interim|O
S1649|data|O
S1649|were|O
S1649|reviewed|O
S1649|annually|O
S1649|by|O
S1649|an|O
S1649|independent|O
S1649|data|O
S1649|monitoring|O
S1649|committee|O
S1649|(|O
S1649|four|O
S1649|meetings|O
S1649|)|O
S1649|using|O
S1649|the|O
S1649|Haybittle-Peto|O
S1649|criterion|O
S1649|(|O
S1649|p|O
S1649|<|O
S1649|0·001|O
S1649|)|O
S1649|.|O
S1124|The|O
S1124|mean|O
S1124|number|O
S1124|of|O
S1124|visits|O
S1124|to|O
S1124|the|O
S1124|clinic|O
S1124|or|O
S1124|general|O
S1124|practice|O
S1124|for|O
S1124|cryotherapy|O
S1124|was|O
S1124|3.6|O
S1124|,|O
S1124|with|O
S1124|a|O
S1124|mean|O
S1124|duration|O
S1124|between|O
S1124|visits|O
S1124|of|O
S1124|18.3|O
S1124|days|O
S1124|.|O
S148|The|O
S148|primary|O
S148|efficacy|O
S148|end|O
S148|point|O
S148|was|O
S148|peak|O
S148|FEV1|O
S148|measured|O
S148|within|O
S148|3|O
S148|hours|O
S148|after|O
S148|dosing|O
S148|(|O
S148|peak|O
S148|FEV1|O
S148|(|O
S148|0-3h|O
S148|)|O
S148|)|O
S148|at|O
S148|the|O
S148|end|O
S148|of|O
S148|each|O
S148|4-week|O
S148|period|O
S148|,|O
S148|analysed|O
S148|as|O
S148|a|O
S148|response|O
S148|(|O
S148|change|O
S148|from|O
S148|study|O
S148|baseline|O
S148|)|O
S148|.|O
S628|Maintenance|O
S628|of|O
S628|cardinal|O
S628|ulcer|O
S628|healing|O
S628|required|O
S628|no|O
S628|recurrence|O
S628|at|O
S628|or|O
S628|contiguous|O
S628|to|O
S628|the|O
S628|original|O
S628|location|O
S628|at|O
S628|week|O
S628|24|O
S628|(|O
S628|if|O
S628|healing|O
S628|occurred|O
S628|before|O
S628|or|O
S628|at|O
S628|week|O
S628|12|O
S628|)|O
S628|or|O
S628|during|O
S628|12|O
S628|weeks|O
S628|of|O
S628|observation|O
S628|with|O
S628|permissible|O
S628|extension|O
S628|of|O
S628|the|O
S628|treatment|O
S628|period|O
S628|(|O
S628|if|O
S628|healing|O
S628|occurred|O
S628|after|O
S628|week|O
S628|12|O
S628|)|O
S628|.|O
S2180|Biomarker|O
S2180|subgroups|O
S2180|did|O
S2180|not|O
S2180|reveal|O
S2180|meaningful|O
S2180|efficacy|O
S2180|benefits|O
S2180|following|O
S2180|quilizumab|O
S2180|treatment|O
S2180|.|O
S309|For|O
S309|determination|O
S309|of|O
S309|the|O
S309|primary|O
S309|outcome|O
S309|,|O
S309|the|O
S309|number|O
S309|of|O
S309|flares|O
S309|per|O
S309|patient|O
S309|during|O
S309|16|O
S309|weeks|O
S309|was|O
S309|modelled|O
S309|using|O
S309|a|O
S309|negative|O
S309|binomial|O
S309|distribution|O
S309|and|O
S309|a|O
S309|common|O
S309|overdispersion|O
S309|(|O
S309|variance|O
S309|divided|O
S309|by|O
S309|expectation|O
S309|minus|O
S309|1|O
S309|)|O
S309|for|O
S309|all|O
S309|treatment|O
S309|arms|O
S309|(|O
S309|see|O
S309|supplementary|O
S309|material|O
S309|for|O
S309|more|O
S309|details|O
S309|)|O
S309|.|O
S1275|Additional|O
S1275|secondary|O
S1275|outcomes|O
S1275|were|O
S1275|to|O
S1275|be|O
S1275|reported|O
S1275|separately|O
S1275|.|O
S25|We|O
S25|performed|O
S25|the|O
S25|REDUCE|O
S25|trials|O
S25|(|O
S25|Registration|O
S25|Endoscopic|O
S25|Studies|O
S25|to|O
S25|Determine|O
S25|Ulcer|O
S25|Formation|O
S25|of|O
S25|HZT-501|O
S25|Compared|O
S25|with|O
S25|Ibuprofen|O
S25|:|O
S25|Efficacy|O
S25|and|O
S25|Safety|O
S25|Studies|O
S25|)|O
S25|to|O
S25|assess|O
S25|whether|O
S25|double-dose|O
S25|famotidine|O
S25|given|O
S25|in|O
S25|a|O
S25|single-tablet|O
S25|combination|O
S25|with|O
S25|ibuprofen|O
S25|(|O
S25|HZT-501|O
S25|(|O
S25|ibuprofen|O
S25|800|O
S25|mg|O
S25|plus|O
S25|famotidine|O
S25|26.6|O
S25|mg|O
S25|)|O
S25|;|O
S25|Horizon|O
S25|Pharma|O
S25|,|O
S25|Northbrook|O
S25|,|O
S25|IL|O
S25|)|O
S25|significantly|O
S25|reduces|O
S25|the|O
S25|proportion|O
S25|of|O
S25|patients|O
S25|who|O
S25|develop|O
S25|gastric|O
S25|ulcers|O
S25|(|O
S25|REDUCE-1|O
S25|)|O
S25|or|O
S25|upper|O
S25|GI|O
S25|(|O
S25|gastric|O
S25|or|O
S25|duodenal|O
S25|)|O
S25|ulcers|O
S25|(|O
S25|REDUCE-2|O
S25|)|O
S25|during|O
S25|24|O
S25|weeks|O
S25|of|O
S25|treatment|O
S25|as|O
S25|compared|O
S25|with|O
S25|ibuprofen|O
S25|in|O
S25|adult|O
S25|NSAID|O
S25|users|O
S25|.|O
S818|Fibrinolytic|O
S818|response|O
S818|Plasma|O
S818|t-PA|O
S818|activity|O
S818|concentrations|O
S818|were|O
S818|similar|O
S818|between|O
S818|groups|O
S818|at|O
S818|baseline|O
S818|and|O
S818|were|O
S818|unaffected|O
S818|by|O
S818|saline|O
S818|placebo|O
S818|(|O
S818|p=1.0|O
S818|)|O
S818|.|O
S1847|The|O
S1847|effects|O
S1847|of|O
S1847|treatment|O
S1847|allocation|O
S1847|on|O
S1847|cholesterol|O
S1847|concentrations|O
S1847|were|O
S1847|assessed|O
S1847|by|O
S1847|assaying|O
S1847|blood|O
S1847|obtained|O
S1847|at|O
S1847|study|O
S1847|clinics|O
S1847|from|O
S1847|a|O
S1847|sample|O
S1847|of|O
S1847|about|O
S1847|5|O
S1847|%|O
S1847|of|O
S1847|participants|O
S1847|scheduled|O
S1847|for|O
S1847|follow-up|O
S1847|at|O
S1847|about|O
S1847|the|O
S1847|same|O
S1847|time|O
S1847|each|O
S1847|year|O
S1847|,|O
S1847|and|O
S1847|from|O
S1847|all|O
S1847|participants|O
S1847|attending|O
S1847|follow-up|O
S1847|between|O
S1847|August|O
S1847|,|O
S1847|2000|O
S1847|,|O
S1847|and|O
S1847|February|O
S1847|,|O
S1847|2001|O
S1847|.|O
S1393|Design|O
S1393|Double|B-Blinding_Double_Blind
S1393|blind|I-Blinding_Double_Blind
S1393|randomised|O
S1393|trial|O
S1393|.|O
S791|Immunolabelling|O
S791|was|O
S791|performed|O
S791|on|O
S791|whole|O
S791|blood|O
S791|to|O
S791|avoid|O
S791|artefactual|O
S791|platelet|O
S791|activation|O
S791|caused|O
S791|by|O
S791|purification|O
S791|procedures|O
S791|.|O
S932|Assessing|O
S932|the|O
S932|primary|O
S932|outcome|O
S932|at|O
S932|six|O
S932|weeks|O
S932|also|O
S932|minimised|O
S932|loss|O
S932|to|O
S932|follow-up|O
S932|and|O
S932|the|O
S932|impact|O
S932|of|O
S932|participants|O
S932|switching|O
S932|to|O
S932|alternative|O
S932|treatments|O
S932|before|O
S932|primary|O
S932|outcome|O
S932|assessment|O
S932|.|O
S1947|In|O
S1947|the|O
S1947|Ca+D|O
S1947|and|O
S1947|Ca|O
S1947|groups|O
S1947|,|O
S1947|the|O
S1947|final|O
S1947|25|O
S1947|(|O
S1947|OH|O
S1947|)|O
S1947|D|O
S1947|concentration|O
S1947|was|O
S1947|greater|O
S1947|in|O
S1947|those|O
S1947|who|O
S1947|achieved|O
S1947|the|O
S1947|primary|O
S1947|outcome|O
S1947|(|O
S1947|56.4±17.2|O
S1947|nmol/L|O
S1947|)|O
S1947|than|O
S1947|in|O
S1947|those|O
S1947|who|O
S1947|did|O
S1947|not|O
S1947|(|O
S1947|37.7±18.5|O
S1947|nmol/L|O
S1947|,|O
S1947|p|O
S1947|<|O
S1947|0.001|O
S1947|)|O
S1947|.|O
S483|Results|O
S483|One|B-Sample_Size_Actual_at_Enrollment
S483|hundred|I-Sample_Size_Actual_at_Enrollment
S483|and|I-Sample_Size_Actual_at_Enrollment
S483|six|I-Sample_Size_Actual_at_Enrollment
S483|girls|I-Sample_Size_Actual_at_Enrollment
S483|with|O
S483|Turner|O
S483|’|O
S483|s|O
S483|syndrome|O
S483|were|O
S483|recruited|O
S483|from|O
S483|36|B-Settings_Multicenter
S483|UK|B-Settings_Location
S483|hospitals|I-Settings_Multicenter
S483|between|O
S483|1999|O
S483|and|O
S483|2003|O
S483|,|O
S483|of|O
S483|whom|O
S483|14|O
S483|withdrew|O
S483|(|O
S483|four|O
S483|of|O
S483|them|O
S483|because|O
S483|of|O
S483|early|O
S483|organisational|O
S483|errors|O
S483|)|O
S483|,|O
S483|leaving|O
S483|92|B-Sample_Size_Actual_at_Outcome_Analysis
S483|to|O
S483|complete|O
S483|the|O
S483|study|O
S483|(|O
S483|fig|O
S483|1|O
S483|)|O
S483|.|O
S1871|During|O
S1871|the|O
S1871|in-trial|O
S1871|period|O
S1871|,|O
S1871|2153|O
S1871|(|O
S1871|21·0|O
S1871|%|O
S1871|)|O
S1871|first|O
S1871|major|O
S1871|vascular|O
S1871|events|O
S1871|arose|O
S1871|in|O
S1871|10|O
S1871|269|O
S1871|participants|O
S1871|allocated|O
S1871|simvastatin|O
S1871|versus|O
S1871|2712|O
S1871|(|O
S1871|26·4|O
S1871|%|O
S1871|)|O
S1871|in|O
S1871|10|O
S1871|267|O
S1871|allocated|O
S1871|placebo|O
S1871|,|O
S1871|corresponding|O
S1871|to|O
S1871|a|O
S1871|significant|O
S1871|23|O
S1871|%|O
S1871|(|O
S1871|SE|O
S1871|3|O
S1871|)|O
S1871|proportional|O
S1871|reduction|O
S1871|(|O
S1871|p|O
S1871|<|O
S1871|0·0001|O
S1871|:|O
S1871|figure|O
S1871|1|O
S1871|)|O
S1871|.|O
S209|Statistical|O
S209|analyses|O
S209|Efficacy|O
S209|data|O
S209|are|O
S209|reported|O
S209|for|O
S209|the|O
S209|full|O
S209|analysis|O
S209|set|O
S209|,|O
S209|which|O
S209|was|O
S209|defined|O
S209|as|O
S209|all|O
S209|randomised|O
S209|patients|O
S209|who|O
S209|were|O
S209|treated|O
S209|with|O
S209|at|O
S209|least|O
S209|one|O
S209|dose|O
S209|of|O
S209|study|O
S209|medication|O
S209|,|O
S209|had|O
S209|baseline|O
S209|data|O
S209|and|O
S209|had|O
S209|at|O
S209|least|O
S209|one|O
S209|on-treatment|O
S209|efficacy|O
S209|measurement|O
S209|after|O
S209|4|O
S209|weeks|O
S209|of|O
S209|treatment|O
S209|within|O
S209|a|O
S209|period|O
S209|.|O
S913|Topical|O
S913|treatment|O
S913|was|O
S913|prohibited|O
S913|during|O
S913|the|O
S913|trial|O
S913|.|O
S1670|Panel|O
S1670|tests|O
S1670|could|O
S1670|also|O
S1670|be|O
S1670|requested|O
S1670|in|O
S1670|both|O
S1670|groups|O
S1670|at|O
S1670|extra|O
S1670|patient-initiated|O
S1670|visits|O
S1670|.|O
S2088|Conclusions|O
S2088|Memantine|O
S2088|treatment|O
S2088|was|O
S2088|associated|O
S2088|with|O
S2088|lower|O
S2088|axial|O
S2088|motor|O
S2088|symptom|O
S2088|and|O
S2088|dyskinesia|O
S2088|scores|O
S2088|but|O
S2088|did|O
S2088|not|O
S2088|improve|O
S2088|gait|O
S2088|.|O
S311|Data|O
S311|were|O
S311|analysed|O
S311|according|O
S311|to|O
S311|an|O
S311|analysis|O
S311|of|O
S311|covariance|O
S311|(|O
S311|ANCOVA|O
S311|)|O
S311|with|O
S311|treatment|O
S311|group|O
S311|,|O
S311|allopurinol|O
S311|dose|O
S311|at|O
S311|baseline|O
S311|and|O
S311|BMI|O
S311|at|O
S311|baseline|O
S311|as|O
S311|covariates|O
S311|.|O
S2119|Stride|O
S2119|length|O
S2119|was|O
S2119|assessed|O
S2119|in|O
S2119|an|O
S2119|optoelectronic|O
S2119|analysis|O
S2119|with|O
S2119|a|O
S2119|6-camera|O
S2119|VICON|O
S2119|Video|O
S2119|System|O
S2119|from|O
S2119|Oxford|O
S2119|Metrics|O
S2119|(|O
S2119|Oxford|O
S2119|,|O
S2119|UK|O
S2119|)|O
S2119|(|O
S2119|sampling|O
S2119|rate|O
S2119|:|O
S2119|50|O
S2119|Hz|O
S2119|)|O
S2119|.|O
S963|Baseline|O
S963|characteristics|O
S963|were|O
S963|balanced|O
S963|between|O
S963|the|O
S963|groups|O
S963|(|O
S963|table|O
S963|1|O
S963|)|O
S963|.|O
S43|A|O
S43|sample|O
S43|size|O
S43|for|O
S43|REDUCE-2|O
S43|of|O
S43|600|B-Sample_Size_Required
S43|was|O
S43|calculated|O
S43|based|O
S43|on|O
S43|a|O
S43|90|B-Sample_Size_Calculation_Power_Value
S43|%|I-Sample_Size_Calculation_Power_Value
S43|power|O
S43|to|O
S43|detect|O
S43|a|O
S43|difference|O
S43|of|O
S43|6|O
S43|%|O
S43|vs.|O
S43|16|O
S43|%|O
S43|in|O
S43|the|O
S43|incidence|O
S43|of|O
S43|upper|O
S43|GI|O
S43|ulcers|O
S43|with|O
S43|a|B-Sample_Size_Calculation_Alpha_Value
S43|two-sided|I-Sample_Size_Calculation_Alpha_Value
S43|α|I-Sample_Size_Calculation_Alpha_Value
S43|of|I-Sample_Size_Calculation_Alpha_Value
S43|0.05|I-Sample_Size_Calculation_Alpha_Value
S43|and|O
S43|assuming|O
S43|a|O
S43|15|B-Sample_Size_Calculation_Dropout_Rate_Value
S43|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S43|drop-out|O
S43|rate|O
S43|.|O
S975|Additional|O
S975|post|O
S975|hoc|O
S975|analysis|O
S975|of|O
S975|data|O
S975|at|O
S975|week|O
S975|2|O
S975|showed|O
S975|no|O
S975|differences|O
S975|between|O
S975|the|O
S975|groups|O
S975|in|O
S975|onset|O
S975|of|O
S975|treatment|O
S975|response|O
S975|(|O
S975|P=0.21|O
S975|)|O
S975|.|O
S1966|Data|O
S1966|were|O
S1966|collected|O
S1966|regarding|O
S1966|symptoms|O
S1966|of|O
S1966|rickets|O
S1966|,|O
S1966|the|O
S1966|frequency|O
S1966|and|O
S1966|quantity|O
S1966|of|O
S1966|dairy|O
S1966|product|O
S1966|intake|O
S1966|,|O
S1966|and|O
S1966|usual|O
S1966|sunlight|O
S1966|exposure|O
S1966|.|O
S1684|All|O
S1684|children|O
S1684|on|O
S1684|routine|O
S1684|laboratory|O
S1684|monitoring|O
S1684|meeting|O
S1684|CD4|O
S1684|switch|O
S1684|criteria|O
S1684|actually|O
S1684|switched|O
S1684|.|O
S2130|Despite|O
S2130|our|O
S2130|use|O
S2130|of|O
S2130|a|O
S2130|more|O
S2130|sensitive|O
S2130|optoelectronic|O
S2130|analysis|O
S2130|in|O
S2130|the|O
S2130|present|O
S2130|study|O
S2130|,|O
S2130|we|O
S2130|adopted|O
S2130|the|O
S2130|same|O
S2130|anticipated|O
S2130|stride|O
S2130|length|O
S2130|difference|O
S2130|,|O
S2130|that|O
S2130|is|O
S2130|,|O
S2130|0.4|O
S2130|m|O
S2130|(|O
S2130|SD|O
S2130|:|O
S2130|0.4|O
S2130|)|O
S2130|.|O
S1339|For|O
S1339|example|O
S1339|,|O
S1339|in|O
S1339|older|O
S1339|patients|O
S1339|the|O
S1339|time|O
S1339|to|O
S1339|randomisation|O
S1339|was|O
S1339|shorter|O
S1339|.|O
S146|Patients|O
S146|were|O
S146|required|O
S146|to|O
S146|continue|O
S146|maintenance|O
S146|treatment|O
S146|with|O
S146|stable|O
S146|medium-dose|O
S146|ICS|O
S146|for|O
S146|at|O
S146|least|O
S146|4|O
S146|weeks|O
S146|prior|O
S146|to|O
S146|and|O
S146|during|O
S146|the|O
S146|treatment|O
S146|period|O
S146|.|O
S1860|Interpretation|O
S1860|Prolonged|O
S1860|follow-up|O
S1860|in|O
S1860|the|O
S1860|Heart|O
S1860|Protection|O
S1860|Study|O
S1860|now|O
S1860|shows|O
S1860|that|O
S1860|reduction|O
S1860|of|O
S1860|about|O
S1860|a|O
S1860|quarter|O
S1860|in|O
S1860|vascular|O
S1860|mortality|O
S1860|and|O
S1860|morbidity—produced|O
S1860|by|O
S1860|an|O
S1860|average|O
S1860|1|O
S1860|mmol/L|O
S1860|reduction|O
S1860|in|O
S1860|LDL|O
S1860|cholesterol|O
S1860|with|O
S1860|5|O
S1860|years|O
S1860|of|O
S1860|statin|O
S1860|therapy—persisted|O
S1860|largely|O
S1860|unchanged|O
S1860|during|O
S1860|the|O
S1860|subsequent|O
S1860|6|O
S1860|years|O
S1860|,|O
S1860|despite|O
S1860|similar|O
S1860|LDL|O
S1860|cholesterol|O
S1860|concentrations|O
S1860|and|O
S1860|statin|O
S1860|use|O
S1860|in|O
S1860|both|O
S1860|treatment|O
S1860|groups|O
S1860|.|O
S442|Participants|O
S442|Members|O
S442|of|O
S442|the|O
S442|British|O
S442|Society|O
S442|for|O
S442|Paediatric|O
S442|Endocrinology|O
S442|and|O
S442|Diabetes|O
S442|recruited|O
S442|patients|O
S442|from|O
S442|participating|O
S442|paediatric|B-Settings_Multicenter
S442|endocrinology|I-Settings_Multicenter
S442|departments|I-Settings_Multicenter
S442|in|O
S442|UK|B-Settings_Location
S442|hospitals|O
S442|.|O
S1885|During|O
S1885|the|O
S1885|post-trial|O
S1885|period|O
S1885|,|O
S1885|vascular|O
S1885|mortality|O
S1885|rates|O
S1885|were|O
S1885|similar|O
S1885|in|O
S1885|both|O
S1885|treatment|O
S1885|groups|O
S1885|(|O
S1885|1019|O
S1885|[|O
S1885|11·5|O
S1885|%|O
S1885|]|O
S1885|vs|O
S1885|1007|O
S1885|[|O
S1885|11·6|O
S1885|%|O
S1885|]|O
S1885|;|O
S1885|RR|O
S1885|0·98|O
S1885|[|O
S1885|95|O
S1885|%|O
S1885|CI|O
S1885|0·90–1·07|O
S1885|]|O
S1885|;|O
S1885|p=0·71|O
S1885|)|O
S1885|,|O
S1885|so|O
S1885|in-trial|O
S1885|survival|O
S1885|gains|O
S1885|persisted|O
S1885|.|O
S46|This|O
S46|approach|O
S46|also|O
S46|requires|O
S46|no|O
S46|α|O
S46|adjustment|O
S46|for|O
S46|multiple|O
S46|comparisons|O
S46|.|O
S632|Patients|O
S632|were|O
S632|evaluated|O
S632|at|O
S632|randomisation/baseline|O
S632|and|O
S632|every|O
S632|4|O
S632|weeks|O
S632|during|O
S632|treatment|O
S632|(|O
S632|or|O
S632|premature|O
S632|withdrawal|O
S632|,|O
S632|week|O
S632|24|O
S632|and|O
S632|,|O
S632|if|O
S632|applicable|O
S632|,|O
S632|12|O
S632|weeks|O
S632|after|O
S632|healing|O
S632|of|O
S632|the|O
S632|cardinal|O
S632|ulcer|O
S632|)|O
S632|,|O
S632|with|O
S632|DUs|O
S632|assessed|O
S632|at|O
S632|each|O
S632|study|O
S632|visit|O
S632|.|O
S292|Patients|O
S292|were|O
S292|followed|O
S292|for|O
S292|24|O
S292|weeks|O
S292|.|O
S2145|Efficacy|O
S2145|criteria|O
S2145|The|O
S2145|‘|O
S2145|off-L-dopa|O
S2145|’|O
S2145|condition|O
S2145|could|O
S2145|not|O
S2145|be|O
S2145|studied|O
S2145|,|O
S2145|since|O
S2145|18|O
S2145|patients|O
S2145|with|O
S2145|very|O
S2145|advanced|O
S2145|PD|O
S2145|were|O
S2145|unable|O
S2145|to|O
S2145|walk|O
S2145|unaided|O
S2145|when|O
S2145|L-dopa|O
S2145|had|O
S2145|been|O
S2145|withdrawn|O
S2145|.|O
S225|Efficacy|O
S225|Primary|O
S225|analysis|O
S225|The|O
S225|addition|O
S225|of|O
S225|tiotropium|O
S225|Respimat®|O
S225|5|O
S225|μg|O
S225|,|O
S225|2.5|O
S225|μg|O
S225|or|O
S225|1.25|O
S225|μg|O
S225|to|O
S225|stable|O
S225|medium-dose|O
S225|ICS|O
S225|therapy|O
S225|was|O
S225|associated|O
S225|with|O
S225|improved|O
S225|lung|O
S225|function|O
S225|:|O
S225|at|O
S225|the|O
S225|end|O
S225|of|O
S225|the|O
S225|4-week|O
S225|treatment|O
S225|period|O
S225|,|O
S225|statistically|O
S225|significant|O
S225|differences|O
S225|from|O
S225|placebo|O
S225|Respimat®|O
S225|in|O
S225|adjusted|O
S225|mean|O
S225|peak|O
S225|FEV1|O
S225|(|O
S225|0-3h|O
S225|)|O
S225|responses|O
S225|were|O
S225|observed|O
S225|for|O
S225|all|O
S225|doses|O
S225|of|O
S225|tiotropium|O
S225|Respimat®|O
S225|(|O
S225|P|O
S225|<|O
S225|0.0001|O
S225|at|O
S225|all|O
S225|doses|O
S225|)|O
S225|(|O
S225|Figure|O
S225|3|O
S225|)|O
S225|.|O
S1108|Cohen|O
S1108|’|O
S1108|s|O
S1108|κ|O
S1108|measure|O
S1108|of|O
S1108|inter-rater|O
S1108|agreement|O
S1108|was|O
S1108|used|O
S1108|to|O
S1108|assess|O
S1108|agreement|O
S1108|between|O
S1108|the|O
S1108|two|O
S1108|assessors|O
S1108|of|O
S1108|the|O
S1108|photographs|O
S1108|for|O
S1108|clearance|O
S1108|.|O
S2203|Quilizumab|O
S2203|also|O
S2203|abrogated|O
S2203|the|O
S2203|increase|O
S2203|in|O
S2203|challenge-specific|O
S2203|IgE|O
S2203|in|O
S2203|patients|O
S2203|with|O
S2203|mild|O
S2203|asthma|O
S2203|following|O
S2203|a|O
S2203|whole-lung|O
S2203|allergen|O
S2203|challenge|O
S2203|,|O
S2203|and|O
S2203|reduced|O
S2203|the|O
S2203|early|O
S2203|and|O
S2203|late|O
S2203|asthmatic|O
S2203|reactions|O
S2203|.|O
S2226|For|O
S2226|the|O
S2226|analyses|O
S2226|of|O
S2226|symptom|O
S2226|scores|O
S2226|,|O
S2226|rescue|O
S2226|medication|O
S2226|use|O
S2226|,|O
S2226|and|O
S2226|nighttime|O
S2226|awakenings|O
S2226|,|O
S2226|daily|O
S2226|scores|O
S2226|were|O
S2226|averaged|O
S2226|over|O
S2226|the|O
S2226|previous|O
S2226|7|O
S2226|days|O
S2226|prior|O
S2226|to|O
S2226|the|O
S2226|time|O
S2226|point|O
S2226|of|O
S2226|interest|O
S2226|.|O
S479|To|O
S479|achieve|O
S479|this|O
S479|,|O
S479|each|O
S479|individual|O
S479|curve|O
S479|is|O
S479|suitably|O
S479|altered|O
S479|in|O
S479|three|O
S479|distinct|O
S479|ways|O
S479|:|O
S479|the|O
S479|curve|O
S479|is|O
S479|shifted|O
S479|up/down|O
S479|(|O
S479|a|O
S479|measure|O
S479|of|O
S479|the|O
S479|child|O
S479|’|O
S479|s|O
S479|size|O
S479|in|O
S479|cm|O
S479|)|O
S479|and|O
S479|left/right|O
S479|(|O
S479|a|O
S479|measure|O
S479|of|O
S479|growth|O
S479|tempo|O
S479|in|O
S479|years|O
S479|)|O
S479|,|O
S479|and|O
S479|the|O
S479|age|O
S479|axis|O
S479|is|O
S479|stretched/squashed|O
S479|(|O
S479|a|O
S479|measure|O
S479|of|O
S479|percentage|O
S479|velocity|O
S479|)|O
S479|.|O
S8|Prespecified|O
S8|pooled|O
S8|analyses|O
S8|showed|O
S8|significantly|O
S8|fewer|O
S8|gastric|O
S8|(|O
S8|12.5|O
S8|%|O
S8|vs.|O
S8|20.7|O
S8|%|O
S8|)|O
S8|and|O
S8|duodenal|O
S8|ulcers|O
S8|(|O
S8|1.1|O
S8|%|O
S8|vs.|O
S8|5.1|O
S8|%|O
S8|)|O
S8|with|O
S8|HZT-501|O
S8|vs.|O
S8|ibuprofen|O
S8|.|O
S1306|An|O
S1306|unadjusted|O
S1306|analysis|O
S1306|is|O
S1306|also|O
S1306|presented|O
S1306|.|O
S1496|Mortality|O
S1496|The|O
S1496|overall|O
S1496|case|O
S1496|fatality|O
S1496|rate|O
S1496|was|O
S1496|21/326|O
S1496|(|O
S1496|6.4|O
S1496|%|O
S1496|,|O
S1496|4.3|O
S1496|%|O
S1496|to|O
S1496|9.6|O
S1496|%|O
S1496|)|O
S1496|.|O
S183|Study|O
S183|medication|O
S183|was|O
S183|to|O
S183|be|O
S183|taken|O
S183|immediately|O
S183|after|O
S183|ICS|O
S183|inhalation|O
S183|if|O
S183|normal|O
S183|ICS|O
S183|dosing|O
S183|was|O
S183|in|O
S183|the|O
S183|evening|O
S183|.|O
S1281|The|B-Randomization_Sequence_Generation_Method
S1281|randomisation|I-Randomization_Sequence_Generation_Method
S1281|system|I-Randomization_Sequence_Generation_Method
S1281|informed|I-Randomization_Sequence_Generation_Method
S1281|local|I-Randomization_Sequence_Generation_Method
S1281|clinicians|I-Randomization_Sequence_Generation_Method
S1281|of|I-Randomization_Sequence_Generation_Method
S1281|the|I-Randomization_Sequence_Generation_Method
S1281|patients|I-Randomization_Sequence_Generation_Method
S1281|'|I-Randomization_Sequence_Generation_Method
S1281|unique|I-Randomization_Sequence_Generation_Method
S1281|trial|I-Randomization_Sequence_Generation_Method
S1281|identification|I-Randomization_Sequence_Generation_Method
S1281|number|I-Randomization_Sequence_Generation_Method
S1281|,|O
S1281|and|O
S1281|the|O
S1281|weight-adjusted|O
S1281|dose|O
S1281|of|O
S1281|drug|O
S1281|or|O
S1281|placebo|O
S1281|in|O
S1281|the|O
S1281|double-blinded|B-Blinding_Double_Blind
S1281|phase|O
S1281|,|O
S1281|or|O
S1281|of|O
S1281|the|O
S1281|weight-adjusted|O
S1281|drug|O
S1281|dose|O
S1281|among|O
S1281|those|O
S1281|allocated|O
S1281|thrombolysis|O
S1281|in|O
S1281|the|O
S1281|open|B-Blinding_Open_Label
S1281|phase|I-Blinding_Open_Label
S1281|,|O
S1281|to|O
S1281|be|O
S1281|given|O
S1281|as|O
S1281|a|O
S1281|10|O
S1281|%|O
S1281|bolus|O
S1281|with|O
S1281|the|O
S1281|remainder|O
S1281|by|O
S1281|an|O
S1281|infusion|O
S1281|over|O
S1281|1|O
S1281|h.|O
S1281|With|O
S1281|the|O
S1281|exception|O
S1281|of|O
S1281|the|O
S1281|276|O
S1281|patients|O
S1281|treated|O
S1281|in|O
S1281|the|O
S1281|double-blinded|O
S1281|phase|O
S1281|of|O
S1281|the|O
S1281|trial|O
S1281|,|O
S1281|treatment|O
S1281|was|O
S1281|given|O
S1281|openly|O
S1281|and|O
S1281|neither|O
S1281|the|O
S1281|patient|O
S1281|nor|O
S1281|the|O
S1281|treating|O
S1281|clinicians|O
S1281|were|O
S1281|masked|O
S1281|.|O
S141|Background|O
S141|Tiotropium|O
S141|,|O
S141|a|O
S141|once-daily|O
S141|long-acting|O
S141|anticholinergic|O
S141|bronchodilator|O
S141|,|O
S141|when|O
S141|administered|O
S141|via|O
S141|Respimat®|O
S141|SoftMist™|O
S141|inhaler|O
S141|(|O
S141|tiotropium|O
S141|Respimat®|O
S141|)|O
S141|significantly|O
S141|reduces|O
S141|the|O
S141|risk|O
S141|of|O
S141|severe|O
S141|exacerbations|O
S141|and|O
S141|improves|O
S141|lung|O
S141|function|O
S141|in|O
S141|patients|O
S141|with|O
S141|severe|O
S141|persistent|O
S141|asthma|O
S141|that|O
S141|is|O
S141|not|O
S141|fully|O
S141|controlled|O
S141|despite|O
S141|using|O
S141|inhaled|O
S141|corticosteroids|O
S141|(|O
S141|ICS|O
S141|)|O
S141|and|O
S141|long-acting|O
S141|β2-agonists|O
S141|.|O
S763|Inclusion|O
S763|criteria|O
S763|were|O
S763|a|O
S763|typical|O
S763|history|O
S763|of|O
S763|myocardial|O
S763|ischaemia|O
S763|lasting|O
S763|more|O
S763|than|O
S763|20|O
S763|min|O
S763|within|O
S763|24|O
S763|h|O
S763|of|O
S763|hospitalisation|O
S763|with|O
S763|ischaemic|O
S763|electrocardiographic|O
S763|changes|O
S763|and|O
S763|an|O
S763|elevated|O
S763|troponin-I|O
S763|concentration|O
S763|(|O
S763|>|O
S763|0.2|O
S763|µg/l|O
S763|)|O
S763|.|O
S982|The|O
S982|Cox|O
S982|regression|O
S982|model|O
S982|for|O
S982|time|O
S982|to|O
S982|healing|O
S982|showed|O
S982|no|O
S982|significant|O
S982|difference|O
S982|between|O
S982|the|O
S982|interventions|O
S982|(|O
S982|hazard|O
S982|ratio|O
S982|0.94|O
S982|,|O
S982|95|O
S982|%|O
S982|confidence|O
S982|interval|O
S982|0.55|O
S982|to|O
S982|1.63|O
S982|;|O
S982|P=0.84|O
S982|)|O
S982|(|O
S982|table|O
S982|3|O
S982|and|O
S982|fig|O
S982|2|O
S982|)|O
S982|.|O
S70|The|O
S70|initial|O
S70|results|O
S70|for|O
S70|the|O
S70|primary|O
S70|end|O
S70|point|O
S70|in|O
S70|REDUCE-2|O
S70|showed|O
S70|the|O
S70|proportions|O
S70|of|O
S70|patients|O
S70|with|O
S70|upper|O
S70|GI|O
S70|ulcers|O
S70|of|O
S70|13.8|O
S70|%|O
S70|for|O
S70|HZT-501|O
S70|and|O
S70|22.6|O
S70|%|O
S70|for|O
S70|ibuprofen|O
S70|(|O
S70|P=0.0304|O
S70|;|O
S70|NNT=11|O
S70|)|O
S70|.|O
S445|Study|O
S445|design|O
S445|We|O
S445|devised|O
S445|a|O
S445|double|B-Blinding_Double_Blind
S445|blind|I-Blinding_Double_Blind
S445|,|O
S445|placebo|O
S445|controlled|O
S445|,|O
S445|randomised|O
S445|controlled|O
S445|trial|O
S445|,|O
S445|including|O
S445|two|O
S445|randomisations|O
S445|in|O
S445|a|O
S445|two|B-Design_Factorial_Factor_Treatment
S445|by|I-Design_Factorial_Factor_Treatment
S445|two|I-Design_Factorial_Factor_Treatment
S445|factorial|B-Design_Factorial
S445|design|O
S445|.|O
S232|Higher|O
S232|mean|O
S232|pre-dose|O
S232|PEFpm|O
S232|responses|O
S232|were|O
S232|also|O
S232|observed|O
S232|with|O
S232|all|O
S232|three|O
S232|tiotropium|O
S232|Respimat®|O
S232|treatments|O
S232|compared|O
S232|with|O
S232|placebo|O
S232|Respimat®|O
S232|(|O
S232|difference|O
S232|from|O
S232|placebo|O
S232|:|O
S232|5|O
S232|μg|O
S232|,|O
S232|21.581|O
S232|L/min|O
S232|;|O
S232|2.5|O
S232|μg|O
S232|,|O
S232|14.577|O
S232|L/min|O
S232|;|O
S232|1.25|O
S232|μg|O
S232|,|O
S232|21.251|O
S232|L/min|O
S232|;|O
S232|all|O
S232|P|O
S232|<|O
S232|0.0001|O
S232|)|O
S232|.|O
S299|Patients|O
S299|also|O
S299|recorded|O
S299|rescue|O
S299|medication|O
S299|use|O
S299|and|O
S299|pain|O
S299|for|O
S299|at|O
S299|least|O
S299|7|O
S299|days|O
S299|after|O
S299|the|O
S299|onset|O
S299|of|O
S299|the|O
S299|flare|O
S299|or|O
S299|longer|O
S299|if|O
S299|the|O
S299|flares|O
S299|persisted|O
S299|for|O
S299|more|O
S299|than|O
S299|7|O
S299|days|O
S299|.|O
S5|After|O
S5|unblinding|O
S5|and|O
S5|initial|O
S5|analyses|O
S5|,|O
S5|12|O
S5|patients|O
S5|were|O
S5|found|O
S5|to|O
S5|be|O
S5|misclassified|O
S5|as|O
S5|having|O
S5|gastric|O
S5|ulcers|O
S5|based|O
S5|on|O
S5|the|O
S5|adjudication|O
S5|of|O
S5|endoscopy|O
S5|reports|O
S5|,|O
S5|and|O
S5|analyses|O
S5|were|O
S5|re-run|O
S5|.|O
S2018|Interestingly|O
S2018|,|O
S2018|baseline|O
S2018|25|O
S2018|(|O
S2018|OH|O
S2018|)|O
S2018|D|O
S2018|concentration|O
S2018|was|O
S2018|not|O
S2018|predictive|O
S2018|of|O
S2018|a|O
S2018|response|O
S2018|to|O
S2018|vitamin|O
S2018|D|O
S2018|,|O
S2018|as|O
S2018|there|O
S2018|was|O
S2018|no|O
S2018|interaction|O
S2018|of|O
S2018|treatment|O
S2018|group|O
S2018|with|O
S2018|baseline|O
S2018|25|O
S2018|(|O
S2018|OH|O
S2018|)|O
S2018|D|O
S2018|(|O
S2018|p=0.42|O
S2018|for|O
S2018|interaction|O
S2018|)|O
S2018|.|O
S182|Patients|O
S182|using|O
S182|ICS|O
S182|plus|O
S182|short-acting|O
S182|β2-agonist|O
S182|or|O
S182|ICS|O
S182|+|O
S182|LABA|O
S182|fixed-dose|O
S182|combinations|O
S182|were|O
S182|switched|O
S182|to|O
S182|the|O
S182|same|O
S182|dose|O
S182|of|O
S182|ICS|O
S182|mono-product|O
S182|at|O
S182|least|O
S182|8|O
S182|or|O
S182|24|O
S182|hours|O
S182|,|O
S182|respectively|O
S182|,|O
S182|prior|O
S182|to|O
S182|Visit|O
S182|1|O
S182|.|O
S664|No|O
S664|difference|O
S664|between|O
S664|treatments|O
S664|was|O
S664|observed|O
S664|in|O
S664|the|O
S664|mean|O
S664|total|O
S664|number|O
S664|of|O
S664|DUs|O
S664|(|O
S664|baseline|O
S664|plus|O
S664|new|O
S664|)|O
S664|per|O
S664|patient|O
S664|among|O
S664|patients|O
S664|with|O
S664|at|O
S664|least|O
S664|four|O
S664|DUs|O
S664|at|O
S664|baseline|O
S664|(|O
S664|−3.4|O
S664|(|O
S664|95|O
S664|%|O
S664|CI|O
S664|−4.8|O
S664|to|O
S664|−1.9|O
S664|)|O
S664|on|O
S664|bosentan|O
S664|and|O
S664|−3.6|O
S664|(|O
S664|−5.4|O
S664|to|O
S664|−1.7|O
S664|)|O
S664|DUs|O
S664|on|O
S664|placebo|O
S664|)|O
S664|and|O
S664|those|O
S664|with|O
S664|fewer|O
S664|than|O
S664|four|O
S664|DUs|O
S664|at|O
S664|baseline|O
S664|(|O
S664|−0.6|O
S664|(|O
S664|−1.0|O
S664|to|O
S664|−0.2|O
S664|)|O
S664|and|O
S664|−0.5|O
S664|(|O
S664|−1.1|O
S664|to|O
S664|0.1|O
S664|)|O
S664|DUs|O
S664|,|O
S664|respectively|O
S664|)|O
S664|.|O
S464|In|O
S464|2008|O
S464|,|O
S464|the|O
S464|decision|O
S464|was|O
S464|taken|O
S464|to|O
S464|terminate|O
S464|the|O
S464|treatment|O
S464|arm|O
S464|forthwith|O
S464|,|O
S464|resulting|O
S464|in|O
S464|eight|O
S464|participants|O
S464|stopping|O
S464|oxandrolone|O
S464|treatment|O
S464|prematurely|O
S464|.|O
S323|(|O
S323|The|O
S323|LS|O
S323|mean|O
S323|number|O
S323|of|O
S323|flares|O
S323|per|O
S323|patient|O
S323|is|O
S323|the|O
S323|best-fitting|O
S323|unbiased|O
S323|estimate|O
S323|calculated|O
S323|from|O
S323|the|O
S323|ANCOVA|O
S323|model|O
S323|.|O
S599|Nifedipine|O
S599|and|O
S599|intravenous|O
S599|iloprost|O
S599|resulted|O
S599|in|O
S599|the|O
S599|reduction|O
S599|from|O
S599|baseline|O
S599|in|O
S599|the|O
S599|mean|O
S599|number|O
S599|of|O
S599|DUs|O
S599|in|O
S599|a|O
S599|small|O
S599|study|O
S599|.|O
S143|Methods|O
S143|In|O
S143|this|O
S143|randomised|O
S143|,|O
S143|double-blind|B-Blinding_Double_Blind
S143|,|O
S143|placebo-controlled|O
S143|,|O
S143|four-way|B-Design_Crossover_Period_Treatment
S143|crossover|B-Design_Crossover
S143|study|O
S143|,|O
S143|patients|O
S143|were|O
S143|randomised|O
S143|to|O
S143|tiotropium|B-Design_Parallel_Group
S143|Respimat®|I-Design_Parallel_Group
S143|5|I-Design_Parallel_Group
S143|μg|I-Design_Parallel_Group
S143|,|I-Design_Parallel_Group
S143|2.5|I-Design_Parallel_Group
S143|μg|I-Design_Parallel_Group
S143|or|I-Design_Parallel_Group
S143|1.25|I-Design_Parallel_Group
S143|μg|I-Design_Parallel_Group
S143|or|I-Design_Parallel_Group
S143|placebo|I-Design_Parallel_Group
S143|Respimat®|O
S143|,|O
S143|once|O
S143|daily|O
S143|in|O
S143|the|O
S143|evening|O
S143|.|O
S2272|Serum|O
S2272|total|O
S2272|and|O
S2272|allergen-specific|O
S2272|IgE|O
S2272|in|O
S2272|quilizumab-treated|O
S2272|patients|O
S2272|gradually|O
S2272|increased|O
S2272|throughout|O
S2272|the|O
S2272|safety|O
S2272|follow-up|O
S2272|period|O
S2272|,|O
S2272|but|O
S2272|did|O
S2272|not|O
S2272|return|O
S2272|to|O
S2272|pre-dose|O
S2272|levels|O
S2272|by|O
S2272|the|O
S2272|end|O
S2272|of|O
S2272|the|O
S2272|study|O
S2272|period|O
S2272|(|O
S2272|Week|O
S2272|84|O
S2272|)|O
S2272|.|O
S336|The|O
S336|incidence|O
S336|of|O
S336|AEs|O
S336|over|O
S336|the|O
S336|24-week|O
S336|period|O
S336|was|O
S336|similar|O
S336|across|O
S336|the|O
S336|six|O
S336|canakinumab|O
S336|groups|O
S336|(|O
S336|51.9|O
S336|%|O
S336|to|O
S336|58.5|O
S336|%|O
S336|)|O
S336|and|O
S336|for|O
S336|the|O
S336|colchicine|O
S336|group|O
S336|(|O
S336|53.7|O
S336|%|O
S336|)|O
S336|(|O
S336|table|O
S336|3|O
S336|)|O
S336|.|O
S281|Three|O
S281|recent|O
S281|trials|O
S281|used|O
S281|colchicine|O
S281|for|O
S281|prophylaxis|O
S281|in|O
S281|patients|O
S281|initiating|O
S281|ULT|O
S281|(|O
S281|with|O
S281|febuxostat|O
S281|)|O
S281|,|O
S281|but|O
S281|provide|O
S281|limited|O
S281|data|O
S281|on|O
S281|the|O
S281|efficacy|O
S281|of|O
S281|colchicine|O
S281|.|O
S1828|During|O
S1828|prolonged|O
S1828|follow-up|O
S1828|in|O
S1828|observational|O
S1828|epidemiological|O
S1828|studies|O
S1828|,|O
S1828|lower|O
S1828|blood|O
S1828|cholesterol|O
S1828|concentrations|O
S1828|have|O
S1828|been|O
S1828|associated|O
S1828|with|O
S1828|higher|O
S1828|rates|O
S1828|of|O
S1828|particular|O
S1828|types|O
S1828|of|O
S1828|cancer|O
S1828|,|O
S1828|and|O
S1828|with|O
S1828|other|O
S1828|non-vascular|O
S1828|morbidity|O
S1828|and|O
S1828|mortality|O
S1828|.|O
S1621|Participants|O
S1621|were|O
S1621|randomly|O
S1621|assigned|O
S1621|(|O
S1621|1:1|B-Randomization_Ratio
S1621|)|O
S1621|to|O
S1621|clinically|O
S1621|driven|O
S1621|monitoring|O
S1621|versus|O
S1621|routine|O
S1621|laboratory|O
S1621|plus|O
S1621|clinical|O
S1621|monitoring|O
S1621|for|O
S1621|toxicity|O
S1621|(|O
S1621|haematology|O
S1621|and|O
S1621|biochemistry|O
S1621|)|O
S1621|and|O
S1621|efficacy|O
S1621|(|O
S1621|CD4|O
S1621|)|O
S1621|.|O
S771|Randomisation|O
S771|was|O
S771|performed|O
S771|by|O
S771|a|B-Randomization_Sequence_Generation_Method
S771|computer|I-Randomization_Sequence_Generation_Method
S771|generated|I-Randomization_Sequence_Generation_Method
S771|sequence|I-Randomization_Sequence_Generation_Method
S771|to|O
S771|ensure|O
S771|concealment|O
S771|of|O
S771|treatment|O
S771|allocation|O
S771|and|O
S771|following|O
S771|minimisation|B-Randomization_Type_Minimization
S771|for|O
S771|age|B-Randomization_Minimization_Criteria
S771|,|O
S771|sex|B-Randomization_Minimization_Criteria
S771|,|O
S771|time|B-Randomization_Minimization_Criteria
S771|to|I-Randomization_Minimization_Criteria
S771|randomisation|I-Randomization_Minimization_Criteria
S771|,|O
S771|peak|B-Randomization_Minimization_Criteria
S771|troponin|I-Randomization_Minimization_Criteria
S771|,|O
S771|serum|B-Randomization_Minimization_Criteria
S771|cholesterol|I-Randomization_Minimization_Criteria
S771|and|I-Randomization_Minimization_Criteria
S771|cardiovascular|I-Randomization_Minimization_Criteria
S771|risk|I-Randomization_Minimization_Criteria
S771|factors|I-Randomization_Minimization_Criteria
S771|including|I-Randomization_Minimization_Criteria
S771|diabetes|I-Randomization_Minimization_Criteria
S771|mellitus|I-Randomization_Minimization_Criteria
S771|,|I-Randomization_Minimization_Criteria
S771|hypertension|I-Randomization_Minimization_Criteria
S771|and|I-Randomization_Minimization_Criteria
S771|smoking|I-Randomization_Minimization_Criteria
S771|.|O
S978|For|O
S978|64|O
S978|participants|O
S978|(|O
S978|32|O
S978|in|O
S978|each|O
S978|group|O
S978|)|O
S978|the|O
S978|pyoderma|O
S978|gangrenosum|O
S978|improved|O
S978|(|O
S978|decreased|O
S978|in|O
S978|size|O
S978|)|O
S978|,|O
S978|with|O
S978|a|O
S978|median|O
S978|decrease|O
S978|of|O
S978|those|O
S978|that|O
S978|decreased|O
S978|of|O
S978|1.96|O
S978|cm2|O
S978|in|O
S978|the|O
S978|ciclosporin|O
S978|group|O
S978|and|O
S978|3.04|O
S978|cm2|O
S978|in|O
S978|the|O
S978|prednisolone|O
S978|group|O
S978|.|O
S74|The|O
S74|results|O
S74|for|O
S74|the|O
S74|analyses|O
S74|were|O
S74|then|O
S74|re-run|O
S74|with|O
S74|these|O
S74|patients|O
S74|no|O
S74|longer|O
S74|listed|O
S74|as|O
S74|having|O
S74|gastric|O
S74|ulcers|O
S74|.|O
S1712|Most|O
S1712|of|O
S1712|the|O
S1712|362|O
S1712|serious|O
S1712|adverse|O
S1712|events|O
S1712|(|O
S1712|217|O
S1712|clinically|O
S1712|driven|O
S1712|,|O
S1712|145|O
S1712|routine|O
S1712|laboratory|O
S1712|monitoring|O
S1712|)|O
S1712|were|O
S1712|malaria|O
S1712|(|O
S1712|113|O
S1712|clinically|O
S1712|driven|O
S1712|,|O
S1712|65|O
S1712|routine|O
S1712|laboratory|O
S1712|monitoring|O
S1712|)|O
S1712|,|O
S1712|and|O
S1712|most|O
S1712|(|O
S1712|179|O
S1712|clinically|O
S1712|driven|O
S1712|,|O
S1712|117|O
S1712|routine|O
S1712|laboratory|O
S1712|monitoring|O
S1712|)|O
S1712|were|O
S1712|admissions|O
S1712|to|O
S1712|hospital|O
S1712|.|O
S91|No|O
S91|significant|O
S91|treatment-by-subgroup|O
S91|interactions|O
S91|were|O
S91|identified|O
S91|for|O
S91|the|O
S91|subgroups|O
S91|assessed|O
S91|(|O
S91|all|O
S91|P|O
S91|values|O
S91|>|O
S91|0.10|O
S91|)|O
S91|.|O
S217|The|O
S217|pre-specified|O
S217|hypotheses|O
S217|were|O
S217|tested|O
S217|using|O
S217|a|O
S217|mixed|O
S217|effects|O
S217|model|O
S217|with|O
S217|repeated|O
S217|measures|O
S217|.|O
S2103|Patients|O
S2103|were|O
S2103|enrolled|O
S2103|between|O
S2103|May|O
S2103|2010|O
S2103|and|O
S2103|November|O
S2103|2010|O
S2103|,|O
S2103|following|O
S2103|their|O
S2103|provision|O
S2103|of|O
S2103|written|O
S2103|,|O
S2103|informed|O
S2103|consent|O
S2103|to|O
S2103|participation|O
S2103|.|O
S1720|At|O
S1720|week|O
S1720|24|O
S1720|,|O
S1720|suppression|O
S1720|was|O
S1720|significantly|O
S1720|greater|O
S1720|in|O
S1720|induction|O
S1720|groups|O
S1720|receiving|O
S1720|four|O
S1720|drugs|O
S1720|(|O
S1720|285|O
S1720|[|O
S1720|88|O
S1720|%|O
S1720|]|O
S1720|of|O
S1720|324|O
S1720|children|O
S1720|in|O
S1720|groups|O
S1720|B|O
S1720|and|O
S1720|C|O
S1720|vs|O
S1720|114|O
S1720|[|O
S1720|77|O
S1720|%|O
S1720|]|O
S1720|of|O
S1720|148|O
S1720|in|O
S1720|group|O
S1720|A|O
S1720|)|O
S1720|.|O
S772|Study|O
S772|procedures|O
S772|were|O
S772|all|O
S772|completed|O
S772|prior|O
S772|to|O
S772|invasive|O
S772|angiography|O
S772|or|O
S772|percutaneous|O
S772|coronary|O
S772|intervention|O
S772|.|O
S660|Pain|O
S660|and|O
S660|disability|O
S660|Patient-rated|O
S660|measures|O
S660|of|O
S660|overall|O
S660|hand|O
S660|pain|O
S660|and|O
S660|pain|O
S660|of|O
S660|the|O
S660|cardinal|O
S660|ulcer|O
S660|,|O
S660|as|O
S660|assessed|O
S660|by|O
S660|visual|O
S660|analogue|O
S660|scales|O
S660|,|O
S660|showed|O
S660|no|O
S660|differential|O
S660|treatment|O
S660|effect|O
S660|in|O
S660|pain|O
S660|at|O
S660|week|O
S660|24|O
S660|(|O
S660|mean|O
S660|treatment|O
S660|effects|O
S660|of|O
S660|−1.7|O
S660|(|O
S660|95|O
S660|%|O
S660|CI|O
S660|−11.4|O
S660|to|O
S660|7.9|O
S660|)|O
S660|,|O
S660|p=0.73|O
S660|and|O
S660|−1.6|O
S660|(|O
S660|−11.5|O
S660|to|O
S660|8.3|O
S660|)|O
S660|,|O
S660|p=0.75|O
S660|,|O
S660|respectively|O
S660|)|O
S660|.|O
S492|For|O
S492|randomisation|O
S492|1|O
S492|,|O
S492|final|O
S492|height|O
S492|was|O
S492|significantly|O
S492|greater|O
S492|with|O
S492|oxandrolone|O
S492|than|O
S492|placebo|O
S492|(|O
S492|4.6|O
S492|cm|O
S492|,|O
S492|95|O
S492|%|O
S492|confidence|O
S492|interval|O
S492|1.9|O
S492|to|O
S492|7.2|O
S492|;|O
S492|P=0.001|O
S492|)|O
S492|.|O
S1945|Baseline|O
S1945|25|O
S1945|(|O
S1945|OH|O
S1945|)|O
S1945|D|O
S1945|did|O
S1945|not|O
S1945|alter|O
S1945|treatment|O
S1945|group|O
S1945|effects|O
S1945|(|O
S1945|p=0.99|O
S1945|for|O
S1945|interaction|O
S1945|)|O
S1945|.|O
S673|In|O
S673|all|O
S673|cases|O
S673|on|O
S673|bosentan|O
S673|,|O
S673|elevated|O
S673|aminotransferases|O
S673|resolved|O
S673|during|O
S673|continued|O
S673|treatment|O
S673|,|O
S673|after|O
S673|a|O
S673|decrease|O
S673|in|O
S673|dose|O
S673|,|O
S673|or|O
S673|following|O
S673|temporary|O
S673|or|O
S673|permanent|O
S673|treatment|O
S673|discontinuation|O
S673|.|O
S450|Randomisation|O
S450|1|O
S450|,|O
S450|to|O
S450|oxandrolone|B-Design_Parallel_Group
S450|or|I-Design_Parallel_Group
S450|placebo|I-Design_Parallel_Group
S450|,|O
S450|took|O
S450|place|O
S450|at|O
S450|age|O
S450|9|O
S450|years|O
S450|(|O
S450|or|O
S450|at|O
S450|enrolment|O
S450|,|O
S450|if|O
S450|older|O
S450|)|O
S450|and|O
S450|was|O
S450|balanced|B-Randomization_Type_Stratified
S450|for|O
S450|enrolling|B-Randomization_Stratified_Criteria
S450|centre|I-Randomization_Stratified_Criteria
S450|,|O
S450|quarter|B-Randomization_Stratified_Criteria
S450|of|I-Randomization_Stratified_Criteria
S450|mid-parental|I-Randomization_Stratified_Criteria
S450|height|I-Randomization_Stratified_Criteria
S450|,|O
S450|and|O
S450|previous|B-Randomization_Stratified_Criteria
S450|exposure|I-Randomization_Stratified_Criteria
S450|to|I-Randomization_Stratified_Criteria
S450|growth|I-Randomization_Stratified_Criteria
S450|hormone|I-Randomization_Stratified_Criteria
S450|treatment|I-Randomization_Stratified_Criteria
S450|.|O
S924|Patient|O
S924|reported|O
S924|outcomes|O
S924|were|O
S924|collected|O
S924|from|O
S924|daily|O
S924|diaries|O
S924|or|O
S924|postal|O
S924|questionnaires|O
S924|.|O
S342|There|O
S342|was|O
S342|no|O
S342|clear|O
S342|pattern|O
S342|with|O
S342|respect|O
S342|to|O
S342|the|O
S342|incidence|O
S342|of|O
S342|infections|O
S342|with|O
S342|either|O
S342|treatment|O
S342|.|O
S414|Design|O
S414|Randomised|O
S414|,|O
S414|double|B-Blinding_Double_Blind
S414|blind|I-Blinding_Double_Blind
S414|,|O
S414|placebo|O
S414|controlled|O
S414|trial|O
S414|.|O
S327|The|O
S327|percentage|O
S327|of|O
S327|patients|O
S327|experiencing|O
S327|at|O
S327|least|O
S327|one|O
S327|flare|O
S327|in|O
S327|the|O
S327|16-week|O
S327|period|O
S327|was|O
S327|lower|O
S327|for|O
S327|all|O
S327|canakinumab|O
S327|groups|O
S327|versus|O
S327|colchicine|O
S327|0.5|O
S327|mg|O
S327|(|O
S327|canakinumab|O
S327|,|O
S327|15|O
S327|%|O
S327|to|O
S327|27|O
S327|%|O
S327|;|O
S327|colchicine|O
S327|,|O
S327|44|O
S327|%|O
S327|,|O
S327|p≤0.05|O
S327|)|O
S327|,|O
S327|and|O
S327|all|O
S327|patients|O
S327|receiving|O
S327|canakinumab|O
S327|were|O
S327|significantly|O
S327|less|O
S327|likely|O
S327|to|O
S327|experience|O
S327|at|O
S327|least|O
S327|one|O
S327|flare|O
S327|compared|O
S327|with|O
S327|patients|O
S327|treated|O
S327|with|O
S327|colchicine|O
S327|(|O
S327|estimated|O
S327|odds|O
S327|ratio|O
S327|(|O
S327|OR|O
S327|)|O
S327|vs|O
S327|colchicine|O
S327|:|O
S327|0.22–0.47|O
S327|,|O
S327|p≤0.05|O
S327|)|O
S327|(|O
S327|table|O
S327|2|O
S327|)|O
S327|.|O
S298|For|O
S298|each|O
S298|flare|O
S298|,|O
S298|patients|O
S298|recorded|O
S298|in|O
S298|a|O
S298|diary|O
S298|the|O
S298|start|O
S298|date|O
S298|,|O
S298|the|O
S298|most|O
S298|affected|O
S298|joint|O
S298|on|O
S298|that|O
S298|day|O
S298|and|O
S298|the|O
S298|severity|O
S298|of|O
S298|pain|O
S298|(|O
S298|see|O
S298|supplementary|O
S298|material|O
S298|for|O
S298|further|O
S298|details|O
S298|)|O
S298|.|O
S1583|Routine|O
S1583|versus|O
S1583|clinically|O
S1583|driven|O
S1583|laboratory|O
S1583|monitoring|O
S1583|and|O
S1583|first-line|O
S1583|antiretroviral|O
S1583|therapy|O
S1583|strategies|O
S1583|in|O
S1583|African|O
S1583|children|O
S1583|with|O
S1583|HIV|O
S1583|(|O
S1583|ARROW|O
S1583|)|O
S1583|:|O
S1583|a|O
S1583|5-year|O
S1583|open-label|B-Blinding_Open_Label
S1583|randomised|O
S1583|factorial|B-Design_Factorial
S1583|trial|O
S1505|The|O
S1505|median|O
S1505|durations|O
S1505|of|O
S1505|these|O
S1505|interventions|O
S1505|were|O
S1505|similar|O
S1505|between|O
S1505|the|O
S1505|two|O
S1505|treatment|O
S1505|arms|O
S1505|(|O
S1505|table|O
S1505|6|O
S1505|)|O
S1505|.|O
S1838|Information|O
S1838|was|O
S1838|sought|O
S1838|about|O
S1838|any|O
S1838|suspected|O
S1838|heart|O
S1838|attacks|O
S1838|,|O
S1838|strokes|O
S1838|,|O
S1838|vascular|O
S1838|procedures|O
S1838|,|O
S1838|cancers|O
S1838|,|O
S1838|or|O
S1838|other|O
S1838|serious|O
S1838|adverse|O
S1838|events|O
S1838|.|O
S229|Exploratory|O
S229|analysis|O
S229|of|O
S229|the|O
S229|difference|O
S229|in|O
S229|response|O
S229|between|O
S229|tiotropium|O
S229|Respimat®|O
S229|doses|O
S229|found|O
S229|that|O
S229|peak|O
S229|FEV1|O
S229|(|O
S229|0-3h|O
S229|)|O
S229|,|O
S229|FEV1|O
S229|AUC|O
S229|(|O
S229|0-3h|O
S229|)|O
S229|,|O
S229|peak|O
S229|FVC|O
S229|(|O
S229|0-3h|O
S229|)|O
S229|and|O
S229|FVC|O
S229|AUC|O
S229|(|O
S229|0-3h|O
S229|)|O
S229|responses|O
S229|were|O
S229|all|O
S229|statistically|O
S229|significantly|O
S229|greater|O
S229|with|O
S229|tiotropium|O
S229|Respimat®|O
S229|5|O
S229|μg|O
S229|than|O
S229|with|O
S229|either|O
S229|of|O
S229|the|O
S229|two|O
S229|lower|O
S229|doses|O
S229|(|O
S229|Table|O
S229|2|O
S229|)|O
S229|.|O
S971|For|O
S971|the|O
S971|other|O
S971|22|O
S971|(|O
S971|20|O
S971|%|O
S971|)|O
S971|participants|O
S971|whose|O
S971|digital|O
S971|images|O
S971|were|O
S971|either|O
S971|unavailable|O
S971|or|O
S971|of|O
S971|insufficient|O
S971|quality|O
S971|to|O
S971|allow|O
S971|assessment|O
S971|,|O
S971|healing|O
S971|speed|O
S971|was|O
S971|assessed|O
S971|using|O
S971|unblinded|O
S971|physical|O
S971|measurements|O
S971|taken|O
S971|during|O
S971|clinic|O
S971|visits|O
S971|.|O
S1041|Participants|O
S1041|240|B-Sample_Size_Actual_at_Enrollment
S1041|patients|O
S1041|aged|O
S1041|12|O
S1041|years|O
S1041|and|O
S1041|over|O
S1041|,|O
S1041|with|O
S1041|a|O
S1041|plantar|O
S1041|wart|O
S1041|that|O
S1041|in|O
S1041|the|O
S1041|opinion|O
S1041|of|O
S1041|the|O
S1041|healthcare|O
S1041|professional|O
S1041|was|O
S1041|suitable|O
S1041|for|O
S1041|treatment|O
S1041|with|O
S1041|both|O
S1041|cryotherapy|O
S1041|and|O
S1041|salicylic|O
S1041|acid|O
S1041|.|O
S44|Statistical|O
S44|comparisons|O
S44|were|O
S44|predefined|O
S44|to|O
S44|be|O
S44|done|O
S44|with|O
S44|a|O
S44|fixed|O
S44|testing|O
S44|sequence|O
S44|(|O
S44|hierarchical|O
S44|)|O
S44|in|O
S44|the|O
S44|following|O
S44|order|O
S44|of|O
S44|primary|O
S44|followed|O
S44|by|O
S44|secondary|O
S44|end|O
S44|points|O
S44|:|O
S44|REDUCE-1|O
S44|:|O
S44|gastric|O
S44|ulcers|O
S44|,|O
S44|upper|O
S44|GI|O
S44|ulcers|O
S44|,|O
S44|duodenal|O
S44|ulcers|O
S44|,|O
S44|GI|O
S44|complications|O
S44|;|O
S44|REDUCE-2|O
S44|:|O
S44|upper|O
S44|GI|O
S44|ulcers|O
S44|,|O
S44|gastric|O
S44|ulcers|O
S44|,|O
S44|duodenal|O
S44|ulcers|O
S44|,|O
S44|GI|O
S44|complications|O
S44|.|O
S322|Secondary|O
S322|outcomes|O
S322|Clinical|O
S322|outcomes|O
S322|The|O
S322|least-squares|O
S322|(|O
S322|LS|O
S322|)|O
S322|mean|O
S322|number|O
S322|of|O
S322|flares|O
S322|per|O
S322|patient|O
S322|for|O
S322|the|O
S322|16|O
S322|weeks|O
S322|(|O
S322|according|O
S322|to|O
S322|the|O
S322|preplanned|O
S322|ANCOVA|O
S322|)|O
S322|was|O
S322|lower|O
S322|for|O
S322|all|O
S322|canakinumab|O
S322|doses|O
S322|compared|O
S322|with|O
S322|colchicine|O
S322|0.5|O
S322|mg|O
S322|;|O
S322|differences|O
S322|were|O
S322|statistically|O
S322|significant|O
S322|for|O
S322|the|O
S322|canakinumab|O
S322|100|O
S322|mg|O
S322|and|O
S322|300|O
S322|mg|O
S322|doses|O
S322|(|O
S322|p≤0.05|O
S322|,|O
S322|table|O
S322|2|O
S322|)|O
S322|.|O
S20|Although|O
S20|many|O
S20|national|O
S20|and|O
S20|international|O
S20|groups|O
S20|recommend|O
S20|protective|O
S20|therapy|O
S20|in|O
S20|NSAID|O
S20|users|O
S20|at|O
S20|increased|O
S20|risk|O
S20|of|O
S20|GI|O
S20|events|O
S20|,|O
S20|most|O
S20|such|O
S20|patients|O
S20|are|O
S20|not|O
S20|prescribed|O
S20|protective|O
S20|therapy|O
S20|.|O
S424|Conclusion|O
S424|Oxandrolone|O
S424|had|O
S424|a|O
S424|positive|O
S424|effect|O
S424|on|O
S424|final|O
S424|height|O
S424|in|O
S424|girls|O
S424|with|O
S424|Turner|O
S424|’|O
S424|s|O
S424|syndrome|O
S424|treated|O
S424|with|O
S424|growth|O
S424|hormone|O
S424|,|O
S424|as|O
S424|did|O
S424|late|O
S424|pubertal|O
S424|induction|O
S424|with|O
S424|ethinylestradiol|O
S424|at|O
S424|age|O
S424|14|O
S424|years|O
S424|.|O
S736|Design|O
S736|and|O
S736|setting|O
S736|and|O
S736|patients|O
S736|A|O
S736|double-blind|B-Blinding_Double_Blind
S736|,|O
S736|parallel|B-Design_Parallel_Group
S736|group|I-Design_Parallel_Group
S736|,|O
S736|randomised|O
S736|controlled|O
S736|trial|O
S736|performed|O
S736|in|O
S736|a|B-Settings_Single_Center
S736|tertiary|I-Settings_Single_Center
S736|referral|I-Settings_Single_Center
S736|cardiac|I-Settings_Single_Center
S736|centre|I-Settings_Single_Center
S736|.|O
S655|Time-to-event|O
S655|analyses|O
S655|up|O
S655|to|O
S655|week|O
S655|24|O
S655|indicated|O
S655|an|O
S655|increasing|O
S655|reduction|O
S655|in|O
S655|risk|O
S655|with|O
S655|bosentan|O
S655|compared|O
S655|with|O
S655|placebo|O
S655|for|O
S655|the|O
S655|appearance|O
S655|of|O
S655|each|O
S655|successive|O
S655|new|O
S655|DU|O
S655|,|O
S655|with|O
S655|a|O
S655|HR|O
S655|of|O
S655|0.45|O
S655|(|O
S655|95|O
S655|%|O
S655|CI|O
S655|0.21|O
S655|to|O
S655|0.95|O
S655|,|O
S655|p=0.03|O
S655|)|O
S655|for|O
S655|the|O
S655|fifth|O
S655|new|O
S655|DU|O
S655|.|O
S241|In|O
S241|the|O
S241|tiotropium|O
S241|Respimat®|O
S241|5|O
S241|μg|O
S241|group|O
S241|,|O
S241|one|O
S241|patient|O
S241|reported|O
S241|dry|O
S241|mouth|O
S241|.|O
S1262|All|O
S1262|patients|O
S1262|in|O
S1262|the|O
S1262|trial|O
S1262|were|O
S1262|to|O
S1262|be|O
S1262|treated|O
S1262|within|O
S1262|that|O
S1262|organised|O
S1262|system|O
S1262|of|O
S1262|stroke|O
S1262|care|O
S1262|,|O
S1262|irrespective|O
S1262|of|O
S1262|treatment|O
S1262|allocation|O
S1262|.|O
S972|There|O
S972|was|O
S972|no|O
S972|between|O
S972|group|O
S972|difference|O
S972|in|O
S972|speed|O
S972|of|O
S972|healing|O
S972|over|O
S972|six|O
S972|weeks|O
S972|(|O
S972|adjusted|O
S972|mean|O
S972|difference|O
S972|0.003|O
S972|cm2/day|O
S972|,|O
S972|95|O
S972|%|O
S972|confidence|O
S972|interval|O
S972|−0.20|O
S972|to|O
S972|0.21|O
S972|;|O
S972|P=0.97|O
S972|)|O
S972|(|O
S972|table|O
S972|2|O
S972|)|O
S972|.|O
S2215|Asthma|O
S2215|exacerbations|O
S2215|were|O
S2215|defined|O
S2215|as|O
S2215|new|O
S2215|or|O
S2215|increased|O
S2215|asthma|O
S2215|symptoms|O
S2215|(|O
S2215|wheezing|O
S2215|,|O
S2215|cough|O
S2215|,|O
S2215|chest|O
S2215|tightness|O
S2215|,|O
S2215|shortness|O
S2215|of|O
S2215|breath|O
S2215|,|O
S2215|or|O
S2215|nighttime|O
S2215|awakening|O
S2215|due|O
S2215|to|O
S2215|symptoms|O
S2215|)|O
S2215|that|O
S2215|led|O
S2215|to|O
S2215|treatment|O
S2215|with|O
S2215|systemic|O
S2215|corticosteroids|O
S2215|for|O
S2215|at|O
S2215|least|O
S2215|3|O
S2215|days|O
S2215|or|O
S2215|to|O
S2215|hospitalization|O
S2215|.|O
S150|Statistically|O
S150|significant|O
S150|improvements|O
S150|in|O
S150|peak|O
S150|FEV1|O
S150|(|O
S150|0-3h|O
S150|)|O
S150|response|O
S150|were|O
S150|observed|O
S150|with|O
S150|each|O
S150|tiotropium|B-Design_Parallel_Group
S150|Respimat®|I-Design_Parallel_Group
S150|dose|I-Design_Parallel_Group
S150|versus|I-Design_Parallel_Group
S150|placebo|I-Design_Parallel_Group
S150|(|O
S150|all|O
S150|P|O
S150|<|O
S150|0.0001|O
S150|)|O
S150|.|O
S208|Vital|O
S208|signs|O
S208|were|O
S208|measured|O
S208|and|O
S208|recorded|O
S208|in|O
S208|conjunction|O
S208|with|O
S208|lung|O
S208|function|O
S208|tests|O
S208|at|O
S208|Visits|O
S208|2–6|O
S208|.|O
S1284|If|O
S1284|appropriate|O
S1284|,|O
S1284|the|O
S1284|IST-3|O
S1284|trial|O
S1284|office|O
S1284|masked|O
S1284|staff|O
S1284|then|O
S1284|mailed|O
S1284|a|O
S1284|postal|O
S1284|questionnaire|O
S1284|to|O
S1284|patients|O
S1284|to|O
S1284|assess|O
S1284|outcome|O
S1284|.|O
S1898|If|O
S1898|cholesterol|O
S1898|lowering|O
S1898|with|O
S1898|statin|O
S1898|treatment|O
S1898|had|O
S1898|effects|O
S1898|on|O
S1898|cancer|O
S1898|then|O
S1898|these|O
S1898|might|O
S1898|be|O
S1898|expected|O
S1898|to|O
S1898|be|O
S1898|restricted|O
S1898|to|O
S1898|particular|O
S1898|types|O
S1898|.|O
S816|There|O
S816|was|O
S816|a|O
S816|dose-dependent|O
S816|increase|O
S816|in|O
S816|forearm|O
S816|blood|O
S816|flow|O
S816|with|O
S816|all|O
S816|intra-arterial|O
S816|vasodilators|O
S816|:|O
S816|substance|O
S816|P|O
S816|,|O
S816|acetylcholine|O
S816|and|O
S816|sodium|O
S816|nitroprusside|O
S816|(|O
S816|p|O
S816|<|O
S816|0.001|O
S816|)|O
S816|.|O
S912|As|O
S912|this|O
S912|was|O
S912|a|O
S912|pragmatic|O
S912|trial|O
S912|,|O
S912|the|O
S912|dose|O
S912|could|O
S912|be|O
S912|adjusted|O
S912|according|O
S912|to|O
S912|normal|O
S912|practice|O
S912|,|O
S912|to|O
S912|a|O
S912|maximum|O
S912|of|O
S912|1|O
S912|mg/kg/day|O
S912|for|O
S912|prednisolone|O
S912|and|O
S912|5|O
S912|mg/kg/day|O
S912|for|O
S912|ciclosporin|O
S912|.|O
S1624|HIV|O
S1624|viral|O
S1624|loads|O
S1624|were|O
S1624|done|O
S1624|retrospectively|O
S1624|on|O
S1624|stored|O
S1624|samples|O
S1624|.|O
S585|Conclusions|O
S585|Bosentan|O
S585|treatment|O
S585|reduced|O
S585|the|O
S585|occurrence|O
S585|of|O
S585|new|O
S585|DUs|O
S585|in|O
S585|patients|O
S585|with|O
S585|SSc|O
S585|but|O
S585|had|O
S585|no|O
S585|effect|O
S585|on|O
S585|DU|O
S585|healing|O
S585|.|O
S1499|The|O
S1499|six|O
S1499|deaths|O
S1499|not|O
S1499|related|O
S1499|to|O
S1499|H5N1|O
S1499|(|O
S1499|two|O
S1499|with|O
S1499|H3N2|O
S1499|,|O
S1499|one|O
S1499|with|O
S1499|influenza|O
S1499|B|O
S1499|,|O
S1499|one|O
S1499|with|O
S1499|H1N1pdm09|O
S1499|,|O
S1499|and|O
S1499|two|O
S1499|negative|O
S1499|)|O
S1499|were|O
S1499|not|O
S1499|significantly|O
S1499|different|O
S1499|between|O
S1499|arms|O
S1499|.|O
S187|Randomisation|O
S187|Each|O
S187|patient|O
S187|received|O
S187|all|O
S187|treatments|O
S187|.|O
S579|The|O
S579|two|O
S579|primary|O
S579|end|O
S579|points|O
S579|were|O
S579|the|O
S579|number|O
S579|of|O
S579|new|O
S579|DUs|O
S579|and|O
S579|the|O
S579|time|O
S579|to|O
S579|healing|O
S579|of|O
S579|the|O
S579|cardinal|O
S579|ulcer|O
S579|.|O
S2134|Non-normally|O
S2134|distributed|O
S2134|data|O
S2134|were|O
S2134|log-transformed|O
S2134|.|O
S30|Patients|O
S30|were|O
S30|stratified|B-Randomization_Type_Stratified
S30|for|O
S30|two|O
S30|risk|O
S30|factors|O
S30|for|O
S30|ulcer|O
S30|development|O
S30|:|O
S30|concomitant|B-Randomization_Stratified_Criteria
S30|use|I-Randomization_Stratified_Criteria
S30|of|I-Randomization_Stratified_Criteria
S30|low-dose|I-Randomization_Stratified_Criteria
S30|aspirin|I-Randomization_Stratified_Criteria
S30|(|I-Randomization_Stratified_Criteria
S30|≤325|I-Randomization_Stratified_Criteria
S30|mg|I-Randomization_Stratified_Criteria
S30|daily|I-Randomization_Stratified_Criteria
S30|)|I-Randomization_Stratified_Criteria
S30|and/or|I-Randomization_Stratified_Criteria
S30|anticoagulant|I-Randomization_Stratified_Criteria
S30|medication|I-Randomization_Stratified_Criteria
S30|and|O
S30|history|B-Randomization_Stratified_Criteria
S30|of|I-Randomization_Stratified_Criteria
S30|gastric|I-Randomization_Stratified_Criteria
S30|or|I-Randomization_Stratified_Criteria
S30|duodenal|I-Randomization_Stratified_Criteria
S30|ulcer|I-Randomization_Stratified_Criteria
S30|.|O
S59|Treatment-by-subgroup|O
S59|interaction|O
S59|was|O
S59|also|O
S59|assessed|O
S59|among|O
S59|these|O
S59|subgroups|O
S59|in|O
S59|the|O
S59|model|O
S59|.|O
S219|Study|O
S219|baseline|O
S219|,|O
S219|defined|O
S219|as|O
S219|pre-treatment|O
S219|values|O
S219|measured|O
S219|at|O
S219|Visit|O
S219|2|O
S219|in|O
S219|the|O
S219|evening|O
S219|,|O
S219|was|O
S219|included|O
S219|as|O
S219|covariate|O
S219|.|O
S606|A|O
S606|previous|O
S606|double-blind|O
S606|,|O
S606|randomised|O
S606|,|O
S606|placebo-controlled|O
S606|trial|O
S606|investigated|O
S606|the|O
S606|role|O
S606|of|O
S606|bosentan|O
S606|in|O
S606|the|O
S606|reduction|O
S606|of|O
S606|new|O
S606|DUs|O
S606|in|O
S606|122|O
S606|patients|O
S606|with|O
S606|SSc|O
S606|and|O
S606|a|O
S606|history|O
S606|of|O
S606|DUs|O
S606|within|O
S606|the|O
S606|previous|O
S606|year|O
S606|.|O
S2229|The|O
S2229|pharmacokinetic|O
S2229|outcomes|O
S2229|included|O
S2229|:|O
S2229|serum|O
S2229|concentrations|O
S2229|prior|O
S2229|to|O
S2229|dosing|O
S2229|at|O
S2229|Weeks|O
S2229|0|O
S2229|,|O
S2229|4|O
S2229|,|O
S2229|12|O
S2229|,|O
S2229|24|O
S2229|,|O
S2229|and|O
S2229|32|O
S2229|;|O
S2229|serum|O
S2229|concentrations|O
S2229|at|O
S2229|Week|O
S2229|5|O
S2229|and|O
S2229|Week|O
S2229|25|O
S2229|;|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentrations|O
S2229|(|O
S2229|Cmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|time|O
S2229|of|O
S2229|maximum|O
S2229|observed|O
S2229|serum|O
S2229|concentration|O
S2229|(|O
S2229|Tmax|O
S2229|,|O
S2229|obs|O
S2229|)|O
S2229|;|O
S2229|and|O
S2229|terminal|O
S2229|elimination|O
S2229|half-life|O
S2229|(|O
S2229|t1/2|O
S2229|)|O
S2229|.|O
S1402|No|O
S1402|differences|O
S1402|were|O
S1402|found|O
S1402|in|O
S1402|clearance|O
S1402|of|O
S1402|virus|O
S1402|in|O
S1402|subgroup|O
S1402|analyses|O
S1402|by|O
S1402|virus|O
S1402|type/subtype|O
S1402|,|O
S1402|age|O
S1402|,|O
S1402|and|O
S1402|duration|O
S1402|of|O
S1402|illness|O
S1402|before|O
S1402|randomisation|O
S1402|.|O
S2132|Next|O
S2132|,|O
S2132|on|O
S2132|the|O
S2132|basis|O
S2132|of|O
S2132|(|O
S2132|i|O
S2132|)|O
S2132|a|O
S2132|coefficient|O
S2132|of|O
S2132|0.4|O
S2132|for|O
S2132|the|O
S2132|correlation|O
S2132|between|O
S2132|the|O
S2132|baseline|O
S2132|measurement|O
S2132|and|O
S2132|the|O
S2132|end-of-study|O
S2132|measurement|O
S2132|in|O
S2132|a|O
S2132|covariance|O
S2132|analysis|O
S2132|,|O
S2132|(|O
S2132|ii|O
S2132|)|O
S2132|a|O
S2132|very|O
S2132|low|O
S2132|dropout|O
S2132|rate|O
S2132|and|O
S2132|(|O
S2132|iii|O
S2132|)|O
S2132|the|O
S2132|replacement|O
S2132|of|O
S2132|dropouts|O
S2132|,|O
S2132|we|O
S2132|calculated|O
S2132|the|O
S2132|required|O
S2132|sample|O
S2132|size|O
S2132|to|O
S2132|be|O
S2132|14|B-Sample_Size_Target
S2132|patients|I-Sample_Size_Target
S2132|per|I-Sample_Size_Target
S2132|group|I-Sample_Size_Target
S2132|.|O
S602|Indirect|O
S602|evidence|O
S602|implicates|O
S602|endothelin|O
S602|(|O
S602|ET|O
S602|)|O
S602|as|O
S602|a|O
S602|potential|O
S602|mediator|O
S602|of|O
S602|the|O
S602|vascular|O
S602|dysfunction|O
S602|in|O
S602|SSc|O
S602|.|O
S949|Analysis|O
S949|was|O
S949|conducted|O
S949|using|O
S949|intention|O
S949|to|O
S949|treat|O
S949|principles|O
S949|;|O
S949|defined|O
S949|as|O
S949|all|O
S949|randomised|O
S949|participants|O
S949|,|O
S949|excluding|O
S949|those|O
S949|with|O
S949|a|O
S949|later|O
S949|diagnosis|O
S949|determined|O
S949|to|O
S949|be|O
S949|something|O
S949|other|O
S949|than|O
S949|pyoderma|O
S949|gangrenosum|O
S949|.|O
S1305|Therefore|O
S1305|,|O
S1305|the|O
S1305|primary|O
S1305|analysis|O
S1305|of|O
S1305|the|O
S1305|effect|O
S1305|of|O
S1305|treatment|O
S1305|on|O
S1305|the|O
S1305|primary|O
S1305|outcome|O
S1305|was|O
S1305|adjusted|O
S1305|by|O
S1305|logistic|O
S1305|regression|O
S1305|for|O
S1305|linear|O
S1305|effects|O
S1305|for|O
S1305|the|O
S1305|following|O
S1305|covariates|O
S1305|:|O
S1305|age|O
S1305|;|O
S1305|National|O
S1305|Institutes|O
S1305|of|O
S1305|Health|O
S1305|stroke|O
S1305|scale|O
S1305|(|O
S1305|NIHSS|O
S1305|)|O
S1305|score|O
S1305|;|O
S1305|time|O
S1305|from|O
S1305|onset|O
S1305|of|O
S1305|stroke|O
S1305|symptoms|O
S1305|to|O
S1305|randomisation|O
S1305|;|O
S1305|and|O
S1305|presence|O
S1305|(|O
S1305|vs|O
S1305|absence|O
S1305|)|O
S1305|of|O
S1305|ischaemic|O
S1305|change|O
S1305|on|O
S1305|the|O
S1305|prerandomisation|O
S1305|brain|O
S1305|scan|O
S1305|according|O
S1305|to|O
S1305|expert|O
S1305|assessment|O
S1305|.|O
S1326|Most|O
S1326|patients|O
S1326|were|O
S1326|cared|O
S1326|for|O
S1326|in|O
S1326|a|O
S1326|stroke|O
S1326|unit|O
S1326|,|O
S1326|and|O
S1326|there|O
S1326|was|O
S1326|no|O
S1326|evidence|O
S1326|of|O
S1326|a|O
S1326|major|O
S1326|imbalance|O
S1326|in|O
S1326|the|O
S1326|use|O
S1326|of|O
S1326|background|O
S1326|treatments|O
S1326|or|O
S1326|place|O
S1326|of|O
S1326|care|O
S1326|(|O
S1326|admissions|O
S1326|ward|O
S1326|,|O
S1326|or|O
S1326|stroke|O
S1326|unit|O
S1326|)|O
S1326|over|O
S1326|the|O
S1326|first|O
S1326|7|O
S1326|days|O
S1326|;|O
S1326|an|O
S1326|analysis|O
S1326|of|O
S1326|blood|O
S1326|pressure|O
S1326|in|O
S1326|patients|O
S1326|measured|O
S1326|after|O
S1326|randomisation|O
S1326|showed|O
S1326|no|O
S1326|significant|O
S1326|difference|O
S1326|at|O
S1326|each|O
S1326|timepoint|O
S1326|over|O
S1326|the|O
S1326|first|O
S1326|24|O
S1326|h|O
S1326|in|O
S1326|either|O
S1326|systolic|O
S1326|or|O
S1326|diastolic|O
S1326|blood|O
S1326|pressures|O
S1326|between|O
S1326|the|O
S1326|two|O
S1326|treatment|O
S1326|groups|O
S1326|.|O
S1448|If|O
S1448|we|O
S1448|assume|O
S1448|that|O
S1448|30|O
S1448|%|O
S1448|of|O
S1448|children|O
S1448|and|O
S1448|55|O
S1448|%|O
S1448|of|O
S1448|adults|O
S1448|treated|O
S1448|with|O
S1448|standard|O
S1448|dose|O
S1448|oseltamivir|O
S1448|would|O
S1448|test|O
S1448|negative|O
S1448|for|O
S1448|virus|O
S1448|on|O
S1448|day|O
S1448|five|O
S1448|,|O
S1448|a|O
S1448|sample|O
S1448|size|O
S1448|of|O
S1448|242|B-Sample_Size_Required
S1448|patients|O
S1448|would|O
S1448|be|O
S1448|required|O
S1448|to|O
S1448|show|O
S1448|a|O
S1448|20|O
S1448|%|O
S1448|absolute|O
S1448|improvement|O
S1448|in|O
S1448|cessation|O
S1448|of|O
S1448|viral|O
S1448|shedding|O
S1448|with|O
S1448|85|B-Sample_Size_Calculation_Power_Value
S1448|%|I-Sample_Size_Calculation_Power_Value
S1448|power|O
S1448|and|O
S1448|a|B-Sample_Size_Calculation_Alpha_Value
S1448|two|I-Sample_Size_Calculation_Alpha_Value
S1448|sided|I-Sample_Size_Calculation_Alpha_Value
S1448|α|I-Sample_Size_Calculation_Alpha_Value
S1448|of|I-Sample_Size_Calculation_Alpha_Value
S1448|0.05|I-Sample_Size_Calculation_Alpha_Value
S1448|.|O
S1091|Digital|O
S1091|photographs|O
S1091|of|O
S1091|the|O
S1091|plantar|O
S1091|wart|O
S1091|(|O
S1091|s|O
S1091|)|O
S1091|were|O
S1091|taken|O
S1091|at|O
S1091|baseline|O
S1091|and|O
S1091|at|O
S1091|the|O
S1091|outcome|O
S1091|assessment|O
S1091|.|O
S1723|Results|O
S1723|were|O
S1723|similar|O
S1723|when|O
S1723|restricted|O
S1723|to|O
S1723|children|O
S1723|younger|O
S1723|than|O
S1723|5|O
S1723|years|O
S1723|(|O
S1723|not|O
S1723|shown|O
S1723|)|O
S1723|or|O
S1723|3|O
S1723|years|O
S1723|(|O
S1723|appendix|O
S1723|)|O
S1723|.|O
S318|The|O
S318|mean|O
S318|number|O
S318|of|O
S318|flares|O
S318|in|O
S318|the|O
S318|past|O
S318|year|O
S318|ranged|O
S318|from|O
S318|3.6|O
S318|to|O
S318|4.7|O
S318|for|O
S318|the|O
S318|different|O
S318|treatment|O
S318|groups|O
S318|.|O
S1464|Confidence|O
S1464|intervals|O
S1464|for|O
S1464|proportions|O
S1464|and|O
S1464|their|O
S1464|differences|O
S1464|were|O
S1464|calculated|O
S1464|with|O
S1464|Wilson|O
S1464|’|O
S1464|s|O
S1464|method|O
S1464|.|O
S1485|In|O
S1485|children|O
S1485|,|O
S1485|the|O
S1485|corresponding|O
S1485|rates|O
S1485|were|O
S1485|77/99|O
S1485|(|O
S1485|71|O
S1485|%|O
S1485|)|O
S1485|in|O
S1485|the|O
S1485|double|O
S1485|dose|O
S1485|versus|O
S1485|62/94|O
S1485|(|O
S1485|66|O
S1485|%|O
S1485|)|O
S1485|in|O
S1485|the|O
S1485|standard|O
S1485|dose|O
S1485|arm|O
S1485|(|O
S1485|P=0.48|O
S1485|)|O
S1485|,|O
S1485|and|O
S1485|in|O
S1485|adults|O
S1485|12/15|O
S1485|(|O
S1485|80|O
S1485|%|O
S1485|)|O
S1485|versus|O
S1485|12/16|O
S1485|(|O
S1485|75|O
S1485|%|O
S1485|)|O
S1485|,|O
S1485|respectively|O
S1485|(|O
S1485|P=0.74|O
S1485|)|O
S1485|.|O
S649|This|O
S649|included|O
S649|subgroups|O
S649|of|O
S649|limited|O
S649|and|O
S649|diffuse|O
S649|SSc|O
S649|,|O
S649|with|O
S649|no|O
S649|difference|O
S649|between|O
S649|the|O
S649|two|O
S649|subgroups|O
S649|in|O
S649|the|O
S649|treatment|O
S649|effect|O
S649|(|O
S649|overlapping|O
S649|95|O
S649|%|O
S649|CIs|O
S649|)|O
S649|.|O
S1719|Viral|O
S1719|load|O
S1719|suppression|O
S1719|less|O
S1719|than|O
S1719|400|O
S1719|copies|O
S1719|per|O
S1719|mL|O
S1719|was|O
S1719|similar|O
S1719|in|O
S1719|the|O
S1719|three|O
S1719|ART|O
S1719|strategy|O
S1719|groups|O
S1719|at|O
S1719|weeks|O
S1719|4|O
S1719|,|O
S1719|36|O
S1719|,|O
S1719|and|O
S1719|48|O
S1719|(|O
S1719|p|O
S1719|>|O
S1719|0·4|O
S1719|)|O
S1719|,|O
S1719|but|O
S1719|differed|O
S1719|significantly|O
S1719|at|O
S1719|weeks|O
S1719|24|O
S1719|(|O
S1719|p=0·009|O
S1719|)|O
S1719|and|O
S1719|144|O
S1719|(|O
S1719|p=0·009|O
S1719|;|O
S1719|figure|O
S1719|4|O
S1719|)|O
S1719|.|O
S989|Notable|O
S989|differences|O
S989|included|O
S989|new|O
S989|onset|O
S989|diabetes|O
S989|and|O
S989|hyperglycaemia|O
S989|in|O
S989|the|O
S989|prednisolone|O
S989|group|O
S989|,|O
S989|and|O
S989|headaches|O
S989|,|O
S989|gastrointestinal|O
S989|disturbance|O
S989|,|O
S989|and|O
S989|renal|O
S989|dysfunction|O
S989|commonly|O
S989|in|O
S989|the|O
S989|ciclosporin|O
S989|group|O
S989|.|O
S337|Most|O
S337|AEs|O
S337|were|O
S337|mild|O
S337|or|O
S337|moderate|O
S337|in|O
S337|severity|O
S337|,|O
S337|and|O
S337|there|O
S337|was|O
S337|no|O
S337|evidence|O
S337|of|O
S337|a|O
S337|dose-response|O
S337|for|O
S337|any|O
S337|AE|O
S337|.|O
S1836|To|O
S1836|allow|O
S1836|unbiased|O
S1836|assessment|O
S1836|of|O
S1836|subsequent|O
S1836|long-term|O
S1836|effects|O
S1836|,|O
S1836|participants|O
S1836|and|O
S1836|their|O
S1836|doctors|O
S1836|were|O
S1836|not|O
S1836|made|O
S1836|aware|O
S1836|of|O
S1836|their|O
S1836|previously|O
S1836|allocated|O
S1836|study|O
S1836|treatment|O
S1836|unless|O
S1836|there|O
S1836|was|O
S1836|a|O
S1836|particular|O
S1836|request|O
S1836|to|O
S1836|do|O
S1836|so|O
S1836|,|O
S1836|and|O
S1836|only|O
S1836|15|O
S1836|%|O
S1836|of|O
S1836|participants|O
S1836|were|O
S1836|unblinded|O
S1836|(|O
S1836|18|O
S1836|%|O
S1836|simvastatin-allocated|O
S1836|vs|O
S1836|13|O
S1836|%|O
S1836|placebo-allocated|O
S1836|)|O
S1836|.|O
S1985|Serum|O
S1985|samples|O
S1985|were|O
S1985|stored|O
S1985|at|O
S1985|−20°C|O
S1985|until|O
S1985|transported|O
S1985|frozen|O
S1985|to|O
S1985|the|O
S1985|Mayo|O
S1985|Clinic|O
S1985|for|O
S1985|analysis|O
S1985|.|O
S1453|Patients|O
S1453|who|O
S1453|died|O
S1453|before|O
S1453|day|O
S1453|five|O
S1453|were|O
S1453|assumed|O
S1453|to|O
S1453|be|O
S1453|virus|O
S1453|positive|O
S1453|on|O
S1453|day|O
S1453|five|O
S1453|unless|O
S1453|the|O
S1453|virus|O
S1453|was|O
S1453|cleared|O
S1453|before|O
S1453|death|O
S1453|.|O
S27|Exclusion|O
S27|criteria|O
S27|included|O
S27|history|O
S27|of|O
S27|erosive|O
S27|esophagitis|O
S27|;|O
S27|history|O
S27|of|O
S27|GI|O
S27|complications|O
S27|(|O
S27|bleeding|O
S27|,|O
S27|perforated|O
S27|ulcer|O
S27|,|O
S27|gastric|O
S27|outlet|O
S27|obstruction|O
S27|due|O
S27|to|O
S27|an|O
S27|ulcer|O
S27|)|O
S27|;|O
S27|history|O
S27|of|O
S27|NSAID-associated|O
S27|asthma|O
S27|exacerbations|O
S27|,|O
S27|acute|O
S27|renal|O
S27|failure|O
S27|,|O
S27|interstitial|O
S27|nephritis|O
S27|,|O
S27|or|O
S27|hepatitis|O
S27|;|O
S27|history|O
S27|of|O
S27|GI|O
S27|malignancy|O
S27|;|O
S27|history|O
S27|of|O
S27|myocardial|O
S27|infarction|O
S27|,|O
S27|unstable|O
S27|cardiac|O
S27|arrhythmias|O
S27|,|O
S27|or|O
S27|stroke|O
S27|within|O
S27|6|O
S27|months|O
S27|of|O
S27|study|O
S27|entry|O
S27|;|O
S27|coronary|O
S27|artery|O
S27|bypass|O
S27|graft|O
S27|surgery|O
S27|within|O
S27|14|O
S27|days|O
S27|of|O
S27|study|O
S27|entry|O
S27|;|O
S27|uncontrolled|O
S27|congestive|O
S27|heart|O
S27|failure|O
S27|or|O
S27|hypertension|O
S27|at|O
S27|entry|O
S27|;|O
S27|acid-suppressive|O
S27|therapy|O
S27|or|O
S27|misoprostol|O
S27|within|O
S27|14|O
S27|days|O
S27|before|O
S27|study|O
S27|entry|O
S27|or|O
S27|investigational|O
S27|drug|O
S27|or|O
S27|NSAIDs|O
S27|(|O
S27|including|O
S27|aspirin|O
S27|>|O
S27|325|O
S27|mg|O
S27|daily|O
S27|)|O
S27|within|O
S27|30|O
S27|days|O
S27|before|O
S27|study|O
S27|entry|O
S27|;|O
S27|ulcer|O
S27|or|O
S27|>|O
S27|5|O
S27|erosions|O
S27|on|O
S27|screening|O
S27|upper|O
S27|GI|O
S27|tract|O
S27|endoscopy|O
S27|;|O
S27|or|O
S27|one|O
S27|of|O
S27|the|O
S27|following|O
S27|abnormalities|O
S27|on|O
S27|baseline|O
S27|laboratory|O
S27|testing|O
S27|:|O
S27|creatinine|O
S27|clearance|O
S27|<|O
S27|45|O
S27|ml/min|O
S27|;|O
S27|aminotransferase|O
S27|>|O
S27|2.5|O
S27|times|O
S27|upper|O
S27|limit|O
S27|of|O
S27|normal|O
S27|;|O
S27|fasting|O
S27|blood|O
S27|sugar|O
S27|>|O
S27|200|O
S27|mg/dl|O
S27|;|O
S27|serum|O
S27|pregnancy|O
S27|test|O
S27|positive|O
S27|;|O
S27|serologic|O
S27|tests|O
S27|positive|O
S27|for|O
S27|human|O
S27|immunodeficiency|O
S27|virus|O
S27|,|O
S27|hepatitis|O
S27|B|O
S27|,|O
S27|or|O
S27|hepatitis|O
S27|C|O
S27|;|O
S27|or|O
S27|stool|O
S27|antigen|O
S27|for|O
S27|H.|O
S27|pylori|O
S27|positive|O
S27|.|O
S1511|Overall|O
S1511|14|O
S1511|(|O
S1511|19|O
S1511|%|O
S1511|)|O
S1511|adverse|O
S1511|events|O
S1511|were|O
S1511|judged|O
S1511|as|O
S1511|possibly|O
S1511|,|O
S1511|probably|O
S1511|,|O
S1511|or|O
S1511|definitely|O
S1511|related|O
S1511|to|O
S1511|oseltamivir|O
S1511|.|O
S1256|Procedures|O
S1256|Clinicians|O
S1256|entered|O
S1256|baseline|O
S1256|data|O
S1256|via|O
S1256|a|B-Randomization_Sequence_Generation_Method
S1256|telephone|I-Randomization_Sequence_Generation_Method
S1256|voice-activated|I-Randomization_Sequence_Generation_Method
S1256|or|I-Randomization_Sequence_Generation_Method
S1256|a|I-Randomization_Sequence_Generation_Method
S1256|secure|I-Randomization_Sequence_Generation_Method
S1256|web-based|I-Randomization_Sequence_Generation_Method
S1256|randomisation|I-Randomization_Sequence_Generation_Method
S1256|system|I-Randomization_Sequence_Generation_Method
S1256|.|O
S2082|Methods|O
S2082|We|O
S2082|performed|O
S2082|a|O
S2082|90-day|O
S2082|,|O
S2082|randomised|B-Randomization_Type_Simple
S2082|,|O
S2082|double-blind|B-Blinding_Double_Blind
S2082|,|O
S2082|study|O
S2082|with|O
S2082|two|O
S2082|parallel|B-Design_Parallel_Group
S2082|arms|O
S2082|:|O
S2082|20|B-Design_Parallel_Group
S2082|mg/day|I-Design_Parallel_Group
S2082|memantine|I-Design_Parallel_Group
S2082|versus|I-Design_Parallel_Group
S2082|placebo|I-Design_Parallel_Group
S2082|(|O
S2082|ClinicalTrials.gov|O
S2082|:|O
S2082|NCT01108029|O
S2082|)|O
S2082|.|O
S1253|Only|O
S1253|if|O
S1253|both|O
S1253|the|O
S1253|clinician|O
S1253|and|O
S1253|the|O
S1253|patient|O
S1253|(|O
S1253|or|O
S1253|a|O
S1253|relevant|O
S1253|proxy|O
S1253|for|O
S1253|the|O
S1253|patient|O
S1253|)|O
S1253|felt|O
S1253|that|O
S1253|the|O
S1253|treatment|O
S1253|was|O
S1253|promising|O
S1253|but|O
S1253|unproven|O
S1253|,|O
S1253|could|O
S1253|the|O
S1253|patient|O
S1253|be|O
S1253|included|O
S1253|in|O
S1253|the|O
S1253|trial|O
S1253|after|O
S1253|appropriate|O
S1253|informed|O
S1253|consent|O
S1253|from|O
S1253|the|O
S1253|patient|O
S1253|or|O
S1253|a|O
S1253|valid|O
S1253|proxy|O
S1253|.|O
S904|Members|O
S904|of|O
S904|the|O
S904|UK|O
S904|Dermatology|O
S904|Clinical|O
S904|Trials|O
S904|Network|O
S904|also|O
S904|identified|O
S904|this|O
S904|research|O
S904|as|O
S904|being|O
S904|a|O
S904|priority|O
S904|area|O
S904|for|O
S904|clinicians|O
S904|treating|O
S904|patients|O
S904|with|O
S904|pyoderma|O
S904|gangrenosum|O
S904|.|O
S338|SAEs|O
S338|were|O
S338|reported|O
S338|in|O
S338|14|O
S338|(|O
S338|4.3|O
S338|%|O
S338|)|O
S338|patients|O
S338|treated|O
S338|with|O
S338|canakinumab|O
S338|and|O
S338|6|O
S338|(|O
S338|5.6|O
S338|%|O
S338|)|O
S338|patients|O
S338|treated|O
S338|with|O
S338|colchicine|O
S338|;|O
S338|2|O
S338|were|O
S338|considered|O
S338|by|O
S338|the|O
S338|investigator|O
S338|to|O
S338|be|O
S338|possibly|O
S338|related|O
S338|to|O
S338|study|O
S338|medication|O
S338|:|O
S338|erysipelas|O
S338|of|O
S338|the|O
S338|left|O
S338|leg|O
S338|in|O
S338|the|O
S338|canakinumab|O
S338|25|O
S338|mg|O
S338|group|O
S338|and|O
S338|cancer|O
S338|of|O
S338|the|O
S338|right|O
S338|kidney|O
S338|in|O
S338|the|O
S338|colchicine|O
S338|group|O
S338|.|O
S908|Histopathology|O
S908|is|O
S908|rarely|O
S908|pathognomonic|O
S908|for|O
S908|pyoderma|O
S908|gangrenosum|O
S908|,|O
S908|and|O
S908|many|O
S908|clinicians|O
S908|avoid|O
S908|biopsy|O
S908|because|O
S908|of|O
S908|the|O
S908|risk|O
S908|of|O
S908|an|O
S908|immunological|O
S908|reaction|O
S908|that|O
S908|results|O
S908|in|O
S908|ulcer|O
S908|extension|O
S908|at|O
S908|the|O
S908|biopsy|O
S908|site|O
S908|.|O
S460|Oestrogen/progesterone|O
S460|therapy|O
S460|continued|O
S460|at|O
S460|an|O
S460|adult|O
S460|replacement|O
S460|dose|O
S460|once|O
S460|pubertal|O
S460|induction|O
S460|was|O
S460|completed|O
S460|.|O
S590|These|O
S590|vascular|O
S590|lesions|O
S590|are|O
S590|the|O
S590|underlying|O
S590|basis|O
S590|of|O
S590|important|O
S590|clinical|O
S590|syndromes|O
S590|in|O
S590|SSc|O
S590|,|O
S590|including|O
S590|scleroderma|O
S590|renal|O
S590|crisis|O
S590|,|O
S590|pulmonary|O
S590|arterial|O
S590|hypertension|O
S590|(|O
S590|PAH|O
S590|)|O
S590|and|O
S590|Raynaud|O
S590|'s|O
S590|phenomenon|O
S590|.|O
S656|However|O
S656|,|O
S656|the|O
S656|mean|O
S656|total|O
S656|number|O
S656|of|O
S656|DUs|O
S656|(|O
S656|baseline|O
S656|and|O
S656|new|O
S656|)|O
S656|per|O
S656|patient|O
S656|decreased|O
S656|to|O
S656|a|O
S656|similar|O
S656|extent|O
S656|in|O
S656|the|O
S656|bosentan|O
S656|and|O
S656|placebo|O
S656|groups|O
S656|(|O
S656|−1.7|O
S656|.|O
S1897|Indeed|O
S1897|,|O
S1897|even|O
S1897|during|O
S1897|the|O
S1897|later|O
S1897|years|O
S1897|of|O
S1897|this|O
S1897|prolonged|O
S1897|follow-up|O
S1897|,|O
S1897|no|O
S1897|suggestion|O
S1897|was|O
S1897|noted|O
S1897|of|O
S1897|any|O
S1897|emerging|O
S1897|difference|O
S1897|in|O
S1897|the|O
S1897|overall|O
S1897|incidence|O
S1897|of|O
S1897|cancer|O
S1897|.|O
S1597|One|O
S1597|or|O
S1597|more|O
S1597|grade|O
S1597|3|O
S1597|or|O
S1597|4|O
S1597|adverse|O
S1597|events|O
S1597|occurred|O
S1597|in|O
S1597|283|O
S1597|(|O
S1597|47|O
S1597|%|O
S1597|)|O
S1597|children|O
S1597|on|O
S1597|clinically|O
S1597|driven|O
S1597|versus|O
S1597|282|O
S1597|(|O
S1597|47|O
S1597|%|O
S1597|)|O
S1597|on|O
S1597|routine|O
S1597|laboratory|O
S1597|monitoring|O
S1597|(|O
S1597|HR|O
S1597|0·98|O
S1597|,|O
S1597|0·83–1·16|O
S1597|,|O
S1597|p=0·83|O
S1597|)|O
S1597|.|O
S19|The|O
S19|RRs|O
S19|for|O
S19|proton-pump|O
S19|inhibitor|O
S19|vs.|O
S19|placebo|O
S19|co-therapy|O
S19|in|O
S19|the|O
S19|meta-analysis|O
S19|were|O
S19|0.40|O
S19|(|O
S19|0.32–0.51|O
S19|)|O
S19|for|O
S19|gastric|O
S19|ulcers|O
S19|and|O
S19|0.19|O
S19|(|O
S19|0.09–0.37|O
S19|)|O
S19|for|O
S19|duodenal|O
S19|ulcers|O
S19|.|O
S1328|76|O
S1328|(|O
S1328|49|O
S1328|%|O
S1328|)|O
S1328|centres|O
S1328|were|O
S1328|classed|O
S1328|as|O
S1328|experienced|O
S1328|in|O
S1328|treating|O
S1328|stroke|O
S1328|with|O
S1328|thrombolysis|O
S1328|,|O
S1328|and|O
S1328|1143|O
S1328|patients|O
S1328|were|O
S1328|recruited|O
S1328|by|O
S1328|these|O
S1328|centres|O
S1328|.|O
S259|Patients|O
S259|recorded|O
S259|details|O
S259|of|O
S259|flares|O
S259|in|O
S259|diaries|O
S259|.|O
S921|Assessors|B-Blinding_Object_Outcome_Assessors
S921|blind|O
S921|to|O
S921|the|O
S921|allocated|O
S921|treatment|O
S921|assessed|O
S921|the|O
S921|ulcer|O
S921|size|O
S921|and|O
S921|global|O
S921|treatment|O
S921|response|O
S921|from|O
S921|digital|O
S921|images|O
S921|of|O
S921|the|O
S921|target|O
S921|lesion|O
S921|.|O
S212|Analysis|O
S212|of|O
S212|adverse|O
S212|events|O
S212|and|O
S212|vital|O
S212|signs|O
S212|was|O
S212|descriptive|O
S212|in|O
S212|nature|O
S212|.|O
S1473|Patients|O
S1473|were|O
S1473|enrolled|O
S1473|a|O
S1473|median|O
S1473|of|O
S1473|5|O
S1473|(|O
S1473|range|O
S1473|1-10|O
S1473|)|O
S1473|days|O
S1473|after|O
S1473|the|O
S1473|onset|O
S1473|of|O
S1473|illness|O
S1473|:|O
S1473|7|O
S1473|(|O
S1473|3-11|O
S1473|)|O
S1473|days|O
S1473|for|O
S1473|patients|O
S1473|with|O
S1473|H5N1|O
S1473|infected|O
S1473|and|O
S1473|5|O
S1473|(|O
S1473|1-10|O
S1473|)|O
S1473|days|O
S1473|in|O
S1473|other|O
S1473|patients|O
S1473|(|O
S1473|P|O
S1473|<|O
S1473|0.001|O
S1473|)|O
S1473|.|O
S1343|Treatment|O
S1343|appeared|O
S1343|at|O
S1343|least|O
S1343|as|O
S1343|effective|O
S1343|in|O
S1343|this|O
S1343|age|O
S1343|group|O
S1343|as|O
S1343|in|O
S1343|younger|O
S1343|patients|O
S1343|.|O
S2111|Randomisation|O
S2111|and|O
S2111|masking|O
S2111|Subjects|O
S2111|were|O
S2111|randomly|B-Randomization_Type_Simple
S2111|assigned|I-Randomization_Type_Simple
S2111|to|O
S2111|memantine|B-Design_Parallel_Group
S2111|or|I-Design_Parallel_Group
S2111|placebo|I-Design_Parallel_Group
S2111|.|O
S1252|Equally|O
S1252|,|O
S1252|if|O
S1252|the|O
S1252|patient|O
S1252|had|O
S1252|a|O
S1252|clear|O
S1252|contraindication|O
S1252|to|O
S1252|treatment|O
S1252|they|O
S1252|were|O
S1252|not|O
S1252|to|O
S1252|be|O
S1252|entered|O
S1252|in|O
S1252|the|O
S1252|trial|O
S1252|.|O
S964|Thirteen|O
S964|of|O
S964|the|O
S964|participants|O
S964|had|O
S964|previously|O
S964|been|O
S964|enrolled|O
S964|in|O
S964|the|O
S964|observational|O
S964|study|O
S964|of|O
S964|topical|O
S964|treatments|O
S964|but|O
S964|had|O
S964|failed|O
S964|to|O
S964|respond|O
S964|to|O
S964|treatment|O
S964|and|O
S964|so|O
S964|were|O
S964|subsequently|O
S964|re-consented|O
S964|for|O
S964|the|O
S964|randomised|O
S964|controlled|O
S964|trial|O
S964|.|O
S511|Figure|O
S511|3|O
S511|(|O
S511|bottom|O
S511|panel|O
S511|)|O
S511|shows|O
S511|the|O
S511|corresponding|O
S511|comparison|O
S511|of|O
S511|summary|O
S511|height|O
S511|curves|O
S511|for|O
S511|randomisation|O
S511|2|O
S511|,|O
S511|late|O
S511|versus|O
S511|early|O
S511|induction|O
S511|.|O
S0|Double-Blind|B-Blinding_Double_Blind
S0|Randomized|O
S0|Trials|O
S0|of|O
S0|Single-Tablet|O
S0|Ibuprofen/High-Dose|O
S0|Famotidine|O
S0|vs.|O
S0|Ibuprofen|O
S0|Alone|O
S0|for|O
S0|Reduction|O
S0|of|O
S0|Gastric|O
S0|and|O
S0|Duodenal|O
S0|Ulcers|O
S1225|Findings|O
S1225|3035|B-Sample_Size_Actual_at_Enrollment
S1225|patients|O
S1225|were|O
S1225|enrolled|O
S1225|by|O
S1225|156|B-Settings_Multicenter
S1225|hospitals|I-Settings_Multicenter
S1225|in|O
S1225|12|B-Settings_Multicenter
S1225|countries|I-Settings_Multicenter
S1225|.|O
S1710|111|O
S1710|(|O
S1710|18|O
S1710|%|O
S1710|)|O
S1710|children|O
S1710|on|O
S1710|clinically|O
S1710|driven|O
S1710|monitoring|O
S1710|versus|O
S1710|109|O
S1710|(|O
S1710|18|O
S1710|%|O
S1710|)|O
S1710|on|O
S1710|routine|O
S1710|laboratory|O
S1710|monitoring|O
S1710|had|O
S1710|one|O
S1710|or|O
S1710|more|O
S1710|grade|O
S1710|4|O
S1710|adverse|O
S1710|events|O
S1710|(|O
S1710|HR|O
S1710|0·99|O
S1710|,|O
S1710|0·76–1·29|O
S1710|,|O
S1710|p=0·94|O
S1710|)|O
S1710|.|O
S1504|After|O
S1504|enrolment|O
S1504|,|O
S1504|an|O
S1504|additional|O
S1504|five|O
S1504|patients|O
S1504|needed|O
S1504|supplemental|O
S1504|oxygen|O
S1504|,|O
S1504|four|O
S1504|required|O
S1504|admission|O
S1504|to|O
S1504|intensive|O
S1504|care|O
S1504|,|O
S1504|and|O
S1504|six|O
S1504|were|O
S1504|mechanically|O
S1504|ventilated|O
S1504|.|O
S768|In|O
S768|order|O
S768|to|O
S768|achieve|O
S768|a|O
S768|rapid|O
S768|onset|O
S768|of|O
S768|action|O
S768|,|O
S768|we|O
S768|elected|O
S768|to|O
S768|use|O
S768|the|O
S768|intravenous|O
S768|route|O
S768|,|O
S768|and|O
S768|single|O
S768|intravenous|O
S768|doses|O
S768|of|O
S768|up|O
S768|to|O
S768|10|O
S768|mg/m2|O
S768|have|O
S768|been|O
S768|used|O
S768|safely|O
S768|in|O
S768|patients|O
S768|with|O
S768|heart|O
S768|failure|O
S768|.|O
S2240|Demographic|O
S2240|and|O
S2240|baseline|O
S2240|characteristics|O
S2240|were|O
S2240|summarized|O
S2240|using|O
S2240|descriptive|O
S2240|statistics|O
S2240|.|O
S308|Efficacy|O
S308|and|O
S308|safety|O
S308|analyses|O
S308|were|O
S308|then|O
S308|performed|O
S308|when|O
S308|all|O
S308|patients|O
S308|had|O
S308|completed|O
S308|the|O
S308|study|O
S308|(|O
S308|24|O
S308|weeks|O
S308|)|O
S308|.|O
S181|All|O
S181|patients|O
S181|were|O
S181|required|O
S181|to|O
S181|continue|O
S181|maintenance|O
S181|treatment|O
S181|with|O
S181|stable|O
S181|medium-dose|O
S181|ICS|O
S181|(|O
S181|400–800|O
S181|μg|O
S181|budesonide|O
S181|or|O
S181|equivalent|O
S181|)|O
S181|for|O
S181|at|O
S181|least|O
S181|4|O
S181|weeks|O
S181|prior|O
S181|to|O
S181|Visit|O
S181|1|O
S181|and|O
S181|until|O
S181|Visit|O
S181|7|O
S181|.|O
S2022|The|O
S2022|final|O
S2022|25|O
S2022|(|O
S2022|OH|O
S2022|)|O
S2022|D|O
S2022|concentration|O
S2022|was|O
S2022|greater|O
S2022|in|O
S2022|those|O
S2022|who|O
S2022|achieved|O
S2022|the|O
S2022|primary|O
S2022|outcome|O
S2022|than|O
S2022|in|O
S2022|those|O
S2022|who|O
S2022|did|O
S2022|not|O
S2022|(|O
S2022|56.4±17.2|O
S2022|nmol/L|O
S2022|vs|O
S2022|37.7±18.5|O
S2022|nmol/L|O
S2022|,|O
S2022|respectively|O
S2022|,|O
S2022|p|O
S2022|<|O
S2022|0.001|O
S2022|)|O
S2022|.|O
S2129|Sample|O
S2129|size|O
S2129|calculation|O
S2129|In|O
S2129|a|O
S2129|previous|O
S2129|study|O
S2129|of|O
S2129|17|O
S2129|patients|O
S2129|on|O
S2129|methylphenidate|O
S2129|,|O
S2129|we|O
S2129|had|O
S2129|observed|O
S2129|a|O
S2129|stride|O
S2129|length|O
S2129|increase|O
S2129|(|O
S2129|relative|O
S2129|to|O
S2129|baseline|O
S2129|)|O
S2129|of|O
S2129|0.4|O
S2129|m|O
S2129|(|O
S2129|SD|O
S2129|:|O
S2129|0.4|O
S2129|)|O
S2129|in|O
S2129|the|O
S2129|stand-walk-sit|O
S2129|test|O
S2129|after|O
S2129|3|O
S2129|months|O
S2129|of|O
S2129|treatment|O
S2129|.|O
S413|Objective|O
S413|To|O
S413|examine|O
S413|the|O
S413|effect|O
S413|of|O
S413|oxandrolone|O
S413|and|O
S413|the|O
S413|timing|O
S413|of|O
S413|pubertal|O
S413|induction|O
S413|on|O
S413|final|O
S413|height|O
S413|in|O
S413|girls|O
S413|with|O
S413|Turner|O
S413|’|O
S413|s|O
S413|syndrome|O
S413|receiving|O
S413|a|O
S413|standard|O
S413|dose|O
S413|of|O
S413|growth|O
S413|hormone|O
S413|.|O
S2026|The|O
S2026|increase|O
S2026|in|O
S2026|distal|O
S2026|and|O
S2026|proximal|O
S2026|1/3|O
S2026|bone|O
S2026|mineral|O
S2026|content|O
S2026|was|O
S2026|unrelated|O
S2026|to|O
S2026|treatment|O
S2026|response|O
S2026|,|O
S2026|as|O
S2026|assessed|O
S2026|by|O
S2026|the|O
S2026|combined|O
S2026|outcome|O
S2026|of|O
S2026|radiographic|O
S2026|and|O
S2026|alkaline|O
S2026|phosphatase|O
S2026|endpoints|O
S2026|.|O
S1595|47|O
S1595|(|O
S1595|8|O
S1595|%|O
S1595|)|O
S1595|children|O
S1595|on|O
S1595|clinically|O
S1595|driven|O
S1595|monitoring|O
S1595|versus|O
S1595|39|O
S1595|(|O
S1595|7|O
S1595|%|O
S1595|)|O
S1595|on|O
S1595|routine|O
S1595|laboratory|O
S1595|monitoring|O
S1595|had|O
S1595|a|O
S1595|new|O
S1595|WHO|O
S1595|stage|O
S1595|4|O
S1595|event|O
S1595|or|O
S1595|died|O
S1595|(|O
S1595|hazard|O
S1595|ratio|O
S1595|[|O
S1595|HR|O
S1595|]|O
S1595|1·13|O
S1595|,|O
S1595|95|O
S1595|%|O
S1595|CI|O
S1595|0·73–1·73|O
S1595|,|O
S1595|p=0·59|O
S1595|;|O
S1595|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1595|criterion|O
S1595|met|O
S1595|)|O
S1595|.|O
S2181|Conclusions|O
S2181|Quilizumab|O
S2181|had|O
S2181|an|O
S2181|acceptable|O
S2181|safety|O
S2181|profile|O
S2181|and|O
S2181|reduced|O
S2181|serum|O
S2181|IgE|O
S2181|.|O
S774|Blood|O
S774|samples|O
S774|were|O
S774|obtained|O
S774|through|O
S774|a|O
S774|17-gauge|O
S774|cannula|O
S774|with|O
S774|careful|O
S774|attention|O
S774|to|O
S774|ensure|O
S774|smooth|O
S774|extraction|O
S774|of|O
S774|blood|O
S774|to|O
S774|avoid|O
S774|artefactual|O
S774|platelet|O
S774|activation|O
S774|ex|O
S774|vivo|O
S774|,|O
S774|and|O
S774|anticoagulated|O
S774|with|O
S774|D-phenylalanyl-L-propyl-L-arginine|O
S774|chloromethyl-ketone|O
S774|(|O
S774|PPACK|O
S774|)|O
S774|.|O
S1662|The|O
S1662|corresponding|O
S1662|author|O
S1662|had|O
S1662|full|O
S1662|access|O
S1662|to|O
S1662|all|O
S1662|data|O
S1662|and|O
S1662|responsibility|O
S1662|for|O
S1662|submission|O
S1662|for|O
S1662|publication|O
S1662|.|O
S1327|However|O
S1327|,|O
S1327|the|O
S1327|proportion|O
S1327|of|O
S1327|those|O
S1327|who|O
S1327|had|O
S1327|spent|O
S1327|at|O
S1327|least|O
S1327|1|O
S1327|day|O
S1327|in|O
S1327|a|O
S1327|high-dependency|O
S1327|area|O
S1327|was|O
S1327|somewhat|O
S1327|higher|O
S1327|among|O
S1327|patients|O
S1327|assigned|O
S1327|to|O
S1327|the|O
S1327|rt-PA|O
S1327|group|O
S1327|than|O
S1327|in|O
S1327|the|O
S1327|control|O
S1327|group|O
S1327|(|O
S1327|328|O
S1327|[|O
S1327|24|O
S1327|%|O
S1327|]|O
S1327|vs|O
S1327|237|O
S1327|[|O
S1327|17|O
S1327|%|O
S1327|]|O
S1327|)|O
S1327|,|O
S1327|though|O
S1327|in|O
S1327|both|O
S1327|groups|O
S1327|,|O
S1327|the|O
S1327|median|O
S1327|stay|O
S1327|in|O
S1327|such|O
S1327|an|O
S1327|area|O
S1327|was|O
S1327|just|O
S1327|1|O
S1327|day|O
S1327|.|O
S341|Infectious|O
S341|AEs|O
S341|were|O
S341|reported|O
S341|in|O
S341|58|O
S341|(|O
S341|18.0|O
S341|%|O
S341|)|O
S341|patients|O
S341|receiving|O
S341|canakinumab|O
S341|and|O
S341|13|O
S341|(|O
S341|12.0|O
S341|%|O
S341|)|O
S341|patients|O
S341|receiving|O
S341|colchicine|O
S341|0.5|O
S341|mg|O
S341|(|O
S341|table|O
S341|3|O
S341|)|O
S341|.|O
S594|In|O
S594|one|O
S594|series|O
S594|,|O
S594|the|O
S594|incidence|O
S594|of|O
S594|finger|O
S594|amputation|O
S594|as|O
S594|a|O
S594|consequence|O
S594|of|O
S594|DUs|O
S594|was|O
S594|1.2|O
S594|%|O
S594|per|O
S594|patient-year|O
S594|.|O
S1731|There|O
S1731|were|O
S1731|no|O
S1731|significant|O
S1731|differences|O
S1731|in|O
S1731|grade|O
S1731|3|O
S1731|or|O
S1731|4|O
S1731|anaemia|O
S1731|or|O
S1731|grade|O
S1731|4|O
S1731|only|O
S1731|anaemia|O
S1731|(|O
S1731|with|O
S1731|or|O
S1731|without|O
S1731|clinical|O
S1731|symptoms|O
S1731|;|O
S1731|grade|O
S1731|3|O
S1731|or|O
S1731|4|O
S1731|:|O
S1731|38|O
S1731|vs|O
S1731|44|O
S1731|vs|O
S1731|44|O
S1731|,|O
S1731|respectively|O
S1731|;|O
S1731|grade|O
S1731|4|O
S1731|:|O
S1731|21|O
S1731|vs|O
S1731|24|O
S1731|vs|O
S1731|25|O
S1731|,|O
S1731|respectively|O
S1731|)|O
S1731|.|O
S896|The|O
S896|trial|O
S896|protocol|O
S896|has|O
S896|been|O
S896|published|O
S896|previously|O
S896|.|O
S1862|These|O
S1862|findings|O
S1862|support|O
S1862|prompt|O
S1862|initiation|O
S1862|and|O
S1862|long-term|O
S1862|continuation|O
S1862|of|O
S1862|statin|O
S1862|treatment|O
S1862|in|O
S1862|people|O
S1862|at|O
S1862|increased|O
S1862|risk|O
S1862|of|O
S1862|vascular|O
S1862|events|O
S1862|.|O
S1842|During|O
S1842|both|O
S1842|the|O
S1842|in-trial|O
S1842|and|O
S1842|post-trial|O
S1842|periods|O
S1842|,|O
S1842|information|O
S1842|about|O
S1842|the|O
S1842|sites|O
S1842|of|O
S1842|registered|O
S1842|cancers|O
S1842|and|O
S1842|certified|O
S1842|causes|O
S1842|of|O
S1842|deaths|O
S1842|was|O
S1842|requested|O
S1842|from|O
S1842|UK|O
S1842|national|O
S1842|registries|O
S1842|for|O
S1842|all|O
S1842|randomised|O
S1842|patients|O
S1842|.|O
S1653|Laboratory|O
S1653|measurements|O
S1653|and|O
S1653|adherence|O
S1653|were|O
S1653|compared|O
S1653|across|O
S1653|randomised|O
S1653|groups|O
S1653|over|O
S1653|time|O
S1653|with|O
S1653|generalised|O
S1653|estimating|O
S1653|equations|O
S1653|(|O
S1653|independent|O
S1653|correlation|O
S1653|;|O
S1653|closest|O
S1653|measurement|O
S1653|to|O
S1653|each|O
S1653|scheduled|O
S1653|visit|O
S1653|within|O
S1653|equally|O
S1653|spaced|O
S1653|windows|O
S1653|)|O
S1653|.|O
S798|Analysis|O
S798|of|O
S798|variance|O
S798|with|O
S798|repeated|O
S798|measures|O
S798|and|O
S798|a|O
S798|two-tailed|O
S798|Student|O
S798|t|O
S798|test|O
S798|were|O
S798|performed|O
S798|as|O
S798|appropriate|O
S798|with|O
S798|the|O
S798|use|O
S798|of|O
S798|GraphPad|O
S798|Prism|O
S798|software|O
S798|.|O
S1661|Role|O
S1661|of|O
S1661|the|O
S1661|funding|O
S1661|sources|O
S1661|The|O
S1661|sponsor|O
S1661|(|O
S1661|UK|O
S1661|Medical|O
S1661|Research|O
S1661|Council|O
S1661|)|O
S1661|,|O
S1661|other|O
S1661|funders|O
S1661|(|O
S1661|UK|O
S1661|Department|O
S1661|for|O
S1661|International|O
S1661|Development|O
S1661|)|O
S1661|,|O
S1661|and|O
S1661|ViiV|O
S1661|Healthcare/GlaxoSmithKline|O
S1661|(|O
S1661|donated|O
S1661|drugs|O
S1661|;|O
S1661|funded|O
S1661|viral|O
S1661|load|O
S1661|assays|O
S1661|)|O
S1661|had|O
S1661|no|O
S1661|direct|O
S1661|role|O
S1661|in|O
S1661|study|O
S1661|design|O
S1661|,|O
S1661|data|O
S1661|collection|O
S1661|,|O
S1661|analysis|O
S1661|,|O
S1661|interpretation|O
S1661|,|O
S1661|report|O
S1661|writing|O
S1661|,|O
S1661|or|O
S1661|the|O
S1661|decision|O
S1661|to|O
S1661|submit|O
S1661|for|O
S1661|publication|O
S1661|.|O
S350|One|O
S350|patient|O
S350|(|O
S350|in|O
S350|the|O
S350|50|O
S350|mg|O
S350|group|O
S350|)|O
S350|developed|O
S350|low|O
S350|levels|O
S350|of|O
S350|anti-canakinumab|O
S350|antibodies|O
S350|at|O
S350|week|O
S350|24|O
S350|.|O
S1250|Briefly|O
S1250|,|O
S1250|patients|O
S1250|were|O
S1250|eligible|O
S1250|according|O
S1250|to|O
S1250|the|O
S1250|following|O
S1250|criteria|O
S1250|:|O
S1250|they|O
S1250|had|O
S1250|symp-toms|O
S1250|and|O
S1250|signs|O
S1250|of|O
S1250|clinically|O
S1250|definite|O
S1250|acute|O
S1250|stroke|O
S1250|;|O
S1250|the|O
S1250|time|O
S1250|of|O
S1250|stroke|O
S1250|onset|O
S1250|was|O
S1250|known|O
S1250|;|O
S1250|treatment|O
S1250|could|O
S1250|be|O
S1250|started|O
S1250|within|O
S1250|6|O
S1250|h|O
S1250|of|O
S1250|onset|O
S1250|;|O
S1250|and|O
S1250|CT|O
S1250|or|O
S1250|MRI|O
S1250|had|O
S1250|reliably|O
S1250|excluded|O
S1250|both|O
S1250|intracranial|O
S1250|haemorrhage|O
S1250|and|O
S1250|structural|O
S1250|brain|O
S1250|lesions|O
S1250|,|O
S1250|which|O
S1250|could|O
S1250|mimic|O
S1250|stroke|O
S1250|(|O
S1250|eg|O
S1250|,|O
S1250|cerebral|O
S1250|tumour|O
S1250|)|O
S1250|.|O
S738|Main|O
S738|outcome|O
S738|measures|O
S738|Leucocyte|O
S738|count|O
S738|,|O
S738|plasma|O
S738|cytokine|O
S738|concentrations|O
S738|,|O
S738|flow|O
S738|cytometric|O
S738|measures|O
S738|of|O
S738|platelet|O
S738|activation|O
S738|and|O
S738|peripheral|O
S738|vasomotor|O
S738|and|O
S738|fibrinolytic|O
S738|function|O
S738|were|O
S738|determined|O
S738|before|O
S738|and|O
S738|24|O
S738|h|O
S738|after|O
S738|study|O
S738|intervention|O
S738|.|O
S1097|Secondary|O
S1097|outcomes|O
S1097|Secondary|O
S1097|outcomes|O
S1097|included|O
S1097|(|O
S1097|a|O
S1097|)|O
S1097|complete|O
S1097|clearance|O
S1097|of|O
S1097|all|O
S1097|plantar|O
S1097|warts|O
S1097|at|O
S1097|12|O
S1097|weeks|O
S1097|after|O
S1097|controlling|O
S1097|for|O
S1097|age|O
S1097|,|O
S1097|whether|O
S1097|the|O
S1097|plantar|O
S1097|wart|O
S1097|had|O
S1097|been|O
S1097|treated|O
S1097|previously|O
S1097|,|O
S1097|and|O
S1097|type|O
S1097|of|O
S1097|wart|O
S1097|and|O
S1097|(|O
S1097|b|O
S1097|)|O
S1097|a|O
S1097|second|O
S1097|model|O
S1097|to|O
S1097|explore|O
S1097|the|O
S1097|effect|O
S1097|of|O
S1097|patient|O
S1097|preferences|O
S1097|,|O
S1097|(|O
S1097|c|O
S1097|)|O
S1097|with|O
S1097|clearance|O
S1097|of|O
S1097|plantar|O
S1097|wart|O
S1097|at|O
S1097|six|O
S1097|months|O
S1097|,|O
S1097|(|O
S1097|d|O
S1097|)|O
S1097|number|O
S1097|of|O
S1097|warts|O
S1097|at|O
S1097|12|O
S1097|weeks|O
S1097|,|O
S1097|(|O
S1097|e|O
S1097|)|O
S1097|time|O
S1097|to|O
S1097|clearance|O
S1097|of|O
S1097|wart|O
S1097|,|O
S1097|(|O
S1097|f|O
S1097|)|O
S1097|patient|O
S1097|satisfaction|O
S1097|with|O
S1097|the|O
S1097|treatment|O
S1097|,|O
S1097|and|O
S1097|(|O
S1097|g|O
S1097|)|O
S1097|adverse|O
S1097|events|O
S1097|.|O
S610|Secondary|O
S610|objectives|O
S610|were|O
S610|to|O
S610|evaluate|O
S610|the|O
S610|effect|O
S610|of|O
S610|bosentan|O
S610|on|O
S610|pain|O
S610|and|O
S610|disability|O
S610|,|O
S610|as|O
S610|well|O
S610|as|O
S610|its|O
S610|tolerability|O
S610|and|O
S610|safety|O
S610|in|O
S610|these|O
S610|patients|O
S610|.|O
S499|The|O
S499|standard|O
S499|deviation|O
S499|for|O
S499|the|O
S499|combined|O
S499|group|O
S499|was|O
S499|5.1|O
S499|cm|O
S499|,|O
S499|rather|O
S499|less|O
S499|than|O
S499|the|O
S499|7.4|O
S499|cm|O
S499|for|O
S499|the|O
S499|placebo/early|O
S499|induction|O
S499|group|O
S499|(|O
S499|P=0.1|O
S499|)|O
S499|,|O
S499|suggesting|O
S499|that|O
S499|treatment|O
S499|preferentially|O
S499|benefited|O
S499|the|O
S499|shortest|O
S499|girls|O
S499|.|O
S1407|Registration|O
S1407|Clinical|O
S1407|Trials|O
S1407|NCT00298233|O
S2100|In|O
S2100|order|O
S2100|to|O
S2100|assess|O
S2100|the|O
S2100|feasibility|O
S2100|of|O
S2100|a|O
S2100|multicentre|O
S2100|clinical|O
S2100|trial|O
S2100|,|O
S2100|we|O
S2100|used|O
S2100|sensitive|O
S2100|measures|O
S2100|and|O
S2100|a|O
S2100|standardised|O
S2100|,|O
S2100|acute|O
S2100|L-dopa|O
S2100|challenge|O
S2100|to|O
S2100|examine|O
S2100|the|O
S2100|impact|O
S2100|of|O
S2100|memantine|O
S2100|on|O
S2100|gait|O
S2100|,|O
S2100|axial|O
S2100|motor|O
S2100|symptoms|O
S2100|and|O
S2100|L-dopa-induced|O
S2100|dyskinesia|O
S2100|(|O
S2100|LID|O
S2100|)|O
S2100|in|O
S2100|advanced|O
S2100|PD|O
S2100|patients|O
S2100|in|O
S2100|a|O
S2100|double-blind|O
S2100|,|O
S2100|placebo-controlled|O
S2100|pilot|O
S2100|study|O
S2100|.|O
S265|The|O
S265|incidence|O
S265|of|O
S265|adverse|O
S265|events|O
S265|was|O
S265|similar|O
S265|across|O
S265|treatment|O
S265|groups|O
S265|.|O
S1872|No|O
S1872|significant|O
S1872|difference|O
S1872|was|O
S1872|noted|O
S1872|during|O
S1872|the|O
S1872|first|O
S1872|year|O
S1872|,|O
S1872|but|O
S1872|significant|O
S1872|reductions|O
S1872|of|O
S1872|about|O
S1872|a|O
S1872|quarter|O
S1872|were|O
S1872|seen|O
S1872|during|O
S1872|each|O
S1872|subsequent|O
S1872|in-trial|O
S1872|year|O
S1872|(|O
S1872|figure|O
S1872|2|O
S1872|)|O
S1872|.|O
S934|Secondary|O
S934|outcomes|O
S934|Time|O
S934|to|O
S934|healing—defined|O
S934|as|O
S934|the|O
S934|time|O
S934|at|O
S934|which|O
S934|sterile|O
S934|dressings|O
S934|were|O
S934|no|O
S934|longer|O
S934|required|O
S934|(|O
S934|reported|O
S934|by|O
S934|patients|O
S934|and|O
S934|confirmed|O
S934|by|O
S934|clinicians|O
S934|at|O
S934|subsequent|O
S934|clinic|O
S934|visits|O
S934|)|O
S934|.|O
S734|Objective|O
S734|The|O
S734|inflammatory|O
S734|cytokine|O
S734|,|O
S734|tumour|O
S734|necrosis|O
S734|factor|O
S734|α|O
S734|(|O
S734|TNF-α|O
S734|)|O
S734|,|O
S734|exerts|O
S734|deleterious|O
S734|cardiovascular|O
S734|effects|O
S734|.|O
S616|Patients|O
S616|were|O
S616|excluded|O
S616|if|O
S616|they|O
S616|had|O
S616|received|O
S616|intravenous|O
S616|prostanoids|O
S616|within|O
S616|the|O
S616|previous|O
S616|3|O
S616|months|O
S616|,|O
S616|had|O
S616|used|O
S616|phosphodiesterase|O
S616|inhibitors|O
S616|other|O
S616|than|O
S616|for|O
S616|intermittent|O
S616|treatment|O
S616|of|O
S616|male|O
S616|erectile|O
S616|dysfunction|O
S616|,|O
S616|or|O
S616|had|O
S616|received|O
S616|inhaled|O
S616|or|O
S616|oral|O
S616|prostanoids|O
S616|or|O
S616|injected|O
S616|botulinum|O
S616|toxin|O
S616|in|O
S616|an|O
S616|affected|O
S616|finger|O
S616|within|O
S616|1|O
S616|month|O
S616|.|O
S1314|Analyses|O
S1314|were|O
S1314|done|O
S1314|with|O
S1314|SAS|O
S1314|(|O
S1314|version|O
S1314|9.2|O
S1314|)|O
S1314|.|O
S1660|This|O
S1660|trial|O
S1660|is|O
S1660|registered|O
S1660|,|O
S1660|ISRCTN24791884|O
S1660|.|O
S945|To|O
S945|provide|O
S945|80|B-Sample_Size_Calculation_Power_Value
S945|%|I-Sample_Size_Calculation_Power_Value
S945|power|O
S945|(|O
S945|5|B-Sample_Size_Calculation_Alpha_Value
S945|%|I-Sample_Size_Calculation_Alpha_Value
S945|level|O
S945|of|O
S945|significance|O
S945|)|O
S945|to|O
S945|detect|O
S945|a|O
S945|difference|O
S945|in|O
S945|means|O
S945|of|O
S945|0.5|O
S945|standard|O
S945|deviations|O
S945|in|O
S945|the|O
S945|primary|O
S945|outcome|O
S945|of|O
S945|speed|O
S945|of|O
S945|healing|O
S945|over|O
S945|six|O
S945|weeks|O
S945|,|O
S945|the|O
S945|target|O
S945|sample|O
S945|size|O
S945|was|O
S945|140|B-Sample_Size_Required
S945|participants|O
S945|,|O
S945|assuming|O
S945|a|O
S945|loss|O
S945|to|O
S945|follow-up|O
S945|of|O
S945|10|B-Sample_Size_Calculation_Dropout_Rate_Value
S945|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S945|.|O
S2001|Because|O
S2001|of|O
S2001|the|O
S2001|nature|O
S2001|of|O
S2001|coin|O
S2001|toss|O
S2001|randomisation|O
S2001|,|O
S2001|the|O
S2001|number|O
S2001|of|O
S2001|subjects|O
S2001|in|O
S2001|the|O
S2001|Ca+D|O
S2001|group|O
S2001|(|O
S2001|n=44|O
S2001|)|O
S2001|was|O
S2001|greater|O
S2001|than|O
S2001|the|O
S2001|number|O
S2001|in|O
S2001|the|O
S2001|Ca|O
S2001|group|O
S2001|(|O
S2001|n=28|O
S2001|)|O
S2001|.|O
S1095|If|O
S1095|no|O
S1095|photographs|O
S1095|were|O
S1095|available|O
S1095|for|O
S1095|a|O
S1095|participant|O
S1095|,|O
S1095|however|O
S1095|,|O
S1095|then|O
S1095|the|O
S1095|blinded|O
S1095|outcome|O
S1095|assessment|O
S1095|undertaken|O
S1095|at|O
S1095|the|O
S1095|site|O
S1095|was|O
S1095|used|O
S1095|.|O
S174|Methods|O
S174|This|O
S174|was|O
S174|a|O
S174|Phase|B-Design_Phase_2
S174|II|I-Design_Phase_2
S174|,|O
S174|randomised|O
S174|,|O
S174|double-blind|B-Blinding_Double_Blind
S174|,|O
S174|placebo-controlled|O
S174|,|O
S174|crossover|B-Design_Crossover
S174|study|O
S174|to|O
S174|investigate|O
S174|the|O
S174|efficacy|O
S174|and|O
S174|safety|O
S174|of|O
S174|three|O
S174|doses|O
S174|of|O
S174|once-daily|O
S174|tiotropium|O
S174|Respimat®|O
S174|.|O
S1981|Enrolled|O
S1981|children|O
S1981|were|O
S1981|randomised|B-Randomization_Type_Simple
S1981|by|O
S1981|coin|B-Randomization_Sequence_Generation_Method
S1981|toss|I-Randomization_Sequence_Generation_Method
S1981|(|O
S1981|performed|O
S1981|by|O
S1981|TDT|O
S1981|)|O
S1981|to|O
S1981|receive|O
S1981|under|O
S1981|direct|O
S1981|observation|O
S1981|either|O
S1981|oral|B-Design_Parallel_Group
S1981|vitamin|I-Design_Parallel_Group
S1981|D2|I-Design_Parallel_Group
S1981|as|I-Design_Parallel_Group
S1981|50|I-Design_Parallel_Group
S1981|000|I-Design_Parallel_Group
S1981|IU|I-Design_Parallel_Group
S1981|(|I-Design_Parallel_Group
S1981|ergocalciferol|I-Design_Parallel_Group
S1981|;|I-Design_Parallel_Group
S1981|Pliva|I-Design_Parallel_Group
S1981|,|I-Design_Parallel_Group
S1981|Inc.|I-Design_Parallel_Group
S1981|,|I-Design_Parallel_Group
S1981|East|I-Design_Parallel_Group
S1981|Hanover|I-Design_Parallel_Group
S1981|,|I-Design_Parallel_Group
S1981|New|I-Design_Parallel_Group
S1981|Jersey|I-Design_Parallel_Group
S1981|)|I-Design_Parallel_Group
S1981|once|I-Design_Parallel_Group
S1981|every|I-Design_Parallel_Group
S1981|4|I-Design_Parallel_Group
S1981|weeks|I-Design_Parallel_Group
S1981|(|I-Design_Parallel_Group
S1981|Ca+D|I-Design_Parallel_Group
S1981|group|I-Design_Parallel_Group
S1981|)|I-Design_Parallel_Group
S1981|or|I-Design_Parallel_Group
S1981|placebo|I-Design_Parallel_Group
S1981|,|O
S1981|which|O
S1981|was|O
S1981|a|O
S1981|single|O
S1981|vitamin|O
S1981|B|O
S1981|complex|O
S1981|tablet|O
S1981|,|O
S1981|once|O
S1981|every|O
S1981|4|O
S1981|weeks|O
S1981|(|O
S1981|Ca|O
S1981|group|O
S1981|)|O
S1981|for|O
S1981|24|O
S1981|weeks|O
S1981|.|O
S1633|Procedures|O
S1633|All|O
S1633|participants|O
S1633|were|O
S1633|examined|O
S1633|by|O
S1633|a|O
S1633|doctor|O
S1633|and|O
S1633|had|O
S1633|routine|O
S1633|full|O
S1633|blood|O
S1633|count|O
S1633|with|O
S1633|white|O
S1633|cell|O
S1633|differential|O
S1633|,|O
S1633|lymphocyte|O
S1633|subsets|O
S1633|(|O
S1633|CD4|O
S1633|,|O
S1633|CD8|O
S1633|)|O
S1633|,|O
S1633|biochemistry|O
S1633|tests|O
S1633|(|O
S1633|bilirubin|O
S1633|,|O
S1633|urea|O
S1633|,|O
S1633|creatinine|O
S1633|,|O
S1633|aspartate|O
S1633|aminotransferase|O
S1633|,|O
S1633|alanine|O
S1633|aminotransferase|O
S1633|)|O
S1633|at|O
S1633|screening|O
S1633|,|O
S1633|randomisation|O
S1633|(|O
S1633|lymphocytes|O
S1633|only|O
S1633|)|O
S1633|,|O
S1633|weeks|O
S1633|4|O
S1633|,|O
S1633|8|O
S1633|,|O
S1633|and|O
S1633|12|O
S1633|,|O
S1633|then|O
S1633|every|O
S1633|12|O
S1633|weeks|O
S1633|.|O
S807|Plasma|O
S807|interleukin-6|O
S807|concentrations|O
S807|were|O
S807|similarly|O
S807|reduced|O
S807|(|O
S807|10.6±4.0|O
S807|vs|O
S807|5.8±2.0|O
S807|pg/ml|O
S807|;|O
S807|p=0.01|O
S807|)|O
S807|.|O
S1502|Hospital|O
S1502|course|O
S1502|During|O
S1502|the|O
S1502|study|O
S1502|,|O
S1502|98/326|O
S1502|(|O
S1502|30.1|O
S1502|%|O
S1502|)|O
S1502|of|O
S1502|all|O
S1502|patients|O
S1502|required|O
S1502|supplemental|O
S1502|oxygen|O
S1502|,|O
S1502|61/326|O
S1502|(|O
S1502|18.7|O
S1502|%|O
S1502|)|O
S1502|were|O
S1502|admitted|O
S1502|to|O
S1502|intensive|O
S1502|care|O
S1502|,|O
S1502|and|O
S1502|40/326|O
S1502|(|O
S1502|12.3|O
S1502|%|O
S1502|)|O
S1502|required|O
S1502|mechanical|O
S1502|ventilation|O
S1502|.|O
S2094|Dopaminergic|O
S2094|depletion|O
S2094|induces|O
S2094|glutamatergic|O
S2094|hyperactivity|O
S2094|in|O
S2094|the|O
S2094|brain|O
S2094|in|O
S2094|general|O
S2094|and|O
S2094|in|O
S2094|the|O
S2094|subthalamic|O
S2094|nucleus|O
S2094|(|O
S2094|STN|O
S2094|)|O
S2094|and|O
S2094|its|O
S2094|efferent|O
S2094|pathways|O
S2094|projecting|O
S2094|to|O
S2094|the|O
S2094|pedunculopontine|O
S2094|nucleus|O
S2094|(|O
S2094|PPN|O
S2094|)|O
S2094|in|O
S2094|particular|O
S2094|.|O
S2149|There|O
S2149|was|O
S2149|no|O
S2149|significant|O
S2149|change|O
S2149|in|O
S2149|drowsiness|O
S2149|over|O
S2149|the|O
S2149|course|O
S2149|of|O
S2149|the|O
S2149|memantine|O
S2149|treatment|O
S2149|.|O
S1495|Persistent|O
S1495|detection|O
S1495|of|O
S1495|viral|O
S1495|RNA|O
S1495|on|O
S1495|day|O
S1495|five|O
S1495|was|O
S1495|found|O
S1495|in|O
S1495|17/34|O
S1495|(|O
S1495|50|O
S1495|%|O
S1495|,|O
S1495|34.1|O
S1495|%|O
S1495|to|O
S1495|65.9|O
S1495|%|O
S1495|)|O
S1495|of|O
S1495|patients|O
S1495|meeting|O
S1495|criteria|O
S1495|for|O
S1495|clinical|O
S1495|failure|O
S1495|on|O
S1495|day|O
S1495|five|O
S1495|compared|O
S1495|with|O
S1495|75/275|O
S1495|(|O
S1495|27|O
S1495|%|O
S1495|,|O
S1495|22.3|O
S1495|%|O
S1495|to|O
S1495|32.8|O
S1495|%|O
S1495|)|O
S1495|of|O
S1495|patients|O
S1495|not|O
S1495|meeting|O
S1495|criteria|O
S1495|for|O
S1495|clinical|O
S1495|failure|O
S1495|(|O
S1495|P=0.006|O
S1495|)|O
S1495|.|O
S344|Upper|O
S344|respiratory|O
S344|tract|O
S344|infections|O
S344|(|O
S344|3.7|O
S344|%|O
S344|)|O
S344|and|O
S344|cystitis|O
S344|(|O
S344|1.9|O
S344|%|O
S344|)|O
S344|were|O
S344|the|O
S344|only|O
S344|infections|O
S344|occurring|O
S344|in|O
S344|more|O
S344|than|O
S344|1|O
S344|%|O
S344|of|O
S344|patients|O
S344|receiving|O
S344|colchicine|O
S344|.|O
S1600|Interpretation|O
S1600|NNRTI|O
S1600|plus|O
S1600|NRTI-based|O
S1600|three-drug|O
S1600|or|O
S1600|four-drug|O
S1600|ART|O
S1600|can|O
S1600|be|O
S1600|given|O
S1600|across|O
S1600|childhood|O
S1600|without|O
S1600|routine|O
S1600|toxicity|O
S1600|monitoring|O
S1600|;|O
S1600|CD4|O
S1600|monitoring|O
S1600|provided|O
S1600|clinical|O
S1600|benefit|O
S1600|after|O
S1600|the|O
S1600|first|O
S1600|year|O
S1600|on|O
S1600|ART|O
S1600|,|O
S1600|but|O
S1600|event|O
S1600|rates|O
S1600|were|O
S1600|very|O
S1600|low|O
S1600|and|O
S1600|long-term|O
S1600|survival|O
S1600|high|O
S1600|,|O
S1600|suggesting|O
S1600|ART|O
S1600|rollout|O
S1600|should|O
S1600|take|O
S1600|priority|O
S1600|.|O
S1972|Anthropometric|O
S1972|z-scores|O
S1972|were|O
S1972|calculated|O
S1972|with|O
S1972|Epi|O
S1972|Info|O
S1972|3.2.2|O
S1972|(|O
S1972|CDC|O
S1972|,|O
S1972|Atlanta|O
S1972|,|O
S1972|Georgia|O
S1972|,|O
S1972|USA|O
S1972|)|O
S1972|.|O
S1078|Randomisation|O
S1078|was|O
S1078|performed|O
S1078|by|O
S1078|a|B-Randomization_Personnel
S1078|member|I-Randomization_Personnel
S1078|of|I-Randomization_Personnel
S1078|the|I-Randomization_Personnel
S1078|research|I-Randomization_Personnel
S1078|team|I-Randomization_Personnel
S1078|either|O
S1078|telephoning|B-Randomization_Sequence_Generation_Method
S1078|an|I-Randomization_Sequence_Generation_Method
S1078|independent|I-Randomization_Sequence_Generation_Method
S1078|,|I-Randomization_Sequence_Generation_Method
S1078|secure|I-Randomization_Sequence_Generation_Method
S1078|,|I-Randomization_Sequence_Generation_Method
S1078|remote|I-Randomization_Sequence_Generation_Method
S1078|,|I-Randomization_Sequence_Generation_Method
S1078|telephone|I-Randomization_Sequence_Generation_Method
S1078|randomisation|I-Randomization_Sequence_Generation_Method
S1078|service|I-Randomization_Sequence_Generation_Method
S1078|(|I-Randomization_Sequence_Generation_Method
S1078|York|I-Randomization_Sequence_Generation_Method
S1078|Trials|I-Randomization_Sequence_Generation_Method
S1078|Unit|I-Randomization_Sequence_Generation_Method
S1078|)|I-Randomization_Sequence_Generation_Method
S1078|or|O
S1078|accessing|B-Randomization_Sequence_Generation_Method
S1078|a|I-Randomization_Sequence_Generation_Method
S1078|secure|I-Randomization_Sequence_Generation_Method
S1078|online|I-Randomization_Sequence_Generation_Method
S1078|web|I-Randomization_Sequence_Generation_Method
S1078|randomisation|I-Randomization_Sequence_Generation_Method
S1078|programme|I-Randomization_Sequence_Generation_Method
S1078|,|O
S1078|thereby|O
S1078|concealing|O
S1078|treatment|O
S1078|allocation|O
S1078|until|O
S1078|the|O
S1078|moment|O
S1078|of|O
S1078|randomisation|O
S1078|.|O
S223|Of|O
S223|the|O
S223|small|O
S223|proportion|O
S223|of|O
S223|patients|O
S223|who|O
S223|had|O
S223|previously|O
S223|smoked|O
S223|(|O
S223|19.5|O
S223|%|O
S223|;|O
S223|n|O
S223|=|O
S223|29|O
S223|)|O
S223|,|O
S223|the|O
S223|mean|O
S223|number|O
S223|of|O
S223|pack-years|O
S223|was|O
S223|5.6|O
S223|.|O
S1475|At|O
S1475|enrolment|O
S1475|,|O
S1475|57|O
S1475|(|O
S1475|17.5|O
S1475|%|O
S1475|)|O
S1475|patients|O
S1475|needed|O
S1475|immediate|O
S1475|admission|O
S1475|to|O
S1475|intensive|O
S1475|care|O
S1475|,|O
S1475|of|O
S1475|whom|O
S1475|34|O
S1475|(|O
S1475|10.4|O
S1475|%|O
S1475|)|O
S1475|required|O
S1475|mechanical|O
S1475|ventilation|O
S1475|,|O
S1475|and|O
S1475|25|O
S1475|(|O
S1475|7.7|O
S1475|%|O
S1475|)|O
S1475|had|O
S1475|acute|O
S1475|respiratory|O
S1475|distress|O
S1475|syndrome|O
S1475|(|O
S1475|table|O
S1475|1|O
S1475|)|O
S1475|.|O
S47|The|O
S47|two|O
S47|different|O
S47|primary|O
S47|end|O
S47|points|O
S47|in|O
S47|the|O
S47|individual|O
S47|studies|O
S47|were|O
S47|chosen|O
S47|to|O
S47|address|O
S47|both|O
S47|the|O
S47|more|O
S47|clinically|O
S47|relevant|O
S47|end|O
S47|point|O
S47|of|O
S47|upper|O
S47|GI|O
S47|ulcers|O
S47|(|O
S47|gastric|O
S47|and/or|O
S47|duodenal|O
S47|)|O
S47|and|O
S47|the|O
S47|traditional|O
S47|US|O
S47|FDA|O
S47|(|O
S47|Food|O
S47|and|O
S47|Drug|O
S47|Administration|O
S47|)|O
S47|end|O
S47|point|O
S47|of|O
S47|gastric|O
S47|ulcers|O
S47|.|O
S42|A|O
S42|sample|O
S42|size|O
S42|for|O
S42|REDUCE-1|O
S42|of|O
S42|875|B-Sample_Size_Required
S42|was|O
S42|calculated|O
S42|based|O
S42|on|O
S42|a|O
S42|90|B-Sample_Size_Calculation_Power_Value
S42|%|I-Sample_Size_Calculation_Power_Value
S42|power|O
S42|to|O
S42|detect|O
S42|a|O
S42|difference|O
S42|of|O
S42|6|O
S42|%|O
S42|vs.|O
S42|14|O
S42|%|O
S42|in|O
S42|the|O
S42|incidence|O
S42|of|O
S42|gastric|O
S42|ulcers|O
S42|with|O
S42|a|B-Sample_Size_Calculation_Alpha_Value
S42|two-sided|I-Sample_Size_Calculation_Alpha_Value
S42|α|I-Sample_Size_Calculation_Alpha_Value
S42|of|I-Sample_Size_Calculation_Alpha_Value
S42|0.05|I-Sample_Size_Calculation_Alpha_Value
S42|and|O
S42|assuming|O
S42|a|O
S42|15|B-Sample_Size_Calculation_Dropout_Rate_Value
S42|%|I-Sample_Size_Calculation_Dropout_Rate_Value
S42|drop-out|O
S42|rate|O
S42|.|O
S330|Differences|O
S330|in|O
S330|average|O
S330|duration|O
S330|between|O
S330|all|O
S330|canakinumab|O
S330|groups|O
S330|versus|O
S330|colchicine|O
S330|0.5|O
S330|mg|O
S330|,|O
S330|however|O
S330|,|O
S330|were|O
S330|not|O
S330|statistically|O
S330|significant|O
S330|.|O
S198|The|O
S198|primary|O
S198|efficacy|O
S198|end|O
S198|point|O
S198|was|O
S198|peak|O
S198|FEV1|O
S198|measured|O
S198|within|O
S198|the|O
S198|first|O
S198|3|O
S198|hours|O
S198|after|O
S198|dosing|O
S198|(|O
S198|peak|O
S198|FEV1|O
S198|(|O
S198|0-3h|O
S198|)|O
S198|)|O
S198|.|O
S1092|The|O
S1092|photographs|O
S1092|were|O
S1092|assessed|O
S1092|by|O
S1092|two|O
S1092|assessors|B-Blinding_Object_Outcome_Assessors
S1092|who|O
S1092|were|O
S1092|blind|O
S1092|to|O
S1092|treatment|O
S1092|allocation|O
S1092|.|O
S1288|To|O
S1288|assess|O
S1288|the|O
S1288|durability|O
S1288|of|O
S1288|any|O
S1288|treatment|O
S1288|benefit|O
S1288|beyond|O
S1288|6|O
S1288|months|O
S1288|,|O
S1288|patients|O
S1288|recruited|O
S1288|in|O
S1288|the|O
S1288|UK|O
S1288|(|O
S1288|and|O
S1288|in|O
S1288|other|O
S1288|countries|O
S1288|where|O
S1288|appropriate|O
S1288|funding|O
S1288|had|O
S1288|been|O
S1288|obtained|O
S1288|)|O
S1288|were|O
S1288|also|O
S1288|followed|O
S1288|up|O
S1288|at|O
S1288|18|O
S1288|months|O
S1288|.|O
S190|A|O
S190|fixed|O
S190|block|B-Randomization_Type_Block
S190|randomisation|O
S190|,|O
S190|with|O
S190|a|B-Randomization_Block_Size
S190|block|I-Randomization_Block_Size
S190|size|I-Randomization_Block_Size
S190|of|I-Randomization_Block_Size
S190|4|I-Randomization_Block_Size
S190|,|O
S190|was|O
S190|used|O
S190|to|O
S190|ensure|O
S190|balanced|O
S190|and|O
S190|equal|O
S190|assignment|O
S190|.|O
S901|Patient|O
S901|involvement|O
S901|Patients|O
S901|were|O
S901|involved|O
S901|in|O
S901|the|O
S901|design|O
S901|and|O
S901|conduct|O
S901|of|O
S901|this|O
S901|research|O
S901|.|O
S1342|However|O
S1342|,|O
S1342|a|O
S1342|significant|O
S1342|difference|O
S1342|did|O
S1342|occur|O
S1342|in|O
S1342|the|O
S1342|adjusted|O
S1342|effect|O
S1342|of|O
S1342|treatment|O
S1342|between|O
S1342|patients|O
S1342|older|O
S1342|than|O
S1342|80|O
S1342|years|O
S1342|and|O
S1342|in|O
S1342|patients|O
S1342|80|O
S1342|years|O
S1342|or|O
S1342|younger|O
S1342|(|O
S1342|p=0·027|O
S1342|)|O
S1342|,|O
S1342|suggesting|O
S1342|greater|O
S1342|benefit|O
S1342|in|O
S1342|those|O
S1342|older|O
S1342|than|O
S1342|80|O
S1342|years|O
S1342|of|O
S1342|age|O
S1342|;|O
S1342|contrary|O
S1342|to|O
S1342|expectations|O
S1342|.|O
S2085|Results|O
S2085|Twenty-five|B-Sample_Size_Actual_at_Enrollment
S2085|patients|O
S2085|were|O
S2085|included|O
S2085|.|O
S1433|Those|O
S1433|with|O
S1433|persistent|O
S1433|tachypnoea|O
S1433|,|O
S1433|dyspnoea|O
S1433|,|O
S1433|or|O
S1433|hypoxia|O
S1433|on|O
S1433|day|O
S1433|five|O
S1433|of|O
S1433|the|O
S1433|study|O
S1433|were|O
S1433|defined|O
S1433|as|O
S1433|meeting|O
S1433|the|O
S1433|criteria|O
S1433|for|O
S1433|clinical|O
S1433|failure|O
S1433|and|O
S1433|continued|O
S1433|to|O
S1433|take|O
S1433|the|O
S1433|randomised|O
S1433|dose|O
S1433|for|O
S1433|an|O
S1433|additional|O
S1433|five|O
S1433|days|O
S1433|.|O
S1618|We|O
S1618|therefore|O
S1618|undertook|O
S1618|the|O
S1618|first|O
S1618|paediatric|O
S1618|trial|O
S1618|(|O
S1618|AntiRetroviral|O
S1618|Research|O
S1618|fOr|O
S1618|Watoto|O
S1618|[|O
S1618|ARROW|O
S1618|]|O
S1618|)|O
S1618|to|O
S1618|evaluate|O
S1618|the|O
S1618|long-term|O
S1618|effect|O
S1618|of|O
S1618|routine|O
S1618|efficacy|O
S1618|and|O
S1618|toxicity|O
S1618|monitoring|O
S1618|and|O
S1618|different|O
S1618|first-line|O
S1618|ART|O
S1618|strategies|O
S1618|in|O
S1618|a|O
S1618|factorial|O
S1618|design|O
S1618|in|O
S1618|African|O
S1618|children|O
S1618|.|O
S866|Intervention|O
S866|Oral|O
S866|prednisolone|O
S866|0.75|O
S866|mg/kg/day|O
S866|compared|O
S866|with|O
S866|ciclosporin|O
S866|4|O
S866|mg/kg/day|O
S866|,|O
S866|to|O
S866|a|O
S866|maximum|O
S866|dose|O
S866|of|O
S866|75|O
S866|and|O
S866|400|O
S866|mg/day|O
S866|,|O
S866|respectively|O
S866|.|O
S62|In|O
S62|addition|O
S62|,|O
S62|we|O
S62|prespecified|O
S62|comparison|O
S62|of|O
S62|the|O
S62|proportion|O
S62|of|O
S62|patients|O
S62|who|O
S62|reported|O
S62|any|O
S62|symptom|O
S62|consistent|O
S62|with|O
S62|dyspepsia|O
S62|(|O
S62|e.g.|O
S62|,|O
S62|dyspepsia|O
S62|,|O
S62|upper|O
S62|abdominal|O
S62|pain|O
S62|or|O
S62|discomfort|O
S62|,|O
S62|epigastric|O
S62|pain|O
S62|or|O
S62|discomfort|O
S62|,|O
S62|stomach|O
S62|pain|O
S62|or|O
S62|discomfort|O
S62|;|O
S62|with|O
S62|and|O
S62|without|O
S62|nausea|O
S62|)|O
S62|.|O
S1260|To|O
S1260|be|O
S1260|eligible|O
S1260|to|O
S1260|join|O
S1260|the|O
S1260|trial|O
S1260|,|O
S1260|participating|O
S1260|hospitals|O
S1260|had|O
S1260|to|O
S1260|have|O
S1260|an|O
S1260|organised|O
S1260|system|O
S1260|of|O
S1260|stroke|O
S1260|care|O
S1260|.|O
S1892|When|O
S1892|the|O
S1892|11|O
S1892|years|O
S1892|of|O
S1892|in-trial|O
S1892|and|O
S1892|post-trial|O
S1892|follow-up|O
S1892|are|O
S1892|considered|O
S1892|together|O
S1892|,|O
S1892|allocation|O
S1892|to|O
S1892|about|O
S1892|5|O
S1892|years|O
S1892|of|O
S1892|statin|O
S1892|treatment|O
S1892|was|O
S1892|not|O
S1892|associated|O
S1892|with|O
S1892|any|O
S1892|increase|O
S1892|in|O
S1892|non-vascular|O
S1892|mortality|O
S1892|,|O
S1892|either|O
S1892|overall|O
S1892|(|O
S1892|1523|O
S1892|[|O
S1892|14·8|O
S1892|%|O
S1892|]|O
S1892|vs|O
S1892|1555|O
S1892|[|O
S1892|15·1|O
S1892|%|O
S1892|]|O
S1892|;|O
S1892|RR|O
S1892|0·96|O
S1892|[|O
S1892|95|O
S1892|%|O
S1892|CI|O
S1892|0·89–1·03|O
S1892|]|O
S1892|;|O
S1892|p=0·24|O
S1892|)|O
S1892|or|O
S1892|for|O
S1892|any|O
S1892|prespecified|O
S1892|category|O
S1892|of|O
S1892|death|O
S1892|.|O
S1841|Follow-up|O
S1841|of|O
S1841|participants|O
S1841|who|O
S1841|did|O
S1841|not|O
S1841|complete|O
S1841|questionnaires|O
S1841|was|O
S1841|sought|O
S1841|from|O
S1841|their|O
S1841|family|O
S1841|doctors|O
S1841|.|O
S1104|In|O
S1104|order|O
S1104|to|O
S1104|give|O
S1104|80|B-Sample_Size_Calculation_Power_Value
S1104|%|I-Sample_Size_Calculation_Power_Value
S1104|power|O
S1104|(|O
S1104|5|B-Sample_Size_Calculation_Alpha_Value
S1104|%|I-Sample_Size_Calculation_Alpha_Value
S1104|two|I-Sample_Size_Calculation_Alpha_Value
S1104|sided|I-Sample_Size_Calculation_Alpha_Value
S1104|significance|I-Sample_Size_Calculation_Alpha_Value
S1104|)|O
S1104|to|O
S1104|show|O
S1104|a|O
S1104|difference|O
S1104|in|O
S1104|cure|O
S1104|rates|O
S1104|of|O
S1104|70|O
S1104|%|O
S1104|for|O
S1104|salicylic|O
S1104|acid|O
S1104|versus|O
S1104|85|O
S1104|%|O
S1104|for|O
S1104|cryotherapy|O
S1104|at|O
S1104|12|O
S1104|weeks|O
S1104|,|O
S1104|a|O
S1104|sample|O
S1104|size|O
S1104|of|O
S1104|120|B-Sample_Size_Required
S1104|patients|I-Sample_Size_Required
S1104|in|I-Sample_Size_Required
S1104|each|I-Sample_Size_Required
S1104|treatment|I-Sample_Size_Required
S1104|group|I-Sample_Size_Required
S1104|was|O
S1104|required|O
S1104|,|O
S1104|or|O
S1104|133|O
S1104|patients|O
S1104|in|O
S1104|each|O
S1104|group|O
S1104|after|O
S1104|allowing|O
S1104|for|O
S1104|10|O
S1104|%|O
S1104|attrition|O
S1104|(|O
S1104|266|O
S1104|patients|O
S1104|in|O
S1104|total|O
S1104|)|O
S1104|.|O
S444|Exclusion|O
S444|criteria|O
S444|were|O
S444|major|O
S444|systemic|O
S444|illness|O
S444|that|O
S444|might|O
S444|affect|O
S444|growth|O
S444|and|O
S444|social|O
S444|or|O
S444|psychological|O
S444|difficulties|O
S444|likely|O
S444|to|O
S444|seriously|O
S444|impair|O
S444|concordance|O
S444|.|O
S597|Nifedipine|O
S597|and|O
S597|intravenous|O
S597|iloprost|O
S597|reduced|O
S597|the|O
S597|frequency|O
S597|and|O
S597|severity|O
S597|of|O
S597|SSc-related|O
S597|Raynaud|O
S597|'s|O
S597|phenomenon|O
S597|attacks|O
S597|,|O
S597|and|O
S597|iloprost|O
S597|was|O
S597|shown|O
S597|to|O
S597|improve|O
S597|DU|O
S597|healing|O
S597|in|O
S597|another|O
S597|trial|O
S597|that|O
S597|included|O
S597|patients|O
S597|with|O
S597|active|O
S597|DUs|O
S597|.|O
S276|During|O
S276|the|O
S276|first|O
S276|weeks|O
S276|and|O
S276|months|O
S276|after|O
S276|initiating|O
S276|ULT|O
S276|,|O
S276|rapid|O
S276|reductions|O
S276|in|O
S276|SU|O
S276|levels|O
S276|can|O
S276|induce|O
S276|acute|O
S276|gouty|O
S276|arthritis|O
S276|flares|O
S276|.|O
S192|Patients|O
S192|were|O
S192|required|O
S192|to|O
S192|have|O
S192|been|O
S192|on|O
S192|maintenance|O
S192|treatment|O
S192|with|O
S192|stable|O
S192|medium-dose|O
S192|ICS|O
S192|(|O
S192|400–800|O
S192|μg|O
S192|budesonide|O
S192|or|O
S192|equivalent|O
S192|)|O
S192|,|O
S192|alone|O
S192|or|O
S192|in|O
S192|a|O
S192|fixed-dose|O
S192|combination|O
S192|with|O
S192|a|O
S192|LABA|O
S192|or|O
S192|short-acting|O
S192|β2-agonist|O
S192|,|O
S192|for|O
S192|at|O
S192|least|O
S192|4|O
S192|weeks|O
S192|prior|O
S192|to|O
S192|Visit|O
S192|1|O
S192|.|O
S1336|rt-PA|O
S1336|was|O
S1336|associated|O
S1336|with|O
S1336|a|O
S1336|significant|O
S1336|increase|O
S1336|in|O
S1336|extracranial|O
S1336|haemorrhages|O
S1336|(|O
S1336|table|O
S1336|3|O
S1336|)|O
S1336|.|O
S2183|Trial|O
S2183|registration|O
S2183|ClinicalTrials.gov|O
S2183|NCT01582503|O
S2183|Electronic|O
S2183|supplementary|O
S2183|material|O
S2183|The|O
S2183|online|O
S2183|version|O
S2183|of|O
S2183|this|O
S2183|article|O
S2183|(|O
S2183|doi:10.1186/s12931-016-0347-2|O
S2183|)|O
S2183|contains|O
S2183|supplementary|O
S2183|material|O
S2183|,|O
S2183|which|O
S2183|is|O
S2183|available|O
S2183|to|O
S2183|authorized|O
S2183|users|O
S2183|.|O
S1708|One|O
S1708|or|O
S1708|more|O
S1708|grade|O
S1708|3|O
S1708|or|O
S1708|4|O
S1708|adverse|O
S1708|events|O
S1708|(|O
S1708|co-primary|O
S1708|endpoint|O
S1708|)|O
S1708|occurred|O
S1708|in|O
S1708|283|O
S1708|(|O
S1708|47|O
S1708|%|O
S1708|)|O
S1708|children|O
S1708|on|O
S1708|clinically|O
S1708|driven|O
S1708|monitoring|O
S1708|versus|O
S1708|282|O
S1708|(|O
S1708|47|O
S1708|%|O
S1708|)|O
S1708|on|O
S1708|routine|O
S1708|laboratory|O
S1708|monitoring|O
S1708|(|O
S1708|HR|O
S1708|0·98|O
S1708|,|O
S1708|95|O
S1708|%|O
S1708|CI|O
S1708|0·83–1·16|O
S1708|,|O
S1708|p=0·83|O
S1708|;|O
S1708|figure|O
S1708|3|O
S1708|)|O
S1708|.|O
S304|Safety|O
S304|variables|O
S304|included|O
S304|the|O
S304|incidence|O
S304|of|O
S304|AEs|O
S304|,|O
S304|serious|O
S304|AEs|O
S304|(|O
S304|SAEs|O
S304|)|O
S304|and|O
S304|infectious|O
S304|AEs|O
S304|,|O
S304|the|O
S304|incidence|O
S304|and|O
S304|severity|O
S304|of|O
S304|injection-site|O
S304|reactions|O
S304|,|O
S304|and|O
S304|immunogenicity|O
S304|.|O
S1251|Additionally|O
S1251|,|O
S1251|if|O
S1251|the|O
S1251|patient|O
S1251|had|O
S1251|a|O
S1251|clear|O
S1251|indication|O
S1251|for|O
S1251|intravenous|O
S1251|thrombolysis|O
S1251|with|O
S1251|rt-PA|O
S1251|,|O
S1251|they|O
S1251|were|O
S1251|to|O
S1251|be|O
S1251|treated|O
S1251|in|O
S1251|accordance|O
S1251|with|O
S1251|local|O
S1251|guidelines|O
S1251|.|O
S155|Conclusions|O
S155|Once-daily|O
S155|tiotropium|O
S155|Respimat®|O
S155|add-on|O
S155|to|O
S155|medium-dose|O
S155|ICS|O
S155|improves|O
S155|lung|O
S155|function|O
S155|in|O
S155|symptomatic|O
S155|patients|O
S155|with|O
S155|moderate|O
S155|asthma|O
S155|.|O
S876|Adverse|O
S876|reactions|O
S876|were|O
S876|similar|O
S876|for|O
S876|the|O
S876|two|O
S876|groups|O
S876|(|O
S876|68|O
S876|%|O
S876|ciclosporin|O
S876|and|O
S876|66|O
S876|%|O
S876|prednisolone|O
S876|)|O
S876|,|O
S876|but|O
S876|serious|O
S876|adverse|O
S876|reactions|O
S876|,|O
S876|especially|O
S876|infections|O
S876|,|O
S876|were|O
S876|more|O
S876|common|O
S876|in|O
S876|the|O
S876|prednisolone|O
S876|group|O
S876|.|O
S18|However|O
S18|,|O
S18|a|O
S18|Cochrane|O
S18|systematic|O
S18|review|O
S18|of|O
S18|placebo-controlled|O
S18|randomized|O
S18|trials|O
S18|≥3|O
S18|months|O
S18|identified|O
S18|one|O
S18|study|O
S18|showing|O
S18|a|O
S18|significant|O
S18|benefit|O
S18|of|O
S18|double-dose|O
S18|H2RAs|O
S18|in|O
S18|reducing|O
S18|both|O
S18|gastric|O
S18|ulcers|O
S18|(|O
S18|relative|O
S18|risk|O
S18|(|O
S18|RR|O
S18|)|O
S18|=0.42|O
S18|,|O
S18|95|O
S18|%|O
S18|confidence|O
S18|interval|O
S18|,|O
S18|0.18–0.97|O
S18|)|O
S18|and|O
S18|duodenal|O
S18|ulcers|O
S18|(|O
S18|RR=0.19|O
S18|,|O
S18|0.04–0.85|O
S18|)|O
S18|.|O
S1149|A|O
S1149|total|O
S1149|of|O
S1149|28|O
S1149|adverse|O
S1149|events|O
S1149|were|O
S1149|reported|O
S1149|in|O
S1149|19|O
S1149|participants|O
S1149|.|O
S466|Radiographs|O
S466|of|O
S466|the|O
S466|left|O
S466|wrist|O
S466|were|O
S466|obtained|O
S466|annually|O
S466|,|O
S466|and|O
S466|a|O
S466|single|O
S466|observer|O
S466|(|O
S466|WFP|O
S466|)|O
S466|analysed|O
S466|them|O
S466|for|O
S466|bone|O
S466|age|O
S466|estimation|O
S466|according|O
S466|to|O
S466|the|O
S466|Tanner|O
S466|Whitehouse|O
S466|II|O
S466|method|O
S466|.|O
S1586|Methods|O
S1586|In|O
S1586|this|O
S1586|open-label|B-Blinding_Open_Label
S1586|parallel-group|B-Design_Parallel_Group
S1586|trial|O
S1586|,|O
S1586|Ugandan|B-Settings_Location
S1586|and|I-Settings_Location
S1586|Zimbabwean|I-Settings_Location
S1586|children|O
S1586|or|O
S1586|adolescents|O
S1586|with|O
S1586|HIV|O
S1586|,|O
S1586|aged|O
S1586|3|O
S1586|months|O
S1586|to|O
S1586|17|O
S1586|years|O
S1586|and|O
S1586|eligible|O
S1586|for|O
S1586|ART|O
S1586|,|O
S1586|were|O
S1586|randomly|O
S1586|assigned|O
S1586|in|O
S1586|a|O
S1586|factorial|B-Design_Factorial
S1586|design|O
S1586|.|O
S1858|Web|O
S1858|Extra|O
S1858|Material|O
S1858|Research|O
S1858|in|O
S1858|context|O
S1858|Systematic|O
S1858|review|O
S1858|Electronic|O
S1858|searches|O
S1858|of|O
S1858|Medline|O
S1858|,|O
S1858|PubMed|O
S1858|,|O
S1858|and|O
S1858|Scopus|O
S1858|,|O
S1858|supplemented|O
S1858|by|O
S1858|hand|O
S1858|searches|O
S1858|of|O
S1858|reference|O
S1858|lists|O
S1858|of|O
S1858|meta-analyses|O
S1858|and|O
S1858|other|O
S1858|review|O
S1858|articles|O
S1858|,|O
S1858|identified|O
S1858|reports|O
S1858|from|O
S1858|five|O
S1858|large|O
S1858|randomised|O
S1858|trials|O
S1858|of|O
S1858|statin|O
S1858|therapy|O
S1858|with|O
S1858|post-trial|O
S1858|follow-up|O
S1858|of|O
S1858|clinical|O
S1858|outcomes|O
S1858|.|O
S878|Treatment|O
S878|decisions|O
S878|for|O
S878|individual|O
S878|patients|O
S878|may|O
S878|be|O
S878|guided|O
S878|by|O
S878|the|O
S878|different|O
S878|side|O
S878|effect|O
S878|profiles|O
S878|of|O
S878|the|O
S878|two|O
S878|drugs|O
S878|and|O
S878|patient|O
S878|preference|O
S878|.|O
S966|Change|O
S966|in|O
S966|treatment|O
S966|occurred|O
S966|before|O
S966|the|O
S966|six|O
S966|week|O
S966|primary|O
S966|outcome|O
S966|assessment|O
S966|in|O
S966|five|O
S966|participants|O
S966|(|O
S966|prednisolone|O
S966|n=1|O
S966|,|O
S966|ciclosporin|O
S966|n=4|O
S966|)|O
S966|.|O
S1936|Objective|O
S1936|To|O
S1936|determine|O
S1936|whether|O
S1936|children|O
S1936|with|O
S1936|calcium-deficiency|O
S1936|rickets|O
S1936|have|O
S1936|a|O
S1936|better|O
S1936|response|O
S1936|to|O
S1936|treatment|O
S1936|with|O
S1936|vitamin|O
S1936|D|O
S1936|and|O
S1936|calcium|O
S1936|than|O
S1936|with|O
S1936|calcium|O
S1936|alone|O
S1936|.|O
S2097|Memantine|O
S2097|(|O
S2097|1-amino-3,5-dimethyladamantane|O
S2097|)|O
S2097|is|O
S2097|an|O
S2097|uncompetitive|O
S2097|,|O
S2097|partial|O
S2097|antagonist|O
S2097|of|O
S2097|the|O
S2097|open|O
S2097|NMDA|O
S2097|receptor|O
S2097|.|O
S2200|We|O
S2200|previously|O
S2200|evaluated|O
S2200|the|O
S2200|safety|O
S2200|,|O
S2200|tolerability|O
S2200|,|O
S2200|and|O
S2200|activity|O
S2200|of|O
S2200|quilizumab|O
S2200|in|O
S2200|Phase|O
S2200|Ia|O
S2200|(|O
S2200|31|O
S2200|healthy|O
S2200|volunteers|O
S2200|)|O
S2200|,|O
S2200|Phase|O
S2200|Ib|O
S2200|(|O
S2200|24|O
S2200|allergic|O
S2200|rhinitis|O
S2200|patients|O
S2200|)|O
S2200|and|O
S2200|Phase|O
S2200|IIa|O
S2200|(|O
S2200|15|O
S2200|mild|O
S2200|asthma|O
S2200|patients|O
S2200|)|O
S2200|studies|O
S2200|.|O
S1338|The|O
S1338|subgroup|O
S1338|analyses|O
S1338|are|O
S1338|of|O
S1338|the|O
S1338|adjusted|O
S1338|effects|O
S1338|and|O
S1338|take|O
S1338|account|O
S1338|of|O
S1338|the|O
S1338|fact|O
S1338|that|O
S1338|,|O
S1338|for|O
S1338|a|O
S1338|specific|O
S1338|prognostic|O
S1338|factor|O
S1338|,|O
S1338|the|O
S1338|distribution|O
S1338|of|O
S1338|other|O
S1338|factors|O
S1338|might|O
S1338|differ|O
S1338|between|O
S1338|subcategories|O
S1338|.|O
S938|Self|O
S938|reported|O
S938|pain—participants|O
S938|self|O
S938|reported|O
S938|the|O
S938|severity|O
S938|of|O
S938|pain|O
S938|daily|O
S938|using|O
S938|a|O
S938|score|O
S938|from|O
S938|0|O
S938|to|O
S938|4|O
S938|(|O
S938|none|O
S938|,|O
S938|mild|O
S938|,|O
S938|moderate|O
S938|,|O
S938|severe|O
S938|,|O
S938|or|O
S938|extreme|O
S938|)|O
S938|.|O
S2192|When|O
S2192|allergen|O
S2192|cross-links|O
S2192|IgE|O
S2192|bound|O
S2192|to|O
S2192|IgE|O
S2192|receptors|O
S2192|on|O
S2192|mast|O
S2192|cells|O
S2192|and|O
S2192|basophils|O
S2192|,|O
S2192|cell|O
S2192|activation|O
S2192|and|O
S2192|allergic|O
S2192|mediator|O
S2192|release|O
S2192|occur|O
S2192|,|O
S2192|which|O
S2192|may|O
S2192|lead|O
S2192|to|O
S2192|mucus|O
S2192|production|O
S2192|and|O
S2192|airway|O
S2192|hyperreactivity|O
S2192|.|O
S213|To|O
S213|control|O
S213|the|O
S213|probability|O
S213|of|O
S213|a|O
S213|type|O
S213|I|O
S213|error|O
S213|in|O
S213|the|O
S213|primary|O
S213|efficacy|O
S213|analysis|O
S213|,|O
S213|stepwise|O
S213|testing|O
S213|of|O
S213|the|O
S213|null|O
S213|hypothesis|O
S213|was|O
S213|used|O
S213|to|O
S213|test|O
S213|the|O
S213|efficacy|O
S213|of|O
S213|tiotropium|O
S213|Respimat®|O
S213|5|O
S213|μg|O
S213|,|O
S213|then|O
S213|2.5|O
S213|μg|O
S213|and|O
S213|then|O
S213|1.25|O
S213|μg|O
S213|,|O
S213|each|O
S213|over|O
S213|placebo|O
S213|Respimat®|O
S213|.|O
S1443|We|O
S1443|also|O
S1443|examined|O
S1443|numerous|O
S1443|secondary|O
S1443|clinical|O
S1443|endpoints|O
S1443|(|O
S1443|such|O
S1443|as|O
S1443|mortality|O
S1443|,|O
S1443|mechanical|O
S1443|ventilation|O
S1443|,|O
S1443|admission|O
S1443|to|O
S1443|intensive|O
S1443|care|O
S1443|,|O
S1443|symptoms|O
S1443|,|O
S1443|resumption|O
S1443|of|O
S1443|activity|O
S1443|)|O
S1443|and|O
S1443|virological|O
S1443|endpoints|O
S1443|.|O
S2123|All|O
S2123|assessments|O
S2123|were|O
S2123|performed|O
S2123|once|O
S2123|before|O
S2123|the|O
S2123|90-day|O
S2123|course|O
S2123|of|O
S2123|study|O
S2123|medication|O
S2123|and|O
S2123|once|O
S2123|afterwards|O
S2123|.|O
S1114|The|O
S1114|time|O
S1114|to|O
S1114|clearance|O
S1114|of|O
S1114|plantar|O
S1114|warts|O
S1114|was|O
S1114|derived|O
S1114|as|O
S1114|the|O
S1114|number|O
S1114|of|O
S1114|days|O
S1114|from|O
S1114|randomisation|O
S1114|until|O
S1114|the|O
S1114|date|O
S1114|of|O
S1114|clearance|O
S1114|,|O
S1114|as|O
S1114|detailed|O
S1114|from|O
S1114|the|O
S1114|participant|O
S1114|’|O
S1114|s|O
S1114|self|O
S1114|reported|O
S1114|questionnaire|O
S1114|.|O
S2135|The|O
S2135|primary|O
S2135|criterion|O
S2135|was|O
S2135|tested|O
S2135|in|O
S2135|a|O
S2135|covariance|O
S2135|analysis|O
S2135|(|O
S2135|with|O
S2135|adjustment|O
S2135|for|O
S2135|baseline|O
S2135|)|O
S2135|for|O
S2135|all|O
S2135|patients|O
S2135|with|O
S2135|data|O
S2135|recorded|O
S2135|in|O
S2135|the|O
S2135|final|O
S2135|assessment|O
S2135|.|O
S1403|Mortality|O
S1403|was|O
S1403|similar|O
S1403|:|O
S1403|12/165|O
S1403|(|O
S1403|7.3|O
S1403|%|O
S1403|,|O
S1403|4.2|O
S1403|%|O
S1403|to|O
S1403|12.3|O
S1403|%|O
S1403|)|O
S1403|in|O
S1403|double|O
S1403|dose|O
S1403|recipients|O
S1403|versus|O
S1403|9/161|O
S1403|(|O
S1403|5.6|O
S1403|%|O
S1403|,|O
S1403|3.0|O
S1403|%|O
S1403|to|O
S1403|10.3|O
S1403|%|O
S1403|)|O
S1403|in|O
S1403|standard|O
S1403|dose|O
S1403|recipients|O
S1403|.|O
S316|Most|O
S316|patients|O
S316|were|O
S316|men|O
S316|(|O
S316|89|O
S316|%|O
S316|to|O
S316|100|O
S316|%|O
S316|)|O
S316|and|O
S316|28|O
S316|%|O
S316|to|O
S316|44|O
S316|%|O
S316|had|O
S316|had|O
S316|gouty|O
S316|arthritis|O
S316|for|O
S316|at|O
S316|least|O
S316|10|O
S316|years|O
S316|.|O
S173|In|O
S173|light|O
S173|of|O
S173|the|O
S173|findings|O
S173|with|O
S173|the|O
S173|10|O
S173|μg|O
S173|and|O
S173|5|O
S173|μg|O
S173|doses|O
S173|of|O
S173|tiotropium|O
S173|Respimat®|O
S173|(|O
S173|outlined|O
S173|above|O
S173|)|O
S173|,|O
S173|the|O
S173|aim|O
S173|of|O
S173|the|O
S173|present|O
S173|study|O
S173|was|O
S173|to|O
S173|further|O
S173|explore|O
S173|the|O
S173|dose–response|O
S173|curve|O
S173|by|O
S173|comparing|O
S173|the|O
S173|efficacy|O
S173|and|O
S173|tolerability|O
S173|of|O
S173|once-daily|O
S173|evening|O
S173|dosing|O
S173|of|O
S173|tiotropium|O
S173|Respimat®|O
S173|5|O
S173|μg|O
S173|,|O
S173|2.5|O
S173|μg|O
S173|or|O
S173|1.25|O
S173|μg|O
S173|,|O
S173|versus|O
S173|placebo|O
S173|Respimat®|O
S173|,|O
S173|each|O
S173|added|O
S173|on|O
S173|to|O
S173|medium-dose|O
S173|ICS|O
S173|,|O
S173|in|O
S173|adult|O
S173|patients|O
S173|with|O
S173|symptomatic|O
S173|moderate|O
S173|asthma|O
S173|.|O
S45|With|O
S45|this|O
S45|approach|O
S45|,|O
S45|the|O
S45|first|O
S45|null|O
S45|hypothesis|O
S45|that|O
S45|is|O
S45|accepted|O
S45|(|O
S45|i.e.|O
S45|,|O
S45|P≥0.05|O
S45|)|O
S45|will|O
S45|cause|O
S45|immediate|O
S45|acceptance|O
S45|of|O
S45|all|O
S45|subsequent|O
S45|null|O
S45|hypotheses|O
S45|in|O
S45|the|O
S45|sequence|O
S45|(|O
S45|subsequent|O
S45|comparisons|O
S45|will|O
S45|be|O
S45|considered|O
S45|not|O
S45|significantly|O
S45|different|O
S45|and|O
S45|no|O
S45|statistical|O
S45|comparison|O
S45|will|O
S45|be|O
S45|performed|O
S45|)|O
S45|.|O
S1429|The|O
S1429|doses|O
S1429|were|O
S1429|75|O
S1429|mg|O
S1429|or|O
S1429|150|O
S1429|mg|O
S1429|twice|O
S1429|daily|O
S1429|in|O
S1429|those|O
S1429|aged|O
S1429|≥15|O
S1429|or|O
S1429|weighing|O
S1429|>|O
S1429|40|O
S1429|kg|O
S1429|;|O
S1429|60|O
S1429|mg|O
S1429|or|O
S1429|120|O
S1429|mg|O
S1429|twice|O
S1429|daily|O
S1429|in|O
S1429|those|O
S1429|weighing|O
S1429|>|O
S1429|23-40|O
S1429|kg|O
S1429|;|O
S1429|45|O
S1429|mg|O
S1429|or|O
S1429|90|O
S1429|mg|O
S1429|twice|O
S1429|daily|O
S1429|in|O
S1429|those|O
S1429|weighing|O
S1429|>|O
S1429|15-23|O
S1429|kg|O
S1429|;|O
S1429|and|O
S1429|30|O
S1429|mg|O
S1429|or|O
S1429|60|O
S1429|mg|O
S1429|twice|O
S1429|daily|O
S1429|in|O
S1429|those|O
S1429|weighing|O
S1429|≤15|O
S1429|kg|O
S1429|.|O
S2277|Subgroup|O
S2277|analysis|O
S2277|by|O
S2277|baseline|O
S2277|serum|O
S2277|periostin|O
S2277|(|O
S2277|≥50|O
S2277|ng/ml|O
S2277|,|O
S2277|<|O
S2277|50|O
S2277|ng/ml|O
S2277|)|O
S2277|,|O
S2277|blood|O
S2277|eosinophils|O
S2277|(|O
S2277|≥300|O
S2277|cells/μl|O
S2277|,|O
S2277|<|O
S2277|300|O
S2277|cells/μl|O
S2277|)|O
S2277|,|O
S2277|FeNO|O
S2277|(|O
S2277|≥20|O
S2277|ppb|O
S2277|,|O
S2277|<|O
S2277|20|O
S2277|ppb|O
S2277|)|O
S2277|and|O
S2277|serum|O
S2277|total|O
S2277|IgE|O
S2277|(|O
S2277|≥200|O
S2277|IU/mL|O
S2277|,|O
S2277|<|O
S2277|200|O
S2277|IU/mL|O
S2277|)|O
S2277|demonstrated|O
S2277|no|O
S2277|consistent|O
S2277|effect|O
S2277|of|O
S2277|quilizumab|O
S2277|on|O
S2277|the|O
S2277|exacerbation|O
S2277|rate|O
S2277|across|O
S2277|all|O
S2277|doses|O
S2277|when|O
S2277|compared|O
S2277|to|O
S2277|the|O
S2277|ITT|O
S2277|population|O
S2277|(|O
S2277|Fig|O
S2277|.|O
S922|If|O
S922|digital|O
S922|images|O
S922|were|O
S922|not|O
S922|available|O
S922|,|O
S922|the|O
S922|assessors|O
S922|used|O
S922|physical|O
S922|measurements|O
S922|of|O
S922|the|O
S922|lesion|O
S922|taken|O
S922|during|O
S922|clinic|O
S922|visits|O
S922|and|O
S922|global|O
S922|response|O
S922|by|O
S922|the|O
S922|treating|O
S922|clinician|O
S922|.|O
S2008|Baseline|O
S2008|dairy|O
S2008|product|O
S2008|intake|O
S2008|was|O
S2008|not|O
S2008|significantly|O
S2008|associated|O
S2008|with|O
S2008|height|O
S2008|for|O
S2008|age|O
S2008|(|O
S2008|r=0.19|O
S2008|)|O
S2008|,|O
S2008|weight|O
S2008|for|O
S2008|height|O
S2008|(|O
S2008|r=0.02|O
S2008|)|O
S2008|,|O
S2008|serum|O
S2008|calcium|O
S2008|(|O
S2008|r=0.07|O
S2008|)|O
S2008|or|O
S2008|25|O
S2008|(|O
S2008|OH|O
S2008|)|O
S2008|D|O
S2008|concentrations|O
S2008|(|O
S2008|r=−0.05|O
S2008|)|O
S2008|.|O
S139|Tiotropium|O
S139|Respimat®|O
S139|in|O
S139|asthma|O
S139|:|O
S139|a|O
S139|double-blind|B-Blinding_Double_Blind
S139|,|O
S139|randomised|O
S139|,|O
S139|dose-ranging|O
S139|study|O
S139|in|O
S139|adult|O
S139|patients|O
S139|with|O
S139|moderate|O
S139|asthma|O
S349|All|O
S349|events|O
S349|were|O
S349|mild|O
S349|except|O
S349|for|O
S349|one|O
S349|moderate|O
S349|event|O
S349|in|O
S349|the|O
S349|canakinumab|O
S349|50|O
S349|mg|O
S349|group|O
S349|.|O
S2176|Quilizumab|O
S2176|was|O
S2176|evaluated|O
S2176|for|O
S2176|effects|O
S2176|on|O
S2176|the|O
S2176|rate|O
S2176|of|O
S2176|asthma|O
S2176|exacerbations|O
S2176|,|O
S2176|lung|O
S2176|function|O
S2176|,|O
S2176|patient|O
S2176|symptoms|O
S2176|,|O
S2176|serum|O
S2176|IgE|O
S2176|,|O
S2176|and|O
S2176|pharmacokinetics|O
S2176|.|O
S815|Baseline|O
S815|forearm|O
S815|blood|O
S815|flow|O
S815|in|O
S815|the|O
S815|non-infused|O
S815|arm|O
S815|was|O
S815|similar|O
S815|and|O
S815|was|O
S815|unaffected|O
S815|by|O
S815|either|O
S815|treatment|O
S815|.|O
S503|SITAR|O
S503|analysis|O
S503|of|O
S503|height|O
S503|curves|O
S503|We|O
S503|applied|O
S503|the|O
S503|SITAR|O
S503|analysis|O
S503|to|O
S503|the|O
S503|105|O
S503|participants|O
S503|with|O
S503|at|O
S503|least|O
S503|one|O
S503|height|O
S503|measurement|O
S503|(|O
S503|one|O
S503|girl|O
S503|in|O
S503|the|O
S503|control|O
S503|group|O
S503|withdrew|O
S503|immediately|O
S503|after|O
S503|randomisation|O
S503|1|O
S503|)|O
S503|.|O
S2190|Allergic|O
S2190|asthma|O
S2190|is|O
S2190|a|O
S2190|hypersensitivity|O
S2190|driven|O
S2190|by|O
S2190|the|O
S2190|complex|O
S2190|interaction|O
S2190|of|O
S2190|epithelial|O
S2190|,|O
S2190|dendritic|O
S2190|,|O
S2190|and|O
S2190|type|O
S2190|2|O
S2190|innate|O
S2190|lymphoid|O
S2190|cells|O
S2190|,|O
S2190|leading|O
S2190|to|O
S2190|activation|O
S2190|of|O
S2190|CD4+|O
S2190|T|O
S2190|helper|O
S2190|2|O
S2190|(|O
S2190|Th2|O
S2190|)|O
S2190|cells|O
S2190|in|O
S2190|response|O
S2190|to|O
S2190|allergen|O
S2190|exposure|O
S2190|.|O
S443|Inclusion|O
S443|criteria|O
S443|for|O
S443|participation|O
S443|of|O
S443|patients|O
S443|were|O
S443|karyotype|O
S443|confirmed|O
S443|Turner|O
S443|’|O
S443|s|O
S443|syndrome|O
S443|(|O
S443|all|O
S443|karyotypes|O
S443|were|O
S443|eligible|O
S443|,|O
S443|including|O
S443|mosaic|O
S443|)|O
S443|,|O
S443|age|O
S443|7-13|O
S443|years|O
S443|,|O
S443|no|O
S443|previous|O
S443|growth|O
S443|hormone|O
S443|treatment|O
S443|or|O
S443|previous|O
S443|treatment|O
S443|in|O
S443|the|O
S443|range|O
S443|8.3-11.7|O
S443|mg/m2/week|O
S443|in|O
S443|five|O
S443|to|O
S443|seven|O
S443|injections|O
S443|a|O
S443|week|O
S443|,|O
S443|no|O
S443|previous|O
S443|oxandrolone|O
S443|and|O
S443|oestrogen|O
S443|therapy|O
S443|,|O
S443|and|O
S443|open|O
S443|epiphyses|O
S443|.|O
S1596|However|O
S1596|,|O
S1596|in|O
S1596|years|O
S1596|2–5|O
S1596|,|O
S1596|rates|O
S1596|were|O
S1596|higher|O
S1596|in|O
S1596|children|O
S1596|on|O
S1596|clinically|O
S1596|driven|O
S1596|monitoring|O
S1596|(|O
S1596|1·3|O
S1596|vs|O
S1596|0·4|O
S1596|per|O
S1596|100|O
S1596|child-years|O
S1596|,|O
S1596|difference|O
S1596|0·99|O
S1596|,|O
S1596|0·37–1·60|O
S1596|,|O
S1596|p=0·002|O
S1596|)|O
S1596|.|O
S2188|These|O
S2188|patients|O
S2188|are|O
S2188|at|O
S2188|the|O
S2188|highest|O
S2188|risk|O
S2188|for|O
S2188|future|O
S2188|exacerbations|O
S2188|and|O
S2188|unscheduled|O
S2188|use|O
S2188|of|O
S2188|healthcare|O
S2188|resources|O
S2188|.|O
S324|)|O
S324|However|O
S324|,|O
S324|as|O
S324|the|O
S324|distribution|O
S324|of|O
S324|flares|O
S324|per|O
S324|patient|O
S324|was|O
S324|observed|O
S324|to|O
S324|be|O
S324|skewed|O
S324|(|O
S324|most|O
S324|patients|O
S324|had|O
S324|no|O
S324|or|O
S324|few|O
S324|flares|O
S324|and|O
S324|few|O
S324|had|O
S324|many|O
S324|flares|O
S324|)|O
S324|,|O
S324|the|O
S324|preplanned|O
S324|ANCOVA|O
S324|was|O
S324|considered|O
S324|inappropriate|O
S324|for|O
S324|these|O
S324|data|O
S324|.|O
S909|If|O
S909|the|O
S909|clinical|O
S909|diagnosis|O
S909|was|O
S909|uncertain|O
S909|,|O
S909|a|O
S909|biopsy|O
S909|was|O
S909|performed|O
S909|to|O
S909|exclude|O
S909|other|O
S909|diagnoses|O
S909|such|O
S909|as|O
S909|malignancy|O
S909|,|O
S909|granulomatous|O
S909|pyoderma|O
S909|gangrenosum|O
S909|,|O
S909|and|O
S909|arteritis|O
S909|,|O
S909|and|O
S909|advice|O
S909|was|O
S909|sought|O
S909|from|O
S909|an|O
S909|expert|O
S909|panel|O
S909|as|O
S909|necessary|O
S909|.|O
S1968|Standing|O
S1968|height|O
S1968|was|O
S1968|measured|O
S1968|with|O
S1968|a|O
S1968|wall-mounted|O
S1968|stadiometer|O
S1968|.|O
S234|Safety|O
S234|and|O
S234|tolerability|O
S234|Overall|O
S234|incidence|O
S234|of|O
S234|adverse|O
S234|events|O
S234|was|O
S234|comparable|O
S234|between|O
S234|placebo|O
S234|Respimat®|O
S234|and|O
S234|the|O
S234|three|O
S234|tiotropium|O
S234|Respimat®|O
S234|treatment|O
S234|doses|O
S234|(|O
S234|Table|O
S234|3|O
S234|)|O
S234|.|O
S1113|These|O
S1113|models|O
S1113|are|O
S1113|used|O
S1113|to|O
S1113|estimate|O
S1113|the|O
S1113|number|O
S1113|of|O
S1113|occurrences|O
S1113|of|O
S1113|an|O
S1113|event|O
S1113|when|O
S1113|the|O
S1113|event|O
S1113|has|O
S1113|Poisson|O
S1113|variation|O
S1113|with|O
S1113|over-dispersion|O
S1113|.|O
S2225|The|O
S2225|modified|O
S2225|total|O
S2225|asthma|O
S2225|symptom|O
S2225|score|O
S2225|(|O
S2225|mTASS|O
S2225|)|O
S2225|was|O
S2225|generated|O
S2225|from|O
S2225|a|O
S2225|subset|O
S2225|of|O
S2225|diary|O
S2225|questions|O
S2225|adapted|O
S2225|from|O
S2225|a|O
S2225|previous|O
S2225|questionnaire|O
S2225|,|O
S2225|scoring|O
S2225|nighttime|O
S2225|awakenings|O
S2225|(|O
S2225|0–3|O
S2225|)|O
S2225|,|O
S2225|symptoms|O
S2225|on|O
S2225|awakening|O
S2225|(|O
S2225|0–1|O
S2225|)|O
S2225|,|O
S2225|and|O
S2225|daytime|O
S2225|symptom|O
S2225|severity|O
S2225|(|O
S2225|0–4|O
S2225|)|O
S2225|,|O
S2225|for|O
S2225|a|O
S2225|total|O
S2225|score|O
S2225|range|O
S2225|of|O
S2225|0–8|O
S2225|.|O
S240|The|O
S240|most|O
S240|commonly|O
S240|reported|O
S240|adverse|O
S240|events|O
S240|by|O
S240|preferred|O
S240|term|O
S240|were|O
S240|asthma|O
S240|exacerbation|O
S240|and|O
S240|nasopharyngitis|O
S240|.|O
S1687|26|O
S1687|[|O
S1687|7|O
S1687|%|O
S1687|]|O
S1687|children|O
S1687|in|O
S1687|group|O
S1687|A|O
S1687|switched|O
S1687|to|O
S1687|second-line|O
S1687|treatment|O
S1687|versus|O
S1687|17|O
S1687|[|O
S1687|4|O
S1687|%|O
S1687|]|O
S1687|in|O
S1687|group|O
S1687|B|O
S1687|and|O
S1687|20|O
S1687|(|O
S1687|5|O
S1687|%|O
S1687|)|O
S1687|in|O
S1687|group|O
S1687|C|O
S1687|;|O
S1687|these|O
S1687|differences|O
S1687|were|O
S1687|not|O
S1687|significant|O
S1687|(|O
S1687|p=0·25|O
S1687|;|O
S1687|figure|O
S1687|2|O
S1687|)|O
S1687|.|O
S1672|In|O
S1672|clinically|O
S1672|driven|O
S1672|monitoring|O
S1672|,|O
S1672|apart|O
S1672|from|O
S1672|week|O
S1672|8|O
S1672|haemoglobin|O
S1672|(|O
S1672|returned|O
S1672|per|O
S1672|protocol|O
S1672|)|O
S1672|,|O
S1672|very|O
S1672|few|O
S1672|results|O
S1672|were|O
S1672|released|O
S1672|(|O
S1672|from|O
S1672|486|O
S1672|[|O
S1672|4|O
S1672|%|O
S1672|]|O
S1672|panels|O
S1672|)|O
S1672|;|O
S1672|most|O
S1672|commonly|O
S1672|requested|O
S1672|results|O
S1672|were|O
S1672|haemoglobin|O
S1672|(|O
S1672|2|O
S1672|%|O
S1672|,|O
S1672|n=265|O
S1672|)|O
S1672|and|O
S1672|neutrophils|O
S1672|(|O
S1672|3|O
S1672|%|O
S1672|,|O
S1672|n=323|O
S1672|;|O
S1672|appendix|O
S1672|)|O
S1672|.|O
S1646|All|O
S1646|WHO|O
S1646|stage|O
S1646|3|O
S1646|or|O
S1646|4|O
S1646|events|O
S1646|,|O
S1646|deaths|O
S1646|,|O
S1646|and|O
S1646|serious|O
S1646|adverse|O
S1646|events|O
S1646|were|O
S1646|reviewed|O
S1646|against|O
S1646|prespecified|O
S1646|criteria|O
S1646|by|O
S1646|an|O
S1646|endpoint|O
S1646|review|O
S1646|committee|O
S1646|with|O
S1646|an|O
S1646|independent|O
S1646|chair|O
S1646|and|O
S1646|members|O
S1646|,|O
S1646|masked|O
S1646|to|O
S1646|randomised|O
S1646|allocations|O
S1646|.|O
S1979|Samples|O
S1979|of|O
S1979|limestone|O
S1979|had|O
S1979|no|O
S1979|toxic|O
S1979|concentrations|O
S1979|of|O
S1979|heavy|O
S1979|metals|O
S1979|.|O
S195|Patients|O
S195|were|O
S195|required|O
S195|never|O
S195|to|O
S195|have|O
S195|smoked|O
S195|,|O
S195|or|O
S195|to|O
S195|be|O
S195|ex-smokers|O
S195|who|O
S195|had|O
S195|stopped|O
S195|smoking|O
S195|at|O
S195|least|O
S195|1|O
S195|year|O
S195|prior|O
S195|to|O
S195|enrolment|O
S195|and|O
S195|had|O
S195|a|O
S195|smoking|O
S195|history|O
S195|of|O
S195|less|O
S195|than|O
S195|10|O
S195|pack-years|O
S195|.|O
S1622|Children|O
S1622|were|O
S1622|also|O
S1622|randomly|O
S1622|assigned|O
S1622|(|O
S1622|1:1:1|B-Randomization_Ratio
S1622|)|O
S1622|in|O
S1622|a|O
S1622|factorial|B-Design_Factorial
S1622|design|O
S1622|to|O
S1622|three|O
S1622|approaches|O
S1622|for|O
S1622|first-line|O
S1622|ART|O
S1622|:|O
S1622|open-label|B-Blinding_Open_Label
S1622|lamivudine|O
S1622|,|O
S1622|abacavir|O
S1622|,|O
S1622|plus|O
S1622|NNRTI|O
S1622|continuously|O
S1622|(|O
S1622|group|O
S1622|A|O
S1622|,|O
S1622|control|O
S1622|)|O
S1622|;|O
S1622|induction-maintenance|O
S1622|with|O
S1622|four-drug|O
S1622|lamivudine|O
S1622|,|O
S1622|abacavir|O
S1622|,|O
S1622|NNRTI|O
S1622|,|O
S1622|plus|O
S1622|zidovudine|O
S1622|for|O
S1622|36|O
S1622|weeks|O
S1622|,|O
S1622|then|O
S1622|lamivudine|O
S1622|,|O
S1622|abacavir|O
S1622|,|O
S1622|plus|O
S1622|NNRTI|O
S1622|(|O
S1622|group|O
S1622|B|O
S1622|)|O
S1622|;|O
S1622|or|O
S1622|induction-maintenance|O
S1622|with|O
S1622|lamivudine|O
S1622|,|O
S1622|abacavir|O
S1622|,|O
S1622|NNRTI|O
S1622|,|O
S1622|plus|O
S1622|zidovudine|O
S1622|for|O
S1622|36|O
S1622|weeks|O
S1622|,|O
S1622|then|O
S1622|lamivudine|O
S1622|,|O
S1622|abacavir|O
S1622|,|O
S1622|plus|O
S1622|zidovudine|O
S1622|(|O
S1622|group|O
S1622|C|O
S1622|)|O
S1622|.|O
S1460|For|O
S1460|multiple|O
S1460|regression|O
S1460|we|O
S1460|forced|O
S1460|important|O
S1460|variables|O
S1460|such|O
S1460|as|O
S1460|age|O
S1460|group|O
S1460|,|O
S1460|(|O
S1460|sub|O
S1460|)|O
S1460|type|O
S1460|of|O
S1460|virus|O
S1460|,|O
S1460|and|O
S1460|treatment|O
S1460|arm|O
S1460|in|O
S1460|the|O
S1460|model|O
S1460|,|O
S1460|while|O
S1460|for|O
S1460|other|O
S1460|factors|O
S1460|we|O
S1460|used|O
S1460|forward|O
S1460|stepwise|O
S1460|variable|O
S1460|selection|O
S1460|procedure|O
S1460|with|O
S1460|5|O
S1460|%|O
S1460|significance|O
S1460|.|O
S263|At|O
S263|16|O
S263|weeks|O
S263|,|O
S263|there|O
S263|was|O
S263|a|O
S263|62|O
S263|%|O
S263|to|O
S263|72|O
S263|%|O
S263|reduction|O
S263|in|O
S263|the|O
S263|mean|O
S263|number|O
S263|of|O
S263|flares|O
S263|per|O
S263|patient|O
S263|for|O
S263|canakinumab|O
S263|doses|O
S263|≥50|O
S263|mg|O
S263|versus|O
S263|colchicine|O
S263|based|O
S263|on|O
S263|a|O
S263|negative|O
S263|binomial|O
S263|model|O
S263|(|O
S263|rate|O
S263|ratio|O
S263|:|O
S263|0.28–0.38|O
S263|,|O
S263|p≤0.0083|O
S263|)|O
S263|,|O
S263|and|O
S263|the|O
S263|percentage|O
S263|of|O
S263|patients|O
S263|experiencing|O
S263|≥1|O
S263|flare|O
S263|was|O
S263|significantly|O
S263|lower|O
S263|for|O
S263|all|O
S263|canakinumab|O
S263|doses|O
S263|(|O
S263|15|O
S263|%|O
S263|to|O
S263|27|O
S263|%|O
S263|)|O
S263|versus|O
S263|colchicine|O
S263|(|O
S263|44|O
S263|%|O
S263|,|O
S263|p|O
S263|<|O
S263|0.05|O
S263|)|O
S263|.|O
S1480|Among|O
S1480|64|O
S1480|samples|O
S1480|from|O
S1480|83|O
S1480|patients|O
S1480|positive|O
S1480|for|O
S1480|RT-PCR|O
S1480|on|O
S1480|day|O
S1480|five|O
S1480|,|O
S1480|samples|O
S1480|from|O
S1480|6/28|O
S1480|(|O
S1480|21|O
S1480|%|O
S1480|,|O
S1480|10.2|O
S1480|%|O
S1480|to|O
S1480|39.5|O
S1480|%|O
S1480|)|O
S1480|double|O
S1480|dose|O
S1480|patients|O
S1480|and|O
S1480|5/36|O
S1480|(|O
S1480|14|O
S1480|%|O
S1480|,|O
S1480|6.1|O
S1480|%|O
S1480|to|O
S1480|28.7|O
S1480|%|O
S1480|)|O
S1480|standard|O
S1480|dose|O
S1480|patients|O
S1480|had|O
S1480|infectious|O
S1480|virus|O
S1480|detected|O
S1480|in|O
S1480|cell|O
S1480|culture|O
S1480|(|O
S1480|P=0.43|O
S1480|)|O
S1480|.|O
S1625|The|O
S1625|hypothesis|O
S1625|was|O
S1625|that|O
S1625|clinically|O
S1625|driven|O
S1625|monitoring|O
S1625|would|O
S1625|result|O
S1625|in|O
S1625|similar|O
S1625|outcomes|O
S1625|to|O
S1625|routine|O
S1625|laboratory|O
S1625|monitoring|O
S1625|(|O
S1625|non-inferiority|B-Design_Comparative_Intent_NonInferiority
S1625|)|O
S1625|and|O
S1625|that|O
S1625|four-drug|O
S1625|induction-maintenance|O
S1625|would|O
S1625|have|O
S1625|greater|O
S1625|efficacy|O
S1625|than|O
S1625|would|O
S1625|standard|O
S1625|three-drug|O
S1625|ART|O
S1625|.|O
S1155|The|O
S1155|remaining|O
S1155|12|O
S1155|adverse|O
S1155|events|O
S1155|in|O
S1155|the|O
S1155|cryotherapy|O
S1155|group|O
S1155|were|O
S1155|either|O
S1155|unrelated|O
S1155|to|O
S1155|the|O
S1155|trial|O
S1155|treatment|O
S1155|(|O
S1155|7|O
S1155|)|O
S1155|or|O
S1155|unlikely|O
S1155|to|O
S1155|be|O
S1155|related|O
S1155|(|O
S1155|5|O
S1155|)|O
S1155|.|O
S54|A|O
S54|pooled|O
S54|analysis|O
S54|of|O
S54|the|O
S54|patients|O
S54|in|O
S54|REDUCE-1|O
S54|and|O
S54|-2|O
S54|was|O
S54|prespecified|O
S54|,|O
S54|with|O
S54|the|O
S54|primary|O
S54|end|O
S54|point|O
S54|being|O
S54|upper|O
S54|GI|O
S54|ulcers|O
S54|,|O
S54|and|O
S54|the|O
S54|secondary|O
S54|end|O
S54|points|O
S54|being|O
S54|gastric|O
S54|ulcers|O
S54|and|O
S54|duodenal|O
S54|ulcers|O
S54|.|O
S468|Standardised|O
S468|pharmacovigilance|O
S468|procedures|O
S468|were|O
S468|followed|O
S468|,|O
S468|with|O
S468|recording|O
S468|of|O
S468|adverse|O
S468|events|O
S468|or|O
S468|reactions|O
S468|at|O
S468|each|O
S468|visit|O
S468|and|O
S468|subsequent|O
S468|review|O
S468|by|O
S468|the|O
S468|Data|O
S468|and|O
S468|Safety|O
S468|Monitoring|O
S468|Group|O
S468|.|O
S979|Nine|O
S979|participants|O
S979|(|O
S979|four|O
S979|in|O
S979|the|O
S979|prednisolone|O
S979|group|O
S979|;|O
S979|five|O
S979|in|O
S979|the|O
S979|ciclosporin|O
S979|group|O
S979|)|O
S979|showed|O
S979|no|O
S979|change|O
S979|in|O
S979|lesion|O
S979|area|O
S979|two|O
S979|weeks|O
S979|after|O
S979|baseline|O
S979|,|O
S979|and|O
S979|two|O
S979|had|O
S979|missing|O
S979|data|O
S979|at|O
S979|week|O
S979|2|O
S979|.|O
S307|A|O
S307|preplanned|O
S307|interim|O
S307|analysis|O
S307|was|O
S307|performed|O
S307|when|O
S307|200|O
S307|patients|O
S307|had|O
S307|completed|O
S307|16|O
S307|weeks|O
S307|.|O
S510|The|O
S510|two|O
S510|curves|O
S510|cross|O
S510|at|O
S510|10|O
S510|years|O
S510|,|O
S510|and|O
S510|height|O
S510|velocity|O
S510|is|O
S510|consistently|O
S510|greater|O
S510|in|O
S510|the|O
S510|oxandrolone|O
S510|arm|O
S510|.|O
S591|Patients|O
S591|with|O
S591|SSc|O
S591|are|O
S591|at|O
S591|high|O
S591|risk|O
S591|for|O
S591|the|O
S591|development|O
S591|of|O
S591|ischaemic|O
S591|digital|O
S591|ulcers|O
S591|(|O
S591|DUs|O
S591|)|O
S591|,|O
S591|which|O
S591|occur|O
S591|in|O
S591|35|O
S591|%|O
S591|to|O
S591|60|O
S591|%|O
S591|of|O
S591|patients|O
S591|with|O
S591|SSc|O
S591|and|O
S591|are|O
S591|an|O
S591|important|O
S591|source|O
S591|of|O
S591|morbidity|O
S591|.|O
S52|Before|O
S52|study|O
S52|termination|O
S52|and|O
S52|unblinding|O
S52|,|O
S52|the|O
S52|primary|O
S52|analysis|O
S52|was|O
S52|changed|O
S52|to|O
S52|a|O
S52|comparison|O
S52|between|O
S52|treatment|O
S52|arms|O
S52|of|O
S52|the|O
S52|life|O
S52|table|O
S52|estimates|O
S52|of|O
S52|the|O
S52|proportion|O
S52|of|O
S52|patients|O
S52|with|O
S52|ulcers|O
S52|at|O
S52|24|O
S52|weeks|O
S52|employing|O
S52|a|O
S52|modified|O
S52|χ2|O
S52|using|O
S52|the|O
S52|sum|O
S52|of|O
S52|squares|O
S52|from|O
S52|the|O
S52|life|O
S52|table|O
S52|in|O
S52|the|O
S52|error|O
S52|term|O
S52|,|O
S52|with|O
S52|the|O
S52|comparison|O
S52|of|O
S52|crude|O
S52|proportions|O
S52|using|O
S52|the|O
S52|Cochran–Mantel–Haenszel|O
S52|test|O
S52|maintained|O
S52|as|O
S52|a|O
S52|secondary|O
S52|analysis|O
S52|.|O
S793|For|O
S793|determination|O
S793|of|O
S793|PMA|O
S793|a|O
S793|total|O
S793|of|O
S793|3000|O
S793|events|O
S793|were|O
S793|collected|O
S793|in|O
S793|the|O
S793|CD14|O
S793|monocyte|O
S793|gate|O
S793|.|O
S607|After|O
S607|16|O
S607|weeks|O
S607|of|O
S607|treatment|O
S607|,|O
S607|patients|O
S607|receiving|O
S607|bosentan|O
S607|had|O
S607|a|O
S607|48|O
S607|%|O
S607|reduction|O
S607|in|O
S607|the|O
S607|mean|O
S607|number|O
S607|of|O
S607|new|O
S607|DUs|O
S607|compared|O
S607|with|O
S607|placebo|O
S607|(|O
S607|1.4|O
S607|vs|O
S607|2.7|O
S607|new|O
S607|ulcers|O
S607|;|O
S607|p=0.01|O
S607|)|O
S607|,|O
S607|but|O
S607|there|O
S607|were|O
S607|no|O
S607|differences|O
S607|between|O
S607|treatments|O
S607|in|O
S607|end|O
S607|points|O
S607|assessing|O
S607|DU|O
S607|healing|O
S607|in|O
S607|the|O
S607|63|O
S607|%|O
S607|of|O
S607|patients|O
S607|with|O
S607|active|O
S607|DUs|O
S607|at|O
S607|baseline|O
S607|.|O
S76|In|O
S76|REDUCE-1|O
S76|,|O
S76|the|O
S76|primary|O
S76|end|O
S76|point|O
S76|of|O
S76|proportion|O
S76|of|O
S76|patients|O
S76|with|O
S76|gastric|O
S76|ulcers|O
S76|at|O
S76|24|O
S76|weeks|O
S76|was|O
S76|12.7|O
S76|%|O
S76|for|O
S76|HZT-501|O
S76|and|O
S76|22.9|O
S76|%|O
S76|for|O
S76|ibuprofen|O
S76|(|O
S76|P=0.0044|O
S76|;|O
S76|NNT=12|O
S76|)|O
S76|.|O
S627|Healing|O
S627|was|O
S627|defined|O
S627|as|O
S627|complete|O
S627|epithelialisation|O
S627|,|O
S627|regardless|O
S627|of|O
S627|residual|O
S627|pain|O
S627|.|O
S1642|See|O
S1642|appendix|O
S1642|for|O
S1642|further|O
S1642|details|O
S1642|.|O
S35|Compliance|O
S35|was|O
S35|determined|O
S35|by|O
S35|pill|O
S35|count|O
S35|of|O
S35|returned|O
S35|bottles|O
S35|of|O
S35|study|O
S35|medication|O
S35|.|O
S178|Each|O
S178|treatment|O
S178|was|O
S178|administered|O
S178|for|O
S178|4|O
S178|weeks|O
S178|,|O
S178|and|O
S178|there|O
S178|was|O
S178|no|O
S178|washout|O
S178|between|O
S178|treatment|O
S178|periods|O
S178|as|O
S178|pharmacodynamic|O
S178|steady|O
S178|state|O
S178|with|O
S178|tiotropium|O
S178|is|O
S178|known|O
S178|to|O
S178|be|O
S178|achieved|O
S178|after|O
S178|3|O
S178|weeks|O
S178|in|O
S178|chronic|O
S178|obstructive|O
S178|pulmonary|O
S178|disease|O
S178|.|O
S1440|Quantitative|O
S1440|RT-PCR|O
S1440|for|O
S1440|influenza|O
S1440|virus|O
S1440|A|O
S1440|and|O
S1440|B|O
S1440|,|O
S1440|with|O
S1440|a|O
S1440|lower|O
S1440|limit|O
S1440|of|O
S1440|quantification|O
S1440|of|O
S1440|103|O
S1440|copies|O
S1440|of|O
S1440|cDNA|O
S1440|per|O
S1440|mL|O
S1440|,|O
S1440|was|O
S1440|performed|O
S1440|as|O
S1440|described|O
S1440|previously|O
S1440|.|O
S1105|Statistical|O
S1105|analysis|O
S1105|All|O
S1105|analyses|O
S1105|were|O
S1105|conducted|O
S1105|on|O
S1105|an|O
S1105|intention|O
S1105|to|O
S1105|treat|O
S1105|basis|O
S1105|,|O
S1105|including|O
S1105|all|O
S1105|patients|O
S1105|in|O
S1105|the|O
S1105|groups|O
S1105|to|O
S1105|which|O
S1105|they|O
S1105|were|O
S1105|randomised|O
S1105|.|O
S977|The|O
S977|increases|O
S977|varied|O
S977|between|O
S977|patients|O
S977|,|O
S977|with|O
S977|a|O
S977|median|O
S977|increase|O
S977|in|O
S977|those|O
S977|that|O
S977|increased|O
S977|of|O
S977|2.16|O
S977|cm2|O
S977|in|O
S977|the|O
S977|ciclosporin|O
S977|group|O
S977|and|O
S977|2.55|O
S977|cm2|O
S977|in|O
S977|the|O
S977|prednisolone|O
S977|group|O
S977|.|O
S1697|Most|O
S1697|deaths|O
S1697|(|O
S1697|19|O
S1697|clinically|O
S1697|driven|O
S1697|and|O
S1697|20|O
S1697|routine|O
S1697|laboratory|O
S1697|monitoring|O
S1697|)|O
S1697|were|O
S1697|primarily|O
S1697|HIV-related|O
S1697|;|O
S1697|only|O
S1697|one|O
S1697|was|O
S1697|drug-related|O
S1697|(|O
S1697|chemotherapy|O
S1697|plus|O
S1697|zidovudine|O
S1697|)|O
S1697|.|O
S2083|The|O
S2083|main|O
S2083|inclusion|O
S2083|criterion|O
S2083|was|O
S2083|the|O
S2083|presence|O
S2083|of|O
S2083|a|O
S2083|severe|O
S2083|gait|O
S2083|disorder|O
S2083|and|O
S2083|an|O
S2083|abnormal|O
S2083|,|O
S2083|forward-leaning|O
S2083|stance|O
S2083|.|O
S154|Incidence|O
S154|of|O
S154|adverse|O
S154|events|O
S154|was|O
S154|comparable|O
S154|between|O
S154|placebo|O
S154|and|O
S154|all|O
S154|tiotropium|O
S154|Respimat®|O
S154|groups|O
S154|.|O
S1088|The|O
S1088|treatment|O
S1088|was|O
S1088|repeated|O
S1088|daily|O
S1088|after|O
S1088|gently|O
S1088|pumicing|O
S1088|or|O
S1088|filing|O
S1088|off|O
S1088|the|O
S1088|dead|O
S1088|part|O
S1088|of|O
S1088|the|O
S1088|verruca|O
S1088|for|O
S1088|a|O
S1088|maximum|O
S1088|of|O
S1088|eight|O
S1088|weeks|O
S1088|.|O
S2116|All|O
S2116|patients|O
S2116|undergoing|O
S2116|STN|O
S2116|stimulation|O
S2116|were|O
S2116|assessed|O
S2116|under|O
S2116|‘|O
S2116|on-stim|O
S2116|’|O
S2116|conditions|O
S2116|.|O
S1222|Methods|O
S1222|In|O
S1222|this|O
S1222|international|B-Settings_Location
S1222|,|O
